<SEC-DOCUMENT>0001185185-26-001072.txt : 20260326
<SEC-HEADER>0001185185-26-001072.hdr.sgml : 20260326
<ACCEPTANCE-DATETIME>20260326162050
ACCESSION NUMBER:		0001185185-26-001072
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260326
DATE AS OF CHANGE:		20260326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		26798552

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>iinn20f123125.htm
<DESCRIPTION>FORM 20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 26 19:16:31 UTC 2026 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:iinn="http://InspiraTechnologiesOXYB.H.N.Ltd/20251231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0px; margin-bottom: 0px; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0"></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b>UNITED
STATES<br/>
SECURITIES AND EXCHANGE COMMISSION</b></span><b><br/>
WASHINGTON, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0px auto; width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 16pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-20377">20-F</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0px auto; width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentRegistrationStatement" id="ixv-20378">&#9744;</ix:nonNumeric> REGISTRATION STATEMENT PURSUANT TO SECTION
12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-20379">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-20380"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-20381">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-20382">2025</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-20383">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentShellCompanyReport" id="ixv-20384">&#9744;</ix:nonNumeric> SHELL COMPANY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No.: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-20385">001-40303</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-89"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of registrant as specified in its
charter)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Translation of registrant&#8217;s name into
English: Not applicable</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>State of <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-20386">Israel</ix:nonNumeric>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Jurisdiction of incorporation or organization)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-20387">2 Ha-Tidhar St</ix:nonNumeric>.,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-20388">Ra&#8217;anana</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-20389">4366504</ix:nonNumeric> Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: +972.4.6230333</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address of principal executive offices)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-127"><b>Dagi Ben-Noon</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-20390">2 Ha-Tidhar St.</ix:nonNumeric>,</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-20391">Ra&#8217;anana</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-20392">4366504</ix:nonNumeric> <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-20393">Israel</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: +<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-20394">972</ix:nonNumeric>.<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-20395">4.6230333</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Name, Telephone, E-mail and/or Facsimile number
and Address of Company Contact Person)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Title of each class</i></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading Symbol(s)</i></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Name of each exchange on which registered </i></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: center"><ix:nonNumeric contextRef="c2" name="dei:Security12bTitle" id="ixv-164"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares, no par value</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c2" name="dei:TradingSymbol" id="ixv-169"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IINN</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c2" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-20396">Nasdaq</ix:nonNumeric> Capital Market</b></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: center"><ix:nonNumeric contextRef="c3" name="dei:Security12bTitle" id="ixv-178"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants to purchase Ordinary Shares</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c3" name="dei:TradingSymbol" id="ixv-183"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IINNW</b></span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c3" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-20397">Nasdaq</ix:nonNumeric> Capital Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate the number of outstanding shares of
each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-20398">35,949,247</ix:nonFraction>
ordinary shares, no par value, as of December 31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-20399">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this report is an annual or transition report,
indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-20400">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-20401">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-20402">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large
accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 3%; text-align: justify">&#160;</td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span></td> <td style="width: 21%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 33%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td> <td style="width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-259"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging Growth Company </span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-266"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange
Act. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="ixv-20403">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board
to its Accounting Standards Codification after April 5, 2012.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-20404">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-20405">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark which basis of accounting
the registrant has used to prepare the financial statements included in this filing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-20406">U.S. GAAP</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International Financial Reporting
Standards as issued by the International Accounting Standards Board &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Other&#8221; has been checked in response
to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#9744; Item 17 &#9744; Item
18</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this is an annual report, indicate by check
mark whether the registrant is a shell company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-20407">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0px; margin-bottom: 0px; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="TableOfContents"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 10%">&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 80%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><b>Page</b></td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTRODUCTION</span></a></td>
    <td style="vertical-align: bottom; text-align: center">iii</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">vi</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY RISK FACTORS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">viii</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEY INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization and Indebtedness.</span></a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons for the Offer and Use of Proceeds</span></a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ON THE COMPANY</span></a></td>
    <td style="vertical-align: bottom; text-align: center">41</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History and Development of the Company</span></a></td>
    <td style="vertical-align: bottom; text-align: center">41</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Overview</span></a></td>
    <td style="vertical-align: bottom; text-align: center">42</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational Structure</span></a></td>
    <td style="vertical-align: bottom; text-align: center">60</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, Plants and Equipment</span></a></td>
    <td style="vertical-align: bottom; text-align: center">60</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">60</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">61</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Results</span></a></td>
    <td style="vertical-align: bottom; text-align: center">61</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity and Capital Resources</span></a></td>
    <td style="vertical-align: bottom; text-align: center">64</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development, patents and licenses, etc.</span></a></td>
    <td style="vertical-align: bottom; text-align: center">67</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trend information</span></a></td>
    <td style="vertical-align: bottom; text-align: center">67</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical Accounting Estimates</span></a></td>
    <td style="vertical-align: bottom; text-align: center">68</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES.</span></a></td>
    <td style="vertical-align: bottom; text-align: center">68</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Senior Management.</span></a></td>
    <td style="vertical-align: bottom; text-align: center">68</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation.</span></a></td>
    <td style="vertical-align: bottom; text-align: center">72</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Practices</span></a></td>
    <td style="vertical-align: bottom; text-align: center">73</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees</span></a></td>
    <td style="vertical-align: bottom; text-align: center">87</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Ownership</span></a></td>
    <td style="vertical-align: bottom; text-align: center">88</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation</span></a></td>
    <td style="vertical-align: bottom; text-align: center">88</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">89</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders</span></a></td>
    <td style="vertical-align: bottom; text-align: center">89</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</span></a></td>
    <td style="vertical-align: bottom; text-align: center">90</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interests of Experts and Counsel</span></a></td>
    <td style="vertical-align: bottom; text-align: center">91</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center">91</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements and Other Financial Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center">91</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant Changes</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFER AND LISTING</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer and Listing Details</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_041"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Markets</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Shareholders</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_043"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_044"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Issue</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_045"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_046"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Capital</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_047"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum and Articles of Association</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_048"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</span></a></td>
    <td style="vertical-align: bottom; text-align: center">93</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 80%"><a href="#a_049"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Controls</span></a></td>
    <td style="vertical-align: bottom; width: 10%; text-align: center">94</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_050"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></a></td>
    <td style="vertical-align: bottom; text-align: center">94</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_051"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends and Paying Agents</span></a></td>
    <td style="vertical-align: bottom; text-align: center">101</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_052"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement by Experts</span></a></td>
    <td style="vertical-align: bottom; text-align: center">101</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_053"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents on Display</span></a></td>
    <td style="vertical-align: bottom; text-align: center">102</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_054"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center">102</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><a href="#a_055"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report to Security Holders</span></a></td>
    <td style="vertical-align: bottom; text-align: center">102</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_056"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="text-align: center">102</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_057"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></td>
    <td style="text-align: center">103</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_058"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities</span></a></td>
    <td style="text-align: center">103</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_059"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants and rights</span></a></td>
    <td style="text-align: center">103</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_060"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Securities</span></a></td>
    <td style="text-align: center">103</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_063"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></td>
    <td style="text-align: center">104</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_064"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">104</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_065"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="text-align: center">104</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_066"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</span></a></td>
    <td style="text-align: center">105</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16A.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_067"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDIT COMMITTEE FINANCIAL EXPERT</span></a></td>
    <td style="text-align: center">105</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16B.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_068"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CODE OF ETHICS</span></a></td>
    <td style="text-align: center">105</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16C.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_069"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="text-align: center">105</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16D.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_070"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></td>
    <td style="text-align: center">106</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16E.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_071"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></td>
    <td style="text-align: center">106</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16F.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_072"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td style="text-align: center">106</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16G.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_073"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATE GOVERNANCE</span></a></td>
    <td style="text-align: center">106</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16H.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_074"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURE</span></a></td>
    <td style="text-align: center">109</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16I</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_075"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></td>
    <td style="text-align: center">109</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16J</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_076"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSIDER TRADING POLICIES</span></a></td>
    <td style="text-align: center">109</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16K</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_077"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CYBERSECURITY</span></a></td>
    <td style="text-align: center">109</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 17.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_079"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center">110</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 18.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_080"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center">110</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19.</span></td>
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#a_081"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</span></a></td>
    <td style="text-align: center">110</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2"><a href="#a_082"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="text-align: center">111</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Inspira Technologies Oxy B.H.N. Ltd. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>INTRODUCTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company focused on the research, development, manufacturing, and commercialization of proprietary life-support technologies. Our
development efforts are directed toward technologies that are intended to address certain limitations associated with traditional mechanical
ventilators, which currently represents the standard of care for the treatment of acute respiratory failure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mechanical ventilation is
widely used as a life-saving intervention for patients with severe respiratory conditions. However, its use may be associated with risks
and complications, as well as significant healthcare costs, prolonged hospital stays, increased incidence of infections, ventilator dependence,
and high mortality rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing life-support
technologies designed to support patients with acute respiratory failure, with the goal of providing potential alternatives or complementary
approaches to mechanical ventilation. These technologies are intended to enable patients to maintain spontaneous breathing and potentially
reduce the need for invasive interventions such as intubation and medically induced coma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our business strategy,
and in parallel with pursuing regulatory approvals, we are seeking to establish collaborations with strategic partners, hospitals, medical
device companies, and distributors to support clinical evaluation, endorsement, and potential early adoption of our technologies. We intend
to focus our commercial efforts on intensive care units, general medical units, operating theaters, and smaller urban and rural hospitals.
These efforts are intended to support our broader strategy to expand market access and adoption of our life-support technologies, subject
to applicable regulatory approvals and successful commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing the following
products:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The INSPIRA<sup>TM</sup> ART</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;The INSPIRA Augmented
Life-support Respiratory Technology, or the ART system, also known as the INSPIRA ART500, is our flagship product. The system is being
developed as an advanced life-support platform intended to monitor and oxygenate blood in patients with acute respiratory failure. The
technology is designed to increase oxygen saturation levels while allowing patients to remain awake and maintain spontaneous breathing,
potentially reducing the need for invasive mechanical ventilation and associated interventions such as intubation and medically induced
coma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART system integrates
blood monitoring and oxygenation capabilities into a single platform and is being developed for use in hospital settings, including intensive
care units and other acute care environments. We believe that, subject to regulatory approvals and successful clinical validation, the
INSPIRA ART system may provide healthcare providers with an additional tool for managing patients with severe respiratory conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART system is
being developed as a potential alternative or complementary approach for patients with acute respiratory failure who currently require
mechanical ventilation in intensive care units, or ICUs. Each year, millions of patients worldwide require mechanical ventilation in ICUs,
and mortality rates may be particularly high among those undergoing prolonged ventilation, in some cases exceeding 50%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mechanical ventilation delivers
oxygen by forcing air into the lungs through an invasive procedure that typically requires intubation and deep sedation or medically induced
coma. The INSPIRA ART system is intended to oxygenate blood directly through an extracorporeal process to elevate and stabilize declining
oxygen saturation levels while simultaneously providing real-time monitoring of key blood parameters. Our objective is to support patient
treatment without the need for invasive mechanical ventilation and potentially reduce certain risks, complications, and costs associated
with such interventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The technology is expected
to enrich small volumes of blood with oxygen while simultaneously removing carbon dioxide and continuously monitoring relevant blood parameters.
By improving oxygen saturation levels within minutes, the system may allow patients to remain awake during treatment. Subject to regulatory
approvals and clinical validation, this approach could potentially expand treatment beyond ICUs to additional care settings such as emergency
departments, general medical units, emergency medical services, and smaller hospitals without ICU capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART system is
being developed to provide prolonged extracorporeal life support for patients with acute respiratory failure, including physiologic gas
exchange through oxygenation and carbon dioxide removal. We believe this approach may enable treatment without intubation, induced coma,
or ventilator weaning, procedures that are often associated with complications such as lung injury and infection that may prolong hospitalization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The INSPIRA<sup>TM</sup> ART100 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 system,
previously referred to as the ALICE, Liby, INSPIRA ART (Gen1) or ECLS system, is also referred to as a device or system. The INSPIRA ART100
is an FDA-cleared advanced form of life support system, better known by the medical industry as a cardiopulmonary bypass, or CPB, system
designed for use in surgical procedures with duration of six hours or less. The INSPIRA ART100 utilizes a technique that circulates, adds
oxygen to and removes carbon dioxide from blood, with the enriched blood being circulated back to the patient. The device takes over the
function of the heart and/or lungs in critical care patients undergoing life-saving procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2024, the INSPIRA ART100
received 510(k) class II regulatory clearance from the FDA. In July 2024, we received an Israeli Medical Equipment Division Ministry of
Health, or AMAR, regulatory approval for extra-corporeal membrane oxygenation, or ECMO, and CPB procedure. In December 2024, the INPIRA
ART100 devices were shipped for deployment to Westchester Medical Center in Valhalla, New York, as part of an evaluation and collaboration
for the INSPIRA ART100.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA&#8482; ART100
system includes software that navigates the physician through the setup process and provides alerts while offering potential troubleshooting
solutions. The system has a compact design, with extended battery life to support intra-hospital patient transfers and is compatible with
various disposable parts, allowing for customization of tubing and oxygenators, which simplifies purchase and inventory management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">INSPIRA<sup>TM</sup> ART100 System and CART</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>The HYLA<sup>TM</sup> Blood
Sensor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA blood sensor, described
herein as the HYLA or HYLA blood sensor, is being designed to perform real-time sampling and analysis of key blood parameter measurements,
without the need for blood drawings. The HYLA is being designed to measure continuously, in real-time, thousands of blood samples during
a single ICU treatment or operating room procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA blood sensor is being
developed to provide continuous, real-time monitoring of key blood parameters that may indicate oxygen deficiencies, without the need
to take intermittent blood draws. Intended for patients undergoing medical procedures or requiring frequent monitoring, the technology
is designed to detect sudden changes in a patient&#8217;s condition by tracking critical blood indicators.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA is being developed
as both an integrated component of the INSPIRA ART100 and INSPIRA ART systems, and as a standalone device. This versatility may expand
our market offering across multiple critical care applications and market segments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our development process combines
in-house laboratory testing with hospital collaborations for clinical research. This comprehensive approach may allow for better validation
of the technology in real-world medical settings, refinement of the sensor&#8217;s accuracy against industry standards, and optimization
of the disposable components for practical clinical use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a goal to set a new
standard of care in various areas of patient care. As part of our strategy to reach these goals, and in parallel to pursuing regulatory
approvals, we are actively working to establish collaborations with strategic partners and globally ranked health centers to provide endorsement
and clinical adoption for regional deployments of our products and technologies. We plan to target ICUs, general medical units, operating
theaters, and small urban and rural hospitals, with the goal of making our solutions more accessible to millions of patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 50%"><img alt="" src="image_003.jpg"/></td>
  <td style="text-align: center; width: 50%"><img alt="" src="image_004.jpg"/>&#160;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hyla <sup>TM</sup> Blood Monitoring System</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an Israeli corporation
based in Ra&#8217;anana, Israel, and were incorporated in Israel in 2018 under the name Clearx Medical Ltd. On April 10, 2018, our name
was changed to Insense Medical Ltd. On July 30, 2020, our name was further changed to our current name, Inspira Technologies Oxy B.H.N.
Ltd. Our principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone number in Israel is
+972 996 644 88. Our website address is&#160;<i>www.inspira-technologies.com</i>. The information contained on, or that can be accessed
through, our website is not part of this annual report. We have included our website address in this annual report solely as an inactive
textual reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain information included
or incorporated by reference in this annual report on Form 20-F may be deemed to be &#8220;forward-looking statements&#8221; within the
meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are often
characterized by the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221;
&#8220;project&#8221; or other similar words, but are not the only way these statements are identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking statements
may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections
of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development,
completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or
developments that we intend, expect, project, believe or anticipate will or may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on
assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Important factors that could
cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements
include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
planned level of revenues, capital expenditures and liquidity;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
available cash and our ability to obtain additional funding;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements for the period ended December 31, 2025, contain an explanatory paragraph regarding substantial doubt about our ability
to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms, if at all;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
expectation regarding the sufficiency of our existing cash and cash equivalents to fund our current operations;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to advance the development of our products and future potential product candidates;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to commercialize and sell our products and future potential products and future sales of our product or any other future potential products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our assessment of the potential of our products and future potential product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our planned level of capital expenditures and liquidity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our plans to continue to invest in research and development to develop technology for new products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to maintain our relationships with suppliers, manufacturers, distributors and other partners;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated actions of the FDA, state regulators, if any, or other similar foreign regulatory agencies, including approval to conduct clinical trials, the timing and scope of those trials and the prospects for regulatory approval or clearance of, or other regulatory action with respect to our products or services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The regulatory environment and changes in the health policies and regimes in the countries in which we intend to operate, including the impact of any changes in regulation and legislation that could affect the medical device industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to meet our expectations regarding the commercial supply of our products and future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to retain key executive members;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to internally develop new inventions and intellectual property;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The overall global economic environment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The impact of competition and new technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The possible impacts of cybersecurity incidents on our business and operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to comply with continued listing requirements and standards of Nasdaq;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General market, political and economic conditions in the countries in which we operate, including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The impact of competition and new technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to internally develop new inventions and intellectual property;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in our strategy; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Readers are urged to carefully
review and consider the various disclosures made throughout this annual report on Form 20-F which are designed to advise interested parties
of the risks and factors that may affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not put undue reliance
on any forward-looking statements. Any forward-looking statements in this annual report on Form 20-F are made as of the date hereof, and
we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the sections
of this annual report on Form 20-F entitled &#8220;Introduction&#8221; and &#8220;Item 4. Information on the Company&#8221; contain information
obtained from independent industry sources and other sources that we have not independently verified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Inspira&#8221; refer to Inspira Technologies
Oxy B.H.N. Ltd. References to &#8220;U.S. dollars, &#8220;dollars,&#8221; and &#8220;$&#8221; are to currency of the United States of
America, and references to &#8220;NIS&#8221; are to New Israeli Shekels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beginning with the year ended
December 31, 2023, we transitioned from preparing and reporting our financial statements in accordance with the International Financial
Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, to preparing and reporting our financial
statements in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, which may cause our financial
results to differ from results, or impact the comparability to our financial statements, prepared in accordance with IFRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
we have retroactively converted the historical financial statements that were prepared in accordance with IFRS and included in this report
to present such financial statements in accordance with U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All trademarks or trade names
referred to in this Form 20-F are the property of their respective owners. Solely for convenience, the trademarks and trade names in this
annual report on Form 20-F are referred to without the &#174; and &#8482; symbols, but such references should not be construed as any indicator
that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use
or display of other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by,
any other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Form 20-F contains various
depictions and illustrations of the various products we are developing. These illustrations are representative of the current expected
designs for our products and are subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The risk factors described
below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should
carefully consider these risk factors, together with the risk factors set forth in Item 3D. of this annual report on Form 20-F and the
other reports and documents filed by us with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial statements for the year ended December 31, 2025, contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. This going concern assessment may prevent us from obtaining new financing on reasonable terms, if at all, and imperil our ability to continue operating as a going concern;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our officers and directors
    currently beneficially own approximately 9.2% of our securities and may therefore be able to exert control over matters submitted to
    our shareholders for approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a limited operating history, and we have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We could fail to maintain the listing of our securities on Nasdaq, which could seriously harm the liquidity of our shares and our ability to raise capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not generated any significant revenue from product sales and may never be profitable;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to raise substantial additional funding, which may not be available on acceptable terms, if at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent on the successful development, marketing and sale of our products and on receiving the required regulatory approvals for such products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our success depends on our ability to generate demand for our products, develop and commercialize new products and generate revenues and identify new markets for our technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical device development is costly and involves continual technological change, which may render certain of our current or future products obsolete;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our customer acquisition strategy may not succeed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are dependent upon third-party service providers. If such third-party service providers fail to maintain a high quality of service, the functionality of our products could be impaired, which in turn may adversely affect our products, business, operating results and reputation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be exposed to foreign currency exchange rate fluctuations, which could adversely affect our results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We manage our business through a small number of employees and key consultants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may need to expand our company but we may experience difficulties in recruiting additional employees and consultants, which could disrupt our operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risk associated with doing business outside of the United States, or U.S., or Israel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If third-party payors do not provide adequate coverage and reimbursement for the use of our products or services or any future product candidates, our revenue will be negatively impacted;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our products and operations are subject to extensive government regulation and oversight both in the U.S. and abroad and our failure to comply with applicable requirements could harm our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not receive, or may be delayed in receiving, the necessary clearances or approvals for our products and failure to timely obtain necessary clearances or approvals for our products would adversely affect our ability to grow our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative or regulatory reforms in the U.S. or the European Union, or the EU, may make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain and maintain effective patent rights for our products and services, we may not be able to compete effectively in our markets. If we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business and operations might be adversely affected by security breaches, including any cybersecurity incidents; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential political, economic and military instability in Israel, where our headquarters, members of our management team and our research and development facilities are located, may adversely affect our results of operations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ix<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART I</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT
AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. <span style="text-transform: uppercase">OFFER
STATISTICS AND EXPECTED TIMETABLE</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. KEY INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_008"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_009"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capitalization
and Indebtedness.</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_010"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reasons
for the Offer and Use of Proceeds.</b></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.5in; text-align: left"><b>D.</b></td><td style="text-align: justify"><b>Risk Factors</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully consider
the risks and uncertainties described below, together with all of the other information in this annual report on Form 20-F. If any of
these risks actually occurs, our business and financial condition could suffer, and the price of our securities could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Business and Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are highly dependent on the successful
development, marketing and sale of our products and on receiving the required regulatory approvals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products, focused on the
treatment of respiratory failure, are the basis of our business. As a result, the success of our business plan is highly dependent on
our ability to develop, manufacture and commercialize our products, and our failure to do so could cause our business to fail. Successful
commercialization of medical devices is a complex and uncertain process, dependent on the efforts of management, manufacturers, local
operators, integrators, medical professionals, third-party payors, as well as general economic conditions, among other factors. Any factor
that adversely impacts the development and commercialization of our products, will have a negative impact on our business, financial condition,
results of operations and prospects. We have limited experience in commercializing our products and we may face several challenges with
respect to our commercialization efforts, including, among others, that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not have adequate financial or other resources to complete the development of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to manufacture our products in commercial quantities, at an adequate quality or at an acceptable cost;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to establish adequate sales, marketing and distribution channels;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare professionals and patients may not accept our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be aware of possible complications from the continued use of our products since we have limited clinical experience with respect to the actual use of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to compete with existing solutions for respiratory failure;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">technological breakthroughs in the respiratory support solutions may reduce the demand for our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party payors may not agree to reimburse patients for any or all of the purchase price of our products, which may adversely affect patients&#8217; willingness to use our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may face third-party claims of intellectual property infringement; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may fail to obtain or maintain regulatory clearance or approvals in our target markets or may face adverse regulatory or legal actions even if regulatory approval is obtained.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to meet any
one or more of these challenges successfully, our ability to effectively commercialize our products and services could be limited, which
in turn could have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our success depends upon market acceptance
of our products, our ability to develop and commercialize new products and generate revenues and our ability to identify new markets for
our technology. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have developed, and are
engaged in the development of, respiratory support technology. Our success will depend on the approval and acceptance of our products
and any future products in the healthcare market. We are faced with the risk that the marketplace will not be receptive to our products
or any future products over competing products and that we will be unable to compete effectively. Factors that could affect our ability
to successfully commercialize our current and any potential future products:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the challenges of developing (or acquiring externally developed) technology solutions that are adequate and competitive in meeting the requirements of next-generation design challenges; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dependence upon referrals from physicians for the sale of our products and provision of our service.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot assure that our
products or any future products will gain broad market acceptance. If the market for our products fails to develop or develops more slowly
than expected, our business and operating results would be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to maintain existing strategic
relationships with Glo-Med, our other distributors, or are unable to identify additional distributors of our products or any future products
and technologies, our revenues may decrease.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently expect to record
revenue through our strategic relationships and distribution agreements with Glo-Med Networks Inc., or Glo-Med, as well as other distributors
for the deployment of our products. If our relationships with our distributors are terminated or impaired for any reason and we are unable
to replace these relationships with other means of distribution, we could suffer a material decrease in revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have a number
of existing distribution agreements that are non-binding, which can be terminated at will. These distribution agreements cover our products
that are still under development and have not received FDA clearance. Therefore, these agreements may not result in any sales at all if
our products that are currently under development do not receive FDA clearance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may need, or decide it
is otherwise advantageous to us, to obtain the assistance of additional distributors to market and distribute our future products and
technologies, as well as to market and distribute our INSPIRA ART system, INSPIRA ART100 system, HYLA blood sensors, and Inspira disposable
devices to existing or new markets or geographical areas. We may not be able to find additional distributors who will agree to and are
able to successfully market and distribute our systems and technologies on commercially reasonable terms, if at all. If we are unable
to establish additional distribution relationships on favorable terms, our revenues may decline. In addition, our distributors may choose
to favor the products of our competitors over ours and give preference to them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our agreements
with the aforementioned distributors, we will be responsible for obtaining and maintaining any and all regulatory approvals for our products.
If we are unable to obtain or maintain such approvals, or if the parties to the distribution agreement fail to purchase the agreed upon
products at the agreed upon pricing, it may adversely impact our relationships with these distributors, and we may never realize any revenues
from these agreements ships as a result.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Medical device development is costly and
involves continual technological change which may render our current or future products obsolete.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market for medical device
technologies and products is characterized by factors such as rapid technological change, medical advances, changing consumer requirements,
short device lifecycles, changing regulatory requirements and evolving industry standards. Any one of these factors could reduce the demand
for our devices or require substantial resources and expenditures for, among other things, research, design and development, to avoid
technological or market obsolescence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success will depend on
our ability to enhance our current technology and develop or acquire new technologies to keep pace with technological developments and
evolving industry standards, while responding to changes in customer needs. A failure to adequately develop or acquire device enhancements
or new devices that will address changing technologies and customer requirements adequately, or to introduce such devices on a timely
basis, may have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We might have insufficient
financial resources to improve our products, advance technologies and develop new devices at competitive prices. Technological advances
by one or more competitors or future entrants into the field may result in our present services or devices becoming non-competitive or
obsolete, which may decrease revenues and profits and adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may encounter significant
competition across our product lines and in each market in which we will sell our products and services from various companies, some of
which may have greater financial and marketing resources than we do. Our competitors may include any companies engaged in the research,
development, manufacture, and marketing of respiratory support solutions and technologies, as well as a wide range of medical device companies
that sell a single or limited number of competitive products and services or participate in only a specific market segment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our customer acquisition strategy may not
succeed and although we have executed distribution agreements with various parties in various geographic region, we may never realize
any significant revenues from such agreements</i>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business will be dependent
upon success in our customer acquisition strategy. To date, we have executed various distribution agreements in various geographic regions
which are subject to regulatory approvals. If we do not obtain regulatory approval, or if the parties to the distribution agreement fail
to purchase the agreed upon products at the agreed upon pricing, we may not realize any revenues from such agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if we fail to
maintain a high quality of device technology, we may fail to retain or add new customers. If we fail, our revenue, financial results and
business may be significantly harmed. Our future success depends upon expanding our commercial operations in the U.S., Israel and Europe,
as well as entering additional markets to commercialize our products and any future products. We believe that our expanded growth will
depend on the further development, regulatory approval and commercialization of our products. If we fail to expand the use of our products
in a timely manner, we may not be able to expand our markets or to grow our revenue, and our business may be adversely impacted. If people
do not perceive our products to be useful and reliable, we may not be able to attract or retain new customers. A decrease in costumer
growth could render less attractive to developers, which may have a material and adverse impact on our revenue, business, financial condition
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business and operations would suffer
in the event of computer system failures, cyber-attacks or a deficiency in our cybersecurity.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures intended to secure our data against impermissible access and to preserve the integrity and confidentiality of our
data, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware,
natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions, attachments to emails,
persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption,
particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally
increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such
an event were to occur and cause interruptions to our operations, it could result in a material disruption of our drug development programs.
For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security
breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur material legal claims and liability, including under data privacy laws such as the General Data Protection Regulation,
or the GDPR, damage to our reputation, and the further development of our drug candidates could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent upon third-party manufacturers
and suppliers, which makes us vulnerable to potential supply shortages and problems, increased costs and quality or compliance issues,
any of which could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are comprised
of multiple components. We are planning to sell an assembled product as well as its disposable respiratory support unit. The components
of the assembled product and the disposable unit consist of both proprietary and off the shelf components. Proprietary components will
be manufactured on our behalf at good manufacturing practices, or GMP, approved production plant to adhere to regulatory requirements,
whereas off the shelf components will be sourced and manufactured by GMP suppliers. GMP sub-contractors will assemble proprietary and
off the shelf components together to create our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therefore, we rely on third
parties to manufacture and supply us with proprietary custom components. Although we rely on a number of suppliers who provide us with
materials and components as well as manufacture and assemble certain components of our products, we do not rely on single-source suppliers.
Our suppliers may encounter problems during manufacturing for a variety of reasons, including, for example, failure to follow specific
protocols and procedures, failure to comply with applicable legal and regulatory requirements, equipment malfunction and environmental
factors, failure to properly conduct their own business affairs, and infringement of third-party intellectual property rights, any of
which could delay or impede their ability to meet our requirements. Our reliance on these third-party suppliers also subjects us to other
risks that could harm our business, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not currently a major customer of many of our suppliers, and these suppliers may therefore prioritize other customers&#8217; needs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to obtain an adequate supply in a timely manner or on commercially reasonable terms;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our suppliers, especially new suppliers, may make errors in manufacturing that could negatively affect the efficacy or safety of our products or cause delays in shipment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may have difficulty locating and qualifying alternative suppliers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">switching components or suppliers may require product redesign and possibly submission to the FDA or other similar foreign regulatory agencies, which could impede or delay our commercial activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one or more of our suppliers may be unwilling or unable to supply components of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the occurrence of a fire, natural disaster or other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us in a timely manner; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our suppliers may encounter financial or other business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to quickly
establish additional or alternative suppliers, if necessary, in part because we may need to undertake additional activities to establish
such suppliers as required by the regulatory approval process. Any interruption or delay in obtaining products from our third-party suppliers,
or our inability to obtain products from qualified alternate sources at acceptable prices in a timely manner, could impair our ability
to meet the demand of our customers and cause them to switch to competing products. Given our reliance on certain suppliers, we may be
susceptible to supply shortages while looking for alternate suppliers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited manufacturing history on
which to assess the prospects for our business and we anticipate that we will incur significant losses once we initiate our in-house manufacturing
until we are able to successfully commercialize our products globally.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our future manufacturing
operation or any current or future contracted manufacturing operations become unreliable or unavailable, we may not be able to proceed
with our intended business operations and our entire business plan could fail. There is no assurance that our manufacturing operation
or any third-party manufacturers will be able to meet commercialized scale production requirements in a timely manner or in accordance
with applicable standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to replace our manufacturing
capabilities in a timely manner.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our future manufacturing
facility or any current or future contracted manufacturing operations suffer any type of prolonged interruption, whether caused by regulator
action, equipment failure, critical facility services (such as water purification, clean steam generation or building management and monitoring
system), fire, natural disaster or any other event that causes the cessation of manufacturing activities, we may be exposed to long-term
loss of sales and profits. There are limited facilities which are capable of contract manufacturing some of our products and product candidates.
Replacement of our current manufacturing capabilities may have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent upon third-party service
providers. If such third-party service providers fail to maintain a high quality of service, the utility of our products could be impaired,
which could adversely affect the penetration of our products, our business, operating results and reputation. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The success of certain services
and products that we provide are dependent upon third-party service providers. Such service providers include manufacturers of proprietary
custom components for our products. As we expand our commercial activities, an increased burden will be placed upon the quality of such
third-party providers. If third-party providers fail to maintain a high quality of service, our products, business, reputation and operating
results could be adversely affected. In addition, poor quality of service by third-party service providers could result in liability claims
and litigation against us for damages or injuries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-U.S. governments often impose strict
price controls, which may adversely affect our future profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to rules
and regulations in the U.S. and non-U.S. jurisdictions relating to our products or any future products. In some countries, including countries
of the EU, each of which has developed its own rules and regulations, pricing may be subject to governmental control under certain circumstances.
In these countries, pricing negotiations with governmental agencies can take considerable time after the receipt of marketing approval
for a medical device candidate. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical
trial that compares the cost-effectiveness of our product to other available products.<b>&#160;</b>If reimbursement of our products is
unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We manage our business through a small number
of employees and key consultants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 22, 2026, we had
37 full-time employees (including our senior management team), four part-time employees, and four additional independent contractors and
consultants in Israel and in the U.S. Our future growth and success depend to a large extent on the continued services of members of our
current management including, in particular, Dagi Ben-Noon, our Chief Executive Officer. Any of our employees and consultants may leave
our company at any time, subject to certain notice periods. The loss of the services of any of our executive officers or any key employees
or consultants would adversely affect our ability to execute our business plan and harm our operating results. Our operational success
will substantially depend on the continued employment of senior executives, technical staff and other key personnel. The loss of key personnel
may have an adverse effect on our operations and financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may need to expand our organization and
we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As our development and commercialization
plans and strategies develop and because we are leanly staffed, we may need additional managerial, operational, sales, marketing, financial,
legal and other resources. The competition for qualified personnel in the medical device industry is intense. Due to this intense competition,
we may be unable to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement
personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management may need to
divert its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities.
We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational
mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of additional
medical device products. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our
ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial
performance and our ability to commercialize medical device products and services and compete effectively will depend, in part, on our
ability to effectively manage any future growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>International expansion of our business
exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the
U.S. or Israel.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than our headquarters
and other operations which are located in Israel (as further described below), our business strategy incorporates significant international
expansion, particularly in anticipated expansion of regulatory approvals of our products. Doing business internationally involves a number
of risks, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain regulatory approvals for the use of our products and services in various countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially relevant third-party patent rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing and managing foreign operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated with managing multiple regulatory, governmental and reimbursement regimes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in our ability to penetrate international markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions or its anti-bribery provisions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these factors could
significantly harm our future international expansion and operations and, consequently, our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face intense competition, and we may
be unable to effectively compete in our industry.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market participants in
the ICU and the acute respiratory care space include Boston Scientific Corporation (NYSE: BSX), ResMed Inc., (NYSE: RMD), Masimo Corporation
(Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq: GTLS), Philips Healthcare, Medtronic plc (NYSE:
MDT), Fisher &amp; Paykel Healthcare Corporation Limited, Dr&#228;gerwerk AG &amp; Co. KGaA, Dr&#228;gerwerk AG, Hamilton Medical AG,
Smiths Medical Inc. (acquired by ICU Medical Inc.), Siemens Healthineers AG ADR (OTCMKTS: SMMNY), Baxter International (NYSE: BAX), Getinge
AB (OTCMKTS: GNGBY), GE HealthCare, Terumo Corporation (TYO: 4543, Nikkei 225 Component), LivaNova PLC (Nasdaq: LIVN), Fresenius SE &amp;
Co. KGaA (OTCMKTS: FSNUY), Johnson &amp; Johnson (NYSE: JNJ), Zoll Medical Corporation (TYO: 3407 ), Resuscitec GmbH, Spectrum Medical
Limited, Abiomed, Inc. (Nasdaq: ABMD), Abbott Laboratories (NYSE: ABT), DataMed s.r.l, Chalice Medical Ltd., APMTD Global Limited, Eurosets
s.r.l. and Braile Biomedica. These companies have either developed or acquired respiratory care devices and solutions, such as ventilators,
ECMO devices and blood sensors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aforementioned companies,
have substantially greater brand recognition, research and development, and regulatory capabilities, as well as financial, technical,
manufacturing, marketing and human resources than we do and significantly greater experience and infrastructure in the research and development
of medical devices, obtaining FDA and other regulatory clearances of those devices and commercializing those devices around the world.
Further, some of these companies hold significant market share. Their dominant market position and significant control over the market
could significantly limit our ability to introduce or effectively market and generate sales of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors have
long histories and strong reputations within the industry. They have significantly greater brand recognition, financial and human resources
than we do. They also have more experience and capabilities in researching and developing testing devices, obtaining and maintaining regulatory
clearances and other requirements, manufacturing and marketing those products than we do. There is a significant risk that we may be unable
to overcome the advantages held by our competition, and our inability to do so could lead to the failure of our business. In addition,
we may be unable to develop additional products in the future or to keep pace with developments and innovations in the market and lose
market share to our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competition in the medical
devices and more specifically respiratory support technologies and solutions markets is intense, which can lead to, among other things,
price reductions, longer selling cycles, lower product margins, loss of market share and additional working capital requirements. To succeed,
we must, among other critical matters, gain consumer acceptance for our products, as compared to other solutions currently available in
the market for the treatment of respiratory failure and potential future medical devices incorporating our principal technology or offering
other advanced respiratory support solutions. If our competitors offer significant discounts on certain products and solutions, we may
need to lower our prices or offer other favorable terms in order to compete successfully. Moreover, any broad-based changes to our prices
and pricing policies could make it difficult to generate revenues or cause our revenues to decline. Moreover, if our competitors develop
and commercialize products and solutions that are more effective or desirable than products and solutions that we may develop, we may
not convince our customers to use our products and solutions. Any such changes would likely reduce our commercial opportunity and revenue
potential and could materially adversely impact our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If third-party payors do not provide adequate
coverage and reimbursement for the use of our products or any future products, our revenue will be negatively impacted.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the exception of the
FDA cleared ART100, which uses an existing code, our products are not yet approved for third-party payor coverage or reimbursement. Such
reimbursement may vary based on the particular device used in providing services and is based on the identity of the third-party. Our
ability to obtain and maintain a leading position in the medical device market, and specifically in the respiratory care market, depends
on our relationships with private third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to engage with private
third parties to allow our customers to receive reimbursement from insurance companies for our products. The loss of a significant number
of private third-party contracts may have an adverse effect on our revenues, which could have an adverse effect on our business, financial
condition and results of operations. Over the past few years, reimbursement rates from certain third parties have declined, in some cases
significantly. There can be no assurance that this trend will not continue or apply on more third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, private third
parties may not reimburse any new products offered by us or reimburse those new products at commercially viable rates. The failure to
receive reimbursement at adequate levels for our existing or future products may adversely affect demand for those products, our revenues
and expected growth. This could have an adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to litigation for a variety
of claims, which could adversely affect our results of operations, harm our reputation or otherwise negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to litigation
for a variety of claims arising from our normal business activities. These may include claims, suits, and proceedings involving labor
and employment, wage and hour, commercial and other matters. The outcome of any litigation, regardless of its merits, is inherently uncertain.
Any claims and lawsuits, and the disposition of such claims and lawsuits, could be time-consuming and expensive to resolve, divert management
attention and resources, and lead to attempts on the part of other parties to pursue similar claims. Any adverse determination related
to litigation could adversely affect our results of operations, harm our reputation or otherwise negatively impact our business. In addition,
depending on the nature and timing of any such dispute, a resolution of a legal matter could materially affect our future operating results,
our cash flows or both.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We could become subject to product liability,
warranty or similar claims and product recalls that could be expensive, divert management&#8217;s attention and harm our business reputation
and financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business exposes us to
an inherent risk of potential product liability, warranty or similar claims and product recalls. The medical device industry has historically
been litigious, and we face financial exposure to product liability, warranty or similar claims if the use of any of our products were
to cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our products
might necessitate a product recall. Although we maintain product liability insurance, the coverage limits of these policies may not be
adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or at reasonable
costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability claim, regardless
of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer dissatisfaction
and frustration and a substantial diversion of management attention. A successful claim brought against us in excess of, or outside of,
our insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business may be impacted by changes
in general economic conditions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is subject to
risks arising from changes in domestic and global economic conditions, including adverse economic conditions in markets in which we operate,
which may harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruption to the global economy
could also result in a number of follow-on effects on our business, including a possible slow-down resulting from lower customer expenditures;
inability of customers to pay for products, solutions or services on time, if at all; more restrictive export regulations which could
limit our potential customer base; negative impact on our liquidity, financial condition and share price, which may impact our ability
to raise capital in the market, obtain financing and secure other sources of funding in the future on terms favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the occurrence
of catastrophic events, such as hurricanes, storms, earthquakes, tsunamis, floods, epidemics and other catastrophes that adversely affect
the business climate in any of our markets could have a material adverse effect on our business, financial condition and results of operations.
Some of our operations are located in areas that have been in the past, and may be in the future, susceptible to such occurrences.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unstable market and economic conditions
may have serious adverse consequences on our business, financial condition and share price.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global economy, including
credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability,
declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates and uncertainty
about economic stability. Any such volatility and disruptions may have adverse consequences on us or the third parties on whom we rely.
If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity
financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Further, inflation can adversely
affect us by increasing our costs. Increased cost of living around the world has caused and may cause increased costs, such as higher
wages, increase direct service costs, increased freight costs and costs of components, and higher manufacturing costs. Any significant
increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations
and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We incur significant increased costs as
a result of the listing of our securities for trading on Nasdaq. Our management is required to devote substantial time to new compliance
initiatives as well as compliance with ongoing U.S. requirements.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company in the
U.S., we incur additional significant accounting, legal and other expenses that we did not incur prior to being a public company in the
U.S. We also incur costs associated with corporate governance requirements of the SEC, as well as requirements under Section 404 and other
provisions of the Sarbanes-Oxley Act. These rules and regulations increase our legal and financial compliance costs, introduce new costs
such as investor relations, stock exchange listing fees and shareholder reporting, and make some activities more time consuming and costly.
The implementation and testing of such processes and systems may require us to hire outside consultants and incur other significant costs.
Any future changes in the laws and regulations affecting public companies in the U.S., including Section 404 and other provisions of the
Sarbanes-Oxley Act, and the rules and regulations adopted by the SEC, for so long as they apply to us, will result in increased costs
to us as we respond to such changes. These laws, rules and regulations could make it more difficult or more costly for us to obtain certain
types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage
or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it more difficult
for us to attract and retain qualified persons to serve on our board of directors, our board committees, or as executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We could fail to maintain the listing of
our securities on Nasdaq, which could seriously harm the liquidity of our shares and our ability to raise capital.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Companies trading on Nasdaq,
such as our Company, must be reporting issuers under Section&#160;12 of the Exchange Act, and must meet the listing requirements in order
to maintain the listing of its shares on the Nasdaq Capital Market. If we do not meet these requirements, the market liquidity for our
securities could be severely adversely affected by limiting the ability of broker-dealers to sell our securities and the ability of shareholders
to sell their securities in the secondary market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 10, 2025, we received
a written notice from Nasdaq indicating that we are not in compliance with the minimum bid price requirement for continued listing set
forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq
Listing Rule 5810(c)(3)(A), we were granted a period of 180 calendar days to regain compliance with the minimum bid price requirement,
or until September 8, 2025. On July 17, 2025, we received a written notice from Nasdaq indicating that we regained compliance with the
minimum bid price requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 9, 2026, we again
received a written notice, or the Notice, from Nasdaq indicating that we are not in compliance with the minimum bid price requirement
for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of
$1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), we were granted a period of 180 calendar days to regain compliance with the
minimum bid price requirement, or until August 10, 2026. There is a risk that we could be subject to additional notices of delisting for
failure to comply with Nasdaq Listing Rule 5550(a)(2) or other Nasdaq Listing Rules and no assurance can be given that we will remain
eligible to be listed on Nasdaq. If we do not regain compliance with Nasdaq Listing Rule 5550(a)(2), our Ordinary Shares will be subject
to delisting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A delisting from Nasdaq would
likely result in a reduction in some or all of the following, each of which could have a material adverse effect on shareholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the liquidity of our Ordinary Shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market price of our Ordinary Shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of information concerning the trading prices and volume of our Ordinary Shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain financing or complete a strategic transaction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of institutional and other investors that will consider investing in our Ordinary Shares; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of market markers or broker-dealers for our Ordinary Shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are not able to attract and retain
highly skilled managerial, scientific, technical and marketing personnel, we may not be able to implement our business model successfully.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends in part
on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly
dependent upon our senior management as well as other employees, consultants and scientific and medical collaborators. Our management
team must be able to act decisively to apply and adapt our business model in the rapidly changing markets in which we will compete. In
addition, we will rely upon technical and scientific employees or third-party contractors to effectively establish, manage and grow our
business. Consequently, we believe that our future viability will depend largely on our ability to attract and retain highly skilled managerial,
sales, scientific and technical personnel. In order to do so, we may need to pay higher compensation or fees to our employees or consultants
than currently expected and such higher compensation payments may have a negative effect on our operating results. Competition for experienced,
high-quality personnel in the medical device field is intense. We may not be able to hire or retain the necessary personnel to implement
our business strategy. Our failure to hire and retain quality personnel on acceptable terms could impair our ability to develop new products
and services and manage our business effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we engage in future acquisitions or strategic
partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities,
and subject us to other risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may evaluate various acquisition
opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies
or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased operating expenses and cash requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the assumption of additional indebtedness or contingent liabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of our equity securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to certain U.S. and foreign
anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences
for violations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among other matters, U.S.
and foreign anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively
referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants,
consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly,
corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws
can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments,
breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials
and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S.
activities to increase over time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent
registrations and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel,
agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business and operations might be adversely
affected by security breaches, including any cybersecurity incidents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on the efficient
and uninterrupted operation of our computer and communications systems, and those of our consultants, contractors and vendors, which we
use for, among other things, sensitive company data, including our intellectual property, financial data and other proprietary business
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While certain of our operations
have business continuity and disaster recovery plans and other security measures intended to prevent and minimize the impact of IT-related
interruptions, our IT infrastructure and the IT infrastructure of our consultants, contractors and vendors are vulnerable to damage from
cyberattacks, computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic events. We could
experience failures in our information systems and computer servers, which could result in an interruption of our normal business operations
and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches
can cause interruptions in our operations and can result in a material disruption of our product development activities and other business
operations. The loss of data from completed or future studies or clinical trials could result in delays in our research, development or
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or
security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur regulatory investigations and redresses, penalties and liabilities and the development of our products could
be delayed or otherwise adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even though we believe we
carry commercially reasonable business interruption and liability insurance, we may suffer losses as a result of business interruptions
that exceed the coverage available under our insurance policies or for which we do not have coverage. For example, we are not insured
against terrorist or cyber-attacks. Any natural disaster or catastrophic event could have a significant negative impact on our operations
and financial results. Moreover, any such event could delay the development of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in laws or regulations relating
to data protection, or any actual or perceived failure by us to comply with such laws and regulations or our privacy policies, could materially
and adversely affect our business or could lead to government enforcement actions and significant penalties against us, and adversely
impact our operating results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to receive health
information and other highly sensitive or confidential information and data of patients and other third parties (e.g., healthcare providers
who refer patients for scans), which we expect to compile and analyze. Collection and use of this data might raise privacy and data protection
concerns, which could negatively impact our business. There are numerous federal, state and international laws and regulations regarding
privacy, data protection, information security, and the collection, storing, sharing, use, processing, transfer, disclosure, and protection
of personal information and other data, and the scope of such laws and regulations may change, be subject to differing interpretations,
and may be inconsistent among countries and regions we intend to operate in (e.g., the U.S., the EU and Israel), or conflict with other
laws and regulations. The regulatory framework for privacy and data protection worldwide is, and is likely to remain for the foreseeable
future, uncertain and complex, and this or other actual or alleged obligations may be interpreted and applied in a manner that we may
not anticipate or that is inconsistent from one jurisdiction to another and may conflict with other rules or practices including ours.
Further, any significant change to applicable laws, regulations, or industry practices regarding the collection, use, retention, security,
or disclosure of data, or their interpretation, or any changes regarding the manner in which the consent of relevant users for the collection,
use, retention, or disclosure of such data must be obtained, could increase our costs and require us to modify our services and candidate
products, possibly in a material manner, which we may be unable to complete, and may limit our ability to store and process patients&#8217;
data or develop new services and features.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In particular, we will be
subject to U.S. data protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal
and state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been
an increasing focus on privacy and data security issues. Numerous federal and state laws, including state data breach notification laws,
state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure of health-related
and other personal information. Failure to comply with such laws and regulations could result in government enforcement actions and create
liability for us (including the imposition of significant civil or criminal penalties), private litigation and/or adverse publicity that
could negatively affect our business. For instance, California enacted the California Consumer Privacy Act, or the CCPA, on June 28, 2018,
which took effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and
security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private
right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and
potential liability, and many similar laws have been proposed at the federal level and in other states.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we expect to
obtain health information that is subject to privacy and security requirements under the Health Information Technology for Economic and
Clinical Health, or HITECH, and its implementing regulations. The Privacy Standards and Security Standards under the federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA, establish a set of standards for the protection of individually identifiable health
information by health plans, health care clearinghouses and certain health care providers, referred to as Covered Entities, and the business
associates with whom Covered Entities enter into service relationships pursuant to which individually identifiable health information
may be exchanged. Notably, whereas HIPAA previously directly regulated only Covered Entities, HITECH makes certain of HIPAA&#8217;s privacy
and security standards also directly applicable to Covered Entities&#8217; business associates. As a result, both Covered Entities and
business associates are now subject to significant civil and criminal penalties for failure to comply with Privacy Standards and Security
Standards. As part of our normal operations, we expect to collect, process and retain personal identifying information regarding patients,
including as a business associate of Covered Entities, so we expect to be subject to HIPAA, including changes implemented through HITECH,
and we could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information in a manner
that is not authorized or permitted by HIPAA. A data breach affecting sensitive personal information, including health information, also
could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our
business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">HIPAA requires Covered Entities
(like many of our potential customers) and business associates, like us, to develop and maintain policies and procedures with respect
to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards
to protect such information. HITECH expands the notification requirement for breaches of patient-identifiable health information, restricts
certain disclosures and sales of patient-identifiable health information and provides for civil monetary penalties for HIPAA violations.
HITECH also increased the civil and criminal penalties that may be imposed against Covered Entities and business associates and gave state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and its implementing
regulations and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Additionally, certain states have
adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Internationally, many jurisdictions
have or are considering enacting privacy or data protection laws or regulations relating to the collection, use, storage, transfer, disclosure
and/or other processing of personal data, as well as certification requirements for the hosting of health data specifically. Such laws
and regulations may include data hosting, data residency or data localization requirements (which generally require that certain types
of data collected within a certain country be stored and processed within that country), data export restrictions, international transfer
laws (which prohibit or impose conditions upon the transfer of such data from one country to another), or may require companies to implement
privacy or data protection and security policies, enable users to access, correct and delete personal data stored or maintained by such
companies, inform individuals of security breaches that affect their personal data or obtain individuals&#8217; consent to use their personal
data. For example, European legislators adopted the EU&#8217;s GDPR which became effective on May 25, 2018, and are now in the process
of finalizing the ePrivacy Regulation to replace the European ePrivacy Directive (Directive 2002/58/EC as amended by Directive 2009/136/EC).
The GDPR, supplemented by national laws and further implemented through binding guidance from the European Data Protection Board, imposes
more stringent EU data protection requirements and provides for significant penalties for noncompliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Virtually every jurisdiction
in which we expect to operate has established its own data security and privacy legal framework with which we must, and our target customers
will need to, comply, including the rules and regulation mentioned above. We may also need to comply with varying and possibly conflicting
privacy laws and regulations in other jurisdictions. As a result, we could face regulatory actions, including significant fines or penalties,
adverse publicity and possible loss of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we are preparing to
implement various measures intended to enable us to comply with applicable privacy or data protection laws, regulations and contractual
obligations, these measures may not always be effective and do not guarantee compliance. Any failure or perceived failure by us to comply
with our contractual or legal obligations or regulatory requirements relating to privacy, data protection, or information security may
result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy
groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and otherwise
materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens imposed by,
the laws, regulations, and policies that are applicable to the businesses of our customers or partners may limit the adoption and use
of, and reduce the overall demand for, our products and services. Additionally, if third parties we work with violate applicable laws,
regulations, or agreements, such violations may put the data we have received at risk, could result in governmental investigations or
enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy groups or others and could result
in significant liability, cause our customers, partners or patients to lose trust in us, and otherwise materially and adversely affect
our reputation and business. Further, public scrutiny of, or complaints about, technology companies or their data handling or data protection
practices, even if unrelated to our business, industry or operations, may lead to increased scrutiny of technology companies, including
us, and may cause government agencies to enact additional regulatory requirements, or to modify their enforcement or investigation activities,
which may increase our costs and risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Condition and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our financial statements for the year ended
December 31, 2025, contained an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. This
going concern opinion could prevent us from obtaining new financing on reasonable terms or at all and risk our ability to continue operating
as a going concern.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, the Company has
not generated significant revenues from its activities and has incurred substantial operating losses. In part because we have incurred
losses in each year since our inception, our audited financial statements for the period ended December 31, 2025 contain an explanatory
paragraph regarding substantial doubt about our ability to continue as a going concern. These events and conditions, along with other
matters, indicated that a material uncertainty existed as of December 31, 2025, that raises substantial doubt on our ability to continue
as a going concern. The financial statements for the year ended December 31, 2025 have been prepared assuming that we will continue as
a going concern. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations
primarily through the utilization of its current financial resources, sales of its products, and through additional raises of capital.
As of December 31, 2025, we incurred accumulated losses of approximately $80 million. A going concern assessment could materially limit
our ability to raise additional funds through the issuance of equity or debt securities or otherwise in the future. Further financial
statements may also include an explanatory paragraph with respect to our ability to continue as a going concern. Until we can generate
significant recurring revenues, we expect to satisfy our future cash needs through existing cash, debt or equity financing. We expect
to require additional financing to fund our operations in the near future. We cannot be certain that additional funding will be available
to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research
or development plans for, or commercialization efforts with respect to our products and it risks our ability to continue operating as
a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our officers and directors currently beneficially
own 9.2% of our Ordinary Shares. They may therefore be able to exert control over matters submitted to our shareholders for approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, our
officers and directors beneficially own approximately 9.2% of our Ordinary Shares. As a result, these shareholders, if they acted in
concert, could influence matters requiring approval by our shareholders, including the election of directors and the approval of mergers
or other business combination transactions. The interests of these shareholders may not always coincide with our interests or the interests
of other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a limited operating history, have
incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company with a limited operating history. To date, we have focused almost exclusively on developing our INSPIRA ART system, INSPIRA
ART100 system followed by our HYLA blood sensor, VORTX device and Inspira disposables. We have funded our operations to date primarily
through our initial public offering, or IPO, convertible loans and royalty-bearing grants that we received from the Israel Innovation
Authority, or the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have only a limited operating
history upon which you can evaluate our business and prospects. In addition, we have limited experience and have not yet demonstrated
an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
fields, particularly in the medical device industry. To date, we have not generated significant revenue from the sale of our products
(see &#8220;Item 5. Operating and Financial Review and Prospects&#8221; for additional information). We have incurred losses in each year
since our inception, including net losses of approximately $13 million and $11 million for the years ended December 31, 2025 and 2024,
respectively. As of December, 2025, we had an accumulated deficit of approximately $80 million. Substantially all of our operating losses
resulted from costs incurred in connection with our development of our products and from general and administrative costs associated with
our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research and
development expenses to increase in connection with our planned expanded studies. Having obtained marketing approval for one of our products,
if we obtain marketing approval for additional products which are currently under development, we will likely incur significant sales,
marketing and outsourced manufacturing expenses, as well as continued research and development expenses and costs associated with operating
as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future.
Because of the numerous risks and uncertainties associated with developing a medical device, we are unable to predict the extent of any
future losses or when we will become profitable, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
significant losses until and even when we are able to commercialize our products, which we may not be successful in achieving. We anticipate
that our expenses will increase substantially if and as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the research and development of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek regulatory and marketing approvals for our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing, and distribution infrastructure to commercialize our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of our current product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to maintain, protect, and expand our intellectual property portfolio;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek to attract and retain skilled personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">create additional infrastructure to support our operations as a public company and our product candidate development and planned future commercialization efforts; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience any delays or encounter issues with respect to any of the above, including, but not limited to, failed studies, complex results, safety issues or other regulatory challenges that require longer follow-up of existing studies or additional supportive studies in order to pursue marketing approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of our future operating
losses will depend, in part, on the rate of our future expenditures. Even though we obtained regulatory approval to market one of our
products and even if we obtain regulatory approval to market the rest of our products or any future product candidates<sub>,</sub> our
future revenue will depend upon the size of any markets in which our products or any future product candidates receive approval and our
ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors for our products or any future product
candidates. Further, the operating losses that we incur may fluctuate significantly from quarter to quarter and year to year, such that
a period-to-period comparison of our results of operations may not be a good indication of our future performance. Other unanticipated
costs may also arise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not generated significant revenue
from product sales and may never be profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we have received
marketing authorization for one of our products from the FDA and from AMAR, to date, we have not generated significant revenue from product
sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners,
to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize all our products
or any future product candidates. We do not know when, or if, we will generate any such revenue. Our ability to generate future revenue
from product sales will depend heavily on our success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete research and development of our products and any future product candidates in a timely and successful manner;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain regulatory and marketing approval for any product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain and enhance a commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for our products and any future product candidates that is compliant with current good manufacturing practices, or cGMPs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish and maintain supply and, if applicable, manufacturing relationships with third parties that can provide, in both amount and quality, adequate products to support development and the market demand for our products and any future product candidates, if and when approved;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify, assess, acquire and/or develop new product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launch and commercialize any product candidates for which we obtain regulatory and marketing approval, either directly by establishing a sales force, marketing and distribution infrastructure, and/or with collaborators or distributors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">accurately identify demand for our products or any future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expose and educate physicians and other medical professionals to use our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain market acceptance, if and when approved, of our products and any future product candidates from the medical community and third-party payors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure our product candidates are approved for reimbursement from governmental agencies, health care providers and insurers in jurisdictions where they have been approved for marketing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any competing technological and market developments that impact our products and any future product candidates or their prospective usage by medical professionals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, protect and expand our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">avoid and defend against third-party interference or infringement claims;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract, hire and retain qualified personnel; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">locate and lease or acquire suitable facilities to support our clinical development, manufacturing facilities and commercial expansion.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even though we obtained marketing
approval for one of our products and even if all our product candidates are approved for marketing and sale, we anticipate incurring significant
incremental costs associated with commercializing such product and product candidates. Our expenses could increase beyond expectations
if we are required by the FDA, or other regulatory agencies, domestic or foreign, to change our manufacturing processes or assays or to
perform studies in addition to those that we currently anticipate. Even if we are successful in obtaining regulatory approvals to market
all our products or any future product candidates, our revenue earned from such product candidates will be dependent in part upon the
size of the markets in the territories for which we gain regulatory approval for such products, the accepted price for such products,
our ability to obtain reimbursement for such products at any price, whether we own the commercial rights for that territory in which such
products have been approved and the expenses associated with manufacturing and marketing such products for such markets. Therefore, we
may not generate significant revenue from the sale of such products, even if approved. Further, if we are not able to generate significant
revenue from the sale of our approved products, we may be forced to curtail or cease our operations. Due to the numerous risks and uncertainties
involved in product development, it is difficult to predict the timing or amount of increased expenses, or when, or if, we will be able
to achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to raise substantial additional
funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis
may require us to curtail, delay or discontinue our product development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, our
cash and cash equivalents, short-term deposits and long-term deposits were approximately $3.1 million, not including restricted cash of
$98,000, and we had a working capital of approximately $1.6 million and an accumulated deficit of approximately $80 million. Based upon
our currently expected level of operating expenditures, we expect that our existing cash and cash equivalent will only be sufficient to
fund operations through the next six months. We expect that we will require substantial additional capital to operate and to commercialize
our products and we need to expect to seek additional funds to enable us to fund our operations for the text twelve months. Our future
funding requirements will depend on many factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress, results and costs of our ongoing and planned studies and, if applicable, clinical trials of products and any future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost, timing and outcomes of regulatory review of products and any future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of maintaining our own commercial-scale cGMP manufacturing facility, including costs related to obtaining and maintaining regulatory compliance, and/or engaging third-party manufacturers therefor;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, progress, results and costs of product development, testing, manufacturing, preclinical development and, if applicable, clinical trials for any other product candidates that we may develop or otherwise obtain in the future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of our future activities, including establishing sales, marketing and distribution capabilities for any product candidates in any particular geography where we receive marketing approval for such product candidates</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and timing of any collaborative, licensing and other arrangements that we may establish;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our products and any future product candidates. In addition, future financing may not be available in sufficient amounts or on terms acceptable
to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of our securities and
the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price
of our securities to decline. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be required
to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to
acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct
our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage
than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product candidates or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even
if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions
are favorable or if we have specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the development or commercialization, if any, of our products or any other product candidates or be unable to expand our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital would cause dilution
to our existing shareholders, and may adversely affect the rights of existing shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional capital
through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements.
To the extent that we raise additional capital through the issuance of equity or otherwise including through convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a shareholder. Future sales of our Ordinary Shares or of securities convertible into our Ordinary Shares, or the perception that such
sales may occur, could cause immediate dilution and adversely affect the market price of our Ordinary Shares and tradable warrants, or
Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Product Development and Regulatory
Approval</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products and operations are subject
to extensive government regulation and oversight both in the U.S. and abroad and our failure to comply with applicable requirements could
harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our products and
any future products we develop to be regulated by the FDA as medical devices. Our product candidates are subject to extensive regulation
in the U.S. and elsewhere, including by the FDA and its foreign counterparts, the U.S. Department of Justice, or the DOJ, and the U.S.
Health and Human Services-Office of the Inspector General, or the HHS. The FDA and foreign regulatory agencies regulate, among other things,
with respect to medical devices: design, development and manufacturing; testing, labeling, content and language of instructions for use
and storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution; pre-market
clearance and approval; conformity assessment procedures; record keeping procedures; advertising and promotion; recalls and field safety
corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to
occur, could lead to death or serious injury; post-market approval studies; and product import and export.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations our product
is subject to are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability
to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales for any approved product. Failure
to comply with applicable regulations could jeopardize our ability to sell our future products, if cleared or approved, and result in
enforcement actions such as: warning or untitled letters; fines; injunctions; consent decrees; civil penalties; customer notifications;
termination of distribution; recalls or seizures of products; administrative detention of medical devices believed to be adulterated or
misbranded; delays in the introduction of products into the market; operating restrictions; total or partial suspension of production;
refusal to grant future clearances or approvals for new products, new intended uses or modifications to our products; withdrawals or suspensions
of current approvals, resulting in prohibitions on sales of our products; and in the most serious cases, criminal prosecution or penalties.
The occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations
and could result in shareholders losing their entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not receive, or may be delayed in
receiving, the necessary clearances or approvals for our products and failure to timely obtain necessary clearances or approvals for our
products would adversely affect our ability to grow our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., before we can
market a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive
either clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or the FDCA, and/or PMA from the FDA, unless an exemption
applies. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is &#8220;substantially
equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which includes a device that has been previously cleared through
the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device that was originally on
the U.S. market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221;
the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as
the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than
the predicate device. Clinical data are sometimes required to support substantial equivalence. In the process of obtaining PMA approval,
the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including,
but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for
devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Modifications to products
that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to products cleared
through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy
and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to twelve months but can last longer. The process of
obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even
longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of one or more clinical
trials. The FDA may not approve or clear any device which we may seek to have approved or cleared. Any delay or failure to obtain necessary
regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they
may include significant limitations on the indicated uses for the device or other restrictions or requirements, which may limit the market
for the device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., we expect to
take a multi-step approach to the regulatory clearance process. As a first step, we intend to submit a Q-Submission, or Q-Sub, application
to the FDA for our advanced INSPIRA ART (Gen 2) device and may also choose to do so, for the VORTX device. The pre-IDE program was established
in 1995, to provide sponsors a mechanism to obtain FDA feedback on future Investigational Device Exemption, or IDE, applications prior
to their submission. An IDE allows an investigational device to be used in order to collect safety and effectiveness data required to
support a premarket approval application or a premarket notification submission to Food and Drug Administration. Over time, the pre-IDE
program evolved to include feedback on PMAs, Humanitarian Device Exemptions, or HDEs, De Novo requests, and 510(k) submissions, as well
as to address whether a clinical study requires submission of an IDE. To capture this evolution, the HHS 2012 Commitment Letter to Congress
regarding the Medical Device User Fee Amendments of 2012 (MDUFA III) included FDA&#8217;s commitment to institute a structured process
for managing these interactions, referring to them as Pre-Submissions, or Pre-Subs. The Q-Submission Guidance, published on June 2, 2023,
named &#8220;Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program&#8221; implemented the broader
Q-Program, which includes Pre-Subs, as well as additional opportunities to engage with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Early interaction with the
FDA on planned non-clinical and clinical studies, risk determination, and careful consideration of the FDA&#8217;s feedback may improve
the quality of subsequent submissions, shorten total review times, and facilitate the development process for new devices. The FDA believes
that interactions provided within Pre-Subs are likely to contribute to a more transparent review process for the FDA and the submitter.
We intend to align and update our regulatory and clinical plans based on the FDA&#8217;s feedback as part of this Q-sub process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We submitted a 510(k) application
for our INSPIRA ART100 system in September 2023. In May 2024, we received 510(k) class II regulatory clearance. Even with this clearance,
any modification to our INSPIRA ART100 system that has not been previously cleared may require us to submit a new 510(k) premarket notification
and obtain clearance, or submit a PMA and obtain FDA approval prior to implementing the change. Specifically, any modification to a 510(k)-cleared
device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design
or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination
in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with our decisions regarding whether
new clearances or approvals are necessary. We may make modifications or add additional features in the future that we believe do not require
a new 510(k) clearance or approval of a PMA. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications
or PMA applications for modifications to our previously cleared products for which we have concluded that new clearances or approvals
are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we
may be subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination
for future products or modifications to existing products than we had expected, product introductions or modifications could be delayed
or canceled, which could adversely affect our ability to grow our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA can delay, limit or
deny clearance or approval of a medical device for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our product candidates are safe or effective for their intended uses;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the disagreement of the FDA or the applicable foreign regulatory body with the design or the interpretation of data from pre-clinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious and unexpected adverse effects experienced by participants in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manufacturing process or facilities we use may not meet applicable requirements; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to sell our products
in member countries of the European Economic Area, or EEA, our products must comply with the General Safety and Performance Requirements
of the EU Medical Devices Regulation (Regulation (EU) 2017/745). Compliance with these requirements is a prerequisite to be able to affix
the Conformit&#233; Europ&#233;ene, or CE, mark to our products, without which they cannot be sold or marketed in the EEA. To demonstrate
compliance with the general safety and performance requirements we must undergo a conformity assessment procedure, which varies according
to the type of medical device and its classification. Except for low-risk medical devices (Class I non-sterile, non-measuring devices),
where the manufacturer can issue a European Community, or EC, Declaration of Conformity based on a self-assessment of the conformity of
its products with the general safety and performance requirements of the EU Medical Devices Regulation, a conformity assessment procedure
requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a Notified
Body. Depending on the relevant conformity assessment procedure, the Notified Body would typically audit and examine the technical file
and the quality system for the manufacture, design and final inspection of our devices. The Notified Body issues a certificate of conformity
following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer
and their conformity with the general safety and performance requirements. This certificate entitles the manufacturer to affix the CE
mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our products may also
need to comply with the following European Directives in order to be sold in the EEA:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROHS Directive 2011/65/EU of the European Parliament and of the Council of June 8, 2011 on the restriction of the use of certain hazardous substances in electrical and electronic equipment, as amended by (EU) 2017/2102.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WEEE Directive 2012/19/EU of the European Parliament and of the Council of July 4, 2012 on waste electrical and electronic equipment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RED Directive 2014/53/EU of the European Parliament and of the Council of April 16, 2014 on the harmonization of the laws of the Member States relating to the making available on the market of radio equipment and repealing Directive 1999/5/EC Text with EEA relevance. Applicable as of June 13, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery Directive 2006/42/EC of the European Parliament and of the Council of May 17, 2006 on machinery, and amending Directive 95/16/EC</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (GDPR)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products may be required
to comply with additional EU Directives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a general rule, demonstration
of conformity of medical devices and their manufacturers with the general safety and performance requirements and essential requirements
must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal
conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions
of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of
its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.
If we fail to remain in compliance with applicable European laws, regulations and directives, we will be unable to continue to affix the
CE mark to our products, which would prevent us from selling them within the EEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with post-marketing regulatory
requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product
from the market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we receive regulatory clearance
or approval of the products or other future products, we will remain subject to ongoing and pervasive regulatory requirements governing,
among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import, export, registration,
and listing of devices. For example, we are required to submit periodic reports to the FDA as a condition of 510(k) clearance. These reports
include information about failures and certain adverse events associated with the device after its clearance. Failure to submit such reports,
or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its review of the periodic
reports, the FDA might ask for additional information or initiate further investigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations to which we
are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue
or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained the proper regulatory
clearance to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The
FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements
could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled letters or warning letters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls, termination of distribution, administrative detention, or seizure of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer notifications or repair, replacement or refunds;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions or partial suspension or total shutdown of production;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in or refusal to grant our requests for future clearances or approvals or foreign marketing authorizations of new products, new intended uses, or modifications to existing products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals or suspensions of product clearances or approvals, resulting in prohibitions on sales of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these sanctions could
result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA or state
or foreign authorities may change their clearance and approval policies, adopt additional regulations or revise existing regulations,
or take other actions, which may prevent or delay clearance or approval of our future products under development on a timely basis. Such
policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances or approvals,
increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products must be manufactured in accordance
with federal, state and foreign regulations, and we could be forced to recall our devices or terminate production if we fail to comply
with these regulations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The methods used in, and the
facilities used for, the manufacture of our products must comply with the Quality System Regulation, or ISO 13485 standard requirements,
as basic reference for requirements to establish a Quality Management System for the company, which is a complex regulatory scheme that
covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging,
handling, storage, distribution, installation, servicing and shipping of medical devices. As manufacturers of electron radiation-emitting
products, we are also responsible for compliance with the radiological health regulations and certain radiation safety performance standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we are required
to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory
requirements. The FDA enforces the Quality System (QS) Regulation, or QSR through periodic announced or unannounced inspections of medical
device manufacturing facilities, which may include the facilities of subcontractors. Our products are also subject to similar state regulations
and various laws and regulations of foreign countries governing manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our third-party manufacturers
may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. In addition,
failure to comply with applicable FDA or state or foreign requirements or later discovery of previously unknown problems with our products
or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties;
suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of production or distribution;
administrative or judicially imposed sanctions; the FDA&#8217;s refusal to grant pending or future clearances or approvals for our products;
clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us, our suppliers or our employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these actions could
significantly and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be
exposed to product liability claims and we could lose customers and experience reduced sales and increased costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The misuse or off-label use of our products
may harm our reputation in the marketplace and result in injuries that lead to product liability suits or result in costly investigations,
fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly
to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advertising and promotion
of our future products that obtains approval in the U.S. may be heavily scrutinized by the FDA, the DOJ, HHS, state attorneys general,
members of Congress, and the public. In addition, advertising and promotion of any future product that obtains approval outside of the
U.S. will be heavily scrutinized by comparable foreign regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that, if cleared
or approved, our products will be cleared by the requisite regulatory authorities for specific indications. We expect to train our marketing
personnel and direct sales force to not promote our devices for uses outside of the FDA-approved indications for use, or any other regulatory
authority approved indications for use in a relevant territory, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician
from using our devices off-label, when in the physician&#8217;s independent professional medical judgment, he or she deems it appropriate.
There may be increased risk of injury to patients if physicians attempt to use our devices off-label. Furthermore, the use of our devices
for indications other than those approved by the FDA or approved by any foreign regulatory body may not effectively treat such conditions,
which could harm our reputation in the marketplace among healthcare providers and patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA or any state or
foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request
that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition
of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal
penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority,
such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in
significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion
from participation in government healthcare programs and the curtailment of our operations. We may become subject to such actions and,
if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial
condition and results of operations. Equivalent laws and potential consequences exist in foreign jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if our products
are cleared or approved, healthcare providers may misuse our products or use improper techniques if they are not adequately trained, potentially
leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may become
subject to costly litigation by our customers or their patients. As described above, product liability claims could divert management&#8217;s
attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products may cause or contribute to
adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, or any other regulatory authority
in a relevant territory, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial
condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily
or at the direction of the FDA or another governmental authority, could have a negative impact on us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our products or our other
future products receive clearance or approval, we will be subject to the FDA&#8217;s medical device reporting regulations and similar
foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that
one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction
were to recur, could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date
we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware
within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if
it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product.
If we fail to comply with our reporting obligations, the FDA or other regulatory bodies could take action, including warning letters,
untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance
or approval, seizure of our products or delay in clearance or approval of future products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and foreign regulatory
bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design
or manufacture of a product or in the event that a product poses an unacceptable risk to health. Generally, a regulator&#8217;s authority
to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death.
We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us
could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design
deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors
may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending on the corrective
action we take to redress a product&#8217;s deficiencies or defects, the FDA and any other regulatory authority may require, or we may
decide, that we will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device.
Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not
adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters,
product seizure, injunctions, administrative penalties or civil or criminal fines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Companies are required to
maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals
or corrections for our products in the future that we determine do not require notification of the FDA or to any other regulatory authority
in a relevant territory. If the FDA or any other regulatory authority in a relevant territory, disagrees with our determinations, it could
require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our
reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action,
whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract
management from operating our business and may harm our reputation and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject, directly or indirectly,
to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable
to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many federal state and foreign
healthcare laws and regulations apply to medical devices. We may be subject to certain federal and state regulations, including the federal
healthcare programs&#8217; Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving,
or paying any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, ordering or arranging for or recommending
the purchase or order of any item or service for which payment may be made, in whole or in part, under a federal healthcare program such
as Medicare and Medicaid; HIPAA, which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute,
a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services; the
federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity that engages
in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for services not provided as claimed
or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is excluded from
participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; (3) violations
of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment; the federal False Statements Statute, which
prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious or
fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false,
fictitious or fraudulent statement or entry, in connection with the delivery of or payment for healthcare benefits, items, or services;
the federal civil False Claims Act, or the FCA, which prohibits, among other things, knowingly presenting, or causing to be presented
claims for payment of government funds that are false or fraudulent, or knowingly making, using or causing to be made or used a false
record or statement material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing,
or concealing an obligation to pay money to the federal government; and other federal and state false claims laws. The FCA prohibits anyone
from knowingly presenting, conspiring to present, making a false statement in order to present, or causing to be presented, for payment
to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent, claims for items or services
not provided as claimed, or claims for medically unnecessary items or services. This law also prohibits anyone from knowingly underpaying
an obligation owed to a federal program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial measures, such as corporate
integrity agreements in FCA settlements. The DOJ announced in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more
aggressive approach in pursuing individuals as FCA defendants in addition to corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The majority of states also
have statutes similar to the federal Anti-Kickback Statute and false claims laws that apply to items and services reimbursed under Medicaid
and other state programs, or, in several states, that apply regardless of whether the payer is a government entity or a private commercial
entity. The Federal Open Payments, or Physician Payments Sunshine Act, program requires manufacturers of products for which payment is
available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, to track and report annually to the federal
government (for disclosure to the public) certain payments and other transfers of value made to physicians and teaching hospitals as well
as disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests
held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations. Our
failure to appropriately track and report payments to the government could result in civil fines and penalties, which could adversely
affect the results of our operations. In addition, several U.S. states and localities have enacted legislation requiring medical device
companies to establish marketing compliance programs, file periodic reports with the state, and/or make periodic public disclosures on
sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain marketing-related activities including
the provision of gifts, meals or other items to certain healthcare providers. Many of these laws and regulations contain ambiguous requirements
that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions
could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The medical device industry
has been under heightened scrutiny as the subject of government investigations and enforcement actions involving manufacturers who allegedly
offered unlawful inducements to potential or existing customers in an attempt to procure their business, including arrangements with physician
consultants. If our operations or arrangements are found to be in violation of such governmental regulations, we may be subject to civil
and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment of our operations. All of
these penalties could adversely affect our ability to operate our business and our financial results.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not obtain and maintain international
regulatory registrations, clearances or approvals for our products, we will be unable to market and sell our products outside of the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our products outside
of the U.S. are subject to foreign regulatory requirements that vary widely from country to country. Approval procedures vary among countries
and can involve additional testing. The time required to obtain approval outside of the U.S. may differ substantially from that required
to obtain FDA approval. While the regulations of some countries may not impose barriers to marketing and selling our products or only
require notification, others require that we obtain the clearance or approval of a specified regulatory body. Complying with foreign regulatory
requirements, including obtaining registrations, clearances or approvals, can be expensive and time-consuming, and we may not receive
regulatory clearances or approvals in each country in which we plan to market our products, or we may be unable to do so on a timely basis.
The time required to obtain registrations, clearances or approvals, if required by other countries, may be longer than that required for
FDA clearance or approval, and requirements for such registrations, clearances or approvals may significantly differ from FDA requirements.
If we modify our products, we may need to apply for additional regulatory clearances or approvals before we are permitted to sell the
modified product. In addition, we may not continue to meet the quality and safety standards required to maintain the authorizations that
we have received. If we are unable to maintain our authorizations in a particular country, we will no longer be able to sell the applicable
product in that country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory clearance or approval
by the FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance
or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory authorities
in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval in
one country may have a negative effect on the regulatory process in others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legislative or regulatory reforms in the
U.S. or the EU may make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture,
market or distribute our products after clearance or approval is obtained.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take
other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify
our currently cleared products on a timely basis. Over the last several years, the FDA has proposed reforms to its 510(k) clearance process,
and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult
for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming
steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things,
the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates.
These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway,
and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate
devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback
on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were
used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with
Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could
impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance,
or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2019, the FDA
finalized guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain,
well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device
meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety
and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a
list device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to develop product-specific
guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the
guidance documents, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors
seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact
our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business. In September 2023,
the FDA introduced draft guidance regarding best practices for selecting a device in 510(k) submissions to enhance the predictability,
consistency, and transparency of the 510(k) Program. The recommendations focus on characteristics of the predicate, including selecting
a predicate device that was cleared using well-established methods, meets or exceeds expected safety and performance, is without unmitigated
use-related or design-related safety issues, and is without an associated design-related recall. According to the FDA, these practices
will encourage the evolution of safer and more effective medical devices in the 510(k) program over time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, particular common
specifications, or sets of technical and/or clinical requirements (other than a standard) that provide a means of complying with the legal
obligations applicable to a device, process or system, are issued by the EU&#8217;s competent authorities and are mandatory as part of
the CE certification process. The EU competent authorities may establish performance criteria for classes of devices for which we or our
competitors seek or currently have received certification and it is unclear the extent to which such performance standards, if established,
could impact our ability to obtain new CE certifications or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, FDA or any other
relevant regulatory authority, regulations and guidance are often revised or reinterpreted by the FDA or any other regulatory authority,
in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of
existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance
or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal
interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among
other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement
or discontinuance of our products; or additional record keeping.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be promulgated that could prevent, limit
or delay regulatory clearance or approval of our future products. We cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative action, either in the U.S. or abroad. For example, certain policies of the Trump
administration, as well as decisions by the U.S.&#8217; legislative or judicial branches may impact our business and industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 27, 2020, the U.S.
Supreme Court reversed a Federal Circuit decision that previously upheld Congress&#8217; denial of $12 billion in &#8220;risk corridor&#8221;
funding. Congress may consider additional legislation to repeal, or repeal and replace, other elements of the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, On June 17, 2021, the U.S. Supreme Court dismissed
a challenge on procedural grounds that argued that the PPACA is unconstitutional in its entirety because the individual mandate was repealed
by Congress. Thus, the PPACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the PPACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies
and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid
or the PPACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which
among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan
year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering
the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the PPACA will
be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and any potential future healthcare
reform measures of the Trump administration will impact the PPACA and our business. We continue to evaluate the PPACA and its possible
repeal and replacement, as the extent to which any such changes may impact our business or financial condition remains uncertain. If we
are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able
to maintain regulatory compliance, we may lose any marketing approval or clearance that we may have obtained and we may not achieve or
sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the EU, similar political,
economic and regulatory developments may affect our ability to profitably commercialize any of our product candidates, if approved. In
addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may
result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU,
including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter
for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches
to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary
constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service
providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could
prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to
commercialize any products for which we obtain marketing approval. Political, economic and regulatory developments may further complicate
pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU
member states, and parallel trade, i.e., arbitrage between low-priced and high-priced member states, can further reduce prices. There
can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any products, if approved in those countries. In international markets, reimbursement and healthcare
payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2017, the European
Parliament passed the Medical Devices Regulation (Regulation 2017/745), which became effective on May 26, 2021 and repeals and replaces
the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations
would be directly applicable, i.e., without the need for adoption of EEA member state laws implementing them, in all EEA member states
and are intended to eliminate current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation,
among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for
medical devices and ensure a high level of safety and health while supporting innovation. Among other things, the Medical Devices Regulation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establish explicit provisions on manufacturers&#8217; responsibilities for follow-up regarding the quality, performance and safety of devices placed on the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthened rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These modifications may have
an effect on the way we conduct our business in the EEA. We expect that these and other healthcare reform measures that may be adopted
in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price
that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result
in a similar reduction in payments from private payors. Further, there is no guarantee that we can use existing reimbursement codes or
receive reimbursement at all. The implementation of cost containment measures or other healthcare reforms may prevent us from being able
to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. We cannot predict what healthcare
reform initiatives may be adopted in the future. However, it is possible that there will be further legislation or regulation that could
harm the business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative and regulatory reform
measures may have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our industry is highly regulated
and changes in law may adversely impact our business, operations or financial results. The Patient Protection and Affordable Care Act,
as amended by the Health Care and Education Reconciliation Act, or the PPACA, is a sweeping measure intended to, among other things, expand
healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion
of the Medicaid program. Several provisions of the law may affect us and increase certain of our costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare payments to providers of
2% per fiscal year, which went into effect on April 1, 2013. These reductions went into effect in April 2013 and, due to subsequent legislative
amendments to the statute, will remain in effect until 2031.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2013, President
Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several
types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three
to five years. These and new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material
adverse effect on our customers and, accordingly, our financial operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that the PPACA,
as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and an additional
downward pressure on the reimbursement our customers may receive for our products. Further, there have been, and there may continue to
be, judicial and Congressional challenges to certain aspects of the PPACA. For example, the U.S. Tax Cuts and Jobs Act of 2017, or TCJA,
includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual
mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional
in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling,
on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 26, 2021 through
August 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. In addition, on August 16, 2022, President Biden
signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals
purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221;
under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly
established manufacturer discount program. Additional legislative and regulatory changes and judicial challenges to the PPACA, its implementing
regulations and guidance and its policies, remain possible. However, it remains unclear how any new legislation, regulation or challenges
in court might affect the prices we may obtain for any of our products for which regulatory approval is obtained. Any reduction in reimbursement
from Medicare and other government programs may result in a similar reduction in payments from private payers. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate significant revenue, attain profitability
or commercialize our products in scale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the delivery
of healthcare in the EU, including the establishment and operation of health services, is almost exclusively a matter for national, rather
than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of
health care and the pricing and reimbursement of products in that context. Coupled with ever-increasing EU and national regulatory burdens
on those wishing to develop and market products, this could prevent or delay marketing approval of our products or any future product
candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing
approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently unable to
predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect
recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval
of such proposals or reforms could result in a decrease in the price of our securities or limit our ability to raise capital or to enter
into collaboration agreements for the further development and potential commercialization of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inadequate funding for the FDA and other
government agencies and/or potentially shifting priorities under the new administration could hinder their ability to hire, retain or
deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared, approved or commercialized
in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of
our business may rely, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA to
review and clear or approve new products, provide feedback on clinical trials and development programs, meet with sponsors and otherwise
review regulatory submissions can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory,
and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that
may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years
as a result. In addition, government funding of other government agencies that fund research and development activities is subject to
the political process, which is inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at the FDA and
other agencies may also increase the time necessary for new medical devices or modifications to cleared or approved medical devices to
be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, the&#160;Trump&#160;administration
has discussed several changes to the reach and oversight of the FDA, which could affect its relationship with the pharmaceutical industry,
transparency in decision making and ultimately the cost and availability of prescription drugs. Additionally, over the last several years,
the U.S. government has shut down multiple times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and
other government employees and stop critical activities. If funding for the FDA is reduced, FDA priorities change, or a prolonged government
shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, including
our future-planned NDA submission for INSPIRA ART, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Environmental, social and corporate governance
(ESG) issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition
and results of operations and damage our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is an increasing focus
from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and
legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet regulatory requirements
or investor, customer, consumer, employee or other stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship
in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management,
employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation,
brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with
us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Customers, consumers, investors
and other stakeholders are increasingly focusing on environmental issues, including climate change, energy and water use, plastic waste
and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory requirements to reduce
or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements may result in
increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic products
and packaging, other components of our products and their environmental impact on sustainability, or increased customer and consumer concerns
or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products. Complying with
these demands or requirements could cause us to incur additional manufacturing, operating or product development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not adapt to or comply
with new regulations, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding ESG issues, investors
may reconsider their capital investment in our Company, and customers and consumers may choose to stop purchasing our products, which
could have a material adverse effect on our reputation, business or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
effective patent rights for our products and services, we may not be able to compete effectively in our markets. If we are unable to protect
the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success and future revenue
growth will depend, in part, on our ability to protect our patent rights. In addition to the protection afforded by any patents that may
be granted, historically, we have relied on trade secret protection and confidentiality agreements with our employees, consultants, and
contractors to protect proprietary know-how that is not patentable or that we elect not to patent, processes that are not easily known,
knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements of our
product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered
by patents. However, agreements may be breached, trade secrets may be difficult to protect, and we may not receive adequate remedies for
any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently discovered by competitors
or other unauthorized third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no guarantee that
the patent applications that we submitted with regards to our technologies will result in patent registration. In the event of failure
to complete patent registration, our developments will not be proprietary, which might allow other entities to manufacture our products
or design our services and compete with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there is no assurance
that all potentially relevant prior art relating to our patent applications has been found, which can invalidate a patent or prevent a
patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our products
or services, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found
unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications and any future patents may not adequately
protect our intellectual property, products or services and provide exclusivity for our new products or services or prevent others from
designing around our claims. Furthermore, there is no guarantee that third parties will not infringe or misappropriate our patents or
similar proprietary rights. In addition, there can be no assurance that we will not have to pursue litigation against other parties to
assert its rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these outcomes could
impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot obtain and maintain
effective patent rights for our products and services, we may not be able to compete effectively, and our business and results of operations
would be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot provide any assurances
that our trade secrets and other confidential proprietary information will not be disclosed in violation of our confidentiality agreements
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual property could
impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our
trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating
any trade secret.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights of third parties
could adversely affect our ability to commercialize our products and services, and we might be required to litigate or obtain licenses
from third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available
on commercially reasonable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is inherently difficult
to conclusively assess our freedom to operate without infringing on third-party rights. Our competitive position may be adversely affected
if existing patents or patents resulting from patent applications issued to third parties or other third-party intellectual property rights
are held to cover our products or services or elements thereof, or our manufacturing or uses relevant to our development plans. In such
cases, we may not be in a position to develop or commercialize products or services or our product candidates (and any relevant services)
unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned or enter into
a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may also be pending
patent applications that if they result in issued patents, could be alleged to be infringed by our new products or services. If such an
infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new products
or services or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable
terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that we
have failed to identify relevant third-party patents or applications. For example, U.S. patent applications filed before November 29,
2000 and certain U.S. patent applications filed after that date that will not be filed outside the U.S. remain confidential until patents
issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority
is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our
new products or services could have been filed by others without our knowledge. Additionally, pending patent applications which have been
published can, subject to certain limitations, be later amended in a manner that could cover our services, our new products or the use
of our new products. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot
guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully
settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation
and may be prevented from or experience substantial delays in pursuing the development of and/or marketing our new products or services.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
our new products or services that are held to be infringing. We might, if possible, also be forced to redesign our new products so that
we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S. and foreign issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing new products and services.
If our business expands and more patents are issued, the risk increases that our products and services may be subject to claims of infringement
of the patent rights of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, designs or methods of manufacture related to the use or manufacture of our products or services. There may be currently
pending patent applications or continued patent applications that may later result in issued patents that our products or services may
infringe. In addition, third parties may obtain patents or services in the future and claim that use of our technologies infringes upon
these patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any third-party patents
were held by a court of competent jurisdiction to cover aspects of our processes for designs, or methods of use, the holders of any such
patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until
such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not be available on commercially
reasonable terms or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one
or more of our products or services. Defense of these claims, regardless of their merit, would involve substantial litigation expense
and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against
us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties,
redesign our infringing products or services, or obtain one or more licenses from third parties, which may be impossible or require substantial
time and monetary expenditure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent policy and rule changes could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in either the patent
laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of any patents that may issue from our
patent applications or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same
extent as the laws of the U.S. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent
applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all.
We therefore cannot be certain that we were the first to file the invention claimed in our owned and licensed patent or pending applications,
or that we or our licensor were the first to file for patent protection of such inventions. Assuming all other requirements for patentability
are met, in the U.S. prior to March 15, 2013, the first to make the claimed invention without undue delay in filing, is entitled to the
patent, while generally outside the U.S., the first to file a patent application is entitled to the patent. After March 15, 2013, under
the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September 16, 2011, the U.S. has moved to a first to file system.
The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also
affect patent litigation. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding
the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could have a material adverse
effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be involved in lawsuits to protect
or enforce our intellectual property, which could be expensive, time consuming, and unsuccessful. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
intellectual property. If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our new products
or services, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent
litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the U.S. Patent and Trademark Office, or USPTO, or made a misleading statement, during prosecution. Under the Leahy-Smith
Act, the validity of U.S. patents may also be challenged in post-grant proceedings before the USPTO. The outcome following legal assertions
of invalidity and unenforceability is unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Derivation proceedings initiated
by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with respect to our patent
or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have
a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our new products or services
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results
of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative,
it could have a material adverse effect on the price of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in, or right to compensation, with respect to our current
patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have
inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our products or services.
Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting, and defending
patents on products and services, as well as monitoring their infringement in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries can be less extensive than those in the U.S. In addition, the laws of
some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may use our technologies
develop their own products or services in jurisdictions where we have not obtained patent protection to and may export infringing products
or services to territories where we have patent protection, but where patents are not enforced as strictly as they are in the U.S. These
products or services may compete with our products or services. Future patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
which could make it difficult for us to stop the marketing of competing products or services in violation of our proprietary rights generally.
Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert
our efforts and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted
narrowly, put the issuance of our patent applications at risk, and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate, and any damages or other remedies that we may be awarded, may not be commercially meaningful.
Accordingly, our efforts to monitor and enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Ownership of our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our securities is likely
to continue to be highly volatile, and you may not be able to resell your Ordinary Shares at or above the price that you paid.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since we completed our IPO
in July 2021, the trading price of our Ordinary Shares and Warrants have been volatile and is likely to continue to be volatile. The stock
market in general, and the market for medical device companies in particular, has experienced extreme volatility that has often been unrelated
to the operating performance of particular companies, which has resulted in decreased share prices for many companies notwithstanding
the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially
worsening economic conditions, inflation and other adverse effects, may negatively affect the market price of our securities, regardless
of our actual operating performance. As a result of this volatility, you may not be able to sell your securities at or above the price
you paid. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market
price of our securities:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inability to obtain the approvals necessary to commence further clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsatisfactory results of clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Announcements of innovations or new products by us or our competitors; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse actions taken by regulatory authorities with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any adverse changes to our relationship with manufacturers or suppliers; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any intellectual property infringement actions in which we may become involved; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Achievement of expected product sales and profitability or our failure to meet expectations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our commencement of, or involvement in, litigation; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any major changes in our board of directors or management; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to recruit and retain qualified regulatory, research and development personnel; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislation in the U.S. relating to the sale or pricing of medical devices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The depth of the trading market in our Ordinary Shares and Warrants; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business interruptions resulting from a local or worldwide pandemic or other health epidemic, geopolitical actions, including war and terrorism, or natural disasters; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The granting or exercise of employee share options or other equity awards; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in investors and securities analysts&#8217; perception of the business risks and conditions of our business. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the stock market
in general, and Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of small companies. Broad market and industry factors may negatively affect the market price of our Ordinary
Shares and Warrants, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related
factors beyond our control may cause our share price to decline rapidly and unexpectedly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of our Ordinary Shares could
reduce the market price of our securities.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantial sales of our Ordinary
Shares on Nasdaq may cause the market price of our securities to decline. Sales by us or our security holders of substantial amounts of
our Ordinary Shares, or the perception that these sales may occur in the future, could cause a reduction in the market price of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of any additional
Ordinary Shares or any securities that are exercisable for or convertible into Ordinary Shares, may have an adverse effect on the market
price of our Ordinary Shares and will have a dilutive effect on our existing shareholders and holders of Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment
in our securities as a source for any future dividend income. Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any,
received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board
of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The JOBS Act will allow us to postpone the
date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information
we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market
price of our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For so long as we remain an
&#8220;emerging growth company&#8221; as defined in the JOBS Act, we take advantage of certain exemptions from various requirements that
are applicable to public companies that are not &#8220;emerging growth companies&#8221; including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&#8217;s report on the financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to take advantage
of these exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an emerging growth company until the
earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of the completion of our IPO, (b) in which
we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, as defined
in the rule under the Exchange Act, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the
prior three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict if investors
will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive
as a result, there may be a less active trading market for our securities, and our market prices may be more volatile and may decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a &#8220;foreign private issuer&#8221;
we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable SEC and Nasdaq
requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our status as a foreign private
issuer also exempts us from compliance with certain SEC laws and regulations and certain regulations of Nasdaq, including the proxy rules,
the short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination
of directors and executive compensation. In addition, we are not required under the Exchange Act to file current reports and financial
statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act,
and we are generally exempt from filing quarterly reports with the SEC. Also, although the Israeli Companies Law, 5759-1999 and the regulations
promulged thereunder, or the Companies Law, requires us to disclose the annual compensation of our five most highly compensated senior
officers on an individual basis (rather than on an aggregate basis), this disclosure will not be as extensive as that required of a U.S.
domestic issuer. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure)
promulgated under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These exemptions and leniencies
will reduce the frequency and scope of information and protections to which you are entitled as an investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The determination of foreign
private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter and,
accordingly, the next determination will be made with respect to us on June 30, 2026. In the future, we would lose our foreign private
issuer status if a majority of our shareholders, directors or management are U.S. citizens or residents and we fail to meet additional
requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance costs to us under U.S. securities
laws as a U.S. domestic registrant may be significantly higher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be a &#8220;passive foreign investment
company,&#8221; or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable
year. There generally would be negative tax consequences for U.S. taxpayers that are holders of the securities if we are or were to become
a PFIC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the projected composition
of our income and valuation of our assets, we do not expect that we will be treated as a PFIC for 2025 and we do not expect to become
a PFIC in the future, although there can be no assurance in this regard. The determination of whether we are a PFIC is made on an annual
basis and will depend on the composition of our income and assets from time to time. We will be treated as a PFIC for U.S. federal income
tax purposes in any taxable year in which either (1) at least 75% of our gross income is &#8220;passive income&#8221; or (2) on average
at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive income for this purpose
generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions
and from the sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of
the temporary investment of funds, including those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC,
a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by
value) is taken into account. The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections
of future income and assets which are relevant to this determination. In addition, our PFIC status may depend in part on the market value
of the securities. Accordingly, there can be no assurance that we currently are not or will not become a PFIC in the future. If we are
a PFIC in any taxable year during which a U.S. taxpayer holds the securities, such U.S. taxpayer would be subject to certain adverse U.S.
federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &#8220;qualified electing fund&#8221;,
or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess distributions&#8221; to the U.S. taxpayer, and any gain realized
on the sale or other disposition of our securities by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer&#8217;s
holding period for our securities; (2) the amount allocated to the current taxable year and any period prior to the first day of the first
taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years
would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge
for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year. In addition,
if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect to which we have determined that
we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S. taxpayers that have held
our securities during a period when we were a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC in subsequent
years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer can make a QEF election
by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. We do not intend to notify
U.S. taxpayers that hold our securities if we believe we will be treated as a PFIC for any taxable year in order to enable U.S. taxpayers
to consider whether to make a QEF election. In addition, we do not intend to furnish such U.S. taxpayers annually with information needed
in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries are
a PFIC. U.S. taxpayers that hold our securities are strongly urged to consult their tax advisors about the PFIC rules, including tax return
filing requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market election with respect to our
securities in the event that we are a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to securities litigation,
which is expensive and could divert management attention.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, companies that
have experienced volatility in the market price of their shares have been subject to securities class action litigation. We may be the
target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#8217;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant
liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations
or publish negative reports regarding our business or our securities, our share price and trading volume could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our
market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover
us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our securities,
or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst
who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial
markets, which in turn could cause the price of our securities or trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience future dilution as a
result of future equity offerings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to raise additional
capital, we may in the future offer additional Ordinary Shares or other securities convertible into or exchangeable for Ordinary Shares
at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering
at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other
securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional Ordinary
Shares, or securities convertible or exchangeable into Ordinary Shares, in future transactions may be higher or lower than the price per
share paid by investors in this offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may need additional financing in the
future. We may be unable to obtain additional financing or if we obtain financing it may not be on terms favorable to us. You may lose
your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current plans,
we believe our existing cash and cash equivalents will be sufficient to fund our operating expense and capital requirements for the next
six months. We expect that we will require substantial additional capital to operate and to commercialize our products and we expect to
seek additional funds to enable us to fund our operations for the next twelve months. We may be unable to obtain additional funds through
financing activities, and if we obtain financing it may not be on terms favorable to us. If we are unable to obtain additional funds on
terms favorable to us, we may be required to cease or reduce our operating activities. If we must cease or reduce our operating activities,
you may lose your entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment
in Ordinary Shares as a source for any future dividend income.&#160;Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any,
received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board
of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Israeli Law and Our Operations
in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our principal executive offices, most of
our research and development activities and other significant operations are located in Israel, and, therefore, our results may be adversely
affected by political, economic and military instability in Israel, including the attack by Hamas and other terrorist organizations from
the Gaza Strip and Israel&#8217;s war against them.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our executive offices, corporate
headquarters and principal research and development facilities are located in Israel. In addition, all of our officers and directors are
residents of Israel. Accordingly, political, economic and military and security conditions in Israel and the surrounding region may directly
affect our business. Any conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption
or curtailment of trade between Israel and its present trading partners could adversely affect our operations. Ongoing and revived hostilities
in the Middle East or other Israeli political or economic factors, could harm our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the October 7, 2023
attacks by Hamas terrorists in Israel&#8217;s southern border, Israel declared war against Hamas and since then, Israel has been involved
in military conflicts with Hamas, Hezbollah, a terrorist organization based in Lebanon, and Iran, both directly and through proxies like
the Houthi movement in Yemen and armed groups in Iraq and other terrorist organizations. Additionally, following the fall of the Assad
regime in Syria, Israel has conducted limited military operations targeting the Syrian army, Iranian military assets and infrastructure
linked to Hezbollah and other Iran-supported groups.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 13, 2025, Israel launched
a strike against Iran, aimed to disrupt Iran&#8217;s capacity to coordinate or launch hostilities against Israel. Iran has retaliated
in response, firing missiles and drones at Israeli military and civilian infrastructure. More recently, in February 2026, hostilities
between Israel and Iran escalated again. In late February 2026, Israel, together with the U.S., conducted a major joint military campaign
of air and missile strikes against targets in Iran, which triggered a broad Iranian response and contributed to significant regional instability.
In addition, in early March 2026, Israel has been engaged with Hezbollah in Lebanon, that has been launching missile, rocket, and shooting
attacks against Israeli military sites, troops, and Israeli towns. In response to these attacks, Israel has carried out a number of targeted
strikes on sites associated with Hezbollah in Lebanon.&#160;The situation remains highly fluid, and we are unable to predict when, or
on what terms, this escalation will be resolved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although certain ceasefire
agreements have been reached with Hamas, and the level of hostilities has since decreased, the situation remains volatile, with the potential
for escalation into a broader regional conflict involving additional terrorist organizations and possibly other countries, including as
a result of instability arising from developments in Syria. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The vicissitudes of the multi-front
conflict are difficult to predict, as are such conflict&#8217;s economic implications on the Company&#8217;s business and operations and
on Israel&#8217;s economy in general. The potential deterioration of Israel&#8217;s economy, as a direct and indirect result of these
events, may have a material adverse effect on the Company and its ability to effectively conduct its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the current
multi-front conflict, Israeli military reservists have been called up to perform military service, four of our employees have been called
up. One employee is engaged in reserve duty as of March 22, 2026. There can be no guarantee that other employees will not be called up
again. Not any of the employees called up holds a key position in our Company. Additional employees may be called up, for service, and
such persons may be absent for an extended period of time. As a result, our operations may be disrupted by such absences, which in turn
may materially and adversely affect our business, prospects, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The State of Israel and Israeli
companies have been the subject of boycotts, divestment and sanctions in the past from state and non-state actors. These actions could
expand in number and scope and may have an adverse impact on our operating results, financial condition or the expansion of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli government has
pursued extensive changes to Israel&#8217;s judicial system. In response to the foregoing developments, individuals, organizations and
institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively impact the business environment
in Israel due in part to the reluctance of foreign investors to invest or transact business in Israel, increased volatility in foreign
exchange rates involving the Israeli new shekel, downgrades in the credit rating of Israel, increased volatility in securities markets,
and other changes in macroeconomic conditions. To the extent that any reaction to judicial reform affect the Israeli economy, they may
have an adverse effect on our business, our results of operations and our ability to raise additional funds, if deemed necessary by our
management and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The termination or reduction of tax and
other incentives that the Israeli government provides to Israeli companies may increase our costs and taxes.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli government currently
provides tax and capital investment incentives to Israeli companies, as well as grant and loan programs relating to research and development
and marketing and export activities. In recent years, the Israeli government has reduced the benefits available under these programs and
the Israeli governmental authorities may in the future further reduce or eliminate the benefits of these programs. We may take advantage
of these benefits and programs in the future; however, there can be no assurance that such benefits and programs will be available to
us. If we qualify for such benefits and programs and fail to meet the conditions thereof, the benefits could be canceled and we could
be required to refund any benefits we might already have enjoyed and become subject to penalties. Additionally, if we qualify for such
benefits and programs and they are subsequently terminated or reduced, it could have an adverse effect on our financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be required to pay monetary remuneration
to our Israeli employees for their inventions, even if the rights to such inventions have been duly assigned to us. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We enter into agreements with
our Israeli employees pursuant to which such individuals agree that any inventions created in the scope of their employment are either
owned exclusively by us or are assigned to us, depending on the jurisdiction, without the employee retaining any rights. A portion of
our intellectual property has been developed by our Israeli employees during their employment for us. Under the Israeli Patent Law, 5727-1967,
or the Patent Law, inventions conceived by an employee during the course of his or her employment and within the scope of said employment
are considered &#8220;service inventions.&#8221; Service inventions belong to the employer by default, absent a specific agreement between
the employee and employer otherwise. The Patent Law also provides that if there is no agreement regarding the remuneration for the service
inventions, even if the ownership rights were assigned to the employer, the Israeli Compensation and Royalties Committee, or the Committee,
a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for these inventions. The Committee
has not yet determined the method for calculating this Committee-enforced remuneration. While it has previously been held that an employee
may waive his or her rights to remuneration in writing, orally or by conduct, litigation is pending in the Israeli labor court is questioning
whether such waiver under an employment agreement is enforceable. Although our Israeli employees have agreed that we exclusively own any
rights related to their inventions, we may face claims demanding remuneration in consideration for employees&#8217; service inventions.
As a result, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to
litigate such claims, which could negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We received Israeli government grants for
certain of our research and development activities, the terms of which may require us to pay royalties and to satisfy specified conditions
in order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy these conditions, we may be required
to pay penalties and refund grants previously received.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts have been financed in part through royalty-bearing and non-royalty-bearing grants in an aggregate amount of $1,194,000 that we
received from the IIA as of December 31, 2025. With respect to the royalty-bearing grants we are committed to pay royalties at a rate
of 3% on sales proceeds from our products up to the total amount of grants received, linked to the U.S. dollar and bearing interest. For
IIA grants approved by the IIA prior to January 1, 2024 but which are outstanding thereafter, as of January 1, 2024 the annual interest
is calculated at a rate based on the 12-month Secured Overnight Financing Rate, or SOFR, as published by the CME Group or any authorized
body of the Federal Reserve on the first trading day of each year, or at an alternative rate published by the Bank of Israel plus 0.71513%;
and, for grants approved on or following January 1, 2024 the annual interest will be the higher of (i)12 month SOFR, plus 1%, or (ii)
a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regardless of any royalty
payment, we are further required to comply with the requirements of the Israeli Encouragement of Industrial Research and Development Law,
5744-1984, as amended, and related regulations, or the Research Law, with respect to those past grants. When a company develops know-how,
technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer of such know-how, and the
transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval
of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer to third parties inside or outside
of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. We may not receive those
approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development
out of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to enforce covenants
not-to-compete under current Israeli law that might result in added competition for our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have non-competition agreements
with all of our employees, all of which are governed by Israeli law. These agreements prohibit our employees from competing with or working
for our competitors, generally during their employment and for up to 12 months after termination of their employment. However, Israeli
courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those provisions for relatively
brief periods of time in restricted geographical areas, and only when the employee has obtained unique value to the employer specific
to that employer&#8217;s business and not just regarding the professional development of the employee. If we are not able to enforce non-compete
covenants, we may be faced with added competition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law and our amended
and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, which could prevent
a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example,
a merger may not be consummated unless at least 50 days have passed from the date on which a merger proposal is filed by each merging
company with the Israel Registrar of Companies and at least 30 days have passed from the date on which the shareholders of both merging
companies have approved the merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover,
a tender offer for all of a company&#8217;s issued and outstanding shares can only be completed if the acquirer receives positive responses
from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires approval of a majority of the
offerees that do not have a personal interest in the tender offer, unless, following consummation of the tender offer, the acquirer would
hold at least 98% of our outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance of the tender
offer, may, at any time within six months following the completion of the tender offer, claim that the consideration for the acquisition
of the shares does not reflect their fair market value, and petition an Israeli court to alter the consideration for the acquisition accordingly,
unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights, and the
acquirer or the company published all required information with respect to the tender offer prior to the tender offer&#8217;s response
date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel
exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent
as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent
on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction
during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect
to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no
disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our merger with another
company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult to enforce a judgment
of a U.S. court against us and our executive officers and directors in Israel or the U.S., to assert U.S. securities laws claims in Israel
or to serve process on our executive officers and directors and these experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated in Israel.
Substantially all of our executive officers and directors reside outside of the U.S., and all of our assets and most of the assets of
these persons are located outside of the U.S. Therefore, a judgment obtained against us, or any of these persons, including a judgment
based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the U.S. and may not be enforced
by an Israeli court. It also may be difficult for you to effect service of process on these persons in the U.S. or to assert U.S. securities
law claims in original actions instituted in Israel. Additionally, it may be difficult for an investor, or any other person or entity,
to initiate an action with respect to U.S. securities laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation
of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an
Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found
to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly
process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses
the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able
to collect any damages awarded by either a U.S. or foreign court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Your rights and responsibilities as a shareholder
will be governed in key respects by Israeli laws, which differs in some material respects from the rights and responsibilities of shareholders
of U.S. companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rights and responsibilities
of the holders of our securities are governed by our amended and restated articles of association and by Israeli law. These rights and
responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies. In particular,
a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing
its obligations towards the company and other shareholders, and to refrain from abusing its power in such company, including, among other
things, in voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s amended and restated articles
of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions requiring
shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder
who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent
the appointment of a director or executive officer in the company has a duty of fairness toward the company. There is limited case law
available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted
to impose additional obligations and liabilities on holders of our securities that are not typically imposed on shareholders of U.S. companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. <span style="text-transform: uppercase">INFORMATION ON THE
COMPANY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_013"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>History and Development of the Company.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an Israeli corporation
based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd. On April 10, 2018, our name
was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira Technologies Oxy B.H.N. Ltd.
On July 16, 2021, our Ordinary Shares and the Warrants issued in our IPO began trading on Nasdaq under the symbols &#8220;IINN&#8221;
and &#8220;IINNW&#8221;, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone number in Israel is +972 996 644 88. Our website address
is <i>www.inspira-technologies.com</i>. The information contained on our website or available through our website is not incorporated
by reference into and should not be considered a part of this annual report on Form 20-F, and the reference to our website in this annual
report on Form 20-F is an inactive textual reference only. Puglisi &amp; Associates is our agent in the U.S., and its address is 850 Library
Avenue, Suite 204, Newark, Delaware 19711.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by
the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable
to other public companies that are not &#8220;emerging growth companies&#8221; such as not being required to comply with the auditor attestation
requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. We could remain an &#8220;emerging growth
company&#8221; for up to five years, or until the earliest of (a)&#160;the last day of the first fiscal year in which our annual gross
revenues exceeds $1.235&#160;billion, (b)&#160;the date that we become a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2
under the Exchange Act, which would occur if the market value of our Ordinary Shares that are held by non-affiliates exceeds $700&#160;million
as of the last business day of our most recently completed second fiscal quarter, or (c)&#160;the date on which we have issued more than
$1&#160;billion in nonconvertible debt during the preceding three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
as defined by the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer also exempts us from compliance
with certain laws and regulations of the SEC and certain regulations of the Nasdaq Capital Market, including the proxy rules, the short-swing
profits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and
executive compensation. In addition, we are not required to file annual, quarterly and current reports and financial statements with the
SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2025, 2024, and 2023 our capital expenditures were $103,000, $164,000, and $206,000, respectively. Our current capital expenditures
are primarily for computers, research and development equipment and office improvements substantially all in Israel, and we expect to
finance these expenditures primarily from cash on hand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_014"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Overview.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company the research, development, manufacturing, and commercialization of proprietary life support technologies. We aim for our
technology to supersede and revolutionize the global mechanical ventilation market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Mechanical Ventilation &#8211; Major Disadvantages</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An estimated up to 20 million patients each year
in ICUs are treated with invasive mechanical ventilation. Mortality rates among patients undergoing prolonged mechanical ventilation may
exceed 50%. Mechanical ventilators are typically used when patients are unable to breathe adequately on their own due to acute respiratory
failure and require assisted breathing provided by a machine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During mechanical ventilation,
patients are generally placed under heavy sedation or medically induced coma, and a tube is inserted into the airway. The ventilator then
delivers oxygen-rich air into the lungs to facilitate the transfer of oxygen into the bloodstream and vital organs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Mechanical Ventilation &#8211; Associated Medical Complications</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patients can often experience
complications associated with the use of mechanical ventilators, such as increased risk, costs of care, extended lengths of stay, frequent
incidence of infections, ventilator dependence and high mortality rates. Associated complications may include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bacterial Infections: </b>The tube in the patient&#8217;s airways can bring bacteria into the lungs, causing infections like pneumonia.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lung Damage: </b>The positive pressure from the ventilator can damage patient lungs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collapsed Lung</b>: If part of patient lung is weak, it might develop a hole, causing the lungs to collapse.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Heart and blood flow changes</b>: Can decrease patient blood pressure or raise patient heart rate, with less oxygen reaching the blood (decreased perfusion).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prolonged Ventilation</b>: The tube from the mouth is replaced with a tube inserted through a small cut (incision) in the patient&#8217;s neck.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prolonging the dying process</b>: If a patient is unlikely to recover from its condition, mechanical ventilation may prolong the dying process. This can cause unnecessary suffering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART novel technology
could potentially assist those ICU patients who are placed on mechanical ventilators. To overcome the risks and medical complication typically
associated with this treatment methodology, the INSPIRA ART is designed to treat the patients while allowing patients to be awake, boosting
oxygen saturation levels to 95% or higher in minutes with small volumes of blood and monitoring patient blood with the HYLA blood sensor
technology for the rapid detection of life-threatening medical conditions. This technology will potentially make the treatment suitable
in the future to migrate from ICUs to emergency rooms, medical units, emergency medical services and smaller rural hospitals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">INSPIRA ART is designed to
enable the following features:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patients are treated awake and without mechanical ventilation. </b>No coma; no tube in the throat; potentially reduces hospital overnight stays.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Oxygen is delivered straight into the blood, with carbon dioxide removed</b>. No lung infection; no lung injury.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#9679;</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Blood parameters measured continuously and in real-time</b>. Early detection of changes; provides decision-making assistance data.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>INSPIRA ART &#8211; Targeted Advantages </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART is being designed
to enable a patient&#8217;s body and vital organs to receive the necessary amount of oxygen. We intend for our INSPIRA ART system to be
a low-cost, high-volume solution for critical care patients requiring advanced respiratory support. It is intended to provide an alternative
to mechanical ventilation, so that patients with respiratory failure will be able to recover from their lung condition without being subjected
to the risk of developing the various common complications brought on by intubation and mechanical ventilation. Our goal is to support
healthcare systems by providing a practical and portable solution facilitating the treatment of respiratory failure, without the need
for mechanical ventilation, and with the ability to deploy INSPIRA ART systems in and outside of ICUs to an ambulatory treatment that
can be administered in all hospital wards as well as in ambulances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our INSPIRA ART system
remains in development, has not been tested in humans, and is not cleared or approved by the FDA or other foreign regulatory bodies, we
believe that our INSPIRA ART has potential competitive advantages over FDA-approved treatments, which are discussed in the table below.
Subject to regulatory clearances, we believe that our product will enable small medical teams to perform a simple bedside procedure, inserting
our dual lumen cannula into the jugular vein. The INSPIRA ART is being designed to enable patients to be treated while awake and breath
spontaneously, which may also result in potentially reducing the need or time of weaning off the INSPIRA ART. Accordingly, our INSPIRA
ART system has the potential to minimize patients&#8217; lengths of stay and costs in the ICU, rehabilitation period in the hospital,
and re-admissions compared to mechanical ventilation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While our INSPIRA ART system
could potentially have unique advantages in comparison to currently available solutions used to provide life support, there are numerous
potential risks that might be associated with the use of our INSPIRA ART system. Such risks may include low blood flow that could be associated
with generation of thrombi, mechanical damage to the superior vena cava, generation of a systemic inflammatory response due to bio-compatibility
issues, allergic reactions to catheter or its components, decreased venous returns, local venous bleeding following the extraction of
our INSPIRA ART system or erroneous puncture of an artery during the insertion of our product. Additionally, any foreign material in a
body increases the risk of infections and the patient&#8217;s membrane might be clogged for a short period of time. Finally, an individual
patient&#8217;s requirements for gas exchange might significantly differ from the average, which means that the use of our INSPIRA ART
system might not meet minimum requirements for blood saturation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the main advantages
of our INSPIRA ART system is that there is no anticipated need for an induced coma because there is no intubation involved, and the treated
patient stays awake. Our INSPIRA ART system has yet to be tested in humans and, as such, these claims of a potential advantage in humans
are unproven and speculative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have developed and continue
to develop the following technologies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The INSPIRA ART100</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 system
utilizes a technique that circulated the patient&#8217;s blood, adding oxygen to the blood and removes carbon dioxide, with the enriched
blood being circulated back to the patient, taking over the functionality of the heart and/or lungs in critical care patients undergoing
life-saving procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Designed in collaboration
with leading U.S. clinicians, the INSPIRA ART100 cardiopulmonary bypass system combines cutting-edge technology with intuitive design
to optimize patient care during crucial times.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 is planned
to be integrated with the HYLA, a continuous blood monitoring technology designed to potentially detect real-time changes in patient condition.
In November 2025, we announced that we completed the clinical study for our HYLA is undergoing clinical evaluations for development purposes
at Sheba Hospital in patients undergoing open-heart procedures..</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The delivered INSPIRA ART100
systems will be distributed to sales targets across hospitals in the U.S., with a view to collaborating with such hospital. We believe
that the delivery of the INSPIRA&#160;ART100 in the U.S. market serves our goal is to introduce physicians and perfusionists to our technology
and brand via initial deployments at leading hospitals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 system&#8217;s
design and advanced capabilities provide a comprehensive platform of efficiency, compatibility and performance, enabling medical technologies
companies to refine and optimize the products for improved patient care. The system features advanced software that navigates the perfusionist
through the setup process, provides alerts while offering potential troubleshooting solutions. The system has a compact design, with extended
battery life to support intra patient transfer in hospitals and is has been uniquely designed to compatible with various disposable parts,
allowing for flexible customization of tubing and oxygenators, which simplifies purchasing and inventory management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 50%"><img alt="" src="image_006.jpg"/></td>
  <td style="vertical-align: middle; text-align: center; width: 50%"><img alt="" src="image_007.jpg"/>&#160;</td>
  </tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 has received
FDA 510(k) regulatory clearance for use in an extracorporeal perfusion circuit to pump blood during short-duration cardiopulmonary bypass
procedures lasting 6 hours or less.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2024, we announced
a program to explore the applicable use of the INSPIRA ART100 for an artificial womb for neonates in need of respiratory support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2024, we announced
that we had signed a collaboration term sheet with Beilinson Hospital for the evaluation of the INSPIRA ART100, under which Beilinson
Hospital would provide us with access to the internally logged data and diagnostics from the use of it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2025, we announced
that we were preparing for a potential ramp-up of the INSPIRA ART100 in light of the outbreak of human metapneumovirus in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2025, we further
announced that we had modified the INSPIRA ART100 to integrate a given hospital&#8217;s established procedures and safety practices and
to include system-activated alarm troubleshooting uniquely designed to provide valuable direction when time is of the essence and user
anxiety is running high. We also integrated a prominent screen with advanced software that displays information in an accessible and visible
manner during complicated and challenging care situations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we announced
that we have successfully completed the installation, training program and operational readiness for its INSPIRA ART100 system for cardiopulmonary
bypass procedures at one of New York&#8217;s premier hospitals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2025, we announced
the successful completion of the first human treatment using our ART100 system in a critical life-support procedure. The procedure was
successfully performed by expert physicians at Westchester Medical Center in New York State, marking the first real-world implementation
of our innovative technology. During the life-support procedure, the INSPIRA ART100 effectively provided comprehensive heart and lung
support by oxygenating and circulating the patient&#8217;s blood. Following the procedure, the patient was safely transitioned off the
system, demonstrating its effective support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2025, we announced
that ART100 has been approved by Israel&#8217;s largest healthcare provider to undergo a clinical validation by leading physicians who
intend to use the innovative life-support and diagnostic device during organ transplant procedures. As part of this advancement, we deployed
ART100 system at one of Israel&#8217;s renowned medical centers affiliated with the largest health care provider. Additionally, in May
2025, we announced a strategic shift to accelerate the commercialization of ART100 system, while maintaining the development and regulatory
pathways of our portfolio of products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2025, we announced
that we have scaled-up our production capabilities for ART100 system, in response to expected demand from a European governmental authority
with which we were in advanced-stage procurement negotiations. Additionally, in June 2025, we announced that the ART100 system has been
successfully integrated into real-world clinical workflows at leading tier-one U.S. hospitals over the past several months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2025, we announced
that a top U.S. hospital, has expanded its clinical use of the INSPIRA&#8482; ART100 system to lung transplantation procedures, one of
the most demanding applications in advanced respiratory care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2026, we announced
that the ART100 system has completed its full clinical evaluation and advanced to a budgeted procurement execution process at a leading
U.S. academic medical center. The ART100 became our first system at this institution to complete a clinical evaluation and to transition
from pilot use to standard clinical workflow, following the successful treatment of approximately 30 patients across multiple medical
indications: life-saving procedures, surgeries and transplants. Based on consistent clinical performance and repeat utilization by medical
staff, the ART100 systems have now been incorporated into that medical center&#8217;s routine workflow, with no remaining open clinical
evaluation phase.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Feb<span style="font-family: Times New Roman, Times, Serif">ruary</span>
2026, we announce<span style="font-family: Times New Roman, Times, Serif">d</span> that we secured official vendor approval from Clalit
Health Services, the world's second-largest <span style="font-family: Times New Roman, Times, Serif">Health Maintenance Organization</span>,
enabling the immediate procurement and deployment of its INSPIRA ART100 medical system across Clalit's extensive network of hospitals
and clinics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 50%"><img alt="" src="image_008.jpg"/></td>
  <td style="text-align: center; width: 50%"><img alt="" src="image_009.jpg"/>&#160;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>HYLA Blood
Sensor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA is being designed
to continuously test and monitor blood and key parameters, including for oxygen deficiencies in real-time without the need to take intermittent
blood draws. The HYLA is designed to perform real-time analysis of blood gases for patients undergoing medical procedures or requiring
more frequent patient monitoring. The HYLA is designed to enable the measurement and tracking of blood oxygen levels and other key indicators
that may reflect sudden changes in medical conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA was tested as part
of the development strategy in a clinical evaluation study in a group of six patients undergoing open-heart procedures at Sheba Hospital
in Israel. The HYLA is designed to measure and accumulate thousands of sampled blood parameter measurements during medical procedures,
with the data being simultaneously validated against other types of blood tests and equipment currently in use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The HYLA may expand our market
offering across critical care applications and multiple market segments, designed for both integration and standalone use. The product
is being developed as an integrated component of the INSPIRA ART100 and INSPIRA ART systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In developing the blood sensor
line, we use in-house lab testing as well as hospital collaborations for the purpose of clinical research and development. This approach
has enabled us to define the blood sensor&#8217;s disposable materials and methods. We also plan to offer a standalone version of the
HYLA blood sensor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, we announced
that we had integrated the new oxygenation indicator into the HYLA, designed to enable the continuous monitoring of tissue oxygenation
and early hypoxia detection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;In September 2025, we
presented HYLA blood sensor to the global medical community for the first time at the U.S. ELSO Annual Conference in Washington, D.C.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November 2025, we announced the completion of
the clinical study for HYLA toward regulatory submission and future commercialization. Based on the clinical trial results and ongoing
lab tests, showing between 95% to 99% accuracy across measured parameters, we are soon entering the final validation and verification
stage ahead of planned regulatory submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2026, we announced the successful validation
in our advanced blood labs of HYLA. In advanced bench testing, the system demonstrated 94.2% accuracy for the continuous optical measurement
of Partial Pressure of Carbon Dioxide (pCO&#8322;), a performance level that aligns with clinical needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>VORTX Orbiting Blood Oxygenation Delivery System</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The VORTX represents a groundbreaking
advancement in blood oxygenation technology, having received the first U.S. patent approval for an orbiting blood oxygenation delivery
system. This innovation is comprised of 16 claims found to be novel. The VORTX technology is designed to enrich small volumes of blood
with oxygen while simultaneously removing carbon dioxide, achieving saturation levels of 95% or higher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The VORTX aims to oxygenate
blood without fiber membranes that exist in current blood oxygenators, known to cause harmful turbulence, friction, and sheer forces,
which result in significant damage to blood components and cells. Unlike the natural laminar blood flow in blood vessels inside the body,
in existing fiber oxygenators, the blood is &#8220;forced&#8221; to flow in a harmful turbulent flow through many layers of fibers while
experiencing friction and sheer forces with the fiber walls. Additionally, since the fiber fabric is a significant resistor to blood flow,
high-pressure differences between the oxygenator inlet and outlet are formed, resulting in significant damage to the various blood components,
including, high hemolysis (the breakdown of red cells), damage to white blood cells, activation of the inflammatory system in the body,
activation of the immune system, and blood clotting. In September 2024, we received an additional U.S. patent allowance for the VORTX.
In January 2025, we unveiled the modular configuration for the VORTX.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2025, we announced
that the in-vivo testing of VORTX achieved above 99% gas exchange target at a defined flow rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dual Lumen Cannula</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_010.jpg"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proprietary dual lumen
cannula design is subject to a patent comprised of 16 novel and unique claims, offering a novel approach to intravascular access and manipulation.
The key innovation lies in the cannula&#8217;s ability to intravascularly convert from a single-lumen to a dual-lumen configuration after
initial insertion, all through the same incision point. This design eliminates the traditional need for multiple incisions when changing
or adding cannulas, potentially reducing patient risk, complications and infection points.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cannula <sub>&#160;</sub>has
numerous proprietary characteristics that makes it superior in comparison to existing commercial cannulas, such as small diameter 16-21Fr
(depending on flow rate required) that allows the lumen to be injected directly into a patient&#8217;s jugular vein while the patient
is awake and breathing spontaneously, short length that eliminates the need for positioning that requires fluoroscopy or other imaging
and simplicity of cannulation and application. The cannula has the potential to as an essential tool in a wide range of medical settings
a dual-lumen cannula is often used for the simultaneous venous drainage and reinfusion of blood during processes such as ECMO in ICUs.
The cannula device may potentially allow for fast action and reduced risk, complications and additional infection points.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Disposables</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also progressing in
our plan to launch single-use disposables to be used during the blood oxygenation procedure, currently in development, for our INSPIRA
ART system, with the design potentially suitable for use with the INSPIRA ART100. The disposables are intended to be compatible with
various other life support machines, tapping into the disposable perfusion systems market. The disposables, anticipated to be submitted
to the FDA for marketing clearance in 2026 for the disposable blood flow technology and in 2027 for the disposable blood oxygenation
technology, are a single-use product designed to be used for efficient blood circulation, blood oxygenation and carbon dioxide removal.
The disposables have the potential to become a recurring revenue model. We are focusing on making the disposables compatible with other
medical devices such as certain types of cardio-pulmonary bypass machines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: 21.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: 21.8pt"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: 21.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquid Biopsy Diagnostics </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2026, we outlined
our strategic vision and proposed transaction framework for our planned expansion into liquid biopsy diagnostics, outlining a structured
approach designed to preserve shareholder value while enabling future dividend distributions from our core respiratory and life-support
technologies. This framework underpins a proposed acquisition of the Target, an advanced liquid biopsy platform alongside a concurrent
equity investment. For more information on the proposed acquisition, see 5.A &#8220;<i>Operating and Financial Review and Prospects.</i>&#8221;
In March 2026, we announced that we chose not to complete the proposed acquisition of the Target.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>New Subsidiary</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In March 2026, we announced the
establishment of a wholly owned subsidiary as part of our corporate structure. We intend to transfer our existing medical business activities
into the newly formed subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Studies and Expected Regulatory Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our regulatory strategy is
to submit certain key technologies and key components for 510(k) pathway clearance based on the assumption that we do not currently expect
to require human trials for FDA clearance. This strategy both provides verification and validation testing as well as anticipated FDA
clearance of key elements that may be integrated as important technologies in our INSPIR ART system, or other product candidates. Taking
this approach is expected to potentially reduce risk certain factors in the planned pivotal clinical studies for the INSPIRA ART system
with a view to submitting an application for regulatory clearance from the FDA Approval through an expected PMA or De Novo regulatory
pathway.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2022, we listed
a component of our INSPIRA ART and INSPIRA ART100 systems on the FDA Class I 510(k) exempt list. The component is intended to reduce the
potential complications associated with jugular vein cannula movement, occurring during a change of a patient&#8217;s posture in bed and/or
during transportation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2023, we announced
the first in-human study of a patient undergoing open-heart surgery in the HYLA research clinical study at Sheba Medical Center in Israel.
The HYLA research clinical study is a first in-human study designed to compare parameters measured by the non-invasive HYLA sensor to
a standard blood gas analyzer that requires blood draw from the patient. Continued data collection will further support the final product
design and part of the development process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2023, we announced
that we received&#160;International Organization for Standardization, or ISO, 13485:2016 Standard Certification, which is the international
standard for quality management systems within the medical device industry, and a requirement for EU regulatory approval. The ISO certification
encompasses key aspects, including design, development, manufacturing, distribution and sales of extracorporeal and blood monitoring devices
and respiratory care devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2024, we received 510(k)
class II regulatory clearance from the FDA for the INSPIRA ART100 system. The INSPIRA ART100 System is FDA 510(k)-cleared for use in an
extracorporeal perfusion circuit to pump blood during short-duration cardiopulmonary bypass procedures lasting 6 hours or less. The system
has been deployed to the U.S. as part of a clinical evaluation agreement through our distributor, Glo-Med.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2025, we announced
pivotal results for HYLA blood sensor, achieving 97.35% accuracy in its latest performance testing phase. These results represent a significant
advancement from the initial data obtained in a clinical study, as announced in March 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2025, we announced
that we have completed the regulatory submission of ART100 system to the United Arab Emirates Ministry of Health and Prevention. As of
March 25, 2026, we have been made aware that the submission by our representative in the United Arab Emirates failed to be delivered,
and we are awaiting new submission process to be submitted in the upcoming weeks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Milestones Achieved in 2025 and early 2026
include:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPIRA ART100 - First in-patient use in a hospital in the U.S. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td>INSPIRA ART 100 - First reported revenue.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPIRA ART &#8211;patent grant for blood flow technology</span></td></tr>
  </table><div>


</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 48px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We showcased our technology at Arab Health 2025 in Dubai in January 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we intend to execute
strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and agreements that
may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven years and subject to completion
of development, and the required regulatory approvals or clearances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Targeted Milestones (2026-2027):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are targeting strategic
collaborations with leading hospitals and medical device companies as part of the company&#8217;s business strategy to develop the market
with the INSPIRA ART100, HYLA Blood Sensor and INSPIRA ART Disposables (Kits compatible with the INSPIRA ART100) in preparation of the
INSPIRA ART system being targeting to replace the need for mechanical ventilators.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HYLA stand alone device - planned FDA submission for regulatory clearance (second half of 2026)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPIRA ART100 - Additional U.S. hospital deployments (first half of 2026) </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSPIRA ART - blood flow disposable - planned FDA submission for clearance (second half of 2026).</span></td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>INSPIRA ART</b> - <b>Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Approximately 20 million patients
annually are admitted to ICUs, requiring acute respiratory care. The respiratory care devices market size is expected to reach $16.09
billion in 2029. The major factors influencing this growth include the high prevalence of respiratory diseases, the rapid growth of the
aging population, the high prevalence of smoking, rising urbanization and pollution levels, the increasing incidence of pre-term births
and lifestyle changes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Go To Market Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our go-to-market strategy
is based upon providing affordable products, based on a razor-blade business model based on disposables and software licensing to maximize
our market reach while enhancing affordability and accessibility to medical care worldwide. We focus on this effort comprehensively, understanding
a multidisciplinary marketing and business approach is necessary to achieve our goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our go-to-market strategy includes, but is not limited to:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursuing world-wide regulatory approvals</i></b><i>: </i>we plan to pursue regulatory approvals in North America, Europe, Asia, Central America, South America, and Africa. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Collaborating with leading medical centers and health organizations</i></b>: we are working with leading medical centers and health organizations as part of our strategy toward reaching regional deployment of our products. This also includes collaborations with top ranked hospitals to expose our INSPIRA ART systems to physicians and the healthcare industry. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Identifying potential customer profiles</i></b>: we will be targeting leading medical centers, group purchasing organizations and medical device companies with a need for updated or revolutionary life support solutions. We believe that due to many recalls within the perfusionist market, and a lack of innovation in the sector, we are identifying potential customers searching for a different experience and result.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Strategic partners</i></b>: we have entered into agreements with medical device companies, manufacturers, distributors. We intend to target similar agreements with distributors in additional territories across the globe, including the U.S., Europe, and Asia.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investing in marketing and public relations to increase awareness of our solution</i></b>: in order to drive market demand for the INSPIRA ART, we are introducing the INSPIRA ART100, to be followed by disposables and the HYLA Blood Sensor (also to be integrated with the INSPIRA ART100). We hope to introduce the industry, as we have in conferences such as the 2025 Annual Extracorporeal Life Support Organization conference, to the caliber of technology and devices that we plan to offer. To date, the INSPIRA ART 100 system has received FDA 510(k) clearance and the INSPIRA ART system is currently in development. The INSPITA ART has not been used or tested in humans.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Garnering appropriate reimbursement and insurance coverage</i></b>: it is paramount for us to receive reimbursement and insurance coverage to enable hospitals and medical centers to provide treatment utilizing our products. With intensive care becoming increasingly expensive, the INSPIRA ART may provide treatment at significantly reduced cost and without compromising quality of care to patients. We are working on a health economics model as part of the reimbursement strategy. Our goal is to publish medical literature to provide the Centers for Medicare and Medicaid Services actual data, presented by us together with top-ranking hospitals.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Working on Collaborations </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2022, we entered
into an exclusive OEM agreement with Terumo Cardiovascular. The agreement provides for the manufacture of a disposable flow mechanism
that may be distributed with our INSPIRA ART systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November 2023,
we entered into a collaboration agreement with Ennocure, a pioneer in the development of bioelectronic wound dressing, for the development
of a proprietary bio-electronic treatment to prevent associated bloodstream infections in ICU patients. The aim of the collaboration is
to research the prevention of growth of bacteria that often results from cannula insertion and is associated with bloodstream infection
(sepsis). Once developed, we plan to combine the bio-electronic novel physical stimulation technology, as a preemptive measure for potentially
at-risk patients, providing a cost-competitive solution to reduce complications. It is estimated that 250,000 bloodstream infections related
to intravenous lines occur worldwide each year, leading to prolonged hospital stays and increasing healthcare costs. In April 2024, we
announced positive results from our collaborative development which showed a 75% reduction in bacterial growth four hours after the application
of the treatment and a 100% reduction within 24 hours. The in vitro study was carried out at the Hebrew University of Jerusalem and involved
testing bioelectric patches in an in vitro environment. As part of the in vitro study, bacteria were cultured and spread on agar in petri
dishes. The bioelectric patch was then applied to the agar plate and activated for a pre-specified duration. Following the procedure,
the agar plates were transferred to an incubation chamber for 24 hours and thereafter examined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2025, we announced
our collaboration with Zriha Medical Ltd to establish a dedicated production line for a crucial component of our innovative respiratory
support system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2025, we announced
a strategic collaboration with Bites Learning Ltd., or Bites, a leader in AI-based digital training and performance enablement solutions.
Through this collaboration, Bites&#8217; advanced AI-powered learning and guidance platform was to be embedded as a built-in standard
across our ecosystem, including future versions of the ART100 cardiopulmonary support system and the HYLA real-time blood sensor. In January
2026, we elected not to proceed with this collaboration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Working to Establish Distribution Partners Around the World</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to enter into strategic
distribution agreements internationally to collaborate with local distribution networks to form a platform for implementation of our go-to-market
strategy. Distribution companies with which we have already entered into such agreements include Innovimed (covering all European countries),
Bepex, WAAS Group (covering Spain and Portugal), Glo-Med (covering Texas, New Jersey, New York, Florida, North Carolina, South Carolina
and Gulf States) and CIO MED GROUP (covering Central America). The agreements are for a period of three to seven years and are conditional
on the completion of product development and receipt of regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we intend to execute
strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and agreements that
may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven years and subject to completion
of development, and the required regulatory approvals or clearances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, we entered
into an exclusive distribution agreement with WAAS Group, one of Spain&#8217;s leading distributors and technical service providers of
medical equipment and supplies. According to the agreement, WAAS Group is committed to purchase a minimum of 1,040 INSPIRA ART systems
and 35,360 disposable units for deployment at hospitals and medical centers within a seven-year period, subject to regulatory approval
for the sale and marketing of the INSPIRA ART systems in Spain and Portugal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2021, we entered
into an exclusive summary distribution agreement with Innovimed, a master distributor specializing in state-of-the-art medical solutions
in Eastern Europe, Middle East and Africa. The agreement has an initial term of 7 years, subject to completion of product development
and regulatory approval. The parties will collaborate on the marketing and deployment of the INSPIRA ART system. In order to maintain
exclusivity in the territory, Innovimed has committed to purchase minimum orders of 1,552 INSPIRA ART systems and 59,040 disposable units
for deployment at hospitals and medical centers, subject to regulatory approvals for the sale and marketing of the INSPIRA ART systems
in Poland, Czech Republic and Slovakia. In August 2023, we entered into an agreement expansion with Innovimed to collaborate towards clinical
trials for Inspira ART respiratory systems, which covers any European country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2022, we entered
into an exclusive summary distribution agreement with Glo-Med, a U.S company that aims to meet the continuously growing demand for innovative
medical devices and related products, for distribution across six states in the U.S. (Texas, New Jersey, New York, Florida, North Carolina,
and South Carolina). The summary distribution agreement will be followed by a more comprehensive agreement. The agreement entered with
Glo-Med has an initial term of seven years, subject to the completion of product development and relevant regulatory approval. The parties
will collaborate on the marketing and deployment of the INSPIRA ART. Pursuant to the agreement, and in order to maintain exclusivity in
the territory, Glo-Med has committed to purchase a minimum order of 2,121 INSPIRA ART systems and 131,413 disposable units for deployment
at hospitals and medical centers over a period of seven years, subject to regulatory approvals for the sale and marketing of the INSPIRA
ART systems in the six states in the U.S. Pursuant to the agreement with Glo-med, Inspira shipped five systems to hospitals in the U.S.,
including a cardiothoracic surgery division at a leading hospital in New York.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2022, we entered
into a summary distribution agreement with Bepex that includes the potential future deployment of our INSPIRA ART systems, designed to
prevent the need for invasive mechanical ventilation. Bepex is a leading Israeli medical technology company that imports, markets and
services medical equipment for global medical device companies such as Hamilton (mechanical ventilators) and LivaNova (ECMO systems).
As part of the collaboration with Bepex, the first systems are slated for deployment at the largest medical centers in Israel. The summary
distribution agreement with Bepex is expected to be followed by a more comprehensive agreement. The agreement has an initial term of seven
years, subject to the completion of product development and relevant regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2022, we entered into
an exclusive summary distribution agreement with Glo-Med, for the distribution of the HYLA blood sensor device and disposable units across
six states in the U.S. (Texas, New Jersey, New York, Florida, North Carlina and South Carolina). The summary distribution agreement will
be followed by a more comprehensive agreement. The agreement has an initial term of three years, subject to completion of product development
and regulatory approvals. The parties will collaborate on the marketing and deployment of the HYLA blood sensor. Pursuant to the agreement,
and in order to maintain exclusivity in the territory, Glo-Med has committed to purchase a minimum order of 3,889 HYLA blood sensors and
264,873 disposable units for deployment at hospitals and medical centers, subject to regulatory approvals for the sale and marketing of
the HYLA blood sensor device in the six states within the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2022, we entered
into an exclusive summary distribution agreement for the HYLA blood sensor with Innovimed. The summary distribution agreement would be
followed by a more comprehensive definitive agreement. The agreement has an initial term of five years, subject to the completion of product
development and the receipt of regulatory approvals. The parties will collaborate on the marketing and deployment of the HYLA blood sensor.
In order to maintain exclusivity in the territory, Innovimed has committed to purchase a minimum order of 1,364 HYLA blood sensors and
128,511 disposable units for deployment in hospital units and operating theaters in Poland, Czech Republic and Slovakia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2023, we entered
into an exclusive summary distribution agreement for the INSPIRA ART systems and disposable kits with CIO MED GROUP in Central America.
The Agreement to potentially generate $28 million, mainly in recurring revenues from disposable kits over five years, subject to the receipt
of regulatory approval.&#160;In addition to the INSPIRA ART100 system intended for patients undergoing CPB procedures, the Agreement also
includes both the flagship INSPIRA&#160;ART systems and HYLA&#160;Blood Sensor Technology, as well as disposable kits to be used with
these Inspira Technologies devices in the procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, we entered
into a summary distribution agreement to enter Gulf States with Glo-Med for deployment of 531 INSPIRA ART systems. The agreement will
potentially provide Inspira Technologies with $32.6 million over a 5-year period, subject to regulatory approvals. Under such Agreement,
Glo-Med shall be designated as the Company&#8217;s distributor in Saudi Arabia, United Arab Emirates and Bahrain. We believe that Saudi
Arabia&#8217;s dual strategy to invest $65 billion and further privatize its healthcare sector, or Vision 2030, signals that the Territory
is a burgeoning market for medical innovation. The summary distribution agreement will be followed by a more comprehensive agreement.
Under the Agreement, Glo-Med shall undertake the role of Territory wholesale distributor, involving the promotion, marketing and sale
of the INSPIRA ART system, the INSPIRA ART system Disposable Kit, the INSPIRA ART100 System and the INSPIRA ART100 Disposable Kit, to
approved customers in the Territory. Glo-Med shall be the exclusive Territory distributor provided that it meets the minimum purchase
targets amounting to 531 INSPIRA ART systems and 8,794 disposable units from when the relevant regulatory approvals for the devices in
the Territory are granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2024, we announced
that we had received the first ever purchase order for five INSPIRA ART100 systems in the U.S. from Glo-Med, which included an option
for the additional purchase of 20 units. In December 2024, we announced that the units were shipped and delivered in fulfillment of the
purchase order.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024, we entered
into a distribution agreement with Glo-Med to use its distribution facility as a support center for the deployment of the INSPIRA ART100
in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2025, we announced
that we have received payment from Glo-Med for a delivery of our INSPIRA&#8482; ART100 systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2025, we announced
that we have secured a binding $22.5 million purchase order for ART100 system, representing a major commercial inflection point for us.
The order was placed by a privately held company headquartered outside the U.S., in a global strategic hub, with an established track
record and active commercial ties to both government entities and institutional healthcare customers. Additionally, in July 2025, we announced
that we were engaged in high-level talks with a government health authority, located outside of the U.S., which are intended to advance
the national integration of ART100 system as a foundational component of the national emergency infrastructure and to establish a global
distribution framework. In these high-level talks, we achieved all key strategic objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2025, we announced
that a national ministry of health in Africa placed a $27 million binding purchase order for ART100 systems. The purchase order, secured
through our exclusive distribution partner, dedicated solely to the commercialization of our products, initiates an immediate nationwide
deployment program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2025 and January
2026, we clarified that we have advanced to the final budgetary validation and fund allocation stage within the relevant governmental
authorities&#8217; procurement processes under our $22.5 million purchaser order and $27 million purchase order. We further clarified
that we expect payment and revenue recognition relating to these purchase orders during 2026 fiscal cycle, aligned with the completion
of the governmental budgetary cycle and subsequent deployment milestones.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2026, we announced the receipt of official
approval from the Medical Equipment Committee of Clalit Health Services, or Clalit, which enables the ART100 system for immediate procurement
and operational use across Clalit&#8217;s extensive medical ecosystem.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2026, we also announced the deployment
and initiation of a structured commercial evaluation of the ART100 system at a new and additional leading U.S. academic medical center.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we intend to execute
on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and agreements
that may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven year and subject to completion
of development, and the required regulatory approvals or clearances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Third-Party Reimbursement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, we do
not have any third-party reimbursement agreements. We aim to use existing CPT Codes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek patent protection
as well as other effective intellectual property rights for our products and technologies in the U.S. and internationally. Our policy
is to pursue, maintain and defend intellectual property rights developed internally and to protect the technology, inventions and improvements
that are commercially important to the development of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our intellectual property
portfolio consists of eight patent families that include: seven granted patents, five in the USA and one in Japan and Israel each; one
patent application allowed in Israel; five International Patent Applications (PCT), four of which are exhausted, and thirteen pending
patent applications that include five U.S. utility and one US provisional patent applications, two European patent applications and additional
national phase filings (two in the Republic of Korea, one in Israel, one in Japan and one in Brazil). Our portfolio also includes the
following registered trademarks: (i) &#8216;INSPIRA&#8217; text and logo in Israel and International Trademark designated in Australia,
EU, China and United Kingdom; (ii) &#8216;INSPIRA ART&#8217; registered in Israel and &#8216;ART&#8221; registered via International Trademark
designated in Australia, EU, United Kingdom and Russia; and (iii) our slogan &#8216;INSPIRA. BREATHING EMPOWERED.&#8217; registered in
the U.S. and Israel and International Trademark designated in the EU and United Kingdom. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Extracorporeal oxygenation system (Initiation
Module)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A novel automated self-priming
module designed for the INSPIRA ART system, this unique innovative operating module further expands the INSPIRA ART system advancement
to potentially ensure patient safety with a proprietary built-in self-automated priming module aimed to ensure an emboli-free connection
to the patient&#8217;s vascular system, thereby potentially reducing risks of the formation of clots that reduces blood flow. Further
innovative concepts include a patient oxygenation low-flow system. Two U.S. patents have been granted: (i) U.S. 11,793,919, which consists
of nine claims and (ii) U.S. 12,453,807, consisting of sixteen claims, all deemed novel with inventive merit and practical applicability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A blood-gas exchange device and methods of
use</b> - Orbiting blood oxygenation delivery system (VORTX)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This innovation has been granted
U.S. Patent No. 11,938,257 with 16 claims found to be novel and is designed to oxygenate blood without fiber membranes, and we believe
it is expected to revolutionize the medical landscape. The current fiber technologies used for blood oxygenation cause substantial damage
to the patient&#8217;s blood cells. Unlike the natural laminar blood flow in blood vessels inside the body, in existing fiber oxygenators,
the blood is &#8220;forced&#8221; to flow in a harmful turbulent flow through many layers of fibers while experiencing friction and shear
forces within the fiber walls. Since the fiber fabric is a significant resistor to blood flow, high-pressure differences are formed and
cause significant damage to the various blood components, including, high hemolysis, damage to white blood cells, activation of the inflammatory
system in the body, activation of the immune system, and blood clotting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dual lumen cannula and methods of use</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This
innovative concept was granted patents in the U.S. (U.S. 11,541,159) and Japan (JP 7777598). and a patent application was recently allowed
in Israel. Inspira&#8217;s convertible dual lumen cannula device uniquely intravascularly converts a single-lumen cannula into a dual
lumen cannula after initial insertion, thus allowing for the same incision point to potentially have multiple uses. The convertible dual
lumen cannula is designed to allow for switching from a single lumen to a dual lumen cannula, and vice versa, without the need for new
incisions required when changing or adding additional cannulas. Inspira&#8217;s convertible dual lumen is designed to potentially allow
for fast action and reduced risk, complications and additional infection points.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cannula fixation device</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The component is intended
to reduce the potential complications associated with jugular vein cannula movement, occurring during a change of a patient&#8217;s posture
in bed and/or during transportation. The component can also be potentially utilized in the treatment of thousands of patients being treated
each year by through ECMO. This component is expected to allow the medical staff a safer mobilization for the awake cannulated patients
within and between hospitals and medical centers. A patent was granted in Israel for this device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table comprises
our technology patents:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; border-bottom: Black 1pt solid; text-align: left; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application; Publication No.</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Effective<br/>
 Filing&#160;Date</b></span></td>
    <td style="padding-bottom: 1pt; text-align: center; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL 286271</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Cannula Fixation Device</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Sep 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANTED</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/IL2022/050902</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Cannula Fixation Device</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18 Aug 2022</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHAUSTED</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP 22856981.0; 4185347</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Cannula Fixation Device</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18 Aug 2022</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US 17/931,134</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Cannula Fixation Device</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11 Sep 2022</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP 21891360.6; 4199990</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL 302851</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALLOWED</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP Patent No. 7777598</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANTED</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR 10-2023-7019401; 20230107622</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Pat. No. 11,541,159</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANTED</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US 18/062,610; 2023/0095678</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transformable Dual Lumen Cannula into a Single Lumen
    Cannula and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Nov 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BR 112023010627-3</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates
    and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP 21900219.3; 4228717</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates
    and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IL 303362</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates
    and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP 2023533325; 2023552754</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates
    and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR 10-2023-7022195; 20230118594</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates
    and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Pat. No. 11,793,919</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates
    and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANTED</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Pat. No. 12,453,807</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates
    and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 Dec 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANTED</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Pat. No. 11,938,257 (18/235,515)</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Blood-Gas Exchange Device and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18 Aug 2023</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANTED</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US 18/896,656</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Blood-Gas Exchange Device and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18 Aug 2023</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US 18/434,809</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automated Monitoring of Extracorporeal Support Patient
    Care and Interactive User Interface Therefor</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7 Jan 2024</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Pat. No. 12,324,877</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Blood-Gas Exchange Device and Methods of Use</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19 Jun 2024</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GRANTED</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Provisional 63/888/266</span></td>
    <td/>
    <td>SENSOR DEVICE FOR EXTRACORPOREAL TUBING</td>
    <td/>
    <td>26 Sep 2025</td>
    <td/>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FILED</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT/IB2025/058472 Published WO 2026/042046</span></td>
    <td/>
    <td>REDUCING THE INCIDENCE OF INFECTIONS ASSOCIATED WITH TRANSDERMAL INSERTION SITES</td>
    <td/>
    <td>22 Aug 2025</td>
    <td/>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PENDING</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,
know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted
with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we
be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends, in part,
on an intellectual property portfolio that supports future revenue streams and erects barriers to our competitors. We are maintaining
and building our patent portfolio through filing new patent applications, prosecuting existing applications, and licensing and acquiring
new patents and patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite these measures, any
of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated. Intellectual
property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide
competitive one. For more information, see &#8220;Item 3.D. - Risk Factors-Risks Related to our Intellectual Property.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development and Governmental Grants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain an active internal
research and development process, which also includes clinical activities and regulatory affairs. Our research and development team consists
of 30 people as of December 31, 2025. We incurred approximately $7.5 million and $6.4 million in research and development and related
expenses during the years ended December 31, 2025 and 2024, respectively. The decrease in research and development expenses is primarily
attributable to decreases in salary and related expenses and IIA grant participation that was deducted from development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts have been financed in part through grants in an aggregate amount of approximately $1,194,000 that we received from the IIA as
of December 31, 2025. We received these grants for the development of a blood oxygenation system with the goal of providing life support
through direct blood oxygenation and elevation of the oxygen saturation level while removing carbon dioxide. These grants have no repayment
obligation, however, once we reach commercialization stage, we will be required to pay royalties for each grant at a rate of 3% of our
revenues up to the total amount of grants received plus interest. Following the full payment of such royalties, there is no further liability
for royalty payment. Nonetheless, the restrictions under the Innovation Law will continue to apply even after our company has repaid the
full amount of royalty payable pursuant to the grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Production and Manufacturing Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our INSPIRA ART and INSPIRA
ART100 systems are comprised of a number of components. We are planning to sell an assembled product (system) as well as a disposable
unit to be used per patient treatment for both the blood oxygenation and blood monitoring. The components of the assembled product and
the disposable unit consist of both proprietary and off the shelf components. Proprietary components will be manufactured on our behalf
at GMP approved production plant to adhere to regulatory requirements, whereas off the shelf components will be sourced by Inspira team.
GMP sub-contractors will assemble proprietary and off the shelf components together to create our INSPIRA ART and or INSPIRA ART100 systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2022, we entered
into a strategic OEM agreement with Terumo Cardiovascular. The agreement provides for the manufacture of a flow mechanism that is intended
to be integrated into our products for use in the extracorporeal circulation of the blood during the oxygenation process. This may also
include integration into the INSPIRA ART and or INSPIRA ART100 systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we have entered
into discussions relating to additional contracted manufacturing and distribution agreements with leading turnkey OEM vendors that provide
end-to-end solutions. The outsourcing of the supply chain management, such as manufacturing, logistics, shipping and after-market support,
reduces capital expenditure, lead times and costs, while providing us with flexibility and agility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2022, we announced
that our INSPIRA ART100 system is being contract manufactured by an end-to-end solution provider that offers New Product Introduction,
NPI, services to mass production capabilities for leading medical electronic device companies. This includes full turn-key manufacturing,
full system integration, including Printed Circuit Board, or PCB, manufacturing, assembly services, testing and packaging in facilities
that meet GMP compliance. The INSPIRA ART100 system underwent verification and validation prior to its submission to the FDA. Having received
FDA clearance, the INSPIRA ART100 system production line will be extended for low-rate initial production, which is an important operational
stage in developing infrastructure to support serial manufacturing, quality control and shipping. Additional units are expected to be
assembled for the targeted future first deployments of the INSPIRA ART100 systems in the U.S. and Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The medical device industry
is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. There are many
medical device companies, biotechnology companies, public and private universities and research organizations actively engaged in the
research and development of products that may be similar to our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market participants in
the ICU and the acute respiratory care space include Boston Scientific Corporation (NYSE: BSX), ResMed Inc., (NYSE: RMD), Masimo Corporation
(Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq: GTLS), Philips Healthcare, Medtronic plc (NYSE:
MDT), Fisher &amp; Paykel Healthcare Corporation Limited, Dr&#228;gerwerk AG &amp; Co. KGaA, Dr&#228;gerwerk AG, Hamilton Medical AG,
Smiths Medical Inc. (acquired by ICU Medical Inc.), Siemens Healthineers AG ADR (Nasdaq: SMMNY), Baxter International (NYSE: BAX), Getinge
AB (OTCMKTS: GNGBY), GE Healthcare, Terumo Corporation (TYO: 4543, Nikkei 225 Component), LivaNova PLC (Nasdaq: LIVN), Fresenius SE &amp;
Co. KGaA (OTCMKTS: FSNUY), Johnson &amp; Johnson (NYSE: JNJ), Zoll Medical Corporation (TYO: 3407 ), Resuscitec GmbH, Spectrum Medical
Limited, Abiomed, Inc. (Nasdaq: ABMD), Abbott Laboratories (NYSE: ABT), DataMed s.r.l, Chalice Medical Ltd., APMTD Global Limited, Eurosets
s.r.l. and Braile Biomedica. These companies have either developed or acquired respiratory care devices and solutions, such as ventilators,
ECMO devices and blood sensors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aforementioned companies
have substantially greater brand recognition, R&amp;D, and regulatory capabilities and financial, technical, manufacturing, marketing
and human resources than we do and significantly greater experience and infrastructure in the research and development of medical devices,
obtaining the FDA and other regulatory clearances of those devices and commercializing those devices around the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation and Product Approval
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products and our operations
are subject to regulation by numerous worldwide regulatory bodies including the FDA and comparable international regulatory agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are subject to
regulation as medical devices under the FDCA, as implemented and enforced by the FDA. The FDA regulates the development, design, non-clinical
and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket
clearance or approval, import, export, adverse event reporting, advertising, promotion, marketing and distribution, and import and export
of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise
meet the requirements of the FDCA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to U.S. regulations,
we are subject to a variety of regulations in the EEA, governing clinical trials and the commercial sales and distribution of our products.
Whether or not we have or are required to obtain FDA clearance or approval for a product, we will be required to obtain authorization
before commencing clinical trials and to obtain marketing authorization or approval of our products under the comparable regulatory authorities
of countries outside of the U.S. before we can commence clinical trials or commercialize our products in those countries. The approval
process varies from country to country and the time may be longer or shorter than that required for FDA clearance or approval. Medical
devices are generally subject to varying levels of regulatory control based on risk level of the device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>FDA Premarket Clearance and Approval Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless an exemption applies,
each medical device commercially distributed in the U.S. requires FDA clearance of a 510(k) premarket notification, granting of a de novo
request, or approval of an application for premarket approval, or PMA. Under the FDCA, medical devices are classified into one of three
classes-Class I, Class II or Class III-depending on the degree of risk associated with each medical device and the extent of regulatory
controls needed to ensure its safety and effectiveness. Class I includes devices with the lowest risk to the patient and are those for
which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance
with the applicable portions of the QSR, facility registration and product listing, reporting of adverse medical events, and truthful
and non-misleading labeling. Class II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed necessary
by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market
surveillance, patient registries and FDA guidance documents. While most Class I devices are exempt from the 510(k) premarket notification
requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of
the FDCA requesting permission to commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject
to a 510(k) premarket notification is generally known as 510(k) clearance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The 510(k) Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 510(k) process,
the manufacturer must submit to the FDA a premarket notification demonstrating that the device is &#8220;substantially equivalent&#8221;
to either a device that was legally marketed prior to May 28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted,
and for which PMA is not required, a device that has been reclassified from Class III to Class II or Class I, or another commercially
available device that was cleared through the 510(k) process. To be &#8220;substantially equivalent,&#8221; the proposed device must have
the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have
different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical
data is sometimes required to support substantial equivalence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a 510(k) premarket notification
is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review,
the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute,
the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical
matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without
clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence,
which may significantly prolong the review process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA agrees that
the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market
the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device
is automatically designated under the FDCA as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements
or can request a risk-based classification determination for the device in accordance with the de novo process, which is a route to market
for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a device receives 510(k)
marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change
or modification in its intended use, will require a new 510(k) marketing clearance or, depending on the modification, a de novo grant
or PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) (or a PMA)
in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Many minor modifications
today are accomplished by a manufacturer documenting the change in an internal letter-to-file. The FDA can review these letters to file
during an inspection. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing
and/or request the recall of the modified device until 510(k) clearance, de novo grant or PMA approval is obtained. In these circumstances,
we may be subject to significant regulatory fines or penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>De Novo Classification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Medical device types that
the FDA has not previously classified as Class I, II or III are automatically classified under the FDCA into Class III regardless of the
level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a route to market for low to moderate
risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request
for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification procedure. This procedure allows a manufacturer
whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class
II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application.
Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, a medical device could be eligible
for de novo classification only if the manufacturer first submitted a 510(k) premarket notification and received a determination from
the FDA that the device was not substantially equivalent to a legally marketed predicate device. FDASIA streamlined the de novo classification
pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification
to the FDA and receiving a not substantially equivalent determination. Under FDASIA, the FDA is required to classify the device within
120 days following receipt of the de novo application. If the manufacturer seeks reclassification into Class II, the manufacturer must
include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of
the medical device. In addition, the FDA may reject the request if it identifies a legally marketed predicate device that would be appropriate
for a 510(k) notification, determines that the device is not low to moderate risk, or that general controls would be inadequate to control
the risks and special controls cannot be developed. After a device receives de novo classification, any modification that could significantly
affect its safety or efficacy, or that would constitute a major change or modification in its intended use, will require a new 510(k)
clearance or, depending on the modification, another de novo petition or even PMA approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Trials</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials are almost
always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of investigational
devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s Investigational Device Exemption, or
IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array
of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant
risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which
must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious
risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially
important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents
a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test
results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically
become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA
determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical
trial to proceed under a conditional approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the study must
be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB. The IRB is responsible for the initial and
continuing review of the study and may pose additional requirements for the conduct of the study. If an IDE application is allowed to
go into effect by the FDA and the study approved by the reviewing IRB(s), human clinical trials may begin at a specific number of investigational
sites with a specific number of subjects as set forth in the study protocol. If the device presents a non-significant risk to the patient,
a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate review from the FDA,
but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed
consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will
allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials
support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted
to, and allowed to go into effect by, the FDA before a sponsor or investigator may make a change to the investigational plan that may
affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During a study, the sponsor
is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators
and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the
promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical
study are also subject to FDA regulations and must obtain patient informed consent, follow the investigational plan and study protocol,
control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after
a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief
that the risks to study subjects outweigh the anticipated benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b><i>Post-market Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a device is cleared
or approved for marketing, numerous and extensive regulatory requirements may continue to apply. These include but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual and updated establishment registration and device listing with the FDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR requirements, which require manufacturers to follow stringent design, testing, control, documentation, complaint handling and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising and promotion requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictions on sale, distribution or use of a device;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labeling and marketing regulations, which require that promotion is truthful, not misleading, and provides adequate directions for use and that all claims are substantiated, and also prohibit the promotion of products for unapproved or &#8220;off-label&#8221; uses and impose other restrictions on labeling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Physician Sunshine Act and various state and foreign laws on reporting remunerative relationships with health care customers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Anti-Kickback Statute (and similar state laws) prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended to induce the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not have to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal False Claims Act (and similar state laws) prohibiting, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing, or knowingly and improperly avoiding or decreasing, an obligation to pay or transmit money to the federal government. The government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statute;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clearance or approval of product modifications to legally marketed devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Complying with the federal law and regulations requiring Unique Device Identifiers on devices and also requiring the submission of certain information about each device to the FDA&#8217;s Global Unique Device Identification Database;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations if there is a reasonable probability that the use of the device would cause a serious, adverse health consequence or death; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has broad regulatory
compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take
a variety of compliance or enforcement actions, which may result in any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recalls, withdrawals, or administrative detention or seizure of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating restrictions or partial suspension or total shutdown of production;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withdrawing 510(k) clearances or PMA approvals that have already been granted;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refusal to grant export or import approvals for our products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 48px; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the EU, we will be required
to comply with the new Medical Device Regulation, or the MDR. The MDR was published in May 2017 with a 3-year transition period, which
has been extended. The CE Mark required to sell medical devices in the EU is affixed following conformity assessment and either approval
from the appointed independent Notified Body or through self-certification by the manufacturer for particular class I devices. The selected
pathway to CE marking is based on product risk classification. CE Marking indicates conformity to the applicable General Safety and Performance
Requirements for the MDR. The MDR change multiple aspects of the existing regulatory framework for CE marking, such as increased clinical
evidence requirements and other new requirements, including Unique Device Identification as well as many other post-market obligations.
MDR also significantly modifies and increases the compliance requirements for the industry and will require significant investment over
the next few years to implement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also required to comply
with the regulations of every other country where we commercialize products before we can launch or maintain new products on the market.
Many countries that previously did not have medical device regulations, or had minimal regulations, are now introducing them. For example,
India is in the process of expanding its current regulations to include all medical device categories while many countries in the Middle
East and Southeast Asia are introducing new regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and other worldwide
regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through review and inspection
of design and manufacturing practices, record-keeping, reporting of adverse events, labeling and promotional practices. The FDA can ban
certain medical devices, detain or seize adulterated or misbranded medical devices, order repair, replacement or refund of these devices
and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial
harm to the public health. The FDA may also enjoin and restrain a company for certain violations of the FDCA and the Safe Medical Devices
Act pertaining to medical devices or initiate action for criminal prosecution of such violations. Regulatory agencies and authorities
in the countries where we do business can halt production in or distribution within their respective country or otherwise take action
in accordance with local laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International sales of medical
devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance
standards, are subject to FDA export requirements. Additionally, exported devices are subject to the regulatory requirements of each country
to which the device is exported. Some countries do not have medical device regulations, but in most foreign countries, medical devices
are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing
regulatory requirements; however, other countries, such as China, for example, require approval in the country of origin first.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most countries outside of
the U.S. require that product approvals be recertified on a regular basis, generally every five years. The recertification process requires
that we evaluate any device changes and any new regulations or standards relevant to the device and, where needed, conduct appropriate
testing to document continued compliance. Where recertification applications are required, they must be approved in order to continue
selling our products in those countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulatory Clearances</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2024, we received from
the FDA 510(k) regulatory clearance for the INSPIRA ART100 system. We also received confirmation that the INSPIRA ART fixation device
was placed on the FDA Class I 510(k) exempt list.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2024, we received AMAR
certification for the INSPIRA ART100 system and for the INSPIRA ART.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Expected Regulatory Filings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, The INSPIRA ART has
not been tested in humans and any future testing in humans will be subject to the request of the appropriate regulators, including the
FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 was approved
for commercialization by the FDA for cardiopulmonary bypass procedures lasting less than 6 hours</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are taking a multi-step
approach to the regulatory clearance process. In January 2022, we listed a component of the INSPIRA ART system and the INSPIRA ART100
system on the FDA Class I 510(k) exempt list. The component is intended to reduce the potential complications associated with jugular
vein cannula movement, occurring during a change of a patient&#8217;s posture in bed and/or during transportation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2026, we plan to apply
for 510(k) regulatory clearance for the HYLA blood sensor and also apply for 510(k) regulatory clearance for our centrifugal pump.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our strategy to
bring our device to market and streamline reimbursement coding and clinical adoption of the INSPIRA ART system that offers a new intent
of use, we will collaborate with top ranking hospitals to perform a human observational study focused on (pending approvals): (i) proving
that the INSPIRA ART system can prevent patient deterioration resulting in the need for invasive mechanical ventilation; and (ii) assisting
in weaning patients off mechanical ventilation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organizational Structure. </b>&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an Israeli corporation
based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd. On April 10, 2018, our name
was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira Technologies Oxy B.H.N. Ltd.
Our principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone number in Israel is +972
996 644 88. Our website address is www.inspira-technologies.com. The information contained on our website or available through our website
is not incorporated by reference into and should not be considered a part of this Annual Report, and the reference to our website in this
Annual Report is an inactive textual reference only. The SEC also maintains an Internet website that contains reports, proxy and information
statements, and other information regarding issuers that file electronically with the SEC. Our filings with the SEC will also be available
to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, we do not have any subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_016"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property, Plant and Equipment. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our main business activities
are conducted in Israel. Our offices, research and development and manufacturing facilities are located at Melisron (Millennium Building),
2 Ha-Tidhar St., Ra&#8217;anana 4366504, Israel, where we occupy approximately 670 square meters. Our lease ends in August 2027. Our monthly
rent payment is approximately NIS 69,000 (approximately $20,000).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. <span style="text-transform: uppercase">OPERATING AND FINANCIAL
REVIEW AND PROSPECTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_019"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Operating Results.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion and analysis of our financial condition
and results of operations should be read in conjunction with our financial statements and the related notes included elsewhere in this
annual report on Form 20-F. The discussion below contains forward-looking statements that are based upon our current expectations and
are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to inaccurate
assumptions and known or unknown risks and uncertainties, including those identified in &#8220;Cautionary Note Regarding Forward-Looking
Statements&#8221; and under &#8220;Risk Factors&#8221; elsewhere in this annual report on Form 20-F. Our discussion and analysis for the
years ended December 31, 2024 and December 31, 2023 can be found in Item 5. &#8220;Operating and Financial Review and Prospects&#8221;
of our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the SEC on March 10, 2025.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception in 2018,
we have incurred operating losses. Our operating loss for the years ended December 31, 2025 and 2024 were approximately $13.6 million
and $11.3 million, respectively; and our net loss for the same periods were $13.2 million and $11 million. As of December 31, 2025, we
had an accumulated deficit of $80 million. We expect to continue to incur significant expenses and operating losses for the foreseeable
future, and our losses may fluctuate significantly from year to year. We anticipate that our expenses will increase significantly in connection
with our ongoing activities, as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue clinical development of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File new applications seeking regulatory approval for the products pursuant to FDA&#8217;s Section 510(K) or other regulatory pathway in the U.S.;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue to invest in the preclinical research and development of any future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establish a commercial infrastructure to support the marketing, sale and distribution of the products if they receive regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hire additional research and development and general and administrative personnel to support our operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintain, expand and protect our intellectual property portfolio; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue to incur costs associated with operating as a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have only one product candidate
approved for sale while the other are still under development and we have not generated any significant revenue from product sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2021, we closed
our IPO whereby we sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants (inclusive of 436,364 tradable warrants pursuant to
the exercise of an overallotment option granted to the underwriters). The aggregate gross proceeds received by us from the IPO were $16
million, before underwriting discounts and other offering costs. Prior to our IPO, we financed our operations primarily through convertible
debt, as well as grants from the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Current Outlook</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have financed our operations
to date primarily through proceeds from sales of our Ordinary Shares, convertible notes and loans and from grants from the IIA. We have
incurred losses and generated negative cash flows from operations since inception in 2018. Since inception, we have not generated significant
revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, our
cash and cash equivalents and cash deposits were $3.1 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that our existing
cash and cash equivalents as of December 31, 2025 will enable us to fund our operating expenses and capital expenditure requirements through
the first quarter of 2026. We expect that we will require substantial additional capital to operate and to commercialize our products
and we expect to seek additional funds to enable us to fund our operations for the next twelve months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operating plans may change
as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future
capital requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress and costs of our research and development activities;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of manufacturing our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the magnitude of our general and administrative expenses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity or Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
recurring revenues, we expect to satisfy our future cash needs through debt and/or equity financings. We cannot be certain that additional
funding will be available to us on acceptable terms, if at all. This may raise substantial doubt about our ability to continue as a going
concern.&#160;The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If funds
are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization
efforts with respect to our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current operating expenses
consist of four components - cost of revenues, research and development expenses, general and administrative expenses and marketing expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenues</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
any significant revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses consist primarily of salaries and related personnel expenses, share-based compensation expenses, materials costs consultants
and other third parties who support the developments of our products and other related research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables discloses
the breakdown of research and development expenses:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">Year Ended December 31,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold; font-style: italic">U.S. dollars in thousands</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">2025</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">2024</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">Increase/Decrease</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Salary and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,461</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">382</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">833</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">812</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(190</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(286</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1863</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">280</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">206</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,496</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,173</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that our research
and development expenses will materially increase as we continue to develop our products and recruit additional research and development
employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of salaries and related expenses, share based compensation, professional service fees for accounting and booking,
legal fees, facilities, travel expenses and other general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables discloses
the breakdown of general and administrative expenses:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">Unaudited</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">Increase/Decrease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,966</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,758</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">208</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,031</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,079</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(64</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">68</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(44</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,185</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,347</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of the Years Ended December 31,
2025 and 2024 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Results of Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables summarizes
our results of operations for the years ended December 31, 2025, and December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Increase/Decrease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">289</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">289</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">287</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">287</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,496</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,173</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,532</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,347</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and Marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">588</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">754</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(166</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,356</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest Income from deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(64</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(172</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">Financial expenses (income), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(339</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(42</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(297</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,220</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss attributable to holders of Ordinary Shares</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,220</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,053</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,167</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b>We recognized revenue for the
first time since our inception, in the amount of $289,000 for the year ended December 31, 2025 compared to nil for the year ended December
31, 2024. Our revenues solely consist of sales of our INSPIRA ART100 systems and carts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of Revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our cost of revenues consists primarily of the
cost of the production of our&#160;products, including sub-contractors, raw materials, testing, quality assurance, shipping and handling
costs to customers, royalties to the&#160; IIA, provisions for assurance, and direct overhead, such as salary and employee related expenses.
The total cost of revenue for the year ended December 31, 2025, was $287,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses for the year ended December 31, 2025, amounted to $7,496,000 an increase of $1,173,000, or 18.6%, compared to $6,323,000 for
the year ended December 31, 2024. The increase was primarily attributable to the impact of exchange rate changes on salary and related
expenses and from share-based compensation grants during 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and administrative expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our general and administrative
expenses totaled $5,532,000 for year ended December 31, 2025, an increase of $1,347,000, or 32%, compared to $4,185,000 for the year ended
December 31, 2024. The increase was primarily attributable to an increase in salary and share-based compensation expenses, mainly resulting
from the acceleration of vesting of restricted share units in connection with the departure of our former president, as well as additional
share-based compensation grants during 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales and marketing expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marketing expenses for the
year ended December 31, 2025, amounted to $588,000 representing a decrease of $166,000, or 22%, compared to $754,000 for the year ended
December 31, 2024. The decrease was primarily due to decrease in payroll expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing,
our operating loss for the year ended December 31, 2025, amounted to $13,623,000 representing a increase of $2,356,000, or 20.9%, compared
to $11,267,000 for the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial expenses (income)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income consists
of deposit interest, revaluation of financial liabilities presented at fair value and foreign currency changes reflections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized interest income
of $64,000 from deposits and net financial income of $339,000. Net financial income was primarily attributable to the revaluation of financial
liabilities and the recognition of a new liability related to the SEPA (as defined below) commitment fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Total net loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing,
our total net loss for the year ended December 31, 2025, amounted to $13,220,000 representing an increase of $2,167,000, or 19.6%, compared
to a loss of $11,053,000 for the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_020"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, we
had $3.15 million in cash, cash equivalents and cash deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below presents our
cash flows for the year ended December 31, 2025 and December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Increase/Decrease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9,861</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9,374</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(487</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(923</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,327</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(575</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase (decrease) in cash and cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,969</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,985</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our incorporation, we
have had ongoing losses and incurred negative cash flows from operating activities. For example, in the year ended December 31, 2025,
we had operating losses of $13,623,000. We have mainly financed our activities in the year ended December 31, 2025 through offerings of
our securities. There are no assurances however, that we will be successful in obtaining the level of financing needed for our operations
or that such financing will be available on terms acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities of $9,861,000 during the year ended December 31, 2025 and net cash used in operating activities of $9,374,000 during the year
ended December 31, 2024 was primarily used for payment of salaries and related personnel expenses, materials expenses, subcontractors,
travel and office maintenance. In addition, cash flows from operating activities are impacted by changes in operating assets and liabilities,
which include trade account payables and financial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities of $565,000 during the year ended December 31, 2025 consisted of $103,000 used for purchasing property and equipment, and $668,000
representing the proceeds from sale of short-term deposits. Net cash used in investing activities of $1,488,000 during the year ended
December 31, 2024 consisted of $164,000 used for purchasing property and equipment, and $1,652,000 representing the proceeds from sale
of short-term deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financing Activities </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $7,327,000 during the year ended December 31, 2025, consisted primarily of $1,759,000 from the issuance of ordinary shares,
$4,646,000 from issuances pursuant to an at-the-market facility, and $912,000 from the exercise of warrants and pre-funded warrants, mainly
from the exercise of ordinary warrants issued to Dawson James Securities, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $7,902,000 during the year ended December 31, 2024, consisted of the issuance of ordinary shares, pre-funded warrants and
ordinary warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an effective Form
F-3 registration statement (File No. 333-289324), filed under the Securities Act of 1933, with the SEC using a &#8220;shelf&#8221; registration
process. Under this shelf registration process, we may, from time to time, sell our Ordinary Shares and warrants to purchase Ordinary
Shares, and units of two or more of such securities in one or more offerings up to a total dollar amount of $75,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 28, 2024, we entered
into a purchase agreement with certain investors providing for the issuance, in a registered direct offering, of an aggregate of 1,339,285
of our Ordinary Shares at a price per share of $1.232. The Company raised approximately $1.65 million in proceeds from this registered
direct offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 14, 2024, we entered
into a purchase agreement with a single investor providing for the issuance, in a registered direct offering, of (i) 941,541 Ordinary
Shares at a purchase price of $1.30 per share and (ii) pre-funded warrants to purchase up to 1,709,760 Ordinary Shares at a purchase price
of $1.30, less $0.001 per pre-funded warrant. We received approximately $3.4 million in gross proceeds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 27, 2024, we entered
into securities purchase agreements for private placement financing with certain accredited investors, pursuant to which the investors
agreed to purchase (i) 3,950,343 of our Ordinary Shares at a purchase price of $0.70 per share, (ii) pre-funded warrants to purchase up
to 658,372 ordinary shares at a purchase price of $0.70, less $0.001 per pre-funded warrant. In addition, the purchasers of such Ordinary
Shares or pre-funded warrants received warrants to purchase up to 4,608,715 Ordinary Shares at an exercise price of $1.10 per share. We
received approximately $3.2 million in gross proceeds. In addition, we entered into a placement agency agreement with Dawson James Securities,
Inc., who served as placement agent in the offering, dated December 27, 2024, pursuant to which we agreed to pay the placement agent a
cash placement fee equal to: (a) 8.0% of the gross proceeds received in the offering from certain investors introduced by the placement
agent and 4.0% of the gross proceeds received by us from the exercise of warrants by such investors, (b) 4.0% of the gross proceeds received
in the offering from certain investors introduced by us and 4.0% of the gross proceeds received by us from the exercise of warrants by
such investors, and (c) 0% of the gross proceeds received in the offering from certain other investors and 0% of the gross proceeds received
by us from the exercise of warrants by such investors. As of December 31, 2025, all the pre-funded warrants and warrants to purchase 855,714
Ordinary Shares were exercised.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 14, 2025, we entered
into a sales agreement with A.G.P./Alliance Global Partners, or AGP, pursuant to which we were able to offer and sell, from time to time,
through AGP, our Ordinary Shares. The Ordinary Shares were to be offered and sold pursuant to our Registration Statement on&#160;Form
F-3&#160;(File No. 333-266748), and a prospectus supplement to the Registration Statement, filed on March 14, 2025 with the SEC. Under
the sales agreement, we sold approximately 5,485,000 of Ordinary Shares, and the gross proceeds were approximately $4,888,000 before deducting
offering costs of approximately $272,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 12, 2025, we entered
into a purchase agreement with YA II PN, Ltd., or YA, providing for the issuance, in a registered direct offering, of 1,565,217 Ordinary
Shares at a purchase price of $1.15 per share. We received approximately $1.8 million in gross proceeds before deducting offering costs
of approximately $50,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 12, 2025, we entered
into a Standby Equity Purchase Agreement, or SEPA, with YA. Pursuant to the terms of the SEPA, YA committed to purchase up to $25 million,
or the Commitment Amount, of Ordinary Shares at any time during the three-year period following the execution date of the SEPA. Pursuant
to the terms of the SEPA, any Ordinary Shares sold to YA will be priced at 97% of the market price, which is defined as the lowest daily
VWAP (as defined in the SEPA) of the Ordinary Shares during the three consecutive trading days commencing on the trading day of our delivery
of an Advance Notice (as defined in the SEPA) to YA. Any sale of Ordinary Shares pursuant to the SEPA is subject to certain limitations,
including that YA is not permitted to purchase any Ordinary Shares that would result in it owning more than 4.99% of our Ordinary Shares.
Pursuant to the SEPA, we also agreed to pay YA a commitment fee, or the Commitment Fee, equal to 2.00% of the Commitment Amount, payable
in two tranches in our Ordinary Shares at a price per share average of the daily volume weighted average prices of the Ordinary Shares
during the three trading days immediately prior to payment due date also agreed to pay to YA a structuring fee in the amount of $25,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 5, 2026, we entered
into a non-binding term sheet, or the Term Sheet, with the Target, to acquire the Target&#8217;s liquid biopsy business in exchange for
40% of our issued and outstanding share capital on a fully diluted basis. As a part of the acquisition, we will obtain a $15 million
equity investment, or the Equity Investment, at our pre-money valuation of $180 million or at such valuation as may be expressly agreed
by the parties in the negotiated definitive agreement to acquire Target&#8217;s liquid biopsy business, or the Purchase Agreement. The
closings of the Equity Investment and the Purchase Agreement are intended to happen concurrently. Our existing shareholders as of a record
date preceding the closing of the Purchase Agreement and the Equity Investment, or such other date agreed by the parties, shall receive
contingent value rights to net proceeds from the sale of the current business assets and/or business activity, or the Legacy Assets,
by us to a third party. We intend to use up to $12 million from the net proceeds of the Equity Investment to fund the ongoing operations
of its Legacy Assets, unless and until we sell the Legacy Assets. If the funding of the Legacy Assets exceeds $5 million in the aggregate,
the Target may be entitled to receive the amount exceeding such $5 million from any net proceeds of a sale of the Legacy Assets, including
up to the entirety of the aggregate net proceeds received from the sale of the Legacy Assets (but in any case no more than such net proceeds),
following a successful sale of the Legacy Assets. In March 2026, we announced that we will not pursue the transaction with the Target.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Term
Sheet, on January 5, 2026, we entered into a binding senior convertible debenture, or the Debenture, with the Target, whereby we agreed
to lend the Target a principal amount of $1 million. The Debenture will bear interest at a 10% annual rate, provided, however, that in
case of an Event of Default (as defined in the Debenture), the annual interest rate shall increase to 18%, retroactively as of the original
issue date. The Target may prepay any portion of the principal amount of the Debenture without the need for our prior written consent.
Any payment thereof (including any partial payment) shall first be made on account of outstanding interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Debenture matures on the
date that is 180 days from January 5, 2026, on or such earlier date where (i) the Purchase Agreement has not been entered into within
60 days from January 5, 2026, (ii) if there is a change in control of the Target (including, without limitations, changes in the composition
of the Target&#8217;s board of directors where the majority of board members (excluding the external members) holding office on the date
hereof, cease to hold office, then the date of such change in control, or the Maturity Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the original issue
date of the Debenture, but no later than the lapse of the Maturity Date, unless otherwise extended by our mutual consent and the Target,
if the closing of the Equity Investment, Purchase Agreement and sale of the Legacy Assets, or the Transaction, shall have occurred, at
the time of such closing, all amounts under the Debenture shall either, according to the discretion of Target (i) be offset from any consideration
payable to Target by us in connection with the Asset Purchase Agreement, (ii) or alternatively, at Target&#8217;s sole discretion (provided
that the interest portion shall be paid in cash to us), the Target shall repay the outstanding amounts under the Debenture. Subject to
the consummation of the Purchase Agreement, we and Target may further agree to redeem the outstanding principal amount under the Debenture
by issuing the most senior class of securities of the entity owning the Target&#8217;s liquid biopsy business at the closing of the Asset
Purchase Agreement (insofar as the Asset Purchase Agreement is consummated by way of a spin-off or a similar transaction), at a price
per share based on a pre-money valuation of $45 million of such entity, and the Target will concurrently make cash payment of any interest
accrued thereof, to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Target (and we, in case
that the Debenture has not been fully discharged by the Maturity Date, or such earlier time in case of an Event of Default which is continuing),
or each, as applicable, an Initiating Party, may, at any time prior to the full discharge of the Debenture, convert, in whole (unless
otherwise agreed by us to convert only part of the outstanding principal amount), the outstanding principal amount (and/or accrued interest
&#8211; if instructed by the Company) of the Debenture, into ordinary shares, NIS 0.001 par value per share, of the Target, at a conversion
price of NIS 0.30 per share (or, if applicable, the then applicable minimum effective conversion price permitted by the Tel Aviv Stock
Exchange, or the TASE; provided that, in no event shall such conversion price be less than the minimum effective share price permitted
by the TASE regulations and bylaws. Any conversion under the Debenture shall be subject to the approval of the TASE for the registration
of the shares to be issued as a result of such conversion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to an ownership
limitation cap of 19.99%, or the Ownership Limitation, and we shall not be entitled to convert any portion of the Debenture in excess
of the Ownership Limitation (the number of Target&#8217;s ordinary shares to be converted shall not exceed 27,783,367 of the Target&#8217;s
ordinary shares).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Debenture contains certain
prerequisites, such as corporate approval and TASE approval of the ordinary shares to be issued upon conversion of the Debenture, and
customary representations, warranties and covenants of the Company and Target, including receipt of $5 million by us pursuant to the
SEPA. The Debenture will be deemed issued at the signing, however, our obligation to pay $1 million is subject to the satisfaction of
the prerequisites. On February 19, 2026, we and the Target entered into an amendment and addendum to the Debenture, or the Amendment.
Pursuant to the Amendment: (i) the period of 45 days from the date of execution of the Debenture for the satisfaction of the certain
prerequisites set forth in clauses 8(a) through 8(c) of the Debenture was extended by additional 30 days, to 75 days; and (ii) the prerequisite
of a $5 million investment to be obtained by us set forth in clause 8(b) of the Debenture was amended and restated in such manner such
that it shall be satisfied by the receipt of $5 million, following the date of the Amendment, from investors introduced to us by the
Target pursuant to the requirements of the placement agent agreement, dated February 5, 2026, by an between us and A.G.P/ Alliance Global
Partners (rather than pursuant to the SEPA). Except as set forth above, all other terms of the Debentures remain unchanged and in full
force and effect. As of March 25, 2026, we have not received any proceeds under the SEPA, and therefore, the Debenture expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 5, 2026, we entered
into a purchase agreement with a single institutional investor providing for the issuance, in a registered direct offering, of (i) 4,000,000
Ordinary Shares at a purchase price of $0.70 per share and (ii) pre-funded warrants to purchase up to 2,785,715 Ordinary Shares at a
purchase price of $0.70, less $0.001 per pre-funded warrant. In a concurrent private placement, we also agreed to issue the investor
ordinary warrants to purchase up to 6,785,715 Ordinary Shares. The ordinary warrants are exercisable six months after their issuance
at an exercise price of $0.70 per Ordinary Share and will expire on the five year anniversary of their initial exercise date. In connection
with the offering, we also entered into an agreement to amend existing warrants that were previously issued in December 2023 to the investor
participating in the offering. Such existing warrants originally entitled the investor to purchase up to 3,031,250 Ordinary Shares, with
an exercise price of $1.28 per share. Such existing warrants have been amended to reduce the exercise price to $0.70 per share, extend
the expiration date from June 27, 2027 to February 5, 2031, revise the fundamental transaction provision in the warrants and revise the
cashless exercise provision with respect to computing the valuation of the Ordinary Shares. We received approximately $4.7 million in
gross proceeds, before deducting offering costs of approximately $460,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 17, 2026, we entered
into a sales agreement with AGP pursuant to which we may offer and sell, from time to time, through the sales agent, our Ordinary Shares
having an aggregate offering price of up to $2,015,985.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_021"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.C</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and development, patents and licenses, etc.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of our research
and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see &#8220;Item
5. Operating and Financial Review and Prospects- A. Operating Results- Operating Expenses- Research and Development Expenses, net&#8221;
and &#8220;Item 5. Operating and Financial Review and Prospects- A. Operating Results- Comparison of the years ended December 31, 2025
and 2024- Research and Development Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_022"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.D</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trend Information</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_023"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical Accounting Estimates</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We describe our significant
accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2025. We believe that the accounting
policies below are critical in order to fully understand and evaluate our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We prepare our financial statements
in accordance with U.S. GAAP. At the time of the preparation of the financial statements, our management is required to use estimates,
evaluations, and assumptions which affect the application of the accounting policy and the amounts reported for assets, obligations, and
expenses. Any estimates and assumptions are continually reviewed. The changes to the accounting estimates are credited during the period
in which the change to the estimate is made. The preparation of financial statements requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities in relation with stock-based compensation expense, fair value financial liabilities,
recognition, measurement, and disclosure of contingent liabilities, Interest rate used for lease liability measurement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. <span style="text-transform: uppercase">DIRECTORS,
SENIOR MANAGEMENT AND EMPLOYEES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_025"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors and Senior Management.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our executive officers, key employees and directors as of the date of this annual report on Form 20-F:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 60%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yafit Tehila</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Shabtai</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operations Officer and VP of Research and Development</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniella Yeheskely Hayon </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Technology Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Amit <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tal Parnes <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sivan Matza <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Compensation Committee</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of the Audit Committee and Financial Statement Examination Committee</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director (as defined under Nasdaq rules)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dagi Ben-Noon, Chief Executive Officer, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Dagi Ben-Noon</i> has
served as our Chief Executive Officer since June 2020 and as a director since March 2020. Prior to that, Mr. Ben-Noon served as our Chief
Operations Officer from March 2018 to June 2020. Mr. Ben-Noon founded our company together with Dr. Udi Nussinovitch and Mr. Joe Hayon
in February 2018. Mr. Ben-Noon has over 15 years of experience in product development from idea inception to illustration, design, manufacturing
and product launch. Mr. Ben-Noon co-founded Nano Dimension Ltd. (Nasdaq: NNDN) and served as the company&#8217;s chief operating officer
and director from July 2012 to October 2017. As Nano Dimension Ltd.&#8217;s chief operating officer, Mr. Ben-Noon was in charge of the
company&#8217;s research and development, operations, production, quality and information technology. Mr. Ben-Noon has a BSc in Mechanical
Engineering from the Ben-Gurion University of the Negev in Beer Sheva, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yafit Tehila, Chief Financial Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Yafit Tehila </i>has
served as our Chief Financial Officer since August 2022. Prior to becoming our CFO, Ms. Tehila served as our Vice President of Finance
and Legal since February 2021. Ms. Tehila served as Director of Finance at Nano Dimension Ltd. (NASDAQ: NNDM) from November 2020 through
February 2021 and Financial Controller from February 2016 through November 2020. Ms. Tehila served as Financial Controller at Migdal Capital
Markets from August 2010 through November 2016. Ms. Tehila received has a B.A. in Accounting, Economics and business management from Tel
Aviv University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Avi Shabtai, Chief Operations Officer and Vice
President of Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Avi Shabtai</i> has
served as our Chief Operations Officer since July 2020 and as our Vice President of Research and Development since June 2019. Mr. Shabtai&#8217;s
expertise lies in engineering, testing, quality management, regulation, risk management and production across a product&#8217;s life cycle
from concept to production. He has over 25 years of experience in management of high-tech companies, particularly in their research and
development and operations departments, including roles of vice president of research and development and vice president of quality and
engineering. From July 2015 to March 2018, Mr. Shabtai worked as vice president of research and development at Nano Dimension Ltd. (Nasdaq:
NNDN). Prior to that, Mr. Shabtai worked as vice president of research and development at ZutaCore from April 2018 to May 2019. Mr. Shabtai
is qualified as software quality engineer by the ALD College and the Israeli Standard Institute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Daniella Yeheskely -Hayon, PhD, MBA, Chief
Technology Officer.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Daniella Yeheskely-Hayon
</i>has served as our Chief Technology Officer since January 2022. Dr. Yeheskely-Hayon has comprehensive project management experience
in biomedical engineering as well as in key roles within medical device companies. Since June 2016, Dr. Yeheskely-Hayon has served as
the director of research and development and chief of operations at O2Cure Ltd., a medical device company that specializes in the development
of long-term oxygenators and respiratory assist devices for hospitals. From October 2009 to May 2016, Dr. Yeheskely-Hayon served as a
senior research associate at the Technion Department of Biomedical Engineering. Dr. Yeheskely-Hayon holds a PhD in Biology from the Technion
Institute, Israel and an MBA from ONO academic college.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tal Parnes, Director, Chairman of the Board
of Directors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Tal Parnes</i> has
served as chairman of our board of directors since February 1, 2025, and has served on our board of directors since July 16, 2021. Mr.
Parnes co-founded and served as a chief executive officer and president of Zuta-Core Ltd. from 2016 to 2020. Prior to that, Mr. Parnes
co-founded and served as a chief executive officer of HQL Pharmaceuticals Ltd. from 2010 to 2015. Mr. Parnes also served as chief operating
officer of Silynx Communications Inc. from 2007 to 2009, served as a vice president of operations of Wavion Inc. from 2005 to 2006 and
vice president of operations of Atrica Ltd. from 2002 to 2004. Between 1999 to 2001, Mr. Parnes also served as a chief financial officer
and business development director of Printlife Ltd. Mr. Parnes holds a B.A. in Economics and History from Tel Aviv University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Lior Amit, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Lior Amit&#160;</i>has
served on our board of directors since August 1, 2021. Since 2014, Mr. Amit has served as a private financial advisor for both high net
worth individuals and companies and serves as a director at Capital link , Nirplex and Ronimar LTD. Mr. Amit was the CFO of the BBR Saatchi
&amp; Saatchi advertising group in Israel from 1996 to 2013, helping to turn it into a leading local advertising company including advertising
agencies, media operations and digital and content, growing from 40 employees to 250 employees. Mr. Amit holds a Master of Business Administration
((Finance and Insurance) and a B.A. in Economics and Accounting from the Tel Aviv University. Mr. Amit is a Certified Public accountant
in Israel and holds an advisor license with the Israeli Securities Authority.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sivan Matza, Director </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mrs. Sivan Matza</i> has
served on our board of directors since October 2025. Mrs. Matza has been serving as a director at the board of directors of Grandby Hotels
since December 2020 and as a consultant and director at the board of directors of Brevan Howard (Tel Aviv) Ltd. since January 2022. Prior
to that, Mrs. Matza worked as executive committee member at Brevan Howard (Israel) Ltd. Mrs. Matza also worked a CPA in the financial
division of Bank Leumi and senior audit manager at Kost Forer Gabbay &amp; Kasierer, a Member of EY Global. Mrs. Matza holds an M.A. with
specialization in Accounting from Bar-Ilan University in Ramat Gan, Israel, and a B.A. in Business Management (Accounting) from the College
of Management in Rishon LeZion, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Scientific Advisory Board</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a Scientific Advisory
Board of several active physicians and experts in the fields of respiratory disease, pulmonary diseases, cardiac disease and laboratory
animal science. The Scientific Advisory Board consults and assists us in the aforementioned fields by conducting clinical research and
participating in pre-clinical studies. The members of our Scientific Advisory Board receive compensation in the form of cash payments
or option grants. All members of the Scientific Advisory Board provided us with their consent to be named in this annual report on Form
20-F and any materials related hereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Avraham Abutbul, M.D.,</i>
has held numerous positions at the Hadassah Medical Center in Jerusalem, Israel, since 2008. Currently, Dr. Abutbul has served a senior
physician the Hadassah Medical Center&#8217;s Medical Intensive Care Unit and its Pulmonology Institute since 2017, in addition to leading
the Hadassah Medical Center&#8217;s nationwide research of chronic obstructive pulmonary disease. Prior to his current roles, Dr. Abutbul
completed fellowship at the Institute of Pulmonology in 2016 and the General Intensive Care Unit in 2014. Dr. Abutbul also completed residency
at the Department of Internal Medicine in 2012. Dr. Abutbul is a lecturer at the Hebrew University of Jerusalem, Israel and at the Hadassah
Medical School, Jerusalem, Israel. Dr. Abutbul received his B.Med.Sc. from the Ruth and Bruce Rappaport Faculty of Medicine in Haifa,
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Professor Daniel Brodie</i>
is the Section Chief for Critical Care within the Division of Pulmonary, Allergy and Critical Care Medicine, the Director of the Adult
ECMO Program and the Director of the Center for Acute Respiratory Failure at the Columbia University/New York-Presbyterian Hospital. Prof.
Brodie is the President-elect of the Extracorporeal Life Support Organization (ELSO) and the chairman of the Executive Committee of the
International ECMO Network (ECMONet), two leading international organizations spearheading scientific knowledge in the field of extracorporeal
life support. He is currently on the Steering Committee of numerous ongoing and upcoming clinical trials in the field. In addition, Prof.
Brodie serves as a member of the National Heart, Lung, and Blood Institute&#8217;s (NHLBI) Protocol Review Committee for the Prevention
and Early Treatment of Acute Lung Injury (PETAL) Network. Prof. Brodie has served as a reviewer in influential scientific journals, including
the New England Journal of medicine, Lancet and JAMA. Prof Brodie has authored more than 300 peer-reviewed publications and book chapters
and has delivered nearly 400 invited lectures throughout the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Eddy Fan</i> is an
associate professor in the Interdepartmental Division of Critical Care Medicine and the Institute of Health Policy, Management and Evaluation
at the University of Toronto and a staff intensivist at the University Health Network/Mount Sinai Hospital in Toronto, Ontario. Prof.
Fan currently is the medical director of the extracorporeal life support program at the Toronto General Hospital. Dr. Fan received an
undergraduate degree from the University of Toronto, his medical degree from the University of Western Ontario and a doctorate in clinical
investigation from Johns Hopkins University. Among his most significant publications are: (1) &#8220;An Official American Thoracic Society/European
Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients
with Acute Respiratory Distress Syndrome&#8221; in the American Journal of Respiratory and Critical Care Medicine; (2) &#8220;Veno-venous
extracorporeal membrane oxygenation for acute respiratory failure: a clinical review from an international group of experts.&#8221; in
Intensive Care Medicine; and (3) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in
intensive care units in 50 countries&#8221; published in JAMA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Orit Cohen Jacob</i>
is veterinary surgeon with a unique certified specialty in laboratory animal medicine. Dr. Jacob held numerous positions at the Israel
Institute for Biological Research in Ness Ziona, Israel, for 16 years, while leading the establishment of the biggest pre-clinical animal
facility and laboratories in Israel. At the Israel Institute for Biological Research, Dr. Jacob founded a GMP stable facility, for anti-serum
production for the State of Israel. Dr. Jacob participated as a surgeon and advisor, in her field of expertise, in a wide variety of research
studies, related to homeland security from 1999 to 2015. Dr. Jacob was a member of the national animal experimentation council of the
ministry of health, and head of the national ethics committee for animal experimentations from 2013 to 2018. Currently, Dr. Jacob is the
co-owner and chief executive officer of SeruMed GMP Ltd., which has been the sole manufacturer and provider of the anti-venom serum against
viper and echis snakes to the Ministry of Health of Israel since 2016. Furthermore, Dr. Jacob is the owner of BioSphera Consulting Ltd.,
through which she has been providing knowledge to bio-tech companies in all aspects of pre-clinical research, facility establishment,
GMP regulations, ethics and science since 2016.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Stefan Ledot</i> is
an expert in various clinical fields including critical care medicine, anesthesia, extracorporeal support and echocardiography. During
his career, he has undertaken a large number of educational duties, including advanced cardiovascular life support (ACLS) instruction,
critical care module for physiotherapists instruction, critical care module nursing school instruction, among others. Dr. Ledot is a highly
appreciated speaker in the critical care space. Dr. Ledot completed his accreditation for transesophageal echocardiography (TOE) from
the European Association of Cardiovascular Imaging and holds a European Diploma in Intensive Care. Dr. Ledot has served as a senior clinician
in critical care and anesthetics at Royal Brompton &amp; Harefield Hospitals in the United Kingdom and became the director of the ECMO
service and critical care. The Royal Brompton ECMO service is one of the largest in Europe and has been recognized as a center of excellence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Yael Lichter </i>is
Director of the Medical Intensive Care Unit at Tel Aviv Sourasky Medical Center, where she completed her residency training in Internal
Medicine and Intensive Care. She also serves as Treasurer of the Israeli ECMO Society. Dr. Lichter served as a Captain in the IDF Medical
Corps, as a field doctor in combat units. She completed her medical training at the Tel Aviv University the Sackler Faculty of Medicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Sharon Marx</i> obtained
a PhD in physical organic chemistry from the Hebrew University, Jerusalem in 1996. Since 1996, Dr. Marx has worked at the Israel Institute
for Biological Research in the physical chemistry department. Dr. Marx was a fellow at the Israel Institute for Biological Researchand
is currently serving as the physical chemistry department head. From 2008 to 2010, Dr. Marx was an Assistant Professor (on sabbatical)
at the University of Pennsylvania and developed biocompatible fuel cells while there. Her research interests include sensor and biosensors
development, chemical sensor networks, molecularly imprinted polymers, chemiresistors, sensors for gas phase (air pollution and toxic
materials) and sensors for water quality.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Dekel Stavi, </i>medical
director, has considerable experience in leading Extracorporeal Life Support programs, and treating cardio and hemato-oncology patients
in the ICU. Prior to joining Critical Care at the University of Toronto, he served as a senior intensive care physician at the Tel Aviv
Sourasky Medical Center in Israel where he initiated its institutional ECMO program. Dr. Stavi&#8217;s notable publications include &#8220;Outcomes
of prolonged mechanical ventilation in patients who underwent bedside percutaneous dilatation tracheostomy in intermediate care units
- a single center study&#8221; and &#8220;Outcome and survival following tracheostomy in patients &#8805; 85 years old.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Dan Gorfil </i>is a
distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive
Care Unit and the ECMO program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil&#8217;s expertise
is expected to significantly contribute to the deployment of the INSPIRA ART100.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Family Relationships</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between any members of our executive management and our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Arrangements for Election of Directors and
Members of Management</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no arrangements
or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management or our directors
were selected. See &#8220;Item 7.B. - Related Party Transactions&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_026"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
all compensation paid by us to our five most highly compensated officers for the year ended December 31, 2025. The table does not include
any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts reported in the
tables below reflect the cost to the Company, in U.S. dollars, for the year ended December 31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amounts paid in NIS are translated
into U.S. dollars at the rate of NIS 3.453 = U.S. $1.00, based on the average representative rate of exchange between the NIS and the
U.S. dollar as reported by the Bank of Israel during such period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><b>Salary,<br/> bonuses<br/> and Related<br/> Benefits</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><b>Pension,<br/> Retirement<br/> and Other<br/> Similar<br/> Benefits</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share<br/> Based<br/> Compensation</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Non, <i>Chief Executive Officer</i></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">335,262</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">23,775</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">666,059</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Hayon, <i>President and Director</i><sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">445,144</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">21,652</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1,012,067</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yafit Tehila, <i>Chief Financial Officer</i></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">223,086</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">46,607</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">421,378</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Shabtai, <i>Chief Operations Officer and VP of Research and Development</i></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">280,492</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">63,810</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">498,767</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniella Yeheskely-Hayon, <i>Chief Technology Officer</i></span></td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">215,958</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">45,666</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">408,146</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0px; margin-bottom: 0px; width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Hayon resigned as a President in May 2025 and stepped down from our board of directors in July 2025.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For so long as we qualify
as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic companies regarding disclosure
of the compensation of certain executive officers on an individual basis. Pursuant to the Companies Law, as a public company we are required
to disclose the annual compensation of our five most highly compensated officers on an individual basis. This disclosure will not be as
extensive as that required of a U.S. domestic issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements with Executive Officers
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition,
confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited
under applicable law. In addition, we entered into indemnification agreements, with each executive officer and director pursuant to which
we indemnify each of them up to a certain amount and to the extent that these liabilities are not covered by directors and officers insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of the terms
of our options and option plans, see &#8220;Item 6.E. Share Ownership-Equity Incentive Plan.<span style="font-variant: small-caps">&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Directors&#8217; Service Contracts</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than with respect to
our directors that are also executive officers, we do not have written agreements with any director providing for benefits upon the termination
of his employment with our company. In our first annual general meeting as a public company, which took place in December 2021, we instituted
a yearly fixed fee in the amount of $40,000 for each of our currently serving directors who are not also executive officers (including
the current Chairman of our board of directors) and amount of $120,000 for the former chairman of our board of directors. However, on
February 20, 2025, the Company&#8217;s compensation committee and board of directors approved an increase in the yearly fixed fee of Mr.
Tal Parnes, the Company&#8217;s chairman of the board of directors, to $80,000, and an increase to the yearly fixed fee of Mrs. Limor
Rozen and Mr. Lior Amit, and generally to the Company&#8217;s non-executive directors, to $46,000, subject to the approval of the Company&#8217;s
shareholders. On May 12, 2025, our shareholders approved the respective increases for Mr. Parnes, Mrs. Rozen and Mr. Amit. On October
15, 2025, Limor Rozen resigned from our board of directors. On October 21, 2025, Sivan Matza was appointed as a director and is also entitled
to receive a year fixed fee of $46,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_027"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Practices. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Introduction</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors consists
of four members. We believe that Sivan Matza, Lior Amit, and Tal Parnes are &#8220;independent&#8221; for purposes of the Nasdaq rules.
Our amended and restated articles of association provide that the number of board of directors&#8217; members shall be set by the general
meeting of the shareholders provided that it will consist of not less than three (3) and not more than twelve (12). Pursuant to the Companies
Law, the management of our business is vested in our board of directors. Our board of directors may exercise all powers and may take all
actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day
management and have individual responsibilities established by our board of directors. Pursuant to the Companies Law, our Chief Executive
Officer is appointed by, and serves at the discretion of, our board of directors, subject to the employment agreement that we have entered
into with him. All other executive officers are appointed by our Chief Executive Officer. According to the Companies Law, their terms
of employment are subject to the approval of the board of directors&#8217; compensation committee and of the board of directors (and in
some cases are also subject to shareholders approval) and are subject to the terms of any applicable employment agreements that we may
enter into with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each director, except external
directors, if applicable, that may be required to be appointed under the Companies Law under certain circumstances, will hold office until
the next annual general meeting of our shareholders following his or her appointment, or until he or she resigns or unless he or she is
removed by a majority vote of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance
with the Companies Law and/or our amended and restated articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under certain
circumstances, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on
our board of directors or in addition to the acting directors (subject to the limitation set forth in our articles of association on the
number of directors), until the next annual general meeting or special general meeting in which directors term may be terminated. External
directors, if applicable, may be elected for up to two additional three-year terms after their initial three-year term under the circumstances
described below, with certain exceptions as described in &#8220;External Directors&#8221; below, and may be removed from office only under
the limited circumstances set forth in the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, any
shareholder holding at least one percent of our outstanding voting power may suggest nominating a director in an Annual General Meeting
of the shareholders. However, any such shareholder may make such a suggestion only if a written and timely notice of such shareholder&#8217;s
intent to make such nomination has been given to our board of directors, in accordance with the provisions of our amended and restated
articles of association and the Companies Law. Any such notice must include certain information, including the consent of the proposed
director nominee to serve as our director if elected, and a declaration that the nominee signed declaring that he or she possesses the
requisite skills and has the availability to carry out his or her duties. Additionally, the nominee must provide details of such skills,
and demonstrate an absence of any limitation under the Companies Law that may prevent his or her election, and affirm that all of the
required election-information is provided to us, pursuant to the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under the Companies
Law regulations (exemptions applicable for Israeli companies whose shares are listed outside of Israel, 5760-2000 (the &#8220;Exemptions
Regulations&#8221;), one or more shareholders may request the company&#8217;s board of directors to include an appointment of a candidate
for a position on the board of directors or the termination of a board member, as an item on the agenda of a future general meeting (if
the company sees fit), provided that the shareholder hold at least five percent (5%) of the voting rights of the company, instead of one
percent (1%) as required in the past.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli law, we
are required to hold an annual general meeting of our shareholders once every calendar year, at such time and place which shall be determined
by our board of directors, that must be no later than 15 months after the date of the previous annual general meeting. All meetings other
than the annual general meeting of shareholders are referred to as special general meetings. Our board of directors may call special meetings
whenever it sees fit and upon the request of: (a) any two of our directors or such number of directors equal to one quarter of the directors
then at office; and/or (b) one or more shareholders holding, in the aggregate, (i) 5% or more of our outstanding issued shares and 1%
of our outstanding voting power or (ii) 5% or more of our outstanding voting power, or the Non Exempted Holding. However, under the Exemptions
Regulations, the board of directors of an Israeli company whose shares are listed outside of Israel, shall convene a special meeting at
the request of: (i) one or more shareholders holding at least ten percent (10%) of the issued and outstanding share capital instead of
five (5%) in the past, and at least one percent (1%) of the voting rights in the company, or (ii) one or more shareholders holding at
least ten percent (10%) of the voting rights in the company, unless the applicable law incorporated in the country in which the Company
is listed for trade, establishes a right to demand convening of such a meeting for those holding less than ten percent (10%) of the voting
rights in the company (in which case, the Non Exempted Holding shall apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
board of directors must determine the minimum number of directors who are required to have accounting and financial expertise. In determining
the number of directors required to have such expertise, our board of directors must consider, among other things, the type and size of
the company and the scope and complexity of its operations. Our board of directors has determined that the minimum number of directors
of our company who are required to have accounting and financial expertise is one.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors must
elect one director to serve as the chairman of the board of directors to preside at the meetings of the board of directors, and may also
remove that director as chairman. Pursuant to the Companies Law, neither the chief executive officer nor any of his or her relatives is
permitted to serve as the chairman of the board of directors, and a company may not vest the chairman or any of his or her relatives with
the chief executive officer&#8217;s authorities. In addition, a person who reports, directly or indirectly, to the chief executive officer
may not serve as the chairman of the board of directors; the chairman may not be vested with authorities of a person who reports, directly
or indirectly, to the chief executive officer; and the chairman may not serve in any other position in the company or a controlled company,
but he or she may serve as a director or chairman of a controlled company. However, the Companies Law permits a company&#8217;s shareholders
to determine, for a period not exceeding three years from each such determination, that the chairman or his or her relative may serve
as chief executive officer or be vested with the chief executive officer&#8217;s authorities, and that the chief executive officer or
his or her relative may serve as chairman or be vested with the chairman&#8217;s authorities. Such determination of a company&#8217;s
shareholders requires either: (1) the approval of at least a majority of the shares of those shareholders present and voting on the matter
(other than controlling shareholders and those having a personal interest in the determination) (shares held by abstaining shareholders
shall not be considered); or (2) that the total number of shares opposing such determination does not exceed 2% of the total voting power
in the company. Currently, we have a separate chairman and chief executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors may,
subject to the provisions of the Companies Law, delegate some of its powers to committees of the board, and it may, from time to time,
revoke such delegation or alter the composition of any such committees, subject to certain limitations. Unless otherwise expressly provided
by the board of directors, the committees shall not be empowered to further delegate such powers. The composition and duties of our audit
committee, financial statement examination committee and compensation committee are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors oversees
how management monitors compliance with our risk management policies and procedures, and reviews the adequacy of the risk management framework
in relation to the risks faced by us. The board of directors is assisted in its oversight role by an internal auditor. The internal auditor
undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to our audit
committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>External Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, except
as provided below, companies incorporated under the laws of the State of Israel that are publicly traded, including Israeli companies
with shares listed on the Nasdaq, are required to appoint at least two external directors who meet the qualification requirements set
forth in the Companies Law. The definitions of an external director under the Companies Law and independent director under Nasdaq rules
are similar such that it would generally be expected that our two external directors will also comply with the independence requirement
under Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under regulations promulgated
pursuant to the Companies Law, a company with no controlling shareholder whose shares are listed for trading on specified exchanges outside
of Israel, including Nasdaq, may adopt exemptions from various corporate governance requirements of the Companies Law, so long as such
company satisfies the requirements of applicable foreign country laws and regulations, including applicable stock exchange rules, that
apply to companies organized in that country and relating to the appointment of independent directors and the composition of audit and
compensation committees. Such exemptions include an exemption from the requirement to appoint external directors and the requirement that
an external director be a member of certain committees, as well as exemption from limitations on directors&#8217; compensation. We do
not currently have a controlling shareholder and we use this exemption from the requirement described herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Independent Directors Under the Companies
Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An &#8220;independent director&#8221;
under the Companies Law is either an external director or a director who meets the same non-affiliation criteria as an external director
(except for (i) the requirement that the director be an Israeli resident (which does not apply to companies such as ours whose securities
have been offered outside of Israel or are listed outside of Israel) and (ii) the requirement for accounting and financial expertise or
professional qualifications), as determined by the audit committee, and who has not served as a director of the company for more than
nine consecutive years. For these purposes, ceasing to serve as a director for a period of two years or less would not be deemed to sever
the consecutive nature of such director&#8217;s service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Exemptions
Regulations, a director in a public company whose shares are listed for trading on specified exchanges outside of Israel, including on
the Nasdaq Capital Market, who qualifies as an independent director under the relevant non-Israeli rules and who meets certain non-affiliation
criteria, which are less stringent than those applicable to independent directors as set forth above, would be deemed an &#8220;independent&#8221;
director pursuant to the Companies Law provided: (i) he or she has not served as a director for more than nine consecutive years; (ii)
he or she has been approved as such by the audit committee; and (iii) his or her remuneration shall be in accordance with the Companies
Law and the regulations promulgated thereunder. For these purposes, ceasing to serve as a director for a period of two years or less would
not be deemed to sever the consecutive nature of such director&#8217;s service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, pursuant to these
regulations, such company may reappoint a person as an independent director for additional terms, beyond nine years, which do not exceed
three years each, if each of the audit committee and the board of directors determine, in that order, that in light of the independent
director&#8217;s expertise and special contribution to the board of directors and its committees, the reappointment for an additional
term is in the company&#8217;s best interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alternate Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association provide, as allowed by the Companies Law, that any director may, subject to the conditions set thereto including approval
of the nominee by our board of directors, appoint a person as an alternate to act in his place, to remove the alternate and appoint another
in his place and to appoint an alternate in place of an alternate whose office is vacated for any reason whatsoever. Under the Companies
Law, a person who is not qualified to be appointed as a director, a person who is already serving as a director or a person who is already
serving as an alternate director for another director, may not be appointed as an alternate director. Nevertheless, a director who is
already serving as a director may be appointed as an alternate director for a member of a committee of the board of directors so long
as he or she is not already serving as a member of such committee, and if the alternate director is to replace an external director, he
or she is required to be an external director and to have either &#8220;financial and accounting expertise&#8221; or &#8220;professional
expertise,&#8221; depending on the qualifications of the external director he or she is replacing. A person who does not have the requisite
&#8220;financial and accounting experience&#8221; or the &#8220;professional expertise,&#8221; depending on the qualifications of the
external director he or she is replacing, may not be appointed as an alternate director for an external director. A person who is not
qualified to be appointed as an independent director, pursuant to the Companies Law, may not be appointed as an alternate director of
an independent director qualified as such under the Companies Law. Unless the appointing director limits the time or scope of the appointment,
the appointment is effective for all purposes until the appointing director ceases to be a director or terminates the appointment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
established two standing statutory committees, the audit and financial statements examination committee and the compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish an audit committee. The audit committee must be comprised of at least three directors,
including all of the external directors, if applicable, (one of whom must serve as chair of the committee). The audit committee may not
include the chairman of the board; a director employed by the company or by a controlling shareholder of the company or by an entity controlled
by a controlling shareholder; a controlling shareholder or a relative of a controlling shareholder; a director employed by or providing
services on a regular basis to the company, to a controlling shareholder or to an entity controlled by a controlling shareholder, or a
director who derives most of his or her income from a controlling shareholder. In addition, a majority of the members of the audit committee
of a publicly traded company must be independent directors under the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under the Exemptions
Regulations, a company with no controlling shareholder might be exempted from certain obligations mentioned above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is comprised
of Lior Amit, Sivan Matza and Tal Parnes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether there are deficiencies in the business management practices of our company, and making recommendations to the board of directors to improve such practices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under Companies Law) and establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; (see &#8220;Item 6.C. Directors, Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221;); </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 0.3in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining the approval process for transactions that are &#8220;non-negligible&#8221; (i.e., transactions with a controlling shareholder that are classified by the audit committee as non-negligible, even though they are not deemed extraordinary transactions), as well as determining which types of transactions would require the approval of the audit committee, optionally based on criteria which may be determined annually in advance by the audit committee;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the handling of employees&#8217; complaints as to deficiencies in the management of our business and the protection to be provided to such employees; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee may not
conduct any discussions or approve any actions requiring its approval (see &#8220;Item 6.C. Directors, Senior Management and Employees-Board
Practices-Approval of Related Party Transactions under Israeli law&#8221;); unless at the time of the approval a majority of the committee&#8217;s
members are present, which majority consists of independent directors under the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
adopted an audit committee charter setting forth, among others, the responsibilities of the audit committee consistent with the rules
of the SEC and Nasdaq rules (in addition to the requirements for such committee under the Companies Law), including, among others, the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal auditor and reviewing effectiveness of our system of internal control over financial reporting;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and monitoring, if applicable, legal matters with significant impact, finding of regulatory authorities&#8217; findings, receive reports regarding irregularities and legal compliance, acting according to &#8220;whistleblower policy&#8221; and recommend to our board of directors if so required.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Stock Market Requirements for Audit
Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Nasdaq rules, we
are required to maintain an audit committee consisting of at least three members, all of whom are independent and are financially literate
and one of whom has accounting or related financial management expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the members
of our audit committee include Lior Amit, Tal Parnes and Sivan Matza. Mr. Amit serves as the chairman of our audit committee. All members
of our audit committee meet the requirements for financial literacy, and are each &#8220;independent&#8221;, as both terms are defined
under the Nasdaq rules. Our board of directors has determined that each member of our audit committee is an audit committee financial
expert as defined by the SEC rules and has the requisite financial experience as defined by the Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee also carries out the duties of a financial statement examination committee. As such, the audit committee is responsible
to discuss and provide recommendations to its board of directors (including the report of any deficiency found) with respect to the following
issues: (i) estimations and assessments made in connection with the preparation of financial statements; (ii) internal controls related
to the financial statements; (iii) completeness and propriety of the disclosure in the financial statements; (iv) the accounting policies
adopted and the accounting treatments implemented in material matters of the company; and (v) value evaluations, including the assumptions
and assessments on which evaluations are based and the supporting data in the financial statements. Our independent registered public
accounting firm and our internal auditor are invited to attend all meetings of our financial statements examination committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish a compensation committee. The compensation committee must be comprised of at least
three directors, including all of the external directors (if applicable), who if applicable must constitute a majority of the members
of the compensation committee. Each compensation committee member that is not an external director must be a director whose compensation
does not exceed an amount that may be paid to an external director. The compensation committee is subject to the same Companies Law restrictions
as the audit committee as to: (a) who may not be a member of the committee; and (b) who may not be present during committee deliberations
as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under the Exemptions
Regulations, a company with no controlling shareholder might be exempted from certain obligations mentioned above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee,
acting pursuant to a written charter, consists of Lior Amit, Sivan Matza and Tal Parnes. Tal Parnes serves as the chairman of our compensation
committee. Our compensation committee complies with the provisions of the Companies Law, the regulations promulgated thereunder, and our
amended and restated articles of association, on all aspects referring to its independence, authorities and practice. Our compensation
committee follows home country practice as opposed to complying with the compensation committee membership and charter requirements prescribed
under the Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
reviews and recommends to our board of directors (and in accordance with the provisions of our amended and restated compensation policy):
with respect to our executive officers&#8217; and directors&#8217;: (1) annual base compensation; (2) annual incentive bonus, including
the specific goals and amounts; (3) equity compensation; (4) employment agreements, severance arrangements, and change in control agreements
and provisions; (5) retirement grants and/or retirement bonuses; and (6) any other benefits, compensation, compensation policies or arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duties of the compensation
committee include the recommendation to the company&#8217;s board of directors of a policy regarding the terms of engagement of office
holders, to which we refer as a compensation policy. Every three years (or following five years from its initial public offering), such
policy must be adopted by the company&#8217;s board of directors, after considering the recommendations of the compensation committee.
The compensation policy is then brought for approval by our shareholders, which requires a special majority (see &#8220;Item 6.C. Directors,
Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221;). Under the Companies
Law, and under certain conditions, the board of directors may adopt the compensation policy if it is not approved by the shareholders,
provided that after the shareholders oppose the approval of such policy, the compensation committee and the board of directors revisit
the matter and determine that adopting the compensation policy is in our best interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 17, 2021, a general
meeting of our shareholders approved the adoption of a compensation policy for our officers and directors for a period of five years,
or the compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy serves
as the basis for decisions concerning the financial terms of employment or engagement of executive officers and directors, including exemption,
insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy
relates to certain factors, including advancement of our objectives, our business and long-term strategy and creation of appropriate incentives
for executives. It also considers, among other things, our risk management, size and the nature of our operations. The compensation policy
further considers the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the education, skills, expertise and accomplishments of the relevant director or executive;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the director&#8217;s or executive&#8217;s roles and responsibilities and prior compensation agreements with him or her;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between the cost of the terms of service of an office holder and the average median compensation of the other employees of the company (including those employed through manpower companies), including the impact of disparities in salary upon work relationships in our company;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service period, our performance during that period of service, the person&#8217;s contribution towards the achievement of our goals and the maximization of our profits, and the circumstances under which the person is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy also
includes the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the exception of office holders who report directly to the chief executive officer, the link between variable compensation and long-term performance and measurable criteria;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation at the time of its grant;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the conditions under which a director or executive are required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum limits for severance compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy also
considers appropriate incentives from a long-term perspective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
is responsible for: (1) recommending the compensation policy to a company&#8217;s board of directors for its approval (and subsequent
approval by the shareholders); and (2) duties related to the compensation policy and to the compensation of a company&#8217;s office holders,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors periodic updates to the compensation policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing implementation of the compensation policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering the Company&#8217;s clawback policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether the terms of compensation of certain office holders need not be brought to approval of the shareholders; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining whether to approve the terms of compensation of office holders that require the committee&#8217;s approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy is
designed to promote our long-term goals, work plan and policy, retain, motivate and incentivize our directors and executive officers,
while considering the risks that our activities involve, our size, the nature and scope of our activities and the contribution of an officer
to the achievement of our goals and maximization of profits, and align the interests of our directors and executive officers with our
long-term performance. To that end, a portion of an executive officer compensation package is targeted to reflect our short and long-term
goals, as well as the executive officer&#8217;s individual performance. On the other hand, our compensation policy includes measures designed
to reduce the executive officer&#8217;s incentives to take excessive risks that may harm us in the long-term, such as limits on the value
of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive
officer and minimum vesting periods for equity-based compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy also
addresses our executive officer&#8217;s individual characteristics (such as his or her respective position, education, scope of responsibilities
and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers the
internal ratios between compensation of our executive officers and directors and other employees. For example, the compensation that may
be granted to an executive officer may include base salary, annual bonuses, equity-based compensation, benefits and retirement and termination
of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base salary. In addition,
our compensation policy provides for maximum permitted ratios between the total variable (cash bonuses and equity-based compensation)
and non-variable (base salary) compensation components, in accordance with an officer&#8217;s respective position with the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An annual cash bonus may be
awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may
be granted to subordinate officeholders may be based entirely on a discretionary evaluation. Our Chief Executive Officer will be entitled
to recommend performance objectives to such executive officers, and such performance objectives will be approved by our compensation committee
(and, if required by law, by our board of directors).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The performance measurable
objectives of our chairman and Chief Executive Officer are determined annually by our compensation committee and board of directors. A
less significant portion of the chairman&#8217;s and/or the Chief Executive Officer&#8217;s annual cash bonus may be based on a discretionary
evaluation of the chairman&#8217;s or the Chief Executive Officer&#8217;s respective overall performance by the compensation committee
and the board of directors based on quantitative and qualitative criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The equity-based compensation
under our compensation policy for our executive officers (including members of our board of directors) is designed in a manner consistent
with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the
alignment between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to strengthen
the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation
in the form of share options or other equity-based awards, such as restricted shares and phantom options, in accordance with our equity
incentive plan then in place. Share options granted to executive officers are subject to vesting periods in order to promote long-term
retention of the awarded executive officers. The equity-based compensation is granted from time to time and be individually determined
and awarded according to the performance, educational background, prior business experience, qualifications, role and the personal responsibilities
of the executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our compensation
policy contains compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, enables our
Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer (provided that the changes
of the terms of employment are in accordance our compensation policy) and allows us to exempt, indemnify and insure our executive officers
and directors subject to certain limitations set forth thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy also
provides for compensation to the members of our board of directors either: (i) in accordance with the amounts provided in the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief
for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to time; or (ii)
in accordance with the amounts determined in our compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Requirements for Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Nasdaq rules, we
are required to maintain a compensation committee consisting of at least two members, each of whom are independent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the members
of our compensation committee include Mr. Parnes, Mr. Amit, and Mrs. Matza, each of whom is &#8220;independent&#8221;, as such term is
defined in under Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Internal Auditor </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of an Israeli public company must appoint an internal auditor nominated by the audit committee. Our internal auditor
Chaim Yechezkely, CPA (Isr) who has been serving as our internal auditor since October 2021, is a Certified Public Accountant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of the internal auditor
is to examine, among other things, whether a company&#8217;s actions comply with the law and proper business procedure. The audit committee
is required to oversee the activities, and to assess the performance of the internal auditor as well as to review the internal auditor&#8217;s
work plan. An internal auditor may not be an interested party or office holder, or a relative of any interested party or office holder,
and may not be a member of the company&#8217;s independent accounting firm or its representative. The Companies Law defines an interested
party as a holder of 5% or more of the outstanding shares or voting rights of a company, any person or entity that has the right to appoint
at least one director or the general manager of the company or any person who serves as a director or as the general manager of a company.
Our internal auditor is not an interested party in the Company and not our employee, but partner of a firm which specializes in internal
auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Remuneration of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, remuneration
of directors is subject to the approval of the compensation committee, thereafter by the board of directors and thereafter, unless exempted
under the regulations promulgated under the Companies Law, by the general meeting of the shareholders. In case the remuneration of the
directors is in accordance with regulations applicable to remuneration of the external directors then such remuneration shall be exempt
from the approval of the general meeting. Where the director is also a controlling shareholder, the requirements for approval of transactions
with controlling shareholders apply. In our 2021 general meeting of shareholders, we instituted a yearly fixed fee in the amount of $40,000
for all of our currently serving non-executive directors, including the chairman of our board of directors. However, on February 20, 2025,
the Company&#8217;s compensation committee and board of directors approved an increase in the yearly fixed fee of Mr. Tal Parnes, the
Company&#8217;s chairman of the board of directors, to $80,000, and an increase to the yearly fixed fee of Mrs. Limor Rozen and Mr. Lior
Amit, the Company&#8217;s non-executive directors, to $46,000, subject to the approval of the Company&#8217;s shareholders. On May 12,
2025, our shareholders approved the respective increases for Mr. Parnes, Mrs. Rozen and Mr. Amit. It shall be noted that Mrs. Rozen stepped
down from our board of directors in October 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Office Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
a duty of care and a duty of loyalty on all office holders of a company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of care requires
an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same
circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the profitability of a given action brought for his approval or performed by him by virtue of his position; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other important information pertaining to these actions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty of an
office holder requires an office holder to act in good faith and for the benefit of the company, and includes a duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any conflict of interest between the performance of his duties in the company and his performance of his other duties or personal affairs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any action that is competitive with the company&#8217;s business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or others; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder has received due to his position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Insurance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
company may obtain insurance for any of its office holders against the following liabilities incurred due to acts he or she performed
as an office holder, if and to the extent provided for in the company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach of his or her duty of care to the company or to another person, to the extent such a breach arises out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable cause to assume that his or her act would not prejudice the company&#8217;s interests; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed upon him or her in favor of another person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have directors&#8217;
and officers&#8217; liability insurance, providing coverage of $5 million for the benefit of our company and all of our directors and
officers with additional excess coverage of $2.5 million for the benefit of the directors and officers, in respect of which we paid a
twelve-month premium of approximately $155,000, which expires in July 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law, and the
Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company may indemnify an office holder against the following
liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance
of an event or following an event, provided its articles of association include a provision authorizing such indemnification:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator&#8217;s award approved by a court;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; or (b) in connection with a monetary sanction;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder or imposed on him or her by a court (1) in proceedings that the company institutes, or that another person institutes on the company&#8217;s behalf, against him or her; (2) in a criminal proceedings of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees. An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law also permits
a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability
imposed on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount
or criterion:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to events that in the opinion of the board of directors can be foreseen based on the company&#8217;s activities at the time that the undertaking to indemnify is made; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into indemnification
agreements with all of our directors and with all members of our senior management. Each such indemnification agreement provides the office
holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities are not
covered by directors and officers insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exemption</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, an
Israeli company may not exempt an office holder from liability for a breach of his or her duty of loyalty, but may exempt in advance an
office holder from his or her liability to the company, in whole or in part, for damages caused to the company as a result of a breach
of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exemption is included in
its articles of association. Our amended and restated articles of association provide that we may exempt, in whole or in part, any office
holder from liability to us for damages caused to the company as a result of a breach of his or her duty of care, but prohibit an exemption
from liability arising from a company&#8217;s transaction in which our controlling shareholder or officer has a personal interest. Subject
to the aforesaid limitations, under the indemnification agreements, we exempt and release our office holders from any and all liability
to us related to any breach by them of their duty of care to us to the fullest extent permitted by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law provides
that the Company may not exempt or indemnify an office holder nor enter into an insurance contract that would provide coverage for any
liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty unless (in the
case of indemnity or insurance only, but not exemption) the office holder acted in good faith and had a reasonable basis to believe that
the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried out intentionally
or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive an illegal personal benefit;
or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, exemption,
indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of (and,
with respect to directors and the chief executive officer, by the shareholders). However, under regulations promulgated under the Companies
Law, the insurance of office holders shall not require shareholders&#8217; approval and may be approved by only the compensation committee
(and, in case a controlling shareholder is an office holder, the board of directors as well), if the engagement terms are determined in
accordance with the company&#8217;s compensation policy that was approved by the shareholders by the same special majority required to
approve a compensation policy, provided that the insurance policy is on market terms and the insurance policy is not likely to materially
impact the company&#8217;s profitability, assets or obligations. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association permit us to exempt (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent
permitted or to be permitted by the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
summarize the material aspects and practices of our board of directors. For additional details, we also refer you to the full text of
the Companies Law, as well as of our amended and restated articles of association, which is an exhibit to this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no service contracts
between us, on the one hand, and our directors in their capacity as directors, on the other hand, providing for benefits upon termination
of service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Approval of Related Party Transactions under
Israeli Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
may approve an action by an office holder from which the office holder would otherwise have to refrain, as described above, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder acts in good faith and the act or its approval does not cause harm to the company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder disclosed the nature of his or her interest in the transaction (including any significant fact or document) to the company at a reasonable time before the company&#8217;s approval of such matter.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of an Office
Holder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at which the transaction
is first discussed, any direct or indirect personal interest that he or she may have and all related material information known to him
or her relating to any existing or proposed transaction by the company. If the transaction is an extraordinary transaction, the office
holder must also disclose any personal interest held by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder&#8217;s relatives; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any corporation in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director or general manager or has the right to appoint at least one director or the general manager.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An office holder is not, however,
obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is
not considered an extraordinary transaction. Under the Companies Law, an extraordinary transaction is a transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not in the ordinary course of business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not on market terms; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that is likely to have a material effect on the company&#8217;s profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law does not
specify to whom within us nor the manner in which required disclosures are to be made. We require our office holders to make such disclosures
to our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, once
an office holder complies with the above disclosure requirement, the board of directors may approve a transaction between the company
and an office holder, or a third party in which an office holder has a personal interest, unless the articles of association provide otherwise
and provided that the transaction is in the company&#8217;s interest. If the transaction is an extraordinary transaction in which an office
holder has a personal interest, first the audit committee and then the board of directors, in that order, must approve the transaction.
Under specific circumstances, shareholder approval may also be required. Generally, a person who has a personal interest in a matter which
is considered at a meeting of the board of directors or the audit committee may not be present at such a meeting unless the chairman of
the audit committee or board of directors (as applicable) determines that he or she should be present in order to present the transaction
that is subject to approval. A director who has a personal interest in a transaction, which is considered at a meeting of the board of
directors or the audit committee, may not be present at this meeting or vote on this matter, unless a majority of members of the board
of directors or the audit committee, as the case may be, has a personal interest. If a majority of the board of directors has a personal
interest, then shareholder approval is generally also required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of a Controlling
Shareholder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company. Extraordinary transactions
with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a
controlling shareholder has a personal interest, as well as transactions for the provision of services whether directly or indirectly
by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions concerning the
terms of engagement and compensation of a controlling shareholder or a controlling shareholder&#8217;s relative, whether as an office
holder or an employee, require the approval of the audit committee or the compensation committee, as the case may be, the board of directors
and a majority of the shares voted by the shareholders of the company participating and voting on the matter in a shareholders&#8217;
meeting. In addition, the shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any extraordinary
transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three
years requires the aforementioned approval every three years; however, such transactions can be approved for a longer term, provided that
the audit committee determines that such longer term is reasonable under the circumstances. In addition, under Companies Law regulations,
subject to certain terms, such transactions can be extended or approved after three years only by the audit committee and the board of
directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law requires
that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling
shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question.
Failure to so indicate will result in the invalidation of that shareholder&#8217;s vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8220;controlling
shareholder&#8221; is defined in the Companies Law as a shareholder with the ability to direct the activities of the company, other than
by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder holds 50% or more of
the voting rights in a company or has the right to appoint 50% or more of the directors of the company or its general manager. In the
context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder who holds 25% or
more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company. For this purpose,
the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Approval of the Compensation of Directors and
Executive Officers</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation of, or an
undertaking to indemnify, insure or exempt, an office holder who is not a director requires the approval of our compensation committee,
followed by the approval of the company&#8217;s board of directors, and, if such compensation arrangement or an undertaking to indemnify,
insure or exempt is inconsistent with our compensation policy, or if the said office holder is the chief executive officer of the company
(subject to a number of specific exceptions), then such arrangement is subject to the approval of our shareholders, subject to a special
majority requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Directors</i>. Under the
Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board
of directors and, unless exempted under the regulations promulgated under the Companies Law, the approval of the general meeting of our
shareholders. If the compensation of our directors is inconsistent with our stated compensation policy, then, provided that those provisions
that must be included in the compensation policy according to the Companies Law have been considered by the compensation committee and
board of directors, shareholder approval by a special majority will be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Executive officers other
than the chief executive officer.</i> The Companies Law requires the approval of the compensation of a public company&#8217;s executive
officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&#8217;s board
of directors, and (iii) only if such compensation arrangement is inconsistent with the company&#8217;s stated compensation policy, the
company&#8217;s shareholders by a special majority. However, if the shareholders of the company do not approve a compensation arrangement
with an executive officer that is inconsistent with the company&#8217;s stated compensation policy, the compensation committee and board
of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of directors reconvene
and provide detailed reasons for their decision (including a discussion regarding the shareholders&#8217; decision).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Chief executive officer.</i>
Under the Companies Law, the compensation of a public company&#8217;s chief executive officer is required to be approved by: (i) the company&#8217;s
compensation committee; (ii) the company&#8217;s board of directors, and (iii) the company&#8217;s shareholders by a special majority.
However, if the shareholders of the company do not approve the compensation arrangement with the chief executive officer, the compensation
committee and board of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of
directors reviewed and reapproved the terms of the compensation, considering that the shareholders did not approve the terms of compensation,
and provides detailed reasons for their decision. In addition, the compensation committee may exempt the engagement terms of a candidate
to serve as the chief executive officer from shareholders&#8217; approval, if the compensation committee determines that the compensation
arrangement is consistent with the company&#8217;s stated compensation policy, that the chief executive officer did not have a prior business
relationship or affiliation with the company or a controlling shareholder of the company, and that subjecting the approval to a shareholder
vote would impede the company&#8217;s ability to attain the candidate to serve as the company&#8217;s chief executive officer (and provide
detailed reasons for the latter).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval of each of the
compensation committee and the board of directors, with regard to the office holders and directors above, should be in accordance with
the company&#8217;s stated compensation policy; however, under special circumstances, the compensation committee and the board of directors
may approve compensation terms of a chief executive officer that are inconsistent with the company&#8217;s compensation policy provided
that they have considered those provisions that must be included in the compensation policy according to the Companies Law and that shareholder
approval was obtained by a special majority requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Duties of Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
shareholder has a duty to refrain from abusing his power in the company and to act in good faith and in an acceptable manner in exercising
his rights and performing his obligations toward the company and other shareholders, including, among other things, in voting at general
meetings of shareholders (and at shareholder class meetings) on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment of the articles of association;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase in the company&#8217;s authorized share capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the approval of related party transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder also has a general
duty to refrain from oppressing other shareholders. The remedies generally available upon a breach of contract will also apply to a breach
of the above-mentioned duties, and in the event of oppression of other shareholders, additional remedies are available to the injured
shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any controlling
shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under
a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or has another power
with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance
of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach
of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_028"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2023, we had
37 full time employees (including our senior management team), five part-time employees, and three independent contractors. On December
31, 2024, we had 39 full-time employees, seven part-time employees and two independent contractors. On December 31, 2025, we had 34 full
time employees (including our senior management team), three part-time employees, and three independent contractors in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025, we
had four members of senior management who are full-time employees. In addition, we had 29 full-time employees in Israel, three part-time
employees and one full-time employee in France.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our employees located
in Israel are represented by labor unions or covered by collective bargaining agreements. However, in Israel, we are subject to certain
Israeli labor laws, regulations and national labor court precedent rulings, as well as certain provisions of collective bargaining agreements
applicable to us by virtue of extension orders issued in accordance with relevant labor laws by the Israeli and Industry of Economy and
which apply such agreement provisions to our employees even though they are not part of a union that has signed a collective bargaining
agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our employment and
consulting agreements include employees&#8217; and consultants&#8217; undertakings with respect to non-competition and assignment to us
of intellectual property rights developed in the course of employment and confidentiality. The enforceability of such provisions is limited
by Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><div><a id="a_029"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share Ownership. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 7.A. Major
Shareholders&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Incentive Plan </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our 2019 Equity Incentive
Plan, or the 2019 Plan, was adopted by our board of directors on December 2019 (although no options were granted until April 20, 2020)
and amended on September 14, 2021. The 2019 Plan provides for the grant of options to our directors, employees, officers, consultants
and service providers who are our employees, officers, directors or consultants, as well as those of our affiliated companies. In September
2021, our board of directors approved an amendment to the 2019 Plan to provide for the grant of restricted share units, or RSUs. As of
March 22, 2026, the total number of Ordinary Shares reserved for the exercise of options under our 2019 Plan was 4,075,686. The shares
subject to our 2019 Plan may be either authorized but unissued Ordinary Shares or reacquired Ordinary Shares, subject to applicable laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our 2019 Plan is administered
by the committee, consisting of our board of directors, regarding the granting of options and the terms of option grants, including exercise
price, method of payment, vesting schedule, acceleration of vesting and the other matters necessary in the administration of this plan.
Eligible employees, officers and directors, as well as those of our affiliated companies, would qualify for provisions of Section 102
of the Israeli Income Tax Ordinance of 1961 (New Version), or the Tax Ordinance. Section 102 of the Tax Ordinance allows employees, directors
and officers who are not controlling shareholders and are considered Israeli residents to receive favorable tax treatment for compensation
in the form of shares or options. Section 102 includes two alternatives for tax treatment involving the issuance of options or shares
to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of options or shares directly
to the grantee. Section 102(b)(2) of the Ordinance, the most favorable tax treatment for the grantee, permits the issuance to a trustee
under the &#8220;capital gain track.&#8221; However, under this track we are not allowed to deduct an expense with respect to the issuance
of the options or shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our consultants and those
of our affiliated companies and our employees, directors and/or officers and those of our affiliated companies who are controlling shareholders
prior to and/or after the issuance of Ordinary Shares underlying the options may only be granted options under section 3(i) of the Tax
Ordinance, which does not provide for similar tax benefits. In addition, the committee may, in its sole discretion, grant restricted shares
to our service providers, subject to terms and conditions of our 2019 Plan and the applicable restricted shares agreement between the
service provider and us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a default, our 2019 Plan
provides that upon termination of a service provider&#8217;s engagement for any reason, other than in the event of death, disability or
cause, all unvested options will terminate and the underlying Ordinary Shares will revert to our 2019 Plan, and all vested options will
generally be exercisable for 90 days following such termination, subject to the terms of the 2019 Plan and the governing option agreement.
Notwithstanding the foregoing, in the event the engagement is terminated for cause (including, inter alia, due to dishonesty toward us
or our affiliate, substantial malfeasance or nonfeasance of duty and conduct substantially prejudicial to our or our affiliate&#8217;s
business; or any substantial breach by the optionee of his or her service agreement) all options granted to such service provider, whether
vested or unvested, will not be exercisable and will terminate on the date of the termination of his service agreement. If a service provider&#8217;s
engagement with us is terminated six months following any exercise, payment or delivery pursuant to an option or restricted share, the
service provider shall pay to us the amount of any gain realized or payment received as a result of the rescinded exercise, payment or
delivery. Upon termination of a service agreement due to death or disability, all the options vested at the time of termination and within
60 days after the date of such termination, will generally be exercisable for 12 months, or such other period as determined by the plan
administrator, subject to the terms of the 2019 Plan and the governing option agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are party to a merger,
acquisition, reorganization or consolidation in which we are not the surviving entity or the sale, transfer, exchange or other disposition
of all or substantially all of our shares or assets, outstanding options, RSUs and shares acquired under the 2019 Plan will be subject
to the agreement of merger or consolidation, which will provide for one or more of the following: (i) the assumption of such options by
the surviving corporation or its parent, (ii) the substitution by the surviving corporation or its parent of new options, or (iii) in
the event that the successor entity neither assumes nor substitutes all outstanding options, then the option shall terminate as of the
date of a merger, acquisition, reorganization or consolidation in which we are not the surviving entity or the sale, transfer, exchange
or other disposition of all or substantially all of our shares or assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_030"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. <span style="text-transform: uppercase">MAJOR
SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_032"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major Shareholders. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding beneficial ownership of our Ordinary Shares as of March 22, 2026 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person, or group of affiliated persons, known to us to be the beneficial owner of 5% or more of our outstanding Ordinary Shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and executive officers; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of our directors and executive officers as a group.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership is determined
in accordance with the rules of the SEC and includes voting or investment power with respect to Ordinary Shares. Ordinary Shares issuable
under share options or warrants that are exercisable within 60 days after March 22, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as indicated in footnotes
to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all shares shown
to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted below, each beneficial
owner&#8217;s address is: c/o Inspira Technologies Oxy B.H.N. Ltd., 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">No. of<br/>
 Shares<br/>
 Beneficially<br/>
 Owned</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1pt solid">Percentage<br/>
 Owned</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Holders of 5% or more of our voting securities:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joe Ronen Hayon <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,204,010</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.4</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Directors and Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon <sup>(2) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,297,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.25</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avi Shabtai <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">820,368</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.88</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yafit Tehila <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">432,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniella Yeheskely Hayon <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.72</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tal Parnes <sup>(6) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.29</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sivan Matza <sup>(7) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lior Amit <sup>(8)*</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">36,665</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.08</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">All Executive Officers and Directors and holder of 5% or more of our voting securities, as a group (7 persons)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,230,670</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">16.61</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates director of the Company.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The beneficial ownership
    is based on the information provided in a Schedule 13G/A, filed on February 17, 2026, and includes (i) 655,623 Ordinary Shares; (ii)
    2,491,228 ordinary shares vested pursuant to issued and outstanding RSUs, (iii) 57,159 ordinary shares issuable upon the exercise of
    vested options. Joe Ronen Hayon&#8217;s address is Derech Klil Hahoresh 14, Gesher Haziv Israel, 22815. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No. of shares beneficially owned consists of 326,739 Ordinary Shares, (ii) 1,773,832 Ordinary Shares vested pursuant to issued and outstanding RSUs, (iii) 57,159 Ordinary Shares issuable upon the exercise of options within 60 days at an exercise price of NIS 0.37 (approximately $0.12) per share and (iv) 140,000 Ordinary Shares vested within 60 days pursuant to issued and outstanding RSUs. Mr. Ben-Noon&#8217;s options expire on April 20, 2030. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 683,712
    Ordinary Shares vested pursuant to issued and outstanding RSUs, (ii) options to purchase 95,239 Ordinary Shares that are exercisable
    within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share, and (iii) 41,417 Ordinary Shares vested within 60
    days pursuant to issued and outstanding RSUs. Mr. Shabtai&#8217;s options expire on April 20, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 393,060 Ordinary
    Shares vested pursuant to issued and outstanding RSUs, (ii) options to purchase 13,605 Ordinary Shares that are exercisable within
    60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and (iii) 25,833 Ordinary Shares vested within 60 days
    pursuant to issued and outstanding RSUs. Ms. Tehila&#8217;s options expire on March 16, 2031.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 293,332 Ordinary
    Shares vested pursuant to issued and outstanding RSUs and (ii) 21,667 Ordinary Shares vested within 60 days pursuant to issued and
    outstanding RSUs.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 99,998 Ordinary
    Shares vested pursuant to issued and outstanding RSUs, (ii) options to purchase 9,402 Ordinary Shares that are exercisable within
    60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and (iii) 15,000 Ordinary Shares vested within 60 days
    pursuant to issued and outstanding RSUs. Mr. Parnes&#8217;s options expire on April 20, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7) </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Matza holds 30,000
    Ordinary Shares issuable from outstanding RSUs, which will not vest within 60 days.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes (i) 31,665 Ordinary
    Shares vested pursuant to issued and outstanding RSUs (ii) 5,000 Ordinary Shares vested within 60 days pursuant to issued and outstanding
    RSUs. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in Percentage Ownership by Major
Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2025, there was a decrease in the beneficial ownership of Joe Hayon from 7.66% to 7.4% and a decrease in the beneficial ownership
of Dagi Ben Noon from 6.49% to 5.25%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2024, there was a decrease in the beneficial ownership of Joe Hayon from 10.02% to 7.66% and a decrease in the beneficial ownership
of Dagi Ben Noon from 8.15% to 6.49%. As of December 31, 2024, Armistice Capital, LLC is no longer a beneficial owner of 5% or more of
the outstanding share capital of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, there was: (i) an increase in the beneficial ownership of Armistice Capital, LLC to 9.89%, (ii) a decrease in the beneficial
ownership of Joe Hayon from 11.86% to 10.02%, and (iii) a decrease in the beneficial ownership of Dagi Ben Noon from 11.86% to 8.15%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Record Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, there
were 23 shareholders of record of our Ordinary Shares, which were located in Israel. We are not controlled by another corporation, by
any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known to us which
would result in a change in control of our company at a subsequent date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_033"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Party Transactions.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6.B. Compensation&#8221;
for compensation to our directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment and Service Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition,
confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited
under applicable law. In addition, we have entered into agreements with each executive officer and director pursuant to which we have
agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered by directors and officers
insurance. Some members of our senior management are eligible for bonuses each year. The bonuses are payable upon meeting objectives and
targets that are set by our Chief Executive Officer and approved annually by our board of directors that also set the bonus targets for
our Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2021, our board
of directors approved and recommended to the shareholders of the Company to approve, the adoption of a compensation policy for a period
of five (5) years, which was approved by our shareholders in a meeting that took place on December 17, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Options/RSUs </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception, we have
granted options to purchase our Ordinary Shares and RSUs to our officers and certain of our directors. Such option agreements may contain
acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option plans under &#8220;Item
6.E. Directors, Senior Management and Employees-Share Ownership-Equity Incentive Plan.&#8221; If the relationship between us and an executive
officer or a director is terminated, except for cause (as defined in the various option plan agreements), options that are vested will
generally remain exercisable for three months after such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shareholders Loans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When we considered pursuing
an initial public offering on the ASX, we focused on an intravenous oxygenation device. As the development of this product did not progress
as planned, we progressed with developing our INSPIRA ART product ahead of plans, reducing the time to market by approximately two years,
and decided to pursue an initial public offering on Nasdaq rather than the ASX. On November 27, 2020, we entered into an agreement, or
the Termination Agreement, with IML, the Founders and Newburyport to terminate the IPO Deed, the Deed of Variation and the 2019 CLA, or
the Previous Agreements. Pursuant to the Termination Agreement, we agreed to convert the loan amount and the interest accrued under the
2019 CLA as of November 27, 2020, into 676,061 of our Ordinary Shares, at price per share of AUD 5.15 (approximately $3.45) or AUD 5.88
(approximately $3.91), and to issue to Newburyport or its affiliates 80,273 of our Ordinary Shares as promoter shares, and options to
purchase 28,572 of our Ordinary Shares, to Daniel Goldstein, who promoted our contract with IML, at an exercise price of NIS 0.37 (approximately
$0.12 per share). We also issued 169,016 warrants to IML, exercisable upon our IPO on the Nasdaq Capital Market. IML&#8217;s warrants
are exercisable for three years. IML purchased its shares and distributed its holdings of our shares as a dividend to its shareholders
following our IPO on the Nasdaq Capital Market. Each party to the Termination Agreement agreed to release each other party to the Termination
Agreement from all the claims related to the IPO Deed, Deed of Variation and CLA. In addition, we agreed to hire Newburyport and Peter
Marks, another affiliate of IML, as our business developers, to identify, introduce and promote us to potential investors, and to pay
cash commission in the amount of 7% from the net proceeds received from an investment consummated within 12 months of our introduction
to the investor by Newburyport or Peter Marks. As of November 28, 2021, we have paid Newburyport and Peter Marks AUD 403,000 (approximately
$321,000) each, as cash commission for investor introductions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_034"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interests of Experts and Counsel.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_035"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 8. <span style="text-transform: uppercase">FINANCIAL
INFORMATION.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_036"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements and Other Financial Information.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 18. Financial
Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation
can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are
not currently party to, and our property is not the subject of, any material legal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2022, Exchange
filed a complaint in the Federal Court for the Southern District of New York against us and our Chief Financial Officer, Joe Hayon, in
connection with a contract between the parties pursuant to which Exchange provided certain consultancy services to us in preparation for
our IPO. The precise damages sought are unclear, however Exchange is seeking approximately $250,000 plus 75,000 Ordinary Shares or the
cash equivalent. On July 1, 2022, we filed a motion to dismiss for failure to state a claim upon relief can be granted based on the language
of the written contract between the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 8, 2023, the court
issued an order granting our motion in part and denying it in part. Specifically, the court dismissed all claims against Joe Hayon and
he is no longer a party in the action. The court also dismissed the breach of contract action (Count I) to the extent it was based improper
termination or frustration. The Court also dismissed Count IV (Quantum Merit on the written agreement), Count VI (Breach of Implied Covenant
of Good Faith) and Count VII (Fraud in the Inducement). The court allowed Count 1 (breach of written agreement based on alleged anticipatory
repudiation), Count II (breach of alleged oral agreement), Count III (Promissory Estoppel to the extent based on alleged oral agreement)
and Count V (Quantum Meruit based on alleged oral agreement) to survive the pleading or early dismissal stage. We will continue to defend
ourselves vigorously with respect to this matter. In July 2023, following a confidential settlement agreement reached between the parties,
this matter was voluntarily dismissed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 12, 2021, we terminated our employment agreement with Dr.
Udi Nussinovitch, who is one of our founders and who served as our Chief Scientific Officer since March 2018. On February 24, 2022, we
sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer of the Company. On November 9,
2022, Mr. Nussinovitch filed a statement of claim against us, as well as a statement of claim with the regional labor court in Tel Aviv
on November 8, 2022. Mr. Nussinovitch alleged certain deficiencies in our Extraordinary General Meeting of Shareholders held on Friday,
December 17, 2021, resulting from his status as a minority shareholder. In addition, with respect to the labor dispute, Mr. Nussinovitch
is seeking renumeration and the issuance of Ordinary Shares. On July 19, 2023, a partial hearing about the labor dispute was held, in
which the parties were required by the court to file their positions on a stay of the proceeding pending the decision on the case initiated
by Mr. Nussinovitch in the District Court. On January 21, 2024, a partial hearing about the civil case was held. During the hearing, the
court suggested the parties consider the possibility of resolving the case through an out-of-court arrangement or mediation. The parties
agreed to a mediation process which did not succeed. On January 7, 2025, Mr. Nussinovitch filed a motion to amend his Statement of Claim,
requesting to modify the requested relief. Instead of the original remedies sought, Mr. Nussinovitch now requests that the Company or
Mr. Ben Noon and Mr. Hayon purchase all of his rights and shares in the Company at their average value from the date of the Company's
IPO until the date of the general meeting held on December 17, 2021. On January 13, 2025, a pretrial hearing was held. The court denied
Mr. Nussinovitch&#8217;s motion to amend and instructed him to notify whether he wishes to withdraw his original claim or maintain it.
On May 7, 2025, the court issued its decision on the motion to dismiss. The judge ruled that the claim would be partially dismissed and
that the continuation of the proceedings would be contingent upon payment of court fees. The court ordered the dismissal of remedies that
Mr. Nussinovitch&#8217;s himself had clarified were no longer relevant and further determined that the declaratory remedies would remain
in the claim and ruled that Mr. Nussinuvich must pay court fees in connection with the operative remedy regarding Mr. Nussinovich&#8217;s
entitlement to receive the benefits granted to the controlling shareholders and the allocation of restricted shares. On June 26, 2025,
Mr. Nussinovich submitted a notice to the court detailing the calculation of the claim value in relation to the operative remedies. On
December 8, 2025, Mr. Nussinovich filed witness statements on his behalf. We believe that it is&#160;not probable&#160;that a payment
will be required to settle this matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash
dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board
of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
further restrictions on our ability to declare and pay dividends. Under the Companies Law, we may declare and pay dividends only if, upon
the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able to meet
the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further
limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according
to our then last reviewed or audited financial statements, provided that the end of the period to which the financial statements relate
is not more than six months prior to the date of distribution. In the event that we do not meet such earnings criteria, we may seek the
approval of a court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable
concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of dividends may be
subject to Israeli withholding taxes. See &#8220;Item 10.E. Taxation&#8221;, for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_037"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Significant Changes.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No significant change, other
than as otherwise described in this annual report on Form 20-F, has occurred in our operations since the date of our financial statements
included in this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><div><a id="a_038"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. <span style="text-transform: uppercase">THE
OFFER AND LISTING</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_039"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offer and Listing Details.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since July 16, 2021, our Ordinary
Shares and Warrants have been traded on the Nasdaq Capital Market under the symbols &#8220;IINN&#8221; and &#8220;IINNW&#8221;, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_040"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan of Distribution.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_041"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Markets.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares and Warrants
trade on the Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_042"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling Shareholders.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_043"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dilution.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_044"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses of the Issue.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_045"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. <span style="text-transform: uppercase">ADDITIONAL
INFORMATION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_046"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share Capital.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_047"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Memorandum and Articles of Association.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of our amended and
restated articles of association is attached as Exhibit 1.1 to this annual report on Form 20-F. The information called for by this Item
is set forth in Exhibit 2(d) to this annual report on Form 20-F and is incorporated by reference into this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_048"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material Contracts. </b>&#160;&#160;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not entered into any
material contract within the two years prior to the date of this Annual Report, other than contracts entered into in the ordinary course
of business, as otherwise described herein in &#8220;Item 4.A. History and Development of the Company&#8221; above, &#8220;Item 4.B. Business
Overview&#8221; above, &#8220;Item 6.C Board Practices - Indemnification,&#8221; &#8220;Item 6.E Share Ownership - Equity Incentive Plan,&#8221;
&#8220;Item 7.A. Major Shareholders,&#8221; or &#8220;Item 7.B. Related Party Transactions,&#8221; above, or as otherwise described below:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#9679; &#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement by and between the Company and certain signatories thereto, dated March 28, 2024. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement by and between the Company and certain signatories thereto, dated June 14, 2024. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement by and between the Company and certain signatories thereto, dated December 24, 2024. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement by and between the Company and A.G.P./Alliance Global Partners, dated March 14, 2025. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement by and between the Company and certain signatories thereto, dated December 12, 2025. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standby Equity Purchase Agreement by and between the Company and YA II PN, LTD., dated December 12, 2025. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Convertible Debenture by and between the Company and Bio-View Ltd., dated January 5, 2026. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement by and between the Company and the signatory thereto, dated February 5, 2026. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement by and between the Company and A.G.P./Alliance Global Partners, dated February 17, 2026. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_049"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange Controls.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on payments of dividends or other distributions with respect to our securities or the proceeds from the
sale of the shares, except for the obligation of Israeli residents to file reports with the Bank of Israel regarding certain transactions.
However, legislation remains in effect pursuant to which currency controls can be imposed by administrative action at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ownership or voting of
our securities by non-residents of Israel, except with respect to citizens of countries that are in a state of war with Israel, is not
restricted in any way by our memorandum of association or amended and restated articles of association or by the laws of the State of
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_050"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxation.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of the material Israeli income tax consequences of the ownership of our securities. The following also contains a description of material
relevant provisions of the current Israeli income tax structure applicable to companies in Israel, with reference to its effect on us.
To the extent that the discussion is based on new tax legislation which has not been subject to judicial or administrative interpretation,
there can be no assurance that the tax authorities will accept the views expressed in the discussion in question. The discussion is not
intended, and should not be taken, as legal or professional tax advice and is not exhaustive of all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our securities.
Shareholders should consult their own tax advisors concerning the tax consequences of their particular situation, as well as any tax consequences
that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli companies are generally
subject to corporate tax. As of January 2016, the corporate tax rate was 25%. As of January 1, 2017, the corporate tax rate was reduced
to 24% and as of January 1, 2018, the corporate tax rate is 23%. However, the effective tax rate payable by a company that derives income
from a Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli company are generally subject
to the prevailing corporate tax rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capital gains derived by an
Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation, a corporation will be
considered as an &#8220;Israeli resident company&#8221; if it meets one of the following: (i) it was incorporated in Israel; or (ii) the
control and management of its business are exercised in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Industry (Taxes),
5729-1969</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for the Encouragement
of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for &#8220;Industrial
Companies.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Industry Encouragement
Law defines an &#8220;Industrial Company&#8221; as an Israeli resident-company, of which 90% or more of its income in any tax year, other
than income from defense loans, is derived from an &#8220;Industrial Enterprise&#8221; owned by it. An &#8220;Industrial Enterprise&#8221;
is defined as an enterprise whose principal activity in a given tax year is industrial production.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following corporate tax
benefits, among others, are available to Industrial Companies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization of the cost of purchased a patent, rights to use a patent, and know-how, which are used for the development or advancement of the company, over an eight-year period, commencing on the year in which such rights were first exercised;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses related to a public offering are deductible in equal amounts over three years.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Eligibility for benefits under
the Industry Encouragement Law is not contingent upon approval of any governmental authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits and Grants for Research and
Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Encouragement
of Research, Development and Industrial Initiative Technology Law, 5744-1984, as amended, and related regulations, or the Research Law,
research and development programs which meet specified criteria and are approved by the IIA are eligible for grants of up to 50% of the
project&#8217;s expenditure, as determined by the research committee, in exchange for the payment of royalties from the revenues generated
from the sale of products and related services developed, in whole or in part pursuant to, or as a result of, a research and development
program funded by the IIA. The royalties are generally at a range of 3.0% to 5.0% of revenues until the entire IIA grant is repaid, together
with an annual interest. As of January 1, 2024, annual interest on IIA grants approved by the IIA prior to January 1, 2024, but which
are outstanding thereafter, will be calculated at a rate based on the 12-month secured overnight financing rate, or SOFR, or at an alternative
rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or following January 1, 2024 the annual interest will
be the higher of (i) the 12 month SOFR, plus 1%, or (ii) a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Research
Law also require that the manufacture of products developed with government grants be performed in Israel. The transfer of manufacturing
activity outside Israel may be subject to the prior approval of the IIA. Under the regulations of the Research Law, assuming we receive
approval from the Chief Scientist to manufacture our IIA-funded products outside Israel, we may be required to pay increased royalties.
The increase in royalties depends upon the manufacturing volume that is performed outside of Israel as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Manufacturing Volume Outside of Israel</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Royalties to <br/> the Chief <br/> Scientist<br/> as a <br/> Percentage <br/> of Grant</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Up to 50%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Between 50% and 90%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">90% and more</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the manufacturing is performed
outside of Israel by us, the rate of royalties payable by us on revenues from the sale of products manufactured outside of Israel will
increase by 1% over the regular rates. If the manufacturing is performed outside of Israel by a third party, the rate of royalties payable
by us on those revenues will be equal to the ratio obtained by dividing the amount of the grants received from the IIA and our total investment
in the project that was funded by these grants. The transfer of no more than 10% of the manufacturing capacity in the aggregate outside
of Israel is exempt under the Research Law from obtaining the prior approval of the IIA. A company requesting funds from the IIA also
has the option of declaring in its IIA grant application an intention to perform part of its manufacturing outside Israel, thus avoiding
the need to obtain additional approval. On January 6, 2011, the Research Law was amended to clarify that the potential increased royalties
specified in the table above will apply even in those cases where the IIA approval for transfer of manufacturing outside of Israel is
not required, namely when the volume of the transferred manufacturing capacity is less than 10% of total capacity or when the company
received an advance approval to manufacture abroad in the framework of its IIA grant application. For applications to manufacture abroad
submitted to the IIA after October 25, 2023, the maximum increased liability is up to 150% of the IIA grants, plus interest accrued thereon,
instead of 300%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The know-how developed within
the framework of the Chief Scientist plan may not be transferred to third parties outside Israel without the prior approval of a governmental
committee charted under the Research Law. The approval, however, is not required for the export of any products developed using grants
received from the Chief Scientist. The IIA approval to transfer know-how created, in whole or in part, in connection with an IIA-funded
project to third party outside Israel where the transferring company remains an operating Israeli entity is subject to payment of a redemption
fee to the IIA calculated according to a formula provided under the Research Law that is based, in general, on the ratio between the aggregate
IIA grants to the company&#8217;s aggregate investments in the project that was funded by these IIA grants, multiplied by the transaction
consideration. The transfer of such know-how to a party outside Israel where the transferring company ceases to exist as an Israeli entity
is subject to a redemption fee formula that is based, in general, on the ratio between the aggregate IIA grants to the total financial
investments in the company, multiplied by the transaction consideration. According to the January 2011 amendment, the redemption fee in
case of transfer of know-how to a party outside Israel will be based on the ratio between the aggregate IIA grants received by the company
and the company&#8217;s aggregate R&amp;D expenses, multiplied by the transaction consideration. According to regulations promulgated
following the 2011 amendment, the maximum amount payable to the IIA in case of transfer of know how outside Israel shall not exceed 6
times the value of the grants received plus interest, and in the event that the receiver of the grants ceases to be an Israeli corporation
such payment shall not exceed six times the value of the grants received plus interest, with a possibility to reduce such payment to up
to three times the value of the grants received plus interest if the R&amp;D activity remains in Israel for a period of three years after
payment to the IIA and maintain at least 75% of the research and development employees the Company had for the six months before the know-how
was transferred, subject to additional conditions specified in the regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Transfer of know-how within
Israel is subject to an undertaking of the recipient Israeli entity to comply with the provisions of the Research Law and related regulations,
including the restrictions on the transfer of know-how and the obligation to pay royalties, as further described in the Research Law and
related regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These restrictions may impair
our ability to outsource manufacturing, engage in change of control transactions or otherwise transfer our know-how outside Israel and
may require us to obtain the approval of the IIA for certain actions and transactions and pay additional royalties to the IIA. In particular,
any change of control and any change of ownership of our securities that would make a non-Israeli citizen or resident an &#8220;interested
party,&#8221; as defined in the Research Law, requires a prior written notice to the IIA in addition to any payment that may be required
of us for transfer of manufacturing or know-how outside Israel. If we fail to comply with the Research Law, we may be subject to criminal
charges or to mandatory repayment of grants received by us (together with interest and penalties).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits for Research and Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli tax law allows, under
certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which they are incurred. Expenditures
are deemed related to scientific research and development projects, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development must be for the promotion of the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development is carried out by or on behalf of the company seeking such tax deduction.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of such deductible
expenses is reduced by the sum of any funds received through government grants for the finance of such scientific research and development
projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested
in an asset depreciable under the general depreciation rules of the income Tax Ordinance, 1961. Expenditures not so approved are deductible
in equal amounts over three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
apply the Office of the Chief Scientist for approval to allow a tax deduction for all research and development expenses during the year
incurred. There can be no assurance that such application will be accepted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Capital Investments,
5719-1959</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for the Encouragement
of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in
production facilities (or other eligible assets).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investment Law grants
tax benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221; (as such terms are
defined in the Investment Law) The definition of a Preferred Company includes a company incorporated in Israel that is not fully owned
by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled and managed from Israel. A Preferred
Company is entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred Enterprise, unless the
Preferred Enterprise is located in a specified development zone, in which case the rate will be 7.5%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends paid out of income
attributed to a Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% or such lower rate as may be
provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required to be withheld.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of our Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Capital Gains Taxes Applicable
to Non-Israeli Resident Shareholders. A non-Israeli resident who derives capital gains from the sale of shares in an Israeli resident
company will be exempt from Israeli tax so long as the shares were not held through a permanent establishment that the non-resident maintains
in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemption if Israeli residents: (i) have a controlling
interest of 25% or more in such non-Israeli corporation or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues
or profits of such non-Israeli corporation, whether directly or indirectly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a sale of securities
by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example,
under Convention Between the Government of the U.S. and the Government of the State of Israel with respect to Taxes on Income, as amended,
or the U.S.-Israel Tax Treaty, the sale, exchange or other disposition of shares by a shareholder who is a U.S. resident (for purposes
of the treaty) holding the shares as a capital asset and is entitled to claim the benefits afforded to such a resident by the U.S.-Israel
Tax Treaty, or a Treaty U.S. Resident, is generally exempt from Israeli capital gains tax unless: (i) the capital gain arising from such
sale, exchange or disposition is attributed to real estate located in Israel; (ii) the capital gain arising from such sale, exchange or
disposition is attributed to royalties; (iii) the capital gain arising from the such sale, exchange or disposition is attributed to a
permanent establishment in Israel, under certain terms; (iv) such Treaty U.S. Resident holds, directly or indirectly, shares representing
10% or more of the voting capital during any part of the 12-month period preceding the disposition, subject to certain conditions; or
(v) such Treaty U.S. Resident is an individual and was present in Israel for 183 days or more during the relevant taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances where our
shareholders may be liable for Israeli tax on the sale of their securities, the payment of the consideration may be subject to the withholding
of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to
avoid withholding at source at the time of sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Taxation of Non-Israeli Shareholders
on Receipt of Dividends. Non-Israeli residents are generally subject to Israeli income tax on the receipt of dividends paid on our securities
at the rate of 25% (before a surtax at a rate of up to 5% on income above a certain threshold), which tax will be withheld at source,
unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence. With respect to a person who is
a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or on any time during the preceding twelve months, the applicable
tax rate is 30% (before a surtax at a rate of up to 5% on income above a certain threshold). A &#8220;substantial shareholder&#8221; is
generally a person who alone or together with such person&#8217;s relative or another person who collaborates with such person on a permanent
basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of the corporation. &#8220;Means of control&#8221;
generally include the right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or
order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. However, a distribution of dividends
to non-Israeli residents is subject to withholding tax at source at a rate of 20% if the dividend is distributed from income attributed
to a Preferred Enterprise, unless a reduced tax rate is provided under an applicable tax treaty. For example, under the U.S.-Israel Tax
Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our securities who is a Treaty U.S. Resident
is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated by a Preferred Enterprise, that are paid to
a U.S. corporation holding 10% or more of the outstanding voting capital throughout the tax year in which the dividend is distributed
as well as during the previous tax year, is 12.5%, provided that not more than 25% of the gross income for such preceding year consists
of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed from income attributed to a Preferred
Enterprise are not entitled to such reduction under the tax treaty but are subject to a withholding tax rate of 15% for a shareholder
that is a U.S. corporation, provided that the condition related to our gross income for the previous year (as set forth in the previous
sentence) is met. If the dividend is attributable partly to income derived from a Preferred Enterprise, and partly to other sources of
income, the withholding rate will be a blended rate reflecting the relative portions of the two types of income. We cannot assure you
that we will designate the profits that we may distribute in a way that will reduce shareholders&#8217; tax liability.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S. FEDERAL INCOME TAX CONSIDERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE FOLLOWING SUMMARY IS INCLUDED
HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD
CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE
OF ORDINARY SHARES INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the limitations
described in the next two paragraphs, the following discussion summarizes the material U.S. federal income tax consequences to a &#8220;U.S.
Holder&#8221; arising from the purchase, ownership and sale of the Ordinary Shares, the Warrants, and the Ordinary Shares issued or issuable
upon exercise of the Warrants, collectively, the &#8220;securities&#8221;. For this purpose, a &#8220;U.S. Holder&#8221; is a holder of
securities that is: (1) an individual citizen or resident of the U.S, including an alien individual who is a lawful permanent resident
of the U.S. or meets the substantial presence residency test under U.S. federal income tax laws; (2) a corporation (or entity treated
as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership that is not treated as a U.S. person
under any applicable U.S. Treasury regulations) created or organized under the laws of the U.S. or the District of Columbia or any political
subdivision thereof; (3) an estate, the income of which is includable in gross income for U.S. federal income tax purposes regardless
of source; (4) a trust if a court within the U.S. is able to exercise primary supervision over the administration of the trust and one
or more U.S. persons have authority to control all substantial decisions of the trust; or (5) a trust that has a valid election in effect
to be treated as a U.S. person to the extent provided in U.S. Treasury regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary is for general
information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations
that may be relevant to a decision to purchase our securities. This summary generally considers only U.S. Holders that will own our securities
as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences to a
person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&#8217;s status as a U.S. Holder. This
summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed U.S. Treasury
regulations promulgated thereunder, administrative and judicial interpretations thereof, and the U.S./Israel Income Tax Treaty, all as
in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to
differing interpretations. We will not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment
in our securities by U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion does not address
all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on such holder&#8217;s particular
circumstances and in particular does not discuss any estate, gift, generation-skipping transfer, state, local, excise or foreign tax considerations.
In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank, life insurance
company, regulated investment company, or other financial institution or &#8220;financial services entity;&#8221; (2) a broker or dealer
in securities or foreign currency; (3) a person who acquired our securities in connection with employment or other performance of services;
(4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our securities as a hedge or as part
of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes;
(6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a U.S. Holder that expatriates out of the U.S. or a
former long-term resident of the U.S.; or (9) a person having a functional currency other than the U.S. dollar. This discussion does not
address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, securities representing
10% or more of our voting power. Additionally, the U.S. federal income tax treatment of partnerships (or other pass-through entities)
or persons who hold securities through a partnership or other pass-through entity are not addressed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each prospective investor
is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing
of our securities, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Exercise or Expiry of Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No gain or loss will be realized
on the exercise of a Warrant. When a Warrant is exercised, the U.S. Holder&#8217;s cost of the common share acquired thereby will be equal
to the U.S. Holder&#8217;s adjusted cost basis of the Warrant plus the exercise price paid for the common share. The expiry of an unexercised
Warrant will generally give rise to a capital loss equal to the adjusted cost basis to the U.S. Holder of the expired Warrant. The holding
period of the common share acquired thru the exercise of a Warrant includes the holding period of the Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Dividends Paid on Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to pay dividends
in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under the heading &#8220;Passive Foreign
Investment Companies&#8221; below and the discussion of &#8220;qualified dividend income&#8221; below, a U.S. Holder, other than certain
U.S. Holders that are U.S. corporations, will be required to include in gross income as ordinary income the amount of any distribution
paid on securities (including the amount of any Israeli tax withheld on the date of the distribution), to the extent that such distribution
does not exceed our current and accumulated earnings and profits, as determined for U.S. federal income tax purposes. The amount of a
distribution which exceeds our earnings and profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder&#8217;s
tax basis for the securities to the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and
profits under U.S. federal income tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution
generally will be reported as dividend income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, preferential tax
rates for &#8220;qualified dividend income&#8221; and long-term capital gains are applicable for U.S. Holders that are individuals, estates
or trusts. For this purpose, &#8220;qualified dividend income&#8221; means, inter alia, dividends received from a &#8220;qualified foreign
corporation.&#8221; A &#8220;qualified foreign corporation&#8221; is a corporation that is entitled to the benefits of a comprehensive
tax treaty with the U.S. which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty satisfies
this requirement and we believe we are eligible for the benefits of that treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our dividends
will be qualified dividend income if our securities are readily tradable on the Nasdaq Capital Market or another established securities
market in the U.S. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend is paid or in the
prior year, as a PFIC, as described below under &#8220;Passive Foreign Investment Companies.&#8221; A U.S. Holder will not be entitled
to the preferential rate: (1) if the U.S. Holder has not held our securities for at least 61 days of the 121 day period beginning on the
date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make related payments
on substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our securities are not counted
towards meeting the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income as &#8220;investment income&#8221;
pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of a distribution
with respect to our securities will be measured by the amount of the fair market value of any property distributed, and for U.S. federal
income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included in the
income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible in
the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such U.S.
dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of them, any subsequent gain or
loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of the Disposition of Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided under the
PFIC rules described below under &#8220;Passive Foreign Investment Companies,&#8221; upon the sale, exchange or other disposition of our
securities, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder&#8217;s tax
basis for the securities in U.S. dollars and the amount realized on the disposition in U.S. dollar (or its U.S. dollar equivalent determined
by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency). The
gain or loss realized on the sale, exchange or other disposition of securities will be long-term capital gain or loss if the U.S. Holder
has a holding period of more than one year at the time of the disposition. Individuals who recognize long-term capital gains may be taxed
on such gains at reduced rates of tax. The deduction of capital losses is subject to various limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Passive Foreign Investment Companies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special U.S. federal income
tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income
tax purposes for any taxable year that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75% or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own 25% or more of the shares by value), in a taxable year is passive; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata share of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For this purpose, passive
income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from
notional principal contracts. Cash is treated as generating passive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we will not
be a PFIC for the current taxable year, although we have not determined whether we will be a PFIC in the foreseeable future. The tests
for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are
relevant to this determination. In addition, our PFIC status may depend in part on the market value of our securities. Accordingly, there
can be no assurance that we currently are not or will not become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we currently are or become
a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions
by us and upon disposition of our securities at a gain:&#160;(1) have such distribution or gain allocated ratably over the U.S. Holder&#8217;s
holding period for the securities, as the case may be; (2) the amount allocated to the current taxable year and any period prior to the
first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of
the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year,
and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other
taxable year. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the tax basis
of such shares would not receive a step-up to fair market value as of the date of the decedent&#8217;s death, but instead would be equal
to the decedent&#8217;s basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also be subject
to these special U.S. federal income tax rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PFIC rules described above
would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held the securities while we
are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election
is required for each taxable year that we are a PFIC to include in income such U.S. Holder&#8217;s pro rata share of our ordinary earnings
as ordinary income and such U.S. Holder&#8217;s pro rata share of our net capital gains as long-term capital gain, regardless of whether
we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain required
information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the
IRS. We do not intend to notify U.S. Holders if we believe we will be treated as a PFIC for any tax year. In addition, we do not intend
to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election
for any year in which we or any of our Subsidiaries are a PFIC. Therefore, the QEF election will not be available with respect to our
securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the PFIC rules
described above would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A U.S. Holder of our securities which
are regularly traded on a qualifying exchange, including the Nasdaq Capital Market, can elect to mark the securities to market annually,
recognizing as ordinary income or loss each year an amount equal to the difference as of the close of the taxable year between the fair
market value of the securities and the U.S. Holder&#8217;s adjusted tax basis in the securities. Losses are allowed only to the extent
of net mark-to-market gain previously included income by the U.S. Holder under the election for prior taxable years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who hold our
securities during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders are
strongly urged to consult their tax advisors about the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax on Net Investment Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who are individuals,
estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including dividends on and gains
from the sale or other disposition of our securities), or in the case of estates and trusts on their net investment income that is not
distributed to beneficiaries of the estate or trust. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder&#8217;s
total adjusted income exceeds applicable thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Information Reporting and Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may be subject
to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of securities. In general, backup
withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply
with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding is
not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that the
required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder with interests
in &#8220;specified foreign financial assets&#8221; (including, among other assets, our securities, unless such securities are held on
such U.S. Holder&#8217;s behalf through a financial institution) may be required to file an information report with the IRS if the aggregate
value of all such assets exceeds $50,000 on the last day of the taxable year or $75,000 at any time during the taxable year (or such higher
dollar amount as may be prescribed by applicable IRS guidance); and may be required to file a Report of Foreign Bank and Financial Accounts,
or FBAR, if the aggregate value of the foreign financial accounts exceeds $10,000 at any time during the calendar year. You should consult
your own tax advisor as to the possible obligation to file such information report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_051"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends and Paying Agents.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_052"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statement by Experts.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_053"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Documents on Display.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements file reports with the SEC.
The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the
SEC. Our filings with the SEC are also available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our principal shareholders
and until March 18, 2026, our officers and directors, are exempt from the reporting provisions contained in Section 16 of the Exchange
Act. Further, our officers, directors and principal shareholders are exempt from the short-swing profit recovery provisions contained
in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports
and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the
Exchange Act. However, we file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by
the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and
may submit to the SEC, on a Form 6-K, unaudited quarterly financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
www.inspira-technologies.com. Information contained on, or that can be accessed through, our website and the other websites referenced
above do not constitute a part of this annual report on Form 20-F. We have included these website addresses in this annual report on Form
20-F solely as inactive textual references.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_054"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsidiary Information.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_055"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual Report to Security Holders</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><div><a id="a_056"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 11. <span style="text-transform: uppercase">QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Quantitative and Qualitative Disclosure About
Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to market risks
in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that
have a credit rating of at least A-minus. Accordingly, a substantial majority of our equivalents is held in deposits that bear interest.
Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced. Our market risk exposure
is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in detail in the following paragraph.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Currency Exchange Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate primarily in Israel,
and approximately 80% of our expenses are denominated in NIS. We are therefore exposed to market risk, which represents the risk of loss
that may impact our financial position due to adverse changes in financial market prices and rates. We are subject to fluctuations in
foreign currency rates in connection with these arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently partially hedge
our foreign currency exchange rate risk to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal
operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interest Rate Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate undertaking
any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents, and short-term deposits.
The primary objective of our investment activities is to preserve principal while maximizing the income that we receive from our investments
without significantly increasing risk and loss. Our investments may be exposed to market risk due to fluctuation in interest rates, which
may affect our interest income and the fair market value of our investments, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impact of Inflation and Currency Fluctuations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation generally affects
us by increasing our NIS-denominated expenses, including salaries and benefits, as well as facility rental costs and payment to local
suppliers. We do not believe that inflation had a material effect on our business, financial condition or results of operations during
the year ended December 31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_057"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. <span style="text-transform: uppercase">DESCRIPTION
OF SECURITIES OTHER THAN EQUITY SECURITIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_058"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt Securities.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_059"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants and rights.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_060"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Securities.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_061"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American Depositary Shares. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_062"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_063"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND
DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, we completed
our IPO of Ordinary Shares and warrants pursuant to Registration Statement on Form F-1, as amended (Registration No. 333-253920), whereby
we sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants (inclusive of 436,364 tradable warrants pursuant to the exercise of
an overallotment option granted to the underwriters). All these Ordinary Shares and warrants were sold at a combined price of $5.50 per
unit, yielding an aggregate net proceeds received by us from the IPO were $14 million, after underwriting discounts and other offering
costs. We continue to use the proceeds from the exercise of warrants related to this offering, as described in the final prospectus filed
with the SEC on July 15, 2021, under File Nos. 333-253920 and 333-279276.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures
(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2025, or the Evaluation Date. Based
on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective
in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under
the Exchange Act and that such information is accumulated and communicated to management, including our principal executive and financial
officers, as appropriate to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the
Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial
Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework and criteria
established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
as of the end of the period covered by this report. Based on that evaluation, our management has concluded that our internal control over
financial reporting was effective as of December 31, 2025 at providing reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Attestation Report of the Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report does not
include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting
due to an exemption for EGCs provided in the JOBS Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2025, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16. [RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
determined that each member of our audit committee is an audit committee financial expert, as defined under the rules under the Exchange
Act, and is independent in accordance with applicable Exchange Act rules and Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_068"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
code of ethics that applies to our officers and employees, including our principal executive officer, principal financial officer, principal
controller and persons performing similar functions as well as our directors. Our Code of Business Conduct and Ethics is posted on our
website at www.icecure-medical.com. Information contained on, or that can be accessed through, our website does not constitute a part
of this annual report on Form 20-F and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct
and Ethics or grant any waivers, including any implicit waiver, from a provision of the code, we will disclose the nature of such amendment
or waiver on our website to the extent required by the rules and regulations of the SEC including the instructions to Item 16B of Form
20-F. We have not granted any waivers under our Code of Business Conduct and Ethics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_069"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ziv Haft., Certified Public
Accountants, Isr., BDO member firm, an independent registered public accounting firm, has served as our principal independent registered
public accounting firm for each of the two years ended December 31, 2024 and 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding fees paid by us to Ziv Haft and/or other BDO member firms for all services, including audit services, for the years
ended December 31, 2024 and 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid"><b>Year Ended<br/> December 31,<br/> (in thousands)</b></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td>
    <td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit fees <sup>(1) </sup></span></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">146</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</td>
    <td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">129.5</td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">Review of registration statements</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">33.5</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1pt solid; text-align: right">16.5</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Total</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">179.5</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right">146</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
professional services rendered in connection with the audit of our annual financial statements and review of our interim financial statements.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pre-Approval of Auditors&#8217; Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee has a
pre-approval policy for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services.
Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee
pre-approves annually a catalog of specific audit and non-audit services in the categories of audit services, audit-related services and
tax services that may be performed by our independent registered public accounting firm. If a type of service, that is to be provided
by our auditors, has not received such general pre-approval, it will require specific pre-approval by our audit committee. The policy
prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in applicable
SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_073"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16G. CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Nasdaq rules, we may
elect to follow certain corporate governance practices permitted under the Companies Law in lieu of compliance with corresponding corporate
governance requirements otherwise imposed by the Nasdaq rules for U.S. domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Israeli
law and practice and subject to the exemption set forth in Rule 5615 of the Nasdaq rules, we have elected to follow the provisions of
the Companies Law, rather than the Nasdaq rules, with respect to the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Quorum</i>. While the Nasdaq rules require that the quorum for purposes of any meeting of the holders of a listed company&#8217;s ordinary voting stock, as specified in the company&#8217;s bylaws, be no less than 33 1/3% of the company&#8217;s outstanding ordinary voting stock, under Israeli law, a company is entitled to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a shareholders meeting. Our amended and restated articles of association provide that a quorum of two or more shareholders holding at least 25% of the voting rights in person or by proxy is required for commencement of business at a general meeting. However, the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of at least one shareholder present in person or by proxy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nomination of our directors</i>. With the exception of directors elected by our board of directors and external directors (if applicable), our directors are generally elected by an annual meeting of our shareholders for a term of office that expires on the annual general meeting following their election or re-election. The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board of directors itself, in accordance with the provisions of our amended and restated articles of association and the Companies Law. Nominations need not be made by a nominating committee of our board of directors consisting solely of independent directors, as required under the Nasdaq rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Compensation of officers. </i>Israeli law and our amended and restated articles of association do not require that the independent members of our board of directors (or a compensation committee composed solely of independent members of our board of directors) determine an executive officer&#8217;s compensation, as is generally required under the Nasdaq rules with respect to the chief executive officer and all other executive officers. Instead, compensation of executive officers is determined and approved by our compensation committee and our board of directors, and in certain circumstances by our shareholders, either in consistency with our office holder compensation policy or, in special circumstances in deviation therefrom, taking into account certain considerations stated in the Companies Law. See &#8220;Item 6.C. Directors, Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221; for additional information.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder approval.</i> We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking approval for corporation actions in accordance with Nasdaq Listing Rule 5635. In particular, under this Nasdaq rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. By contrast, under the Companies Law, shareholder approval is required for, among other things: (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, (ii) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval, and (iii) terms of employment or other engagement of the controlling shareholder of us or such controlling shareholder&#8217;s relative, which require special approval. In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq rules. See &#8220;Item 6.C. Directors, Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221; for additional information.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual Shareholders Meeting. </i>As opposed to the Nasdaq Listing Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within one year of the company&#8217;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders&#8217; meeting each calendar year and within 15 months of the last annual shareholders meeting.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution of periodic reports to shareholders; proxy solicitation.</i> As opposed to the Nasdaq rules, which require listed issuers to make such reports available to shareholders in one of a number of specific manners, Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. In addition to making such reports available on a public website, we currently make our audited financial statements available to our shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC&#8217;s proxy solicitation rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholder approval is generally
required for officer compensation in the event (i) approval by our Board of Directors and our compensation committee is not consistent
with our office holder compensation policy, or (ii) compensation required to be approved is that of our chief executive officer or an
executive officer who is also the controlling shareholder of our company (including an affiliate thereof). Such shareholder approval shall
require a majority vote of the shares present and voting at a shareholders meeting, provided either (i) such majority includes a majority
of the shares held by non-controlling shareholders who do not otherwise have a personal interest in the compensation arrangement that
are voted at the meeting, excluding for such purpose any abstentions disinterested majority, or (ii) the total shares held by non-controlling
and disinterested shareholders voted against the arrangement does not exceed 2% of the voting rights in our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, approval of
the compensation of an executive officer who is also a director requires a simple majority vote of the shares present and voting at a
shareholders meeting, if consistent with our office holder compensation policy. Our compensation committee and board of directors may,
in special circumstances, approve the compensation of an executive officer (other than a director, a chief executive officer or a controlling
shareholder) or approve the compensation policy despite shareholders&#8217; objection, based on specified arguments and taking shareholders&#8217;
objection into account. Our compensation committee may further exempt an engagement with a nominee for the position of chief executive
officer, who meets the non-affiliation requirements set forth for an external director, from requiring shareholder approval, if such engagement
is consistent with our office holder compensation policy and our compensation committee determines based on specified arguments that presentation
of such engagement to shareholder approval is likely to prevent such engagement. To the extent that any such transaction with a controlling
shareholder is for a period exceeding three years, approval is required once every three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director or executive officer
may not be present when the board of directors of a company discusses or votes upon a transaction in which he or she has a personal interest,
except in case of ordinary transactions, unless the chairman of the board of directors determines that he or she should be present to
present the transaction that is subject to approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Independent directors. </i>Israeli law does not require, nor do our independent directors conduct, regularly scheduled meetings at which only they are present, which Nasdaq rules otherwise require.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shareholder approval. </i>We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking approval for corporation actions in accordance with Nasdaq Listing Rule 5635. In particular, under this Nasdaq rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) below a specified minimum price. By contrast, under the Companies Law, shareholder approval is required for, among other things: (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, subject to applicable relief, (ii) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval, and (iii) terms of employment or other engagement of the controlling shareholder of us or such controlling shareholder&#8217;s relative, which require special approval. In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Annual Shareholders Meeting.</i> As opposed to the Nasdaq Listing Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within one year of the company&#8217;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders&#8217; meeting each calendar year and within 15 months of the last annual shareholders meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_075"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_076"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16J. INSIDER TRADING POLICIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-20408">adopted</ix:nonNumeric> an&#160;insider
trading policy governing the purchase, sale and other transactions in our securities that applies to our directors, senior management,
employees, consultants, contractors and other covered persons, including immediate family members and entities controlled by any of the
foregoing persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This policy prohibits, among
other things, insider trading and certain speculative transactions in our securities (including short sales, buying put and selling call
options and other hedging or derivative transactions in our securities) and establishes a regular blackout period schedule during which
directors, senior management, employees, and other covered persons may not trade in our securities, as well as certain pre-clearance procedures
that directors and officers of the Company, the Company&#8217;s subsidiaries and/or affiliates must observe prior to effecting any transaction
in our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the policy&#160;is
reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and listing standards applicable
to us. A copy of the policy&#160;is filed as Exhibit 11.1 to this Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_077"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16K. CYBERSECURITY.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-12091"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has developed
and maintained a cybersecurity risk management strategy, consisting of cybersecurity policies, procedures, compliance and awareness programs
to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="ixv-20409"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="ixv-20410">The cybersecurity process
has been integrated into the Company&#8217;s overall risk management system and process and is solely internally managed</ix:nonNumeric>.</ix:nonNumeric> <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="ixv-20411">Management is
<ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="ixv-20412">responsible</ix:nonNumeric> for identifying risks that threaten achievement of the control activities stated in the management&#8217;s description of
the services organizations systems. The risk assessment occurs annually, or as business needs change, and covers <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="ixv-20413">identification</ix:nonNumeric> of risks
that could act against the company&#8217;s objectives as well as specific risks related to a compromise to the security of data.</ix:nonNumeric></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The level of each identified
risk is determined by considering the impact of the risk itself and the likelihood of the risk materializing and high scoring risks are
actioned upon. Risks are analyzed to determine whether the risk meets company risk acceptance criteria to be accepted or whether a mitigation
plan will be applied. Mitigation plans include both the individual or department responsible for the plan and may include budget considerations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-20414">As of the date of this report,
we are <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-20415">not</ix:nonNumeric> aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition</ix:nonNumeric>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-12106"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Governance</b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-12114"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-20416">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts</ix:nonNumeric>. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Management and Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="ixv-12125"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the critical elements
of our overall risk management approach, our cybersecurity program is focused on the following key areas:</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_2" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborative Approach: The Company has implemented a comprehensive, cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_3" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technical Safeguards: The Company deploys technical safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incident Response and Recovery Planning: The Company has established and maintains comprehensive incident response and recovery plans that fully address the Company&#8217;s response to a cybersecurity incident, and such plans are tested and evaluated on a regular basis.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><div><a id="a_078"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_079"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 17. <span style="text-transform: uppercase">FINANCIAL
STATEMENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to provide
financial statements and related information pursuant to Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_080"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 18. <span style="text-transform: uppercase">FINANCIAL
STATEMENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements and
the related notes required by this Item are included in this annual report on Form 20-F beginning on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_081"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 19. <span style="text-transform: uppercase">EXHIBITS
</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b>&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-1_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. (filed as Exhibit 99.1 to Form 6-K (File No. 001-40303)
    filed on December 20, 2021 and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="iinnex2-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of Securities.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-1_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement (filed as Exhibit 10.1 to Form F-1 (File No. 333-253920) filed on March 12, 2021 and incorporated herein
    by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390025020699/ea023315301ex99-1_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended
    and Restated Inspira Technologies Oxy B.H.N. Ltd. 2019 Equity Incentive Plan, (filed as Exhibit 99.1 to Form S-8 (File No. 333-285565)
    filed on March 5, 2025, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-2_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inspira
    Technologies Oxy B.H.N. Ltd. Compensation Policy for Company&#8217;s Executives, (filed as Exhibit 99.2 to Form 6-K (File No. 001-4030)
    filed on December 20, 2021, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-2_inspiratech.htm">&#8239;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Agent Agreement (filed as Exhibit 4.2 to Form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein
    by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-4_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant (filed as Exhibit 4.4 to Form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024025316/ea020216701ex4-6_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Amendment of Warrant Agreement by and between the Company and American Stock Transfer &amp; Trust Company, LLC, dated August 8,
    2022 (filed as Exhibit 4.6 to Form 20-F, filed on March 25, 2024 and incorporated herein by reference.) </span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-7_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Simple Agreement for Future Equity (filed as Exhibit 10.7 to Form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated
    herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021034372/ea143325ex10-8_inspiratec.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    Loan Agreement, dated March 1, 2018, by and between the Company and Dagi Ben-Noon (filed as Exhibit 10.8 to form F-1 (File No. 333-253920)
    filed on July 1, 2021, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-8_inspiratech.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Convertible Loan Agreement (filed as Exhibit 10.9 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein
    by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390023098916/ea190727ex10-1_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement (filed as Exhibit 10.1 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2023,
    and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024041365/ea020565001ex4-7_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    to Purchase Ordinary Shares (filed as Exhibit 4.7 to Form F-1 on May 9, 2024, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024053164/ea020795901ex4-1_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
    Ordinary Share Purchase Warrant (filed as Exhibit 4.1 to the Report of Foreign Private Issuer on Form 6-K on June 17, 2024, and incorporated
    herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024053164/ea020795901ex10-1_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement (filed as Exhibit 10.1 to the Report of Foreign Private Issuer on Form 6-K on June 17, 2024, and
    incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024113079/ea022602101ex99-3_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Ordinary Share Purchase Warrant (filed as Exhibit 99.3 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2024,
    and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024113079/ea022602101ex99-2_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
    Ordinary Share Purchase Warrant (filed as Exhibit 99.2 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2024,
    and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024113079/ea022602101ex99-1_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
    Purchase Agreement (filed as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2024, and incorporated
    herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000101376225000316/ea023443301ex99-1_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    Agreement by and between Inspira Technologies Oxy B.H.N. Ltd. and A.G.P./Alliance Global Partners, dated March 14, 2025 (filed as
    Exhibit 99.1 the Report of Foreign Private Issuer on Form 6-K on March 14, 2025, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390025121495/ea026964801ex10-1_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement (filed as Exhibit 10.1 the Report of Foreign Private Issuer on Form 6-K on December 15, 2025, and
    incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390025121495/ea026964801ex10-2_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standby
    Equity Purchase Agreement by and between Inspira Technologies Oxy B.H.N. Ltd. and YA II PN, LTD., dated December 12, 2025 (filed
    as Exhibit 10.2 the Report of Foreign Private Issuer on Form 6-K on December 15, 2025, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390026013042/ea027579501ex10-2_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement (filed as Exhibit 10.2 the Report of Foreign Private Issuer on Form 6-K on February 6, 2026, and
    incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390026013042/ea027579501ex4-1_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Ordinary Warrant (filed as Exhibit 4.1 the Report of Foreign Private Issuer on Form 6-K on February 6, 2026, and incorporated
    herein by reference).</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390026013042/ea027579501ex4-2_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
    Ordinary Share Purchase Warrant (filed as Exhibit 4.2 the Report of Foreign Private Issuer on Form 6-K on February 6, 2026, and incorporated
    herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390026013042/ea027579501ex4-3_inspira.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Warrant Amendment Agreement (filed as Exhibit 4.3 the Report of Foreign Private Issuer on Form 6-K on February 6, 2026, and incorporated
    herein by reference).</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000118518526000601/iinnex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    Agreement by and between Inspira Technologies Oxy B.H.N. Ltd. and A.G.P./Alliance Global Partners, dated February 17, 2026 (filed
    as Exhibit 10.1 the Report of Foreign Private Issuer on Form 6-K on February 18, 2026, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="iinnex11-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider
    Trading Policy.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="iinnex12-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="iinnex12-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="iinnex13-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of the Chief Executive Officer pursuant to 18 U.S.C. 1350.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="iinnex13-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification
    of the Chief Financial Officer pursuant to 18 U.S.C. 1350.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="iinnex15-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ziv Haft, a member firm of BDO, independent registered public accounting firm.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024025316/ea020216701ex97-1_inspira.htm">Inspira Technologies Oxy B.H.N. Ltd. Clawback Policy (filed as Exhibit 97.1 to Form 20-F, filed on March 25, 2024, and incorporated herein by reference).</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following financial
    information from the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2025, formatted in XBRL (eXtensible
    Business Reporting Language): (i) Balance sheets as of December 31, 2025, December 31, 2024 and December 31, 2023; (ii) Statements
    of Comprehensive Loss as of December 31, 2025, December 31, 2024 and December 31, 2023; (iii) Statement of Changes in Shareholders&#8217;
    Equity as of December 31, 2025, December 31, 2024 and December 31, 2023; (iv) Statements of Cash Flows as of December 31, 2025, December
    31, 2024 and December 31, 2023; and (v) Notes to the financial statements.</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0px; margin-bottom: 0px; width: 10%"><div style="font-size: 1pt; border-top: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_082"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
annual report on Form 20-F filed on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 26, 2026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dagi Ben-Noon</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#TableOfContents">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="toc_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">TABLE OF CONTENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 86%">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 13%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><a href="#fina_001"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm (BDO Ziv Haft; Tel-Aviv, Israel; PCAOB#<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-20417">1185</ix:nonNumeric>)</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-2</span></td></tr> <tr style="vertical-align: bottom"> <td><a href="#fina_002"><span style="font-size: 10pt">Statements of balance sheet</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-3</span></td></tr> <tr style="vertical-align: bottom"> <td><a href="#fina_003"><span style="font-size: 10pt">Statements of comprehensive loss</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: bottom"> <td><a href="#fina_004"><span style="font-size: 10pt">Statements of changes in shareholders&#8217; equity</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: bottom"> <td><a href="#fina_005"><span style="font-size: 10pt">Statements of cash flows</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-8</span></td></tr> <tr style="vertical-align: bottom"> <td><a href="#fina_006"><span style="font-size: 10pt">Notes to the financial statements</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-size: 10pt">F-10 &#8211; F-35</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">________________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">____________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The amounts are stated in thousands of U.S. dollars</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fina_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">To The Board of Directors and Shareholders of
Inspira Technologies Oxy B.H.N. Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ha-Tidhar Street 2, Ra&#8217;anana, Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Opinion on the Financial Statements&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance sheets
of Inspira Technologies Oxy B.H.N. Ltd. (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, the related statements of comprehensive
loss, changes in shareholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2025, and the
related notes (collectively, the &#8220;Financial Statements&#8221;). In our opinion, the Financial Statements present fairly, in all
material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its
cash flows for each of the three years in the period ended December&#160;31, 2025, in conformity with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Going Concern</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying Financial Statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 1.3 to these Financial Statements, the Company
is at its deployment stage with respect to the INSPIRA ART100, and is in development stage with its other technologies, therefore, it
has suffered recurring losses and negative cash flows from operations since inception. As of December 31, 2025, the Company had incurred
accumulated losses of $80 million. The Company&#8217;s operations have been funded substantially through issuance of shares and warrants.
Considering the above, the Company&#8217;s dependency on external funding for its operations raises a substantial doubt about the Company&#8217;s
ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding
these matters are described in Note 1.3 The Financial Statements do not include any adjustments that might result from the outcome of
these uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis for Opinion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These Financial Statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on these Financial Statements based on our audits. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to
be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the Financial
Statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to
assess the risks of material misstatement of the Financial Statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the Financial
Statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well
as evaluating the overall presentation of the Financial Statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="vertical-align: bottom; width: 50%"><span style="font-size: 10pt">We have served as the Company&#8217;s auditors since 2018.</span></td> <td style="vertical-align: top; width: 50%; text-align: center"><span style="font-size: 10pt">BDO Member Firm /s/</span></td></tr> <tr style="vertical-align: bottom"> <td><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-12714"><span style="font-size: 10pt">Tel-Aviv, Israel</span></ix:nonNumeric></td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-12717"><span style="font-size: 10pt">Ziv Haft</span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-size: 10pt">March 25, 2026</span></td> <td style="padding-left: 2.85pt; text-align: center"><span style="font-size: 10pt">Certified Public Accountants (Isr.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 2; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fina_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Current Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">3</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20418">3,159</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20419">5,111</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Deposits</td><td>&#160;</td>
    <td style="text-align: center">4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd" id="ixv-20420">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd" id="ixv-20421">668</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other current assets</td><td>&#160;</td>
    <td style="text-align: center">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-20422">517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-20423">587</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Inventory</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">6</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-20424">735</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-20425">444</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Total current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-20426">4,411</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-20427">6,810</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-Current Assets:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Right of use assets, net</td><td>&#160;</td>
    <td style="text-align: center">10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-20428">478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-20429">761</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Property, plant and equipment, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">7</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20430">452</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20431">499</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Total non-current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-20432">930</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-20433">1,260</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-20434">5,341</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-20435">8,070</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Trade accounts payables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-20436">107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-20437">154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other accounts payables</td><td>&#160;</td>
    <td style="text-align: center">8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-20438">1,349</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-20439">1,364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center">10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-20440">286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-20441">277</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Financial liabilities at fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">11</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20442">1,082</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20443">1,575</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Total current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20444">2,824</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20445">3,370</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Non-Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">10</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-20446">194</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-20447">378</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Total non- current liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-20448">194</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-20449">378</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.25in">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: center">9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shareholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Ordinary shares, <ix:nonFraction contextRef="c4" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-20450"><ix:nonFraction contextRef="c5" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-20451">no</ix:nonFraction></ix:nonFraction> par value:<br/> <b>Authorized</b> <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-20452"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-20453">100,000,000</ix:nonFraction></ix:nonFraction> ordinary shares as of December 31, 2025 and December 31, 2024;<br/> <b>Issued and outstanding </b><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-20454"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-20455">35,949,247</ix:nonFraction></ix:nonFraction> ordinary shares as of December 31, 2025 and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-20456"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-20457">24,252,096</ix:nonFraction></ix:nonFraction> shares as of December 31, 2024</span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-20458">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-20459">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share capital and additional paid in capital</td><td>&#160;</td>
    <td style="text-align: center">12</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-20460">82,117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-20461">70,896</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Accumulated losses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-20462">79,794</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-20463">66,574</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Total Shareholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20464">2,323</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20465">4,322</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total liabilities and Shareholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-20466">5,341</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-20467">8,070</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These Financial Statements were authorized by the Board of Directors
on March 25, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fina_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands except for loss per
share)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Note</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">13</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-20468">289</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-20469">-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-20470">-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">14</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-20471">287</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-20472">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-20473">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">Gross Profit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" unitRef="usd" id="ixv-20474">2</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GrossProfit" scale="3" unitRef="usd" id="ixv-20475">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GrossProfit" scale="3" unitRef="usd" id="ixv-20476">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-20477">7,496</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-20478">6,323</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-20479">7,320</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: center">16</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-20480">5,532</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-20481">4,185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-20482">4,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: center">17</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-20483">588</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-20484">754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-20485">746</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-20486">9</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-20487">5</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-20488">4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 9pt">Operating loss</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20489">13,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20490">11,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20491">12,133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest income from deposits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-20492">64</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-20493">172</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-20494">318</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Finance expenses (income), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">18</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-20495">339</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-20496">42</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-20497">529</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 9pt">Loss before tax</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-20498">13,220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-20499">11,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-20500">11,286</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Taxes on income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1pt">19</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-20501">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-20502">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-20503">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total comprehensive and net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20504">13,220</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20505">11,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20506">11,286</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Net loss per ordinary share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-20507"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-20508">0.45</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-20509"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-20510">0.60</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-20511"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-20512">0.93</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Weighted average number of ordinary shares outstanding basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-20513"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-20514">29,623,194</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-20515"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-20516">18,515,545</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-20517"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-20518">12,095,477</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fina_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">For the year ended December 31, 2025:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ordinary Share Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share&#160;capital<br/> and<br/> Additional<br/> Paid in<br/> Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold">Balance as of January&#160;1, 2025:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-20519">24,252,096</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20520">70,896</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-20521">66,574</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20522">4,322</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Issuance of ordinary shares, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-20523">1,565,217</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-20524">1,739</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-20525">1,739</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares (pursuant to an at-the-market facility)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-20526">5,485,898</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-20527">4,616</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-20528">4,616</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-20529">101,376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-20530">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-20531">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" scale="0" unitRef="shares" id="ixv-20532">1,514,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" scale="3" unitRef="usd" id="ixv-20533">942</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" scale="3" unitRef="usd" id="ixv-20534">942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Restricted share unit (&#8220;RSU&#8221;) vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-20535">2,711,947</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" unitRef="usd" id="ixv-20536">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" unitRef="usd" id="ixv-20537">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares- advisor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-20538">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-20539">116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-20540">116</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares- commitment fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="iinn:IssuanceOfOrdinarySharesCommitmentFeesinShares" scale="0" unitRef="shares" id="ixv-20541">218,627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" scale="3" unitRef="usd" id="ixv-20542">223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" scale="3" unitRef="usd" id="ixv-20543">223</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-20544">3,575</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-20545">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-20546">3,575</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Comprehensive and net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-20547">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20548">13,220</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20549">13,220</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-20550">35,949,247</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20551">82,117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-20552">79,794</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20553">2,323</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">For the year ended December 31, 2024:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ordinary Share Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share&#160;capital<br/> and<br/> Additional<br/> Paid in<br/> Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold">Balance as of January&#160;1, 2024:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-20554">15,652,176</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20555">61,259</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-20556">55,521</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20557">5,738</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares, private warrants and pre- funded warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-20558">6,231,169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-20559">7,679</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-20560">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-20561">7,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-20562">19,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-20563">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-20564">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-20565">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Exercise of June 2024 pre-funded warrants into ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" scale="0" unitRef="shares" id="ixv-20566">1,709,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" scale="3" unitRef="usd" id="ixv-20567">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:fixed-zero" name="iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" scale="3" unitRef="usd" id="ixv-20568">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" scale="3" unitRef="usd" id="ixv-20569">2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">RSU vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-20570">594,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" unitRef="usd" id="ixv-20571">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" unitRef="usd" id="ixv-20572">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares- advisor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-20573">45,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-20574">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-20575">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-20576">62</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-20577">1,892</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-20578">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-20579">1,892</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Comprehensive and net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-20580">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20581">11,053</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20582">11,053</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-20583">24,252,096</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20584">70,896</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-20585">66,574</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20586">4,322</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">For the year ended December 31, 2023:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ordinary Share Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share&#160;capital<br/> and&#160;<br/> Additional<br/> Paid in<br/> Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; font-weight: bold">Balance as of January&#160;1, 2023:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-20587">11,338,940</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20588">57,866</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-20589">44,235</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20590">13,631</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Changes during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares and private warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-20591">3,031,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-20592">1,806</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-20593">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-20594">1,806</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of placement agent warrants (Note 11.3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-20595">131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-20596">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-20597">131</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares (pursuant to an at-the-market facility)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-20598">17,566</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-20599">26</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-20600">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-20601">26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Exercise of share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" scale="0" unitRef="shares" id="ixv-20602">37,972</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" scale="3" unitRef="usd" id="ixv-20603">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:fixed-zero" name="iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" scale="3" unitRef="usd" id="ixv-20604">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" scale="3" unitRef="usd" id="ixv-20605">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">RSU vesting</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-20606">1,226,448</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" unitRef="usd" id="ixv-20607">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" unitRef="usd" id="ixv-20608">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-20609">1,427</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-20610">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-20611">1,427</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Comprehensive and net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NetIncomeLoss" scale="3" unitRef="usd" id="ixv-20612">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20613">11,286</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20614">11,286</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-20615">15,652,176</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20616">61,259</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-20617">55,521</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-20618">5,738</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fina_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CASH FLOW</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOW FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20619">13,220</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20620">11,053</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-20621">11,286</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash provided by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20622">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20623">171</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20624">111</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Capital loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherLosses" scale="3" unitRef="usd" id="ixv-20625">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherLosses" scale="3" unitRef="usd" id="ixv-20626">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProvisionForOtherLosses" scale="3" unitRef="usd" id="ixv-20627">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Share based compensation expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-20628">3,575</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-20629">1,892</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-20630">1,427</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Share based compensation &#8211; placement agent warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" unitRef="usd" id="ixv-20631">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" unitRef="usd" id="ixv-20632">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" unitRef="usd" id="ixv-20633">59</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Evaluation of financial liability at fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" unitRef="usd" id="ixv-20634">720</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" sign="-" unitRef="usd" id="ixv-20635">47</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" unitRef="usd" id="ixv-20636">306</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Expiration of financial liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="iinn:ExpirationOfFinancialLiability" scale="3" unitRef="usd" id="ixv-20637">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExpirationOfFinancialLiability" scale="3" unitRef="usd" id="ixv-20638">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="iinn:ExpirationOfFinancialLiability" scale="3" unitRef="usd" id="ixv-20639">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitRef="usd" id="ixv-20640">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitRef="usd" id="ixv-20641">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitRef="usd" id="ixv-20642">205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Issuance of ordinary shares - advisor fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IssuanceOfOrdinarySharesAdvisorFees" scale="3" unitRef="usd" id="ixv-20643">116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IssuanceOfOrdinarySharesAdvisorFees" scale="3" unitRef="usd" id="ixv-20644">62</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="iinn:IssuanceOfOrdinarySharesAdvisorFees" scale="3" unitRef="usd" id="ixv-20645">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Prepayments of lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-20646">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-20647">9</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-20648">7</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Decrease (increase) in right of use assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInLeasingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-20649">99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInLeasingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-20650">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInLeasingReceivables" scale="3" unitRef="usd" id="ixv-20651">5</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Decrease (increase) in other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-20652">78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-20653">84</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-20654">190</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">(Decrease) increase in trade accounts payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd" id="ixv-20655">47</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd" id="ixv-20656">44</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-20657">46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">(Decrease) increase in other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-20658">58</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-20659">118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-20660">190</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">(Increase) decrease in inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" unitRef="usd" id="ixv-20661">291</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" unitRef="usd" id="ixv-20662">444</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInInventories" scale="3" unitRef="usd" id="ixv-20663">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Unrealized foreign exchange (gain) loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" unitRef="usd" id="ixv-20664">25</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" unitRef="usd" id="ixv-20665">55</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" sign="-" unitRef="usd" id="ixv-20666">65</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Financial expenses due to commitment fee &#8211; Standby Equity Purchase Agreement (SEPA)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinancialExpensesDueToCommitmentFee" scale="3" unitRef="usd" id="ixv-20667">250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="iinn:FinancialExpensesDueToCommitmentFee" scale="3" unitRef="usd" id="ixv-20668">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="iinn:FinancialExpensesDueToCommitmentFee" scale="3" unitRef="usd" id="ixv-20669">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Issuance of ordinary shares - commitment fee (SEPA)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IssuanceOfOrdinarySharesCommitmentFee" scale="3" unitRef="usd" id="ixv-20670">223</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="iinn:IssuanceOfOrdinarySharesCommitmentFee" scale="3" unitRef="usd" id="ixv-20671">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="iinn:IssuanceOfOrdinarySharesCommitmentFee" scale="3" unitRef="usd" id="ixv-20672">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 27pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-20673">9,861</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-20674">9,374</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-20675">9,691</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOW FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Purchase of property, plant, and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20676">103</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20677">164</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20678">206</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.25in">Change in deposits, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromInvestments" scale="3" sign="-" unitRef="usd" id="ixv-20679">668</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromInvestments" scale="3" sign="-" unitRef="usd" id="ixv-20680">1,652</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromInvestments" scale="3" sign="-" unitRef="usd" id="ixv-20681">4,800</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 27pt">Net cash provided by investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-20682">565</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-20683">1,488</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-20684">4,594</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.25in">Issuance of ordinary shares, pre-funded warrants and ordinary warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-20685">1,759</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-20686">7,898</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-20687">3,424</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-20688">10</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-20689">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-20690">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Exercise of warrants and pre-funded warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd" id="ixv-20691">912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd" id="ixv-20692">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd" id="ixv-20693">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Issuance of ordinary shares (issuances pursuant to an at-the-market facility), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-20694">4,646</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-20695">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-20696">26</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 27pt">Net cash provided by financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-20697">7,327</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-20698">7,902</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-20699">3,453</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Effect of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-20700">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-20701">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-20702">65</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Net increase (decrease) in cash and cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-20703">1,969</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-20704">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-20705">1,644</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents and restricted cash at the beginning of the period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-20706">5,201</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-20707">5,130</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-20708">6,839</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Cash, cash equivalents and restricted cash at the end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-20709">3,257</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-20710">5,201</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-20711">5,130</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of the Financial Statements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>STATEMENTS OF CASH FLOW</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(US dollars in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">APPENDIX A - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED
CASH:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides a reconciliation
of cash, cash equivalents and restricted cash reported on the balance sheet that sum to the total of the same such amounts shown in the
statement of cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20712">3,159</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20713">5,111</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20714">5,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-20715">98</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-20716">90</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-20717">89</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20718">3,257</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20719">5,201</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20720">5,130</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">APPENDIX B &#8211; NON-CASH TRANSACTIONS:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Other receivable in connection to December private placement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="iinn:OtherReceivableInConnectionToPrivatePlacement" scale="3" unitRef="usd" id="ixv-20721">-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OtherReceivableInConnectionToPrivatePlacement" scale="3" sign="-" unitRef="usd" id="ixv-20722">70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="iinn:OtherReceivableInConnectionToPrivatePlacement" scale="3" unitRef="usd" id="ixv-20723">-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued issuance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccruedIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-20724">43</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccruedIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-20725">220</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="iinn:AccruedIssuanceExpenses" scale="3" unitRef="usd" id="ixv-20726">-</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Financial liability- placement agent fee (Note 10-A)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="iinn:FinancialLiabilityPlacementAgentFee" scale="3" unitRef="usd" id="ixv-20727">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinancialLiabilityPlacementAgentFee" scale="3" sign="-" unitRef="usd" id="ixv-20728">69</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="iinn:FinancialLiabilityPlacementAgentFee" scale="3" unitRef="usd" id="ixv-20729">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Share based compensation- placement agent warrants against additional paid in capital (Note 11)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-20730">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" scale="3" sign="-" unitRef="usd" id="ixv-20731">254</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" scale="3" sign="-" unitRef="usd" id="ixv-20732">73</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NonCashTransactions" scale="3" sign="-" unitRef="usd" id="ixv-20733">43</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NonCashTransactions" scale="3" sign="-" unitRef="usd" id="ixv-20734">473</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NonCashTransactions" scale="3" sign="-" unitRef="usd" id="ixv-20735">73</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration:underline">APPENDIX C - AMOUNT PAID DURING THE PERIOD:</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Interest paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-20736">65</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-20737">72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-20738">93</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>


</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fina_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-15217"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">Inspira Technologies Oxy B.H.N. Ltd (the &#8220;Company&#8221;) was
                                            incorporated in Israel and commenced its operations on February 27, 2018. The Company operates
                                            in the medical technology industry in the field of respiratory support technology engaged
                                            in the research, development, manufacturing related activities, and go-to-market activities
                                            of proprietary products and technologies. The Company is developing the following products:</td></tr></table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The INSPIRA ART (Augmented
                                            Respiratory Technology), which is a respiratory support technology targeted toward utilizing
                                            blood monitoring and direct blood oxygenation to boost patient saturation levels within minutes
                                            while the patient is awake. The aim is to provide an alternative to invasive mechanical ventilation,
                                            associated with high risks, complications, high costs and high mortality rates.</td></tr></table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The HYLA blood sensor,
                                            which is a non-invasive optical blood sensor designed to perform real-time and continuous
                                            blood parameter measurements, potentially reducing the need for intermittent blood samples
                                            from patients.</td></tr></table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The INSPIRA ART100
                                            System, an advanced form of life support system, better known by the medical industry as
                                            a cardiopulmonary bypass system, has been designed for use in procedures requiring cardiopulmonary
                                            bypass for six hours or less.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company&#8217;s INSPIRA ART100 system received U.S.
Food and Drug Administration (&#8220;FDA&#8221;) 510(k) regulatory clearance for cardiopulmonary bypass procedures and Israeli Medical
Equipment Division certification for extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures. The Company&#8217;s
other products, including the INSPIRA ART and HYLA&#8482; blood sensor, have not yet been tested or used in humans and have not been
approved by any regulatory entity.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">2.</td><td style="text-align: justify">On March 14, 2025, the Company entered into a sales agreement pursuant to which the Company could offer and sell, from time to time, through the sales agent, ordinary shares, no par value, of the Company (&#8220;Ordinary Shares&#8221;) pursuant to an at-the-market facility (the &#8220;March 2025 ATM&#8221;), having an aggregate offering price of up to $<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateOfferingPrice" scale="3" unitRef="usd" id="ixv-20739">1,019</ix:nonFraction>. On April 10, 2025, the maximum aggregate offering price was increased to $<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateOfferingPrice" scale="3" unitRef="usd" id="ixv-20740">1,917</ix:nonFraction>, On July 1, 2025, the maximum aggregate offering price was increased to $<ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateOfferingPrice" scale="3" unitRef="usd" id="ixv-20741">7,118</ix:nonFraction>. On September 16, 2025, the maximum aggregate offering price was increased to $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateOfferingPrice" scale="3" unitRef="usd" id="ixv-20742">14,687</ix:nonFraction>. As of December 31, 2025, the Company has sold <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-20743">5,485,898</ix:nonFraction> Ordinary Shares under the ATM for aggregate gross proceeds received of approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateGrossProceeds" scale="3" unitRef="usd" id="ixv-20744">4,888</ix:nonFraction>, before deducting offering costs of approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeductingOfferingCosts" scale="3" unitRef="usd" id="ixv-20745">272</ix:nonFraction>. Subsequent to December 31, 2025 and following the expiration of the Sales Agreement due to expiration of the related Registration Statement on Form F-3 (File No. 333-266748), the Company entered into a new sales agreement pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (&#8220;ATM&#8221;), having an aggregate offering price of up to $<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateOfferingPrice" scale="3" unitRef="usd" id="ixv-20746">2,016</ix:nonFraction> To date, no Ordinary Shares have been sold pursuant to the March 2025 ATM.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">3.</td><td style="text-align: justify">The accompanying financial statements (the &#8220;Financial Statements&#8221;) have been prepared assuming that the Company will continue as a going concern. To date, the Company is at the deployment stage with respect to the INSPIRA ART100, and is in development stage with its other technologies. Therefore, the Company has suffered recurring losses from operations and negative cash flows from operations since inception. As of December 31, 2025, the Company had incurred accumulated losses of $<ix:nonFraction contextRef="c4" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" unitRef="usd" id="ixv-20747">80</ix:nonFraction> million and expects to continue to fund its operations through fundings such as issuance of convertible securities, Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that such financing will be obtained. Considering the above, our dependence on external funding for our operations raises a substantial doubt about our ability to continue as a going concern. The Financial Statements do not include any adjustments that might result from the outcome of these uncertainties.</td></tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">4.</td><td style="text-align: justify">Our offices are located in Ra&#8217;anana,
                                            Israel. On October 7, 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from
                                            the Gaza Strip and conducted a series of attacks on civilian and military targets. Following
                                            the October 7, 2023 attacks by Hamas terrorists in Israel&#8217;s southern border, Israel
                                            declared war against Hamas and since then, Israel has been involved in military conflicts
                                            with Hamas, Hezbollah, a terrorist organization based in Lebanon, and Iran, both directly
                                            and through proxies like the Houthi movement in Yemen and armed groups in Iraq and other
                                            terrorist organizations. Additionally, following the fall of the Assad regime in Syria, Israel
                                            has conducted limited military operations targeting the Syrian army, Iranian military assets
                                            and infrastructure linked to Hezbollah and other Iran-supported groups.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 13, 2025, Israel launched a
strike against Iran, aimed to disrupt Iran&#8217;s capacity to coordinate or launch hostilities against Israel. Iran has retaliated in
response, firing missiles and drones at Israeli military and civilian infrastructure. More recently, in February 2026, hostilities between
Israel and Iran escalated again.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In late February 2026, Israel, together
with the United States, conducted a major joint military campaign of air and missile strikes against targets in Iran, which triggered
a broad Iranian response and contributed to significant regional instability. The situation remains highly fluid, and we are unable to
predict when, or on what terms, this escalation will be resolved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Although certain ceasefire agreements
have been reached with Hamas, and the level of hostilities has since decreased, the situation remains volatile, with the potential for
escalation into a broader regional conflict involving additional terrorist organizations and possibly other countries, including as a
result of instability arising from developments in Syria. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Other regional hostilities, since October
7, 2023, concurrently became more pronounced. This includes and has included a northern front war igniting between Israel and Hezbollah,
which as of February 24, 2025 we are under a ceasefire, hostilities between Israel and Iran, which have included Iranian strikes against
Israel in April 2024 and October 2024, and subsequent retaliation by Israel to both instances, and a continued conflict between Israel
and the Houthi Movement in Yemen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">Currently,
one of our employees is serving in military reserve duty. In addition, due to the ongoing security situation, we may experience occasional
delays in the shipment of inventory. However, as of the date of these Financial Statements, these events have no material impact on the
Company&#8217;s operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">5.</td><td>These Financial Statements were authorized by the Board of Directors
                                            on March 25, 2026</td></tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-15313"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying Financial Statements have been
prepared in conformity with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The
significant accounting policies followed in the preparation of the Financial Statements are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-15320"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Use of estimates:</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of Financial Statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting
period.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation continuedAt="_UseOfEstimates-c0_cont_3" id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Items subject to such estimates and assumptions include:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_4" id="_UseOfEstimates-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">stock-based compensation expense;</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_5" id="_UseOfEstimates-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">fair value financial liabilities;</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_6" id="_UseOfEstimates-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">recognition, measurement, and
disclosure of contingent liabilities;</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_7" id="_UseOfEstimates-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Interest rate used for lease
liability measurement.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#8217;s Financial Statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-15401"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Foreign Currency</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#8220;USD&#8221;). The Company&#8217;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#8211; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#8211; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-15413"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>C. Property,
Plant, and Equipment</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" id="ixv-15421"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual rates of depreciation are as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-20748">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-20749">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-20750">6</ix:nonFraction>-<ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-20751">15</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-20752">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-15459"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Inventory</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_2" id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost or
net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items, technological obsolescence, excess
inventories, discontinued products, and for market prices lower than cost, if any.</p></ix:continuation>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_3" id="_InventoryPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company periodically evaluates the quantities on hand relative
to historical and projected sales volume (which is determined based on an assumption of future demand and market conditions) and the
age of the inventory. At the point of the loss recognition, a new lower cost basis for that inventory has been established.</p></ix:continuation>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost is determined for all types of inventory
using the moving average cost method plus indirect costs.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-15504"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Leases</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company implemented Accounting Standards
Update (&#8220;ASU&#8221;) 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;) using the modified retrospective approach for all
lease arrangements as of such date. The Company leases office space and vehicles under operating leases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Arrangements meeting the definition of a lease
are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability,
calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental
borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized
over the lease term.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing rate. The Incremental Borrowing Rate
applied was <ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="iinn:IncrementalBorrowingRate" scale="-2" unitRef="pure" id="ixv-20753">11.27</ix:nonFraction>%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-15520"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. Revenue recognition</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s revenues are measured according
to Accounting Standards Codification (&#8220;ASC&#8221;) 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).
Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange
for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from product sales is recognized when
control of the goods transferred to the customer, which is generally upon shipment, unless contractual terms indicate otherwise.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the five-step model under
ASC 606:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify the contract with
a customer;</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_6" id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify the performance obligations
in the contract;</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_7" id="_RevenueRecognitionPolicyTextBlock-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">determine the transaction price;</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_8" id="_RevenueRecognitionPolicyTextBlock-c0_cont_7"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(iv)</span></td><td style="text-align: justify"><span style="font-size: 10pt">allocate the transaction price
to the performance obligations; and</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_9" id="_RevenueRecognitionPolicyTextBlock-c0_cont_8"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(v)</span></td><td style="text-align: justify"><span style="font-size: 10pt">recognize revenue when (or
as) performance obligations are satisfied.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_10" id="_RevenueRecognitionPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Standard product warranties that provide assurance
that the product complies with agreed specifications do not represent a separate performance obligation and are accounted for under ASC
460.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_11" id="_RevenueRecognitionPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Determining whether the Company acts as a principal
or as an agent in the purchase and sale of machines requires significant judgment. While none of the evaluated factors are independently
determinative, after analyzing the guidance under ASC 606 for principal versus agent considerations, the Company concluded that it is
acting as an agent in these transactions. As such, revenues are presented on a net basis. This conclusion is based on the contractual
relationships involved and the manner in which business is conducted, indicating that the Company does not control the machines before
they are transferred to the end customer. In addition, the Company does not bear significant inventory or credit risk.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the Company accounts for variable
consideration related to discounts and rights of return in accordance with ASC 606. Given the Company's role as an agent, it does not
bear the primary obligation for machine performance or the ultimate risk of product returns. Accordingly, the Company recognizes net
revenue only to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Estimates for returns
and discounts will be recognized as a reduction of the net commission at the time of sale, once the Company has established sales and
sufficient historical data to provide a basis for such estimates.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock" id="ixv-15622"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>G. Cost of revenues</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_CostOfSalesPolicyTextBlock-c0_cont_2" id="_CostOfSalesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues consists of products purchased
from sub-contractors, raw materials, shipping and handling costs to customers, salary, employee-related expenses, depreciation, royalties
to the Israeli Innovation Authority (&#8220;IIA&#8221;), provision for assurance and overhead expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CostOfSalesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues are expensed commensurate with
the recognition of the respective revenues.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-15632"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H. Research and Development Costs.</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_GovernmentAssistancePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="ixv-15640"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>I. Government Grants </b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_GovernmentAssistancePolicyTextBlock-c0_cont_2" id="_GovernmentAssistancePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives royalty-bearing grants from
the IIA for approved research and development projects Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_GovernmentAssistancePolicyTextBlock-c0_cont_3" id="_GovernmentAssistancePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grants are linked to the exchange rate of
the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) per year (SOFR is
a benchmark interest rate which replaced LIBOR).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_GovernmentAssistancePolicyTextBlock-c0_cont_4" id="_GovernmentAssistancePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts of grants received and recorded into
income should be disclosed for each period presented. The research and development grants are presented in the statement of operations
as an offset to related research and development expenses. Companies are required to pay royalties in connection with such grants at
specified rates, up to the total dollar-linked amount of such grants. research and development (&#8220;R&amp;D&#8221;).&#160;As of December
31, 2025, the Company generated sales in the amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:SalesAmount" scale="0" unitRef="usd" id="ixv-20754">288</ix:nonFraction> and paid royalties in the amount of $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="iinn:PaidRoyalties" scale="0" unitRef="usd" id="ixv-20755">9</ix:nonFraction>. </p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_GovernmentAssistancePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No liability was recorded in these Financial
Statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="iinn_FinanceIncomeAndExpensesPolicyTextBlock-c0_cont_1" escape="true" name="iinn:FinanceIncomeAndExpensesPolicyTextBlock" id="ixv-15657"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>J. Finance Income and Expenses.</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="iinn_FinanceIncomeAndExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance income is composed of interest on deposits
and revaluation of financial liabilities at fair value, while finance expenses are composed of the revaluation of certain financial liabilities
at fair value, bank charges and net currency exchange rates differences.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-15664"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>K. Current Taxes</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 2 </b>- <b>SIGNIFICANT
ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-15705"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>L. Share-Based Compensation.</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Share-based compensation
expenses related to employees, directors and subcontractors&#8217; options or restricted share units (&#8220;RSU&#8221;) which recognized
based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using
the graded vesting method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_DerivativesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DerivativesPolicyTextBlock" id="ixv-15718"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>M. Warrants and Pre-Funded Warrants</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DerivativesPolicyTextBlock-c0_cont_2" id="_DerivativesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues warrants and pre-funded warrants
as part of its financing activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder
to purchase a specified number of the Company&#8217;s Ordinary Shares at a predetermined exercise price. Warrants and pre-funded warrants
issued by the Company may have various terms, including expiration dates, exercise prices, and conditions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_DerivativesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#8220;ASC&#8221;)
815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as equity if they meet the criteria for equity classification
outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="iinn_SeverancePolicyTextBlock-c0_cont_1" escape="true" name="iinn:SeverancePolicyTextBlock" id="ixv-15728"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>N. Severance</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="iinn_SeverancePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli labor law generally requires payment
of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#8217;s
pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation
Act, 1963 (&#8220;Section 14&#8221;), the Company&#8217;s employees are entitled to monthly deposits, at a rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" unitRef="pure" id="ixv-20756">8.33</ix:nonFraction>% of their monthly
salary, made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance
payments in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance
pay.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-15735"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>O. Basic and Diluted Loss Per Share</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares and pre-funded warrants
outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants issued during the year, if applicable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-15742"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>P. Fair Value Measurements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;), ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC
820&#8221;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; unadjusted quoted prices are
available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; "><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><b>&#160;</b></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "><b>&#160;</b></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Line Financing Arrangements- </b>The Company may enter into
standby equity purchase agreements or similar equity line financing arrangements with third-party investors. For example, on December
12, 2025, the Company entered into the Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) with Yorkville pursuant to which the Company
has the right to sell to Yorkville up to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iinn:OrdinarySharesSEPAAmount" scale="0" unitRef="usd" id="ixv-20757">25,000</ix:nonFraction> of Ordinary Shares, subject to certain limitations and conditions set forth in the SEPA,
from time to time during the term of the SEPA. Under such arrangements, the Company has the right, but not the obligation, to require
the investor to purchase shares of the Company&#8217;s Ordinary Shares from time to time, subject to certain conditions and limitations,
up to a specified maximum commitment amount during the term of the agreement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates these arrangements under
ASC 480, &#8220;Distinguishing Liabilities from Equity&#8221;, and ASC 815, &#8220;Derivatives and Hedging,&#8221; (&#8220;ASC 815&#8221;)
to determine whether any component of the arrangement should be classified as a liability or as a derivative instrument.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_10" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that the Company maintains the
discretion to initiate drawdowns and settlement occurs through the issuance of the Company&#8217;s Ordinary Shares in exchange for cash,
the issuance of shares under the agreement is accounted for as an equity transaction. Proceeds received upon the issuance of shares are
recorded within stockholders&#8217; equity, typically as Ordinary Shares and additional paid-in capital.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_11" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares issued to the investor as commitment shares
at the inception of the agreement are generally accounted for as equity issuance costs associated with establishing the equity facility.
The fair value of the commitment shares on the grant date is recognized as a reduction to additional paid-in capital, consistent with
the accounting for costs incurred in connection with raising equity capital.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_12" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When shares are issued in connection with drawdowns
under the facility, the Company records the gross proceeds received as an increase to stockholders&#8217; equity. Any issuance costs
directly attributable to the specific drawdown are recorded as a reduction to additional paid-in capital.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_13" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also evaluates whether any features
embedded within the arrangement meet the definition of a freestanding or embedded derivative under ASC 815. If such features do not qualify
for equity classification, they are recognized as derivative instruments and measured at fair value, with subsequent changes in fair
value recognized in the statement of operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the December 31, 2025, the Company has
not sold any Ordinary Shares pursuant to the SEPA, and therefore all issuance expenses were recorded as financial expenses.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-15855"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Q. Concentration of Credit Risk</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Part of the Company&#8217;s operating expenses
are denominated in New Israeli Shekel (&#8220;NIS&#8221;), and therefore, subject to foreign currency risk.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-15865"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R. Cash and Cash Equivalent</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_2" id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from the date of purchase that are
not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_3" id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash consists of funds that are contractually
restricted to bank guarantee due to rental agreements. The Company has presented restricted cash separately from cash and cash equivalents
in the balance sheets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank deposits with maturities of more than three
months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at cost which
approximates market value. As of December 31, 2025, the Company had no short-term deposits, and as of December 31, 2024 the Company had
short-term deposits in the amounts of $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="6" unitRef="usd" id="ixv-20758">0.7</ix:nonFraction> million.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-15879"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>S. Segment Information</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a single operating and reportable
segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Chief Executive Officer, evaluates the performance
of its business based on financial data consistent with the presentation in the accompanying Financial Statements for the purposes of
making operating decisions, assessing financial performance, and allocating resources.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-15887"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>T. New accounting Pronouncements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounting Standards Issued and Not Yet Adopted
in 2025</b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03, Income Statement &#8211; Reporting Comprehensive
Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;),
which requires the disaggregation of certain expense captions into specified categories in disclosures within the notes to the consolidated
financial statements to provide enhanced transparency into the expense captions presented on the face of the statement of income and
comprehensive income. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted,
and may be applied either prospectively or retrospectively to financial statements issued for reporting periods after the effective date
of ASU 2024-03 or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating
the impact that the adoption of ASU 2024-03 will have on its related disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-04,
Induced Conversions of Convertible Debt Instruments (&#8220;ASU 2024-04&#8221;). This new guidance is intended to improve the relevance
and consistency in application of the induced conversion guidance in Subtopic 470-20 for (a) convertible debt instruments with cash conversion
features and (b) debt instruments that are not currently convertible. ASU 2024-04 is effective for fiscal years beginning after December
15, 2026. Early adoption is permitted. The Company does not plan to early adopt this standard. The Company is currently evaluating the
effect of adoption of this standard on its consolidated financial statements and disclosures.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES
(CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2025, the FASB issued ASU 2025-10,
Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which provides comprehensive guidance
on the recognition, measurement, and presentation of government grants. The amendments are effective for annual reporting periods beginning
after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company is currently
evaluating the impact of this guidance on its accounting for government assistance arrangements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Newly issued and recently adopted accounting pronouncements:</b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company:&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_8" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups (&#8220;JOBS&#8221;) Act. Under the JOBS Act, emerging growth companies can delay adopting
new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as to those standards apply to
private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards
that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging
growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories
for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective
for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="ixv-15952"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 3 - CASH AND CASH EQUIVALENT:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company's cash and
cash equivalents are primarily held in U.S. Dollars and New Israeli Shekels (NIS), in current accounts and short-term deposits with leading
banking institutions in Israel and the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company had cash
and cash equivalents in amount of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20759">3,159</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As of December 31, 2024,
the Company had Cash and cash equivalents in amount of $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-20760">5,111</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DepositLiabilitiesDisclosuresTextBlock" id="ixv-15964"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 4 -
DEPOSITS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company&#8217;s
deposits consist of short-term bank deposits with maturities of more than three months but less than one year. The deposits bear annual
interest. Interest earned is recorded as finance income, net in the statement of operations during the years for which the Company held
short-term deposits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company had no deposits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company had a deposit
in NIS at Bank Leumi in the amount of $<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="3" unitRef="usd" id="ixv-20761">668</ix:nonFraction>, including interest that bore a fixed annual interest of <ix:nonFraction contextRef="c42" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-20762">4.108</ix:nonFraction>%.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-16000"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 5 - OTHER CURRENT ASSETS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-16005"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-20763">216</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-20764">240</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestBearingDepositsInBanks" scale="3" unitRef="usd" id="ixv-20765">200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestBearingDepositsInBanks" scale="3" unitRef="usd" id="ixv-20766">183</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-20767">98</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-20768">90</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OthersAsset" scale="3" unitRef="usd" id="ixv-20769">3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OthersAsset" scale="3" unitRef="usd" id="ixv-20770">74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-20771">517</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-20772">587</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-16070"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 - INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-16075"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Finished goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" unitRef="usd" id="ixv-20773">461</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" unitRef="usd" id="ixv-20774">293</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Raw materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" unitRef="usd" id="ixv-20775">208</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" unitRef="usd" id="ixv-20776">96</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Work in progress</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" unitRef="usd" id="ixv-20777">66</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" unitRef="usd" id="ixv-20778">55</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-20779">735</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-20780">444</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-16131"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 - PROPERTY AND EQUIPMENT, NET:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-16135"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">For the year ended December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Computers</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">R&amp;D<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-weight: bold">At January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20781">182</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20782">36</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20783">535</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20784">116</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20785">869</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20786">21</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20787">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20788">80</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20789">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20790">103</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At December 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20791">203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20792">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20793">615</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20794">118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20795">972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At January 1, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20796">146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20797">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20798">189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20799">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20800">370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20801">32</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20802">3</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20803">107</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20804">8</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20805">150</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in"><b>At December 31, 2025</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20806">178</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20807">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20808">296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20809">31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20810">520</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">As of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20811">25</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20812">21</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20813">319</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20814">87</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20815">452</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">For the year ended December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Computers</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">R&amp;D<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20816">172</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20817">36</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20818">381</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20819">116</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20820">705</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20821">10</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20822">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20823">154</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20824">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-20825">164</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20826">182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20827">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20828">535</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20829">116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-20830">869</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20831">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20832">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20833">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20834">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20835">199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20836">44</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20837">4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20838">116</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20839">7</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-20840">171</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20841">146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20842">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20843">189</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20844">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-20845">370</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">As of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20846">36</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20847">24</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20848">346</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20849">93</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-20850">499</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-16822"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 - OTHER ACCOUNTS PAYABLE:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-16827"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-20851">506</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-20852">508</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employees&#8217; salaries and related liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-20853">429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-20854">414</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccountsPayableToRelatedParties" scale="3" unitRef="usd" id="ixv-20855">384</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccountsPayableToRelatedParties" scale="3" unitRef="usd" id="ixv-20856">421</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-20857">30</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-20858">21</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-20859">1,349</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-20860">1,364</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-16900"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A.&#160;Royalties to the IIA:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-indent: -0.7pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2019, the IIA approved a grant to
the Company for the development of intravenous blood oxygenation system for an aggregate budget of NIS&#160;<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="ils" id="ixv-20861">4,880,603</ix:nonFraction> (approximately
$<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="usd" id="ixv-20862">1,500</ix:nonFraction>). The IIA committed to fund&#160;<ix:nonFraction contextRef="c61" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfApprovedBudget" scale="-2" unitRef="pure" id="ixv-20863">60</ix:nonFraction>% of the approved budget. Eventually the project budget concluded in the aggregate amount of
NIS <ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ProjectBudgetAggregateAmount" scale="3" unitRef="ils" id="ixv-20864">4,623,142</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ProjectBudgetAggregateAmount" scale="3" unitRef="usd" id="ixv-20865">1,333</ix:nonFraction>). The program is for the period beginning October 2019 through November 2020. From 2019 to 2021,
the Company received total funds in the amount of NIS <ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="ils" id="ixv-20866">2,773,885</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="usd" id="ixv-20867">809</ix:nonFraction>) from the IIA, which were recorded as IIA participation
and were deducted from R&amp;D expenses. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2023, the IIA approved a grant to support another development
project of the Company at an aggregate budget of NIS&#160;<ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="ils" id="ixv-20868">3,850,869</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="usd" id="ixv-20869">1,062</ix:nonFraction>). The IIA committed to fund&#160;<ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfApprovedBudget" scale="-2" unitRef="pure" id="ixv-20870">40</ix:nonFraction>% of the
approved budget. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The program is for the period beginning January
2024 through March 2025, and as of December 31, 2025, the Company received total funds in the amount of NIS <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="ils" id="ixv-20871">1,410,925</ix:nonFraction> (approximately
$<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="usd" id="ixv-20872">385</ix:nonFraction>) from the IIA, which were recorded as IIA participation and were deducted from the R&amp;D expenses. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the agreements with the IIA, the
Company will pay royalties of&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:RoyaltiesPercentage" scale="-2" unitRef="pure" id="ixv-20873">3</ix:nonFraction>% of future sales up to an amount equal to the accumulated grant received linked to the USD and bearing
interest at an annual rate of SOFR. Repayment of the grants are contingent upon the successful completion of the Company&#8217;s R&amp;D
programs and generating sales. The Company has no obligation to repay these grants if the R&amp;D programs fail, are unsuccessful or
aborted or if no sales are generated. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2025 the Company generated revenues in
the amount of approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-20874">289</ix:nonFraction>; accordingly, royalties to the IIA in the amount of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" unitRef="usd" id="ixv-20875">9</ix:nonFraction> were incurred and recorded as cost of sales,
and were paid during the year. As of December 31, 2025, the maximum obligation with respect to the grants received from the IIA, contingent
upon entitled future sales, is $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ContingentUponFutureSales" scale="3" unitRef="usd" id="ixv-20876">1,363</ix:nonFraction> includes SOFR interest and after deduction of the royalties payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has obligations regarding know-how,
technology, or products, not to transfer the information, rights thereon and production rights which derive from the research and development
without the IIA Research Committee approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B.&#160; Legal Claims</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, various legal
claims and other contingent matters may arise. Management believes that any liability that may arise from such matters would not have
a material adverse effect on the Company&#8217;s results of operations or financial condition as of and for the years ended December
31, 2025, and 2024.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - COMMITMENTS AND CONTINGENCIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 12, 2021, the Company terminated
its employment agreement with Dr. Udi Nussinovitch, one of its founders who served as the Company&#8217;s Chief Scientific Officer since
March 2018. On February 24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and
former officer of the Company. On November 9, 2022, Mr. Nussinovitch filed a Statement of Claim against the Company, as well as a Statement
of Claim with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch alleged certain deficiencies in the
Company&#8217;s&#160;Extraordinary General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a
minority shareholder. In addition, with respect to the labor dispute, Mr.&#160;Nussinovitch is seeking renumeration and the issuance
of Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2023, a partial hearing about the
labor dispute was held, in which the parties were required by the court to file their positions on a stay of the proceeding pending the
decision on the case initiated by Mr. Nussinovitch in the District Court. On January 21, 2024, a partial hearing about the civil case
was held. During the hearing, the court suggested the parties consider the possibility of resolving the case through an out-of-court
arrangement or mediation. The parties agreed to a mediation process which did not succeed.&#160;&#160;On January 7, 2025,&#160;Mr. Nussinovitch&#160;filed
a motion to amend his Statement of Claim, requesting to modify the requested relief. Instead of the original remedies sought,&#160;Mr.
Nussinovitch&#160;now requests that the Company or Mr. Ben Noon and Mr. Hayon purchase all of his rights and shares in the Company at
their average value from the date of the Company&#8217;s initial public offering until the date of the general meeting held on December
17, 2021. On January 13, 2025, a pretrial hearing was held. The court denied Mr. Nussinovitch&#8217;s motion to amend and instructed
him to notify whether he wishes to withdraw his original claim or maintain it.,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2025, Mr. Nussinovitch informed
the court that he would proceed with the original claim, despite the court&#8217;s instruction to address the Company&#8217;s motion
to dismiss and explain how the case could continue after he had stated it was moot. On May 7, 2025, the court partially granted the motion
to dismiss, ruling that continuation of the case is subject to payment of court fees. Claims deemed no longer relevant by Mr. Nussinovitch
were dismissed, including requests to nullify past resolutions, reverse his removal from the board, challenge director independence,
invalidate certain decisions, and appoint an auditor. The court allowed certain declaratory claims to proceed, including allegations
of breach of duties, minority oppression, and wrongful removal from the board. The remaining operative claim&#8212;entitlement to benefits
granted to controlling shareholders&#8212;also requires payment of court fees. A preliminary hearing was held on September 8, 2025, setting
deadlines for witness statements. On September 18, 2025, Mr. Nussinovitch agreed to dismiss claims against the directors of the Company.
On December 8, 2025, he submitted his witness statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that it is&#160;not probable&#160;that
a payment will be required to settle this matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, in accordance with ASC 450,&#160;no
provision has been recorded&#160;in the financial statements</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-16969"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 - LEASE LIABILITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Lease Commitments &#8211; Operating Leases:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, the Company entered into a
lease agreement for its facilities in Ra&#8217;anana, Israel. The lease agreement is for a period of 69 months commencing September 1,
2021, and the Company began to pay lease and related expenses after completing 3 months of lease. The Company has the option to shorten
the period and terminates the lease agreement after completing 45 months of rent by paying an amount of NIS <ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="ils" id="ixv-20877">500,000</ix:nonFraction>, (approximately $<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="usd" id="ixv-20878">157</ix:nonFraction>).
This amount of reimbursement will be deducted monthly in NIS <ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="iinn:MonthlyDeductionFromTerminationFee" scale="3" unitRef="ils" id="ixv-20879">30,000</ix:nonFraction>, (approximately $<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="iinn:MonthlyDeductionFromTerminationFee" scale="3" unitRef="usd" id="ixv-20880">9</ix:nonFraction>) if the Company terminates the agreement after
45 months of rent. The Company is reasonably certain that it will not exercise the termination option. During 2025, the monthly lease
payment, including management fees, was approximately NIS <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LeaseMonthlyPayment" scale="3" unitRef="ils" id="ixv-20881">69,000</ix:nonFraction> ($<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:LeaseMonthlyPayment" scale="3" sign="-" unitRef="usd" id="ixv-20882">20</ix:nonFraction>). As security for the obligations under this lease agreement, the
Company provided a bank guarantee in an amount equal to three monthly lease payments plus the Israeli value added tax and an unlimited
guarantee according to the terms specified in the contract.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 - LEASE LIABILITIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 27, 2025, the Company signed a new lease
agreement replacing the prior lease agreement for a new period of 60 months starting at the date of the facility acceptance by the Company.
According to the new lease agreement, the Company has the option to shorten the period and terminate the lease agreement after completing
48 months of rent by paying an amount of NIS <ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="ils" id="ixv-20883">650,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="usd" id="ixv-20884">204</ix:nonFraction>). This amount of reimbursement will be deducted monthly in NIS
<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="iinn:MonthlyDeductionFromTerminationFee" scale="3" unitRef="ils" id="ixv-20885">50,000</ix:nonFraction>, (approximately $<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="iinn:MonthlyDeductionFromTerminationFee" scale="3" unitRef="usd" id="ixv-20886">16</ix:nonFraction>) if the Company terminates the agreement after the 48 months of rent. The new rent agreement started on January
2026, therefore, as of December 31, 2025, the Company did not incur any operating liability or lease assets regarding the new lease agreement.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has various operating leases for
vehicles that expire through 2028. The Company leases vehicles for approximately three-year periods from multiple different leasing companies
and from time to time increases or decreases the number of leased vehicles according to its current needs. The leased vehicles are used
by the Company&#8217;s headquarters staff and other employees whose employment agreements include an obligation to the Company to provide
a vehicle. The agreements with the leasing companies include termination options, allowing for early cancellation by paying a penalty
of <ix:nonNumeric contextRef="c0" name="iinn:PercentageForCarsLeaseAgreementCancellationPenalty" id="ixv-20887">up to 400%</ix:nonNumeric> of the monthly costs. The Company is reasonably certain that it will not exercise this option or that the employee will
bear the cost for early termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total expenses related to the leases were
$<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-20888">469</ix:nonFraction>&#160;for the year ended December 31, 2025, and $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-20889">390</ix:nonFraction>&#160;for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use asset and lease liability are
initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate
cannot be readily determined, the Company&#8217;s incremental borrowing rate based on the information available at the date of determining
the present value of the lease payments. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s incremental borrowing rate
is estimated to approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has various operating leases for
vehicles that expire through 2028. <ix:nonNumeric contextRef="c0" continuedAt="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock-c0_cont_1" escape="true" name="iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" id="ixv-20890">Below is a summary of the Company&#8217;s operating right-of-use assets and operating lease liabilities
as of December 31, 2025, and 2024:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:continuation id="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Operating lease liabilities, current</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-20891">286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-20892">277</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1pt">Operating lease liabilities long-term</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-20893">194</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-20894">378</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-20895">480</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-20896">655</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Weighted average of remaining lease term</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-20897">1.74</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-20898">2.52</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average discount rate - operating leases</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-20899">11.27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-20900">9.92</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 - LEASE LIABILITIES (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-17139"><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lease payments for the Company&#8217;s right-of-use
assets over the remaining lease periods as of December 31, 2025, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Year ended December&#160;31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">U.S.&#160;dollars<br/> in&#160;thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-20901">324</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-20902">201</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">Total undiscounted lease payment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-20903">525</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Interest (*)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd">45</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-20905">480</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Future lease payments were discounted by&#160;<ix:nonFraction contextRef="c66" decimals="4" format="ixt:num-dot-decimal" name="iinn:PercentageOfFutureLeasePaymentsDiscounted" scale="-2" unitRef="pure" id="ixv-20907">7.98</ix:nonFraction>%-<ix:nonFraction contextRef="c67" decimals="4" format="ixt:num-dot-decimal" name="iinn:PercentageOfFutureLeasePaymentsDiscounted" scale="-2" unitRef="pure" id="ixv-20908">25.59</ix:nonFraction>% interest
rate.</ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-17201"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 - FINACIAL LIABILITIES AT FAIR
VALUE:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="ixv-17205"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Financial liability (A)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20909">296</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20910">69</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">Private warrants (B)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20911">786</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20912">1,506</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><b>Total</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20913">1,082</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-20914">1,575</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A Financial Liability</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The Company agreed to pay fees of <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfPayFees" scale="-2" unitRef="pure" id="ixv-20915">4</ix:nonFraction>% from the funds that will be received in an event of exercise of part of the Company&#8217;s ordinary warrants that were issued in a certain December 2024 private placement which created a financial liability presented on the total potential amount which was $<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-20916">46</ix:nonFraction> as of December 31, 2025 &#160;and $<ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-20917">69</ix:nonFraction> as of December 31, 2024 (Note 11).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The Company agreed to pay a commitment fee in the amount of <b>$</b><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="3" unitRef="usd" id="ixv-20918">500</ix:nonFraction>, representing <ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfPayFees" scale="-2" unitRef="pure" id="ixv-20919">2</ix:nonFraction>% of the $<ix:nonFraction contextRef="c72" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:OtherCommitment" scale="6" unitRef="usd" id="ixv-20920">25</ix:nonFraction> million SEPA. As of December 31,2025, the first half of the commitment fees was settled while the second tranche of the commitment fee amount, which represents <ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfPayFees" scale="-2" unitRef="pure" id="ixv-20921">1</ix:nonFraction>% of the SEPA, settled on the 30-day anniversary of the SEPA through the issuance of a variable number of ordinary shares determined based on the VWAP formula defined therein, created a financial liability in amount of $<ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-20922">250</ix:nonFraction>, measured at fair value through profit or loss until settlement. As of the date of these Financial Statements, the settlement amount of the committee fee shares were issued and transfer to the investor (see note 12(13)).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The financial liability as of December
31, 2025, and 2024 is $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-20923">296</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-20924">69</ix:nonFraction> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B Private warrants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 26, 2023, the Company entered into
a certain securities purchase agreement (Note 11.3), pursuant to which it issued unregistered warrants, to purchase up to an aggregate
of <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares" id="ixv-20925">3,031,250</ix:nonFraction> Ordinary Shares at an exercise of $<ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-20926">1.28</ix:nonFraction> per share (the &#8220;Private Warrants&#8221;). The Private Warrants were exercisable
immediately upon issuance and will expire three and a half years following their issuance.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 - FINACIAL LIABILITIES AT FAIR
VALUE (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Private Warrants include cashless exercise
mechanism, according to the terms specified in the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Private Warrants may create obligation to
transfer cash to the investors at fundamental transactions within the Black Scholes option pricing framework.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therefore, the Company accounts for the Private
Warrants as financial liability instruments that are measured at fair value and recognized financial expenses or income through profit
and loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company measured fair value by using Black-Scholes
option pricing model;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the Private
Warrants fair value as of December 31, 2024, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">risk-free interest rate <ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-20927">4.26</ix:nonFraction>%</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected volatility <ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-20928">88.61</ix:nonFraction>%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected dividend yield of
<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-20929">0</ix:nonFraction>%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">expected term of warrants &#8211; <ix:nonFraction contextRef="c79" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-20930">2.5</ix:nonFraction> years.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the Private
Warrants fair value as of December 31, 2025, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">risk-free interest rate <ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-20931">3.48</ix:nonFraction>%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected volatility <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-20932">80.59</ix:nonFraction>%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected dividend yield of
<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-20933">0</ix:nonFraction>%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected term of warrants &#8211;
<ix:nonFraction contextRef="c83" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-20934">1.5</ix:nonFraction> years.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Private Warrants as of
December 31, 2025 and 2024 was $<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-20935">786</ix:nonFraction> and $<ix:nonFraction contextRef="c85" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-20936">1,506</ix:nonFraction> respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C<b>. Standby Equity Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 12, 2025, the Company entered into
the SEPA with Yorkville pursuant to which the Company has the right to sell to Yorkville up to <span style="-sec-ix-hidden: hidden-fact-0">$25,000</span> of Ordinary Shares, subject to
certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA. The Company also entered into
a Registration Rights Agreement with Yorkville pursuant to which it will register the resale of Ordinary Shares issued to Yorkville pursuant
to the SEPA. Sales of Ordinary Shares to Yorkville under the SEPA, and the timing of any such sales, are at the Company&#8217;s option,
and the Company is under no obligation to sell Ordinary Shares to Yorkville under the SEPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each advance (each, an &#8220;Advance&#8221;)
the Company requests in writing to Yorkville under the SEPA (notice of such request, an &#8220;Advance Notice&#8221;) may be for a number
of Ordinary Shares. The Ordinary Shares purchased pursuant to an Advance delivered by the Company will be purchased at a price equal
to <ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="iinn:OrdinarySharesPurchasePricePercentage" scale="-2" unitRef="pure" id="ixv-20937">97</ix:nonFraction>% of the lowest daily VWAP of the Ordinary Shares during the three consecutive trading days commencing on the date of the delivery
of the Advance Notice, other than the daily VWAP on a day in which the daily VWAP is less than a minimum acceptable price as stated by
the Company in the Advance Notice or there is no VWAP on the subject trading day. The Company may establish a minimum acceptable price
in each Advance Notice below which the Company will not be obligated to make any sales to Yorkville. &#8220;VWAP&#8221; is defined as
the daily volume weighted average price of the Ordinary Shares for such trading day on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;)
during regular trading hours as reported by Bloomberg L.P.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 - FINACIAL LIABILITIES AT FAIR
VALUE (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEPA will automatically terminate on December
12, 2028. The Company has the right to terminate the SEPA at no cost or penalty upon five trading days&#8217; prior written notice to
Yorkville, provided that there are no outstanding Advance Notices for which Ordinary Shares need to be issued and the Company has paid
all amounts owed to Yorkville. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any purchase under an Advance would be subject
to certain limitations, including that <ix:nonNumeric contextRef="c71" name="us-gaap:CommonStockVotingRights" id="ixv-20938">Yorkville shall not purchase or acquire any shares that would result in it and its affiliates
beneficially owning more than 4.99% of the then outstanding voting power or number of Ordinary Shares.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In connection with
the execution of the SEPA, <ix:nonNumeric contextRef="c71" continuedAt="iinn_DescriptionOfFeePayments-c71_cont_1" name="iinn:DescriptionOfFeePayments" id="ixv-20939">the Company agreed to pay a legal and structuring fee in the amount of $<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-20940">25</ix:nonFraction>, of which (a) $15 has been paid
prior to the execution date, and (b) $10 has been paid within 3 days of the execution of the agreement. The company also agreed to pay
a commitment fee of $500 in ordinary shares to Yorkville, payable as follows: (i) $250 has been paid three days following the date the
SEPA was entered into, in the form of the issuance of 218,627 Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date, and (ii) $250 has been paid on the 30-day
anniversary of the date of the SEPA in the form of the issuance of Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date. The Commitment Shares issuable hereunder were
included in the initial Registration Statement. Throughout the month ended December 31, 2025, the Company did not issue any</ix:nonNumeric></span><ix:continuation id="iinn_DescriptionOfFeePayments-c71_cont_1">&#160;<span style="font-size: 10pt">Ordinary
Shares pursuant to the SEPA.</span></ix:continuation></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-17452"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Share capital:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="ixv-17460"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares as of<br/> December 31,&#160;2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares as of<br/> December 31,&#160;2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Authorized</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issued and outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Authorized</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issued and outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 2.5pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c150" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-20941">100,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c150" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-20942">35,949,247</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c151" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-20943">100,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c151" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-20944">24,252,096</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On April 4, 2023, the Company entered into a sales agreement (the &#8220;Roth Sales Agreement&#8221;) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (&#8220;Roth ATM&#8221;). In 2023, the Company sold <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-20945">17,566</ix:nonFraction> Ordinary Shares under the Roth ATM. On October 23, 2023, the Company terminated the Roth Sales Agreement and the associated Roth ATM, effective immediately.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On December 26, 2023, the Company entered into a securities purchase agreement with an institutional investor in a registered direct offering , pursuant to which the Company issued (i) <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-20946">1,375,000</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-20947">1.28</ix:nonFraction> per share, (ii) pre-funded warrants, to purchase up to <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-20948">1,656,250</ix:nonFraction> Ordinary Shares, at a purchase price of $<ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-20949">1.28</ix:nonFraction>, less $<ix:nonFraction contextRef="c97" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-20950">0.001</ix:nonFraction> per pre-funded warrant and (iii) Private Warrants, to purchase up to an aggregate of <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="iinn:ClassOfPrivateWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-20951">3,031,250</ix:nonFraction> Ordinary Shares at an exercise of $<ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-20952">1.28</ix:nonFraction> per share (Note 10-B).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company concluded that the pre-funded
warrants are not within the scope of ASC480. Further, applying ASC 815-40, the Company concluded that the pre-funded warrants are indexed
to the Company&#8217;s own stock and meet the conditions for equity classification, and thus should be presented within equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As for the Private Warrants, the Company
concluded that they should be classified as a liability under ASC 815-40, as they are not indexed to the Company&#8217;s own stock.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The pre-funded warrants were exercised
on the same day and the day after the transaction in full in an exercise price of $<ix:nonFraction contextRef="c95" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-20953">0.001</ix:nonFraction> per share and the Company issued <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="iinn:NumberofAdditionalOrdinaryShares" scale="0" unitRef="shares" id="ixv-20954">1,656,250</ix:nonFraction> additional
Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The aggregate proceeds received by
the Company from the December 2023 offering were approximately $<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-20955">3,424</ix:nonFraction>, after deducting underwriting discounts and commissions and additional
cash offering costs totaled in approximately $<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-20956">454</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company issued the placement agent
in the December 2023 offering a number of warrants equal to a total of <ix:nonFraction contextRef="c20" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ProductWarrantyLiquidationProceedsPercentage" scale="-2" unitRef="pure" id="ixv-20957">7.0</ix:nonFraction>% of the aggregate number of Ordinary Shares sold in the transaction,
total to <ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-20958">212,188</ix:nonFraction> warrants to purchase up to <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-20959">212,188</ix:nonFraction> Ordinary Shares, were issued (the &#8220;Placement Agent Warrants&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Placement Agent Warrants were substantially
on the same terms as the Private Warrants issued to the investor in the offering, except an exercise price of $<ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-20960">1.60</ix:nonFraction> per share. The Placement
Agent Warrants were exercisable immediately upon issuance and will expire <ix:nonNumeric contextRef="c102" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-20961">five years</ix:nonNumeric> following their issuance. The Company accounts for
the Placement Agent Warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC
718. The fair value of the Placement Agent Warrants at the issuance date was $<ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" unitRef="usd" id="ixv-20962">131</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Those cash and non-cash issuance costs
were accounted proportionally to issuance expenses and decrease of additional paid in capital, according to the ratio of the liability
versus equity in the December 2023 offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">During the year ended December 31, 2023, the Company issued an aggregate amount of <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-20963">1,226,448</ix:nonFraction> Ordinary Shares in connection with vested RSUs and an additional <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-20964">37,972</ix:nonFraction> Ordinary Shares in connection with option exercises.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On April 1, 2024, the Company completed offering, whereby the Company sold <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-20965">1,339,285</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c106" decimals="3" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-20966">1.232</ix:nonFraction> per share. The gross proceeds received by the Company from this offering were approximately $<ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-20967">1,651</ix:nonFraction>.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On May 20, 2024, the Company issued warrant to purchase <ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-20968">220,000</ix:nonFraction> Ordinary Shares to a service provider, at an exercise price of $<ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-20969">2.25</ix:nonFraction> per share. These warrants are immediately exercisable and are due to expire <ix:nonNumeric contextRef="c107" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-20970">six months</ix:nonNumeric> from the initial issuance date. The Company accounting treatment for those warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" unitRef="usd" id="ixv-20971">125</ix:nonFraction>. The warrants were not exercised within the designated timeframe and expired on November 21, 2024.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">6.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On June 14, 2024, the Company completed an offering, whereby the Company sold: (i) <ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-20972">941,541</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-20973">1.30</ix:nonFraction> per share, and (ii) pre-funded warrants to purchase up to <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-20974">1,709,760</ix:nonFraction> Ordinary Shares, at a purchase price of $<ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-20975">1.30</ix:nonFraction>, less $<ix:nonFraction contextRef="c113" decimals="3" format="ixt:num-dot-decimal" name="iinn:PreFundedWarrantsPerShare" scale="0" unitRef="usdPershares" id="ixv-20976">0.001</ix:nonFraction> per pre-funded warrant. Each pre-funded warrant is exercisable for <ix:nonFraction contextRef="c114" decimals="0" format="ixt-sec:numwordsen" name="iinn:NumberOfSharesPerUnits" scale="0" unitRef="shares" id="ixv-20977">one</ix:nonFraction> Ordinary Share at an exercise price of $<ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-20978">0.001</ix:nonFraction> per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. As of December 31, 2024, all of the pre-funded warrants were exercised, and the company issued <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-20979">1,709,760</ix:nonFraction> Ordinary Shares.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Net proceeds received by the Company
from the 2024 June Offering were approximately $<ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-20980">3,102</ix:nonFraction>, after deducting cash offering costs which were approximately $<ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-20981">343</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company also received $<ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-20982">2</ix:nonFraction> from an
exercise of the June Pre-Funded Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company concluded that the pre-funded
warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded that the June Pre-Funded Warrants are
indexed to the Company&#8217;s own stock and meet the conditions for equity classification, and thus should be presented within equity.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 - SHAREHOLDERS&#8217;
EQUITY (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company issued the placement agent
in this offering warrants equal to a total of <ix:nonFraction contextRef="c119" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ProductWarrantyLiquidationProceedsPercentage" scale="-2" unitRef="pure" id="ixv-20983">7.0</ix:nonFraction>% of the aggregate number of Ordinary Shares sold in the transaction. A total of185,<ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-20984">591</ix:nonFraction>
warrants to purchase up to <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-20985">185,591</ix:nonFraction> Ordinary Shares were issued. The placement agent warrants had an exercise price of $<ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-20986">1.56</ix:nonFraction> per share.
The placement agent warrants were exercisable immediately upon issuance and will expire <ix:nonNumeric contextRef="c119" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-20987">four years</ix:nonNumeric> following their issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company accounting treatment for
the placement agent warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC
718. The fair value of the placement agent warrants at the issuance date was $<ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" unitRef="usd" id="ixv-20988">254</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The cash and non-cash issuance costs
were recorded against additional paid in capital, due to the classification of the Ordinary Shares and the pre-funded warrants as equity
instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">7.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On June 30, 2024, the Company issued <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-20989">45,000</ix:nonFraction> Ordinary Shares to an advisor in connection with a consulting service agreement.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On December 27, 2024, the Company completed private placement, whereby the Company sold (i) <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-20990">3,950,343</ix:nonFraction> Ordinary Shares and private warrants to purchase up to <ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="iinn:PrivateWarrants" scale="0" unitRef="shares" id="ixv-20991">3,950,343</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerUnit" scale="0" unitRef="usdPershares" id="ixv-20992">0.70</ix:nonFraction> per unit, and (ii) pre-funded warrants to purchase up to <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="iinn:PreFundedWarrants" scale="0" unitRef="shares" id="ixv-20993">658,372</ix:nonFraction> Ordinary Shares and private warrants to purchase up to <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="iinn:PrivateWarrants" scale="0" unitRef="shares" id="ixv-20994">658,372</ix:nonFraction> Ordinary Shares, at a purchase price of $<ix:nonFraction contextRef="c128" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerUnit" scale="0" unitRef="usdPershares" id="ixv-20995">0.70</ix:nonFraction>, less $<ix:nonFraction contextRef="c129" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-20996">0.001</ix:nonFraction> per unit with pre-funded warrant. Each pre-funded warrant is exercisable for <ix:nonFraction contextRef="c130" decimals="0" format="ixt-sec:numwordsen" name="iinn:NumberOfSharesPerUnits" scale="0" unitRef="shares" id="ixv-20997">one</ix:nonFraction> Ordinary Share at an exercise price of $<ix:nonFraction contextRef="c126" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-20998">0.001</ix:nonFraction> per share. Each private warrant is exercisable for <ix:nonFraction contextRef="c131" decimals="0" format="ixt-sec:numwordsen" name="iinn:NumberOfSharesPerUnits" scale="0" unitRef="shares" id="ixv-20999">one</ix:nonFraction> Ordinary Share at an exercise price of $<ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-21000">1.10</ix:nonFraction> per share. The private warrants are immediately exercisable and may be exercised at any time until the end of June 2026. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. As of December 31, 2025, all pre-funded warrants and amount of <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="iinn:IssueOfPrivateWarrantsShares" scale="0" unitRef="shares" id="ixv-21001">855,714</ix:nonFraction> of private warrants were exercised.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company concluded that the private
warrants and pre-funded warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded that the private
warrants and pre-funded warrants are indexed to the Company&#8217;s own stock and meet the conditions for equity classification, and
thus should be presented within equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The gross proceeds received by the
Company from the private offering were approximately $<ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-21002">3,228</ix:nonFraction>, before deducting underwriting discounts and commissions and additional cash
offering costs totaled approximately $<ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-21003">233</ix:nonFraction>. In addition, the Company agreed to pay fees of <ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfPayFees" scale="-2" unitRef="pure" id="ixv-21004">4</ix:nonFraction>% from the funds that may be received in an
event of exercise of part of the Company&#8217;s private warrants issued in December 2024 which created a financial liability in amount
of $<ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-21005">69</ix:nonFraction> which is the total potential amount (Note 10-A) following the exercise of <ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="iinn:PrivateWarrantsExerciseShares" scale="0" unitRef="shares" id="ixv-21006">855,714</ix:nonFraction> of the private warrants , the financial liability
as of December 31, 2025 is $<ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-21007">46</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The cash and non-cash issuance costs
were recorded against additional paid in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">9.</span></td><td style="text-align: justify"><span style="font-size: 10pt">During the year ended December
31, 2024, the Company issued an aggregate amount of <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-21008">594,943</ix:nonFraction> Ordinary Shares in connection with vested RSUs and an additional <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21009">19,048</ix:nonFraction> Ordinary
Shares in connection with option exercises.</span></td>
</tr></table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">10.</td><td style="text-align: justify">On March 14, 2025, the Company entered into a sales agreement
with A.G.P./Alliance Global Partners, as sales agent, pursuant to which the Company could offer and sell, from time to time, through
the sales agent, Ordinary Shares pursuant to the March 2025 ATM, having an aggregate offering price of up to $<ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" unitRef="usd" id="ixv-21010">1,019</ix:nonFraction>. On April 10, 2025,
the maximum aggregate offering price was increased to $<ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" unitRef="usd" id="ixv-21011">1,917</ix:nonFraction>, On July 01, 2025, the maximum aggregate offering price was increased to
$<ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" unitRef="usd" id="ixv-21012">7,118</ix:nonFraction>. On September 16, 2025, the maximum aggregate offering price was increased to total $<ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" unitRef="usd" id="ixv-21013">14,687</ix:nonFraction>. As of December 31, 2025, the Company
sold <ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-21014">5,485,898</ix:nonFraction> Ordinary Shares under the March 2025 ATM for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-21015">4,888</ix:nonFraction>, before deducting offering
costs of approximately $<ix:nonFraction contextRef="c144" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-21016">272</ix:nonFraction>.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">11.</td><td style="text-align: justify">On August 8, 2025, the Company issued <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-21017">100,000</ix:nonFraction> Ordinary Shares
to an advisor in connection with a consulting service agreement.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">12.</td><td style="text-align: justify">On December 12, 2025, the Company completed its 2025 December
Offering, whereby the Company sold <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-21018">1,565,217</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c147" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-21019">1.15</ix:nonFraction> per ordinary share The gross proceeds received
by the Company from the offering were $<ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-21020">1,800</ix:nonFraction>.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">13.</td><td style="text-align: justify">On December 17, the Company issued <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-21021">218,627</ix:nonFraction> Ordinary Shares,
in connection with the commitment fees issuable pursuant to the terms of the SEPA.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">14.</td><td style="text-align: justify">During the year ended December 31, 2025, the Company issued
an aggregate amount of <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-21022">2,711,947</ix:nonFraction> Ordinary Shares in connection with vested RSUs and an additional <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21023">101,376</ix:nonFraction> Ordinary Shares in connection
with option exercises.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Warrants reserves -</b>Composition and
movements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 29px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-17750"><span style="font-size: 10pt">The following table reconciles the movement in warrants outstanding at the beginning and end of the period:</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.8pt; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining contractual term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in years)</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold; padding-bottom: 1pt">Balance as of December 31, 2024</td><td style="width: 1%; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c152" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21024">7,728,611</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-21025">4.14</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c153" format="ixt-sec:duryear" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" id="ixv-21026">1.63</ix:nonNumeric></td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt">Issued</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c153" decimals="INF" format="ixt:fixed-zero" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" scale="0" unitRef="shares" id="ixv-21027">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c153" decimals="0" format="ixt:fixed-zero" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" scale="0" unitRef="usdPershares" id="ixv-21028">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c153" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" scale="0" sign="-" unitRef="shares" id="ixv-21029">1,514,086</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c153" decimals="2" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-21030">1.09</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c153" format="ixt-sec:duryear" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" id="ixv-21031">0.49</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c153" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" scale="0" sign="-" unitRef="shares" id="ixv-21032">277,835</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c153" decimals="1" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-21033">5.5</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonNumeric contextRef="c153" format="ixt-sec:duryear" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" id="ixv-21034">0.54</ix:nonNumeric></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Balance as of December 31, 2025</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c154" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21035">5,936,690</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-21036">4.20</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c153" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-21037">0.80</ix:nonNumeric></td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 29px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="ixv-17907"><span style="font-size: 10pt">The following table summarizes information about the Company&#8217;s outstanding warrants as of December 31, 2025</span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants<br/> outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, <br/>
2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 31%; text-align: center"><ix:nonFraction contextRef="c155" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21038">5.5</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 31%; text-align: right"><ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-21039">1,640,455</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 32%; text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c156" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21040">15/07/2026</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c157" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21041">6.875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-21042">145,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c158" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21043">15/01/2027</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c159" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21044">1.6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-21045">212,188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c160" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21046">28/06/2027</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21047">1.56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-21048">185,591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c162" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21049">14/06/2028</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center"><ix:nonFraction contextRef="c163" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-21050">1.1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-21051">3,753,001</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 1.4pt"><ix:nonNumeric contextRef="c164" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21052">30/06/2026</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Balance as of December 31, 2025</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-21053">5,936,690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt">&#160;</td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Loss per share:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-17994"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share has been calculated using the
weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant financial periods, the weighted average
number of equity shares in issue and profit for the period as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21054">13,220</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21055">11,053</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-21056">11,286</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 9pt">Total number of Ordinary Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21057">35,949,247</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21058">24,252,096</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-21059">15,652,176</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average number of Ordinary Shares and pre-funded warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-21060">29,623,194</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-21061">18,515,545</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-21062">12,095,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Basic and diluted loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-21063"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-21064">0.45</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-21065"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-21066">0.60</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-21067"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-21068">0.93</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-18099"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 - REVENUES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company has only
one stream of revenue from sales of the INSPIRA ART100 systems and carts to a distributor in the U.S, therefore the company has one segment
at this stage.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="iinn:CostOfRevenuesTextBlock" id="ixv-18107"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 - COST OF REVENUES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfCostOfRevenuesTableTextBlock" id="ixv-18112"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Materials and subcontractors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c165" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-21069">235</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Payroll and related</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-21070">23</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Warranty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-21071">20</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1pt">Royalties to IIA</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-21072">9</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd" id="ixv-21073">287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="ixv-18187"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 - RESEARCH AND DEVELOPMENT EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" id="ixv-18192"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-21074">4,461</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-21075">4,079</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-21076">4,429</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" unitRef="usd" id="ixv-21077">1,634</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" unitRef="usd" id="ixv-21078">801</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" unitRef="usd" id="ixv-21079">663</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-21080">737</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-21081">812</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-21082">1,365</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-21083">334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-21084">371</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-21085">291</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd" id="ixv-21086">150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd" id="ixv-21087">340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd" id="ixv-21088">304</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IIAParticipation" scale="3" unitRef="usd" id="ixv-21089">100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IIAParticipation" scale="3" unitRef="usd" id="ixv-21090">286</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="iinn:IIAParticipation" scale="3" unitRef="usd" id="ixv-21091">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21092">280</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21093">206</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21094">268</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21095">7,496</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21096">6,323</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-21097">7,320</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="iinn:GeneralAndAdministrativeExpensesTextBlock" id="ixv-18338"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 16 - GENERAL AND ADMINISTRATIVE EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" id="ixv-18342"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21098">1,966</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21099">1,758</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21100">1,432</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21101">1,747</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21102">716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21103">675</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-21104">1,079</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-21105">808</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-21106">766</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-21107">178</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-21108">196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-21109">300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-21110">175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-21111">239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-21112">241</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-21113">122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-21114">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-21115">129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21116">115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21117">117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-21118">115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-21119">82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-21120">104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-21121">100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fundraising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:fixed-zero" name="iinn:FundraisingExpenses" scale="3" unitRef="usd" id="ixv-21122">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:fixed-zero" name="iinn:FundraisingExpenses" scale="3" unitRef="usd" id="ixv-21123">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FundraisingExpenses" scale="3" unitRef="usd" id="ixv-21124">260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21125">68</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21126">112</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21127">45</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c169" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21128">5,532</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c170" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21129">4,185</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c171" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-21130">4,063</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="iinn:SalesAndMarketingExpensesTextBlock" id="ixv-18530"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SALES AND MARKETING EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock" id="ixv-18535"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Share-based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="3" unitRef="usd" id="ixv-21131">194</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="3" unitRef="usd" id="ixv-21132">250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="3" unitRef="usd" id="ixv-21133">89</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21134">176</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21135">266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21136">248</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21137">125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21138">187</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-21139">348</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21140">93</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21141">51</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21142">61</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;&#160;&#160;<b>Total</b></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21143">588</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21144">754</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-21145">746</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="ixv-18668"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 18 - FINANCIAL (INCOME) AND EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ixv-18673"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-21146">247</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" unitRef="usd" id="ixv-21147">36</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-21148">306</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign currency transaction income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-21149">101</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-21150">77</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-21151">233</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" unitRef="usd" id="ixv-21152">9</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-21153">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" unitRef="usd" id="ixv-21154">10</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-21155">339</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-21156">42</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-21157">529</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-18763"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 19 - TAXES ON INCOME: </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Taxes on income:</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Israeli corporate
tax rate was <ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-21158"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-21159">23</ix:nonFraction></ix:nonFraction>% in 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Net operating losses carry forwards</b>:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Carryforward tax losses of the Company
as of December 31, 2023, amounted to approximately $<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-21160">24,000</ix:nonFraction>; however, a full valuation allowance of $<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-21161">7,000</ix:nonFraction> was recorded against the potential
future tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Carryforward tax losses of the Company
as of December 31, 2024, amounted to approximately $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-21162">29,000</ix:nonFraction>; however, a full valuation allowance of $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-21163">8,000</ix:nonFraction> was recorded against the potential
future tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Carryforward tax losses of the Company
as of December 31, 2025, amounted to approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-21164">41,000</ix:nonFraction>; however, a full valuation allowance of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-21165">11,000</ix:nonFraction> was recorded against the potential
future tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-18796"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The deferred tax assets and liabilities
are composed of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-21166">9,404</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-21167">6,739</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetsAccruedExpenses" scale="3" unitRef="usd" id="ixv-21168">86</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetsAccruedExpenses" scale="3" unitRef="usd" id="ixv-21169">97</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">R&amp;D temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-21170">1,310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-21171">1,218</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Fund raising costs 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="iinn:DeferredTaxAssetsFundRaisingCost2023" scale="3" unitRef="usd" id="ixv-21172">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetsFundRaisingCost2023" scale="3" unitRef="usd" id="ixv-21173">35</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxLiabilitiesOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-21174">10</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxLiabilitiesOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-21175">8</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-21176">10,810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-21177">8,097</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-21178">10,810</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-21179">8,097</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd" id="ixv-21180">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd" id="ixv-21181">-</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Net deferred taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" unitRef="usd" id="ixv-21182">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" unitRef="usd" id="ixv-21183">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 19 - TAXES ON INCOME (CONT.): </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="iinn_ScheduleOfTheoreticalTaxTableTextBlock-c0_cont_1" escape="true" name="iinn:ScheduleOfTheoreticalTaxTableTextBlock" id="ixv-18958"><span style="font-size: 10pt"><b>Theoretical tax:</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="iinn_ScheduleOfTheoreticalTaxTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss before taxation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21184">13,220</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21185">11,053</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-21186">11,286</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Theoretical tax credit at applicable statutory rate: 23%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-21187">3,041</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-21188">2,542</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-21189">2,596</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-allowable expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" sign="-" unitRef="usd" id="ixv-21190">704</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" sign="-" unitRef="usd" id="ixv-21191">391</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" sign="-" unitRef="usd" id="ixv-21192">244</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" sign="-" unitRef="usd" id="ixv-21193">2,337</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" sign="-" unitRef="usd" id="ixv-21194">2,151</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" sign="-" unitRef="usd" id="ixv-21195">2,352</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-21196">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-21197">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-21198">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Effective tax rate reconciliation:</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-19074"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Tax</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">IL statutory tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-21199">3,041</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-21200">23</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Non-taxable or non-deductible items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-21201">747</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" sign="-" unitRef="pure" id="ixv-21202">5.7</ix:nonFraction></td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" unitRef="usd" id="ixv-21203">166</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="iinn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="-2" unitRef="pure" id="ixv-21204">1.3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="3" unitRef="usd" id="ixv-21205">123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" sign="-" unitRef="pure" id="ixv-21206">0.9</ix:nonFraction></td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-21207">2,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-21208">20.5</ix:nonFraction></td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" sign="-" unitRef="usd" id="ixv-21209">376</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure" id="ixv-21210">2.8</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-21211">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:fixed-zero" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-21212">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary reconciling item between the Company&#8217;s statutory
tax rate and the effective tax rate is the recognition of a valuation allowance against of deferred tax assets related to accumulated
net operating losses carried forward, due to uncertainty regarding their realization.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-19196"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 20 - SHARE-BASED PAYMENT:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">On January 22, 2024, the Company&#8217;s Board of Directors
approved a grant of <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21213">320,000</ix:nonFraction> RSUs to employees and a grant of options to purchase <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-21214">80,000</ix:nonFraction> shares to consultants. The RSUs represents the
right to receive Ordinary Shares at a future time, <ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-21215">245,000</ix:nonFraction> of which vest over a period of <ix:nonNumeric contextRef="c174" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-21216">three years</ix:nonNumeric>, with a one-year cliff period and
<ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-21217">70,000</ix:nonFraction> vesting immediately on the grant date. <ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21218">10,000</ix:nonFraction> of the options were vested immediately on the grant date, <ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21219">25,000</ix:nonFraction> option vest over
a period of <ix:nonNumeric contextRef="c179" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-21220">three years</ix:nonNumeric> and <ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-21221">45,000</ix:nonFraction> option vests over a period of one year and nine months. The RSUs designated to employees were granted
under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a <ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="iinn:CapitalGainTaxRate" scale="-2" unitRef="pure" id="ixv-21222">25</ix:nonFraction>% capital gain tax upon exercise.</td>
</tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 20 - SHARE-BASED PAYMENT (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">On February 5, 2024, the Company&#8217;s Board of Directors
approved a grant of <ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21223">2,277,000</ix:nonFraction> RSUs to officers, a grant of options to purchase <ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-21224">30,000</ix:nonFraction> Ordinary Shares and <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21225">90,000</ix:nonFraction> RSUs to directors. The
RSUs and options represents the right to receive Ordinary Shares at a future time and vest over a period of <ix:nonNumeric contextRef="c181" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-21226">three years</ix:nonNumeric>, with a one-year
cliff. The RSUs designated to employees and directors were granted under Section 102 of the Israeli Tax Ordinance, which enables the
employee to pay a <ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfCapitalGainTax" scale="-2" unitRef="pure" id="ixv-21227">25</ix:nonFraction>% capital gain tax upon exercise.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">On February 20, 2025, the Company&#8217;s Board of Directors
approved a grant of <ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21228">644,000</ix:nonFraction> RSUs to employees, a grant of <ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21229">2,360,000</ix:nonFraction> RSUs to certain of its executives and directors and options to purchase
an aggregate of <ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-21230">55,000</ix:nonFraction> Ordinary Shares to service providers under the 2019 Equity Incentive Plan. The RSUs and options represents the
right to receive Ordinary Shares at a future time and vest over a period of <ix:nonNumeric contextRef="c188" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-21231">three years</ix:nonNumeric>, with a one-year cliff. The RSUs designated to
employees and directors were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a <ix:nonFraction contextRef="c188" decimals="2" format="ixt:num-dot-decimal" name="iinn:CapitalGainTaxRate" scale="-2" unitRef="pure" id="ixv-21232">25</ix:nonFraction>% capital
gain tax upon exercise.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">On August 6, 2025, the Company&#8217;s Board of Directors
approved a grant of <ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21233">1,200,000</ix:nonFraction> RSUs to certain of its executives. The RSUs represents the right to receive Ordinary Shares at a future
time and vest over a period of <ix:nonNumeric contextRef="c190" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-21234">three years</ix:nonNumeric>, <ix:nonFraction contextRef="c191" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" unitRef="pure" id="ixv-21235">25</ix:nonFraction>% of the amount will vest on January 1, 2026, <ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" unitRef="pure" id="ixv-21236">25</ix:nonFraction>% of the amount will vest on July 1, 2026
and the rest will be vested equal quarterly amounts along two more years. The RSUs designated to employees and directors were granted
under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a <ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="iinn:CapitalGainTaxRate" scale="-2" unitRef="pure" id="ixv-21237">25</ix:nonFraction>% capital gain tax upon exercise. The board also
approved a grant of <ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21238">300,000</ix:nonFraction> RSUs to certain of its executives based on revenue milestones to be measured at the end of the fiscal year
of 2027.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">On November 18, 2025, the Company&#8217;s Board of Directors
approved a grant of <ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21239">490,000</ix:nonFraction> RSUs to employees, a grant of <ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21240">30,000</ix:nonFraction> RSUs to certain director, options to purchase an aggregate of <ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-21241">20,000</ix:nonFraction>
Ordinary Shares to employee and options to purchase an aggregate of <ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-21242">20,000</ix:nonFraction> Ordinary Shares to service providers under the 2019 Equity
Incentive Plan. The RSUs and options represents the right to receive Ordinary Shares at a future time and vest over a period of <ix:nonNumeric contextRef="c197" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-21243">three
years</ix:nonNumeric>, with a one-year cliff. The RSUs designated to employees and directors were granted under Section 102 of the Israeli Tax Ordinance,
which enables the employee to pay a <ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="iinn:CapitalGainTaxRate" scale="-2" unitRef="pure" id="ixv-21244">25</ix:nonFraction>% capital gain tax upon exercise.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all granted options was estimated
by using the Black Scholes option pricing model, which was aimed to model the value of the Company&#8217;s assets over time. The simulation
approach was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company
and the volatility of its assets, on the date of grant based on certain assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-19265"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following inputs were used to measure the
fair value of the option at grant date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">November 18,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">February 22,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%">(i)</td><td style="width: 1%">&#160;</td> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><ix:nonFraction contextRef="c197" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-21245">123.41</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><ix:nonFraction contextRef="c201" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-21246">128.78</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>(ii)</td><td>&#160;</td> <td style="text-align: justify">Dividend rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-21247">0</ix:nonFraction>%</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c201" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-21248">0</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">(iii)</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Expected term (vesting period)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c197" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19312"><span style="font-size: 10pt">Three years</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">One year - Three years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: top">(iv)</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Contractual life</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c197" format="ixt-sec:durwordsen" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" id="ixv-19327"><span style="font-size: 10pt">Ten years</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>(v)</td><td>&#160;</td> <td style="text-align: justify">Free risk rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c197" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-21249">4.12</ix:nonFraction>%</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c201" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-21250">4.5</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">January 22,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">February 5,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%">(i)</td><td style="width: 1%">&#160;</td> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><ix:nonFraction contextRef="c177" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-21251">144.83</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center"><ix:nonFraction contextRef="c184" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-21252">143.98</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>(ii)</td><td>&#160;</td> <td style="text-align: justify">Dividend rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-21253">0</ix:nonFraction>%</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-21254">0</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>(iii)</td><td>&#160;</td> <td style="text-align: justify">Expected term (vesting period)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Three years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c184" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19397"><span style="font-size: 10pt">Three years</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>(iv)</td><td>&#160;</td> <td style="text-align: justify">Contractual life</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c184" format="ixt-sec:durwordsen" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" id="ixv-19412"><span style="font-size: 10pt">Ten years</span></ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>(v)</td><td>&#160;</td> <td style="text-align: justify">Free risk rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c204" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-21255">4.03</ix:nonFraction>%-<ix:nonFraction contextRef="c205" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-21256">4.07</ix:nonFraction>%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c184" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-21257">4.16</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 20 - SHARE-BASED PAYMENT (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all granted RSUs was the Company&#8217;s
quote price at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2025, the Company recorded
share-based payment expenses to employees, directors and subcontractors in the amount of $<ix:nonFraction contextRef="c198" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21258">3,575</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2024, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $<ix:nonFraction contextRef="c199" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21259">1,767</ix:nonFraction>.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2023, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $<ix:nonFraction contextRef="c200" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21260">1,427</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-19469"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to services providers and advisers outstanding
as December 31, 2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c206" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21261">185,111</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c206" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21262">3.359</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c207" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21263">105,111</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c207" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21264">4.085</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c208" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21265">114,512</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c208" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21266">3.058</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c209" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21267">55,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c209" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21268">3.405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c210" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21269">80,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c210" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21270">3.779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c209" decimals="INF" format="ixt:fixed-zero" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" scale="0" unitRef="shares" id="ixv-21271">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21272">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c211" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" scale="0" unitRef="shares" id="ixv-21273">9,401</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c211" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21274">0.367</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c212" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21275">240,111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c212" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21276">3.370</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c206" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21277">185,111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c206" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21278">3.359</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c207" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21279">105,111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c207" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21280">4.085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c212" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21281">200,111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c212" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21282">3.362</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c206" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21283">162,154</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c206" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21284">3.251</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c207" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21285">94,242</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c207" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21286">3.267</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21287">44</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c210" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21288">66</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c211" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21289">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-19696"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to services providers and advisers outstanding as of December
31, 2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c220" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21290">-</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c221" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21291">7,433</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c222" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21292">18,266</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c223" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-21293">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c224" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-21294">7,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c225" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-21295">10,833</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSUs outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c223" decimals="INF" format="ixt:fixed-zero" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" scale="0" unitRef="shares" id="ixv-21296">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c224" decimals="INF" format="ixt:fixed-zero" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" scale="0" unitRef="shares" id="ixv-21297">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c225" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" scale="0" unitRef="shares" id="ixv-21298">7,433</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSU&#8217;s Vested</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c223" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-21299">32,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c224" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-21300">32,500</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c225" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-21301">25,067</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21302">-</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21303">1</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21304">9</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to employees and directors outstanding as of December
31, 2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c213" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21305">368,641</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21306">0.70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c214" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21307">357,689</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21308">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c215" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21309">386,260</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c215" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21310">0.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21311">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21312">3.42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c217" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21313">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c217" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21314">3.56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c218" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-21315">-</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c218" decimals="0" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21316">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" scale="0" unitRef="shares" id="ixv-21317">101,376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c216" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21318">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c217" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" scale="0" unitRef="shares" id="ixv-21319">19,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c217" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21320">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c218" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21321">0.37</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c216" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-21322">30,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c216" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21323">3.56</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-21324">28,571</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c218" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21325">0.37</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c219" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21326">277,265</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21327">0.91</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c213" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21328">368,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21329">0.70</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c214" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-21330">357,689</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21331">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c219" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21332">244,765</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21333">0.57</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c213" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21334">338,641</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21335">0.45</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c214" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-21336">350,131</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-21337">0.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" sign="-" unitRef="usd" id="ixv-21338">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c217" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21339">17</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c218" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21340">47</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#toc_001">Table of Contents</a></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>In thousands $ (except
share and per share data)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 20 - SHARE-BASED PAYMENT (CONT.):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to employees and directors outstanding as of December 31,
2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c226" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21341">2,518,796</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c227" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21342">445,140</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c228" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-21343">1,727,842</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c229" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-21344">5,024,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c230" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-21345">2,687,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-21346">-</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c229" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-21347">85,337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c230" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-21348">25,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-21349">67,087</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c229" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-21350">2,711,947</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c230" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-21351">587,508</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction contextRef="c231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-21352">1,215,615</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSUs outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c229" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" scale="0" unitRef="shares" id="ixv-21353">4,745,512</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c230" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" scale="0" unitRef="shares" id="ixv-21354">2,518,796</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c231" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" scale="0" unitRef="shares" id="ixv-21355">445,140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSU&#8217;s Vested</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c229" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-21356">6,396,644</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c230" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-21357">3,684,697</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c231" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-21358">3,097,189</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21359">3,536</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21360">1,683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction contextRef="c231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-21361">1,352</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-20224"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 21 - RELATED PARTIES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The following transactions arose with related parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Transactions and balances with related parties</span><b>:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-20242"><span style="font-size: 10pt"><span style="text-decoration:underline">Shareholders and other related parties&#8217; benefits</span></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Salary and related expenses &#8211; officers and directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21362">1,819</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21363">1,710</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-21364">1,761</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share based payment &#8211; officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-21365">3,107</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-21366">1,376</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c234" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-21367">1,009</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Balances with related parties</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nature of transaction</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%">Officers</td><td style="width: 1%">&#160;</td>
    <td style="width: 69%; text-align: left">Salaries and related</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" sign="-" unitRef="usd" id="ixv-21368">343</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c236" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" sign="-" unitRef="usd" id="ixv-21369">381</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Directors</td><td>&#160;</td>
    <td style="text-align: left">Compensation for directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" sign="-" unitRef="usd" id="ixv-21370">41</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" sign="-" unitRef="usd" id="ixv-21371">40</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-20341"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 22 - SUBSEQUENT EVENTS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">1.</td><td style="text-align: justify">On February 5, 2026, the Company&#160;entered into a Securities Purchase Agreement with a single institutional investor (the &#8220;Purchaser&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering: (i) <ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-21372">4,000,000</ix:nonFraction> Ordinary Shares, at an offering price of $<ix:nonFraction contextRef="c240" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-21373">0.70</ix:nonFraction> per share; and (ii) pre-funded warrants to acquire up to <ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="iinn:PreFundedWarrants" scale="0" unitRef="shares" id="ixv-21374">2,785,715</ix:nonFraction> Ordinary Shares at an offering price of $<ix:nonFraction contextRef="c240" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-21375">0.6999</ix:nonFraction> per re-funded warrant and (iii) private warrants, to purchase up to an aggregate of <ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-21376">6,785,715</ix:nonFraction>
Ordinary Shares at an exercise of $<ix:nonFraction contextRef="c241" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-21377">0.70</ix:nonFraction> per share. The gross proceeds were approximately $<ix:nonFraction contextRef="c239" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" unitRef="usd" id="ixv-21378">4.7</ix:nonFraction> million. To date, prefunded warrants to purchase <ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="iinn:WarrantsToPurchaseOrdinaryShares" scale="0" unitRef="shares" id="ixv-21379">2,197,714</ix:nonFraction> Ordinary Shares were exercised. The Company also amend the terms of <ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-21380">3,031,250</ix:nonFraction> Private Warrants held by the same purchaser, which were issued in December 2023 from $<ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-21381">1.28</ix:nonFraction> per share to $<ix:nonFraction contextRef="c244" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-21382">0.70</ix:nonFraction> per share, amended the expiration date from June 27, 2027 to February 5, 2031, and revised the fundamental transaction provision in the warrants and the cashless exercise provision with respect to computing the valuation of the Ordinary Shares. Following such amendments the Company concluded that the revised Warrants are indexed to the Company&#8217;s own stock and meet the conditions for equity classification, and thus should be reclassified within equity.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0"/><td style="text-align: justify; width: 0.25in">2.</td><td style="text-align: justify">Subsequent to December 31, 2025 and following the expiration of the March
                                            2025 Sales Agreement due to expiration of the Company&#8217;s Registration Statement on Form
                                            F-3 (File No. 333-266748), the Company entered into a new sales agreement with A.G.P./Alliance
                                            Global Partners, as sales agent, pursuant to which the Company could offer and sell, from
                                            time to time, through the sales agent, Ordinary Shares pursuant to the ATM, having an aggregate
                                            offering price of up to $2,016.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0"/><td style="text-align: justify; width: 0.25in">3.</td><td style="text-align: justify">Subsequent to December 31, 2025, the second half of commitment fee amount of the SEPA, which represents <ix:nonFraction contextRef="c245" decimals="2" format="ixt:num-dot-decimal" name="iinn:StandbyEquityPurchaseAgreementPercentage" scale="-2" unitRef="pure" id="ixv-21383">1</ix:nonFraction>% of the SEPA, or $<ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinancialExpensesDueToCommitmentFee" scale="3" unitRef="usd" id="ixv-21384">250</ix:nonFraction>, was settled as agreed on the 30-day anniversary of the SEPA through the issuance of a variable number of Ordinary Shares determined based on the VWAP formula defined therein. Following the filing of the re-sale registration statement in connection with the SEPA, the Company&#8217;s share price declined. As a result, the Company issued the registered <ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-21385">245,098</ix:nonFraction> Ordinary Shares as commitment shares in lieu of cash, which were valued at $<ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-21386">231</ix:nonFraction> based on the VWAP calculation as of the due date. The remaining balance of $<ix:nonFraction contextRef="c246" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCommitment" scale="3" unitRef="usd" id="ixv-21387">19</ix:nonFraction> was agreed to be settled in cash.</td></tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35; Options: Last --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c86" decimals="-3" id="hidden-fact-0" name="iinn:SaleOfRightsValue" unitRef="usd">25000000</ix:nonFraction>
<ix:nonNumeric contextRef="c153" id="hidden-fact-1" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms">P0Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-21392">0001837493</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-21393">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-21394">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityIncorporationStateCountryCode" id="ixv-21395">L3</ix:nonNumeric>
<ix:nonNumeric contextRef="c202" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-21396">P1Y</ix:nonNumeric><!--From Schedule of Measure the Fair Value of the Option at Grant Date with text 'One year '-->
<ix:nonNumeric contextRef="c203" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-21397">P3Y</ix:nonNumeric><!--From Schedule of Measure the Fair Value of the Option at Grant Date with text ' Three years'-->
<ix:nonNumeric contextRef="c201" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" id="ixv-21398">P10Y</ix:nonNumeric><!--From Schedule of Measure the Fair Value of the Option at Grant Date with text 'Ten years'-->
<ix:nonNumeric contextRef="c177" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-21399">P3Y</ix:nonNumeric><!--From Schedule of Measure the Fair Value of the Option at Grant Date with text 'Three years'-->
<ix:nonNumeric contextRef="c177" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" id="ixv-21400">P10Y</ix:nonNumeric><!--From Schedule of Measure the Fair Value of the Option at Grant Date with text 'Ten years'-->
</ix:hidden>
<ix:references><link:schemaRef xlink:href="iinn-20251231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact" toRefs="ix_0_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:OrdinarySharesNoParValueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">iinn:BankLeumiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-30</xbrli:startDate>
    <xbrli:endDate>2021-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-27</xbrli:startDate>
    <xbrli:endDate>2025-04-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:SecondTrancheMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-26</xbrli:startDate>
    <xbrli:endDate>2023-12-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">iinn:YorkvilleMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberStandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-12-12</xbrli:startDate>
    <xbrli:endDate>2025-12-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-12-12</xbrli:startDate>
    <xbrli:endDate>2025-12-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-04</xbrli:startDate>
    <xbrli:endDate>2023-04-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-26</xbrli:startDate>
    <xbrli:endDate>2023-12-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-26</xbrli:startDate>
    <xbrli:endDate>2023-12-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourAprilOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourAprilOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-20</xbrli:startDate>
    <xbrli:endDate>2024-05-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-14</xbrli:startDate>
    <xbrli:endDate>2024-06-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-14</xbrli:startDate>
    <xbrli:endDate>2024-06-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-30</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivateOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivateOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-14</xbrli:startDate>
    <xbrli:endDate>2025-03-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-10</xbrli:startDate>
    <xbrli:endDate>2025-04-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-07-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-09-16</xbrli:startDate>
    <xbrli:endDate>2025-09-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:AdvisorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-08</xbrli:startDate>
    <xbrli:endDate>2025-08-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:December2025OfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-12-12</xbrli:startDate>
    <xbrli:endDate>2025-12-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:December2025OfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-12-17</xbrli:startDate>
    <xbrli:endDate>2025-12-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice156Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice156Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iinn:MaterialsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iinn:PayrollAndRelatedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iinn:WarrantyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iinn:RoyaltiesToIIAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-05</xbrli:startDate>
    <xbrli:endDate>2024-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-05</xbrli:startDate>
    <xbrli:endDate>2024-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-05</xbrli:startDate>
    <xbrli:endDate>2024-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-05</xbrli:startDate>
    <xbrli:endDate>2024-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-20</xbrli:startDate>
    <xbrli:endDate>2025-02-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:ExecutivesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-20</xbrli:startDate>
    <xbrli:endDate>2025-02-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:ServiceProvidersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-20</xbrli:startDate>
    <xbrli:endDate>2025-02-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-20</xbrli:startDate>
    <xbrli:endDate>2025-02-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-06</xbrli:startDate>
    <xbrli:endDate>2025-08-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-06</xbrli:startDate>
    <xbrli:endDate>2025-08-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-01</xbrli:startDate>
    <xbrli:endDate>2026-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-07-01</xbrli:startDate>
    <xbrli:endDate>2026-07-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:RevenueAchievementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-06</xbrli:startDate>
    <xbrli:endDate>2025-08-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-11-18</xbrli:startDate>
    <xbrli:endDate>2025-11-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-11-18</xbrli:startDate>
    <xbrli:endDate>2025-11-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:ServiceProvidersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-11-18</xbrli:startDate>
    <xbrli:endDate>2025-11-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-11-18</xbrli:startDate>
    <xbrli:endDate>2025-11-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-22</xbrli:startDate>
    <xbrli:endDate>2025-02-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-22</xbrli:startDate>
    <xbrli:endDate>2025-02-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-22</xbrli:startDate>
    <xbrli:endDate>2025-02-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-02-05</xbrli:startDate>
    <xbrli:endDate>2026-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-02-05</xbrli:startDate>
    <xbrli:endDate>2026-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
<!-- [WMV6][kJ7ByJ5YFjHNa10rsvkTrvKjzx4SsjL6cMlFKKfj2NGerNJAMK7zm28oRnm9clJc6IswmWYsDaa5ADFUSiRgK16c0vp8xm2nbCTgcpIwnmP0Tx7Q+XYo0tUcWRGZoUPW+rd0F8YcLDpe4WdwnHMSxAqKY8lsROn/3xUBapKNMIYhBSCuWGkBwv+e9HwSCik9FklwrySL81a4kk0MwPR0PcjEpJ/SoDKKeUwhEXDLRYASPRTaLr4n+fbsLa5PeL5pe4WDKVjyi6F7s2MacScnhbSC4lER4mNMAd/GAFwuTn4Dhrb4syvQFqrDCv/B21217djfGLNvdTmzBRi1YWJlobVpwaw/C6vzX23ZHVcyyNL7FCogQc8=] CSR-->
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit></ix:resources></ix:header>
</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>iinnex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Description of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of the share capital of Inspira Technologies Oxy B.H.N. Ltd. (the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; or &ldquo;our&rdquo;),
provisions of the Company&rsquo;s amended and restated articles of association<FONT STYLE="background-color: white">, as they may be amended
and restated from time to time </FONT>(our &ldquo;Articles<FONT STYLE="background-color: white">&rdquo;), and Israeli law</FONT> are summaries
and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our Articles as well as the Israeli
law and any other documents referenced in the summary and from which the summary is derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, our
authorized share capital consisted of 100,000,000 Ordinary Shares, no par value (&ldquo;Ordinary Shares&rdquo;), of which 43,579,260 Ordinary
Shares were issued and outstanding as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, we had
issued and outstanding warrants to purchase up to 1,640,455 of our Ordinary Shares issued in our initial public offering (the &ldquo;IPO
Warrants&rdquo;). Each IPO Warrant is exercisable for one Ordinary Share at an exercise price of $5.50 per share and expires five years
from the date of issuance, or July 16, 2026, and underwriter warrants to purchase up to an aggregate of 145,455 Ordinary Shares at an
exercise price of $6.875 per share, which expire five and half years from the date of issuance, or January 15, 2027, issued to Aegis Capital
in connection with our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, we also
had issued and outstanding warrants to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise price of $0.70 per share,
which expire on February 5, 2031, issued to an institutional investor. In addition, we had issued and outstanding placement agent warrants
to purchase up to an aggregate of 212,188 Ordinary Shares at an exercise price of $1.60 per share, which expire three and a half years
following their date of issuance, or June 28, 2027, that the Company agreed to issue to H.C. Wainwright &amp; Co., LLC, the placement
agent, or its designees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, we had
issued and outstanding placement agent warrants to purchase up to an aggregate of 185,591 Ordinary Shares at an exercise price of $1.56
per share, which expire four years following their date of issuance, or June 18, 2028, that the Company agreed to issue to Newbridge Securities
Corporation, the placement agent, or its designees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, we also
had issued and outstanding warrants to purchase up to an aggregate of 3,753,001 Ordinary Shares at an exercise price of $1.10 per share,
which expire eighteen (18) months from the date of issuance, or June 30, 2026, issued in a private placement financing with certain accredited
investors, on December 31, 2024.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, we had
outstanding options to purchase up to an aggregate of 450,074 Ordinary Shares and 3,625,612 unvested Restricted Share Units issued to
certain employees, directors, consultants and service providers who are our employees, officers, directors or consultants under our Amended
and Restated 2019 Equity Incentive Plan (the &ldquo;Plan&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, we also
had issued and outstanding warrants to purchase up to an aggregate of 6,785,715 Ordinary Shares at an exercise price of $0.70 per share,
which are exercisable six months after their issuance and will expire on the five year anniversary of their initial exercise date, or
August 5, 2031, issued in a private placement financing with a single institutional investor, on February 6, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 24, 2026, we also
had issued and outstanding pre-funded warrants to purchase up to an aggregate of 588,001 Ordinary Shares at an exercise price of $0.0001
per share, issued in a registered direct offering with a single institutional investor, on February 6, 2026. The pre-funded warrants are
exercisable immediately and may be exercised at any time until the pre-funded warrants are exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Name of Exchange on which Registered</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares have been
listed on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;IINN&rdquo; since July 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our IPO Warrants have been
listed on Nasdaq under the symbol &ldquo;IINNW&rdquo; since July 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No transfer of shares may
be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to the board of
directors (the &ldquo;Board of Directors&rdquo;)) has been submitted to the Company (or its transfer agent), together with any share certificate(s)
and such other evidence of title as the Board of Directors may reasonably require. The Board of Directors, may, from time to time, prescribe
a fee for the registration of a transfer, and may approve other methods of recognizing the transfer of shares in order to facilitate the
trading of the Company&rsquo;s shares on the Nasdaq or on any other stock exchange on which the Company&rsquo;s shares are then listed
for trading. The ownership or voting of our Ordinary Shares by non-residents of Israel is not restricted in any way by our Articles or
the laws of the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liability to Further Capital Calls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors may
make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by
such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon him or her.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, our Board
of Directors must consist of at least three (3) and not more than twelve (12) directors, including two external directors, if applicable,
which will be elected if and when required under the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than external directors,
if applicable (who shall be elected and serve in office in strict accordance with the provisions of the Companies Law), and other than
directors elected by our Board of Directors (due to the number being less than the maximum amount, or due to a director&rsquo;s office
becoming vacant), directors of the Company shall be elected solely at an annual general meeting and shall serve in their office until
the next annual general meeting, or until they cease to serve in their office in accordance with the provisions of our Articles or any
law, whichever is earlier. Prior to every annual general meeting of the Company, and subject to clause 39 (a) and (f) of our Articles,
the Board of Directors (or a committee thereof) shall select, by a resolution adopted by a majority of the Board of Directors (or such
committee), a number of persons to be proposed to the shareholders for election as Directors at such annual general meeting.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&rsquo;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided that the number of the serving directors
shall not be less than three (3). If the number of serving directors is lower than their minimal one, the Board shall not be permitted
to act, they may only act in an emergency or to fill the office of director which has become vacant up to a number equal to the minimum
number provided for pursuant to our Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">External directors, if applicable,
are elected for an initial term of three years, and may be elected thereafter for up to two additional three-year terms under certain
circumstances, and may be removed from office pursuant to the terms of the Companies Law. Under certain circumstances, the term of office
for external directors for Israeli companies traded on certain foreign stock exchanges, including the Nasdaq Stock Market, may be extended
indefinitely in increments of additional three-year terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividend Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors may
from time to time declare, and cause the Company to pay, such dividend as may appear to the Board of Directors to be justified by the
profits of the Company and as permitted by the Companies Law. The Board of Directors shall determine the time for payment of such dividends
and the record date for determining the shareholders entitled thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according
to our then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more
than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with Israeli
court approval. In each case, we are only permitted to distribute a dividend if our Board of Directors and the court, if applicable, determines
that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations
as they become due.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Annual and Special Shareholder Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months
after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred
to in our Articles as special meetings. Our Board of Directors may call special meetings whenever it sees fit, at such time and place,
within or outside of Israel, as it may determine. In addition, the Companies Law provides that our Board of Directors is required to convene
a special meeting upon the written request of (i) any two of our directors or one-quarter of the members of our Board of Directors or
(ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares and 1% or more of our
outstanding voting power or (b) 5% or more of our outstanding voting power (the &ldquo;Non Exempted Holding&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under an exemption
applicable for Israeli companies whose shares are listed outside of Israel (the &ldquo;Exemption Regulations&rdquo;), the Board of Directors
shall convene a special meeting at the request of one or more shareholders holding at least ten percent (10%) of the issued and outstanding
share capital instead of five (5%) in the past, and at least one percent (1%) of the voting rights in the company, or one or more shareholders
holding at least ten percent (10%) of the voting rights in the company, provided that if the applicable law to companies incorporated
in the country which the company is listed for trade, establishes a right to demand convening of such a meeting for those holding a percentage
of holdings lower than ten percent (10%), then the Non Exempted Holding shall apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, one
or more shareholders holding at least 1% of the voting rights at the general meeting may request that the Board of Directors include a
matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the
general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under the Exemption
Regulations, one or more shareholders may request the Board of Directors to include a nomination of a candidate for a position on the
Board of Directors or the termination of a director, as an item on the agenda of a future general meeting if they hold at least five percent
(5%) of the voting rights of the company, instead of one percent (1%) as required in the past.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the Board, which according to the Companies Law may be between four (4) and sixty
(60) days prior to the date of the meeting, as applicable according to the matters on the general meeting agenda. According to the Companies
Law, resolutions regarding the following matters must be passed at a general meeting of the Company&rsquo;s shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">amendments to our Articles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the exercise of the Board of Director&rsquo;s powers by a general meeting if the Board of Director&rsquo;s is unable to exercise its powers and the exercise of any of its powers is required for the Company&rsquo;s proper management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appointment or termination of the Company&rsquo;s auditors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appointment of directors (other than in the cases specified in our Articles);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approval of acts and transactions requiring general meeting approval pursuant to the provisions of the Companies Law and any other applicable law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">increases or reductions of the Company&rsquo;s authorized share capital;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a merger (as such term is defined in the Companies Law); and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">dissolution of the Company by the court, voluntary dissolution, or by voluntary dissolution in an expedited procedure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Notices</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, we are
not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required by law. The Companies
Law requires that a notice of any annual or special general meeting be provided 14 or 21 days (as applicable) prior to the meeting, and
if the agenda of the meeting includes certain matters prescribed under the Companies Law and the regulations promulgated thereafter, among
others, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, approval
of the Company&rsquo;s general manager to serve as the chairman of the Board of Directors or an approval of a merger, notice must be provided
at least 35 days prior to such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every shareholder shall have
one vote for each share held by him of record, on every resolution, without regard to whether the vote thereon is conducted by a show
of hands, by written ballot or by any other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Quorum Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted under the Companies
Law and as stated in our Articles, the quorum required for the Company&rsquo;s general meetings consists of two or more shareholders,
present in person or by proxy and holding shares conferring in the aggregate at least twenty five percent (25%) of the voting power of
the Company. If within half an hour of the time set forth for the general meeting a quorum is not present, the general meeting shall stand
adjourned either (i) to the same day of the following week, at the same hour and in the same place (ii) to such other date, time and place
as prescribed in the notice to the shareholders and in such adjourned meeting or (iii) to such day and at such time and place as the chairperson
of the general meeting shall determine (which may be earlier or later than the date pursuant to clause (i) above). If no quorum is present
within half an hour of the time arranged to the adjourned meeting, any number of shareholders participating in the meeting, shall constitute
a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a special general meeting
was called following the request of a shareholder according to applicable law, and within half an hour a legal quorum has not been formed,
the meeting shall be canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Vote Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles provide that
all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our Articles.
Under the Companies Law, each of (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of
employment or other engagement of the controlling shareholder of the company or such controlling shareholder&rsquo;s relative (even if
not extraordinary) requires the approval described under &ldquo;<FONT STYLE="background-color: white">Item 6.</FONT>C. <FONT STYLE="background-color: white"><I>Directors,
Senior Management and Employees</I></FONT><I>&mdash;Board Practices&mdash; Fiduciary Duties of Office Holders</I> and Approval of Related
Party Transactions under Israeli Law &mdash; Disclosure of Personal Interests of an Office Holder.&rdquo; Certain transactions with respect
to remuneration of our office holders and directors require further approvals described under &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&mdash; Fiduciary Duties of Office Holders and Disclosure
of Personal Interests of an Office Holder.&rdquo; Another exception to the simple majority vote requirement is a resolution for the voluntary
winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law,
which requires the approval of the court and the approval of the majority of the shareholders voting their shares, other than abstainees,
holding at least 75% of the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on the resolution.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Access to Corporate Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, shareholders
are entitled to have access to: minutes of the Company&rsquo;s general meetings; the Company&rsquo;s shareholders register and principal
shareholders register, articles of association and annual audited financial statements; and any document that the Company is required
by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. These documents are publicly available
and may be found and inspected at the Israeli Registrar of Companies. In addition, shareholders may request to be provided with any document
related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law.
The Company may deny this request if the Company believes it has not been made in good faith or if such denial is necessary to protect
the Company&rsquo;s interest or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special or Class Rights; Modification of Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the share capital
of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by the Companies
Law or our Articles, may be modified or cancelled by the Company by a resolution of the general meeting of the holders of all shares as
one class, without any required separate resolution of any class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of our Articles
relating to general meetings shall, <I>mutatis mutandis</I>, apply to any separate general meeting of the holders of the shares of a particular
class. It being clarified that the requisite quorum at any such separate general meeting shall be two or more shareholders present in
person or by proxy and holding not less than 15 percent of the issued shares of such class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise provided
by our Articles, an increase in the authorized share capital, the creation of a new class of shares, an increase in the authorized share
capital of a class of shares, or the issuance of additional shares thereof out of the authorized and unissued share capital, shall not
be deemed to modify or derogate or cancel the rights attached to previously issued shares of such class or of any other class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Acquisitions under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Full Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, as a result of an acquisition
of shares, the acquirer will hold more than 90% of an Israeli public company&rsquo;s outstanding shares or of certain class of shares,
the acquisition must be made by means of a tender offer for all of the outstanding shares, or for all of the outstanding shares of such
class, as applicable. In general, if less than 5% of the outstanding shares, or of applicable class, are not tendered in the tender offer
and more than half of the offerees who have no personal interest in the offer tendered their shares, all the shares that the acquirer
offered to purchase will be transferred to it by operation of law. However, a tender offer will also be accepted if the shareholders who
do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares.
Any shareholders that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may request, by
petition to an Israeli court, (i) appraisal rights in connection with a full tender offer, and (ii) that the fair value should be paid
as determined by the court, for a period of six months following the acceptance of the offer. However, the acquirer is entitled to stipulate,
under certain conditions, that tendering shareholders will forfeit such appraisal rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Special Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law also provides
that, subject to certain exceptions, an acquisition of shares in an Israeli public company must be made by means of a &ldquo;special&rdquo;
tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more of the voting rights in the company,
unless there is already another holder of at least 25% or more of the voting rights in the company or (2) the purchaser would become a
holder of 45% or more of the voting rights in the company, unless there is already a holder of more than 45% of the voting rights in the
company. These requirements do not apply if, in general, the acquisition (1) was made in a private placement that received shareholders&rsquo;
approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting rights in the company which resulted in the
acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was from a holder of more than 45% of the voting
rights in the company which resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A &ldquo;special&rdquo;
tender offer must be extended to all shareholders. In general, a &ldquo;special&rdquo; tender offer may be consummated only if (1) at
least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the offeror and (2) the offer is accepted
by a majority of the offerees who notified the company of their position in connection with such offer (excluding the offeror, controlling
shareholders, holders of 25% or more of the voting rights in the company or anyone on their behalf, or any person having a personal interest
in the acceptance of the tender offer). If a special tender offer is accepted, then the purchaser or any person or entity controlling
it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase
of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the
offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under the Exemption
Regulations, the aforesaid limitations regarding a special tender offer do not apply for an Israeli company whose shares are listed outside
of Israel, provided that if the applicable law as applicable to companies incorporated in the country which the company is listed for
trade, provide a restriction on the acquisition of control of any proportion of the company or that the acquisition of control of any
proportion requires the purchaser to also offer a purchase offer to shareholders from among the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law includes
provisions that allow a merger transaction and requires that each company that is a party to the merger have the transaction approved
by its board of directors and, unless certain requirements described under the Companies Law are met, a vote of the majority of its shareholders,
and, in the case of the target company, also a majority vote of each class of its shares. For purposes of the shareholder vote of each
party, unless a court rules otherwise, the merger will not be deemed approved if shares representing a majority of the voting power present
at the shareholders meeting and which are not held by the other party to the merger (or by any person or group of persons acting in concert
who holds 25% or more of the voting power or the right to appoint 25% or more of the directors of the other party) vote against the merger.
If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder or if the controlling shareholder has a personal
interest in the merger, then the merger is instead subject to the same Special Majority (as defined below) approval that governs all extraordinary
transactions with controlling shareholders. Upon the request of a creditor of either party to the proposed merger, the court may delay
or prevent the merger if it concludes that there exists a reasonable concern that as a result of the merger the surviving company will
be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors.
If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the
exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the petition of holders of
at least 25% of the voting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable,
taking into account the value of the parties to the merger and the consideration offered to the shareholders. In addition, a merger may
not be completed unless at least (1) 50 days have passed from the time that the requisite proposals for approval of the merger were filed
with the Israeli Registrar of Companies by each merging company; and (2) 30 days have passed since the merger was approved by the shareholders
of each merging company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;Special Majority&rdquo;
will be defined as described in section 275(a)(3) of the Companies Law as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">at least a majority of the shares held by shareholders who are not controlling shareholders and do not have personal interest in the merger have voted in favor of the proposal (shares held by abstaining shareholders shall not be considered); or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the total number of shares voted against the merger does not exceed 2% of the aggregate voting rights of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowing Powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and our Articles, our Board of Directors may exercise all powers and take all actions that are not required under law or under our
Articles to be exercised or taken by a certain organ of the Company, including the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles enable us to
increase or reduce our authorized share capital. Any such changes are subject to the provisions of the Companies Law and must be approved
by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital,
such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both
our Board of Directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>IPO Warrant Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants were issued
in registered form pursuant to the warrant agent agreement dated July 13, 2021, by and between the Company and VStock Transfer, LLC, as
warrant agent (the &ldquo;Warrant Agreement&rdquo;). On August 8, 2022 the Company and American Stock Transfer &amp; Trust Company, LLC,
as a successor warrant agent, entered into an amendment to the Warrant Agreement (the &ldquo;Amendment to the Warrant Agreement&rdquo;).
You should review a copy of the Warrant Agreement, the Amendment to the Warrant Agreement and the form of IPO Warrant filed as exhibits
to our Annual Report on Form 20-F for the year ended December 31, 2025, for a complete description of the terms and conditions of the
Warrants, the Warrant Agreement and the Amendment to the Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Duration and Exercise Price Adjustments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants expire at
5:00 p.m., New York City time on July 16, 2026. The exercise price and number of Ordinary Shares issuable upon exercise is subject to
appropriate adjustments in the event of stock dividends, stock splits, reorganizations or other events affecting our Ordinary Shares and
the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants may be exercised
upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form
completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by paying
in full, in lawful money of the United States by wire transfer to the warrant agent, for the number of Warrants being exercised. The warrant
holders do not have the rights or privileges of a shareholder of the Company and any voting rights until they exercise their IPO Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fractional Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No fractional shares will
be issued in connection with the exercise of an IPO Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal
to the fractional amount multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transferability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable laws,
each warrant may be transferred at the option of the holder upon surrender of the warrant to the Company or its designated agent together
with a written assignment substantially in the form attached to the warrant as an exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Agent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrant agent for the
IPO Warrants is Equinity&nbsp;Trust Company, LLC (formerly known as American Stock Transfer &amp; Trust Company, LLC) <FONT STYLE="background-color: white">Its
address</FONT> is 48 Wall Street, 23rd floor, New York, NY 10043.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exchange Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants are listed
on Nasdaq under the symbol &ldquo;IINNW&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">6</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.1
<SEQUENCE>3
<FILENAME>iinnex11-1.htm
<DESCRIPTION>EXHIBIT 11.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 11.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INSIDER TRADING POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND GUIDELINES WITH RESPECT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN TRANSACTIONS IN COMPANY SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date: March 25, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Insider Trading Policy
(the &ldquo;<B>Policy</B>&rdquo;) provides guidelines to directors, officers, employees and other related persons of Inspira Technologies
Oxy B.H.N. Ltd., an Israeli company (the &ldquo;<B>Company</B>&rdquo;), with respect to transactions in the Company&rsquo;s securities.
The Company has adopted this Policy in order to ensure compliance with securities laws and to avoid even the appearance of improper conduct
by anyone associated with the Company. Failure to comply with these procedures could result in a serious violation of the securities laws
by you and/or the Company and can result in both civil penalties and criminal fines and imprisonment. We have all worked hard to establish
the Company&rsquo;s reputation for integrity and ethical conduct, and we are all responsible for preserving and enhancing this reputation.
The appearance of insider trading can cause a substantial loss of confidence in the Company and its shares on the part of the public and
the securities markets. This could result in an adverse impact on the Company and its shareholders. Accordingly, avoiding the appearance
of engaging in share transactions on the basis of material undisclosed information can be as important as avoiding a transaction actually
based on such information. The Company has appointed its VP Finance, or in his or her absence, the Company&rsquo;s Chief Executive Officer
(the &ldquo;<B>Compliance Officer</B>,&rdquo; as the case may be), as the Company&rsquo;s Insider Trading Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">I.</TD><TD STYLE="text-align: justify"><U>Applicability of Policy</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy applies to all
transactions in the Company&rsquo;s securities, including ordinary shares, American depositary shares, American depositary receipts, options
and any other securities the Company may issue from time to time, such as preferred shares, warrants, notes, and convertible debentures,
as well as to derivative securities relating to the Company&rsquo;s shares, whether or not issued by the Company, such as exchange-traded
options and debt securities. It applies to all officers of the Company, all members of the Company&rsquo;s Board of Directors, and all
employees of, and consultants and contractors to, the Company and its subsidiaries/branches who receive or have access to Material Nonpublic
Information (as defined below) regarding the Company (collectively, &ldquo;<B>Company Affiliated Persons</B>&rdquo;). Company Affiliated
Persons, members of their immediate families (which include spouse and minor children), members of their households, other family members
living with them or who are supported by them, are sometimes referred to in this Policy as &ldquo;<B>Insiders</B>&rdquo;. This Policy
also applies to any trust or other estate in which an Insider has a substantial beneficial interest or as to which he or she serves as
trustee or in a similar fiduciary capacity, and to any trust, corporation, partnership or other entity which the Insider controls, including
venture capital partnerships. This Policy also applies to any person who receives Material Nonpublic Information from any Insider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any person who possesses Material
Nonpublic Information regarding the Company is an Insider for so long as the information is not publicly known. Any employee can be an
Insider from time to time and would at those times be subject to this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Policy imposes additional
restrictions upon Insiders who have routine access to Material Nonpublic Information, referred to as &ldquo;<B>Access Insiders</B>.&rdquo;
Access Insiders are: (1) members of the board of directors, (2) the executive officers, (3) the controller, and (4) the investor relations
department of the Company. In addition, other employees of the Company who have routine access to Material Nonpublic Information as determined
by the Compliance Officer, who were notified that these additional restrictions apply to them shall also be Access Insiders until otherwise
determined by the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company itself
must comply with securities laws applicable to its own securities trading activities, and must not engage in any transaction involving
a purchase or sale of its securities, including any offer to purchase or offer to sell or other disposition of its securities, when it
is in possession of Material Nonpublic Information concerning the Company, other than in compliance with applicable law, subject to the
policies and procedures adopted by the Company and the exceptions listed in Section XII of this Policy to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">II.</TD><TD STYLE="text-align: justify"><U>General Policy</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is the policy of the Company
to oppose the unauthorized disclosure of any nonpublic information acquired in the work-place and the misuse of Material Nonpublic Information
in securities trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">III.</TD><TD STYLE="text-align: justify"><U>Specific Policies</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><B><U>Trading
on Material Nonpublic Information</U>. </B>No Insider shall engage in any transaction involving a purchase or sale of the
Company&rsquo;s securities, including any offer to purchase or offer to sell or gift, or any other disposition of the
Company&rsquo;s securities, during any period commencing with the time that he or she first receives Material Nonpublic Information
concerning the Company, and ending at the close of business on the second Trading Day following the date of public disclosure of
that information, or at such time as such nonpublic information is no longer material. As used herein, the term &ldquo;<B>Trading
Day</B>&rdquo; shall mean a day on which the Nasdaq Capital Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <B><U>Tipping</U>. </B>No
Insider shall disclose (sometimes called a &ldquo;<B>Tip</B>&rdquo;) Material Nonpublic Information to any other person (including
family members) where such information may be used by such person to his or her profit by trading in the securities of companies to
which such information relates, nor shall such Insider or related person make recommendations or express opinions on the basis of
Material Nonpublic Information as to trading in the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <B><U>Confidentiality
of Nonpublic Information</U>. </B>Nonpublic information relating to the Company is the property of the Company and the unauthorized
disclosure of such information is forbidden. In the event any officer, director or employee of the Company receives any inquiry from
outside the Company, such as a stock analyst, for information (particularly financial results and/or projections) that may be
Material Nonpublic Information, the inquiry should be referred to the Compliance Officer, and to the other appropriate Company
officers, as provided for in the Disclosure Policy of the Company, if any, as may be in place from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">IV.</TD><TD STYLE="text-align: justify"><U>Potential Criminal and Civil Liability and/or Disciplinary Action</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <B><U>Liability for
Insider Trading</U>. </B>In the United States and many other countries, the personal consequences to an Insider of illegally trading
securities while in possession, or on the basis of, Material Nonpublic Information can be quite severe. In the United States there
are substantial civil penalties and criminal sanctions which may be assessed for insider trading. Civil penalties are a payment of a
penalty of up to three times the illicit windfall. In addition, Insiders may be subject to criminal fines of up to $5,000,000 and up
to twenty years in prison for engaging in transactions in the Company&rsquo;s securities at a time when they have knowledge of
Material Nonpublic Information regarding the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are located or engaged
in dealings outside the U.S., be aware that laws regarding insider trading and similar offenses differ from country to country. Employees
must abide by the laws in the country where located. However, you are required to comply with this Policy even if local law is less restrictive.
If a local law conflicts with this Policy, you must consult the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If securities transactions
ever become the subject of scrutiny, they are likely to be viewed after-the-fact with the benefit of hindsight. As a result, before engaging
in any transaction an Insider should carefully consider how the transaction may be construed in the bright light of hindsight. If you
have any questions or uncertainties about this Policy or a proposed transaction, please ask the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <B><U>Liability for
Tipping</U>. </B>Insiders may also be liable for improper transactions by any person (commonly referred to as a
&ldquo;<B>Tippee&rdquo;</B>) to whom they have disclosed Material Nonpublic Information or any person to whom the Tippee discloses
such Material Nonpublic Information regarding the Company or to whom they have made recommendations or expressed opinions on the
basis of such information as to trading in the Company&rsquo;s securities. The civil penalties and criminal sanctions for tipping by
an Insider are the same as the ones for an Insider conducting insider trading, even if the disclosing person did not profit from the
trading. The U.S. Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;), the Financial Industry Regulatory Authority
(&ldquo;<B>FINRA</B>&rdquo;) and the stock exchanges use sophisticated electronic surveillance techniques to uncover insider
trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <B><U>Possible
Disciplinary Actions</U>. </B>The seriousness of securities law violations is reflected in the penalties and criminal sanctions such
violations carry. These violations may also create negative publicity for the Company and a director&rsquo;s resignation may be
sought, or an officer or other employee will be subject to possible Company disciplinary action including ineligibility for future
participation in the Company&rsquo;s equity incentive plans or termination of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">V.</TD><TD STYLE="text-align: justify"><U>Individual Responsibility</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every Company Affiliated Person
has the individual responsibility to comply with this Policy against insider trading, regardless of whether the Company has recommended
a trading window to that person or any other Insiders of the Company. The guidelines set forth in this Policy are not intended to provide
a conclusive solution for all circumstances, and appropriate judgment should be exercised in connection with any trade in the Company&rsquo;s
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Insider may, from time
to time, have to forego a proposed transaction in the Company&rsquo;s securities even if he or she planned to make the transaction before
learning of the Material Nonpublic Information and even though the Insider believes he or she may suffer an economic loss or forego anticipated
profit by waiting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">VI.</TD><TD STYLE="text-align: justify"><U>Applicability of Policy to Inside Information Regarding Other Companies</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy and the guidelines
described herein also apply to Material Nonpublic Information relating to other companies, including the Company&rsquo;s customers, vendors
or suppliers (&ldquo;<B>Business Partners</B>&rdquo;), when that information is obtained in the course of employment with, or other services
performed on behalf of, the Company. Civil penalties and criminal sanctions, and termination of employment, may result from trading on
inside information regarding the Company&rsquo;s Business Partners. All employees should treat Material Nonpublic Information about the
Company&rsquo;s Business Partners with the same care required with respect to information related directly to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">VII.</TD><TD STYLE="text-align: justify"><U>Dissemination of Company Information</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prohibition of the disclosure
of Material Nonpublic Information applies to all contacts made within and outside the Company. Care should be taken to prevent the disclosure
of Material Nonpublic Information during all contact including phone calls and casual conversation. If in doubt about whether information
falls into the category of Material Nonpublic Information, then the information should not be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to disclosure to any
third party, any officer, director or employee of the Company who is aware of any Material Nonpublic Information concerning the Company
that has not been disclosed to the public should report the intention to disclose such information promptly to the Compliance Officer
and obtain approval to do so, or otherwise act in accordance with the Company&rsquo;s Disclosure Policy, if any, as may be in place from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">VIII.</TD><TD STYLE="text-align: justify"><U>Definition of Material Nonpublic Information</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Material Nonpublic Information
is information which is material, and that has not been disclosed or otherwise made available to the general public by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is not possible to define
all categories of material information. Generally, information should be regarded as material if a reasonable investor would consider
it important in making an investment decision regarding the purchase or sale of the Company&rsquo;s securities or the information, if
made public, would likely affect the market price of the Company&rsquo;s securities. Either positive or negative information may be material.
Information may be material even if it relates to future, speculative or contingent events and even if it is significant only when considered
in combination with publicly available information. Nonpublic information can be material even with respect to companies that do not have
publicly traded stock, such as those with outstanding bonds or bank loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While it may be difficult
under this standard to determine whether particular information is material, there are various categories of information that are particularly
sensitive and, as a general rule, should always be considered material. If any Insider has questions as to the materiality of information,
he or she should contact the Compliance Officer for clarification. Examples of information which is deemed to be material include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Financial results;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Projections of future earnings or losses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">News of a pending or proposed merger or acquisition;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">New product or project announcements of a significant nature;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Expansion or curtailment of operations or the gain or loss of a substantial customer;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Changes in control of the Company or major changes in senior management;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant new joint ventures, alliances, or strategic partnerships or material developments in existing
arrangements;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Impending bankruptcy or financial liquidity problems;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Cybersecurity risks and incidents;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant product defects or modifications;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant pricing changes;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Events regarding the Company&rsquo;s securities (e.g. stock splits, repurchases, or changes in dividend
policy);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Changes in auditors or auditor notification that the Company may no longer rely on an audit report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">A significant purchase or sale of assets or disposition of a subsidiary or division;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">New equity or debt offerings, significant borrowings, or other material financial transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant litigation exposure due to actual or threatened litigation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Significant actions by regulatory bodies;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Receipt, cancellation or deferral of significant purchase orders;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Proposed payment of a dividend; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Any of the above with respect to a subsidiary, or other affiliate of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nonpublic information is information
that has not been previously disclosed to the general public and is otherwise not available to the general public. It is important to
note that information is not necessarily &ldquo;public information&rdquo; merely because it has been discussed in the press, which will
sometimes report rumors. You should presume that information is nonpublic unless you can point to its official release by the Company
in at least one of the following ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. Information contained
in publicly available documents filed with securities regulatory authorities (e.g., filings with the SEC);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. Issuance of press
releases; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. Meetings with members
of the press and the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">IX.</TD><TD STYLE="text-align: justify"><U>Additional Circumstances Where No Exceptions Apply</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are almost no exceptions
to the prohibition against insider trading. For example, absent a Qualified Plan (as defined below), it does not matter that the transactions
in question may have been planned before the Insider came into possession of the undisclosed material information, regardless of the economic
loss that the person may believe he or she might suffer as a consequence of not trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the definition
of Insiders, to which this Policy applies, includes immediate family members of Company Affiliated Persons. Although immediate family
is narrowly defined, a Company Affiliated Person should be especially careful with respect to family members or to unrelated persons living
in the same household.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, there are no limits
on the size of a transaction that will trigger insider trading liability; relatively small trades have in the past occasioned investigations
and lawsuits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">X.</TD><TD STYLE="text-align: justify"><U>Trading Window</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The period beginning two weeks
before the end of the last month of each calendar quarter and ending two Trading Days following the date of public disclosure of the financial
results for that quarter, is a particularly sensitive period of time for transactions in the Company&rsquo;s shares from the perspective
of compliance with applicable securities laws. This sensitivity is due to the fact that directors, officers and certain other employees
will, during that period, often possess Material Nonpublic Information about the expected financial results for the quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, to ensure compliance
with this Policy and applicable federal and state securities laws, it is the Company&rsquo;s policy that all directors, officers and employees
refrain from conducting transactions involving the Company&rsquo;s securities other than during the period (the &ldquo;<B>Trading Window</B>&rdquo;)
commencing at the close of business on the second Trading Day following the date of public disclosure of the financial results for a particular
fiscal quarter or year and continuing until the day that is two weeks before the last day of the last month of the next fiscal quarter.
As a courtesy to the persons subject to this Policy, the Company may provide advance notice before the Trading Window opens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Company
may also notify that directors, officers, selected employees and others are required to suspend trading because of developments known
to the Company and not yet disclosed to the public. In such event, such persons are advised not to engage in any transaction involving
the Company&rsquo;s securities during such period and should not disclose to others the fact of such suspension of trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose behind the self-imposed
Trading Window period is to help establish a diligent effort to avoid any improper transaction. It should be noted, however, that even
during the Trading Window, any person possessing Material Nonpublic Information concerning the Company may not attempt to &ldquo;beat
the market&rdquo; by trading simultaneously with, or shortly after, the official release of Material Nonpublic Information. Although there
is no fixed period for how long it takes the market to absorb information, out of prudence a person aware of Material Nonpublic Information
should refrain from any trading activity for at least two full Trading Days following its official release, whether or not the Company
has recommended a suspension of trading to that person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOTWITHSTANDING THESE TIMING
GUIDELINES, IT IS ILLEGAL FOR ANY PERSON TO TRADE WHILE IN POSSESSION OF MATERIAL NONPUBLIC INFORMATION, INCLUDING SITUATIONS IN WHICH
THE PERSON IS AWARE OF MAJOR DEVELOPMENTS THAT HAVE NOT YET BEEN PUBLICLY ANNOUNCED BY THE COMPANY. TRADING IN THE COMPANY&rsquo;S SECURITIES
DURING THE TRADING WINDOW SHOULD <U>NOT</U> BE CONSIDERED A &quot;SAFE HARBOR,&quot; AND ALL DIRECTORS, OFFICERS AND OTHER INSIDERS SHOULD
USE GOOD JUDGMENT AT ALL TIMES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">XI.</TD><TD STYLE="text-align: justify"><U>Inquiries</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Insiders should review
this Policy carefully and contact the Compliance Officer if they have a concern that a contemplated transaction in the Company&rsquo;s
securities might not conform with this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">XII.</TD><TD STYLE="text-align: justify"><U>Certain Exceptions</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Policy,
the Company considers that the exercise of share options for cash under the Company&rsquo;s share option plans or the purchase of shares
under employee purchase plans in effect at the time of the adoption of this Policy and that may be adopted in the future (but <U>not</U>
the sale of any such shares) is exempt from this Policy, since the other party to the transaction is the Company itself and the price
does not vary with the market but is fixed by the terms of the option agreement or the plan. Accordingly, cashless exercises of options
are subject to the Policy when they involve the sale of shares into the public marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The restrictions set forth
in this Policy shall not apply to purchases or sales made pursuant to a Qualified Plan. For purposes of this exception, a &ldquo;<B>Qualified
Plan</B>&rdquo; is a written plan for purchasing or selling the Company&rsquo;s securities which meets each of the following requirements:
(a) the plan is adopted by the Insider during a Trading Window and when the Insider is not in possession of material non-public information;
(b) the plan is adhered to strictly by the Insider; (c) the plan either (i) specifies the amount of securities to be sold and the date
on which the securities are to be sold, (ii) includes a written formula or algorithm, or computer program, for determining the amount
of securities to be purchased or sold and the price at which and the date on which the securities are to be purchased or sold, or (iii)
does not permit the Insider to exercise any subsequent influence over how, when, or whether to effect sales; provided, in addition, that
any other person who, pursuant to the plan, does exercise such influence must not have been aware of the material nonpublic information
when doing so; (d) d) the plan includes a representation from the Insider adopting the plan that such Insider (i) is not aware of any
material nonpublic information about the Company or its securities and (ii) is adopting the plan in good faith and not as part of a plan
or scheme to evade the prohibitions of Rule 10b-5 under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;);
(e) the plan provides that trading under the plan cannot begin until the later of (i) 90 days after the adoption of the plan or (ii) two
business days following the disclosure of the Company&rsquo;s financial results in a Form 6-K or Form 20-F (such period being referred
to as the &ldquo;cooling-off period&rdquo;, but, in either case, not to exceed 120 days following the adoption of the plan, and provided
that if the Insider is not a director or officer of the Company, such cooling-off period shall be at least 30 days rather than the longer
periods set forth above); and (e) at the time it is adopted the plan conforms to all other requirements of Rule 10b5-1 under the Exchange
Act as then in effect. Rule 10b5-1 provides an affirmative defense from insider trading liability under the U.S. federal securities laws
for trading plans that meet the above requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Rule 10b5-1
under the Exchange Act, any change to the amount, price, or timing of the purchase or sale of securities underlying a Qualified Plan constitutes
termination of the Qualified Plan and the adoption of a new Qualified Plan, which triggers the cooling-off period described above. No
Insider may have more than one Qualified Plan for purchases or sales of securities on the open market during the same period. In addition,
no Insider may have more than one single-trade Qualified Plan during any 12-month period. A single-trade plan is one that has the practical
effect of requiring the purchase or sale of securities as a single transaction. With respect to overlapping Qualified Plans, an Insider
may have two separate plans provided (i) the later-commencing plan does not begin until all trades have been completed under the first
plan or the first plan expires without execution, and trading during the cooling-off period that would have applied if the later-commencing
plan was adopted on the date the earlier-commencing plan terminates and (ii) the separate plans satisfy all other conditions applicable
to Qualified Plans. With respect to overlapping Qualified Plans, an Insider may have separate plans for &ldquo;sell-to-cover&rdquo; transactions
in which an Insider instructs an agent to sell securities in order to satisfy tax withholding obligations at the time an equity award
vests. Any such additional plan must only authorize qualified &ldquo;sell-to-cover&rdquo; transactions. With respect to single-trade Qualified
Plans, an Insider may have a single-trade plan for &ldquo;sell-to-cover&rdquo; transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the above requirements,
a Qualified Plan shall be signed and dated by the Insider, and submitted to the Compliance Officer at least two (2) trading days before
it is filed with the broker who executes it. The Company shall have the right, at all time, to suspend purchases or sales under a Qualified
Plan, for instance in the event that the Company needs to comply with requirements by underwriters for &ldquo;lock-up&rdquo; agreements
in connection with an underwritten public offering of the Company&rsquo;s securities. Any cancellation, suspension, expansion or other
modification of a Qualified Plan by the Insider who established it must: (1) be in writing, signed and dated by such Insider, (2) be submitted
to the Compliance Officer within two (2) trading days before the cancellation, suspension, expansion or other modification was reduced
to writing, and (3) be made during a Trading Window, and when the Insider who established it has no Nonpublic Material Information about
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">XIII.</TD><TD STYLE="text-align: justify"><U>Additional Information for Directors, Officers and Certain Employees with Routine Access to Material
Nonpublic information</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy imposes additional
restrictions upon Access Insiders, because of their routine access to Material Nonpublic Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <B><U>Preclearance of
Trades</U>. </B>The Company has determined that all Access Insiders should refrain from trading in the Company&rsquo;s securities,
even during the Trading Window, without first complying with the Company&rsquo;s &ldquo;preclearance&rdquo; process. Each Access
Insider should contact the Compliance Officer prior to commencing any trade, gift or other transaction in the Company&rsquo;s
securities. At the time of executing a trade in the Company&rsquo;s securities, such individuals will be responsible for verifying
that the Company has not imposed any restrictions on their ability to engage in transactions. If the individual has not completed
the transaction within ten Trading Days of notification of the intention to execute a transaction, then the individual must again
notify the Compliance Officer that he or she intends to execute a transaction and re-verify the nonexistence of any restrictions on
such trade. For the avoidance of doubt, this paragraph shall not apply to a Qualified Plan, after it has been set up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before each transaction in
the Company&rsquo;s securities by a Company each officer and director should contact the Compliance Officer regarding compliance with
Rule 144 under the U.S. Securities Act of 1933, as amended (&ldquo;<B>Rule 144</B>&rdquo;), which contains guidelines for the sale of
privately issued shares and sales by affiliates of the Company, if such sales are not covered by an effective registration statement,
to the extent applicable, and regarding compliance with the provisions of Section 16(a) of the U.S. Securities Exchange Act of 1934, as
amended (&ldquo;<B>Section 16</B>&rdquo;), which effective March 18, 2026, require the Company&rsquo;s directors and officers (as defined
in Section 16) to make public electronic filings with the U.S. Securities and Exchange Commission reporting their beneficial ownership
and to disclose their transactions in the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <B><U>Rule 144 and
Section 16 Matters for Directors and Officers</U>. </B>Directors and principal officers of the Company must also comply with Rule
144, or another applicable exemption from registration. The practical effect of Rule 144 is that directors and officers who sell the
Company&rsquo;s securities may be required to comply with a number of requirements including holding period, volume limitation,
manner of sale and SEC filing requirements. The Company may provide separate memoranda and other appropriate materials to its
directors and officers regarding compliance with Rule 144. Directors and officers (as defined in Section 16) of the Company must
also comply with the provisions of Section 16, which effective March 18, 2026, requires the Company&rsquo;s directors and officers
to report transactions in the Company&rsquo;s securities through filing of Form 3, Form 4 and Form 5 with the U.S. Securities and
Exchange Commission. It is the responsibility of each director and officer to comply with their Section&nbsp;16 reporting
obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">XIV.</TD><TD STYLE="text-align: justify"><U>Specific Requirements</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. <B><U>Speculative
Trading</U></B>. No Insider may engage in transactions of a speculative nature at any time. All Insiders are prohibited from
short-selling the Company&rsquo;s securities or engaging in transactions involving the Company&rsquo;s based derivative securities.
A short sale, for these purposes, means any transaction whereby one may benefit from a decline in the price of the Company&rsquo;s
securities. &ldquo;<B>Derivative Securities</B>&rdquo; are options, warrants, stock appreciation rights or similar rights whose
value is derived from the value of an equity security, such as the Company&rsquo;s ordinary shares. This prohibition includes, but
is not limited to, trading in the Company&rsquo;s based put and call option contracts, transacting in straddles, hedging or
monetization transaction with respect to the Company&rsquo;s securities, and the like. In addition, no Insider shall engage in a
transaction with respect to securities of the Company if he or she owns the security, but does not deliver it against such sale (a
&ldquo;short sale against the box&rdquo;) within twenty days thereafter, or does not within five days after such sale deposit it in
the mails or other usual channels of transportation. The above does not derogate from Insiders&rsquo; right to hold and exercise
options or other derivative securities granted under the Company&rsquo;s employee share option or equity incentive plans as long as
such exercise is not prohibited by this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. <B><U>Margin Accounts
and Pledges</U></B>. Securities held in a margin account may be sold by the broker without the consent of the owner thereof if such
owner fails to meet a margin call. Similarly, securities pledged as collateral for a loan may be sold if the owner thereof defaults
on the loan. In case of an owner who is subject to this Policy, these sales may occur at a time when such person is aware of
material, non-public information or otherwise not permitted to trade such securities. Therefore, this policy prohibits holding any
Company securities in a margin account or pledging any Company securities as collateral for a loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. <B><U>Post-Termination
Transactions</U>. </B>If an Insider is aware of Material Nonpublic Information at the time such Insider&rsquo;s association with the
Company is terminated, whether by the Insider or the Company, the Insider may not trade in Company securities until such information
is no longer material or until two Trading Days after such information has become public. In addition, if the Company is not in a
Trading Window at the time such association with the Company is terminated, the Insider may not trade in Company securities until
two Trading Days after the next announcement of quarterly earnings or of the material, non-public information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4. <B><U>Ad hoc
Restrictions</U>. </B>The Compliance Officer has the authority to impose restrictions on trading in the Company&rsquo;s securities
by appropriate individuals at any time. In such event, the Compliance Officer will notify the affected individuals, either
personally, by email or by voicemail, to inform them of the restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5. <B><U>Open
Orders</U></B>. Any Insider who has placed a limit order or open instruction to buy or sell the Company&rsquo;s securities shall
bear responsibility for canceling such instructions immediately upon becoming in possession of Material Nonpublic Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">XV.</TD><TD STYLE="text-align: justify"><U>Acknowledgement</U></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please sign the attached acknowledgement
form and return it to the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any questions
with respect to this Policy, please contact the Company&rsquo;s Compliance Officer, at yafit@inspirao2.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ACKNOWLEDGEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I have received, read and understand the Insider
Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities of Inspira Technologies Oxy B.H.N. Ltd., a copy
of which is attached hereto, and agree to comply with the provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Date:</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">7</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>iinnex12-1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Dagi Ben-Noon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of Inspira Technologies
Oxy B.H.N. Ltd. (the &ldquo;company&rdquo;);</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">c)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">d)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee
of the company&rsquo;s board of directors (or persons performing the equivalent function):</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 60%">Date: March 26, 2026</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 40%">/s/ Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>iinnex12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Yafit Tehila, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of Inspira Technologies
Oxy B.H.N. Ltd. (the &ldquo;company&rdquo;);</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">c)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">d)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee
of the company&rsquo;s board of directors (or persons performing the equivalent function):</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">a)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in">b)</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; width: 60%">Date: March 26, 2026</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; width: 40%">/s/ Yafit Tehila</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">Yafit Tehila </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt">Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>iinnex13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2025 (the &ldquo;Report&rdquo;) by Inspira Technologies Oxy B.H.N.
Ltd. (the &ldquo;company&rdquo;), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C.
Section 1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: March 26, 2026</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%">/s/ Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Dagi Ben-Noon</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>iinnex13-2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. Section 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2025 (the &ldquo;Report&rdquo;) by Inspira Technologies Oxy B.H.N.
Ltd. (the &ldquo;company&rdquo;), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C.
Section 1350, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: March 26, 2026</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%">/s/ Yafit Tehila</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Yafit Tehila </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>iinnex15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex15-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inspira Technologies Oxy B.H.N. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2 Ha-Tidhar St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rananna 4366504, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8&nbsp;(Nos. 333-259057,333-277980, 333-285565, 333-290162 and 333-292592) and Form F-3 (Nos. 333-284308 and 333-289324)
of Inspira Technologies Oxy B.H.N Ltd (&ldquo;the Company&rdquo;) of our report dated March 25, 2026, relating to the financial statements
of the Company which appears in this Annual Report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our report contains an explanatory paragraph regarding the Company&rsquo;s
ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">/s/ Ziv Haft</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certified Public Accountants (Isr.)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">BDO Member Firm</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 26, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex15-1_002.jpg" ALT="">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !0 .4# 2(  A$! Q$!_\0
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M@WRM)I*2=U=+3F=KJRZZZOT=D?7Y9;WM==K6\W_7<_5K0O _["GP[_X("?\
M!-']LS]LOP(_Q%\-?LY6_B;6/ 7P4TJUTNP7]H/XP^/M8UFR\%>%_B#K2H9M
M9\.:5-H.H:W<QGY!!'ND&%P_X]VG_!U7_P %$=%\80RZ-\-OV8-*_9YANUM;
M;]E^P^"^@VWP^T[P;']SPA9:VRC76DETP-#+,K@,"\@3D1GT?_@IWJIM_P#@
MV]_X(D:&)66'4/&'CVYO( Q"R-I-GJ,@R <$HNH$ID%AYG'4U_*>Q!4XZ8)
M]!C _3CZ<5\;%/$W;NFVW>^UVWOOY[Z^FA[&Q_4=_P %NOV>?V<[#3OV*O\
M@H=^RCX-L_A?\%O^"AWPRN/'WB'X>6-O#I_A7P?\6K"TTS5]9M=)T>(+;Z"L
MDFL0I/H^A(DMUKT=Y*$PX!_"K3--U'7=4TKP]IMN;S6M?U71O#>F*05+:AJ^
MKIINC\'+ M<:F.&^8'AOF4U^\W_!2^:5/^#=+_@A[J,,A%Q8^+?BE!;S-_RS
M,EC,,9.?N^3L'&/D''%?A_\ LR7-]KOQ9_9],D7VC4=1^-?PB@5K7[UZ1\0M
M"418ZE_8#/!/05Z&%Q-L&XWV;MU?7^OZU^FRS$Z)=M%]UE:UOE=]+MO=_P!>
MG[1_[0'[-'_!O5X2^ _[)_[/W[)_P8_:0_:Y\4_"C1?BI^T-\:?C1I*:I)!/
MK"1MIECHBN)-9\U;QI+RQL-/:/1-"\/V]O<W@:4R)'\N?L4_\%#O'G_!3+_@
MM3_P3J\:?%7X*?!+X='X?)\0?"D7AWX9:4(M&U^RUC0?$&JRZIXETS54:*;5
M(3-FRE567&V2,#(%>3?\'031G_@JG?PQR!)[+]G/X*_;$P"8T_L.ZX."<83.
M[/I@\8-?,/\ P0/P/^"O'[&+ C!\7>)R3C^'_A#-8(/ R>/\.HK!4/\ 9'.[
MN[RW=[6D[)WZ]MT>MALM;R>KCKRYG"K+64[ZQJ.R][1=-$K;I[6_7?\ ;G_;
M?_9O_P""/?[2GQZ^$W["WP7^&GQ7_;1\;_$#6OB!^T%^TU\7?"B:UIWPKO/$
MLPU;2/AA\,?#L08:5%X?MKB*VG;3UCT.-YRU[EN4^9OA!_P<@?&3XBZDOPV_
MX*6? CX#?M4_LR^+KQ;'QQ8)\.M#\/\ BSPAH.JDV]UK>@7<<#>&M<;PU$7N
MOLL4&B^(V";;6[,@CEK\B?\ @IOX0\>_#W_@HG^VMX8^)4=T_BV']H?QQK%S
M/>%OMVKV7BR^;5?#NNP,1\UOK>AW(\H@E!]D4*01BOB2=XH+&Z9X=D,4)_T9
MNK1QIR<=2S*N2 ,L3@<UA;2U[_K;Y^6FME^?U&4\.X3%X+FQ<Y2<HIJHIN[;
MC%W351J*VLHM1M;?=_K;_P %H/\ @GOX&_8?^)_P_P#'?[.OB&Z\6_L=?M8>
M"K;XF_L_>(GN&U'4_#MM?O;7-]\.+K5B[OJUMIJW<=_I,\KM-I>AS&WD9I86
M+?>?_!P5H>AZ'\8_^"6<&C:#H>D1:G^R-\#;K4ET;2-*L;+4F7Q'X3:03S*J
M&X=FW%II 7ERSLS$D58_X*ZZ-J_PP_X(;?\ !&/X*?$])+;XR11:YXT&AWC'
M^UM,\(MH8O1<7J-ADLWMM3TR,8."D:K@%"*E_P"#A_)^,G_!*4%@Y_X8^^!R
M[UX5R/$7A3++[,<LN.@(K@>[LK:_JQ9+B,96Q630]I*:IXSB*E&4FTZD:>&E
M3BY-.,9-JG'5)IRYG%1;T_6[_@L_^UG\,/\ @F7XW^#GQC_9^^#GPT\2?MT_
M'WX'^%?#F@>//'^AZ3JOA3X*_!GP%I]FMSJ&EZ(J(LGB/Q3KEW+!9D@F7[.N
M6*_*?QU_8Q^&6I_\%?/C_P#'[_@I'_P4T\2:5IW[-G[*7@?0]4^,$7AK2$\,
MZ-XHG\(:;/>:#\--+T^'8+&W$3#5/$WE_-KU[J-IIBL-^19_X.?]2N[_ /;F
M_9ZT=YO/L[']C;X?I;Z=_P ^\NHZD9WE( R2S0@DX) 4# '-:/[&MKJGQ-_X
M-QO^"CGP]^%PO=2^(/@_XY:=XP^).B:2P_MO5O !N=%U:[N6C7]X^D7.BV4S
MS!58&.RF &16&\G=:+F?+T;BF]OO\]+61ZV P"P7!^#S/#59_P!L9SC'@HUI
M5).5*G/&3I<RG*<E3LK*+;C:<HS=W&-\KXC_ /!R'^TEX7UJ7PI^PE\%_@/^
MR]^SSX:N8[;P5X)NOA?H>M:WJ>EPL8K+4/%\\L2VFGZC=V2P7"6>E@W\$CF"
M=GFC9C]M?\$U_P!JO]D__@KA^V#\$;;]K;X,?#OX)_M\?!3QG:_%;X4?&SX6
M:)I6@>%_VB]%T-FEU_X;>.?"ES$(M0U&\L#<W:KK"OJ1,)DTW:1Y;?QXO<Q.
M@O864Q2JLD1& A1P)(R.V-K+WX '.:_2G_@BYX0\;^._^"LG[$EMX)M]1DU;
M3/B^GC#59+,;[G0O OAO3);OQ5XBU,<I]CCM -/17P&CNU7!.17G_6'S6>MY
M6:LK/WK*RT2L]5:R3\KGW'%/!/#V7<,9AF%.53)LZIX6G4555:LO:5/81E-N
M7M*CE[27.WK)RYM=;27C'_!6A[RS_P""G?[>6C:$PT/1[/X_Z_-;:?I$VI:-
MIMHW]EZ2!*T,6U+=2N&,(4!&R-N *\A\/_LO2^+O@!I_Q/\ ^$J\6/<7OA_5
M-9A6;3+-OAZ-2L?%MKX?B\&C63JZZFOB'4'O1J-O/JD4=B7E!.%/'MW_  5R
MTJ>[_P""I7[>\\0*P-^T+KC.DY!4!M,THX[Y4 X4\@J%!SC%>.Z3\0?BGX6^
M#GAW5;3X>60\-:!I'B7P;I7Q%>\U!=/O= U_7+:YUS3)-$75T77)(;J""R_M
M%(A]@,Y"A=@ Y7JV_.7YOTWZ&F68;%X?)\FE.3DY0I-RE+63E3IN[N];IWNV
MUKO=W..F_9;\=Z#8^*=1U3PU;Q6WA"66/5L^(])FN8%ABMY=4N[9(G>+4!X?
MBNK:75;B-W339KB1$+J@8[FE?LL7^J+?7GB&]LM$LK>+P;J-B;?Q-IU\_BO0
M_%/B:U\-2WOA>[; U%M*N;@_:[/!)>)EY &*Y_:D\8S^&-=T:;2[348+[QWK
MGQ&L98=6U6STZ"Y\3):2>(-+UG0[<MI_C'3KV?3-/"B\=WMHVV2%F#M5#Q;^
MUAXK\1ZM876H?#S2GMM,T2ULM$LTUK7Y9[?4;/Q8OBVRUR*\@ @@T?3[_P"T
M:78Z-#B"RLHX[1!MB5JP^K81ZWO?5ZW3;U\_S^;/2Q.<Y]@E]6AE,)1J.ZE&
M,7=25U*\5>THV=[]>IWMM^SKK'AWQ3K.CVNGOKKI/J+>#-=T;Q!I=W8ZM;)X
MH3P28M5==53^S+M]6^R"ZM=J-:S.T&T; !?OOV:/BQ/XAUK1SI&APWAT&XDF
MO9?%NF?V%9/+J+^&[C1;WQ SLMCK#ZW):VUKI/F'[9)B,.VXM7B'PS_:3\7Z
M?XCTBWN/#VBPV6GWWB&[W3MJ9ADBU_QKI_CU[96<EBL>L6%K&C,-VP'<<DY^
MF?A)^T7IUSJ&I67Q*'AZ'P>U]XDUJXTR_P!)UG68=8U1_%Z>/(H%;0=5BUS2
MK[3Y<P:7>(BZ7F.,ZFJC>*\?%86+O9_:?S_/I;6_;56/UCA/B7-,QR"=%Y7&
M#BY1Y;PC[T5RR:C*SON[J*?6_?Y*\3Z?<Z%XCM?#NHV$5EK&B6&L:?JUF^W=
M;:G974UM>P2;#M+P7,,L1VY4E?E)%<YINJ6-EKSB606L<EI;;67[OV@Q1[L'
ML#(6QG\J]$\2>*]-^*'Q6 \,>&IK*]\17WBXQ"*\6]U'Q)=^(-:O=7TF&\1&
M=%NK73[F"*X$;LAF#;)& 4MX;XAMGTOQ%J^FZA ]O<Z?/+87-LXQ);7%G)]G
MFMW4?=:*1&C8<X92!7G8C#:;[M>FL5VW]?Q/5PO$'L&LTPVE6A+D<5O%P7+*
M*ZVYHRVT?334]'UCXBR6X,<#[VLB8]_]\N2F[Z9Y]?KBN8^WG60\LW^O,0=?
M3)7/UKS^2$7#M'!G[S3!NN<G=U]OPKM="A;R;?S^A$P_0\],COGWKG6&PF&M
M/J]7:VC>K_7_ (?0ZZ7$.=\08N,<VYE0;]Q7=N1N\4UM?E:337>Y#: K+<*W
M4" 'ZA&HJQ:@">["_=#0A?H$('Z4473U6SU7IT_ RGAHJ<TDK*4DMME)I=.R
M1Y;_ &E#>RV$$/\ CR>_^>M9$_PR.IWT][/JV/M%U]JRMISCDY!'3.0#CO4T
M44%G?P0V_P#J/\D=._UY_*LF;XA:K!*;>$Z?;_93C'V4XZ^A)^OY8K^L,Q_L
MM-/-[WZ6OOT_&WRL?Y&Y=]:_Y@[6>FJ5[?/YWZ7/1M(\*V^D(8O[4U'4+<C[
MMR#@=.G_ .O%?MWXT_:[_9WD_P"#>6+]AZ+QM+-^TI9?M=3_ !?E^'O]A:J6
MA\%0ZIJ;3:L=672/[#50FHJ!EBW4$$ [OYW9O&WB.8'S]4N!SG%IQSVX[<X.
M?_KUGS:Q?3',U]<W)/4_:QD@]B<<C';IZC(KQ<RS'!8O"+"1T4;.+TOHFHW?
M6Z:TOKIVU^IPV'=VWN]7ZWN^RWNM+=?0_>S]N/\ ;?\ V;?C/_P1J_X);?LD
M?#WQU-K_ ,>/V==>^(MS\6_ C:%JED/"UEK8E&DRC6]3T9= U<LI3"Z/-,Y!
M(*KM!;\"B."/8C&,?I@8^F!CT%0>=YIS]GP?7.#Q[\YZYHS-_P ^_P#+_"OE
MU%13MYO\V=Y_29\>OVROV(_C[_P2U_X(X_L6Z]\7=6L]=^!/QAOH?VL=-T;P
MKXGLM<^&_P .=>O;<:UX@TC6M4T9?#FKZO%HDM\]G%HMQKT@D5T>%& 5_O\
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M?P7X^^&^@ZW<6WA;PW\6M'$<WGW>@QJ\D:LESA02FNV2GRE\H^&7P"_X-_\
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M2V^?]&N<X_Q&.X_R?;J##/%_RW^S \8/3GVX'O\ X]!_5&*POUS_ 'RS^7_
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M],=.OXXZ=>IKCX_M@UE=5\G,-M!+!;#D?O)2Q.#[D\=OQKJKH?N&$W3&![C
MSC'/W<_A52:7RH+>[D'RRD1J1_=7@''/;CUK@Q&[^?\ [=_P#Z%=_P"OZL7U
M9YXK;[3_ *3=EE,TW&88FP=OUC'RYSCCC/;S7QM-);:C&L6/-GMI(T_B^7D*
M1G&"1CH<<^_'<3WL-I#<74QPMJGF9ZG:>0>..0 >A QSDUY0=<N-;UV+4;B'
M;:1-@0?\]8U^Z1_O+R>@&<#'%<VW]+[]BLXQF&Q$(X)RDVU%/WGU23MK;>]]
M.FW4V_"EC=:9]KU#4)[>TFFMU6. GYI5,8VLV0.2,,<'C)SZ5T=SJ$^GVTMR
MTBRV]Q$JFUMK7<S?*#UQ@DCG.,=<CL=B]M-$NM(?4[^WVR1QCRU_NI@%1QGH
M@ )_PY\VN]4NKE0MG;?8+9!M63'WD'"MZ988)Y/4YP37 ]WZO\SMG%</X%8?
M^>$9+3^:,6NCULUJOF:>G:G;SVIMX+'7H4>5BYCMU9<LYW!<#[H.0%ZX %7K
ME;?:!!/,"!AEU*P$8' R/[3', '(X'R]<\9K&L]!/EPW*:X;6Y9O*\\#BY-P
M23#@_P!TN5)(YXY[UV&E^%=7^UW:1Z\T1M?(AN5N;4,EU'*%'DC(.Y=K;1GJ
M,'FN?$:)ZZV]/P6W_ .W)*.;XRS66<Z>JE9+FO:2=KZ733Z_/4T_!T<=NVL7
M&J!8L61ABD2^$JM'-'\K(P)#*RMD-QO&&R*TKF[6RL-)9SNBL);B5&!#!H["
MV-TC9SCYA.#D8)_&J2Z.EM+);0K:P16KM]M:W!#^6K$,Q!/RG&1MZ#D \&JU
M]%$FB7RQL;@/;3QVHY)$-S=-Y9(ZYVE:\9[OY_FS]+H0Q> RJ>&<(QE-7:LD
MTWJUHD]&[:;6.6TVT@B\*ZKJDG$NH7=Q)'CJ DC,HZ]P>@_2O,]-U34K:Y:*
MVO+BTBG=G>(=)MY+$@C!PWZ#W%=MXR8Z5IEAHB2;9'A@DD4\;':-2RG/ P<@
MY/7/2O+2T\>7R3Y1*YZ9*G!X]#W_ )5VX974;]E^A^0\4X]X7&95ES?O9956
M*E9VUJ2]J]4T]Y-V?JSJ-9>'R%6<DSR2%@2<DEL$DD]^N??GM77Z$ODV=F2!
MGRGZ< ?)GI^O]:\^T.,ZKJMJDQP&CEFQ[0YQCMT!YZ\<=:]15D6V"D^>TJ*T
M*#&%5QE5R,= 0,?IG KEQ6CEZNWX_P"1[G"D_P"TL;F>;)_PJ6BUZ+S;Z+RU
M,;53,5LR,X,3D8]"5Q_GUS16OX@A6VTWP]'LPS6MY*ZG'R-+<*Q4=>AR.O:B
>N18FR2OLDM^VG<^H=&$O>?*G+WG=*_O+F_E?<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &% 4(# 2(  A$! Q$!_\0
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M\5MI</DQWZ!P)!/*D=OM#S, 8XY/T<^$OB_]B[X/V]O=Z5=:C!XA1-MQXO\
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M.[T_I]OQ*CS:=N_3?_AOEU/GV#X=HS F-B""/E48R!\H.<'OSD8R/7%;MO\
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MJ3TR!T/.,G(!/<9KW;P/HZW'BCQI:%06>^BDR5SQ$LQ 'X$GKCMD=:];7PA
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MMSN^O-%K?7:_;2^IC6A'E7)"%W))Z<K:L^J7E?Y=V>1>(/$_B&+6[R**!3!
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MP:&Y3IG*\YSC/ /;C(Z?0$GU:?X5HI 6# ' (CX [CL>/49/3D XK*N/AHB
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MM=/P_7I$XV=TM5^OZ:GC'A_1!\F%R"1CY0,#C&,]..G(!QT]?8](T8 19C)
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M('7.<X.,=J4EJ#G .2IZ $'&1@\=#D8QP1^%+W6VG;[UY]&^O^0G%IV=UO\
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MXP!Z4C1E><9'.3N4<''4;OX>0#UX..H%2T]NO2^OY_@O,)4URV3=[62E9O\
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MBYX#3X?^#_!\SQ2'R+N^\$^'_'_BGQ3I4+K+)9WQBU:)$ET^.6+[\P!_#G/
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MM:R2M&*[*[UV^<QN85<74YHIT:<8QA2I4Y2M&$;VO*Z<I._-)Z)MNR6EO M
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M;FNU<AX&!Y)C8>I *D 'KDGD^V<>M><Z%)F-/]GMGKTP??N.>F.!VKT*'YD
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MK'L#729  .,=V !_#G'H>GOQ4(E5B3G& W'!Y''(YZ@D=.<<&LAI7)X(P>@
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MFU?TXRP=:"NZV'J2A&I#VWNJ<)IN,W"<:<_9S2=G!RTNXN:3M^ZLOQL^#ER
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MD;0.HXX'7)^'OVEKS4O!VLV?B:?2XY/#/B2TM_#M_K6Z&]BLKJVAGDM])O\
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MB@E/ZQ1IU*4*\V[5)TJ%64Y4:=24'4A3J5YU*<9*C.4YP]I/V_XQ^ KWQ?\
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M>\0>*=2CMX]+^'WAR_U98'55#W6FV$LEI8VUN0/M%S-,D<*0Q*SA6^4945^
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M&-K13E))*3]U**;=OKKXSK$=0^$=[*JLL'Q*BB#*I8K]N\+>)('W $8W,J9
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MQMUO+J\*W^T8RCAXJ$%R3>'Y(OD=Y*52=*I)S=FHMNW*DHI2=_:/@E\5-/\
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MAZY^&NCS^.=#^([^-O&WA_[7X'C%OK6I>*+_ $GP9H?A;R&\06][J9LM.M]
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MKH\%_HUO=R*OR88J"-RJ\:N^?GSQ3'J:ZNZQW,%L8KB1UFVH9(&#D*VX[6+
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M3JWC?60D$/C/Q/ %$DU[,(O"OAFX?9I5D9AY]U^-T_C'PU\;O@=KNM:-XO\
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MTF\$:NLUK;PVTJI]B9!)!&L3A&%^ RAE(4@ $8( HK]&I?B)\/1+(/\ A,/
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MYBU.;XA0K)?M9:'XDL@KL1%#-I=]$"NYR42:XB*G!#>65="-I0J":_6?Q_\
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M:?%35?!4;B_M?$NM0ZQJ5]=:UJ$%R)%TNV\3>)[R.[N3)' '-O<W.]HTBD_
M;]F"XO-=M?B'I%W*][>P^-?V?_&40O2\US]NT;XO:?I%S?!BVYI_L/BV\CFD
MR=RW+=VK/"9EBJ%6G2IU&G#V$9-J]ZMNL;\KM&M*G*Z?Q-IJ6IOBLCR_-Z%5
M8G#0:@JJBTDIPIR4).-.HDIQ7/0IU&E.*;C%.,XJS_K!\&QZU,YLK#Q'IVC"
MS\'Z%<'2;O2H]0FUFVFO=5FD6!%N()HGM7FC1Y_)G0M<QO(\9VL;OB>>/27T
M2VNKNV8S:A<7$BVSM-:@002%5D7EH&\]T!28*4?9M^4BOQ'_ ."DGQ_^(/PM
M\=?!]? >N7/AO49/A_J]VFKZ7<S:?K6F:G;75C:66H:7J=L1+ \<+S%H65X+
M@2LLL?"E.?\ "7_!3_XF?"2W^$]I\=?#@^,&G^,OAMIGBW4?$V;72/%@L]=U
MO6+616M7M(=%\01P0:3'%$[#2;J243&359&59:]S!YQA<-&&$J*I34+J5365
M-.<YR2<;.2NFKN*:6LFKWO\ G_$? V:YG7KYKE[HXCV_+..$35'$VHT:=-N-
M6=J%1R]D^6,JD9W:IW:Y3]NA9W"7AUOPGJ>HZ%JKLS2:EX>OFL)6V\ 7"Q[K
M+4(B 2\&H6UPI)8;6SFLT:[K'B'6(;/Q>9]<VE8S>V4$6AW64Z-/9PDZ)?/M
MW&5K?^S)9'(81L"#7!?!?XN_!3X^>%9?$7P,^(-CJJF&.;7/!%S+);>*/#$T
MZE72^TJ[47R6 )*.\@E6,Y-KJ5W'^\/M.JR:?X=T98KS=#>&/9:6TD+.LDSK
M^[O$?;F6V*E=D@=HSDH>017T%&<*D83IRC*F_?4J<U*$KO6UFONDDU>UKH_-
ML51K82I4H8FC4HXJ%J<Z56E*CB*-EI*::4D]G=<T)I<RE)-,W[:]TG3X38:A
MXITOP]HMU(9(&\4WLME$!;ML@AB/E7-ND.]6EN&$RP$M&K.65@)M6\'Z;#IJ
M>(M'\6^'/$,9D4W<FA>(;'4M/6'EB&-O,S'YN"CQC!!'4X/B&M>';/Q%<W-_
M?ZY+#8PVD-I;I!>V5Q#!#:0B("6$,[VX=U:1TE"99\<$5\]:[X0TMKESI-X(
MI//BM+>[L'>ROKRZFD2*WA_T-X3NDF=%)96CR<Y(!QT3J3YM(0E'9+FUT=EI
MJDNJ7^9C1ITW%/V]6$]Y7IQ<7?=-Z2<K-WD]-^A]93_$+03K$FHZO);R:7X;
M1=.TZ"<D02ZC=P![NX$4;*9#9V;I#&HVC-S("../1= \3^"/&7E&RTO5=1:V
MDRD,5G-IVFM)M 1I9U"RR88G9#$8RV4S*3R/F72/(\ V5II]A;:5X@O--1GO
ME\7:*GBY=9U(R"2^EDCD2VOH(KB<.JRV>IIY$"PJBDJ-W<2?M4Z=!90V,O@/
M4/A]JZJ8Y)=*M;NY\*3JH*>?:L(6O+'<OW8[I7,)("SMP]2W-M:<EEHU>W7J
MKK;\.IM&,4FU>JF[)N4;M=/<;4G=;ZOXMDEK]@QZM?11QQ+I.DJL2+&JM!>N
MRJBA0K.]Z79@  6<EF()8DDFBO@A_CG;2,T@AL) [%P[:RVYPQ+!VS= Y8')
MR <GD9HHY7_S\?W+_P"2)YW_ ,^5]W_VI^RU[;_:M'N$$T=M''87<]S=W!9;
M:QM;6WEFNKVZD4$16UK$CRRRM\H V@AF7/\ +O\ M$_"GQ3\9_C'XN\=31K#
MX6MB=+\*1W,3,]IHL3N(KF9_E5+S5&#ZC=#ED%Q%'D+$E?TO?'CQ##X:\"6W
M@"P)?Q1X_LX;K71%)L;3O![SJ=-TF5@-\<OB:\C%Y>KE6&CV\:,-ET17S+I/
MAO0],M!IQTNWO,#S;N26&%DGGD \U\-$=R=%10/EC55[$U^'X_'\T(X:+:4+
M3J/^^U>,7J]8Q?,[K>23^%G]-8&^#3JJ/[RJDK/2U.]]W>SD_P#R5+:Y_/39
M>+/AWX$\2ZS::[I.GR^(=)L5L_A^NF1:,+G3/$$2V46D[6EA>YCL%3S1.MHT
M-RS%&:3RFFW>:1?LX7NJ7ES<M933/>W=S?2P:1:S/9QSWLSW<T5IY4<D?D1R
MRN(U1V48(4G&:_I63X9?#6XU(7Y^&W@Q=0SO:_D\-Z3)>EFP WVMK0RJQ "Y
M);H!GC [RS\)Z*AC6#1M+AP"FRVL[>,1[>01MB7"C. .!U ZXK/%YJ\7"A"4
M$O80Y4TXVNX0A+EY81:BU!2M*4FI-V=M#2A*.&E4E3C)NJU?FDK63E+ETYKN
M\FVTE>^J;NS^:G2/V0==O3%Y'A7Q%<<+A([&;<Y8G@?Z/N&>O+ 94$XZ#UO2
MOV&?&\CQ?9/ ^L!)"H5)]B,2<84,[@@\9QCOCC'']'>E>&M-@VJ+*WW,JAVC
M^0;<\?NP&4*I8X^48/!( &>^M]+TN&2-5TY)"I55_<K$J Q\G>5#,<'G:X_#
MI7G>TAKLT]=;V_![K]>^W0\96?V(QM;:4KOR=HM:_+;IL?A'X(_8V^*UI]G0
M^$DC3"!%N-3L4W $8#<G)(5@0>@)()8U[YIW[)WQ1TAFGMO!%G*\UM-&LEOJ
M5J\\<LL;('3(*EXI&5@25*E"0W.3^QMM'$) L5I @M84D601J4)!RP"JI*L
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MT 1?&?&$ESXG,6F321W3JF9X;2UBT_3[*V+;Y(!#:J%596P#&9)I[@A6ED4
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M"->1)FP[1ZKX=TN]*N\3.K2I),RR%<H90RYQU_E2_P""4M[JGP%_:4O?#_Q
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ML F]8R2@R7+</@#GOQS][%3;^K/S_4>O;NOUZOR_X>UBC;:8F<*C(R!=_ )
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M,BS*5!UI5<-B:KIU:-2=HSE*=54VV]I1DX0IS:NHRE"3<-(?H5\&/#MGK[_
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M#]JM)D"N0Q>"6,AESP 6W(QKY\^,WQB\"_ ?P%KWQ*\?ZQ9Z+H>@6DKQ1RW
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MY1=89[D?.+4/YJ*Q+[6P*\^\(:'JTZL;O5KM;.":=%:S@E@=+?S9,Q'5K_\
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M17PGY41_$O38XTCMO$=^+:-%2W$/A35981 JA8A#(8E,D7EA?+<JI=,,5!.
M5^OVF?LU_LLV^FZ?!<^!_$E[<P6-I#<7EUX\GL[F[GC@C26YN+.U7[+:3SR*
MTLUM;?Z/!([10_NT6BI_XB9GW2.4I=%[','9=%?ZTKV6E[*]KV5['/\ \0_R
MQZ\N/UU_WS"+\/JCMZ=-NA^D^@O,94C:)G1 IWEU"L9=I5BQ*X+!I J;R=RX
M("X8^O:>TIC5%:..1(]J&:=224)&0%"[?XF?AP=Q!+ MGQG0I#!Y'V@%XU,:
M[07823"-?+?<ORD+(1(['^$$,<;@/5=,=A"9FD;RF"OP&,D !)$9YR5?< @\
ML;<9W.LAQ^ QCI;RVV_/RT/TM>=[_=_5D^__  /4-($_F898B("#E)"KR$*6
M.4"+G#,R_<P>Y4E<>L:4A A9E R%. F-PV8\D'(!1" -[9*CH&* UXOH=T2Z
MI 4>3;F7=RP9AEMY!9@=R!BB%2IRV-I4#T_2;M0+97=V"K(H5I-R[MR=509^
M02! -NWY2H9CNK2$7?;M_7W?\$&UI?;3^M/Z^\]CTIV4+\@*!2IC)CQ(Q^\\
MK<Y\H<QX4NQ8!2/FQW5HRB14@&V(KYCNQ"NK.%&V,L2?+P64YY V+@XPOF>E
M3*SR!9#)Y \Q!\F?+=>'!R%+-)PK'>H &_D5W.GS6X6*21G=3$?-5'\N1'?:
M A50VXH.& YWJS#"C%=-JC22YK-K9I-+:]WTZJW;7S$WM9^7EW>M].^FS3TO
M<[NU5VE82E)51U\L$E6BSM;;OVA"205Y R 0W. =%WM_/56AW%&1W144J9!)
ME51_E(8 $;\@':59.YY.)UC3=YLQB+JVUB&4(P&TL5'FDO\ *%VXP!EB213Q
MJ&Q9!L:X D2)B$QY8.&W9"8F9&;:QPK;B0R@*HK:\807-+_P+J[=>N_K;K<W
MBHQA;35W:>N]]$U9I]FWIK?5'83W%K*H1OE(*&,$,"74$*96&&7/";B0K*X*
MY;@4':-Y)8XYY&,?EP2C ,C  %EB:0;!&6R!(O &1C/W>7N;_N_G)O54#EXT
M545P'=P=C"3:Q*$%2=Y;;E2HB-W;^64\QWG>0;&8;D$<S-(SF1F+(D:!@TI
M8L2O&!7%4J**:3C=MWMM[V_K;?\ X8TBEK[KYFGJM-(Z)J^]K+^5M:W.W5E0
M,BRM(T@C:)&5#*$ 7DKP5._LI(*G.!M->>?%#6I]"^'GCWQ#;:!I7B:X\.>
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MX67UB6%EB,OCA*E5N2CBIX>K4J4:4K2YZM2/-AY4^:"7/.W/:5YS_GWQ/R'
MY=5H8JE&M3I8]8B"IVE.@JM*G&=5WM&$7*-93Y)/W8N3BN5-1_17P!XP%]<0
M:?:36LT\X*06INXX9'VQ[I7A25E)V*"\AP0B DCYB:]@?Q#"B+'))&9/GB8(
M/,#.F\%!(K.,)\R!ARR  $@D'\H?!UG\0+TBYUW5]%\-:(B1M+I&G0:JLFL[
M769;*ZN+J4ZAJ[Y"JEBMRM@[@-+ _)7ZKTKQ@]Y<QZ-$#!)#92R)''Y4*0&*
MW\U(V0.40! 2R*6PPV%@#S_2\\WI5;J5*4+TK)S2BY-Q:E[E^:,59ZSY7+=*
MRN?B^!R^=-7552C[1M*,E)1C=./O)<LF]+\K:CLG<_=_P7\=?!'@O]FWP?XZ
M^)/BRR\.:3H/AV[T[4M9U)O/#CP[?WMB?LEO'F\NI(+*WM=T5K$3;V[(9I%5
MES_*E_P4A_;IUW]HWXM2R^#[AC\'-,\-+X8T#0I6-Q'<7%IK-_J$GBF]MR3%
M#KFIF:VF8P!5L;>&RTQY9FLY)7K_ +<GC+QKI?B'X81Z/XHU2&&Q\.^+!8:$
M]UOT=M(UF_TNXOT&E3%K2::]NRT=Z)HI!=Q6MLH4-;(S_F'J5SK$L\MS;Z9%
M'-.6WPPVS6MN9'P6'EJ?*C"GYB$C4 $A0"17\KX3@/*>&,]SC.J+Q.)S;%9C
MF57#RA2BL+@,%CL14KJA@Z4(SO7<*TZ6)J5K.46HT%3IM\W[WBN*,?GN!R_*
M9QPM'+J&#P<*\*E:2KXO$X:E"DZE>I*4%"BI4XU*,:2DE).59SDDE%:E+F9I
M%DG3S&>9Q-$P>,L2S&)U( (;.WYB%# ?-V_:C_@EE;+)HWQY2S9+F1M*ABD"
MNLLB";PSK: G:<)C!=TXR,MC=G/X?KHVL:A(R:SJ/V. /\UI:/Y;2\DE&(((
M+#IECCC()SG]TO\ @CKI-A WQOTNUAD6&YT6.1W,FYY'C\+>(V,KN2"FP(H8
M=< D## UGQ92K5>&<?S484XNM@7S59)56WC::=Z492Y(ZWDYS3WLD:Y'"C'.
M\+RXF5:I['&+V>'C*=&,5AI-N6(G&FJDE%6@J=-INW-*Z3?YO?"_P/\ $S]H
M+Q_HGPU\'Z7)%J/B?Q$?#/A_0].\\O>W;W4BR7&HW&/DL+.VAFOM3NF6*TL;
M"VN;@HWE,S?V=_ W]G'P;^RG^S)=?"?PDEM+-8^#?%.K>,?$D<,<5YXM\8W?
MA:\_MC7KLE6N&MP8OL&BV<C;;'2+6SB.)FN'?XZ_X);_ +'I^!'@_4OC?\0]
M,AA^*7Q/2ZD\+V&H6\,=[X"^&NIRRS6<0MY5,]GXA\8E8+S6IB([BTT4:;I1
M*//J4,GV]^U/\7](^"7P"^,GQ1U^RO-5T3P/\,_$NM7VG:48([V:T^PG2I5M
M5G=('G4WQD1'8 [<LZ%\U^0^)_&RSW'4N&<HQ$JV2Y94IQQV(C*\<US2"HQE
MRS5HSPF!DYTJ*^">)5:O%24:,W^A<%\-?V;AIYSC</&CF..YY8;#\MGE^!FZ
MDE"4&N:.)Q5HU:TOCC2E3H.S]I$\B_8WL;31_"T<6^6../X"?L]-!&L1=HE7
MP]K+I<&0 H_FNP< C<I1TR&->T>#]$DNKOQUX7M7L].T[P[J9\167B+6+ZUT
M7POH_@[QS/=Z@DNIZKJ$\<$%II'B.U\3Z<\4"SW8AA2&WMG91'7XF?LU_P#!
M36X\<?'GX0_!S]D;X=6OQ&OO%WPT\'^&/&=Y\;O"_B+0M"\&GP#X,U<)XFM&
MT/5KJQO=.TN\3%U9Z]:R:;J33V]M'-#<R0>;^C?Q!^$&N^)=7T/XA_M->/+W
MXQ1RZMIVGZ[X9ME/A3X7Z!H4MS<V^B6FF^'=+$"W&@Z/KVH0SW^G7T36<]M<
MS3S6S&.24_&8^A@_K=>KB*ZM5:=/"T+NO-\L&G*5^2FFU."=KOFY4KZGU-.I
M5G1IT:=*2ERMRJS25))2DK/>4VT]DU;ENVEH>G>)_B7X5^,?@^#X)_#*XS\%
MM(U*ZO?C+X_L?M L/CQX[TV]V:+X)\,WR()K_P"&>AW5M:ZIXFN8-UKJXM=-
M\,*\T4OB M^8?QD/Q(T[]M#X6:7?:2!\/[WX:>)YTU]+6<VY\4V&MZ>\U@)_
MFM+7[3I=[!,EFQCD=;21H_-BA(C_ %MNGT^PAT[1K73(M+TO3H;>RLK'3XK2
MSLM,MEXMK*PL[-(H;:WMX@@184B5&;9M/.?FG]H"U#6?@ZYA0I<#QS8PH7,@
M8P#0O$+2R[G1%P2RQ[ &(8$L "*QPF:U88IRHQC0I5<-7P,:<$TJ>%Q%"=.K
M#WDVW-0ASRW=K-QW?/7P-%0ITZMZLJ<J=:,VD_W].I&<*GN/22E)M1:LK;M:
M'\NO[>?Q4TC2_P!H'Q_X7V3P7RV&CR7[NUNEGJ5DRSRV]I&\LN5:-0Q:%=D4
MY<*P<*%KP/X/P:]KNH>!?&=S9V5AX:B^)'AS2M$L+.X9KKQ=J\6K:4+^VGEB
M$;QZ+H*7<5S?O:.D]_?O;Z-;3HHOS#_0+K/[%GP#^/\ H@\:^/OAUH_B#Q1J
M6K^*+&[U[==6VKW2:5KEWI^G1W5_82V\\=M;6J;+5V9A <*?+7+5L?LX_P#!
M,?X1:%\41\5=&/BB#PS\!O _B";2?"-_?1:AH%QXBO-.U73O#MW<F>#[7?W-
MCJNHWOB%Y9;B9IM0L+:64Y@6.OKL/QEF%;#1R64YPPM'#PP$88:"C*=*$$DJ
MLUS2]D[RE5:=-U-I*2;3\N?#N I5IYK3A&>+E7EBYSQ#E4C"I)W;I0;C",]E
M3;C4Y&[III6WOB'^T!X2_9>^&O[3/Q+\0WM_#;-\//A+\-M+@TZ!+J]EO_&O
MB/7M.EEBA66)I/[/TJ*^U.9(V$B6MI.\*.Z(C?E7\2OAEH.N>#6MO#FHI_8_
MC9=-UJ2]M-[Q3:)96_VS0[&$F+$EM<75TFI2PRKB0P6&Z,F$ ?47[6O[+_B'
M]ISQK-X-C\:2^%? 7A6YT35?$NCVFG&\F\0:RVG7]EHEUYGG1A!I>GR:TGSP
MW!0ZE)+'$LO-=AX3^$?]F> M TFWF2?3;2PAL=*-Q&I*:?I48TVW82",N 8K
M196211))([-PG3X_-,3&%27)*HJM)NGUY;5)RJ/ELFE)1M?R=CW\OI15%.:C
M%5%SZ7TM&,(7M:R5GU>ZO9L_G;^(G[/6L^'KV]N]%*W=K&\I>VD58TFV#<Y7
M:H6"0<H2BF!V&&53DC]+_P#@EA=^,+3P9^U1K&MV6N2^'O!W@?3]/>]O+>22
M+P\?(U6^O(;B_E4>78@_V<(HO->));JU\L*EPF[Z7\4? Z]UC4+.QTG1#?ZK
MJMY#IFEV5E"9+O4=3U*1+:PL[1$!)FO;F:&"(,_EF61][*58C]#?VS_!>E_L
M#?\ !/Y_V$_AUI>BW/[1/[4?AW2OB#^T=XZT]([C4_!OA>ZU*UN--\.:?,Y9
M;3_A(KK3+&PT_P U8I7T'P];:D<+K+,OHY;C'6H2E7DG2H\KE.=N:$W[MH2:
MNG*+;<8MWV2UN<U>E)UG2DHQYDY1G3;:=-2NE45TKN24>9Z+5NZB?S8>"(-'
M\7ZE?^)_#>JRRW#:O=W\UQ8L]CJ>F3S7DTL;2;6$]M_K,QR$".8'Y'=20/I>
M;P1+XJTL-!?6^D^*X5)2]N(W_LC6I-I91J\-LKOIMTS$?\3*R@D@D9P]Q9$G
MSQ^8^I>%OB'\%]=75H)KNQ-@_DPZ]8Q31P%2Y"66LV;AHU23;^\AN5ELIU*F
M*0,R8^UO@]^T_H7BV2T\/^,$M?#'B.01VT%T"(O#^LRLZJIM[F60_P!EWDQ(
M*V=TYAE8;+:Y)*Q#;%X>NJ+KX.K]=PD5=PFOWM%;\M2%^:R6BJ15TK73W-J%
M6E[3V=6G&A5^RXZ4ZJT5XR^%WWY6WK?52L>;^,;CQ/X0U^31/%L-SI.K+&+F
M.VFB,EI=VK$8OM.O5W6M_9OM!CN;266+'R,8Y R"'1/'<<5]!'*XYF4-A2I*
MCD_[) R3R1VSD'%?IBMOX"\6V^F^%OB3X<LO%GA6[U&S5]/O9IK:\MWN9T6:
MZT#6K7_B8Z%J,B*X6^LI=F6_TJVO(P8&_,;7=)\%:9KNMS>&- DM]*AUK51H
M]KK6M7^NSV6G1:A.+*VFNP=.74);6W6&.2Z>R@%VR-*UO%YAC'FT:N#J1YJL
M:U-IOFAR\W->Z7+.T=+IK6*DO.]S;$5*M-/D5.SLHRFY+J[WC%-Z*S71M]KG
MDGQFUD:WXN:ZW#R;>SA@7)4$@%VZC@;BPP!Z8 S7F>FV>HWTR1Z;I^H7SLV4
M-A97=VX9.00UK'(P*XY*\C/'>O=-1\0RQR-+;6FDVLC'#26FAZ5%(6'K-):3
M3D#G&96P3V[7=*\5ZS>J8[G4=28!AA%NIXT*GN(HY%B8@ #.P<'H,'/T=+BF
MC@L+2H8?!5)JC3C33G5C!-*^MHPG*SYM;N^^A\W7RWZQ7JU:M;6K4E-\E.]N
M:UM9RM?W5;3U[GU5^S'\0_B[I5K=Z-XYU::7PQ;K!'HEIXZDM-/>U<\[H-8U
MFZL]0CM(4"(D+R2K$3NCV8V-^@G@[QSI?B:UU*2WO;6ZGL%/VNR-]::H(GM2
MWG1V^H6$MQ;7MI(\86WNDFFMYH7#LZLS*GX=ZWK45MYL]Q&X7G#^6TTLC.V
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M/K?H?*<2U'.IA80NU!3DW%7M)R25M.D8ROH_F; ^(E^ !=^'/ NH76!]IO\
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MH.@>-;K[!"MCJ%G<744[7-M'%#<V=G,WV8W]C9"Y?\>[>VW3[6C99+>55E4
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MTQ\/-8B\(>)_B-?W/VOX9^"-1\-^&]$:3Q;\*-&UJPL%TC4==M9EO]4\8Z]
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M ,3^0)!Y@A\W=Y0?YPFW=\V:*]GN_A[I;75RS6VQFN)BR!H"$8R,2H)Y(4Y
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M%'@3H\C);^5=(Y8-=+%;;SL\S?,<@""1(XR7:2,5)*;M)*SUY4WOYMMOS?\
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MX$?=7A^XAE9I9@5N9F5HDGD:*WM@BB'9&8HI%B-PQBE,EP3/*7($(*QN/6K
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M!^4@@$%%'LZ>GN0TV]U:7WMV#V-)7M2IJ^_N1UZZZ=]1LG_!*#]@&6&:"3X
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5/O<FBBBCZOA_^?%'_P %P_R*/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $C .T# 2(  A$! Q$!_\0
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MTM%  #GU'UZT444 %)GD<'D9Z=/K[TM% "9Z<'DXZ?S]J,]>#P<=/Y>U+10
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MOQ-O94O^?=-_]N1?_MK/(5_8#_8O3[O[-GPJQZ'PY"PX]FD/_P!?O3Q^P/\
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MW9]=#$M_VG/^"@=OG=IWP=N,D$M'K?C& @<$JN)6"G.><CGGG JY_P -;_\
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MP3;49-)O=I6M?SU/6CI.J=?^$9U7D9/_ !+)<].G /;_ #TRS^QM2Y+^&]6
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M&R78 >(?' ;!(R#\.?%F,X/."!]#SSBOQ'^'SD_$CX?@D$#QMX7/IS_;%H,
MC'.1[^F*_;GQ"^WXI?!XEASXA\9J00,9;X=^+2<X&<_+T]L5RQL\9AT[W=+%
M;=WAJO\ 6O0UKI0H2E=\KJ8:4>LM:]!).W5MK;ON<_XR_9G_ &;_ !OXKUKQ
MKXS^%'A75?&_B+6O"NO^(/%L3ZOI?B35]8\$>&-3\$^%[C4=9T/5=-OYX-,\
M&:WJWA:33//&E:KH.H7&G:S8ZC;LJ+P^K_L0_L9^(;G4;G5/@-X+EFU6WMH=
M0GMKSQ9IDUQ+91V5OI^I(=*\160L]?TNQL+?2=+\3V2V_B/3M$-YH=EJL&CZ
MEJ5C=_2?C+XL:3\,+7P79:AH\=X?%@O+.RU"XU*VTRP36S=6=OIUC?7#V]VU
MG!>2WCW5]K-[#;Z5I&DZ;J%U-<SW26>FWG2>&?BYX'\26OA(I+';ZAXNO]5T
M6RL4"W\,.NZ):&_U'2Y]3LT>Q5I; '4]'GE>%=;TF6UU"Q1HKF)3@ZBO948^
MZVE+G=Y6;5VN7R?73NSIE"3;M-I.VEE;1Z_>>9_"WX3_  ?^"VFZQHOPF\(Z
M9X+TWQ)JMMK>N6NGSZK=MJFIV>BZ;X;L+BZN]9U'4[LQ:;X?T;2=#TNS6X2R
MTW2]/M;*R@@@CVGTV6:VB^^Z*6R4&,@KG&X8!XSQGIGBO5S;6Y!!AB((P044
M@@^Q%>#Z_P"/6^'/A9M<A\*:MXRNKOQA'H*Z3H<,UQJGV:2WN;R>>UM[>RO7
MG:TM;2X:*V9+>":9HDN+VR@+W45JIS0E)PBG#E23E=-2;3OI=6MIO>YFZ*<D
MN:6JD[M7ZJW;N:7VR'.#(HY .&! Z?[()[]/0XK(\2Z-X=\7Z+<Z!KWVN73K
MMH)'_L_4]1T:_AFMW$D4]CJFE7%GJ-E,OSQ-);7$9DMY9[>7=#/(C2>%_P!H
M'X=ZUX8O_%&N7FF^&+33K_3K2X,UY%J]OY>LZ?8:EI4\5[IEL\<K&'4%T[5H
MD0C1O$%AJVCW,SM8"YFZOP;\7_AC\0->UGPSX1\1V.JZ_H"/-J>FK:7UG<16
MT=Q]D>[A^V6=LMW:)=YM7N+9I8TN T+E9 RC-5>75481:MJI.^C[\O3<J="-
M1WFV]+66S]4[H\?^*C0I9?#.*UVQP0_%;P3:Q1I]Q+:#3M;@@A49)"1QQ)&H
M)SM4;LGFH!X%\%_$KP9X@\)?$'P_IGBSPK-\21KUSX?UF$W>D7^I>$O$&A>*
M-!;5=/++:ZK966OZ5IVH/I6I1W>E:@UI'#J-G=VY>%KGQL;RM4\'11A4C7XP
M^"2JJH"AI-.UEWP , L6+'W.:Z?X9XD>[C<*RMX]\1 J5R"JQ0/@@C'RR+NS
MCC [4LSO*&!:M&4Z<FK=+SBU=K6ZYE=[_KM@;*&9*-FH?5XV:T24HIJU]^W;
M?H?.R?L1_LB1:/H.@6?PFTS2](\+:_XA\4^'-/T7Q+XTT>#0_$/BG6_#GB+6
M=1TL:9XBMQ9NVJ>%- ?3+>$K:Z#9V1TS0X=/TVYN;66";]AG]C^7Q?X:\>GX
M/:4?%W@Y_#<WAC5AK_B]AHT_@^WTNT\,W%K8/KS::9]'L]&TVTMYY;22:2VM
M_)N7G1W!]T\'_M*:'XG\41^';OPTGA^$>(;SPI=W=YKNGWD]IK\<^LQ:="+*
MRLY(+S2[LZ.NGWFNV.IW&FZ=XAUC1-"CEOY[V2>W]X\(>*M \;Z0=<T R2V
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MP0:_$OP%+N\=_&%3D!M9F8 YZC6M2SP>.I(XR<=:_:[PGS^S%\",$$_V1JP
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M87=K.8VEBNK%7=/NL&GA=6&0"H(/0\C!Y(Q5CPO!)<V%C:V[HDDUQ>G<X+!
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MHRUE.I>[^TD[7TO:.MOZL-5IMI-)*SNUT?17N_R/V@D_;B_9YB#%==\27"Y
M'E>$=5QW! W^7@DD<8QR">U49/V[_@!&2([GQG<<9Q'X0N%( /0-+?1C&.G
MSU/'3\;A9R$Y6-R< ?=X]B?K@ 'D]N:5M/N<G$(!QR-K;N>@X7Z >IXYJY8&
M@W>3FWYU&O\ TE(%4FU\<4_\%[:[[_\  /V%;]OCX' _N['QU*O//_"-PQDX
M&>!)J0X/KG'\ZHS?\% _@W'Q%X>^($YQD?\ $KTF$<>TNKCC..O09'6OR(73
MKK .U^ < !CR<'!!&>W/X^E/73YB261M^.X(P"3P,C(QSD_A26!PRDFN:^NG
MM)/\-=+ ZD[:3BW:WP7OY[].RT/UD/\ P4&^%JD>7X+\?R9'):/0H\>N =3;
M)S@8..N<U3E_X*&^ 5SY7P[\:28.!YE]H<61V)*S38R.PW8/!/>ORK6PE7.U
M>QR03^'7H?2G+870;<(93@8.T;@<X[=SD]/\*I8'#1D^7FDVDOCE^B'&=1?%
M);.ZY%IV;U/T\E_X*)>%O,/D_"SQ,X(X,OB+28QTZX6Q?\MV?0]*S9_^"A^E
MN08/A-J^03AI?%5BN!GCY4TI^>QYP/>OSCBTC4)6RMA=L<#)6WE)&<8Z(P _
M'.:MKX:UYP FC:J_S<%+"Y(..<#]T,\^G;WI_5,.OLVOO><KW^_]$-RJ/::7
M>T$_U?0_0IO^"AX;'D_"&8$9_P!;XPCQ@ G=B+1CWQQWSU':HW_!0Z_9B(OA
M+9H<#F;Q==$$XYRL>CY7GH,Y'I7P7%X(\52I^Z\-:^_/)CTF_/RG)P"MN1DG
MID#MR*U[?X=>.)0!'X0\32$#/RZ)J+9'J +;GU/3 YY[MT</"*C&$;;+WI.S
M^]W]']Y$JDX_;;3TMR+33>Z77YGV;+_P4$\5-S!\,/#L?)QYGB757R.G\&GQ
MG/J3@]?I5-_V_/'[C]U\/?!T?O-J>N3#U'"O#G'<]".PZU\EK\*/B1*28_ ?
MBQUXP1X?U+OZ?Z-CV]<]CS6I;?!OXGRA=G@'Q8IW9_>:+>QYY'_/6)1Q]<GT
MJ?985Z2ITM/YFM_E)._],495&VG*=GMIMII;W;V^_P ['TK)^W9\3WV&+P9X
M&C!!+@MKLNT^W_$PC.!]"/IGFBW[=7Q8.X#P[X&C/(798ZL_)R.KZINST[X_
M6O$%^!WQ<DSY?@#Q*<C!+6B1CIT!DF3J<=,Y'(/&0]/V?_BVS MX#UH9)!+O
MI\94_22\0X&>22!GIGO7LL*MX4;^EG;YLI.=_P"))V6B47?3R2U3\]#UZ3]N
M'XPR E-+\$QCGA=(U!\X/?S-4;!_+W'I5;]M3XW2*[0'P;;C&5'_  CKR%2.
MX+ZBP/4<,K GMBO-/^&?/BMCYO"DUN"" +K5=#MST/7S-149SUR>QSU%2+^S
MW\3P%\S1;",' /F>)O#$>?0'=JP(SC/3Z=*7LL'?6%&[[VO^+_R*4JO*WS2;
MV2L]-KKE:MI\['$^.OB!XS^)>N_\)%XXU=M7U-;:.RMV6&&UL[.SC+R1VEA9
M6ZI!;6XD>24@ R2R.\DKNYS57PAX3O\ Q)XV\'7<-L[V?AN]N=9N95!.;AK1
M[/3H  #EIIIWV@C)V9'2O8--_9Y\0(#-XHUWPEX8TRW0S7=Q=^(M/U">*&,9
M=H;/2I[N2=U4_<:2!&) ,J#+#[M_9E^ 6FZOJ^E^)K"QU&#X=Z#<0WMKJ>LV
MQMKWQ[K%L T-Q;V[#"Z%;7"^:9TWV\WEQVEM+<[KJ9*E5IPBXT^5\JTM\*NF
MMU=7[+KY;DRASM*<6G)[/=IK>VW*MW>R]7H?HOX*TN71/!_A?2)UV3Z=H&E6
MEPG]RXALH4G3_@,H=>O:NGI,CH2,]^?_ -7\A2UP/77N=*5DEV27W*Q^1?\
MP79(7_@E1^ULQ)&/#_@$Y[$_\+6\"8!XZ$X!/;(/%?YS :6X^ NMED&P?$V
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M/S/^%'/7 SZY_P#L: %HI.?0?F?\*.?0?F?\* %HI.?0?G_]C1SZ#\S_ (4
M+12?-Z#\S_A1SZ#\S_A0 M%)SZ#\S_A1\WH/S/\ A0 M%)SZ#\S_ (4?-Z#\
MS_A0 M%)SZ#\_P#[&CGT'YG_  H 6BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $0 &X# 2(  A$! Q$!_\0
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M451OM1M=.C,MU(L:!2Y).6V+]]@H!8K&.7;&U<C<5!!H NY'Y<D=QGIQUHW
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M_P ^E40,?F3^9S6G>+L2!?[MO$H]E$,1Q_WTS')Y.>?09E>36UJU'U]I4_\
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M4OVMO'K?$Y/C+JNA:6;30M-U[P*NG+ )-!TQK:.Z@T;7+-VNHI]0E#^;'/#
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M /H/08'Y#CZ<4M%%=I\V%%%% !1110 4A_0\'\>/YD4M(3C_ #Z<G],_EZT
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4]N63?7JD?3U%%%=!Y(4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %" :$# 2(  A$! Q$!_\0
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MFOJR]FE=Q_MI_N]5)[M6GI=2BD[-GVE1117AGU84444 %%%% !1110 4444
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M),,HRS*K5E)+F<YRG&ZW:]I*4M7=ZMVNUZ6****\H^E>WR_0^>?@-][XT?\
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M)?8?VB/^@Y\%_P#PEO&G_P U5'V']HC_ *#GP7_\);QI_P#-51[.'\\/Q_\
MD?)?<NR"[[O[SVS8OI^I_P :-B^GKW/?KW[]_6O$_L/[1'_0<^"__A+>-/\
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MA][_ ,A7_K^D>V;%]/U/^-(54 D#D D<G_&O%/L/[1'_ $'/@O\ ^$MXT_\
MFJH-C^T1@_\ $\^"_P"'A;QIG\/^*JH5.%U[T-U^?^$&W9ZO9]7V9C_ ;[WQ
MH_[. ^('\M"KZ% P,9S[_C7PW\#[3X^9^+_V+6_@^3_PO?QZ;K[5X;\9\G9H
MAP,>)<D[<X)QR00<]/=OL/[1'_0<^"_! _Y%;QIWQC_F:OSJL125[.4=+:7?
MD]K>??JO,,/LT>V[5/;]3_C1M4=OU/\ C7B8L?VB" ?[<^"_/_4K>-/_ )JJ
M#8_M$8/_ !//@N./^A6\:?\ S55/LX?SP7Z?^2]!MN[U;U>E_/;]#T75M T'
M7C8/K6C:;J_]E7JZOI3:C9PWYL-1C7]UJ.G>8LC)(GF$!HMCC<-I7(!YKQ-\
M+OASXSN8K_Q;X#\&^*[ZW@^RVL_B/POHNO7D=B6!,*RZU;R.B,Q)90P4DG()
M=JYH6?[0V3_Q/?@T<=?^*6\:?_-4*D^P?M$$?\ASX,<]/^*6\:9&<?\ 4U=O
M?)^M4GBL.E;,FDN9)*<THJ;3DDERV4FES)64FDVFTFLJV%P>*;>*RV$I-QE*
M3A3DY."M!R?*Y-QVC*3;BM(M([C3_"'A;2'6?2?#VAZ=<+I-AH_VG3--T[3V
M&CZ4Q.DZ2#'"S+I, >1+>V5C%"N%B5 %V1P^#/!L%IH]E'X5\/)9>&KI=4T"
MV72-+2QT34(Q(\>IZ)$J.FCNK23%9;<12J&81MC>7XDV7[1 ./[<^#/_ (2W
MC3_YJO?]1CM@%E^T0?\ F.?!GG_J5O&G?'_4U>_Z\=L/GQ;_ .9G+6U_WDW=
M<KC9O=I1E**N](RE%>[*46+"X%-/^S:5UL^2DGNI;\M_B2>_Q)2^)*2[#5/
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MW'E:_4,5KIMOI'?7SOTZI.S3M9W9]>PW?\7_ )GZ:\^W^?\ )_R>$Y]!^?\
M];Z_Y/'P5HW_  40_9@U>YU\0^*O%5GI6E>$?BAX\TCQ5JGPV^(VD>"?B!X8
M^"$:M\5=6^%7CG6O#T7AKXK)X1_=M/\ \(C<7DI0*(@X8,OH_P "OVN/@_\
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M+US\2-6LO OQ2^&MK=W'AO4E\5^+=/\ B=\3_#_Q#7Q3\4?&7B7Q/XON-?\
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M/PZUI/"_A)+2/P3 X,\MVI=I=WV7\*OV:X?AU\7D^*7_  EU[K,T?[.GPN^
M#:3)I4=@C_\ "L=<\2ZS)XL)1W!?Q%)KN)(@2B!$2.1^J_6H*]N/P(^O;V_3
MVI>#_GT__5^E8U\=B\1JUOO[L8I^MK:N[;;ZZZ;+?ZMAE;W8W6WO(6BBBLCH
MNNZ^]?YA1110,\:_X1#XP?\ 17M._P##9Z5_\T='_"(?&#_HKVG?^&STK_YH
MZ]EHJ_;/^Y]R.;V"[_C_ , \:_X1#XP?]%>T[_PV>E?_ #1T?\(A\8/^BO:=
M_P"&STK_ .:.O9:,CU%'MG_<^Y#^K_U_2/&O^$0^,'_17M._\-GI7_S1T?\
M"(?&#_HKVG?^&STK_P":.O9:*/;/^Y]R%[!=_P ?^ >-_P#"(_&'_HK^G_\
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M #1U[+11[9_W/N0O8+O^/_ /&O\ A$/C!_T5[3O_  V>E?\ S1T?\(A\8/\
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M[GW(/8+O^/\ P#QK_A$/C!_T5[3O_#9Z5_\ -'1_PB'Q@_Z*]IW_ (;/2O\
MYHZ]EHH]L_[GW(?L%W_'_@'FG_"/_$3_ **-!_X26E?_ !5%>ET4N;RC]R-N
M6/9?U\Q"!C!Z>Y/\Z\8^(7CK4_"_BWX5:'9"V%EXP\1^)K#6&N1RNG:)X+\0
M>(=T9[-G1QD]\\Y&<^SY!&>H^A_E7 >)O!FB>)]7\,:OJ7G+>^%+_4;O1W@N
M&7]YK&C3Z'<LX 4D&#52$)/RR!6.5; K!?5EB;XI/[7-HV_@=K+1/WK=5T\S
MAS#ZT\-)8-KF:5M?/37^NMSYRT#]IZX\1Z'I.LVGPL\::0_CGX>>(?'OPV37
MK[P?#)XL71M!M]<&DR"#Q%*?#TQBU>/8/$PLX0KR.2H4FN^^%_QMN_&VF?#"
M/Q%X2N?"WB3X@?#C_A8!L(K[3=0LM/L430"T;3Q2EV9CKT(55C!0 JPD)!3I
M[#X,^";"P^'VFPQ7SV'PT\/W_A7P[9SW9E"Z7J.@P>'I8]4.Q3<,-%A"*7\I
ME,F\ /M0\I!^SMX7LM)\&Z;8>*?'MA/X L[_ $;PWKEKXD9/$%CX<U=M$6?P
MH]VMLWFZ(8_#^@((64E%LT(D4,Q7V:M;)*]XJ/)K*S?M)VTJ1IR^)MM6IRJ1
MUYFWR6:9X-"AQ1AU=RC)-+1N*[-IZ>;46DK=6[H\LTW]I;Q5XA^(VGZ=X,\"
M>)/%?A_6?A9?^*+;P_$OA'2-1T[5M)^)>L^"]6U'4]<UWQ);1^8(]-A2+P_#
MYKAL[Y#+&Z1=-KW[5/AC1M&\,>*?[$O+CPGX@@M;^[U&YU_PEI^H:.%UPZ#J
MAF\)ZUKL/B35SX;UE8UNQX:M;M5D.RW:7R4:77L_V6? &AQ^&)?#6L>./"VH
M>$O"7_"!Z/K&A^+M534/^$8&KC7!IFL.7F_ME?[:+2'S09 ',>]5R:J:O^RO
M\,-2MY-(MVU[2-'NO#6D^&M=TW2M4GB;7--T$JNBIJFKLK^(IB&65+C_ $Q#
MXB.TW/FA6+=L:W#+Q%I<ZA:R2A4<VE[2ZF_:)7:=/DE!-J49\\97BUPNCQI]
M6T<7*[;O*.UU;E5K][I[II)K4I+\<_$UZOCY=5\(ZEX-T[PC\8_!'PVT/7].
MU3POXB?Q'%KOC#PWH"RMH[>8^AX;Q#"C_:%:11*)4(>(QOMZ?^T3:7KZ=J$O
M@WQ/:>"_$.KZKX>\.^.YK[0?[+UC5-#;6@?+T0ZTGB32EUH:)JR6<]Q8*[".
MW,ZQF4D=;<_ [PG>:SXBU:XO==:#Q'XC\+^+]4T,ZH_]@GQ+X)U?0-;T75UB
M\L-$[3>'-$\U%9E*0$E<@&/,L?V>? EGJL%TEWXG;1[;5?$>MZ7X-N=<9_!N
MBZ[X@;7O[7U;2=%58O)D=]>UTJK-)&!K<KB-?F$7+[;(VXW4K7BY)1FK+EBI
M17O?'SIN+;=-QO=<[.[V'%*3M*&VEY1>MW:]UM:U[6E?RVROAK^T$GQ$U+P7
M#=> /&/@ZR^(/A34_&7@F_\ $-SH8;7=-T:+P[-JL<^C:)KM]<Z%*J>(;=X!
MXB,#NS @$E8J^GOE"@9.#T/?KGMG'->2:/\ "[PUHC?#TV27@'PL\/7WAGPD
M#=L$&F/I.CZ,ZZJV%,SF'1X$5RJC<AE*Y8I7K?R[02.!_CCMCO7DXQX5U[X:
M+C?FLGS-I<TN57E?['(VGM)M=#W<O69+#_\ "HTY66NBZ+FOR^=[=6K,?111
M7*>B%%%% !1110!X%J?_ "<SX&_[(5\4/_4Y^$=>]O\ =/X?SKP34_\ DYGP
M-_V0KXH?^IS\(Z][?[I_#^8K2K\,?\'_ ,D8+=>J_,=11169N?+'[9?Q@\0?
M ?\ 95^.WQE\'IH\_B7X:?#CQ/XKT5?$,4ESX?.HZ'$KHNK")DD\L?-N7>O*
MOG<%8'X6^ _[=/Q*O/#'QMU+Q59>$?VC?"GPOU?X.V7@WXR?!^ST[X%^"_&^
MJ^/?#&N^(O'.@:MK7Q\^)*_#S^U?A4^F:(LOB1?'D=CXFMO&W@^UCMD\6F:-
M?TM^.'P>\.?'GX/_ !!^"_BV]U>P\,?$;PSJ?A;6;[0+QM-U:TT[5T*.=,N$
MC=4< !0S YPR_P 0V^-_';]D7P3\<?"_PP\/3^)/$_@63X.>(['Q3X%U7PWI
M_@[4[*VU&#P]K7APIK'@CQWX;\6?#S7%&BZW=+L\1>$+@Q3R"2!HVD91V8>M
MA5A6L4M92O?MIMW=VDFE;1MO9'GXGZU]9?U5JUNKZ_\ #>7D?'S_ /!2ZX\>
MZO?K\._ACXMM_A%JW["_B;]K;1?CA>-X,U#4?"3:'-X@T<V^K>!)?$LAUY/#
M6O:*;::)&/G>+ RX'@-F\:UZ!:?\%*?@OI?C/P5\,]0_X2#5KNYOO@YX(\>>
M/;._\$:)I/AOXC_'#PCHVO\ @;09O UW\1)/B4QOT\0:%+=OX1\)>*O#'A4Z
M[#'<Z@&A$RZ.E_\ !-'X5>'/#/A#P?X7^)?Q=T'0/#_[-GQ$_90\16:7W@[4
M&\<_#'QM<:WK9779]3^'_P#Q)?$?A+Q/JS:_X1\2>$)/"0R6M[F&YLI=DO5>
M#?V"/ /@#XMV?Q3\">/?%GAQ;_\ X5^WC7PO/X:^#?B;3/'FJ?##P3I'@+P_
MKEQKOCOX9^*/B3X<UA] T#0;?Q/+X1\9^%GNY-$B<1I*A>NE?V4[Z-=K7U6J
MUNGJM+6WO=K9+G_X5O+S^']+?UL>*>)?^"H.C:?X1^(/B/P?\!?C)>+;?#_]
MJ'Q3\'+_ ,6V7A#PQX:^+'B;]E=O$*?%/P[H_E^)_P#A(M%@@.CC7;3Q'XHM
MK5?&%LFOCP6UW):K))]P_#3XVR>(OV</#O[07Q+\+W/P?M+KX8CXE^,?#^O:
MUH6IOX5T5-&?Q%J^J76N:!K,_AMH(M"$FO%TD4I$SO(WFK(1XV__  3_ /@W
M<^&O /@R^U?Q[?\ A_X>V/[3>DV-I>:QI0_MO3OVKV\1I\58M>=/#F)Y4/C'
M6_\ A$T1(Q:*R*YN$W..RU3]DK1/$/[*J?LG^+_B-\1/&7@ZZ\*Z5X UWQE?
M'P9IGCGQ'X$T?7-#>Z\'ZVWACP?X=\,#1/$_A;2'^'7BR.W\+(M]X3NKJ*?R
MI9'G7FQ']G75DE[RO\3?+=]TE=QLVGLVTCHP_P!;MJ^C^^W3YWV/C/\ 9G_X
M*.>(M;^&'Q;\5?M/^']&T/Q+X&\??!O7K+1OAJ3JHT#]GK]JK6_#Y^ ^N>-1
M<>(YA%X@\'-K&L>'?C*(%CCBF\.M<!)?,;=]$>&O^"B?P3\:ZWK/AOP/H?CK
MQ9XETS]H/XH?LX#P]H^CZ0-5O_%/PG\$ZWXZ\;^,=''_  D@,_PX1]"D\,+X
MK#PH?%Q%LUNP_>TS7/\ @F[^S#>:G\0;_P +^%9OA?I_Q8_9[\1_LX>/?#WP
MQ&B>&O#VO>%=>:)=(U\PC0B4\?\ @]C.G@SQ3(R26QU:3]W<#%<)H7_!*W]G
M70[G5KVSUWXLWEWK'[*&I?LD:M=7?B[28SJ>E:QI>M:'XC^,(&C^&H1_PNSQ
M?!K^MCQ;XPW_ &2>1E8^#HD.1TK^R;7M*[LTK-6VT=F^M]4SG?\ :VOPVU[>
M9Y!\6O\ @J/X5L?"^C^)$U&#X)VWPQ_:R^$/PT_:(?Q-K/PV^(&FZ7\*_'?@
MSQSXZ&J:1XP\!>*/&/A6<^*O#>AQL?\ A%_%$GBSP>0ZSV\>=EQZYXI_X*??
M"+PIK>E:!XL\#?$'PQ-#HGPT\0_%"W\37_P[\,^)_A1I/Q>UR71/A5%XB\#:
MS\1X?%VL>(O$"*GBCQ5H'@WP]XME\$>$W<^.#;Y2*2/1?^"5WP%MM/U_2?'/
MB7Q9\3[#QC\0?@Y\0?&.C^(O#WP?\/>%]<F^"/@_5?A_X9T1O!OP^^&W@[PX
MGAV;0=>FC\7P"UE>^*H8I8&#1/O^#_\ @G3X)\#^,/#OCOPA\6/BM8ZQINE>
M!/#'B*X\7Z+\(/B1J_COPI\)]6UO_A56B^(-=\?_  Q\7Z]H$OA31-?;PA!X
MG\&7/A;Q7>>"4$WC&[N/'A;QE'M_PDZZRTO;2:TM%+OK?G=NBY;7L[B_M:ZV
MMI?X>_\ E^I^F?6BCI17B'L+97WLK^O7\0HHHH$]GZ/\F?//P&^]\:/^S@/B
M!_+0J^AJ^>?@-][XT?\ 9P'Q _EH5?0U:5]WZ/\ )'/0V?S_ $*LTODQ33=<
M=.W0 #_'Z]J_'CX=?\%0KE?@Y\-/%'C3X0?$GXB_$;Q)\#_''[1'CZ+X0^&M
M-/A?PE\,/ _Q+\0>#/$FM12:_P"*;9FF\,PZ8BQ>&A+<^+/%)A7R8A*DL:_L
M;*@E1HSCD#\.<Y_S_6O@/P7_ ,$]OA%X%\+CPGH_B/Q]/8M^SGXX_9A:\O-6
MTB34!X!\=>+M;\;^(-7\Q-!3?XGD\0:W,L5WL$4<80-;2E"7WPSPW_,2KNZM
MO9JR2VUTU]=/,QQ/UK_F%\[W_'?0\N\.?\%&+>Z\6?M&CQ/\'_%FE_"?X/>/
M/@-X,\$_$_1]<\':F/B"G[1'A#X/:YX,9O#L7B>+Q%H<R_\ "T4\0M.8E5/!
MNQ)H'\9;K&5?CA^V[XC\-?&/X4?#_P"$/@3QQX\N--_:F\2_L_\ Q1\">'M$
M\'MXA\<7Y_9,\??'?0U\.:YKGBB'P[X;\-#7G\&'Q;XI\5S^#_LIT7Q*%=XH
MPK]7?_\ !.GX=7^C?%;PW:_%#XNZ-X5^*_@WX1Z5K7A_3;KP2K:-X\^!NC>
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M_P#]')?%O_PG/@!_\Y.CE7\WX/\ R ]QHKP[_A5GC_\ Z.2^+?\ X3GP _\
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M)?%O_P )SX ?_.3JJZU>M]&MGV7^2^\,/_G^A[C17AW_  JSQ_\ ]')?%O\
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M<^ '_P Y.C_A5GC_ /Z.2^+?_A.? #_YR='+'^9?<&OG^)[C17AW_"K/'_\
MT<E\6_\ PG/@!_\ .3H_X59X_P#^CDOBW_X3GP _^<G1RK^;\'_D![C17AW_
M  JSQ_\ ]')?%O\ \)SX ?\ SDZ/^%6>/_\ HY+XM_\ A.? #_YR='*OYOP8
M'N-%>6_\(+XJ_P"BP_$#_P $_P ,_P#YW5%0=!Z=A0 3SU[Y]CV'YX'UZ4@;
MLJ]??/\ GOWI3@*!R??IQGDCZ]O;K[_-'QO^(_B+P%XA^$*Z%I_B+6M/\2^,
M=3T?Q!H?AG2-.U;4+VPA\'^(M:5BDQC95AFM$D812JKXSN4X=M,%AWBJ[PN&
MLFDWJ[*Z4I;MI;1:U:5[7:6J\_,,?A\NPKQ>*3T:B^6+D]6EHDI/1M7LF^Q]
M-T5\ Z;^T?XTD\=?$O25\+>(;62;Q9\*/ OPS\$>-;2Q\)-;7OB#P9X@\1:Y
MKFIZS:#Q0\FC2#0]8E+QV\\H;0);:U1C<"4:WB+]H_QQX;>30=3\%Z%:ZYX>
MUAM'\:ZY<:UXFO?AYI+OH6@ZUH977/#_ (5\2^);9O$<.O+%:OXB\+VD:G3+
MKSUR8I#ZBX<S&325^9QYU'FAS<MHMR44YN23G"#<'.\Y*,5*Z;\C_6C+-[NR
M=K\KM?72]E9V3>MM-7:SM]T9'J/\Y_P/Y&D)X..N#CZ\_P"'Z5\3:Q^T'XSC
MA^)GB;2O!GA6_P# 'PDN+1O$.K)X\$VJ:_IS>$-$\5ZOK/@X'05T-DTW1?$)
MEM$\07EM_P ).5"6LULI3&;IWQD^)FH?%31_"GA*R\.W/AB?XG?%OP]XR_X3
M/Q)JC:J-,\#Z5X=>*7P3'I'AZ6!3YVKY'A^X8B$+))]H0+)*J>18]*=W"/)'
MFE=I<ONJ=I:>[+EE&5GK9W=M4FN*,L;C:[O))65[ZVTMTNFKI]#[D4Y"Y/.3
MSQZ_TY/IU]Z0G:&)YS@ 9^G^'IW^F?AJY_:7U/5?$'C7P3:KH'[WP3\6-6\(
M^)O#E_XJU%;:^\#F"-CK!UKPIX9\/>9$=8R$\+^*_$ZM)HTV)8HF$D'4^,/$
MOC&X^"OP,OM*\6:WH&N^-O$/P1T;Q#XBT==&;5FLO&4^BKKLD1\1Z%XJMUEF
M#LOS0J^Y_GN50$,JF3XO"N$<2^5U))+F3>G).M=*T79*#3O%7:5KQ=S>&?X/
M$K'/"OF=)+717UBGJW;JFM?74^P\@ ?3@$X)_P _K4+;,98-D<8S_D]!Z=J^
M,]2\>>,O@YXOO/"^O>.&\<Z/J7P]\2>,]%U7Q\VEZ9J?A34O#^N:!I,>C:[K
M'@3PS;IK6B>*GU\-X1">#I_%S?\ "/\ B:)I[DJ4B;X+_:>.N7-HOBC1=)L+
M;3?&S> ?%/B32;[6/^$=T"^UKP9;^-_!^M[O$WA[PKK)T#Q29HO"P9X"Z^+Y
M?#\,)(N)&4CD6.EAWBL-#GIM*TXWUYG))*+BVVY1Y;)N3>T6FI"?$.5K$_5,
M3-1DM7=7C=)/5WMZZI6>Y]J+P.F.G^3WZ^OM3J^*=/\ VD/$>H^(/!-MJGAG
M2O!?A+Q>NEWFF^(/%EUXL*:WI>N:A)'HJZ%J.C>&+SPRNMNK:$PM?%'BKPS*
M6UZ+9%,5);[1\SY >YX_$$?XC_ZU<>-P.(RYI8FSDU=<LHS6CLUS0O%M-\LD
MI2Y9)Q=I)I>A@,QPN8IRPKNHZ:KE_/7S\UJM'<EHHHKE/0"BBB@#P+4_^3F?
M W_9"OBA_P"IS\(Z]\;@9]"/YBO ]3_Y.9\#?]D*^*'_ *G/PCKWM_NG\/YB
MM*OPQ_P?_)&"W7JOS(U!)],=?;_)%.;DX+>G&.GU/Z\T;R0WX8'7Z]OQYK\U
M]>\0_P#!2/3O"/Q#T<^"?@+<ZQ<?##XG^(O!WCCP#K6OR7_A?QPO@?79/AC\
M-F\'>)X[@>(=?7XA/HK3^,RR>#9O"Z_9YO""W$K!G1H_6%O%;6YGRWN[=;?=
MI?;1BK5G3T2>FK=K_HS]*2Y!(VGKC_/'N/SI-Y_N_K_];W'YU^ OA;]J+XPQ
M>%O '[.EW\;?VB_#O[4_Q ^._P"SS\/OC#?_ !^^'7P!T[QO\)?#/Q-\'?$+
M6]>\7?!3_A77PW_X5GXB\/>*)OA;XD\+^"?$?BR/QNL5PCL56X1,T]0_:9_;
M2\#W'B6YU'QIX@\:?#K]E[X_^._A/XD\?V'AOX;?VC\5QH_C3X1ZYHNB_&K1
MQX8B8^(?^%+^.-?\*^"C\)5\%OXU^,S>%RZJ) #WK*<2WRW@I-7BI/EYE?E3
M5W9WDFE9MNS:V:7/]?PW]).WX=#^@K(]1_G_ /6/SHR/4?Y__6/SKX._8P^/
MD/QR\+>,[W6O'MKXB^(J>(5\9^(? UAH_P!AT_X4>$O'<FK0>"O!^@ZLFA6@
M\;:# G@S7H3XSC61/%?BW1?$SL\<2F _/7@O]NK6_AE^PM\-_CW\6(;KXB_$
M7XA_&WQ-\'/#EI9V!TS^W/%.O?M"?$#P)X(75WT'PR1H&A>&_#VB-]JD'A(L
M(M!VB-9;AKBN3ZEB.9Q^TI1@U97O)-KY63UVLKWM:^_UG#6OS+:^R/UVR/4?
MY_\ UC\Z,CU'^?\ ]8_.OR5M_P#@HS=ZCI7P;?6/@M?>!X_B#\5O'7PS\3^-
M/B1K^O\ @'X0Z#JW@+4]!MH3H/CS6?AU%+K0^*2:VC_#_P#X2;PEX+_X2VZ@
M\1>$X6CO$\ZOHOX#_M4W?QH^,?QU^%VL^#K#P#=?"+Q)JFAVWAO7_$<G_"V-
M4T[0M7;1H_&<W@0>'+>V'P[\7>6NO^"O%OASQAXFBN@ZV\K(\L,8<L!BHIMK
M2*;?P[1:BWOM=KMYVT#ZSAOYE]R/M_(]1_G_ /6/SHR/4?Y__6/SK\*OBC^U
M]^UY=V?QY@LO"'AW3YOA-_P4?^"W[/OPK3P9XUCTO4/B!X0UR3X3ZX_@WQM)
MKL$<>B-XM\/^.P+GQ&DCI /$4#F"W'AM&N/1O$?_  5"U;P_9Z+X2O?@DVE_
M'.[^*'QS^&?B+P7>^+]9U+P;H;_ O1_#_B'7M8/C'P+X4\6^(M67Q7X<\;>
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M5VV7^1^O%%'6BN0[]U\OT/GGX#?>^-'_ &<!\0/Y:%7T-7SS\!OO?&C_ +.
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MXC\+>(K#0?$?[.FC^'-;UH_VQH,I&M:#XIC\:6Y\)2JJ%O)DD:*+=M3P^?\
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M8O&$MO;;O%:Z&C7D;M',[8WB;]B;X$^)=4F\1VD/C[P?XXO/B7XY^+%EX[\
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M?[XH_P#A]?C5_P#/#KV^BL_K$MN9^E_^ ;+#KI;^OD>(?\*$\!?\_P!\4?\
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M^Q59ZS=/KGB_Q1X(\0_##]JK_A.(-%\%1!] /B&V\0^'/$?@'5Y/&_B.W%M
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MTCXD)XF\$:I\#_$FL^##XO\ '6MZUX:MOA?)H'B[Q)X>UVWC\+^&/&+^,?"
MF\-B^CO5DFCD];_X*4^./&_@']E+7M<^'VJ>-M&\43?%+]G3PS:7/PUOM)TS
MQW>6'CO]H3X<>"==T3P7J^N@6ND>(_%'AS7-6\,0W!4R0-KA6)BSR-6'U?%K
M%+"-VNTM7I=WTNM.^NWF;?6<+]5^MZ^EM>U[;^>WR/IK_A0GP_\ ^?[XI_\
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M<+D\(%7P^+PU"]VK-)133UWNTKVO9VOJ[/1-6"AB,+BKV5M][KNNMOZ:U&_
MGX$^ YO^%S&2]^)Q%O\ ';Q[:?Z/\;OC.F,+H!Z#XADCDC.<87/RYP1] ?\
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M31R2NM5J[I*TF^K:5^[L[).27UG"M?6[.]_._;;_ ('XGZE?\*%\ ?\ /_\
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M\3OBA\)? $'PD\0R7_@_]JC2OA?XMT6Q^,K+X$^*?[/GPUU[QW+:?%#7-?\
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M'Y?%?A<_$S2H?$OCC4_$EU^UCX$O#H'BIUOAI/@77_B;X=#:IH8BT%3%X?\
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M;2PU#QW\+/)/@7QC+H US_A'8_$_A,:5HJP:_P#8_/<PCSFW,Z'Z: QQZ?\
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M #]H/XG>,_V@OC=\&/C##HW@GQAX:NO%?B3X??#BU\.ZPNJ:A\(-*\:+X?\
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MHPNM/8,D@PCACA2%?#8&25)JW:-HFG6UM8V4^G06]M;BUL[;[4@"JOW4P6W
M<<MRW4YK@?\ A1/P7_Z)7X$_\)K2/_C5'_"B?@O_ -$K\"?^$UI'_P :HOTY
MI6O>U]+^E[7\][:!RI_93^2?Z,])_M'3/^?W3_\ P,B_QH_M'2_^?S3_ /P,
MB_QKS;_A1/P7_P"B5^!/_":TC_XU1_PHGX+_ /1*_ G_ (36D?\ QJCYR^\7
M+'^6/_@,?_D3TG^T=,_Y_=/_ / R+_&C^T=,_P"?W3__  ,B_P :\V_X43\%
M_P#HE?@3_P )K2/_ (U1_P *)^"__1*_ G_A-:1_\:HT[R^__@ARQ_EC_P"
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M_ V/_&O-/^%%_!?_ *)7X%_\)C2?_C5'_"BO@O\ ]$K\"_\ A,Z3_P#&J/\
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MUK0/'>L^#%.Z.WE\2+K;S2) 8HKF4!=PW%!ZI_PHGX+_ /1*_ G_ (36D?\
MQJC_ (43\%_^B5^!/_":TC_XU5?6'_,_O?\ \D+ZLNR^[_[4\S^'?[+O[-/P
MJ\,_\(QX$^$_PHT2QEUGPOXDU--+\*:#8+JOBOP(5/A_6GVE6_MGPH$(\*9N
M&?P@VPVCP#9NL:_^S1^S%XIN/!-SXB^$/PCUV7X<ZUJNL> 1JGAKP]J/_"*Z
MCXE\0+X@UF31 ]OF-_$'B0-XAD7YQ)XH(N29KK:B^B?\*)^"_P#T2OP)_P"$
MUI'_ ,:H_P"%$_!?_HE?@3_PFM(_^-4?6'_/+[W_ /)?TM ^K1[+[E_\B<'I
M'[-W[,^A>,]7\?:'\(/A#8>-_$P\66VKZ_;>%?#XU+46\=RD^-ED<J!GQ:H#
M>+O+5&\5[%:^,Q8!BQ_9G_9FT_PQ)\/['X/_  JM/!USX//P\N?",?AK1%TN
M[\"#5Y=?/A1](*F-_#_]OO\ \)"+>1)(O.VS;,*LB=Y_PHGX+_\ 1*_ G_A-
M:1_\:H_X43\%_P#HE?@3_P )K2/_ (U1]8?\[_\  NVWVNG3L'U9=E]W_P!J
M<OX3^!GP$^'^C^&O#G@CX<?#[PSI'@SQ1J/CCP]::/I.CZ<N@^,]5T>XT;5_
M&< CC"MXDN=!UC5X[GQ VZ<VT[1M*Q$97*N?V<OV;=1U[PQXHD^$7PMEU[P'
MK6JZWX5U<^&M&1]#U/6]?E\<:WJULXC(7SO$^K+XE>3"&/Q1(MRDL$[K(.]_
MX43\%_\ HE?@3_PFM(_^-4?\*)^"_P#T2OP)_P"$UI'_ ,:H^L?WW_X%_P#;
M>H?5EV7W+_Y$]*_M/3?^?ZP_\#8_\:/[3TW_ )_K#_P-C_QKS3_A1?P7_P"B
M5^!?_"8TG_XU1_PHOX+_ /1*_ O_ (3&D_\ QJH_V;^:7W0_^2*L^QZ7_:>F
M_P#/]8?^!L?^-!U/3<'_ $ZPZ?\ /Y$?ZUYI_P *+^"__1*_ O\ X3&D_P#Q
MJC_A17P7_P"B5^!?_"8TG_XR::^K7WE]T/\ Y(3O9[[/\GYG$? 34K$GXT'[
M;8?\G ^/AQ=IU(T'KDYW>@^[Z\9KZ"_M/3?^?ZP_\#8_\:^/?@?\%?@]=GXR
M"?X9^"+GR/CQX]'_ "+>CYSLT)B,;".H'WBO X!/!]X_X43\%_\ HE?@3_PF
MM(_^-4Z]KO?_ (%OOV\@P^W]>1Z5_:>F_P#/]8?^!L?^-']IZ;_S_6'_ (&Q
M_P"->:?\**^"_P#T2OP+_P"$SI/_ ,:H_P"%%_!?_HE?@7_PF-)_^-5/^S=Y
M?=#_ .2&T[O1[OIYLT/'7@SX:_%+PIJ_@#XC:#X4\:^#==M/L>K>$_$]II>J
MZ5J$0.?+GTJ=7#YR2!A77.(PNYB?%]6_9(_9(UO0_!WA?6O@3\&-8\.^ 9-5
M;P)I5[X3T*_T[PV/$=RFKZR;>.9'BB&NZLC7$R,C+=S'(5WD>O6?^%$_!?\
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MQOHK#_A*-!\2-T8^+#_PAC#[QS7<7_QC\:P>*==1O&VGZ?X@T;XN67@3P_\
M!#_A'M(.K>(_!3ZWHB-K,4LB?\)/&WB7P[--XAB\4;QX1MT58O+V!BKGPYBH
M.*<Z?,[[2DT]>6RMJFIW4I2M"'Q3G&*NZ7%^6R3:A6LE_P ^Y::7_D[=-WLD
MV??A!;80>!G)^AY_#U/H>]*&#;\'I_4@_P"'\_K\$>$O'_QF&E_#OQSKWCJR
MU#3?''CKQGX2NO"\_A/2M*TO1=.23X@MH.JC6UV^)&"_\(_H.]"S+(LI#H 0
M6[/]F_XG>(?&5]KWAWQ5XKD\6>)M/\.>&/$.H7FB-X2O_!+/XA?7HD;P;K7A
MY#*49M%9I-$\4-]JMP%F0O"\SKE5R;$T<-4Q7-2E"$IP=I/FO"IRU+II?#*R
M;UO=-:7D;8?B7"8G%8#"J%2+K:W<797B^76W5;+[S[*'0?04M X 'I17C'TX
M4444 >!:G_R<SX&_[(5\4/\ U.?A'7O;_=/X?S%>":G_ ,G,^!O^R%?%#_U.
M?A'7O;_=/X?S%:5?AC_@_P#DC!;KU7YBD9!'K43_ 'C^'\A4B] /KV]S^5?F
M/XZ_9.^-.E^ ?B9I-_\ MT_%"^\(^*/A=\3;#73\3K+P?(FG^/O&O@C7?",/
MC>+QSH,?@[Q!X%^'/A&76!XFM_AKX9> V]QH2LGCA7<H3#TE=Q3L]%LW>[Z>
M@J[LO37\'_D?I<)X)(U<2PD8'S<$<<$9)S^&*D-S!^Z_>K^__P!3Q][Y=V5X
MYX.>?7%?R[:3KWAWP1H_AK]C_P 0Z1\.M!^'GA?]IC]CW0OVC/C=\!_BG\1[
M_P"$OQ6\#>.?!?Q 30_!GC77?$GB"3Q)\/\ Q$WB7P+H/_":^&&\7RPLNO>%
M7*R)XO&[:LO WC$6^I>-/A!\39-9\%_#O]LGXI?!S]D+X9W7B'QIJE[X@V?$
MWX?>.'7X7^(QKPB7P_\ \)+I'Q2^&/C3Q/XL/BOPAX1^"R>*7C4Q13JO>LHN
MU=V3U3>S3=DK]);RY9<K4%=I-G!_:+_E>FCT[?+^F?TX?+ZG\A[_ .U['\C3
MMH_O?^.G_/8_D:_+[_@G1\9;/XD>'?B'X=O]'U*3QM;W/A?XN>.?B#?>)-,\
M0K\2-7^.%QXUD_M4:3 "?A[+X;D\#:MX:@^%L@;_ (0SPA;>&(4!%PVWXW\%
M?M<^+?A!_P $\_AAJ'PU\5:?XH^*'B+]I;Q9\)O$NK7FI^'_ !'XE^$'AKQQ
M^T[\5/#[>+=<TC7O%">'WB\.A!X;\%1^+O%/A;P4[:QX;66ZCA$-K+S?4<1S
M.-_>346K+2Z;3OJK65[Z=.KL;K'QW<?NO_D?T'9'K_G_ "1^=&1ZC_/_ .L?
MG7X4>)/VI_VL_AAX(^#_ (M^*OC3P[X?\!:)\6/'.E?%/Q9X/@^!?C?XM^*?
M "^-O#/AOX8:]K/PST#XB7'A>/1!%K[^'_C7'\)V\7>./"]R?#S^!/!BE[FY
MC^G_ -G+]H3XF>)OVJ?C9\&_C%XTL]1U*T@\2>-/@]X3\#:/X/U?X=+\'],\
M;_\ "-:#K4OCKP[XAN/%4?CR&25/#?C[PW\5/"/A".'Q9$[>!2;..16;P&(B
MFV]%>]E?9V?3I=7[+774%F&'?J_(_2J>ZMK9099X(!N$"FX( 8XR #E<Y'.,
M@'J2.*N;U]?T/^%?S;?$:X^-FO77[3?AF_\ VEW\2:YH/_!5_P#9Q\,?#?PK
MXO\ "GA;5F^"VEZZ_P (O$&@:VVAZ*&\3^)=$E/B"7PWX0\/2R#PM*^@*\_F
MEO&;)W>N_MI_M=Z1K'AO]GS_ (3?0)O'%M\??VK/A/K7QYT7P-\.-/OO%+?
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MM\.-;'PNW^&9AO\ !N@^)_'4DH#,]>X>+OAJ9Y_VFC\$?B7=V_P(^#_[1H\
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M"NE?&/PM);>._&GAO]D+]J!=:\<?$?X=Z/X6\4Z'XZ\#?M6? /X2:XVM:/\
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M/^%E_#7_ *'WP9_X4NC?_)-7?$O=RUWUGKI:[][5I;7VZ6,.2G_)'_P""_\
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MA]\&?^%-HW_R31_PLOX:_P#0^^#/_"FT;_Y)I7Q/=_?/IIW_ "L.T?Z2(_\
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MJLVL:)<0-HVM,\L<=PYN$E1I(ANE8+O6S_PLWX;?]#WX,_\ "ET3_P"2J/\
MA9OPV_Z'OP9_X4NB?_)5%\3>^M]-5SIZ*RU3OHM%KHM%9!9=E]R_R+WAWPSX
M7\)Z#8^%O"_A[1?#GA32[(6.D:!H6C:7I?A[3M- .[3=(T;1D@A@B"KN,4=O
MLW;VC!R8ZXO3?@9\%M&T+7O!^B?"'X8Z1X-\3VOV+Q-X2TGP'X3T[PWXCL@)
M,Q:YHEOH:6NKH/[4U-AY\3H3++&WSW$A/3?\++^&O_0^^#/_  IM&_\ DFC_
M (67\-?^A]\&?^%-HW_R33OB>[UU>L_\S"T>WX+_ "(=!^&GP^\*P:/;^&O
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M76.@6GBSX9_#WQ'8^#S_ ,4?:>)/!V@ZM9>%2L9TO_B1IJ^A2QZ*QC_=;+9
MS*H" QK&5MZI\*_AMJM_K>L:IX \"ZCJ6O\ A=_!&L:C>^#M%U&]UKP5M=CX
M2UJ5[5Y=<\-EE(7PY*9+0* %@+,,Z'_"S?AM_P!#WX,_\*71/_DJC_A9OPV_
MZ'OP9_X4NB?_ "55<V*75]>LNN_7KU[G/RX3^5?^ K_Y$L>#/ G@OX;Z!;^%
MO '@[PKX%\-V2L+3P_X+\,Z1X:\/69P /*T70XK:WC) ^;RXU5@!G! -=O7
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M9P7_  K'X>_]"%X(_P#"3T7_ .,4?\*Q^'O_ $(7@C_PD]%_^,5WM% S@O\
MA6/P]_Z$+P1_X2>B_P#QBC_A6/P]_P"A"\$?^$GHO_QBN]HH X+_ (5C\/?^
MA"\$?^$GHO\ \8H_X5C\/?\ H0O!'_A)Z+_\8KO:* ."_P"%8_#W_H0O!'_A
M)Z+_ /&*/^%8_#W_ *$+P1_X2>B__&*[VB@#Y4U+X<> 1^T=X(@'@'P7Y'_"
ME/BAS_PC.C9S_P )K\(AC'EGCM]PG'/3YJ]M/PR^'H!/_"!>"!_W*>B__&#_
M "K@-3_Y.9\#?]D*^*'_ *G/PCKWM_NG\/YBM*S;BK]8>>_O>9@MUZHX3_A6
M/P]_Z$+P1_X2>B__ !BC_A6/P]_Z$+P1_P"$GHO_ ,8KLYKB&VAFFGE6""W!
M,\\V%4* "6+'  P1SC'(P#FN!UKXF_#;PKI&BZQXF^(W@?PUI'B39%H&J:_X
MQT+3=-UEO+61ET?5M9N8H]9?:Z.!"TA*2*V &7.=F]DWZ)_Y&UTMVEZM+\V6
M_P#A6/P]_P"A"\$?^$GHO_QBC_A6/P]_Z$+P1_X2>B__ !BM'_A*?#?V?5[D
M^(-)$/A]B_B"X.I6&-!VZ6-79M<8,%TC;H^R<O*8\6THGX0F2J_BKQMX/\$^
M'+_QEXS\3^'_  OX9TZU-S>>(/$&KZ9I>CV*8.]GU::18D !P#ERW\&XG%:>
M_P!WVV>X:>7X%;_A6/P]_P"A"\$?^$GHO_QBC_A6/P]_Z$+P1_X2>B__ !BM
M'PQXG\.>,M!TWQ3X3UO1_$7AS6[,7FCZ_HEZFHZ=J&F[04F35X7DC96.[!#Y
M4HPSN1L+IGB7PYXA@O[K1-9T?6;72KN_TC6;O2]0TZ_CL=2TAF35='U-PS>1
M+"1MGB8)*@(DD6*-D=HU\_Q#W?[O_DIF_P#"L?A[_P!"%X(_\)/1?_C%'_"L
M?A[_ -"%X(_\)/1?_C%;^AZ]HGB/2K36O#VJZ;K6E:C&7L]3TJ]34;"\0956
M34;<R1LN<JIW$Y^5<G K*\2^)O#O@ZP@U;Q/K.F^'-'N=6TO1CJ&JWD&FZ?)
MK.O:U;:#H6F$RD@R^(-=U>*&)B2&>1?-8 AP:^?XA[O]W_R4J_\ "L?A[_T(
M7@C_ ,)/1?\ XQ1_PK'X>_\ 0A>"/_"3T7_XQ6OHOB+0]?M1>Z-JFGZM8M>:
MK8O>:=<QWEB-3TC5&T76-.\X;AYEMK,<UN^!S+%(.$52\NLZOI6A:;?:WKUY
M:Z9I&F6=]JNK:E>77V2RT_3])5IIM1E8DA42)4D=MP&P Y) 5B[\_P 0NNZ^
M]?YF'_PK'X>_]"%X(_\ "3T7_P",4?\ "L?A[_T(7@C_ ,)/1?\ XQ5VT\6^
M&[_2?#VOVOB'1KK1/$W]G'P[JR:M&VGZU_;81]&32)%;9K$ETKQM$JL)&4F4
M8"MY=^'5])NM0U'3(KZRGU'2SIO]K:;!.IOK$:J/^)1_::*[2)YZ+(\>\G>H
M+H'4#*L^S^Y_Y!==U]Z_S,/_ (5C\/?^A"\$?^$GHO\ \8H_X5C\/?\ H0O!
M'_A)Z+_\8K4O/$>B:;JNE:'=ZQIUGK6N?VA/I6E7%TJZEK*Z,JR:O_96F22;
MY1$CJ\C0%RBRERC$[JZG(]?\_P"0?RHL^S"Z[K[U_F<%_P *Q^'O_0A>"/\
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M-.NZ1!>B]U/0WU>-M4T<ZSI2N9-',T*F6V,R(TL*+(&55#1FOG^(77=?>O\
M,SO^%8_#W_H0O!'_ (2>B_\ QBC_ (5C\/?^A"\$?^$GHO\ \8KIM3U/3]%L
M+S5-5O;73],TZV:[O=0N[E;*PL[*/<6>25G*+L5#R<9R &!*(6:?J6GZQ:6U
M]IE[;7^G7MJ+JTO+2Z%_8WUE)@!T=6*L2#_#N[J6;#*#7S_$5UW7WK_,YS_A
M6/P]_P"A"\$?^$GHO_QBC_A6/P]_Z$+P1_X2>B__ !BN]KC?"GB_PIXTT*S\
M4>#]?TCQ#X<NVU VNNZ5?QZCIEY_9<SZ7*W]K1O)&622-U9]SLWENRNZJSN:
M^?XA==U]Z_S*G_"L?A[_ -"%X(_\)/1?_C%'_"L?A[_T(7@C_P )/1?_ (Q7
M>UA7NIZ5IKZ?:W][86$^IW0L=+M;NZCLFOK\("(M,0L9)'8,QV0HSG<"1\WS
MEWW?XAIY?@<__P *Q^'O_0A>"/\ PD]%_P#C%'_"L?A[_P!"%X(_\)/1?_C%
M4T^*?PU_X2#6_";?$#P*/$_AVP35]?T ^+]%;Q#H6F;=IU36]%\Y;G1H\]7N
M88HF^]O XKJCKVBK<:?9G5-/-SK5L;K2[?[9&&U5!&'+Z;NF E4*5<F+<2&5
MP!RQOW_[WW/^OZZ+4+KNOO7^9@_\*Q^'O_0A>"/_  D]%_\ C%'_  K'X>_]
M"%X(_P#"3T7_ .,5WM%1=]W][_S"R[+[E_D<%_PK'X>_]"%X(_\ "3T7_P",
M4?\ "L?A[_T(7@C_ ,)/1?\ XQ7>T4AG*?\ "&>#_P#H4_#G_@ETO_XU175T
M4 - .T#T()_/_/Y5\M?'S4;3P[XN^!?B75#<0Z)HGCG5VU748[74K\6(E\$>
M(5C,AMUD*QRNC@NR,Q"L0K8VU]3U&T8<Y/3/I@^_Y_3WKHP=?ZMB/K%N:\9)
MQO9-3A.#UM*SY9NSMHTNQP8[#_6</]63:UBU);IQ::V:ZK77;R/SU^(_C?5O
M$'BCQ'J]OXT^*FD:'-X1T74?@2WP[MM:.G^)_$R_VTNN:3K>AC07CUSQ%'K<
M.DK_ ,(IXC7R)/#+"X6.))KJ1=/P9K7C&;Q[>3_%?7OB1HWQ(L]5M!X:\">"
MY=?/P[U?P[+X0T'SDC3RSX:UU%\2_P!OJWB3Q5- 8W18%6%(U"_>QC']Q"/3
M'\^<?YS0(Q_<0#TQ_+G'^<UZ:SO#+#_5?[-3^'W^9>T7)96C+V-E"I;FK1?,
MY3M.$Z5N0\=Y!B_K/UK^U))V:Y>5VLTUMSVNMHNRLM&GN?D=+/\ $GXB^#_C
M)X6L(/BK'I/B_P#9V\2:P--'B[QAK_B30_B>-2>%/!J:WKGAWPI_PC_B%4D:
M#QEX3\,E<<HH ,9?V/Q/K7C-KN2Y^'NN_$#4/APWPQ^&,EQXDM(=9O\ QF]G
M_P +9UV+QSJNE2ZY&WBB;Q ?"X))DMY66)4D6%C%&%_0W$7/RC]><YS_ )/K
M3C'Z!/\ OD?US6];B*/,I?V;&R37(N1P;=.--RDO9)N:Y8R3O;F2E.,FM>2C
MPQ-7_P"%2HVW=OWKKWG*VL]$[OSMHFD?F_9K\0?$FKZ!X7\+>-?BO#\)]1^.
M6EV5CXRGN=7?Q-KGA.'X-?$#6/%>B'7M>2+Q,OA\_$'1M%2+Q$!@222V]K-(
MBO*_TY\!#XLAT#Q?HOBF_P#$>K-X5^)'C/P[X?U'Q0LRZW?>%;62&31I=2U<
M[GULE)V*>(2"]PB1J>87W?017@$*O.>BCM]1]<=_J:0K(<#.,\X"@9QCKS].
MM<&,S18G#O#_ %&$8^ZM.2[E&2<IR:IP;E.*Y9:J/\L(GI8'(GA,3]:_M"I-
MZW3NTU:W+K*2M?7:_=D]%%%>8?0!1110 4444 %%%% '@6I_\G,^!O\ LA7Q
M0_\ 4Y^$=>]O]T_A_,5X)J?_ "<SX&_[(5\4/_4Y^$=>]MT(^G\__K'\C5U?
MAC_@_P#DC!;KU1Y?\:HI9?A!\5(HHC-+<?#CQQ&L&<[G?PEK")&,?\])-L?N
M6K^?+X'77P"^'.O?!36/V[/".DCX;ZS_ ,$Z_P!E#PS^SAJ7Q3^&FJ^(_!.B
MZWHT7CZ+]HKP=HVBW&@>*8M"^+GB0>(?A=-)$ WC?QSX12 I(!!+!/\ TO\
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M72S:,O[.=[\SW[OH_P#$.HHHKSCU>GR_0^>?@-][XT?]G ?$#^6A5]#5\\_
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M_+0:P"33Y]FNKZ._<DHHHK@/0"BBB@ HHHH ^<O^&K?V?O\ HIFC?^ >M?\
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MK[:2JKL<>'+>5+B;<,QA@ZKN&X>@[U]?T/\ A0_8]*;??5?_ " [OO\ BO\
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MO_ /6O\ Y24?\-6_L_?]%,T;_P  ]:_^4E?17ECU/^<__6_7UX/+'J?\Y_\
MK?KZ\/\ V?\ D?W_ /VI-\1_,OP_^2/G7_AJW]G[_HIFC?\ @'K7_P I*/\
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MG7_AJW]G[_HIFC?^ >M?_*2C_AJW]G[_ **9HW_@'K7_ ,I*^BO+'J?\Y_\
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MA?\ MW77\"^%\QA4T2V9XG_X0\EZ?Q(^%/QV^).C:9XQ_: \"_'KQ/I?P_\
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M% !1@'J,T44!83 '0 ?A1@>@_(4M%%WW?WL5EV7W+_(****!V"BBB@ HHHH
M**** "BBB@ HHHH \"U/_DYGP-_V0KXH?^IS\(Z][?[I_#^8KQW4?#FK3?'?
MPCXLCTX1Z#I?PF^(/AN]U7< QU36O&?PGU71-,(]&@T#7GSCD=]W7V)_NG\/
MYBKJNZ7E#O?N_P!3!;KU7YCJ, ]1FBBH-Q,<$=R#R>OMGZ5^;?\ P4!T'QSK
MNA? J.W\(?%/XC? ^P^,]E>?M)^!/A FL3>./%7@2/P=XB&@Q#1/#B1^(_$?
MAF+XA-X;E\7^%O#,BW5[; R,#Y$K1_I+2$#J1G'MFM*%;ZNU*R=MK^C5UN]I
M.SWB[-.YSXB@JZ2O;T=KZWZ=/+9G\^GA+]F#XS_%*/X3^%OB9X7^/L'P)LO#
M_P"W1=>$O!7B#QYXPT7Q'X4\+>(/&GAR7]E7PC\3WT?Q+_PD<NM^$/"C23>"
MO#'B>23_ (0M8_#T,<AN/!C*OTWX_P# 'QZ\=?L#_L?^'/%/A7QGXD^-6F>*
M_P!B7Q1\4=,U$#4/&>FZUX+\<_#KQ%X_UCQ&P<(\_A]M*U63Q<0A9]MR0X+G
M?^N&!Z#\O\^I_.EP/0?YS_B?S-=#S"[B^6/NM->J4E_+_>U\TGN<WU!?SO[V
M?DG^RUK/C/X%:Y\1_P!F;QW^SE\:+OQ)XH_:D^._Q"L_C7X<\&R:[\(O'/AC
MXO\ Q2\0?$WPO\2M>^(R^(XX=(UKP[X<UO3/"OBSPU<.?%R7/AB![."X+.\7
MSE^S_P"&/C-K7A'_ ()S?LNZW^S]\5_!WB;]C'XC:?J7QL^(7B?PX+/X0G3?
MA#\-OB#\.M(U;P3XS8-'X]/Q/N=?T;Q'X3;PPHCMB'^W&*.%RO[\X'H/\Y_Q
M/YFC ]/\_P"2?SI?V@]?=W;;U=N9Q<6TK-+1Z))):;V#^SX_S?U>Y^-_[7&B
M_$[PK^TYX<^)?[*/@3]HBW_:*\00_"/P=XRU;2_!FD^)OV1_C)\(8_'V_6?#
MWQNU_79)/^$!U_X2>'M9\?>)O!_B/PI/X/\ %\;:\;6./QA:>+!;1?(]W\$O
M$GPMT']H#X8:!^R)\3M2TOQ[^V[\3O%/BWQI+X/^)WQ"\._\*S\0:&WB+P+X
MT\&^!? ?Q$\(R?%D+KX3PN WBWP<_@G?+YD8***_I##'OR/I[C/I_AV(YIVT
M'!!_+I[\'I6M',906D;I-6?-*_NWLMKM*^B=UM?16"O@%+;YVMUT[_CH_P S
M^9;3_P!BKXP?%+X?'Q+\:_@Q\0_$_P 4YO\ @CUXZ^%%QJNOWNK#Q'??'/2O
M&&O/X&\':N8M?Q)\0Y=!_LB?<S/YKO(WGA=L:?O;^S5X L_A3\ O@U\.K/1I
M?#A\*_#OPO8WV@W=R;R_TW45T>*36H7=GD+R+KKS,7!"%F;Y(R H]ZRH/ S]
M?Q]O?]!3E*]N">O4]^,GWK+%8_$8E)2V3ND[)+>UDNFKTVVT'AL!##WM*]_S
M^?\ 5Q]%%%<AZ 4444">S]'^3/GGX#?>^-'_ &<!\0/Y:%7T-7B/PA\.:UX<
M;XG_ -LV::=_;WQ?\<>(M)QMD%_I.LMHQTG5._+B-HV4_==<-AE%>W5I7W?H
M_P D84-G\_T"BBBLSHLNR"BBB@ P/0?YS_B?S-&!Z?Y_R3^=%% K+LON7^04
M444!9=E]R_R"BBB@++LON7^04F!Z#\A2T4!9/=)^J7^04444#L%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 & .@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $T -8# 2(  A$! Q$!_\0
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MH50HR0H !9F=L#U9BS,?4L23W- "T444 %%%% !1110 4444 %%%% !1110
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M^W&$JR;DQM9F<8).1(QD5OFY!97#$= 6(& ,4 2T444 %%%% !1110 4444
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M:?\ \%O_ /@L-JGB+4]7\1?M)^$/"-VUI;MHVB6?@GPQ-H]_J?EB>?3I;!?
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MTDW@NH3POX'_  =_9N_8R\;^(4_9>73_ -K'X^>%GOK34OCG\2[*+P5^S?\
M NPVA+G4;_3;.\U&+QIXJTP>9=W6EZ-+XET^"VO=*;6'\*6TD&JZG^-/[?\
MX^_9=D_:3\,?'W]J#XB:9^VA+HVG>)-+\:?![Q'\/_!OPX\"^)HM:6X>Q\._
M"*[^'/B#P%X[\,RKK<R:GX9\7SW.M:*YL=3MY;J\C2=  ?J7^T5^R5_P3E_X
M.%/CX?CI^Q1^T':?"/\ :"\5:5+IOQ&\$_$#P?J%AI?Q(U3P-8VL6H:Y;SZ+
M?:[]@\8Z3X533#K%A#:/<7&GBRU?4A<RW(N#_/S_ ,%#O^";P_X)7?$G1?AU
MK?Q6\&_%#XR0VW@WQ-K_ ,.?">F^.WT;5/!VO7M[%IEW)XEU'PCHMLTNJ/I6
MKP+HMI'-=6US')+]O>*XMX+3]J/^"*?[-VF>*/VV_P!DSXT?LW_%+P9X+^%_
MPWM/&?Q;^-GPP\/7%YIO@CX?0?$OP[?:-X<^%.AWOCK5M1^(7Q$\?:HVJ6VF
M^+_$VI7&HP2MI-I:Z3>Q:?IT-K!3_P"#K*3P&O[;7[/'B/2O&OASQ/<M\'GT
M3XL_#W0KZPU36-#U_P +^+=:30]9UO[#=7<WAZX:#Q-<P1V4LECJ4*Z<+J6(
MP/8S, ?G_P#\$Q?^"5'QB_X*%?&"&724\/\ P6T+PQXCLO&/Q+_X3Y=.UZ]\
M,?#?6Y+Z+1-#\*?#C5=&CU#5M<U*]2)8M9NI9M(TB)[.;6$<WG[[^UOX<_\
M!OK_ ,$S/AS\9M*^,^F_"G7-;\0Z;::?#>>&O$/BR?4?AWJFIZ;!+"^J:EX,
M=5CO'O;B:>XN-(O)KK05>3;;Z=#"J)7R;_P2C\8?L0_L2? +]C#QQ\;?B%_P
M@/Q\_;/^ 7A[7]+\;_$<:A8^ ;BSN+W34_X12+XAWFGMX1T;Q),DWA]+F/7]
M>L;_ %2TT_28"XC"_:JW[6W_  =/_L&?L[:MX@\#>!?"_P 8OC/\0]'U#6]!
M\C1O#>F^&_ MIJ^F/=:;9WTOBK5=<MQJ_AVZU*U,T,V@)>+<V;[K>_8R".U
M/Z'O@Q\ ?@G^SWX7N/!OP-^%'@7X1^%KW4[O6+W0/ /AG2O"VGWFJWLF^XU&
M\@TFWM_MEX2 D-U=F2>W@1+>W:&W2.)?8L =!BO\V3Q9_P '9'_!3F\N[FZ\
M/^%/V9/"-A-=W!MM*B^%VO:Y?017EU*-(2^U'4/BL6WFU@6.;4$T>:U,KL=K
MF-DC_L,_X(U?\%3;G_@J3^S[X@^(&M?#8?#+X@_#B]T#PQXYT^RU4:QX=U/7
MM4TZYF.JZ)(UG!<:?93RV4\JZ3<37\]NI#&_EBECBA /V/HJ.)F=26!4B690
M" /ECF=%/T95# ]2"#4E !1110 4444 %%%% !1110 445QWCWQSX5^&OA3Q
M!X[\=>(],\(^#/"VD7FL^(O$NM7-M8Z1HFG62AYKW4+V[=(D0EHH((01)-+(
M8XQ)(T80 ZB=Y8R'0KM&Q0CD1H7=B@$DFR5VW,T8BCAC5O,&'=ED4+\)?M@?
M\%$_V>_V-8M+T+QOK>H>-_C!XN<:=\.O@!\,--D\;?&7QUKETLYL(=*\':5(
M9K716:"1M6\1ZU=:1I6A6BK=WL\B3(!^*7[0?_!<BZ_:,TWXDV7[#_Q!\$?!
MK]G[X;:K)X4^+7[;_P 38X-2O(=36R>>[\*? ;X8Q7-O-XJ\02374%K8>,O$
MVJ:%X/LIY%>+6$U"VO('_'.U\5WUO'J^I?#2^\8?";1?B59VTGCW]J#XOWT'
MQ!_;0_:5M+D"[N8O!5AK<6D1^"/!6LS3W5I%!-/X+\%LD%UY.D^-A;_VCJ03
M/1:=T>\_M=?\%:/CY^W_ *9XI_9P^)W[*-S\*_ TOB?3+CPQ\(H;L^*OC)X\
MUKP]J%VBGQ3;V>JQ>'?!WA6RF+?;-=U;4M*TL&*[:_N[6T2QFN_KC_@GU_P1
MA^%?C32M-\=?M#^+O@V^C2:O#XFL/V1_A)XEA'P_N-5WPS02_'+Q9HWV'6OB
M'XC@=!'/X9LIK;3+>VM]))GU?3;B"[N/@FUT?]CU/#L?ACP9JWQV^$-CKBVD
MGB_[?I7@/XHW?C+4K61V?4_'GBZ36?#/C7Q7!'>&0V.A7'AZ'P]X=6(6V@6*
MD37=U9MO@'\.;Z:%OA_^U]\++&[MP9;0>,_#7Q9^$VK6D4C$^0NK1:/KFB>7
MN)Q+_;44!D,T?V"*.-9[D,KON_O9_<%X:^'GAWPCINGZ!X-\)>&/!NA:1IT6
MC6NG^'-%73K73-/2,$6-C8:=IUK8Z0(UE*Q"S1[L0F*66_ED?$?0S^%M,@T-
M-,M]<UW0["UO(=374[;6I)=0C:%]\D1O_$B:@+.P4J))8PRQRK),L020-O\
MXYO _@;]N3P$EAK/A#]IJWA\"6OF1W'C3PI^TFGCCP7H6GPHDT]YJ?AV>9!I
M*VL+K<L-2TW3;#9+%B^OYC/9VW$_M8_\%N=0_9[^%MO\.+'X\>(_C%XGO1=F
M+XC:WI$%[_PD=Q A@NK?X8>!M T;PF_CR"U>U)A\4:U]L\$Z?<RW0CAO[VPU
M/<%0;;U;V?4_I@_:>_X*#?"/]G$":;QE)XCU[4;>XT[PMX.T"QN-:\5>*M9A
MCV);^%_"FGVIU3Q+J+S,UL9=3N['1=.>)KYKB[MY/LL/\WW[<G[?7C/Q!I&J
M:K^TGXTN?AUX6U&V%SX6_92\/^,IT^)?Q%A62.ZM[7XU^-]!CNGT+2=O]H+<
M>#_#=EX<TBV@C(GNM4O+F[AA_ETU;]L/]JO]H'Q#X@^)^H_%&_\ @M\.-5;4
MTE\=WFLWEY\2-=\GRY+?1X_$\(B6ZN8Y9VEA\*_#NV\-^%](>Y9I89;ZXU6>
M?P/Q;\1[GQ-::SH.IRZWX]T!;Z2X\9:[\1];U#7_ !1XR\3ZMI=IIVB/J<TD
MGV:'1] AM8M3TWPSI;F"QOM2O=2EW7NH2N U/O#XZ_\ !0[XO_%6PU'X;^#)
M?"W@7PMX8\/2GPU\,O#6@R:;\.+?6+(6C&_O#:3VRZ]JNGQ78V7.I:?I]L)D
M6>'1HKIIM2O_ ,D[K3KR_P!:NO%'C?Q#>>-_%D]Y+<QW^JPS?8-+=7NHI7M+
M"[EFLKL*MQ<0V]S<02R(0K1%);>*1?2[WQ5IUW97UU%H5U=^,=>L?[,\0:WJ
M&IR2V,\<#);S7D,%Y--<6L[Q6EO;A4\N6.VM;>%&6 (@\XU33H=2M5LGG:&V
M659%FMWEB$A!#,$975_*\S<<*1&Q+'!.: /6M)^(FJ^ 'UG6;"\$<?BO3=.D
MBNM;>[O;+2M0LKAK>UUS2]/C=EE\2QQ"2WMKJ:.1K>V@T](#']EA\OZ"U;X$
MC7/V$/"?[>%SXXU_Q)J?Q&_:D\8?LZ-I?B)+VXO;BU\/_"L^-X?$TVN27?VB
M2>[U*2/0GT_45NEAACAO"/,D1D^(/'<$DO@:&6&:4-I5_!NE25TD,,%K+-;E
M65E:-5G3<0A4.01(&#,#^HMYYDG_  ;\_L^6EM(L.H2_\%,/C-);RSQNX6%/
M@196\S-<9,AD\J[:;>SM)&;171E;+$ ^H-9_X+O^+/BG_P $R_#W_!.:Z^!'
MAO1O WA#3_AW\)D^*VC?$"ZGUJ\TCX6^(='UV\GU7PY<>']7M6F\3PV**(=-
M\@VD; RQBV,5?C-^UGK_ ,.OB+\8M4^(/P=^'TGPZ^'4\VF16OAG^T5UM_"]
MK8Z+I>GQW::F^G6!NY-1N89;LK+'<F(S;C.TS2+'_2G_ ,$L?^"%^C_\%#_V
M8O!_QE_X3RV^#O@B6#6(K7QQHVA:=KVN7GQ*TG4[_1O%%A+H6NWD,JZ597>Z
MSMM6MQ#!J5M$J-+<26Y"?G7_ ,%BO^":-E_P3>^.?P0_9Y@^)_B+XF:3X[\
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M?&V\^)?_  3\^ W[!/A3X<>+M2^*?AK]KGXC?&N"\L98-2L_%EAX_P# 5EX
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M^LZTNA^%/#^E'4-*OM'NKFW\+^'X9+BZ>6SU;58$75=5U&&,7"2K L]I#=
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MHZ"^KPHXFT[4!_9FIW=L;34[.[@ E:6.-+A8YHOYM/CQ_P &SMKX:T?4M?\
MA#^TG)<6VGDW4FG_ !!\%RV[F.XU2 >6=7TO5Q:2/(MQ(KR1V5LH+-*(5;#5
M_880"0><C'0D=.@.",CGH<CVKE/%VBV>J>&]>TPVD#'4=)U.&-?(C9&NWMO.
MBDDB*F.2036MM(K.K,&@3!H _P U+XE?\$S?VG/!^I_%W0/#'AR#XGZK\()=
M"M_&FG^$+R'^U[*RUS1AJ<.J6.GW*&;4-,O$DB6'[.KW0N(;J-)@JA!\2:=^
MR%^TQX<TI/B-KWP,^(5K:^)K(C2)$T*[GN;?3@#:.\EF$-Q97$EY;7@E5PMP
M8Q&6;RFB5?[A-0MW\$_M_7#VR/&GQ[_9FLY8+AGDB">*_@WXG)90^[FZ_L3Q
M7=S&!2(YK>TS/%*(8RG1^/3?0&[1+JZ"+>73I&;B9D2V-Q*%4QLY0."'R^WS
M&!&YB * /X"=5^"OQ\U286.G?!7XL:OJ<UW;6VGVMEX#\27=U<3SLT1AM[==
M*N[=0R+&!Y4\)WEG$:,[2R^S?#?_ ((R_P#!47XJ-;W_ (=_8Z^,EO#J2W(C
MO/%>BQ^#+:%&<&U;^TO%-Y8011 2,Q1)(A)EP^['']VO[+GAR7QQ\;/!=E)*
ML]II.IIX@OH;F220?8-*M[JYG!0L4V7$D4%LI(RKR#803D_NV%5H@K(&7>\9
M61$*G[/YBJRQ[=BAGB$JX4?> Z   '^5IXL_X(@?MO\ @._FTGXH:;\-_ E]
M%J.B:=+'K/BNSUQK2ZU!)(XA.?"!\3V=NT-W<V\LD OK.Y)7=-IZ031S77V3
M\</^#=WXD?LVZ_\ "33_ (R_M&>$;G2_B5\0?#OP]_M#P'X:US4XO"MWXWL]
M731[F[NM=M[."Y-GJFELHT^.UDB!NXI"\GVCRD_IT_X*2QJOCSQ?=LH9H_%W
M@2!';YBBO'X;N65-V0F997D!4 J78*0"17T?_P %CO"=UJ?[*FH>,].)DU/X
M=OX6^*&G!PTSVM]\,O$VF>)#>6H<R(EU_9]]JC,P0^9!;M'*)(HU10#^8R3_
M (("_LZ>"K"&]\0_$[XK^-9G;8Y=M"\.:>T?VB50B6:VS:M%'P2'FNA)AMH
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MI^./Y4V,!44#@;5XR2!A0  "< 8 X&!G)QDDE]!J-VKG.T9]0,'\QSWIU%%
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M(XPG,_\ !+5 O[)6@@@#;XX\?!0 !@+KLB#IU.%RS'YG8L[EG9F(![5^S_\
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M'J<]?TK]\M- 6PLP!@"VB 'ML'K7X$_\%(F/_"7^.^>GC7X?*.G0Z7H+$?\
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M\$]?VGYSM#3?'WQ0S!<\%OBA?,X.2>3(6;VW #"@"OMG_@G6F?VH?VF&/1?
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M>\*>"=-E6/Q+\7=>E6%H-,TJ"(+=Z?H-O<BW:[U/_1VOHQ=V<,BF.>,^;_\
M!.7]E?QUH>I^(/VJOCI96&C_ !/^).GSV7A;P7H]M-9Z-X \+WRPW"V>GV3!
M?L\]POF6UU]KB>?S(YYHY$BN%#\_^Q;^Q;XQ\9^,HOVO/VN!::]\1=<2.\\$
M> );:0^'?A]I61/I=OINE2[(X9K8W%T)%O;>:8W;372.$F5Z_9M$"[@"<$\
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MV[X>\36NH0:FMR@V6Z00Q2"Y0*ZMD0NK!B/Y;/\ @C]_P3WT;_@I9^T1X_\
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M%P\VUL^9E6!1B21B+: 5SCFOH[P/9>*=$M[6'3/$.J6UI8QJD-NMY.T2;!G
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M->6S6J^.X[BV:59U-E-/<1ZE;9E54CN!J/F*T18\,VX*@VWJWL^I_1-\1_\
M@LQ^Q-\*3=IX[\6:;XEN[9WBN8_ \4'B6<JCNT-MYET46V,>2"K1.1D2O,[2
M.%_-3XP_\'0/P0\/33V'P4_9]O\ Q3.CD6]]XM\6Z9I^\9>.-X](\/:?=W3
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MS_Z%I,"$2")6'E[5^^?AY^WC\#?&RQ0:I>ZKX&U.9%D-MXFLY%LOF"C=;:I
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M]^($UAIU_#I#ZI\//[7%W;2(E_$UUXBCTO8DFUI%,<,4QA<$/#).\L3)(%<
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MQ:5:W<.N6"S%!;W&FQHL:O;A5N;F\B=7AA56:.-&=B?S/_9:T+PQ^T%^T?\
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M2@D9'<^OI6HD:8SCD'U/I]:IQ1A2,CKD]3Z?_6K1  Z4 +1110 4444 5Y0
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# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "@ ,4# 2(  A$! Q$!_\0
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M,##H6!SV&"9* "BBB@ HHHH **** ()P2IQ&LWR2'RF((8A<K\A4[SN"IU7
M<GG-?Y<W_!8_]EV/X!?MD?M#_"RRTA+;1-)^*EWXK\%0&&6>.Z^%OQTMI/'O
MA[=;QC=#;>'_ !M-XX\+Z;#$UTOV>U-SFS4+8C_4:FQ@<$,V8@ZG#()2 6!Y
MP<A2..H'(K^8_P#X.)?V>8OB+\/O!OC'X3^$-(NOVGQ?^&;31_$%J;**_N_
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MM1#5K>WNIRMIHJ)9>689B;QS<@6WJ?PJLO%6@Z'/I7B;Q!XB\9W]WKFK7_\
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M"Z\,>'76_P##/ARYGFO],TJ6UO+JXT^6PL+C6_M<=O8WCL88(S.A\@^9M\Q
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M6#4_LVJ6UY9/-.EG-91J+ZZ9RD/[E DE@1@C'?.00#D<#ON7_@.>,X'\$O\
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M9I!L.!)^$\NI6]O<O<0:!H=G$B))&EXFH:B(CSY2M%>QO$@DYRUHT8^0&42
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M4OK+4_VJOV>;3P;J6HF'XI^'_C9X;\1Z7:02VS:CXH\++;:IX4UZ)_*^S_\
M"0VW@_7[G2]1:Z,#F/58GMHY;>'[;\>WWC#X=>&/^"B'QL^"OAXV5K\$/CY9
M^+OA+HNCK(\ATCQ!#H6G:UIUHT$\7VA($\3W5Q/9QSSV[2S6US''%;(JRS4O
MV _B#XL^ O\ P4>MT\.:W8VD_P 1O 'BKP)<>"O$-U_9>A?%:[\%^+OM[^"X
MI'E>"T\7WVAV6NQ>!+VX*QW$TMS&;FU6\$-S^8O[5OQ2N4_;0TWXK0/>:+XB
M;]IO6/%FZ!DLX=3T2W\=FVTC6+V-(G@M]<T[2-.U'PGKUM"QC^T:2DBD#BX
M,K5O"GBC3/$.L^&[?0M8O+G1M9U/23'86%W=I_H-Y+:L_FI$%!N+J*ZG\KYO
M)\PQ[Y-N]NNTCX!_&WQ>DEAIWPO\<7<%[ \$LJZ'<"*-)49H9':5DP/M,< &
M/4DD8 ;^I+X%ZW\%O#O@_P 4WWC"/P3I>HVOC/4[R2\UJWTB#4;F/7(;3Q)%
M+OO)89)(XK;5X&5HU?=YNX^7N"UK>+/VZ_V4/AZCM+\0O#DQMP56UT@VDTSP
MQ%;BYB2WLXW4DM#"H9YAMW%E#?," ?R&-IGB/PD\WASQQIMYH_BC0YY-,U^R
MN4S-!JD#D&(KE6+?9C:E_E'EE@,-G-:<%G?W:(]GIFK7H<G:;+2=1NU<#&[R
MVM[:0.5R-PP,9')[>I?M<_$;PE\4OVD_C)XS^&K)<>&=1UW2-9LIYAY=PUUK
M5FQU*0PDGRUC%O9@%E(."=JY('Z4?\$J?%-W'9>*]-U_QAH^E6&A7*YOM9TO
M2=2CM8YUOGC=9[DQRPEA$P"1PW.XQKN9=J!@#\L-+^'GQ#UD[='\ >-M2<A6
M$=OX6UL2,K9VE5ELDW%L-@*6^Z<D<9Z.Z^"?QBL+3^T-2^&?C#2[/G,NIZ)J
M&GL@7[Q=;NWB15&1AA*P(Z[>,_TX>/\ ]J;X9:*OV'2/&OQ%\:7MI!$K+X2M
M=!\.Z#).A;Y)-1_L6^NO*)R%\J)"H5\EMRX_.WXW?%>'XLK?1ZA NC6B(8WW
M^(-=U75-MQ@1"Y FL+1W(@8[DM(U4YRC#  2Y).S?YGXZW'A;5;/<U]]@L8T
M&6-UJ-HL@(^\###).ZE.-PE\O.1MW8;;R>J2:$D$EK?:KI5S%,"#;A_M4,FP
M<^;#A064./*.[C+'%??TOP9^%1,QO+;5]8NK>WCNYXF*B!Q<;C$B.D*.2XC?
M<9&N",*%VY;?M6?PM^$]C(PL_AW;2E+&*\$ERBN6D.\^1ATY(_BD'8CY !@@
M<\>_X,_(6[\)>"?/G;3)M0M'N#D165M]I@#X)9DBDMW"!MW"JRYP<EB!BII7
MPOT]M5M[\Z3XHUZ:&83VT/\ 9+):[T.X>9##"JR!R%*[W&W:VW[QQ^V5CH7A
MRUE@BL? ?A_2X6@262XEL[<L20VQ%4Q$R&/#9;>GWQ\I/-=)%<Q6ZL+2VL;4
M@%$6UM[:%7ZX+?Z.2P3'RX88W-DG- <\>_X,_)FT\)?%35BKVW@OQ:I<LD9@
MTP6EOY2X%O"J-)*5"#>-Y(SG[G:NBM?@I\<]5, A\+:W;?O"P::_BMBQ"LCP
M2[K&93'(DC!@5W!UC=&!7G]-3>ZX/+*ZG# L<Z2!(8BC2K\V58HS;L#&" N"
M6^5MW$F_43\DNK7KJ+LW7[O?;>8K\F#<SR$A,#YP/XN8^> .>/?\&?G!;_LM
M?&*[2%;K3M-LTC\N%Y=1U:[OYVN&>4F>YE:6-[J8Q^5"[.R+%'#&$502!;U/
M]C?XB7.F7T$^L>&--N;R&6"W>"ZOI51P%WSL+?S=K?.G[MC'CG#MSM_0Y8'3
M:'N;Y]MQ-,%^TD?)/LW129C;S"NP;'PNTEB$.>)+6%+='BB$QC,KRJ)9I68-
M)]X%HS%O' P&7 YQC)R#33U1^,^L?L(?&>S!DLM5\/ZZZ6[&2*'5[N*:1+;G
M>([NU(5I/-P$1F^[\S?=KC?!7PF^(7@[QD_AGQAX3U?3_P"WM%U*TMUN;3S-
M.U!H&M;V*."\B!1Q+Y B9I8XS#YR2*)L,E?N@%4DHT,9##,F$E+F ,JS .\S
ME>9(R=H&[&#GC'CWA_Q=<ZMXT\6^ M<M(99= 6;4-+O%B42FS\F6*UB9I5F:
M' G+!TE^;RR&4Y4H#/A*W_9O\5SO:%_AW:$Q/8S1^:8UVR"XBU&.-)P/F$$<
MSV\A:-?,$RR!$VF-O]!O_@U6LO$'A;]@GXC_  YUNP738?!OQ[U^?3K*-]T4
M$?B7PWX>U2Z6,9(53<*6."0S,6X)P/Y+!)IZK]GCE3)AC\Q,2/,TZ6]N':-P
M^&*+ 6*A4QN R< U_;A_P;Y^!AX=_8CU3QC]G:V7XD?%#6M8M1)')'--9Z'H
MNA>'3._F,2ZG5+#5848*N?(8\Y& #]UJ*** "BBB@ KX>_X* :)XYG^!%QXR
M^'R-?:I\-];M/%WB/PZMH^H2>*/AS;6UW!\1=)L;!)$-SK4/A:6^UC1(L2M/
M?Z7'8HD;WHNK;[AJK=1>=&T;*KQ-',LL917>17B9-B*WR G<=Q<.C)NB:)Q+
MN0 _R%OV_-=?X#_M/Z=\1O"/]C:OI5_J_BB+1=:NDNKSP_-X9\8: -$M;ZRE
M@6"6WN8!'8ZWI]Y!<6=Y9:Q#!/'.5$ZS_CSKOCS7-5N?!.F>(I[G6;O0?&5W
MJ;W=W)YU_?1ZIJT4\ADNRADE?4(U>621D8&Z$ER4:6ZE(_T%_P#@OY_P2/\
M,T+Q-\4/@YX1:V^%/C#2VMM=L=#LK:2Q^&_BNW-O)9:G%8K*+RP\/73/=K#9
M6%J\-@+:19KE08D/\%%K\&O%WP_^)^@Q?$W1;^VT;P_KEE'<^)K:PO+S3-6A
MNKB/3M#CA$<.^2*>_P#*C^U*'%N;K_2(UPGF@'[C?M$?"B?XG:YX$\21^*=9
MT.PU?X>>%KV\L+>+S(;Z_.E6EC+>+NN85@<V>GV%JR^3+N^S"1GY"+X[9_LP
M>";4*]_?:UJ<H$F&DGMH0P$$V]%\NV8KY@P"6+XVC:!DY^^/BAH@T9OA]HL\
M=PEYI?PY\,VUQ;SHT4T;-!+,)6B42I'%(TKP1$2NTOV1W=(LB-?-5TV4R0LB
M%BTC%8@'9I28)U$8.SAF9AC"G//&!B@#\V[SX)6>N?&GQ]X3\$VG]F)_9VES
MS7%Q,;C[-;V]C;?:YI<_9UG=5<>6-T.W+?,V<+]L^!/ 'ASX9Z8+#PY LEU-
MY;7NJ.\AEGE6)1))% LACA$K.^1*UT#M&TC#;N2^&5A'>_$SX[:P0JE=;TSP
M[:S)E]\$.FEK[9-^[V,92D$UN YC,:LTA+;5]P%@P' 0 D+&HC/R(JJJ(S#=
MN(Y);"_>Z4 4#+/(-N^4(&W ,QSD\G/E"%2#CNAQT&.<L<1B1Y#%&#)$T;9C
M4EB<8=BRDLR<[<XQN//-;4>FSDG]V&![QJSXZ_>^48SVZYP?3F[%HMQ(2#$F
M, KO98B3W"A\;NV<'CC/44&4HMMM+\NQR\:H%(,DKD(JGYE#%5W<#$8RHSP"
M3M'0\UE7.H;6VBVN[A80X\UPP4(=H\M=N>/5B3T&!C->F0>%[N8+MMAF994!
M5[<[2-HR,SH[9ST1&Z<XXS:T_P"&VL?9)X"MQ*UVQ =HY#M"ECA%E2-3][!\
MJ23^'<5^7<"Y)=OQ1YI)-,PAA@MO.:>$3*79D$,:<E"")-WWNN4Z<J>,5&GU
M(*ET8[2*V8R)$O#$-'M$I)P,_>3M[<@U]!6'P>\1R(5MM)O9IY(HX%;:&) #
M@E49T(W;AD*7Q@<YQ7?^'OV4OB1JL4-K8^"M<N][E@@TR\N"[3$8\OR8Y%4G
M;_&R[N I(#8 Y)=OQ1\<*-3F9[AKE4B)1$%O$ ?GR&9F+$?+@$ *,Y/(K2L;
M"[2YD5[VZU!8A&P,R *GF!R410QV#Y>3EMV!@*!S^GOA;_@G#^TCXB$46E_!
MSQD\4GEA9!X?DC@&\MM9I9;F+CAB,(<<Y XS]-^&?^",7[5NK);/<?#J335F
M* 2W=Q;VQ^<GF='G&Q(\99B[8W'"GL!R2[?BC\1_[/G<EBGEYQM5E)SCKMP#
MG&1GIU&,U,ND:AQY5G))N[[&1!CIN8J<9SZ=N]?L=\4O^";/Q9^"6J+I/BCX
M3_&/Q?<&*%X9_A?\.[OQMI=S-(,K9Q:K8:HD45RY9%B$\<*2MYF'Q"Q'W3^S
M/_P1BOOB_P##_3_'GQ&A\<_!*?4+N2%? ?Q$T,V7C"*VA8A;R_TVQU2Y2P2<
M,#!#+*96&XMMV@D-(II)/^M3^8^/P_KDXD6WM(4EPL>]I6,>UW61ED80EHXS
M'"[M*J2!/+ *_.",K]E[X">//CO\2OB-?>!_#]]XJGO;V[L89],TR]NI&TK0
M&6*^N+=;:&5C&L]]%"OG&V$O+1NVQU3^O/X@?\$($OM+N/#_ ($^*6B:'%JE
MK)9WOB.]TS4/[:TV"=X0[:5;K<-#+--"+F.5I+R(IN@9"^74?IW^P;_P3N^#
M7[!W@N[\/^ D?6_%&KV]O;>(?&.H6KQ7U_;1&:86T.9I0F^ZN+B>XG2023!H
MHY(T$8+A1_*-\,O^"0?[2GC[7-*TW_A5^O\ A[3=1U:T@U'5M7MWTI-+M98F
M2\NC+=!3((8)$F,8$6\,%:2/ =O[3?V;?@MX=_9V^"/PY^"OA<QOIGP_\-V6
MCRSH #>ZLYDO-;U)U&?+;4M6N+R]$3-(\ F$+32[!(WM@B 9B"=K$,5+2,=^
M I;<TA&W8J@(% !!;)+</50HP, >BJ%4'DD@ 9Y)R<D\T .HHHH **** "F.
MI;&&VX!((&6#<8(.<;<;@RE3NR.1CE]% &;J.DV.KV<VG:E:VM]I]TICOK&[
ML[.[L]0AD1TGMKVVO(+B">VG5@)8S&&(&/,VD@_FMXM_X))_L4:EXI\0?$;P
M_P#!;PUI?C;5M"UC3EM_*:X\*O<ZD8+LW"Z!?/=65E,FIV=C>6SVGDK;-#(B
M "4/%^G=(RA@01D'J* /Y6_%G_!$'XX?$7QMJOB#4M;\':%I<DL=M86\NJRY
M2RA:3#Q06]O<R*&9C*89)$2(2+'"7 =AH>*/^"$^H>"_ 7BOQ4?B1I-]KVA>
M'[K5-)TRPTZ^G:;5+26W,;F>2XA"1P123LVVWF\S<%/EL%W_ -2)C'&,*>^W
M<N1_P!EZ>^?;'.6O"LBE&+%&R)(VQ(DJ$$-&ZRB3,; D,J[2PX)(R" ?Y^GP
MD_X)5?%.Z\::Y\/?A;I6M_$(_:]6\3>(O&$NCSZ9I=WK^H3->:A!%]HNKC;Y
M*M'9K''<W)S;*X5?/$2XOB7]G*'P#XQN/A]K_AWXO:KXXM_W;^%_!?P0^(?B
M6YFN(I!'-#;:E8Z8VCR!'D0"6:_M%8,6C$@60I_H,66D6&FQM%IMG9:;&Y9Y
M(=/LK:R@DE<YDF:.WCC<R287>WF[CL4YR"3=\IA@K(5(!&T*IC9N=K/NS,=I
MZ@3KNY!.#0!_*E\&/^"&WB/Q_P""M \8^)_$X^'Y\16=O?KX7\3:/JECXJTV
M"0%ECUC2V*+8W15US:M.TD?(DQE2?L3PK_P0B^$FF+&=>^)FK73 )YD>EZ!$
M%EQG?F>_U*1D RNPQPG.6WYPE?O1' D9=AC?(=TC*"NYN222#O*@D[$=W\L$
MJIQ4B*5SDYSC'WSC&?[SOZ]L>^>P!^3WAG_@C7^R)H:Q&_M?%VNRI@N;O4-,
MAA<_Q8B3299(PW\02X!( RQP,>^^&_\ @F]^QUX8"&R^$&D74JE"9M3N+J_=
MS'NVG;-(8H_O-N\F.,/QN!VIM^YZ* /#M#_9I^ ?ALH=&^$7@"T*!-K-X;L;
MF0>7NV%9+I)RI!9B<#YLC(X&/4+/PIX:TX;=.T#1;! %"QV6CZ7:HH3.T*(;
M-#QDXR3CMC)ST-% #$01J%4_*  JA455 [*$50![?EBADW9R?X6 Y<8W8ZX<
M9''(&#Z$4^B@"%(BJ@;]I"! (E"1K@DDI&QD +9 .XO@ ;<$DE!;QK+),,AY
M @;:%0$INPS-&J/(3N_Y:O($Q^[";GW3T4 ,"8S\Q)/7YI",C.-H+G;UY Z\
D<\"A4VYY))ZY9V'&>@=VQUYQC/&>@I]% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $D /,# 2(  A$! Q$!_\0
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MC1D=N?7';@_X4C+GGN!P.Q^M.P!T %9&@444A&<<D8]#_.@!:*** "OY&/\
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M2BA8BHE:U*W;D;W^?]=0>'B[WJ57=6UDM+=4^1-,_!K3/V#_ -O;>6UCX@?
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M)!$WYC>#-1C\-?&__@E-XIEA#6_AOP'X3U:ZV(6<VMDH:ZE +D!DM]YV],]
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M4^&\HXU)""<#;/$<D<X'R+S^/;G%?R^?\,I_"K(6&TU^V., V_BKQ#'CG/\
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MJ"B*;?5EV@\_*-B(N3E>&[8KU?X?+YO@?P7)&Q/^E8(((VE?$EUD9)Z[B3T
M_N@#%>PO=I34HMW4)QDFN5-Q;L^MW=66VC[GG5N6<HMTY7MHKV<H^ZFU:ZZ+
M6VVA^_\ \4F-O<>'++DQV7A+0(8X225B46K.0A'3<2 ?<9/>N/\  /@?5/B;
MXZ\+^!-&>.WO_$VJ1V*7,RM)%8VJQ2W-]?SQKAGBL+*">X9%(:4HL096D!'7
M_%N+&K:2RY(_X1C0BN>23]D/'/;GOU^G7L_V/RP_:4^&N<Y,GB+@<8QX:U3/
M'IUR/;\^:=6]-S;N^7OK>W*OR6W8Z8.,^6*6UU?1ZIZ^7=-;71]!_P##"WP3
MU#Q2?!%I^U$6\;10W,MQX-LY_AM/XE1=.0?VE,?#K&?6HH+3.ZZ\V!_L:$">
M4'+G%LOV'/@9K4MW::)^UO9:E=6-HFH7L%C<?"[49K/3Y+J*PCOKN"SN1)!9
MR7L\-FES,$A:[FBMU;S9%C;Z$U?]@^P?Q#\6O&?A;XAQ>'?&OQ2^*FK_ !,/
MB6[\!:3K%[H(UWX8?$/X67_AM)HM7TF_U73H-)^(^J:II<UQJ-M]BU2RMV-I
M/#-<(_D_B+_@FO+XVO/B1I.J>.O"GA#P%K/CM?%/@BP\*?#+0V\8VL"?"SX=
M?#22R\5>+$O=)@U;PW=VO@_4-2D\&QZ''&NMW.EZE+KUS9:1I^C6W IO7][-
M-)?.^]NF_P K'1R4^1/V:YW.UK145!1;YW+>[E9**6S;;NDCE=-_X)_?#?7+
M^+2O#_[5-MK>I206MVNG:=H?@S6;XVE]:O>V5XUKI6O":.SO+1'N;:[>-;>X
M@ DBE92I/5-_P3#0 ^7\<[T]=HE^'=GWSC<8O%<1;'4[54GV%>T^'_V*IO"^
MO)<Z'XV\*6/AO1]#\>Z9X7LK?X66-EXMM9_B)XF\(^)]1CU[QIIOB6QFU7PY
MX<G\*KI'A7PUINE:##::!<V.GWU]?-X?TR<^Q_#WX*^+? _B&SUY_'>EWB&*
M:#6M,M- \36]MJ<%S*]Q+L;6/B#X@MH+R.9+86^I-ITEXD"W5MYGDW*K".K/
M2TY/J]$OEL1&E%N7-3C%)VC[TFVK:M^];?:Q\22?\$QM3.3!\=;/(!(:?X9S
M.O'0GR_B!$"%[X/)!Z=*%_X)EZ\H8?\ "]=,9]GR ?"^[C4'CDY^(LA*^W!!
M[\5]X7/P@\6+\09?&&D_%WQ9I?A_4-<CU;6/ :6UC-H5U$MB]O<6L-Q,LFIQ
M-?RQV0N'-W]FM;6!X]-L[*>7SQC77P.\57'AF;PTGQ.U2(/K.F:K'K<"^((-
M8ABT[0_[%:Q$T?BU69;U8H;O49Y)G-[-->B2!)98;F%>UJ:>^]/3_+7YW+]E
M#^6WHVOU/AF?_@FAXS#XM_C1X9=/NXF^'VJ1,<@9^:/QE,!UR!@XX!8XS4+?
M\$T_'P+%/B[X2<<! WA#6(N.=Q?&O2\G@ #C&?FYK]'?AY\,M:\$R:\VH>-M
M5\3QZW:Z?&L-_)JC)87UFM_'-J-HU_K6IR69O8+FU6XL]/>TMVNK634/^/FZ
M8Q\DWP;^(C1V41^,^N#[->QWSS)!K:W#/!'I44-NK/XKEAGL'73Y7O;'4H;^
M&]FF25O*=]2.IOVU1*W,]+]%U]4P5*"7+;1WNKOKN? %Q_P39^*2L/LWQ0\!
M2*. 9]#\10GCH2L5U,HZ#=\V#[577_@F_P#&((__ !<OX;%LY7_B4>*BN, <
M_O 3DCG&>#QBOT"_X4W\4EL[ZUM_CUXDM)KW7K36'OQI?VZ[2T@M-6M;C1+8
MZAJMQ%8:?=OJ<&H.+:(A-1TZW>***S(L4]L\&:'K'ASPY8Z/K_B>^\8ZM:O?
M/=>(]2M[6TO=2-UJ%U>1&:ULDCL[<6T-PEG##;(D,<%O$B*%4"A5ZJUYM][I
M/\U^5B50I+:/_DTG^;:_ _(Q?^"=/QF$S0I\1OA?*T:([AM.\70L!(6[^7,G
M\.1U8\@@=:27_@G7\;XV!3QI\,+@+SD2>*8"0>""KZ3(H..>"?Q-?L5%D:E>
M#D;K:U8$]1\TRGEN"!C_ #G-?SQ?M.?'-?A%\=/COX3M?C'\3+_QC\)]<^''
M_"J/B;K7Q<U&'P5^SUX=\2V.C?$7XI>#?&WA:/7+?1/'NNZ]X1U'QM>:!JGQ
M+M-=UJX\-Z?I7AC3O[%L_ -CJNHMUZK6\?*\5^EK_J#P])]&O1L^BW_X)^?'
M&VV%O$7PSE#RQQ KJ?B*(AG)"DAO#SXQCG!ZG@<9"R_L"_'6,F.'5?AQ<RA5
M=HQXFUNV8*S,$DRWA65@C%64'8 S!E!R#C]>K*QM],\.>'-.T_4;[6+:QM]$
MLK/5]3U.;6M2U6WMK>*&'4=1UF=Y9]6O;V%!=7>I32R2WTTDEU([M*2?D/1?
MA[\4X?VD;WQ%-9:Q;Z0-5U;49?%K7T4NA:AH-U916]KICVWF_:)YU2-+&#2.
M(;*0"Z:WACTRTO+MTJE5^UYJU&"A3=7WXM<W+T7OIZ:;7>J21AB+452C"G6J
M>UJQIOV;3Y;V]Z5XRLDKZOECH[R5T?'/_#!?[0:=OAHP'1CXSUH-QCG'_"%*
MOKQGMUYJ"?\ 80_:'7=Y</P\?/(D'C"_"\G/_+3PPA.?N@D=2..]?=$/PW_:
M[CM9(Y/C;X:DE.L1WD3QZ9:^:NEA"KZ?]HG\(2(VZ+$(9[<O]H)U$3*56SKT
M;X8^%_CUHGB/Q5>_%?Q[H/B_P]>P6J>'+#1-/BT\:?,M\KR2-:)HUC+ #%Y[
M,)=4U4^3<VEEO+:8]]?U*<XQE+VV&DHQ32BJG-)Z72O%+2]]UHGJ3%\TH1>&
MQ4%*23DU3Y8JS?--JHVHZ6T3=VM-[?F&W[#/[1\;*PTKP1,@ !:+QF.23C:J
MS:/".^ 2PYXQZB_L2_M'*QQX<\,L!G)C\8Z;P?[OS1IR,_Q ?KQ]U:MX8^*D
MWQ]T_7_!_P /M*DT_1O']M>^*O'6N^+_ !/X8N+[P)K7A^TTF]TC2-(TZVGT
M?QW#IT1FOK32]4E73-*UFUM;IC;:I;0I<>T?&_2/$&M^")=/\-2^*H-2/BG0
MKT2>#KC5K75Q%IM_;:@5DET7QGX"OI-+EEMHH=6M?[?^S7MA+/97>GW]O</$
M*=6I3=+]Y0Y:B3=O>=-N7+::4URM_$E*2;B[Z75RG-3CB)*E6BZ$Y02DG%5K
M1O>E*4/?C?W>:,7'FT3E9L_*67]BS]I(%R/!V@L3P,>-=#7>3Q@;I%P>^"1Q
MG'. 8'_8T_:97;Y?@/2)%'0IXY\,888X8"2Y3@_4?0U^L/P/N?$]_P##?0KO
MQAI_BG3-=GUG6I;G3_&=M?66O6\*:CJ$-KY]MJ/BWQK=16TL"1W%BKZ_.OV.
M6$K;6((M8_ECP3I>KZ=^UIJEE-XHU*WF?Q?XMUFX:]M+U[#5]%O=#U.ZM/!.
MCW TV"UD\LW=IK=U-J>J7EQ9KX<:VT>!;9G%O49U*CKQE*G%T8REI&4E+ENF
MDXR:NG973:L[WW8JM51CAG&E4J1Q%2$.;F5.5+G5U*49P3M:]TU&2M;1L^1$
M_8]_:41B&^'MHFT\,OC#PO*"?;;J&3]<8X[YKR'Q?X%\9?#_ %M_#?C[P[>>
M'M92WCO((+EH9[>\LIF>-;S3K^TDFL[^W\V)X9'@E9X)D:*=(GP#^SWQUO?'
MUCI?AP^ F\8+>-<ZN+UO"=K=W1$9B'V=M12U\)>+?D$A8VOFVD"[]Y#S, @^
M,?VYYK_^S_V>7U03C5)?#/B>359;M&2_>\%IX,-Q'>"2TL)EF6XEG>9)+&S9
M;C?FTMF+1)-.I/FIMN#4W)-*Z<>5=?>>G^:O9EN45.I",*BE246ZDO@GSOEM
M'1)M;NQ^1GQ*TV#P]\0OA-\4]+/]G:[X?\;:)X?EU"-=S3Z3XAOH;2>TO(U9
M6N+6.Z%M=K$67$D9"LOF,:_J;^&^K/K?@?PSJ,LIN)9=*@BFG,8B\V>S+V<S
M^6,A0TD#$ $\8.3G-?S#_%Z&&YT?PXN<)_PL+P"Q8<,/^*GT\$CCDY';MUSC
M%?TM_!0 ?#'PJ <@6MV,]CC4KT$X[$GEO?)I8F-N5MW=VOE9->9K1?O5%HVU
M%MK;JK'JE%%%<IT!7\Q7_!U8@D_X)_\ P[CS@M^T1X9 [\#PKXL)_+&?3UXK
M^G6OYD_^#J!=W[ WPY.!E?VA_#9&>?\ F5?%G;T(ZGL..]:T/X]+?>>W;V4[
M_E^)%3X)7_K5?YGX/?LX1S'P_P#!Y%9%0?LQ^(X$+1^8<&WUHC:1C:5VY()/
M)],"NH^%[RM\//!SMM)6]<#;'C('B"YY;KG.XGD9 ('IC-_9=G6_\+?":(1*
M?L_[/'B:*0@%G&VVU\ C<P&[H!Z#IG QH?"K#?#3PP53_5ZG<1C!))":TS<D
MG&0, 8P ,\$C->O%NSC+2,J46M>O*U&_2_Y7..JE92M9PDX1NK>[[KO\U:]M
M#]__ (MS.-2T=01D^%O#[D@=2;,@-Z9.>@XZ>HJ]^S#-*?C]X!59I86,NLA)
M8)#'(I_L._W!60A@&&0P!Z9[<5C?%:0_;-"<@;CX3\/L>3CFTR%&>W&3CT^A
MK0_9@^;]H'X=X.";G6@3TX_L#4B<?@3C/>N"K=4I.VZM9;76O3IH:0Y82@H:
MII13>CNW[S];OYZ'[+/'?;LC6=51<'&-0N@!C';S<>I)Z^_:FYNU()U_5EXP
M-NIW2Y]3Q,,\=^_7M7%:MI5IXN^(&E>#]:EU5_#\/@OQ!XGGL-,UW6_#WV_5
M;77/#FCV$E_>^'M0TO4I[:RM-2OY(+);R.U-W.ES<13R06_E;+_ 7X:K@OI'
MBI &95S\3OBPJ[EVEE&?&^,KN4D#E=RDXR*YH4X<M.=6M*$JE-5%&G1YX\LW
M-1O)U8/F]QW7+IIKU+]K5E*HJ=*$HTYNFW*JX-R48R=E[.2Y;32NW>Z>FQT*
MMJ.[*>(=:R!VU.Z/'_?['^<5*)]47.?$.L_^#*XR/_(I-<V/@?\ #8=--\4#
M'(Q\3OBIQR.A_P"$V/\ DTX_!/X<D\6/BI20,X^)GQ/Y ^OC \^_6J<:%]*U
M2WGAU?\ ]/V7W%\U?7]W3>FG[V6K[?P]/7\#HS=:ID8\1:T/3-_,W)/7+,>!
M^'3KQ2?;=;7A/$^K \D!KK.1D]2<].>2"37/'X)_#_.4B\91@<83XG?$<CH<
M??\ %+].N>M)_P *6\#C&R;QS'C."GQ+\>$@GK@RZ_)^&<X[5+C2OI5E;SHO
M]*OZ"YZ^G[F#[VKJ]_*]*WXG3K?Z\H_Y&75.V,SH>,?[2X_$8[5(-1\0]1XD
MU3VY@(]^L1SU]>*Y)_@[X,CV;M;^(-L&;:F?BAXNBWM@X1/-U4[VYSL7+'L*
MR9-'7P/XP\*Z1I6L>*=0TSQ79>*8[ZR\2^(;_P 1QVESX?M]-O[*^TZ?4VEN
M[.>2.[NK.[B2=K6Y@>%W@%Q;Q2E.*U4)N<E&4[.C.$6H1<I)3=22NDMK,2JU
M$USTE&+:C=58S:<KI>ZHIZOST6NNQZ'_ &KXB4_\C-?\=F6T/YYAY_3ZTIUG
MQ#_T,]V/7Y++C\X:Y;PUX8M_%6CV6N:EJ?BD7VIO?RM;:;KUY865O'#?WEO%
M;VEE9HJ)%#;VR9=]\TC"26:1F8D:A^'6B\EM8\:HO0%/%^I#<!ZY#9(R/SY'
M0CE52JTI*DFGJOWD5IYW5[G>Z5*#<9UI1G'225&4DI+=*7M%S)/JDK]C5M?$
M^MZ5JEMJ-YJL^JZ<(WMK^RDCM3*8)"&2>V,21N9[>0!A&21-&94PI(9?FS6O
MV$OV&/&_B"3X@^-/!'A+QCXUU";QM=>+/%OBF72Y-;\>7/C@S+</\1K86=E8
M^-'\+VS6MAX'3Q'I=\OA*RTC1H-+2,:7;,GO<GPVT20$'5_'JX1925\6ZFI$
M;%=LA.P8C;<N&.%8LN#R,U%^&_A=R0FO^,)W0\M%XQO9Y%Y'H'(YXR?SS0ZE
M:.KHZ6U:DY6=TES6BTD^FJ)<*'2NW_W DG\U[1Z>AT#ZM<VNG^'/#OAGQ%?W
M.G^%])LK ^(=4CL+O4]?FL+*&PAN[MDL+2TDG,<+W%Y<6MC9P75Y,[0VT$ 2
M.F'7_&6!M\4H1U/_ !*M,)ST&0;88)_'VZYK,3X=:0H.W7_':@#OXGO">AP0
M'A8?EQU [U(OP^TP_,OB+QH<=0WB)F'KR&LR<]>_Y@#"O5DKNG!WU2;3LFE=
M*ZNEIUL)PI=*^OG1J+_V[_,O#Q+XVZ#Q*C'GAM(TL?3E;<8[=O7FE/B?QNOW
MM>@X_O:5IXW>PQ$!S[G\JHS_  _BL4:>'Q!XPM[CR9'MWGU&WN(PWELR2-;W
M.FM'<1AE!9'RLB[ER,Y%OX>6L'C6UBN-769/^)+I%^\5I/+;+]IU")Y)/G1A
M)Y:&,^7&'P-^&+ +2C5DI>SE#WNFO,K/OY+^K;-2A%1YX34XJ2@_=E%J3BY+
M1WTLGK?<D3Q;XSS_ ,ART;COI5H,$@\Y4#O^M/'BSQH.NM6##_:TF#GD<G;(
MO;/XXKT(_#GPT>BZD/IJEYC\C(1GWII^''AL_P#03_\ !G<_U8Y_'-;VO:^G
M>*V?KW,SSX>,/&A^[JFFY)R6.DQD;?0[9QR#U/3KSTQ./%WC'!;[=HY; ^8:
M4<DCUQ>9Z$XSTR:[K_A7/A[& ^JK]-2GZ>AR",4I^'6@=I=5&.F-0DX_-"/Z
M55EZ?@!PQ\9>,R<K<Z+Z8.FRC_V_SSZ=*_/+]N77=:U/7/A7'J\EFSP:9XQF
MM_LENT&!+=^'HIA+OFF#[A#&$P%*D-R2W'ZA2?#_ $:&&:2*ZU42)&[HTEVL
MBJR*67*-#AER!N4G!'&1UK\IOVUY!/XB^%K-N#MX:\3SKMPRXDU32%;<3R/]
M7QP1^6:THV52+LNO3?1]M29\O*^9V6E_OT/SM^)09K+PM&2 &^(W@$%B#M"G
MQ'8D@CO]T8Y)'!'-?TN?!K8/AIX5V@*#9W) !XYU"[.0>_KQ^-?S3?$$/)%X
M*4*6,GQ+\!C:.#QKUMGIC[H!//7MUK^ESX/KL^&_A-1G']GR,<\'YKRY;)P<
M'.<=.@' K;$N_+?1WEINM%%:?>94=7)Z+9)+LF]?GL>F4445RFX5_,U_P=,1
M^9^P7\.AAB5_:!T%A@9'R^$/%S'=UX^7(]P.V:_IEK^:;_@Z*!;]@_X>*/O'
MX^:/@8R#CP9XQP3VX'/^<5MA_P#>*+>UZEUW3I31G4BI0<7L[7_\"1^"7[&9
MBOO#OP_RS221?!;Q%8N%< *C6>O,8PH^ZP;!/&=KJ00<5K_"M#_PK71.ORZW
M?JP&=JF/4U&U!G)7')([D^U<_P#L,1E=-\#1.C".7X8^(2#E1N M=84[=O!!
M"D8ZCH><5T?POD+?#FQ!.TQ^(=55,C 5/MT+C &!_%R1S^5>C'13NFTX*VNW
M_#7U1R8B7NT^;WN6I'163Y4U:]NW5^1^]_Q<)6]\.C!^;PAX= &>,?9&XX[Y
M/)ZXX]*V/V7&V_M!_#AF[7FK9'3(.A:DO]>/I6;\69(9+CPS*I!!\&>'CDJ.
M&^SLIZYY&W@]1@U=_9A<']H'X<$'_F(:GD9.2!HNHYX/;'7MC/O7+5LX24ND
M'JMKVDK>JZW+IQ;:DMU*.EG>S=[^B6C\T?KSI,ZQ?&FR+0K*/^%5>(VD5^4>
M-?%O@\O$ZGJ'#8(_NY'>OR_C_8X_X*">"_%VK-\)_P!IN/POX"-[XL\"^#=/
MT_Q0)M4\/_!CPU=23_ B#Q(_C3P1XLBU?7]+TOQ=\1-(\0_V,EOJ-CJ\7@K7
MQK6M0::UK:?IY8NJ?&&W?G,?PJ\3Y&,*1_PE'@]BIQS@X Z@=^HP?</^$>!C
MAFGUQ+-IH(KAH2ELBHDC(H(,LJN4$DL4&\X#2NJ\,X!R:IJA@W4E)*6%@ER1
M<GS*=>]TM5;;ML.DFWB>6SDL5/>5MZ=!]GT_JQ^.,?P:_P""M>DW%W'I_P"T
M/X/\2PQ'4-'M9M9\<:192WFBW5E<Z1X-U^".'X(3-HOB[P+ &UOX@27$VM6?
MQ;U_4K"?3[/PQ%H,]M?_ *(?LX>'OC-X5^#GASP]\?O$</B_XJ6&H>)QK'B<
M:M'KMWJ^DS^)=3NO#%QK&I6VC>'].?7%\/S:?#JEMHFDV>A6,\?V/288[.%(
MT^BQX0G4G&L3?-U(MHASCKP_/T(_^NV;PS<VT,UQ_:LDYABDD$<ENBJ^Q&8A
MBK[CD#@]CSS6:]@]'S-O2[IR2UT5_O\ U-9*JT]DE>ROJU;]3"W2J, C:!GZ
MX&3TX['Z?A4)F9L#KWZ8'U)_/&.M:FFZ6-4L[:ZEU/[!]L,JVUOM@8R>2',N
M/-</(P2.21E0?)$K,25!:KT7@]'2.6+69)(W4212);P.CI( RNC*Y5T=3E64
MX8$$$@U,Z>'NXR4TX-Q]V+:TOL^U_EU%%55!Z^\[.+;3MIU1\Z?''X<2?$W3
M_!=LGAV+Q WA_P 766KI'+XAE\.?V-,'MS#XD\Z*:!M5M]':W=[O029SJD4Z
MQBSN]AC&[\0)8S\1_ABR XFD^(\B=!A?[(TI@"/X<C&%'"C %>Z?\(C*",:O
M.0#G/V:$'KT/S9(]<8]J^>_&[A?B%\+X7<&2VD^)$#L%X+QZ)I@9AW"G:& /
MO773E"K2JP3E)4</7<$TTH<\'=J[T4FK62U\SF=!TZBJMWG5K45)ZV]UV3MY
M1MMYZ'@/[1OPN^-WQK_9I\,?#7X#>,],^&_B/5_&VCZYX@\=:CJ&NV$^B^'O
M NNZUXUL=,TV/PU>Z9K-Z_BOQOH7A#PUK4-OJMC;P^%M1UZ:_34[(3Z1?_,^
MK_"C_@K"-9A\4^'/CI9:9J_C31['4_'.C7?B?X9>)O"/@7Q);ZC\6YM,\'_#
M[1-8^&6FP1^#M'MM=^'\/B#7)#?^(O%%IIT!\V>^T7=+^IGPQM7U#POX?M5G
M\@O;:O*TFW<0L6M7X;C(!8LZ\N<$9.<UZ/#X?AN24M_$*SN(XI62%+64K%/O
M\B0^7,SK'+Y<GE/]V78^TG#5XM*55)J*O%-VO&_K9IJY[6+Y?K%;22:FTT[.
M^D7=:*RLUH[GX_>#?@A_P4,L_C5X'C\:^,O#-_\  /PEXN\:>+]8GC\;Z5<>
M,/&?B'Q!I7Q L]/\5ZCINB>$M!DL=0GG\7@:[X6BNY/"(:+2KW1=-TK^QX;"
MU^WM"\$?$1M \8Z3X;\17/PN\3:G!H2Z1XQN-+@UE+8:?JR76HQ#3WE,=T+Z
MR$EJ1*T1"S&92'0$?5A\).P/_$VG)]X$P#P>/GY[<8P165>Z5-97NGZ>ET)6
MU(NBRR1A3%Y)4R-M4X?$9!0':-WRGBO7P^;8K"83$X2GAZ$H8J=*4IU::J2C
M*G*$HJ*?N\LI0BI1FI*2;3/*Q&"I8BK3J.=:+A&47[.;A>,E)/9J49*]U*+4
MDU=,\\^&.D?$+0/A]X<T/XJ>-M/^(WCK38M1M]6\8Z;IG]DP:M;-J%P^DB6T
M\BUW7EOIK00WER+>(SSJSMYLFZXE["*Y$$J-("0)$8*!D@(P)ZCDC'0]<\]*
MZ8>&!(VU=9E? 4L$A@^56^X2%DZ, =I(&X#C."*4^#\_\Q27O]ZUB;^;_GZU
MQ5*U6K4E4E2493E*<HTXPIT^:3;:A!>[3BF[1@K**LDDDDNJC3A1I1HQE.48
MQC%2J.4YM1V<YRO*<N\I-N3U;OJ?/7PD\!7?@72/%T-UIUWI]QKOBN_UB22[
MUY=>.JC[%' VKV\@N;DZ=97[AYK?2Y?L]W;?O&NK6&23YNQ^$.GVNK^';[2;
MY9FLM1\':'IUXMO=75C.]K>65[;7"P7MA-;7MG*T+N(KFSN(+JW8B6WFBF1)
M%[[5]+DTE(0;MKF.=;B,>8@1E=+=W&-I(VD9X..0.M<)\$I773)F3+LGA?PV
M43GYG$%WM&!C))P,=\X[UFISJ8FI.I93E3BVDK*UU%?<HK_AK6Z8TH4\$E"_
M+&O%)O=_NZC?EHY/Y6\S\U?"7[.G_!3?X4Z#X;\!?"[XT:?I?@>./7HKW_A(
M]>TGXL>+='NKN;P]<IJ7_"=?&'2_%'B?4I+G[=XP;3DU"?Q#9:5>:9X<L%T2
MUT%K@-[/^S)X&_X*-Z%\>T\5_M#^+O#>M?#;Q/HM[%X\T/2M7\'R:-IVOZ1X
M<L[/PK?> ]/TSPE9ZY8:3)?_ &E+_2+F\M[J\O[O5]<U?7KRTL_#N@U]A^/?
MB1\5_#.M0VW@_P"$-_\ $K0W@1KG4=,\8^&/"]_;74EO++Y$>G^)H8(+F.*X
MC2WG<7R/$DZ3*LI5TKXJ_P""HW[5_P"U5^R[\ O 'CC]F#X8#X@>+/$WQ6\.
M^%/'6J2> /%?Q-MOAIX-U#2=2OK[7;CP?X*N++6-:+:M:V6AQ:E"ZZ=;/=&2
M:/?-!CW^'\CQG$N=Y9D&7U,#1QN;8N&#PU7,L=A\MP%.I.%:ISXK'8J4:&&I
M*-"=YU'K-TZ<(RJ5:<)>+G&:X;),KQN;XN&)J87 4)8BM#!X>IB\5.$90CRT
M,-13J5JC=2-H1ULI2;48R:_5JH;@,T$X0$N89 @5@K%BC;0K,0%8G&&) !P2
M0!7\B7A__@K5_P %8KO6/A\-(^$%E\1[C7?%_A/3=3\ 1_L7_M">!-8O-.U3
M7+;3M9LCXIUC5I-!T;[-;R2SC69))[2"W$=](QC26"OZB/B!XX^(_AF[TW_A
M#_AQ-X^M9PCZU!:^)M&\/7^DQ_;;>&XCL%UN VNKW4%E)<7L<0NK:.[:!;=)
M86E1V^DXY\.\\\/YY5#.L;P]BWF]+%U<-_8>>83-Y4E@JU&C5CC:6'C"K@Y3
ME6@\.ZT/9XF"JRHU9^RJ*/A\*\:95QA','EF&SC#?V=4H4J_]JY97R[GEB:<
MZE-X>5652%=1C!^TY)7I2<%.*OIY=^SYX*^)6E>)?B_X\^)6H>*X]0\:)X5L
M]+\+:O?_ &O0M"T[PUX?>P:33<WMZIU74+Y[J?6;BT,>G7$C0W%F-D[10?"G
M[9<N/%/PQ4@ #P1K3 Y!(9]?M5(4#'R@*N3R0>]?K%X,\0^(?$GAU-3\2^&+
M_P &ZK<6>HF]\+ZE?:5JUUI!@N9H+3S=6T*232KPZC:HE\$MW9[59!;RDNC,
M?R1_;/<#Q;\+>A_XH+6"<#!&?$5N!P2"0/O ^IKXAUJE3$PJ3L[I0M",8J,8
M4XTZ:M%+:*U;O*6KE*4FV?3PH1I4O9TW)KFE.\Y.4G*4W.3;DV]6W9:):)))
M6/@;QXRR3_#Z)@Q63XG^!E(5BC,PU4.H!!'\2#(QTSQUK^F3X0KL^&O@\8VD
MZ1&Q&<GYIIF_J>G'I7\SOC-5DU/X; D^7_PM#P:YXRW[J\ED)XY !4<\<9]:
M_IG^%9+?#KP@5S\VAVA';.2YSZ\CG/0_E6E=/E@[IIRG:WI'\OU+C%1G)):<
ML7O?=R;/0Z***YC0*_FR_P"#GY _["?P_P"X7X\:0Q ZD+X,\8;OR7<3]/7%
M?TFU_-K_ ,'/3!/V$? 4A *I\=],+=1P?!7C0<$<YR<X')(K6A?ZQ1LKN\]/
M^X<_TOZD5/@EZ?U^-C\ ?V*IXXM.^%HC0A;CX?\ B2+YL\K(NJ!,9)VC+%0,
M Y//;&[\*U#_  ]0;=IB\3:JO).%)NK?)]U 8?,0.A]*XS]B*9)].^%4N';/
M@7Q B$G!VK<:BB,5ZX&3C'H"3S7;?#0B/X>W&T8QXBU9AP<G=/:O@@Y.0#U_
M+I7I*Z4NMH*S[ZZ^MSAK6C%2GMSQ;2U]U*[6FME?1=3]Y_BL I\)%G!SX*\/
ML,8Y_<RC.!G@G/3UQV!J[^S$VS]H+X; XPVJ:B,]-P_L34>1['CI69\5FWQ>
M"WQ@GP+X>) '0>3,0>?4<_7%7?V82?\ AH+X9\':VK7Z9ZG_ ) FH]?KR.E<
MD_X4]+>[*Z6U_>37HW>[.NG9R<XIJ#A'E=K+?HOZ[GZ^0N8_B]:MP0WPM\5)
MR,GCQ-X/P>F.,GD=B.Y%=MX\^"$GCWQ#IGBNV\1V6E&'PU:Z/<Z1J/AF#Q)I
M6M;$OEM9M:M;W4[9)HM'35;R_P!$@T\:8\&OBRU74+C4TTZRLX>$WC_A;5FI
M &?A?XLR<G(V^(_!F #DC!/4>W6OK?3CFPLO7[':D^G,"'BLIK_9<!+;_9ME
MLU[2ND_P_JYCA9+VN-BMUBYN7D_9873TLT_FT>;^#?!'BW0Y_#UUKOCN_P!7
M71/#^H^&[G2%A4Z5J\":J9O#NN7;2[;A/$>GZ/'!I^I7T8$>J227,LL8_<E/
M2[S_ (\[OG_EVG]/^>3^U6:KWG_'I=?]>T__ **:L#K>S]';[F?/?B;X-:+\
M7O#/A8:SJNJZ7)X>C\1/I,NER)&8M1U1[>."]N-PW3Q6;60$U@)(H=1MY[BR
MNG-M-*DFEH_PL\>:/H\.@Z;\49= L;#6KW4K-M \*Z%'%-::L6OM0TG^S-2@
MOK;1])L]6NKXZ!I^GSS#3=.^QVKW-RD'ECTWP.V[PSIS?]?73I_Q]3=?<=*Z
MVM*RM5JKM4FONDT*+O&+[Q3^](\Q^'WA#QMX2NM=3Q1\1]1^(&EWPTV31?[9
MTG3;#5-(N8X[D:PCW6EQVUO=6-Y*;62QA>V\^R6.2)[BX#!Z\.\=<_$KX=''
MS?VA\3SC(!Q_96FJ![X&>>_?W^O6(P.AZ_0\'_'IWKY"\=8/Q-^'3 8/]H?$
MY2./^@38GM]!^7M6V#CS?7EVP=62Z7:A5:3\N_HCFQ5OW"NT_K%.UNMGK?Y'
M<?"ZQCU;PIIVEW 1H-0T'Q/8S*X=XS'>:I>V\@=8I8)&39(P98YX9""0LL;8
M=<;P+^SI=_#Z:PDT;QW<RM]BU'1M9OUT+3-*UJ_T;5-.A@-LNJV8FN6;0K[3
M-%G\(^<YET"WBU*(W=_)J<\IZ7X-Y71_#P ./L&NYSUXUVZ_QSC'MP:]Z) Z
M]_<?Y_*O,PK;IW_O/\D>KC?]ZK_X[KS3C!K\/R,3PUI5YH>@:3H^H:S>^(KW
M3K*&TN==U&.&/4-5DA7:;V]6W5(/M4P :=HD1))-SA$W;1G:SG_A(O# SQOO
MR<D#.(H\ >O4G\.YKK00>17(ZT<>(O# VYS)?<^F(X^?R_']:UJ?"O\ '#_T
MI'-'=^C_ "/"M%_9OO\ PAKFN^(_!OQ3\6:?J6L>&],T&.'5E36=/MKC3WLT
M.IO;O<VYN7:SANH+6U<K%ITET'LY(X8FMYO<O!?AG5?"UA?V6J^+=7\8/=ZM
M>:C;WVMQP+>V=O=%"NFI);[8Y+2U*G[,!'%Y:L4"X QV&1TR,^F:6M!'%>,S
MB+3><'S[K'_@%+_^K\:\H^#/VU-!NY-.2WDU'_A#_#[V4=TSK;27HLKLVR7+
M1_O$MY)@B2M'\ZQEBGS 5ZIXV)$&G$?\]KSGN#]AFQC^?U KS/X(.4TMR!DI
MX6\-D#."0D%UW!XSZY%81_WBI_UZA_Z5(ZW=X*/98AV\[P:U].AQMC\=OCJD
M).M?LH^-8W2Z$!DTOQAX2NQ-$Q23[5%:?:6D2&.WF3<);@227$%W"D:ND"3S
M:A\6_CZ+ZU^P? ^]MK&[M?#UPJ7JG4;BRFUBTM_[5TW4+O3]7@ACG\-:CYB:
MA>6]G<6MWIUU!<Z<+BZT[4;(^B>'+;QC:QZDOB+7FU>6;4;RZTV:VM4MS::4
M\=N+>PF6U@L%DD@F^T-YC+<N8VB#W4C9"Z)N=1 <F6\.QL JCDMA006!N >>
M>,\UOY'(>MT5Y +B_81_/= NP4XCEXRI)P!<=01QS] >#4R-?F1T\V]^55(W
M1;OO%A@AILC@ CJ3GGI2LO+L!ZE=<VMR/6WF_P#1;5^)O[9Q_P"*V^&: 94?
M#_5V!.22Q\36Z\]L 9S[$=P*_8+0GF\G44FEE<+:SX$H"GY2Z@[0S\X!YSDC
M P !7Y%_M@6-QJ/CSX:V]I#+/=2> =0C@MK>)YIKB:;Q-"%@AAC!DDE9E551
M%9G8JJJ>#6%?$4<*E7Q%:-"C33E4J3DHPBKKWI-[)='YVW:O%2:IP<WLK=]6
MVDEI=ZM]#X!\7!CKOPO0,,-\3?#!X ;&UKKJ.<X)!X]!^/\ 33\*E*_#CP6"
M<G_A'M..<8R#"&''T-?S<>./#.LZ/XI^&UEK&EZAI-];?$GP_P#:++5+*YL;
MRV<)-*([BVNECFB9HRLB!T&],,A88-?TE_"_Y?AWX+!P#_PCFE\?6V3]*UPV
M/P>8X2&(P.)I8JA[6K!5*4N://!\M2.R:<9*TDTFGNEH<^&JJI*;4N;1*5[W
M34I*S32:TO:Z7H=Y129]B?R_QHJSK%K^;/\ X.>U#?L)>  3@?\ "^-,R3]T
M >"?&A)8]NG!]J_I,K^;/_@Z ?9^P;X#)Q\WQXTA/Q;P/XV 'T/.?;\CMAO]
MYH_XI7].2:?X&=7^'+Y?^E(_G5_8FN0D?P:2W<XF\+^);>0;N!LO-1&T+VW9
MR"2,CIP!7IWPR/F^ [\%R0GB76,GIC8EFRCG'7/RC/7KQ7C?[$K$GX,R6R9$
M6@>(C*,''F_:[XL!TRO(SC@$XSTKV;X9@+X"U8=/^*EU9@!GC_1[)F')]1SS
MCMS7ITY*FV]FTEKW?K?I8\_$24(Q4W?EGH^UE^CW[]3]U/B:?]$\#.._@3P^
M.Y.5CF&<GL/;BM/]F+<W[0OPL53][6;YCN P -$U(L6YSVX/7-8WQ$8OI?@)
MCDE_ >@R$DC=@I(!G& 3C.<<<GCFM?\ 9D!_X:$^%C+@_P#$]NQD>^BZD/IQ
M[^O'6N.K_#JZ_9GKUVDWOZL[J<VVE*T?<B^6R5Y/3\=['ZZRIM^+>G$ C=\,
M/%ZC.>#_ ,)%X)QU]=W'L#@8KSW]M+]N;Q)^Q/X/A\;?\,??M'?M"_#K0/AG
MXD^)'Q%^(WP:NO@M:>$_AAX=\%:<^I:R_C&7XH?%GX?:J)DT:UO-8C&@Z3K4
M36=K(AD%XT5J_I5P\?\ PM[2XRP+/\,O&$@/3&/$'@D '/7&,KUQTQ7CO_!0
M+X#_ !;_ &K?"?[-O[-/A31(W^ ?Q#^.7@3Q-^V/XKEUW3M-^R_L_?")%^)<
MGPSMM)EGCU?7)OC?X_T#P7\/M5CTFWG@LO!MWXM?5_*M)X]\U;+ 95HU?#2B
MKV5U&I7:]=']YS85_P"T8]?]1%WZNG07Y(\9T;_@LU\']3^+'P[\!WOP#_:(
MT#X?^*?%7[/_ ,(/B!\?-7T'P?!\+O@?^TO^TQX!\-_$/X8_LZ_$@+XP?Q8/
M&8TOQEX/T/QAK_AWPYK?@OP=XQ\7>&O#6M:[#=ZC*]I^P=[_ ,>=W_UZS_\
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M5UK;4[.BBBOJ#V1!P!["OYM/^#H"40_L&^ 9"%)_X7[HN%89)SX%\<MP#SG
MSQS7])G?\#_3_/XU_-M_P<_Q(_[!G@%Y%)"?'[1,8..#X$\>#KV&5!/0G%;8
M>WUBC?;FE_Z;F95G:E-^2_\ 2HG\W7[#EVA?X1RQ*3&_ASQ%$X(P=[7LS2-@
MY((/&..HKV3X9L)/ VMJ"% \2ZL/FR=N;2P//7&2>.V.G2O"/V'KJ%!\(YI"
MD<9TOQ4C C"L5NGR".3G@D'USBO;/A<V?!/B58P3CQ-J!7H>&T^P8D=>FW/K
MD\\UZ=-)KT4;7ZZJ]^VE_P #S\3'2%VGJWKM=I-_C]]V?NS\1 4T;X=%0 /^
M%>Z F!\QPJ2@#DDA>X/;(&1VU/V8Y#_PT)\+<'@:_=Y "_\ 0%U/CGI@\CV!
M'K5+X@1#^P?AP6/+_#WP^W(_O1N001SUZCT'7)Q5K]F3"_M$?"WCY/\ A(;K
M/7!_XD^IKT]#G)ZGDUS5_@J)Z7C/5;V<9?+S_ ZHOGE%QL^51DVW9M:+YI,_
M8&<Q_P#"X_#R,8_M%W\-_&<=O"64371M]>\#32I!%D/*\<1,L@B5F6(,Y 12
MP]@CUSQ=:Q1P170$,,:11";3 \@C0;4W2D#>0H522-Q())).:\_\5>$?#OB^
M.SL=>\,V7B7^SY1J%E%=6T<TEA<B*2 W=M.SQ36DCP326TLD$T;312-#()(S
MMKA3\#/ ;D%?AAII/.%8G W'D?-J#=@,\8]?6EA,?@Y8;#T,1AYU'AZ?LXRC
M&G--<\Y.2YZD.5M5$I1:?PZ.SL<\\+B85:]3#U(+VU15'S2E%J\81<;*,TTN
M2Z>CU:T6_NC^*_%408RZI:Q8S@OI]J@XZ??(Z5FS>-=9F22WN_$&G+#*CQR!
M1IMN[(P*LH?>'C)'&Y2",\<UXY'\#/ @W*OPQT%5S@K*EM(!CD9\ZYD!')'3
MH.>]:,/P8\'PDE/AEX1 (PIDT[1925 Z'S('/U!)!XY].I8S+(RNL%-I:J7L
MZ"E=6M[LJK7FO-:B6'Q\DU+$02:M;GF[WT=VJ:?W/TLST"U\8SZ9&+/3O%&E
MVMMN9UB-QI$P0N<OY;3-(R#/) (&XEA@D@O;XAW<>3/XXTE0"3EKOP_$/3@E
ME.!Z@^Q%<0/@YX1#8'PN\!]B2VA>&3].3ISENG0GU/L9C\(/"Y&$^&OP_4<
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MF<<#@X/T]Z1_"UPY!;4+?CTT_D_4FY_H<^HJOJ];75;V6SNO6_K]Y+Q^&_Z
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M\-R^+M1^'7AR^\06VF21:<6&HP:=:6-M>F./ZI^!_P"S/\/_ ($>)/B1XO\
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M-9OC8E_!7PA=>H^&7ASG@D_Z/SS]3D]>>O6KG[-CD?M _"=<$?\ %5;<\?\
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MU.ZL;S0;W2HK6ZU#3FOYKJPD@N-3A:X&F65CY!)NGOI;8:5J#J5.@^([S3=
MOT-Q?1R+[?J<4<6J^&XH8HXXH[BYV)&BHD8$(&%50%4 D< #FOF.3]M+X#W>
MF?'&[TO3_B9XGO/V>M>T72?%7AG0_@I\2-0\3^)M:\0^);_PEX<F^%&A2>%X
M;KXFVFM>.=&UKPMIWB+P:-1T,:YHFJ2W.JVVFVC:D0#T?P=\=K3Q/XF'AG4_
M!OB/PC+-<SZ7;2ZY"RO<ZQ:#R[VW6&&W,0TT7\&J:39:Q]J:#4+_ $B]$$(M
M&M;NXE\8$*4"@*$URZ5   %4Q7. %& .Y.!7:_"OXF>#?C9\-O WQ9\!W=QJ
M?@SQ]X=TOQ9X9N]0TR\TF_.GZI;"> 7NE:G!;ZAI>I6WF26M[974$5S:74<]
MO(H9#GA_&;?O%&!SKMR2?3]U==OT_.@#7TO4-2T_P]>ZAH^F?VWK&F^#;N]T
MC20YB;4]2M[=&LK 2JKM%]KF2*W:148JKEL&KEMX^\56^FI-JOPY\17FI#4-
M7L9[3PY$DT4::9,(H[I9=;DT=9;>^#*]M-!)/;W +FRGO(8GGJOH>M:1X7T2
MY\2^(=4L-%T'P_X.N]:UO6-2N([/3=)TG2[>.^U'4M0NYF2&WLK&S@EN;JXE
M9$AACD=V 4FN3_96_:3\*_M9_![3_C5X+\/>*/"_AS5_%7Q \-Z=I'C.TMM-
M\3>5X$\;Z]X-35=2TJVN;MM)7Q#'HD?B'3M,O94U2STK5+&+5+:TU 7%K" >
M_P"FWCZAI]E?2V-YIDEW;0W$FG:BL*7]D\L:NUK>);3W-NMQ 28Y1#<31!U.
MR5UPQNTP<DD$XXP ?SR#VI] '*^)\@:9Z&[DW?3[.XYK@/AEL^U>(!* \7V2
MTWJ5#*4^U:D7# C# @\J<@C((Q7?>*#A=.7C+74F,_\ 7!N!]0#7G_PU&9_$
M6!PUG; =!UN=2&![\\>]*R>_38#1TC6;V[@AU1_#]MH&JWD4EW=V<\.DOJ-H
M\4CVT<5W>6KM%/,ULL3J\<TBB&58MYV,*TAXDU8DAGB ! SFU4]B2.7[$>OX
MUP6J^)]$T^Z2""#5]>NI;=I/)\,: ==\MB(61;C4;=TTBRE>.1)DM]2U*SN9
MH"L]O%+&RM6+;ZSXRECGU.'PGH\.G0R2Q'0[[Q5H%MXNG6.)2=0A>SN-5\,1
M(Y(C@TFZUB&ZPC275]:2R&U@B:DX2U5-W:A*4XQYFM4U[UTNFMEW9+DEW;[)
M-O\ !?UTN>G#Q-JK*#]HMP"P48GM<\@G_GD>PYYR#C@TY->U>65T2Y4E4#D+
M+"1M<E0<)"S'E3M.1GDCI7DS>)]=U=8H-"CL?!HA:$ZCJGQ".EK.EPZ@I9:+
MH.F:S"FI0JC;[G6KG5X=.C^6*S@OYC(]M'-K7BS0+^VOE\:>&/''V^"72Y="
M6_\ "GA'3M.OI_WNDZQ!=QW5[JDME:7"2VVO+-?:A<MI]Y'/IFF&[LMES*=1
M6C)P4W]A3O)^ZFM>6<8IZN[F[I+:Y#J/F24)--KW[>[;6^[4KK1;=>MF>\Z3
M?7EU;:E]JE,FVSF9=Q5@I E0X(1,9VY*D<#;GM7XB_MFL'^,.B1CJ/A;X38X
M&3\VM^+2-P&<# R#QG)Z@5^S_@QM0;2+B74]3L-7OI;&Y:YOM+A$&G/+NE+P
MVB&YNY#!;ONCBDGN)+AX@C3MYA.?Q6_;(E*_&K30!G;\+O!ZY(X_Y"WBU@%(
M/3#'\5XXKKPMW5AU:ISN_P#P%=E?7R7>R'4<5!2EIJDK:N[T];=V?(M@"?C)
M\(VRK;+KQ,PQSC&DA=Q]COP!TW5_4IX779X;\/#TT+2%/U6P@!K^7#0R9?C-
M\*@ !M_X2B0 ].+" $$<'^(8X]NW/]2>@8&A:(@SQI&FC P.EE!CD^WH:UQ,
M>54?.$I6[7J3T7EH946W4JWZ*":\_>U\V^K-FBF[?]IOSHKE.D=7\Y?_  <Y
M(7_X)^^"L?>'[2G@0#/&2WA'X@J#Z<^F.1TYK^C2OYR_^#G.01_\$_? ['_H
MYOX=KZ@Y\*^/^"._'2M*-U7HM*]I_A9W,JW\.>E]-OFC^3_]DFYV6GPK9WVL
MNE>-8R,=TC!&/ICD8Z$9'2OIGX'.&\(^+$8\KK<>2#G<6TU]K#C@94CT/88K
MY!_9@U 0VGPJ)4H"GC2W0LV26>'.#CN>BX/(&,YKZ\^!QC3PQXS08!&L6@[#
MYO[,D+=,9.3@GGWQ7L1BFW%)N\;I+HM]7Y;'ES7+"G%]K/T3OZ]?P/WT\8_\
MB#\(&;M\-] 4>ORVR9ZXR2>1[$5+^S9+G]H7X1#!R?%\>.G0V%^&'O@=3VQF
MH?&;*/AW\'&)/S_#?0ATP2?LT9/L?0'T]<9J+]FN1!^T3\(]V?\ D<8 .^ ]
MC?#C&!R,YZC!([XKDJQ;IU7=?!4VZI1G;[U8[K7C!O67NMR6W*E9:+:R2U_S
M/WSTOC7KM3QG1XL,0,#_ $F-3GODCG@\CWKYH_;;_9_\:?'OX=?L^1?#GX8_
M#_XC>-?@_P#M5? KXZ:3=_$'QK=>!8?!=E\*?B3I_BWQ'K?A?5+7PCXTDD\8
M:MX=TW4O!^D1G3+:.W7Q'=74VI6L,4B3?3>F@?V[<'&=VD1<D$_=NH\\GC@G
M& .@KJHKS4K53#9WSPPAF?RS##(%:0[FVM(I8 G+%0=NXL0.:\JDU[.FO[BM
M]QUGX+:W_P $P_VL_B9XQ^+7CCQ9X/\ V4OAYK'Q4U?XL?">33O"7BSQ/J?A
M/P;^S?\ $B7PM;>#_%G@?PUIWP@\+0Z?\</@[9>#[SQ)NU*\OA\2OB%\4O&6
ML77CGPEHVB:)I$GW]^PE^QI\1?V3= ^*\GQ*\2?#_7[_ %;P1\&OA%X3_P"%
M<6>N6=KJOP[_ &>_#GBCP[X/\>>-H]<M;-H?BKXZM_%=S<>.-/TI=1T33I-*
MTR'3M=U=&DEB^ZQ?:VQ(?59U!R052W4]#@<0D8SCH >^:8[ZA.K)<:E>7$3@
M!X79!&Q#!AD1HN0" =IX_&M /B3]LW_@GQI'[;]M\$]8U+XU?$WX:7'PGU&T
MO=-T;PNGA&_\*ZA9ZIXB\.WOB[4Y]*\1^%M8OK/QS<^&-%O?"OAKQ7INJ6,F
M@Z=KNMVCVE[9:QJ5O<?*GP\_X(__ !!\.^//#GCGQ7^T?X9U)M3M?V>O OQC
MT7PW\([K2+/Q=\)?V/\ 6OA#XC_9ZTOP1=7_ (\U.Z\"^.+S6_@QHMU\6?$M
MV/%&G:[8^)-6TOPMHGAG^Q="OT_7X17D>$AO]1@AYQ%!>3PQ+N)9MD:,%7))
M) XSDTC1SJ"TFIZHX)P?,O[EN3VP9!Z?3 I75[;/71];=5Y =EK+JNL^'@QY
M-S.",C"AXPH)Z'!;Y02,$D#KBOSV\5_\$_\ Q_XAU;]IWQ%I/[7WQ$\$^)?V
MG="M_!'B3Q+X6^''PUL-<TSP#HH\00>#=/GNAIODZUXT\(Z-XKUKP?8?$?[+
MI6OWG@NW\-:/J$,^H>';?6KC[49K<'][,SN JEYIBTA Y WN^[@\C!X/(P>:
MK-)IW.Z\'7D/?<@Y]'FSU_\ KT76CNM=O/T Z#X2^!5^%7PN\ ?#7^V+;6T\
M ^#]!\)0ZM;>'M \(6M[;>']-M]-M9;7PMX7M+#P[X?M1;VT4=OI.C6=OI]C
M"B06\81 3QGC#:ZB1"&5M=N'1ASD&*Y4,O9@1G!'! R*T3/HR?>O;/D$?-=P
M'MR?FD)/ [ ]P.PK(UNZL+^&RM;2Z@GD2Y+[8&6411QPRH6<QY"C>R*H)&2<
M+T."Z2;NK+?R TX?#?A3QAX5O?!_CO1=$\2>#O%WA"[\.>)/#?B2PM-3\/Z_
MHNK6B6NJ:-K6G:A%+8W^G:A8R7%M>6-Y%);W4$DD,L;JQ4U?@3\#?@3^S%X(
MO/AQ\#/"7A?X;^!KSQ?XO\=2>&O#S0VNF1^)?'6NW?B'Q%=V]N)"MO%<:A>,
MEK9Q;;>PL8;6PM(XK2U@B2+3=<T>/3K*UN[V"&>"WCAF@G#"1'B4QDD%&!+$
M!E()RK C(JT?$'AR/<3?6YP"3MAG<XSV"P$G]3U/2GOJ@/73K>D*,G4K/'M.
MA_D34#>(M%7_ )B-N?H7;\MB-GZ5Y,?%F@*2/M3],_)I]YR"/:V7J/Z4P^*M
M$X.;QP3QMTRZ)YYS@H.XZX[&@#OM;U*RU%K%;*4W!@F>5V5'5%5HF106D106
MW,"%7<< DXX!Y/X;KNGUY5!W-:VJCDY+?:]2&2><<X((Z=?2L^/Q7IC-MBM]
M2) ) _LZ1%+=0&=V55!.%W$<9SR*9X6URW\,W%Y+>6UW-'>V\"@64*2O#-'-
M<2E&1GC^4K<'YPV R8*_," #G$^"L]MXE76=,O;O3]&5M*E?PC)I&B:QI,\]
M@MS'?-)?:S'>ZFL>LQS0B[CM[BW,3VEN\+\,IJ:7\!]4LXM42Y\8^)=0?4[6
MVMXIYM+\#V5SI,D&J)J,EWITMGH$1$UW#&=+F%RMR%L)94BV.RLGL ^)6E'[
MFE:ZPZ FTMUY/0?->9_'FHV^)%L/N:%JS ]"YM(Q_P "_?MM_7_ \KNW:^GW
M!]WW'F=[\";B_P!-L=,D\7^/;,V=_J]^VHZ/XCL-&U.\&JW"31V-[<V6E[)=
M/T=$^S:+;)&@M+=F$AG<AQOI\'83KUQX@N-3\3W-Q<0W]N=.G\3ROHT4.I:;
M%IEPMOIJVZQ0,D40N+5T8-:WC-<P,K' Z<_$HYPOAV]SV+7EJH_$@/CGVZ<^
MU,/Q&O&_U?ATCI_K=30?7[EFWX?S%)M*]VM%=^20$W@WP!;>![;Q$UK>ZQ>'
M652XG&L:U>:U)'+:69MD6VDN@%M(&C +00J!)*&FD+.<U^)G[90*_'"%,@%?
MAIX)SD]-UWXD?'/USQZ^]?M'+X^U6Z22!=)L[994>,SM?33&,.C*2L2VL(=P
M#E27"@@;ABOQ>_;2*CX^3("2(OA]X*B!QUVOKK@'U($@+=!D^IYWPNM926J]
MG*R6[O):^:27XF-9J*BWMS6^]6_6Y\I^&HVE^-GPR VDI:>*I3NR #]FLAU&
M0/J< 9%?U+Z*NW1M)7^[IE@OY6L0K^6SPEEOC=\/!AL)I/B=N .2RV*Y]2>,
M?0XS7]2^EX73=.7IBPM !Z8MX_RX^E:XI?P79J\):/?XY/\ )F>'UG5?^!6Z
MV2=O\ODR_1117(=05_.1_P '.YQ_P3Z\#'T_:?\ AP<8SG_BE_B"V,8/.?R_
M"OZ-Z_G(_P"#GH-_P[V\$LF2X_:@^&H4 =2WA?XA#!Z=AU[=36E&_MZ5OYOT
M9G5_AR]+?-N*1_&W\)-931M)^"KVX*)/J^NQ8)QN-Q $=&)(Y\PL>.XQ]/O/
MX,1F/0?&BY< ZM9L !PN;"93G/&6PN1SW]:_,W1[@:3X$^"=],=LC>+=0W,I
M.(T/D2, I/0 G.."3G/-?H1\$?%5CJ-YXPT6*X,DU]!::C$BJ00]HT]E=*>2
M#Y7VB!CCH0<YXKV*495;6TERV;6UNMW^"74\S$^[=R5ES65NGY6N?T/^-"X^
M''P6!!R?AOH+'(QG_1(<CGZ]!Z'TJC\ M3L-(^/7PDU+4IUM+&#QOI4=S<RL
MJQ0B\$UE$TCL0J(9[F%&=B @;<>!4FFZG#\0?V;_ (+^-+$I)_9&A_\ "'ZY
M''C=::KIJ16RPS<Y1Y)K&]"*<9"J1P06\CF0B5AY;</P>A5U.5*X.X,K ,&X
M((XQUKG=JBG';6<7%6TOS1L_S^9VI)QCRVLDK);-<JM?R>_WG]*]Y!<+.S07
M,UE<*AA\R+:)%4D[T(96##('#J=K#<,'!&9]CU5\>9KVI/EN2'11C'0!8U /
M\Z_"&Q_:8_:#TO3[33+#XK^)DLK*!;:V2<Z;>W$<,8V)&][?Z?<WDZHH"J9K
MB1U  W<<2-^TQ^T/./WOQ=\6'&,JC:5$#GKCRM,0J#Z;NP]*\Z.$KI\J=&T/
M=4FYMV6VB5M>NNA<JW*M(2=K7LK1[;W^ZZU/W<^P76W#:MJA!XYNI!GG./E8
M<<= >W;%(--9P5>^U)P",%KVX !SG(/F  9'KWZU^"5Q^T/\?9\[_BUXV'?$
M>J^5CCK^YB0_R)!QFJ#_ !U^.<VX2?%SQ^59<$+XDU! !G."%<#/H2.@QGTO
MZK5?NN=--WU2GIIIOYDK$Q=]'HK_ -?/0_?Q=$1CDO>L.OS7-V^=N1U\P=>1
MD<\^YI__  C]K(0S03,<E0)7G<,>.1N8YYZ<DYQWK^?1_C#\8;A=LGQ2\?RK
MM*G=XKU@9R<9.VY7D9P,\#T[UER?$3XDS$^?\0?'+X_C;Q7KASSD[L7P/H<^
MO0^J6!JV=ZT6[JSY)-KO;WNO6Y7MF^6T+\RO\25E\_T/Z(#X?L&)#V )P%Q)
M%+D9!ZEAU]/09I1H6F*<_8X <=T &/J3G%?SF2^,_&DN[S_&GB^X)QQ+XHUX
MXYSP3J#8/T _H:I\1^))<B7Q%XCD! R9-?UB0G/^]>$MT')SU)-3_9]2VF(:
MMK_#T^7O7_+U&JD[N\%TM[ZU[WTTM\S^D%M-TJ,,3;VB''\31J1_WTPQSCKW
MHB?3+9AMN+"!@#@?:;:,D'.<[I 2!^F*_FT>^U:?F74]4D!QM$NI7LA_-[@D
M9/;\>]1B2X;<9)[AVXZW,['OG.Z0GZ@]>F*MY=.4/X]M+2]W5OO;F_5D^WE>
MWLU_X'N__ 4?TCRZGX:3+3ZOH,>>K3:OIL?)SWDNACH?YUFR>)_!<182>*?"
M2;21A_$6B \8[&^R>O-?SD>7O8APY7@@AW;.#T(+< >PZX- L(=S-Y:8&>P)
MP<Y!W#]!UYI_4GHE5DK=HV3_ /)OZ9?M';2">G\W7ML?T22^//A[ X\WQMX+
MCR-JA_%.AC\=OVXY /4]/QJO+\3?A9#CSOB)X#CVJ3SXKT12  ,D!;TGZXZ=
MZ_GD^P6^ ?L\9.,'*(> .<\>N,YIPLXD Q;0C=D +&B]"-V,#CMT_.KC@DG=
MU9ORLK?/5_(GVE37W(K73WWMY^Z?T%O\8_@_;;C)\3_ ";1DY\5Z0V._\-R<
M<<_48ZUFR_M _!&'[_Q5\"XP3E=>M9,XZX$1D.>N ,D^U?@E%9QKRJ!2>3A5
MZG&> .G^>]2&/#%0B$ \@KCW.>PYS_.CZM3;=ZE1=K67X*^WGN0\1/2T8)7U
MO=Z=;-6U[=C]V9OVD_@1$!N^*OA$9[I>7$_YB&TD Y[$@X&>E9LO[47P(B8J
M?B=X?8@9(BAU:7@]"#'IK GT /?\:_$2*W)V!HP V20 #USUSZ^I^O:K9C !
MS&-W12.N 0.H[<C /X4_J5/^>N[]7.*MZ+E6GKJ5[6I:Z4'?9:K[[]?30_:1
M_P!JOX"!23\1+&0#C,>EZTP)(QD$::&8 '^Z!FJ,G[6WP&3"KXY64#IY>AZX
MXY[?\>"'KC@X[8/K^,"VTK$A4R,9 '!/H>#]3[''UIYMW5<;"2 .XR<8[9Q]
M/_K4G@:3NO:5=='[ZNUVVV^0>TGLU%OK;HGY)JWK^!^QLO[8WP%MU,C^)]5N
M/+YV6OAC6G>0@=(M]M&A8GY0'D49Y) YK\W?CW\3M/\ BW\3]6\9Z+97=AI+
MZ?I6C:;!J C6\EL](@>-;NZBB:1+>:[FGFF\A9)#%&8T9RRM7C*QR8""/D88
M9&.5YY/J>.@R>PK;TCP_J^NWUMIVD:?<W]]=2B.&SM())IY7<@!4CB5FX.<M
MC:HRS,J@L-:.'IX=\T9STCR^])-)7]%;7L_+84YJI[LDE:2MHWKY7T3^\L?#
M?3I]0^-W@Z2)?,BT_0-9><@9\MKZ[LK2V4X'620$#KG! &<9_J&LHS%9VD;#
M#QVUNC<G[R1(IS]"#UK\<?V6_@//+\2+&#4;"*:YT26SU?Q=>1XFMM/MK"83
MV&@/<(S0M<7E]&%>)&8L%N7!,4!:OV8K#$5%.44KOE6[ZIZZ>0Z-/D<Y7OS6
M3\G&^ENF_P [IA1117.= 5_.A_P<X[1_P3Y\%L_1?VG?AL>N,?\ %+_$'C/.
M,],]1GC.:_HOK^<S_@YX4G_@GGX- )R?VF_AN2!_$!X7^(>0>00,<Y'((!]Z
MTH-*O2;VYM?3K^%_F9UM*4];:+\6E_E_3/X7_$=[)'\(?@Q+;S$>3KFM2-\S
M=42)^21V& #S@8QQP?H3P5X\N_ 47@WQC#%Y]Q+#-=3PY*"YL[FYGAO;:?GY
MXKBWR 1\R2+'.HR@S\\>)UAC^#7PA PZKJ>N-DD,V?*@XR<G R%!YX) YKN9
MIOM/@OX<*>$F\,3/+SD!EU"Z100>N " 3T'MT]2&\)1;A9W6MERZOE=M]%ML
M<=2GS)N6M]&_5+6WF]5^)_0[^S;^T)K?P732;?XC^#_%,7P.^,.DZ7XCBT[Q
M-HFIZ5.=/UNV@N;#Q7X8GN(8DU.RN(!#=&]TB6XP8XK^W<OYD4OZ36G@OX:>
M/[1-:^%'Q-\,ZMI5R!)';:W>-97]H'&X0S75G;WEK<R1Y*L\B:?/G_76R,2!
M^J_[%GPT^'OQ2_X)Z?LG>$_B-X)\,>.?#<W[/_PT231O%.C6&M62N/"VGQ&:
M"*^AF^S7(4$1W-LT,\?6.5<"N>OO^"3O[$$]])>Z1\-?$/@V2=BTMOX+^)/Q
M \/63$DE@+:V\1,BH2<A%PJ[5"!54"N2IB*4YR?+4HU$VFZ:YZ4VFU=J\91E
MWUZFD:=6,8Q2IU8<JY>=N$X.VD4^649+I=I-=F?F.WP'UIG+-XB\"J#PI/B0
M%<XX^7[ 6;/)QQG''LX? B^X,OC3P!;@#YLZ[=2$$\D 1Z4Q&, 8&[)/7@U^
MH<'_  2O_9"A"K)H7Q,N]O0WGQI^*,QQG)''B=!@^P'%:47_  2\_8Q3;Y_P
MX\07VTY'V_XG_$RYY/4_-XL')[GJ>YJ?;4TOCFWU_<O1^5ZW4?)6:^!*^Z]L
MK>5E[*Z2Z)'Y81_!*U4_O_B1\/(@.6']I:NQ."<@8T4+N!';)'7IDU'+\(-
M0D2?%?P @QDXN=48]>20=-3IVY!/7@$&OUF@_P""9/[#D2D/\"=,N]QR3>^+
MOB#=$D'.3YOBP@\\D8P3DD9K2M_^";G[#UN<K^SGX(<#@?:KCQ'>Y Z9%YKL
MX[#J#FD\12LK>UU=OX4-/.ZJ_FDO-@J51_%&*2V7M9/7_P $K_,_(<?"?P4B
MYN/C-X%A(.0B+?N<''!WI$.^<D\],#G%<^ _@_;;A??'#PB"G$ACMI $'H3+
M>IW[@D$X QG%?L_;?\$_OV++1D:+]FCX3,4Q@W7AF"]Z>OVQYPWON#9[YKJ+
M/]B_]D?3\?8_V:?@A"1R&_X5KX3=\GN7DTMW/XL:/K$;-1=57MJXTT_DN:7Y
MC5*6ND.EOWE33OJH)_F_,_#"31/V>;<-]L^/7AY-K G9#I^ /0>9KL1'4'GG
ML>,U4=OV5H01-^T)HV1R0D.@#C('.[Q.&X/'([]NM?O_ &O[+_[-ED +3]G_
M ."\ '("?#'P7@8]FT4^M;T'P(^!]L +;X-?"FW .<0?#OPC$ 1T(\O2% (Q
MZ4E6CU=5^?-!?*W*T4Z,F[_NUHM%[3_AOU[G\[7]J_LCQ9S\>[>8YQB"/PUG
M@XR OB&<_3(Y/0<8IA\2?L@Q,%/QFU*X+#D0V^@G/<[-EW*<#CGYO?L3_2);
M_"[X9V9S:?#KP):GUM_"/A^ \=.8M/7I6Y;^%?#%IC[+X<T&VV_=^SZ/I\./
MIY=NN/PI_6(VLXU'Y\\5I\J:O\[B=&HU92II:?8E?1_XEJ?S0IXG_9$P?^+@
M>,K\AO\ EPTRSDW=>%%O873,#ZCISQTK4B\1?LO#<]N?B[J:#D"R\-ZO*Q[?
M\N_A*<;3D<J6X/ SBOZ8$L[2( 16MM&!T"01(!] JBIP !@  >@&!^0I?6%V
MJ?\ @R*7X4UY=1^RJ/[<%JF[4Y.]MMZGWV1_-)'X@_9U<C[-\/OC[J)ZYM_"
M'C%]P')8>5\/WZC[O.,\>E:*:W\$V"_9?@3^TA?[B"I3P1\17WD],"/P-$",
MXZ<_7I7])=%"Q"ZQJ/UK22^Y0!T9O_EY#_P2G^+F?SDVU[X#GP--_9-_::U,
M-P O@7XC+EAQG+:!:8S[M@@DC! %:B6D,P867["7[35[C&TOX-\=(#[EIYK0
M*,8/(&3C)!(K^B*BI]M&R2IO1WNZM3KZ)?F+V$O^?D5?=JC"[^^3_"Q_/=;Z
M9XKW 67_  3V^/$BCA3?:1J, (Z9(OO%-MC/\0)''4 9QL0:!\4)0/LG_!.3
MXBR-V:_N= M3D?=RU_\ $>#;T!P5(R>>E?OS13]NEM1C\ZM=_/62M\F#H2::
M]J^EFJ5)6[^M_-GX/6W@GX[W7%M_P3JO8"02C:IXJ^'UN,#KO+?$6X<,QQ@%
M<]>G%;$'PR_:CGP+/]@CP;:*0 IU#XA_#&+;U(WB77;YQ@XR<GIWK]R<#T%&
M!Z=.GM2]O_TZA;LYUONTJ;#]A+_G].Z[4Z*_]L9^)4'P>_;!E=?+_8S^"FGD
MY!>^^(OP]FVCLSBUTN]8@?[ )Z?2OHCX:_LX?M$ZPA@^($WPM^#>A7/R7NG?
M#2-/$?BFZ@!W-;IJG_".^&](TSSERC3.VNHJYQ:.<8_2S '0 ?A2U$JKDK>S
MIQ_P^T?_ *75FK>5BXTFKWJU))VNG[-)V_P4XNW_ &]?S.*\!?#_ ,,_#?08
MO#WA>R:VM%D:XNKJYG>[U/5+V0*)M0U6^E EN[R8KRY"Q1(%AMXH8$2)>SY.
M<'VYQCK[9/YTZBL_Q]31)))))););(****!A7\Z7_!SEM'_!/+PC(<8C_:9^
M&YY_O'PS\0L _P"R>K'MCL:_HLR/4?F*_G6_X.<H]_\ P3G\/,!ED_:8^&6W
MVW>&OB$IQVZ'OQ6M!-XBBD[7D]?D^W=Z&5?^%/T_6)_!MXLN=_P8^&+HK)Y>
MH:TIZA=["V)88Z ]B.HR1ZUZ'#<AO _PH0%@3X09W9E 9F;5+W<2.3R.>?7W
M.?+_ !/<#_A2_P - 5?_ )"FJ*"8W^8F*WQG*X)'OCG&.E=]:;SX-^%;$,Q/
MAB2+D$<)JMPN"#CIN[8YR<C->F[IM=5^J_K^KG#.HW>FFY2=N5MV6F[;[]C_
M $\_^"=39_83_9).<Y^ OPYYP.<>'K(#H.G7V]:^SZ^+?^"<^%_81_9)!."/
M@-\.^">>= M/Y8XK[1R/4?G7DR^.?^.7_I3/1CI&*_NK\A:0'/3^1'\Z-P]1
M^=&5]1^8J2A>?P^O],?UHI-P]1^=&1ZC\Q0 M%)D>H_,49'J/S% "T9_S@TF
M1ZC\_P#Z]&1ZC\Q0 M%)D>H_,49'J/S% "^OZ?D/ZYHI,CU'YBC(]1^8H 6B
MFY&<[A^?_P!?'Z4N1ZC\Q0 M%)D>H_,?XT9'J/S_ *9_GF@!:*3(]1^8HRO3
M(_/'ZT '/H,?7^F/ZTM)D>H_,49'J/S% "T4FY?4?G1D>H_,4 +129'J/S'^
M-&1ZC\Q_C0 M%)D>H_,44 +1110 4444 %%%% !1110 4444 %%%% !1110
F4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $/ '(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** .=\5>*] \$Z!JOBCQ/?_P!F:%HEG-J&IWWV6]O?LMI;IYDTWV;3
M[:[O)MB#/EV]O+*W148\5^=:?\%CO^"<$D$]RG[1FZ"VFG@G?_A47QW&R6V9
MDF3:?A@';8RL-R*RMC*%A@U]8_M4 ?\ "@_BD6^Z?!^LY Y./LI!X[G'0=Z_
MSI],=6T77U5@VW6]=Y X -U+A3G!W#'(Q^)K*K4<-DGHWK?L^WH=^"PU+$^T
M]I*<7&4(I1:5U*UV[Q?Z']\/PA_X*A_L+?'G4+K2_A1\<O\ A*[ZR69KJ#_A
M6?Q@T/RA "93YOB3X?Z/"^T \1R.6QA0QK[B\.^(='\5Z'I7B30+S[?HNMV,
M&I:7>?9[JU^TV5R@D@F^S7L%M=P%T(/E7$$,R='C4\5_!!_P2&<CXB^)T'.Y
M-4R&^[CRY.F,G]/6O[E/V>E ^"?PR7 ^3PEIB ^\<1C_ )*!^!'I3I3=2"DT
MDVWMM^;,L90AAZ\J<')Q233DTWKOLDOP/9:***T.4**** "BBB@ HHHH ***
M* "BBB@#Y]_:E_Y(-\3^=I_X0[7"&&,J1:Y##/'!YYXXYXK_ #HM+"C2?$H&
M>->UU3NQN;%U+\QP%7!]@*_T7?VI03\!OB>  Q_X0W7,!NA/V7@'V)ZU_G0:
M<V=+\2G:$_XGNN$@'<.;R7D-UVD9P/T%<]?HNZM^>OXGK94K>WE?:='3U37_
M +;^)]N?\$BI,?$SQ,N3RFIY_&)^1_G)/'2O[F_V=7#_  2^&K9))\,6H]L)
M/<+]>H(^@]J_A5_X)&.1\5?$2GDYU08/O&Y Q^/&?<5_=%^S8ZR? [X;LN"1
MH#(6'(S'?WB%<]#@KSCH??-/#_PEZLQS/_>Y?X8_D>Y4445N>>%%%% !1110
M 4444 %%%% !1110!X!^U%C_ (4-\3\C(/@[7![_ /'HQ.#@XZ5_G,:60-+\
M3*!P-:UHC)S_ ,O<O^/6O]&C]J ;O@3\3EZ;O!VN@?7[&P'ZFO\ .5TG)L/%
M(/W5UW74[8^6]N0.1[!1U[=>>>:ONO+_ ";/7ROX<3_BH?\ MY]D?\$DI GQ
MBUX;CS)J65Q_TQ<@YY_E7]TO[,,AF^!/PZ?<6!TJ\&222=NKZBO)8D_J?N]L
MXK^$[_@DK*%^-.M(2,O+J8YQT$,G\L=?_P!8_NH_97D\WX"_#T\?+8ZJF.!R
MGB#5D.<<9&.1@#)/ &!58?\ A+U9AF?^]S_PQ_(^A****W//"BBB@ HHHH *
M*** "BBB@ HHHH \"_:?7=\"?B:O SX.ULY.< BU."<9XYYX/X]#_G)Z8,Z?
MXL4$'_B?^(#GG'%W*.X!Z^U?Z-W[3A*_ SXF$=1X.UPC(R,BVR.._P!*_P X
MS293):>+F..=?\0 G'<7<O'!]3U].W<\U?=>7_#GK97M7C_-*BT[:)0;O=]/
MB27>Y]8_\$GI0OQPU4;@/](U(,#G)S Y]/\ /TSG^[+]D]MWP$\"DC!5=?4@
M=./$VKX[#G:%S[YK^#__ ()12D?'?4D)()N]0QC'>";/49/W!^O8X']W/[)#
M!O@%X&Z@@^(B0>NX^*-;!'0< YQP#QR3WK#_ ,)>K,LT_P!ZEWY8WMZ'TE11
M16YYP4444 %%%% !116/?ZYIVGN([J?RV)9<(&=@RJ9-I"@[6,:M(%)#%!N
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M"VD%Y%9Z0)+?3V@NI3;:A(\4ZJI^??'."KU:T)^TI^SY6K:WO>]_NLOO#/\
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M***ZSP0HHHH **** "BBB@ KS_XL2>3\+OB3*3@1> ?&$O\ W[\/:B3^F/\
M]6:] KRWXXS"#X+?%^8\"'X7>/Y#]$\*:LV?P"MQ[>XH _AJ_P""#\!/_!33
MX:MC_5^!?BPYQV_XI+5AST]2._\ 6O[YESCGL6 ^@8X'X# K^"__ ((-1"7_
M (*5>!)UYV?#?XK-G_?\.WR#K@]'7KW;V./[T%Z?B?U.1^A%!I4W7^%?FSYZ
M_:6)'PR\4$=1X9\2D?7[# /Z_P">*_S1--4#QG\5R.K>,_$K'ZG4+BO]+?\
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?9T^27/RZO35<K>FG6QZ]1116YY@4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "6 ,@# 2(  A$! Q$!_\0
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M$8 *,I_"3C)]221G-:8\4>*-,7S++5;+7(%.Z1+B,+*RYS\UYC#XY53_  J
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M:@_X)9_!O]HRTFBUK2H;6[9S+::EI[_9K^QRBA@UQCDN1O0\80J.V*^!+_\
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MX4_M"Z5=WNDZ/I7@WQXEOJ45GJ%K%]@L)YAIJ2:=;7ES_P P?3[C4@?M$/\
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K-%% &K9QQ0VT$,,4<$,,8BAAB7;'%#%\D4:*. J(JJ ... !Q1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% (D# 2(  A$! Q$!_\0
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex15-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !B JT# 2(  A$! Q$!_\0
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M>(M&(9(H/+$ + $ %"6(&3D9R#VJC'-XI2.6]-I>#49K"W22808;:L[A\#!
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M_(-PT VS EMH)9AQR!AOQ%06OC*SN;6"7RF#S7*P*FX=#MR_..!O /OQSUH
MP)K[Q;'?Z./*OMTK1S7.V,-$JO*=T9 7@HA R3VKT.N?_P"$I52WF6,B+#(R
MW!W@^4H?8#QUR>PZ"KVDZM_::R;K=H'0(X5F#91QE3Q^/';% $6A_P"OU?\
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M]HF\K.[H<J.,C/\ &.N.AZ\9 -+7O]9I/_80C_\ 06K8K(U[_6:3_P!A"/\
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MN(8))566?=Y2$\O@9./H*H:CXCTO2KP6MY.\<AC$K$1.RHA) 9F PHR#R2*
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M0@DE2%90 3D@5G0:7K+ZG'K=U9*8;ZYDCN(0&\\6\@"*K#IA0J-[<^]>A44
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ML=.%W<ZE&3!< -;JY:20.HC.,9.1TW#D=:ZO5[\Z9IDMVL8<H5 5B0.6"\D
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MU"V5%2:S/V=7?[.RL_F!MS#GY<;1QCO5H>*M,^SSS,9D6+& T9!DRQ0%?7+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>iinn-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 26 19:16:31 UTC 2026 -->
<xs:schema elementFormDefault="qualified" xmlns:iinn="http://InspiraTechnologiesOXYB.H.N.Ltd/20251231" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://InspiraTechnologiesOXYB.H.N.Ltd/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20251231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20251231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20251231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20251231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet" id="iinn_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals" id="iinn_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement" id="iinn_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3" id="iinn_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow" id="iinn_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - STATEMENTS OF CASH FLOW</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERAL" id="iinn_r_GENERAL">
        <link:definition>995306 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIES" id="iinn_r_SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>995307 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENT" id="iinn_r_CASHANDCASHEQUIVALENT">
        <link:definition>995308 - Disclosure - CASH AND CASH EQUIVALENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITS" id="iinn_r_DEPOSITS">
        <link:definition>995309 - Disclosure - DEPOSITS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETS" id="iinn_r_OTHERCURRENTASSETS">
        <link:definition>995310 - Disclosure - OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORY" id="iinn_r_INVENTORY">
        <link:definition>995311 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNET" id="iinn_r_PROPERTYANDEQUIPMENTNET">
        <link:definition>995312 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLE" id="iinn_r_OTHERACCOUNTSPAYABLE">
        <link:definition>995313 - Disclosure - OTHER ACCOUNTS PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIES" id="iinn_r_COMMITMENTSANDCONTINGENCIES">
        <link:definition>995314 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIES" id="iinn_r_LEASELIABILITIES">
        <link:definition>995315 - Disclosure - LEASE LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUE" id="iinn_r_FINACIALLIABILITIESATFAIRVALUE">
        <link:definition>995316 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITY" id="iinn_r_SHAREHOLDERSEQUITY">
        <link:definition>995317 - Disclosure - SHAREHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/REVENUES" id="iinn_r_REVENUES">
        <link:definition>995318 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUES" id="iinn_r_COSTOFREVENUES">
        <link:definition>995319 - Disclosure - COST OF REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSES" id="iinn_r_RESEARCHANDDEVELOPMENTEXPENSES">
        <link:definition>995320 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSES" id="iinn_r_GENERALANDADMINISTRATIVEEXPENSES">
        <link:definition>995321 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSES" id="iinn_r_SALESANDMARKETINGEXPENSES">
        <link:definition>995322 - Disclosure - SALES AND MARKETING EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSES" id="iinn_r_FINANCIALINCOMEANDEXPENSES">
        <link:definition>995323 - Disclosure - FINANCIAL (INCOME) AND EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOME" id="iinn_r_TAXESONINCOME">
        <link:definition>995324 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENT" id="iinn_r_SHAREBASEDPAYMENT">
        <link:definition>995325 - Disclosure - SHARE-BASED PAYMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIES" id="iinn_r_RELATEDPARTIES">
        <link:definition>995326 - Disclosure - RELATED PARTIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTS" id="iinn_r_SUBSEQUENTEVENTS">
        <link:definition>995327 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy" id="iinn_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESTables" id="iinn_r_SIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>996001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETSTables" id="iinn_r_OTHERCURRENTASSETSTables">
        <link:definition>996002 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORYTables" id="iinn_r_INVENTORYTables">
        <link:definition>996003 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNETTables" id="iinn_r_PROPERTYANDEQUIPMENTNETTables">
        <link:definition>996004 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLETables" id="iinn_r_OTHERACCOUNTSPAYABLETables">
        <link:definition>996005 - Disclosure - OTHER ACCOUNTS PAYABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables" id="iinn_r_LEASELIABILITIESTables">
        <link:definition>996006 - Disclosure - LEASE LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUETables" id="iinn_r_FINACIALLIABILITIESATFAIRVALUETables">
        <link:definition>996007 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables" id="iinn_r_SHAREHOLDERSEQUITYTables">
        <link:definition>996008 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUESTables" id="iinn_r_COSTOFREVENUESTables">
        <link:definition>996009 - Disclosure - COST OF REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSESTables" id="iinn_r_RESEARCHANDDEVELOPMENTEXPENSESTables">
        <link:definition>996010 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSESTables" id="iinn_r_GENERALANDADMINISTRATIVEEXPENSESTables">
        <link:definition>996011 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSESTables" id="iinn_r_SALESANDMARKETINGEXPENSESTables">
        <link:definition>996012 - Disclosure - SALES AND MARKETING EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSESTables" id="iinn_r_FINANCIALINCOMEANDEXPENSESTables">
        <link:definition>996013 - Disclosure - FINANCIAL (INCOME) AND EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables" id="iinn_r_TAXESONINCOMETables">
        <link:definition>996014 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables" id="iinn_r_SHAREBASEDPAYMENTTables">
        <link:definition>996015 - Disclosure - SHARE-BASED PAYMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIESTables" id="iinn_r_RELATEDPARTIESTables">
        <link:definition>996016 - Disclosure - RELATED PARTIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails" id="iinn_r_GENERALDetails">
        <link:definition>996017 - Disclosure - GENERAL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" id="iinn_r_SIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>996018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" id="iinn_r_ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable">
        <link:definition>996019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENTDetails" id="iinn_r_CASHANDCASHEQUIVALENTDetails">
        <link:definition>996020 - Disclosure - CASH AND CASH EQUIVALENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails" id="iinn_r_DEPOSITSDetails">
        <link:definition>996021 - Disclosure - DEPOSITS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable" id="iinn_r_ScheduleofOtherCurrentAssetsTable">
        <link:definition>996022 - Disclosure - OTHER CURRENT ASSETS - Schedule of Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable" id="iinn_r_ScheduleofInventoryTable">
        <link:definition>996023 - Disclosure - INVENTORY - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable" id="iinn_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996024 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable" id="iinn_r_ScheduleofOtherAccountsPayableTable">
        <link:definition>996025 - Disclosure - OTHER ACCOUNTS PAYABLE - Schedule of Other Accounts Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails" id="iinn_r_COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>996026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails" id="iinn_r_LEASELIABILITIESDetails">
        <link:definition>996027 - Disclosure - LEASE LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" id="iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable">
        <link:definition>996028 - Disclosure - LEASE LIABILITIES - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" id="iinn_r_ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable">
        <link:definition>996029 - Disclosure - LEASE LIABILITIES - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails" id="iinn_r_FINACIALLIABILITIESATFAIRVALUEDetails">
        <link:definition>996030 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable" id="iinn_r_ScheduleofFinancialLiabilityTable">
        <link:definition>996031 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails" id="iinn_r_SHAREHOLDERSEQUITYDetails">
        <link:definition>996032 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable" id="iinn_r_ScheduleofShareCapitalTable">
        <link:definition>996033 - Disclosure - SHAREHOLDERS&#8217; EQUITY - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable" id="iinn_r_ScheduleofMovementinWarrantsOutstandingTable">
        <link:definition>996034 - Disclosure - SHAREHOLDERS&#8217; EQUITY - Schedule of Movement in Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" id="iinn_r_ScheduleofInformationabouttheCompanysOutstandingWarrantsTable">
        <link:definition>996035 - Disclosure - SHAREHOLDERS&#8217; EQUITY - Schedule of Information about the Company&#8217;s Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" id="iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable">
        <link:definition>996036 - Disclosure - SHAREHOLDERS&#8217; EQUITY - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable" id="iinn_r_ScheduleofCostofRevenuesTable">
        <link:definition>996037 - Disclosure - COST OF REVENUES - Schedule of Cost of Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable" id="iinn_r_ScheduleofResearchandDevelopmentExpensesTable">
        <link:definition>996038 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES - Schedule of Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable" id="iinn_r_ScheduleofGeneralandAdministrativeExpensesTable">
        <link:definition>996039 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable" id="iinn_r_ScheduleofSalesandMarketingExpensesTable">
        <link:definition>996040 - Disclosure - SALES AND MARKETING EXPENSES - Schedule of Sales and Marketing Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable" id="iinn_r_ScheduleofFinancialIncomeandExpensesTable">
        <link:definition>996041 - Disclosure - FINANCIAL (INCOME) AND EXPENSES - Schedule of Financial (Income) and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails" id="iinn_r_TAXESONINCOMEDetails">
        <link:definition>996042 - Disclosure - TAXES ON INCOME (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" id="iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable">
        <link:definition>996043 - Disclosure - TAXES ON INCOME - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable" id="iinn_r_ScheduleofTheoreticalTaxTable">
        <link:definition>996044 - Disclosure - TAXES ON INCOME - Schedule of Theoretical Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable" id="iinn_r_ScheduleofEffectiveTaxRateReconciliationTable">
        <link:definition>996045 - Disclosure - TAXES ON INCOME - Schedule of Effective Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails" id="iinn_r_SHAREBASEDPAYMENTDetails">
        <link:definition>996046 - Disclosure - SHARE-BASED PAYMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" id="iinn_r_ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable">
        <link:definition>996047 - Disclosure - SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" id="iinn_r_ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable">
        <link:definition>996048 - Disclosure - SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" id="iinn_r_ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable">
        <link:definition>996049 - Disclosure - SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" id="iinn_r_ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable">
        <link:definition>996050 - Disclosure - RELATED PARTIES - Schedule of Shareholders and Other Related Parties&#8217; Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails" id="iinn_r_SUBSEQUENTEVENTSDetails">
        <link:definition>996051 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfFinancialLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialLiabilityAbstract"/>
  <xs:element name="ScheduleOfMovementInWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract"/>
  <xs:element name="CostOfRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CostOfRevenuesAbstract"/>
  <xs:element name="ScheduleOfCostOfRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfCostOfRevenuesAbstract"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="ScheduleOfFinancialIncomeAndExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
  <xs:element name="ScheduleOfTheoreticalTaxAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfTheoreticalTaxAbstract"/>
  <xs:element name="ScheduleOfEffectiveTaxRateReconciliationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract"/>
  <xs:element name="ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract"/>
  <xs:element name="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
  <xs:element name="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
  <xs:element name="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract"/>
  <xs:element name="ChangesDuringThePeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract0"/>
  <xs:element name="ChangesDuringThePeriodAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract1"/>
  <xs:element name="ChangesDuringThePeriodAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract2"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CostAbstract"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract3"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccumulatedDepreciationAbstract"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract4"/>
  <xs:element name="NetBookValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NetBookValueAbstract"/>
  <xs:element name="CostAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CostAbstract0"/>
  <xs:element name="AccumulatedDepreciationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccumulatedDepreciationAbstract0"/>
  <xs:element name="NetBookValueAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NetBookValueAbstract0"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_UnlabeledAbstract5"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetsAbstract"/>
  <xs:element name="NonTaxableOrNonDeductibleItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NonTaxableOrNonDeductibleItemsAbstract"/>
  <xs:element name="ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet"/>
  <xs:element name="ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares"/>
  <xs:element name="StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees"/>
  <xs:element name="IssuanceOfOrdinarySharesCommitmentFeesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares"/>
  <xs:element name="ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares"/>
  <xs:element name="ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments"/>
  <xs:element name="StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments"/>
  <xs:element name="ExpirationOfFinancialLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExpirationOfFinancialLiability"/>
  <xs:element name="IssuanceOfOrdinarySharesAdvisorFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
  <xs:element name="FinancialExpensesDueToCommitmentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialExpensesDueToCommitmentFee"/>
  <xs:element name="IssuanceOfOrdinarySharesCommitmentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_IssuanceOfOrdinarySharesCommitmentFee"/>
  <xs:element name="OtherReceivableInConnectionToPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_OtherReceivableInConnectionToPrivatePlacement"/>
  <xs:element name="AccruedIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccruedIssuanceExpenses"/>
  <xs:element name="FinancialLiabilityPlacementAgentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialLiabilityPlacementAgentFee"/>
  <xs:element name="ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
  <xs:element name="NonCashTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_NonCashTransactions"/>
  <xs:element name="CostOfRevenuesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CostOfRevenuesTextBlock"/>
  <xs:element name="GeneralAndAdministrativeExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GeneralAndAdministrativeExpensesTextBlock"/>
  <xs:element name="SalesAndMarketingExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SalesAndMarketingExpensesTextBlock"/>
  <xs:element name="FinanceIncomeAndExpensesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
  <xs:element name="SeverancePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SeverancePolicyTextBlock"/>
  <xs:element name="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
  <xs:element name="ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock"/>
  <xs:element name="ScheduleOfCostOfRevenuesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfCostOfRevenuesTableTextBlock"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfSalesAndMarketingExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfTheoreticalTaxTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
  <xs:element name="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable"/>
  <xs:element name="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems"/>
  <xs:element name="AnnualDepreciationRatesOfPropertyPlantAndEquipment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
  <xs:element name="OthersAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_OthersAsset"/>
  <xs:element name="AccountsPayableToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccountsPayableToRelatedParties"/>
  <xs:element name="FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable"/>
  <xs:element name="FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems"/>
  <xs:element name="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable"/>
  <xs:element name="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
  <xs:element name="COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable"/>
  <xs:element name="COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems"/>
  <xs:element name="Subcontractors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_Subcontractors"/>
  <xs:element name="IIAParticipation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_IIAParticipation"/>
  <xs:element name="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
  <xs:element name="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems"/>
  <xs:element name="FundraisingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FundraisingExpenses"/>
  <xs:element name="RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
  <xs:element name="DeferredTaxAssetsAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetsAccruedExpenses"/>
  <xs:element name="DeferredTaxAssetsFundRaisingCost2023" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetsFundRaisingCost2023"/>
  <xs:element name="DeferredTaxLiabilitiesOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
  <xs:element name="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
  <xs:element name="EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
  <xs:element name="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable"/>
  <xs:element name="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife"/>
  <xs:element name="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
  <xs:element name="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi"/>
  <xs:element name="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
  <xs:element name="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
  <xs:element name="GENERALDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_GENERALDetailsTable"/>
  <xs:element name="GENERALDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GENERALDetailsLineItems"/>
  <xs:element name="AggregateOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateOfferingPrice"/>
  <xs:element name="AggregateGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateGrossProceeds"/>
  <xs:element name="DeductingOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeductingOfferingCosts"/>
  <xs:element name="IncrementalBorrowingRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_IncrementalBorrowingRate"/>
  <xs:element name="SalesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_SalesAmount"/>
  <xs:element name="PaidRoyalties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_PaidRoyalties"/>
  <xs:element name="OrdinarySharesSEPAAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_OrdinarySharesSEPAAmount"/>
  <xs:element name="DEPOSITSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_DEPOSITSDetailsTable"/>
  <xs:element name="DEPOSITSDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DEPOSITSDetailsLineItems"/>
  <xs:element name="AggregateBudget" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateBudget"/>
  <xs:element name="PercentageOfApprovedBudget" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfApprovedBudget"/>
  <xs:element name="ProjectBudgetAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ProjectBudgetAggregateAmount"/>
  <xs:element name="RoyaltiesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RoyaltiesPercentage"/>
  <xs:element name="ContingentUponFutureSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ContingentUponFutureSales"/>
  <xs:element name="LEASELIABILITIESDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_LEASELIABILITIESDetailsTable"/>
  <xs:element name="LEASELIABILITIESDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_LEASELIABILITIESDetailsLineItems"/>
  <xs:element name="MonthlyDeductionFromTerminationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_MonthlyDeductionFromTerminationFee"/>
  <xs:element name="LeaseMonthlyPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_LeaseMonthlyPayment"/>
  <xs:element name="PercentageForCarsLeaseAgreementCancellationPenalty" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageForCarsLeaseAgreementCancellationPenalty"/>
  <xs:element name="PercentageOfFutureLeasePaymentsDiscounted" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfFutureLeasePaymentsDiscounted"/>
  <xs:element name="AgreementDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AgreementDomainDomain"/>
  <xs:element name="FINACIALLIABILITIESATFAIRVALUEDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable"/>
  <xs:element name="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems"/>
  <xs:element name="PercentageOfPayFees" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfPayFees"/>
  <xs:element name="SaleOfRightsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_SaleOfRightsValue"/>
  <xs:element name="OrdinarySharesPurchasePricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OrdinarySharesPurchasePricePercentage"/>
  <xs:element name="DescriptionOfFeePayments" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DescriptionOfFeePayments"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SHAREHOLDERSEQUITYDetailsTable"/>
  <xs:element name="SHAREHOLDERSEQUITYDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SHAREHOLDERSEQUITYDetailsLineItems"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PurchasePricePerShare"/>
  <xs:element name="ClassOfPrivateWarrantOrRightOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_ClassOfPrivateWarrantOrRightOutstanding"/>
  <xs:element name="NumberofAdditionalOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NumberofAdditionalOrdinaryShares"/>
  <xs:element name="PreFundedWarrantsPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PreFundedWarrantsPerShare"/>
  <xs:element name="NumberOfSharesPerUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NumberOfSharesPerUnits"/>
  <xs:element name="PrivateWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PrivateWarrants"/>
  <xs:element name="PurchasePricePerUnit" type="srt-types:perUnitItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PurchasePricePerUnit"/>
  <xs:element name="PreFundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PreFundedWarrants"/>
  <xs:element name="IssueOfPrivateWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_IssueOfPrivateWarrantsShares"/>
  <xs:element name="PrivateWarrantsExerciseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PrivateWarrantsExerciseShares"/>
  <xs:element name="TAXESONINCOMEDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_TAXESONINCOMEDetailsTable"/>
  <xs:element name="TAXESONINCOMEDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TAXESONINCOMEDetailsLineItems"/>
  <xs:element name="SHAREBASEDPAYMENTDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SHAREBASEDPAYMENTDetailsTable"/>
  <xs:element name="SHAREBASEDPAYMENTDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SHAREBASEDPAYMENTDetailsLineItems"/>
  <xs:element name="CapitalGainTaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CapitalGainTaxRate"/>
  <xs:element name="PercentageOfCapitalGainTax" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfCapitalGainTax"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SUBSEQUENTEVENTSDetailsTable"/>
  <xs:element name="SUBSEQUENTEVENTSDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SUBSEQUENTEVENTSDetailsLineItems"/>
  <xs:element name="WarrantsToPurchaseOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsToPurchaseOrdinaryShares"/>
  <xs:element name="StandbyEquityPurchaseAgreementPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_StandbyEquityPurchaseAgreementPercentage"/>
  <xs:element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="iinn_AgreementAxis"/>
  <xs:element name="AdvisorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdvisorMember"/>
  <xs:element name="BankLeumiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_BankLeumiMember"/>
  <xs:element name="December2024PrivatePlacementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_December2024PrivatePlacementMember"/>
  <xs:element name="December2025OfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_December2025OfferingMember"/>
  <xs:element name="DecemberPreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DecemberPreFundedWarrantsMember"/>
  <xs:element name="DecemberPrivateOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DecemberPrivateOfferingMember"/>
  <xs:element name="DecemberPrivatePlacementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DecemberPrivatePlacementMember"/>
  <xs:element name="DecemberPrivateWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DecemberPrivateWarrantsMember"/>
  <xs:element name="DecemberStandbyEquityPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DecemberStandbyEquityPurchaseAgreementMember"/>
  <xs:element name="EmployeesAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesAndDirectorsMember"/>
  <xs:element name="EmployeesDirectorsAndSubcontractorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesDirectorsAndSubcontractorsMember"/>
  <xs:element name="EmployeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesMember"/>
  <xs:element name="ExecutivesAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExecutivesAndDirectorsMember"/>
  <xs:element name="Exercise6875Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_Exercise6875Member"/>
  <xs:element name="ExercisePrice156Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice156Member"/>
  <xs:element name="ExercisePrice55Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice55Member"/>
  <xs:element name="ExercisePriceOnePointOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePriceOnePointOneMember"/>
  <xs:element name="ExercisePriceOnePointSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePriceOnePointSixMember"/>
  <xs:element name="JunePlacementAgentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_JunePlacementAgentWarrantsMember"/>
  <xs:element name="JunePreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_JunePreFundedWarrantsMember"/>
  <xs:element name="MaterialsAndSubcontractorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_MaterialsAndSubcontractorsMember"/>
  <xs:element name="OfficersAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OfficersAndDirectorsMember"/>
  <xs:element name="OrdinarySharesNoParValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OrdinarySharesNoParValueMember"/>
  <xs:element name="PayrollAndRelatedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PayrollAndRelatedMember"/>
  <xs:element name="PlacementAgentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PlacementAgentWarrantsMember"/>
  <xs:element name="PreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PreFundedWarrantsMember"/>
  <xs:element name="PrivateWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PrivateWarrantsMember"/>
  <xs:element name="PurchaserMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PurchaserMember"/>
  <xs:element name="RDEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RDEquipmentMember"/>
  <xs:element name="RegisteredDirectOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RegisteredDirectOfferingMember"/>
  <xs:element name="RevenueAchievementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RevenueAchievementMember"/>
  <xs:element name="RothCapitalPartnersLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RothCapitalPartnersLLCMember"/>
  <xs:element name="RoyaltiesToIIAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RoyaltiesToIIAMember"/>
  <xs:element name="SecondTrancheMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SecondTrancheMember"/>
  <xs:element name="ServiceProvidersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ServiceProvidersMember"/>
  <xs:element name="ServicesProvidersAndAdvisersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ServicesProvidersAndAdvisersMember"/>
  <xs:element name="StandbyEquityPurchaseAgreementSEPAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_StandbyEquityPurchaseAgreementSEPAMember"/>
  <xs:element name="TwoThousandTwentyFourAprilOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TwoThousandTwentyFourAprilOfferingMember"/>
  <xs:element name="TwoThousandTwentyFourJuneOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TwoThousandTwentyFourJuneOfferingMember"/>
  <xs:element name="WarrantsToPurchaseOrdinarySharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsToPurchaseOrdinarySharesMember"/>
  <xs:element name="WarrantyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantyMember"/>
  <xs:element name="YorkvilleMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_YorkvilleMember"/>
<!-- [WMV6][yEv5kQ3X+xv/ahfMPTK0eeM52hgSmVaZFgD2kuS0DIC6wGkY6dez11M+NvvQuXgW5BSyYlqeDMQGCMtyXHH/oXncTuzqn00UhuFll0KiwQSKOopPc9IZkE8caEYcbLH53jRdu0nJQpl1adfIiCQYKsRhg10Jh0izSNteS98XP2Og0e+H3fRxgL3VeESZWQKsJKz3DTExPFHKXdfObME0kev7LN6nkI2TSI4GcsggALWm3ou0yulxR2LfaHQSY/jC3XsCfX9naOajsOKKW/ZdJYVS0GGag7VMZuUVdHQQs34J2vWFVi8atZ5HA0K+sEfzNpoh+s82ppMy7nfn+gYCQn5rOHqZDrH2bt6uF+jZZfx4mvcJRTE=] CSR-->
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>iinn-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 26 19:16:31 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofInventoryTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOtherAccountsPayableTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofEffectiveTaxRateReconciliationTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"/>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingAndMarketingExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForOtherLosses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpensesDueToCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialExpensesDueToCommitmentFee"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iinn_FinancialExpensesDueToCommitmentFee" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesCommitmentFee"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iinn_IssuanceOfOrdinarySharesCommitmentFee" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpirationOfFinancialLiability" xlink:href="iinn-20251231.xsd#iinn_ExpirationOfFinancialLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iinn_ExpirationOfFinancialLiability" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCash" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_NonCashTransactions" xlink:href="iinn-20251231.xsd#iinn_NonCashTransactions"/>
    <loc xlink:type="locator" xlink:label="iinn_AccruedIssuanceExpenses" xlink:href="iinn-20251231.xsd#iinn_AccruedIssuanceExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_AccruedIssuanceExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialLiabilityPlacementAgentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialLiabilityPlacementAgentFee"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_FinancialLiabilityPlacementAgentFee" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:href="iinn-20251231.xsd#iinn_OtherReceivableInConnectionToPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_OtherReceivableInConnectionToPrivatePlacement" order="4" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_InterestBearingDepositsInBanks" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_OthersAsset" xlink:href="iinn-20251231.xsd#iinn_OthersAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="iinn_OthersAsset" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_AccountsPayableToRelatedParties" xlink:href="iinn-20251231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="iinn_AccountsPayableToRelatedParties" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_LaborAndRelatedExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_DepreciationNonproduction" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20251231.xsd#iinn_Subcontractors"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="iinn_Subcontractors" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_IIAParticipation" xlink:href="iinn-20251231.xsd#iinn_IIAParticipation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="iinn_IIAParticipation" order="7" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_ProfessionalFees" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_LaborAndRelatedExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralInsuranceExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_LegalFees" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_CostMaintenance" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_Depreciation" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_FundraisingExpenses" xlink:href="iinn-20251231.xsd#iinn_FundraisingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="iinn_FundraisingExpenses" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="10" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_OfficersCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_ProfessionalFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxAssetsAccruedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
<!-- [WMV6][Pf4ZlVB3qiPih3802XTIv9TVTxZuCTPJ3WJWCrOyue+AtIF2KEJ34FDSB/4FxJRhKqD9Ww+h3ESAwqkQ6cmTBswEs+iMQVL5JZkZdAVdZiM0VBESbU2LQk+fgsWGVp/EymmZVBL19T5eZiD1MuSZZYYe2h9Z2jyyBZMcdtxHLgjBSntX15Z8OruYbynWSOCIXNFwFv5WakHM4xn6/dzl3Yyfw1FtaAZAF/YpWw0tCKyQii4namiu44MYIjtWKbysvNZcWqX7ZqzSC8Ujzu3l3Sznr4tRitzhMsTaRGquV1JjsntP01JJ9IntBgQJPbTqAbdNfi/+3T57uiATj60tDLqO9ENFG+lBFVSPF3MjZmVqnFH9Rns=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>iinn-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 26 19:16:31 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ShareholdersEquityType2or3" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_GENERAL" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERAL"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_CASHANDCASHEQUIVALENT" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENT"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_DEPOSITS" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITS"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_OTHERCURRENTASSETS" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETS"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_INVENTORY" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORY"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_PROPERTYANDEQUIPMENTNET" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNET"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_OTHERACCOUNTSPAYABLE" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLE"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_LEASELIABILITIES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINACIALLIABILITIESATFAIRVALUE" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUE"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREHOLDERSEQUITY" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_REVENUES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/REVENUES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_COSTOFREVENUES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_RESEARCHANDDEVELOPMENTEXPENSES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_GENERALANDADMINISTRATIVEEXPENSES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SALESANDMARKETINGEXPENSES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINANCIALINCOMEANDEXPENSES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_TAXESONINCOME" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOME"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREBASEDPAYMENT" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENT"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_RELATEDPARTIES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SUBSEQUENTEVENTS" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_AccountingPoliciesByPolicy" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_OTHERCURRENTASSETSTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETSTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_INVENTORYTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORYTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_PROPERTYANDEQUIPMENTNETTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNETTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_OTHERACCOUNTSPAYABLETables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLETables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_LEASELIABILITIESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINACIALLIABILITIESATFAIRVALUETables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUETables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREHOLDERSEQUITYTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_COSTOFREVENUESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_RESEARCHANDDEVELOPMENTEXPENSESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_GENERALANDADMINISTRATIVEEXPENSESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SALESANDMARKETINGEXPENSESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINANCIALINCOMEANDEXPENSESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_TAXESONINCOMETables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREBASEDPAYMENTTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_RELATEDPARTIESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofInventoryTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOtherAccountsPayableTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofFinancialLiabilityTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofShareCapitalTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofMovementinWarrantsOutstandingTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofCostofRevenuesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofFinancialIncomeandExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofTheoreticalTaxTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofEffectiveTaxRateReconciliationTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_GENERALDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_CASHANDCASHEQUIVALENTDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_DEPOSITSDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_LEASELIABILITIESDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINACIALLIABILITIESATFAIRVALUEDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREHOLDERSEQUITYDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_TAXESONINCOMEDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREBASEDPAYMENTDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SUBSEQUENTEVENTSDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#DocumentAndEntityInformation" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" xlink:href="iinn-20251231.xsd#iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20251231.xsd#iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20251231.xsd#iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProvisionForOtherLosses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpirationOfFinancialLiability" xlink:href="iinn-20251231.xsd#iinn_ExpirationOfFinancialLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_ExpirationOfFinancialLiability" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpensesDueToCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialExpensesDueToCommitmentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_FinancialExpensesDueToCommitmentFee" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesCommitmentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_IssuanceOfOrdinarySharesCommitmentFee" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCash" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:href="iinn-20251231.xsd#iinn_OtherReceivableInConnectionToPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_OtherReceivableInConnectionToPrivatePlacement" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AccruedIssuanceExpenses" xlink:href="iinn-20251231.xsd#iinn_AccruedIssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_AccruedIssuanceExpenses" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialLiabilityPlacementAgentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialLiabilityPlacementAgentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_FinancialLiabilityPlacementAgentFee" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NonCashTransactions" xlink:href="iinn-20251231.xsd#iinn_NonCashTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_NonCashTransactions" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="38" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERAL" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositLiabilitiesDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORY" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNET" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLE" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUE" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITY" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/REVENUES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_CostOfRevenuesAbstract" xlink:href="iinn-20251231.xsd#iinn_CostOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_CostOfRevenuesTextBlock" xlink:href="iinn-20251231.xsd#iinn_CostOfRevenuesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_CostOfRevenuesAbstract" xlink:to="iinn_CostOfRevenuesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:href="iinn-20251231.xsd#iinn_GeneralAndAdministrativeExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20251231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="iinn_SalesAndMarketingExpensesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOME" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:href="iinn-20251231.xsd#iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SeverancePolicyTextBlock" xlink:href="iinn-20251231.xsd#iinn_SeverancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_SeverancePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORYTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLETables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUETables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_CostOfRevenuesAbstract" xlink:href="iinn-20251231.xsd#iinn_CostOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfCostOfRevenuesTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfCostOfRevenuesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_CostOfRevenuesAbstract" xlink:to="iinn_ScheduleOfCostOfRevenuesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems" xlink:to="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:href="iinn-20251231.xsd#iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestBearingDepositsInBanks" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OthersAsset" xlink:href="iinn-20251231.xsd#iinn_OthersAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="iinn_OthersAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RDEquipmentMember" xlink:href="iinn-20251231.xsd#iinn_RDEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iinn_RDEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AccountsPayableToRelatedParties" xlink:href="iinn-20251231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="iinn_AccountsPayableToRelatedParties" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems" xlink:to="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="iinn_PrivateWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" xlink:to="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55Member" xlink:href="iinn-20251231.xsd#iinn_ExercisePrice55Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePrice55Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Exercise6875Member" xlink:href="iinn-20251231.xsd#iinn_Exercise6875Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_Exercise6875Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePriceOnePointSixMember" xlink:href="iinn-20251231.xsd#iinn_ExercisePriceOnePointSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePriceOnePointSixMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice156Member" xlink:href="iinn-20251231.xsd#iinn_ExercisePrice156Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePrice156Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePriceOnePointOneMember" xlink:href="iinn-20251231.xsd#iinn_ExercisePriceOnePointOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePriceOnePointOneMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" xlink:href="iinn-20251231.xsd#iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems" xlink:to="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_MaterialsAndSubcontractorsMember" xlink:href="iinn-20251231.xsd#iinn_MaterialsAndSubcontractorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iinn_MaterialsAndSubcontractorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PayrollAndRelatedMember" xlink:href="iinn-20251231.xsd#iinn_PayrollAndRelatedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iinn_PayrollAndRelatedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantyMember" xlink:href="iinn-20251231.xsd#iinn_WarrantyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iinn_WarrantyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RoyaltiesToIIAMember" xlink:href="iinn-20251231.xsd#iinn_RoyaltiesToIIAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iinn_RoyaltiesToIIAMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems" xlink:to="us-gaap_CostOfRevenue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_DepreciationNonproduction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20251231.xsd#iinn_Subcontractors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="iinn_Subcontractors" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_IIAParticipation" xlink:href="iinn-20251231.xsd#iinn_IIAParticipation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="iinn_IIAParticipation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:href="iinn-20251231.xsd#iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_LegalFees" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_CostMaintenance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_Depreciation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FundraisingExpenses" xlink:href="iinn-20251231.xsd#iinn_FundraisingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="iinn_FundraisingExpenses" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_OfficersCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_ProfessionalFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxAssetsAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20251231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ServicesProvidersAndAdvisersMember" xlink:href="iinn-20251231.xsd#iinn_ServicesProvidersAndAdvisersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="iinn_ServicesProvidersAndAdvisersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="iinn_EmployeesAndDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iinn_EmployeesAndDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OfficersAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_OfficersAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_OfficersAndDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OfficersCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_GENERALDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_GENERALDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_GENERALDetailsTable" xlink:href="iinn-20251231.xsd#iinn_GENERALDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_GENERALDetailsLineItems" xlink:to="iinn_GENERALDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GENERALDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivatePlacementMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_DecemberPrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateOfferingPrice" xlink:href="iinn-20251231.xsd#iinn_AggregateOfferingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALDetailsLineItems" xlink:to="iinn_AggregateOfferingPrice" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateGrossProceeds" xlink:href="iinn-20251231.xsd#iinn_AggregateGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALDetailsLineItems" xlink:to="iinn_AggregateGrossProceeds" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeductingOfferingCosts" xlink:href="iinn-20251231.xsd#iinn_DeductingOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALDetailsLineItems" xlink:to="iinn_DeductingOfferingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_GENERALDetailsLineItems" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_IncrementalBorrowingRate" xlink:href="iinn-20251231.xsd#iinn_IncrementalBorrowingRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_IncrementalBorrowingRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAmount" xlink:href="iinn-20251231.xsd#iinn_SalesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_SalesAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PaidRoyalties" xlink:href="iinn-20251231.xsd#iinn_PaidRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_PaidRoyalties" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesSEPAAmount" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesSEPAAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_OrdinarySharesSEPAAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShortTermInvestments" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_DEPOSITSDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_DEPOSITSDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_DEPOSITSDetailsTable" xlink:href="iinn-20251231.xsd#iinn_DEPOSITSDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_DEPOSITSDetailsLineItems" xlink:to="iinn_DEPOSITSDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_DEPOSITSDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_DEPOSITSDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_BankLeumiMember" xlink:href="iinn-20251231.xsd#iinn_BankLeumiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="iinn_BankLeumiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DEPOSITSDetailsLineItems" xlink:to="us-gaap_Deposits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_DEPOSITSDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateBudget" xlink:href="iinn-20251231.xsd#iinn_AggregateBudget"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="iinn_AggregateBudget" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfApprovedBudget" xlink:href="iinn-20251231.xsd#iinn_PercentageOfApprovedBudget"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="iinn_PercentageOfApprovedBudget" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ProjectBudgetAggregateAmount" xlink:href="iinn-20251231.xsd#iinn_ProjectBudgetAggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="iinn_ProjectBudgetAggregateAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RoyaltiesPercentage" xlink:href="iinn-20251231.xsd#iinn_RoyaltiesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="iinn_RoyaltiesPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_Revenues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ContingentUponFutureSales" xlink:href="iinn-20251231.xsd#iinn_ContingentUponFutureSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="iinn_ContingentUponFutureSales" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_LEASELIABILITIESDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_LEASELIABILITIESDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_LEASELIABILITIESDetailsTable" xlink:href="iinn-20251231.xsd#iinn_LEASELIABILITIESDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_LEASELIABILITIESDetailsLineItems" xlink:to="iinn_LEASELIABILITIESDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_LEASELIABILITIESDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LEASELIABILITIESDetailsLineItems" xlink:to="us-gaap_PaymentsForRent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_MonthlyDeductionFromTerminationFee" xlink:href="iinn-20251231.xsd#iinn_MonthlyDeductionFromTerminationFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LEASELIABILITIESDetailsLineItems" xlink:to="iinn_MonthlyDeductionFromTerminationFee" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_LeaseMonthlyPayment" xlink:href="iinn-20251231.xsd#iinn_LeaseMonthlyPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LEASELIABILITIESDetailsLineItems" xlink:to="iinn_LeaseMonthlyPayment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:href="iinn-20251231.xsd#iinn_PercentageForCarsLeaseAgreementCancellationPenalty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LEASELIABILITIESDetailsLineItems" xlink:to="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LEASELIABILITIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:href="iinn-20251231.xsd#iinn_PercentageOfFutureLeasePaymentsDiscounted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_LEASELIABILITIESDetailsLineItems" xlink:to="iinn_PercentageOfFutureLeasePaymentsDiscounted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AgreementAxis" xlink:href="iinn-20251231.xsd#iinn_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="iinn_AgreementAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AgreementDomainDomain" xlink:href="iinn-20251231.xsd#iinn_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="iinn_AgreementAxis" xlink:to="iinn_AgreementDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AgreementDomainDomain_0" xlink:href="iinn-20251231.xsd#iinn_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="iinn_AgreementAxis" xlink:to="iinn_AgreementDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberStandbyEquityPurchaseAgreementMember" xlink:href="iinn-20251231.xsd#iinn_DecemberStandbyEquityPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_DecemberStandbyEquityPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PrivateWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StandbyEquityPurchaseAgreementSEPAMember" xlink:href="iinn-20251231.xsd#iinn_StandbyEquityPurchaseAgreementSEPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_AgreementDomainDomain" xlink:to="iinn_StandbyEquityPurchaseAgreementSEPAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SecondTrancheMember" xlink:href="iinn-20251231.xsd#iinn_SecondTrancheMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iinn_SecondTrancheMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_YorkvilleMember" xlink:href="iinn-20251231.xsd#iinn_YorkvilleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="iinn_YorkvilleMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_December2024PrivatePlacementMember" xlink:href="iinn-20251231.xsd#iinn_December2024PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="iinn_December2024PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPayFees" xlink:href="iinn-20251231.xsd#iinn_PercentageOfPayFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="iinn_PercentageOfPayFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_PaymentsForFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_OtherCommitment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SaleOfRightsValue" xlink:href="iinn-20251231.xsd#iinn_SaleOfRightsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="iinn_SaleOfRightsValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesPurchasePricePercentage" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesPurchasePricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="iinn_OrdinarySharesPurchasePricePercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DescriptionOfFeePayments" xlink:href="iinn-20251231.xsd#iinn_DescriptionOfFeePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="iinn_DescriptionOfFeePayments" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_LegalFees" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_SHAREHOLDERSEQUITYDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AgreementAxis" xlink:href="iinn-20251231.xsd#iinn_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="iinn_AgreementAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AgreementDomainDomain" xlink:href="iinn-20251231.xsd#iinn_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="iinn_AgreementAxis" xlink:to="iinn_AgreementDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AgreementDomainDomain_0" xlink:href="iinn-20251231.xsd#iinn_AgreementDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="iinn_AgreementAxis" xlink:to="iinn_AgreementDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RegisteredDirectOfferingMember" xlink:href="iinn-20251231.xsd#iinn_RegisteredDirectOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_RegisteredDirectOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandTwentyFourAprilOfferingMember" xlink:href="iinn-20251231.xsd#iinn_TwoThousandTwentyFourAprilOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_TwoThousandTwentyFourAprilOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandTwentyFourJuneOfferingMember" xlink:href="iinn-20251231.xsd#iinn_TwoThousandTwentyFourJuneOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_TwoThousandTwentyFourJuneOfferingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivateOfferingMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPrivateOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_DecemberPrivateOfferingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_December2024PrivatePlacementMember" xlink:href="iinn-20251231.xsd#iinn_December2024PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_December2024PrivatePlacementMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_December2025OfferingMember" xlink:href="iinn-20251231.xsd#iinn_December2025OfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_December2025OfferingMember" order="5" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PreFundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PrivateWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PlacementAgentWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PlacementAgentWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePlacementAgentWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_JunePlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_JunePlacementAgentWarrantsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePreFundedWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_JunePreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_JunePreFundedWarrantsMember" order="5" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_TwoThousandTwentyFourJuneOfferingMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_DecemberPrivateWarrantsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPreFundedWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_DecemberPreFundedWarrantsMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="iinn_PrivateWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StandbyEquityPurchaseAgreementSEPAMember" xlink:href="iinn-20251231.xsd#iinn_StandbyEquityPurchaseAgreementSEPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_AgreementDomainDomain" xlink:to="iinn_StandbyEquityPurchaseAgreementSEPAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RothCapitalPartnersLLCMember" xlink:href="iinn-20251231.xsd#iinn_RothCapitalPartnersLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iinn_RothCapitalPartnersLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdvisorMember" xlink:href="iinn-20251231.xsd#iinn_AdvisorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iinn_AdvisorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PurchasePricePerShare" xlink:href="iinn-20251231.xsd#iinn_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_PurchasePricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:href="iinn-20251231.xsd#iinn_ClassOfPrivateWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_ClassOfPrivateWarrantOrRightOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberofAdditionalOrdinaryShares" xlink:href="iinn-20251231.xsd#iinn_NumberofAdditionalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_NumberofAdditionalOrdinaryShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyLiquidationProceedsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsPerShare" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrantsPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_PreFundedWarrantsPerShare" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberOfSharesPerUnits" xlink:href="iinn-20251231.xsd#iinn_NumberOfSharesPerUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_NumberOfSharesPerUnits" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrants" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_PrivateWarrants" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PurchasePricePerUnit" xlink:href="iinn-20251231.xsd#iinn_PurchasePricePerUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_PurchasePricePerUnit" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrants" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_PreFundedWarrants" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_IssueOfPrivateWarrantsShares" xlink:href="iinn-20251231.xsd#iinn_IssueOfPrivateWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_IssueOfPrivateWarrantsShares" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPayFees" xlink:href="iinn-20251231.xsd#iinn_PercentageOfPayFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_PercentageOfPayFees" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsExerciseShares" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsExerciseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_PrivateWarrantsExerciseShares" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_TAXESONINCOMEDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_TAXESONINCOMEDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_TAXESONINCOMEDetailsTable" xlink:href="iinn-20251231.xsd#iinn_TAXESONINCOMEDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_TAXESONINCOMEDetailsLineItems" xlink:to="iinn_TAXESONINCOMEDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_TAXESONINCOMEDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TAXESONINCOMEDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TAXESONINCOMEDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_TAXESONINCOMEDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="iinn_SHAREBASEDPAYMENTDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREBASEDPAYMENTDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREBASEDPAYMENTDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREBASEDPAYMENTDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SHAREBASEDPAYMENTDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RevenueAchievementMember" xlink:href="iinn-20251231.xsd#iinn_RevenueAchievementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="iinn_RevenueAchievementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_EmployeesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExecutivesAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_ExecutivesAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_ExecutivesAndDirectorsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ServiceProvidersMember" xlink:href="iinn-20251231.xsd#iinn_ServiceProvidersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_ServiceProvidersMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesDirectorsAndSubcontractorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_EmployeesDirectorsAndSubcontractorsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_CapitalGainTaxRate" xlink:href="iinn-20251231.xsd#iinn_CapitalGainTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="iinn_CapitalGainTaxRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfCapitalGainTax" xlink:href="iinn-20251231.xsd#iinn_PercentageOfCapitalGainTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="iinn_PercentageOfCapitalGainTax" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SUBSEQUENTEVENTSDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SUBSEQUENTEVENTSDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SUBSEQUENTEVENTSDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="iinn_SUBSEQUENTEVENTSDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SUBSEQUENTEVENTSDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PurchaserMember" xlink:href="iinn-20251231.xsd#iinn_PurchaserMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iinn_PurchaserMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_PrivateWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrants" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="iinn_PreFundedWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToPurchaseOrdinaryShares" xlink:href="iinn-20251231.xsd#iinn_WarrantsToPurchaseOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="iinn_WarrantsToPurchaseOrdinaryShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StandbyEquityPurchaseAgreementPercentage" xlink:href="iinn-20251231.xsd#iinn_StandbyEquityPurchaseAgreementPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="iinn_StandbyEquityPurchaseAgreementPercentage" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpensesDueToCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialExpensesDueToCommitmentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="iinn_FinancialExpensesDueToCommitmentFee" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_OtherCommitment" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesNoParValueMember" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iinn_OrdinarySharesNoParValueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20251231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iinn_WarrantsToPurchaseOrdinarySharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
<!-- [WMV6][UFCzxiNWp2jtih9U754Ga2y28Xl2c+SHWsDmZQ0sX8H2qT+tXNE27aTPQvT+jJWaThWeRM9e6R1WprJssMWsdqEVFBzRukKBBU3zK+lTBR1xUk7mVOsV6O8zyuiuUuHyMsRshickOzcoO1mZ2lVacpJzlzf6kIO5C/DSLNAwVrhFNAaeLWGme3Y4sMwpd/SeTq2o2DyYVhLVMdzRqL2TqEVJn0BUr8rXd24+8L/MQuIIcoZLaNHbtEia+wXoCAWnNwDuaJRKuawO2WIJF+cU3kf9pD9oTm+FMPJg7okJ4Q85XrV9tqaSrcsSuHntdq4sk88s374Amwwx35ndpij/54mp/jSZUew92Hgxn9M2v3GE2m6nQrXf] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="38" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>iinn-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 26 19:16:31 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non- current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance as of</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance as of</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Loss before taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Total comprehensive and net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Comprehensive and net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Loss for the period (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance as of (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance as of (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NonCashTransactions" xlink:href="iinn-20251231.xsd#iinn_NonCashTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iinn_NonCashTransactions_lbl" xml:lang="en-US">Total non cash transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_NonCashTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Cost, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Cost, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated depreciation, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Other accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted-average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Outstanding at beginning of year (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of options, Options outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price NIS, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average Exercise price NIS, Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating lease liabilities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Financial liabilities at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating lease liabilities long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, no par value: Authorized 100,000,000 ordinary shares as of December 31, 2025 and December 31, 2024; Issued and outstanding 35,949,247 ordinary shares as of December 31, 2025 and 24,252,096 shares as of December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, Authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Authorized, Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, Issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, Outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Issued and outstanding, Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Total number of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Share capital and additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per ordinary share, basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per ordinary share, diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of ordinary shares outstanding basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average number of Ordinary Shares and pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of ordinary shares outstanding diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract" xlink:href="iinn-20251231.xsd#iinn_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract" xlink:to="iinn_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract" xlink:href="iinn-20251231.xsd#iinn_ChangesDuringThePeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ChangesDuringThePeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Ordinary shares value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of ordinary shares (pursuant to an at-the-market facility)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of ordinary shares (pursuant to an at-the-market facility) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Issued an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet_lbl" xml:lang="en-US">Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" xlink:to="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares_lbl" xml:lang="en-US">Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" xlink:to="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share unit (&#8220;RSU&#8221;) vesting (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share unit (&#8220;RSU&#8221;) vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of ordinary shares- advisor fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of ordinary shares- advisor fees (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Ordinary shares issued for consulting service agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" xlink:href="iinn-20251231.xsd#iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees_lbl" xml:lang="en-US">Issuance of ordinary shares- commitment fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" xlink:to="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares_lbl" xml:lang="en-US">Issuance of ordinary shares- commitment fees (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares" xlink:to="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract0" xlink:href="iinn-20251231.xsd#iinn_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract0" xlink:to="iinn_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract0" xlink:href="iinn-20251231.xsd#iinn_ChangesDuringThePeriodAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract0_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="iinn_ChangesDuringThePeriodAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl" xml:lang="en-US">Exercise of June 2024 pre-funded warrants into ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl" xml:lang="en-US">Exercise of June 2024 pre-funded warrants into ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract1" xlink:href="iinn-20251231.xsd#iinn_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract1" xlink:to="iinn_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract1" xlink:href="iinn-20251231.xsd#iinn_ChangesDuringThePeriodAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract1_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_ChangesDuringThePeriodAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract2" xlink:href="iinn-20251231.xsd#iinn_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract2" xlink:to="iinn_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of placement agent warrants (Note 11.3)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20251231.xsd#iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl" xml:lang="en-US">Exercise of share-based payments (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20251231.xsd#iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl" xml:lang="en-US">Exercise of share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOW FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForOtherLosses_lbl" xml:lang="en-US">Capital loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherLosses" xlink:to="us-gaap_ProvisionForOtherLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share based payment &#8211; officers and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Share based compensation &#8211; placement agent warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl" xml:lang="en-US">Issuance of ordinary shares - advisor fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Prepayments of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">(Decrease) increase in trade accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">(Decrease) increase in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialExpensesDueToCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialExpensesDueToCommitmentFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialExpensesDueToCommitmentFee_lbl" xml:lang="en-US">Financial expenses due to commitment fee &#8211; Standby Equity Purchase Agreement (SEPA)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpensesDueToCommitmentFee" xlink:to="iinn_FinancialExpensesDueToCommitmentFee_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_FinancialExpensesDueToCommitmentFee_lbl0" xml:lang="en-US">Commitment fee amount of SEPA (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpensesDueToCommitmentFee" xlink:to="iinn_FinancialExpensesDueToCommitmentFee_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesCommitmentFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFee_lbl" xml:lang="en-US">Issuance of ordinary shares - commitment fee (SEPA)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesCommitmentFee" xlink:to="iinn_IssuanceOfOrdinarySharesCommitmentFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOW FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of ordinary shares, pre-funded warrants and ordinary warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants and pre-funded warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of ordinary shares (issuances pursuant to an at-the-market facility), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AccruedIssuanceExpenses" xlink:href="iinn-20251231.xsd#iinn_AccruedIssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AccruedIssuanceExpenses_lbl" xml:lang="en-US">Accrued issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccruedIssuanceExpenses" xlink:to="iinn_AccruedIssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialLiabilityPlacementAgentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialLiabilityPlacementAgentFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialLiabilityPlacementAgentFee_lbl" xml:lang="en-US">Financial liability- placement agent fee (Note 10-A)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityPlacementAgentFee" xlink:to="iinn_FinancialLiabilityPlacementAgentFee_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl" xml:lang="en-US">Share based compensation- placement agent warrants against additional paid in capital (Note 11)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US">Interest income from deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Finance expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US">Evaluation of financial liability at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpirationOfFinancialLiability" xlink:href="iinn-20251231.xsd#iinn_ExpirationOfFinancialLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_ExpirationOfFinancialLiability_lbl" xml:lang="en-US">Expiration of financial liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpirationOfFinancialLiability" xlink:to="iinn_ExpirationOfFinancialLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl" xml:lang="en-US">Decrease (increase) in right of use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Decrease (increase) in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">(Increase) decrease in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized foreign exchange (gain) loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant, and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Change in deposits, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:href="iinn-20251231.xsd#iinn_OtherReceivableInConnectionToPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl" xml:lang="en-US">Other receivable in connection to December private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:to="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesNoParValueMember" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OrdinarySharesNoParValueMember_lbl" xml:lang="en-US">Ordinary Shares, no par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesNoParValueMember" xlink:to="iinn_OrdinarySharesNoParValueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20251231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl" xml:lang="en-US">Warrants to purchase Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:to="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Share capital and Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:href="iinn-20251231.xsd#iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Annual depreciation rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositLiabilitiesDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl" xml:lang="en-US">DEPOSITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestBearingDepositsInBanks_lbl" xml:lang="en-US">Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDepositsInBanks" xlink:to="us-gaap_InterestBearingDepositsInBanks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OthersAsset" xlink:href="iinn-20251231.xsd#iinn_OthersAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OthersAsset_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OthersAsset" xlink:to="iinn_OthersAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CostAbstract" xlink:href="iinn-20251231.xsd#iinn_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CostAbstract_lbl" xml:lang="en-US">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostAbstract" xlink:to="iinn_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract3" xlink:href="iinn-20251231.xsd#iinn_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract3" xlink:to="iinn_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AccumulatedDepreciationAbstract" xlink:href="iinn-20251231.xsd#iinn_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciationAbstract" xlink:to="iinn_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract4" xlink:href="iinn-20251231.xsd#iinn_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract4" xlink:to="iinn_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValueAbstract" xlink:href="iinn-20251231.xsd#iinn_NetBookValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NetBookValueAbstract_lbl" xml:lang="en-US">Net book value:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract" xlink:to="iinn_NetBookValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CostAbstract0" xlink:href="iinn-20251231.xsd#iinn_CostAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CostAbstract0_lbl" xml:lang="en-US">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostAbstract0" xlink:to="iinn_CostAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AccumulatedDepreciationAbstract0" xlink:href="iinn-20251231.xsd#iinn_AccumulatedDepreciationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AccumulatedDepreciationAbstract0_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciationAbstract0" xlink:to="iinn_AccumulatedDepreciationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValueAbstract0" xlink:href="iinn-20251231.xsd#iinn_NetBookValueAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NetBookValueAbstract0_lbl" xml:lang="en-US">Net book value:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract0" xlink:to="iinn_NetBookValueAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Employees&#8217; salaries and related liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AccountsPayableToRelatedParties" xlink:href="iinn-20251231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AccountsPayableToRelatedParties_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccountsPayableToRelatedParties" xlink:to="iinn_AccountsPayableToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASE LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:to="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average of remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Right-of-Use Assets Over the Remaining Lease Periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FINACIAL LIABILITIES AT FAIR VALUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Movement in Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_UnlabeledAbstract5" xlink:href="iinn-20251231.xsd#iinn_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract5" xlink:to="iinn_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl" xml:lang="en-US">Number of Warrants, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl" xml:lang="en-US">Weighted-average exercise price, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Number of Warrants, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US">Number of Warrants, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Information about the Company&#8217;s Outstanding Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Exercise Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CostOfRevenuesTextBlock" xlink:href="iinn-20251231.xsd#iinn_CostOfRevenuesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CostOfRevenuesTextBlock_lbl" xml:lang="en-US">COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostOfRevenuesTextBlock" xlink:to="iinn_CostOfRevenuesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfCostOfRevenuesTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfCostOfRevenuesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfCostOfRevenuesTableTextBlock_lbl" xml:lang="en-US">Schedule of Cost of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfCostOfRevenuesTableTextBlock" xlink:to="iinn_ScheduleOfCostOfRevenuesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xml:lang="en-US">Share based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl" xml:lang="en-US">Materials and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationNonproduction_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20251231.xsd#iinn_Subcontractors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Subcontractors_lbl" xml:lang="en-US">Subcontractors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:href="iinn-20251231.xsd#iinn_GeneralAndAdministrativeExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Number of options, Share-based payment expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Share-based payment expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Director fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Office maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Travel abroad</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FundraisingExpenses" xlink:href="iinn-20251231.xsd#iinn_FundraisingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FundraisingExpenses_lbl" xml:lang="en-US">Fundraising expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FundraisingExpenses" xlink:to="iinn_FundraisingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20251231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl" xml:lang="en-US">SALES AND MARKETING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of Sales and Marketing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OfficersCompensation_lbl0" xml:lang="en-US">Salary and related expenses &#8211; officers and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">FINANCIAL (INCOME) AND EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial (Income) and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Revaluation of financial liabilities at fair value through profit or loss, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsAbstract" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="iinn_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxAssetsAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAccruedExpenses" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D temporary differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl" xml:lang="en-US">Fund raising costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl" xml:lang="en-US">Schedule of Theoretical Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Theoretical tax credit at applicable statutory rate: 23%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">IL statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-allowable expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20251231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl" xml:lang="en-US">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Tax Rate Reconciliation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">IL statutory tax rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NonTaxableOrNonDeductibleItemsAbstract" xlink:href="iinn-20251231.xsd#iinn_NonTaxableOrNonDeductibleItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NonTaxableOrNonDeductibleItemsAbstract_lbl" xml:lang="en-US">Non-taxable or non-deductible items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonTaxableOrNonDeductibleItemsAbstract" xlink:to="iinn_NonTaxableOrNonDeductibleItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Share-based compensation, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Revaluation of financial liabilities at fair value through profit or loss, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Others, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Changes in valuation allowances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Changes in valuation allowances, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other adjustments, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED PAYMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Measure the Fair Value of the Option at Grant Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (vesting period)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl" xml:lang="en-US">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Free risk rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options to Services Providers and Advisers Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of shares granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price NIS, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl" xml:lang="en-US">Number of options, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price NIS, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Options exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price NIS, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, Forfeited (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price NIS, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSUs to Services Providers and Advisers Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne_lbl" xml:lang="en-US">RSUs outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl" xml:lang="en-US">RSU&#8217;s Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Shareholders and Other Related Parties&#8217; Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_IIAParticipation" xlink:href="iinn-20251231.xsd#iinn_IIAParticipation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_IIAParticipation_lbl" xml:lang="en-US">IIA participation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IIAParticipation" xlink:to="iinn_IIAParticipation_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Revaluation of financial liabilities at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RDEquipmentMember" xlink:href="iinn-20251231.xsd#iinn_RDEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RDEquipmentMember_lbl" xml:lang="en-US">R&amp;D equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RDEquipmentMember" xlink:to="iinn_RDEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xml:lang="en-US">Financial liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PrivateWarrantsMember_lbl" xml:lang="en-US">Private warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsMember" xlink:to="iinn_PrivateWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_PrivateWarrantsMember_lbl0" xml:lang="en-US">Private Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsMember" xlink:to="iinn_PrivateWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="iinn_PrivateWarrantsMember_lbl1" xml:lang="en-US">Private Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsMember" xlink:to="iinn_PrivateWarrantsMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55Member" xlink:href="iinn-20251231.xsd#iinn_ExercisePrice55Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice55Member_lbl" xml:lang="en-US">5.5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55Member" xlink:to="iinn_ExercisePrice55Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Exercise6875Member" xlink:href="iinn-20251231.xsd#iinn_Exercise6875Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Exercise6875Member_lbl" xml:lang="en-US">6.875 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Exercise6875Member" xlink:to="iinn_Exercise6875Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePriceOnePointSixMember" xlink:href="iinn-20251231.xsd#iinn_ExercisePriceOnePointSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePriceOnePointSixMember_lbl" xml:lang="en-US">1.6 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePriceOnePointSixMember" xlink:to="iinn_ExercisePriceOnePointSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice156Member" xlink:href="iinn-20251231.xsd#iinn_ExercisePrice156Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice156Member_lbl" xml:lang="en-US">1.56	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice156Member" xlink:to="iinn_ExercisePrice156Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePriceOnePointOneMember" xlink:href="iinn-20251231.xsd#iinn_ExercisePriceOnePointOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePriceOnePointOneMember_lbl" xml:lang="en-US">1.1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePriceOnePointOneMember" xlink:to="iinn_ExercisePriceOnePointOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_MaterialsAndSubcontractorsMember" xlink:href="iinn-20251231.xsd#iinn_MaterialsAndSubcontractorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_MaterialsAndSubcontractorsMember_lbl" xml:lang="en-US">Materials And Subcontractors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MaterialsAndSubcontractorsMember" xlink:to="iinn_MaterialsAndSubcontractorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PayrollAndRelatedMember" xlink:href="iinn-20251231.xsd#iinn_PayrollAndRelatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PayrollAndRelatedMember_lbl" xml:lang="en-US">Payroll And Related [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PayrollAndRelatedMember" xlink:to="iinn_PayrollAndRelatedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantyMember" xlink:href="iinn-20251231.xsd#iinn_WarrantyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantyMember_lbl" xml:lang="en-US">Warranty [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantyMember" xlink:to="iinn_WarrantyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RoyaltiesToIIAMember" xlink:href="iinn-20251231.xsd#iinn_RoyaltiesToIIAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RoyaltiesToIIAMember_lbl" xml:lang="en-US">Royalties To IIA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesToIIAMember" xlink:to="iinn_RoyaltiesToIIAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ServicesProvidersAndAdvisersMember" xlink:href="iinn-20251231.xsd#iinn_ServicesProvidersAndAdvisersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ServicesProvidersAndAdvisersMember_lbl" xml:lang="en-US">Services Providers and Advisers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ServicesProvidersAndAdvisersMember" xlink:to="iinn_ServicesProvidersAndAdvisersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesAndDirectorsMember" xlink:to="iinn_EmployeesAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Vested RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_OfficersAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_OfficersAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OfficersAndDirectorsMember" xlink:to="iinn_OfficersAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AgreementAxis" xlink:href="iinn-20251231.xsd#iinn_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AgreementAxis" xlink:to="iinn_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateOfferingPrice" xlink:href="iinn-20251231.xsd#iinn_AggregateOfferingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateOfferingPrice_lbl" xml:lang="en-US">Aggregate offering price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateOfferingPrice" xlink:to="iinn_AggregateOfferingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Ordinary shares sold (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateGrossProceeds" xlink:href="iinn-20251231.xsd#iinn_AggregateGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateGrossProceeds_lbl" xml:lang="en-US">Aggregate gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateGrossProceeds" xlink:to="iinn_AggregateGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeductingOfferingCosts" xlink:href="iinn-20251231.xsd#iinn_DeductingOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeductingOfferingCosts_lbl" xml:lang="en-US">Deducting offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeductingOfferingCosts" xlink:to="iinn_DeductingOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl" xml:lang="en-US">Incurred accumulated losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_IncrementalBorrowingRate" xlink:href="iinn-20251231.xsd#iinn_IncrementalBorrowingRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_IncrementalBorrowingRate_lbl" xml:lang="en-US">Incremental borrowing rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IncrementalBorrowingRate" xlink:to="iinn_IncrementalBorrowingRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAmount" xlink:href="iinn-20251231.xsd#iinn_SalesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SalesAmount_lbl" xml:lang="en-US">Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAmount" xlink:to="iinn_SalesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PaidRoyalties" xlink:href="iinn-20251231.xsd#iinn_PaidRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PaidRoyalties_lbl" xml:lang="en-US">Paid royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PaidRoyalties" xlink:to="iinn_PaidRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Employees monthly deposits rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesSEPAAmount" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesSEPAAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OrdinarySharesSEPAAmount_lbl" xml:lang="en-US">Ordinary shares SEPA amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesSEPAAmount" xlink:to="iinn_OrdinarySharesSEPAAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Fixed annual interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateBudget" xlink:href="iinn-20251231.xsd#iinn_AggregateBudget"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateBudget_lbl" xml:lang="en-US">Aggregate budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateBudget" xlink:to="iinn_AggregateBudget_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfApprovedBudget" xlink:href="iinn-20251231.xsd#iinn_PercentageOfApprovedBudget"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfApprovedBudget_lbl" xml:lang="en-US">Percentage of approved budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfApprovedBudget" xlink:to="iinn_PercentageOfApprovedBudget_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ProjectBudgetAggregateAmount" xlink:href="iinn-20251231.xsd#iinn_ProjectBudgetAggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ProjectBudgetAggregateAmount_lbl" xml:lang="en-US">Project budget aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProjectBudgetAggregateAmount" xlink:to="iinn_ProjectBudgetAggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Total funds received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RoyaltiesPercentage" xlink:href="iinn-20251231.xsd#iinn_RoyaltiesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RoyaltiesPercentage_lbl" xml:lang="en-US">Percentage of royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesPercentage" xlink:to="iinn_RoyaltiesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Liability amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ContingentUponFutureSales" xlink:href="iinn-20251231.xsd#iinn_ContingentUponFutureSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ContingentUponFutureSales_lbl" xml:lang="en-US">Contingent upon future sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContingentUponFutureSales" xlink:to="iinn_ContingentUponFutureSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent termination penalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_MonthlyDeductionFromTerminationFee" xlink:href="iinn-20251231.xsd#iinn_MonthlyDeductionFromTerminationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_MonthlyDeductionFromTerminationFee_lbl" xml:lang="en-US">Monthly deduction from termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MonthlyDeductionFromTerminationFee" xlink:to="iinn_MonthlyDeductionFromTerminationFee_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeaseMonthlyPayment" xlink:href="iinn-20251231.xsd#iinn_LeaseMonthlyPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_LeaseMonthlyPayment_lbl" xml:lang="en-US">Lease monthly payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeaseMonthlyPayment" xlink:to="iinn_LeaseMonthlyPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:href="iinn-20251231.xsd#iinn_PercentageForCarsLeaseAgreementCancellationPenalty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl" xml:lang="en-US">Percentage for car lease agreement cancellation penalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:to="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Lease expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:href="iinn-20251231.xsd#iinn_PercentageOfFutureLeasePaymentsDiscounted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl" xml:lang="en-US">Percentage of future lease payments discounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:to="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPayFees" xlink:href="iinn-20251231.xsd#iinn_PercentageOfPayFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfPayFees_lbl" xml:lang="en-US">Percentage of pay fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPayFees" xlink:to="iinn_PercentageOfPayFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Financial liability fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Commitment fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitment_lbl" xml:lang="en-US">Total commitment amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCommitment_lbl0" xml:lang="en-US">Remaining balance of commitment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Aggregate purchase (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Warrants price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Fair value of private warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and rights outstanding (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl0" xml:lang="en-US">Exercise amount of warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_SaleOfRightsValue" xlink:href="iinn-20251231.xsd#iinn_SaleOfRightsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SaleOfRightsValue_lbl" xml:lang="en-US">Sale of rights value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SaleOfRightsValue" xlink:to="iinn_SaleOfRightsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesPurchasePricePercentage" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesPurchasePricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OrdinarySharesPurchasePricePercentage_lbl" xml:lang="en-US">Ordinary shares purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesPurchasePricePercentage" xlink:to="iinn_OrdinarySharesPurchasePricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Voting power limitation description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DescriptionOfFeePayments" xlink:href="iinn-20251231.xsd#iinn_DescriptionOfFeePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DescriptionOfFeePayments_lbl" xml:lang="en-US">Description of fee payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DescriptionOfFeePayments" xlink:to="iinn_DescriptionOfFeePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PurchasePricePerShare" xlink:href="iinn-20251231.xsd#iinn_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchasePricePerShare" xlink:to="iinn_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Pre funded warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:href="iinn-20251231.xsd#iinn_ClassOfPrivateWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl" xml:lang="en-US">Private warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:to="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberofAdditionalOrdinaryShares" xlink:href="iinn-20251231.xsd#iinn_NumberofAdditionalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NumberofAdditionalOrdinaryShares_lbl" xml:lang="en-US">Number of additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberofAdditionalOrdinaryShares" xlink:to="iinn_NumberofAdditionalOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyLiquidationProceedsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl" xml:lang="en-US">Percentage of agreement warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Warrants to ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Ordinary shares price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants expire, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of the warrant (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Options exercise shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Vested options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsPerShare" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrantsPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PreFundedWarrantsPerShare_lbl" xml:lang="en-US">Pre funded warrants per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrantsPerShare" xlink:to="iinn_PreFundedWarrantsPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberOfSharesPerUnits" xlink:href="iinn-20251231.xsd#iinn_NumberOfSharesPerUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NumberOfSharesPerUnits_lbl" xml:lang="en-US">Number of shares per units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfSharesPerUnits" xlink:to="iinn_NumberOfSharesPerUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrants" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PrivateWarrants_lbl" xml:lang="en-US">Private warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrants" xlink:to="iinn_PrivateWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PurchasePricePerUnit" xlink:href="iinn-20251231.xsd#iinn_PurchasePricePerUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PurchasePricePerUnit_lbl" xml:lang="en-US">Purchase price per unit (in Dollars per Share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchasePricePerUnit" xlink:to="iinn_PurchasePricePerUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrants" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PreFundedWarrants_lbl" xml:lang="en-US">Pre funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrants" xlink:to="iinn_PreFundedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_IssueOfPrivateWarrantsShares" xlink:href="iinn-20251231.xsd#iinn_IssueOfPrivateWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_IssueOfPrivateWarrantsShares_lbl" xml:lang="en-US">Issue of private warrants shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssueOfPrivateWarrantsShares" xlink:to="iinn_IssueOfPrivateWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsExerciseShares" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsExerciseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PrivateWarrantsExerciseShares_lbl" xml:lang="en-US">Private warrants exercise shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsExerciseShares" xlink:to="iinn_PrivateWarrantsExerciseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">ATM aggregate offering price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Carryforward tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Option to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Grant shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CapitalGainTaxRate" xlink:href="iinn-20251231.xsd#iinn_CapitalGainTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CapitalGainTaxRate_lbl" xml:lang="en-US">Capital gain tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTaxRate" xlink:to="iinn_CapitalGainTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfCapitalGainTax" xlink:href="iinn-20251231.xsd#iinn_PercentageOfCapitalGainTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfCapitalGainTax_lbl" xml:lang="en-US">Percentage of capital gain tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfCapitalGainTax" xlink:to="iinn_PercentageOfCapitalGainTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Percentage of vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToPurchaseOrdinaryShares" xlink:href="iinn-20251231.xsd#iinn_WarrantsToPurchaseOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsToPurchaseOrdinaryShares_lbl" xml:lang="en-US">Warrants to purchase ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToPurchaseOrdinaryShares" xlink:to="iinn_WarrantsToPurchaseOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_StandbyEquityPurchaseAgreementPercentage" xlink:href="iinn-20251231.xsd#iinn_StandbyEquityPurchaseAgreementPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StandbyEquityPurchaseAgreementPercentage_lbl" xml:lang="en-US">Standby equity purchase agreement percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StandbyEquityPurchaseAgreementPercentage" xlink:to="iinn_StandbyEquityPurchaseAgreementPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xml:lang="en-US">Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:href="iinn-20251231.xsd#iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl" xml:lang="en-US">Finance Income and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Current Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants and Pre-Funded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SeverancePolicyTextBlock" xlink:href="iinn-20251231.xsd#iinn_SeverancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SeverancePolicyTextBlock_lbl" xml:lang="en-US">Severance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SeverancePolicyTextBlock" xlink:to="iinn_SeverancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivatePlacementMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DecemberPrivatePlacementMember_lbl" xml:lang="en-US">December Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivatePlacementMember" xlink:to="iinn_DecemberPrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_BankLeumiMember" xlink:href="iinn-20251231.xsd#iinn_BankLeumiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_BankLeumiMember_lbl" xml:lang="en-US">Bank Leumi [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BankLeumiMember" xlink:to="iinn_BankLeumiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_December2024PrivatePlacementMember" xlink:href="iinn-20251231.xsd#iinn_December2024PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_December2024PrivatePlacementMember_lbl" xml:lang="en-US">December 2024 Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_December2024PrivatePlacementMember" xlink:to="iinn_December2024PrivatePlacementMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_December2024PrivatePlacementMember_lbl0" xml:lang="en-US">December2024 Private Placement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_December2024PrivatePlacementMember" xlink:to="iinn_December2024PrivatePlacementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_StandbyEquityPurchaseAgreementSEPAMember" xlink:href="iinn-20251231.xsd#iinn_StandbyEquityPurchaseAgreementSEPAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StandbyEquityPurchaseAgreementSEPAMember_lbl" xml:lang="en-US">Standby Equity Purchase Agreement SEPA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StandbyEquityPurchaseAgreementSEPAMember" xlink:to="iinn_StandbyEquityPurchaseAgreementSEPAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SecondTrancheMember" xlink:href="iinn-20251231.xsd#iinn_SecondTrancheMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SecondTrancheMember_lbl" xml:lang="en-US">Second Tranche [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SecondTrancheMember" xlink:to="iinn_SecondTrancheMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_YorkvilleMember" xlink:href="iinn-20251231.xsd#iinn_YorkvilleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_YorkvilleMember_lbl" xml:lang="en-US">Yorkville [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_YorkvilleMember" xlink:to="iinn_YorkvilleMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberStandbyEquityPurchaseAgreementMember" xlink:href="iinn-20251231.xsd#iinn_DecemberStandbyEquityPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DecemberStandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US">December Standby Equity Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberStandbyEquityPurchaseAgreementMember" xlink:to="iinn_DecemberStandbyEquityPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RothCapitalPartnersLLCMember" xlink:href="iinn-20251231.xsd#iinn_RothCapitalPartnersLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RothCapitalPartnersLLCMember_lbl" xml:lang="en-US">Roth Capital Partners, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RothCapitalPartnersLLCMember" xlink:to="iinn_RothCapitalPartnersLLCMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_RothCapitalPartnersLLCMember_lbl0" xml:lang="en-US">Roth Capital Partners LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RothCapitalPartnersLLCMember" xlink:to="iinn_RothCapitalPartnersLLCMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_RegisteredDirectOfferingMember" xlink:href="iinn-20251231.xsd#iinn_RegisteredDirectOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RegisteredDirectOfferingMember" xlink:to="iinn_RegisteredDirectOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrantsMember" xlink:to="iinn_PreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PlacementAgentWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PlacementAgentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PlacementAgentWarrantsMember" xlink:to="iinn_PlacementAgentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePlacementAgentWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_JunePlacementAgentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_JunePlacementAgentWarrantsMember_lbl" xml:lang="en-US">June Placement Agent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_JunePlacementAgentWarrantsMember" xlink:to="iinn_JunePlacementAgentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandTwentyFourAprilOfferingMember" xlink:href="iinn-20251231.xsd#iinn_TwoThousandTwentyFourAprilOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TwoThousandTwentyFourAprilOfferingMember_lbl" xml:lang="en-US">2024 April Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandTwentyFourAprilOfferingMember" xlink:to="iinn_TwoThousandTwentyFourAprilOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandTwentyFourJuneOfferingMember" xlink:href="iinn-20251231.xsd#iinn_TwoThousandTwentyFourJuneOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TwoThousandTwentyFourJuneOfferingMember_lbl" xml:lang="en-US">2024 June Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandTwentyFourJuneOfferingMember" xlink:to="iinn_TwoThousandTwentyFourJuneOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePreFundedWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_JunePreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_JunePreFundedWarrantsMember_lbl" xml:lang="en-US">June Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_JunePreFundedWarrantsMember" xlink:to="iinn_JunePreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPrivateWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DecemberPrivateWarrantsMember_lbl" xml:lang="en-US">December Private Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivateWarrantsMember" xlink:to="iinn_DecemberPrivateWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPreFundedWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DecemberPreFundedWarrantsMember_lbl" xml:lang="en-US">December Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPreFundedWarrantsMember" xlink:to="iinn_DecemberPreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivateOfferingMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPrivateOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DecemberPrivateOfferingMember_lbl" xml:lang="en-US">December Private Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivateOfferingMember" xlink:to="iinn_DecemberPrivateOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AdvisorMember" xlink:href="iinn-20251231.xsd#iinn_AdvisorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdvisorMember_lbl" xml:lang="en-US">Advisor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdvisorMember" xlink:to="iinn_AdvisorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_December2025OfferingMember" xlink:href="iinn-20251231.xsd#iinn_December2025OfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_December2025OfferingMember_lbl" xml:lang="en-US">2025 December Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_December2025OfferingMember" xlink:to="iinn_December2025OfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Share Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesMember" xlink:to="iinn_EmployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExecutivesAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_ExecutivesAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExecutivesAndDirectorsMember_lbl" xml:lang="en-US">Executives and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExecutivesAndDirectorsMember" xlink:to="iinn_ExecutivesAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ServiceProvidersMember" xlink:href="iinn-20251231.xsd#iinn_ServiceProvidersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ServiceProvidersMember_lbl" xml:lang="en-US">Service Providers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ServiceProvidersMember" xlink:to="iinn_ServiceProvidersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RevenueAchievementMember" xlink:href="iinn-20251231.xsd#iinn_RevenueAchievementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RevenueAchievementMember_lbl" xml:lang="en-US">Revenue Achievement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevenueAchievementMember" xlink:to="iinn_RevenueAchievementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesDirectorsAndSubcontractorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl" xml:lang="en-US">Employees, Directors and Subcontractors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:to="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PurchaserMember" xlink:href="iinn-20251231.xsd#iinn_PurchaserMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PurchaserMember_lbl" xml:lang="en-US">Purchaser [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchaserMember" xlink:to="iinn_PurchaserMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems" xlink:to="iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable_lbl" xml:lang="en-US">FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" xlink:to="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems_lbl" xml:lang="en-US">FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems" xlink:to="iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY - Schedule of Share Capital (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" xlink:to="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY - Schedule of Share Capital (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" xlink:to="iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" xlink:href="iinn-20251231.xsd#iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable_lbl" xml:lang="en-US">COST OF REVENUES - Schedule of Cost of Revenues (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" xlink:to="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems_lbl" xml:lang="en-US">COST OF REVENUES - Schedule of Cost of Revenues (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems" xlink:to="iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:href="iinn-20251231.xsd#iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable_lbl" xml:lang="en-US">SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:to="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems_lbl" xml:lang="en-US">SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable_lbl" xml:lang="en-US">SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems_lbl" xml:lang="en-US">SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable_lbl" xml:lang="en-US">SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems_lbl" xml:lang="en-US">SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GENERALDetailsTable" xlink:href="iinn-20251231.xsd#iinn_GENERALDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GENERALDetailsTable_lbl" xml:lang="en-US">GENERAL (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GENERALDetailsTable" xlink:to="iinn_GENERALDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GENERALDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_GENERALDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GENERALDetailsLineItems_lbl" xml:lang="en-US">GENERAL (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GENERALDetailsLineItems" xlink:to="iinn_GENERALDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DEPOSITSDetailsTable" xlink:href="iinn-20251231.xsd#iinn_DEPOSITSDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DEPOSITSDetailsTable_lbl" xml:lang="en-US">DEPOSITS (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DEPOSITSDetailsTable" xlink:to="iinn_DEPOSITSDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DEPOSITSDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_DEPOSITSDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DEPOSITSDetailsLineItems_lbl" xml:lang="en-US">DEPOSITS (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DEPOSITSDetailsLineItems" xlink:to="iinn_DEPOSITSDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LEASELIABILITIESDetailsTable" xlink:href="iinn-20251231.xsd#iinn_LEASELIABILITIESDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LEASELIABILITIESDetailsTable_lbl" xml:lang="en-US">LEASE LIABILITIES (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LEASELIABILITIESDetailsTable" xlink:to="iinn_LEASELIABILITIESDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LEASELIABILITIESDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_LEASELIABILITIESDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LEASELIABILITIESDetailsLineItems_lbl" xml:lang="en-US">LEASE LIABILITIES (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LEASELIABILITIESDetailsLineItems" xlink:to="iinn_LEASELIABILITIESDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AgreementDomainDomain" xlink:href="iinn-20251231.xsd#iinn_AgreementDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AgreementDomainDomain_lbl" xml:lang="en-US">AgreementDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AgreementDomainDomain" xlink:to="iinn_AgreementDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable_lbl" xml:lang="en-US">FINACIAL LIABILITIES AT FAIR VALUE (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems_lbl" xml:lang="en-US">FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREHOLDERSEQUITYDetailsTable_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsTable" xlink:to="iinn_SHAREHOLDERSEQUITYDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREHOLDERSEQUITYDetailsLineItems_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="iinn_SHAREHOLDERSEQUITYDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TAXESONINCOMEDetailsTable" xlink:href="iinn-20251231.xsd#iinn_TAXESONINCOMEDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TAXESONINCOMEDetailsTable_lbl" xml:lang="en-US">TAXES ON INCOME (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TAXESONINCOMEDetailsTable" xlink:to="iinn_TAXESONINCOMEDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TAXESONINCOMEDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_TAXESONINCOMEDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TAXESONINCOMEDetailsLineItems_lbl" xml:lang="en-US">TAXES ON INCOME (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TAXESONINCOMEDetailsLineItems" xlink:to="iinn_TAXESONINCOMEDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREBASEDPAYMENTDetailsTable_lbl" xml:lang="en-US">SHARE-BASED PAYMENT (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREBASEDPAYMENTDetailsTable" xlink:to="iinn_SHAREBASEDPAYMENTDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SHAREBASEDPAYMENTDetailsLineItems_lbl" xml:lang="en-US">SHARE-BASED PAYMENT (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SHAREBASEDPAYMENTDetailsLineItems" xlink:to="iinn_SHAREBASEDPAYMENTDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SUBSEQUENTEVENTSDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SUBSEQUENTEVENTSDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SUBSEQUENTEVENTSDetailsTable_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SUBSEQUENTEVENTSDetailsTable" xlink:to="iinn_SUBSEQUENTEVENTSDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SUBSEQUENTEVENTSDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SUBSEQUENTEVENTSDetailsLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SUBSEQUENTEVENTSDetailsLineItems" xlink:to="iinn_SUBSEQUENTEVENTSDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AccountsPayableToRelatedParties_lbl0" xml:lang="en-US">Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccountsPayableToRelatedParties" xlink:to="iinn_AccountsPayableToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AccruedIssuanceExpenses_lbl0" xml:lang="en-US">Amount of accrued issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccruedIssuanceExpenses" xlink:to="iinn_AccruedIssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateBudget_lbl0" xml:lang="en-US">The amount of aggregate budget.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateBudget" xlink:to="iinn_AggregateBudget_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateGrossProceeds_lbl0" xml:lang="en-US">Aggregate gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateGrossProceeds" xlink:to="iinn_AggregateGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateOfferingPrice_lbl0" xml:lang="en-US">Aggregate offering price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateOfferingPrice" xlink:to="iinn_AggregateOfferingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Percentage of annual depreciation rates of property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_CapitalGainTaxRate_lbl0" xml:lang="en-US">Capital gain tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTaxRate" xlink:to="iinn_CapitalGainTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Represent the number of private warrant or right outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:to="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ContingentUponFutureSales_lbl0" xml:lang="en-US">The amount of contingent upon future sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContingentUponFutureSales" xlink:to="iinn_ContingentUponFutureSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_CostOfRevenuesTextBlock_lbl0" xml:lang="en-US">Disclosure of cost of revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostOfRevenuesTextBlock" xlink:to="iinn_CostOfRevenuesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeductingOfferingCosts_lbl0" xml:lang="en-US">Deducting offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeductingOfferingCosts" xlink:to="iinn_DeductingOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses_lbl0" xml:lang="en-US">Represents amount of deferred tax accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAccruedExpenses" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl0" xml:lang="en-US">Fund raising costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl0" xml:lang="en-US">Operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DescriptionOfFeePayments_lbl0" xml:lang="en-US">Description of fee payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DescriptionOfFeePayments" xlink:to="iinn_DescriptionOfFeePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Percentage of revaluation of financial liabilities at fair value through profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Revaluation of financial liabilities at fair value through profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet_lbl0" xml:lang="en-US">The amount of exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" xlink:to="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares_lbl0" xml:lang="en-US">Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" xlink:to="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl0" xml:lang="en-US">The amount of exercise of june 2024 pre-funded warrants into ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl0" xml:lang="en-US">Number of exercise of June 2024 pre-funded warrants into ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExpirationOfFinancialLiability_lbl0" xml:lang="en-US">Amount of expiration of financial liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpirationOfFinancialLiability" xlink:to="iinn_ExpirationOfFinancialLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for finance income and expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinancialExpensesDueToCommitmentFee_lbl1" xml:lang="en-US">Financial expenses due to commitment fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpensesDueToCommitmentFee" xlink:to="iinn_FinancialExpensesDueToCommitmentFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinancialLiabilityPlacementAgentFee_lbl0" xml:lang="en-US">Amount of financial liability placement agent fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityPlacementAgentFee" xlink:to="iinn_FinancialLiabilityPlacementAgentFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FundraisingExpenses_lbl0" xml:lang="en-US">The amount of fundraising expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FundraisingExpenses" xlink:to="iinn_FundraisingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl0" xml:lang="en-US">The entire disclosure for general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_IIAParticipation_lbl0" xml:lang="en-US">The expenses of IIA participation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IIAParticipation" xlink:to="iinn_IIAParticipation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_IncrementalBorrowingRate_lbl0" xml:lang="en-US">The percent of Incremental borrowing rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IncrementalBorrowingRate" xlink:to="iinn_IncrementalBorrowingRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl0" xml:lang="en-US">Amount of issuance of ordinary shares advisor fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFee_lbl0" xml:lang="en-US">Issuance of ordinary shares commitment fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesCommitmentFee" xlink:to="iinn_IssuanceOfOrdinarySharesCommitmentFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares_lbl0" xml:lang="en-US">Issuance of ordinary shares- commitment fees (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares" xlink:to="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_IssueOfPrivateWarrantsShares_lbl0" xml:lang="en-US">Issue of private warrants shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssueOfPrivateWarrantsShares" xlink:to="iinn_IssueOfPrivateWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_LeaseMonthlyPayment_lbl0" xml:lang="en-US">The amount of lease monthly payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeaseMonthlyPayment" xlink:to="iinn_LeaseMonthlyPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_MonthlyDeductionFromTerminationFee_lbl0" xml:lang="en-US">Represent the value of monthly deduction from termination fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MonthlyDeductionFromTerminationFee" xlink:to="iinn_MonthlyDeductionFromTerminationFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NonCashTransactions_lbl0" xml:lang="en-US">The total amount of non cash transactions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_NonCashTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NumberOfSharesPerUnits_lbl0" xml:lang="en-US">Number of shares per units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfSharesPerUnits" xlink:to="iinn_NumberOfSharesPerUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NumberofAdditionalOrdinaryShares_lbl0" xml:lang="en-US">Number of additional ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberofAdditionalOrdinaryShares" xlink:to="iinn_NumberofAdditionalOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OrdinarySharesPurchasePricePercentage_lbl0" xml:lang="en-US">The percent of ordinary shares purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesPurchasePricePercentage" xlink:to="iinn_OrdinarySharesPurchasePricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OrdinarySharesSEPAAmount_lbl0" xml:lang="en-US">The amount of ordinary shares SEPA.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesSEPAAmount" xlink:to="iinn_OrdinarySharesSEPAAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl0" xml:lang="en-US">Amount of other receivable in connection to private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:to="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OthersAsset_lbl0" xml:lang="en-US">Amount of assets classified as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OthersAsset" xlink:to="iinn_OthersAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PaidRoyalties_lbl0" xml:lang="en-US">The amount of paid royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PaidRoyalties" xlink:to="iinn_PaidRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl0" xml:lang="en-US">Represent the description of percentage for car lease agreement cancellation penalty.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:to="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfApprovedBudget_lbl0" xml:lang="en-US">Percentage of approved budget.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfApprovedBudget" xlink:to="iinn_PercentageOfApprovedBudget_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfCapitalGainTax_lbl0" xml:lang="en-US">Percentage of capital gain tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfCapitalGainTax" xlink:to="iinn_PercentageOfCapitalGainTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl0" xml:lang="en-US">Percentage of future lease payments discounted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:to="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfPayFees_lbl0" xml:lang="en-US">Percentage of pay fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPayFees" xlink:to="iinn_PercentageOfPayFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PreFundedWarrants_lbl0" xml:lang="en-US">Pre funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrants" xlink:to="iinn_PreFundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PreFundedWarrantsPerShare_lbl0" xml:lang="en-US">Pre funded warrants per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrantsPerShare" xlink:to="iinn_PreFundedWarrantsPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PrivateWarrants_lbl0" xml:lang="en-US">Private warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrants" xlink:to="iinn_PrivateWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PrivateWarrantsExerciseShares_lbl0" xml:lang="en-US">Private warrants exercise shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsExerciseShares" xlink:to="iinn_PrivateWarrantsExerciseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ProjectBudgetAggregateAmount_lbl0" xml:lang="en-US">The amount of project budget aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProjectBudgetAggregateAmount" xlink:to="iinn_ProjectBudgetAggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PurchasePricePerShare_lbl0" xml:lang="en-US">Purchase price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchasePricePerShare" xlink:to="iinn_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PurchasePricePerUnit_lbl0" xml:lang="en-US">Purchase price per unit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchasePricePerUnit" xlink:to="iinn_PurchasePricePerUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">The amount of revaluation of financial liabilities at fair value through profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RoyaltiesPercentage_lbl0" xml:lang="en-US">Percentage of royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesPercentage" xlink:to="iinn_RoyaltiesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SaleOfRightsValue_lbl0" xml:lang="en-US">Sale of rights value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SaleOfRightsValue" xlink:to="iinn_SaleOfRightsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SalesAmount_lbl0" xml:lang="en-US">The amount of generated sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAmount" xlink:to="iinn_SalesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl0" xml:lang="en-US">Disclosure of sales and marketing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfCostOfRevenuesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of cost of revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfCostOfRevenuesTableTextBlock" xlink:to="iinn_ScheduleOfCostOfRevenuesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of depreciation on straight-line method, over the estimated useful life of the assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of lessee operating leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:to="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of sales and marketing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl0" xml:lang="en-US">Disclosure of theoretical tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SeverancePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for severance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SeverancePolicyTextBlock" xlink:to="iinn_SeverancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl0" xml:lang="en-US">Number of warrants, exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted-average exercise price, exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl0" xml:lang="en-US">Number of warrants, expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted-average exercise price, expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne_lbl0" xml:lang="en-US">The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_lbl0" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl0" xml:lang="en-US">Number of warrants, issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl0" xml:lang="en-US">Per share or unit weighted-average fair value of other than option under share-based payment arrangement. Excludes share and unit options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl0" xml:lang="en-US">Contractual life of award under share-based payment arrangement, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl0" xml:lang="en-US">Number of RSUs vested under share based payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl0" xml:lang="en-US">The amount of share based compensation-placement agent warrants against additional paid in capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StandbyEquityPurchaseAgreementPercentage_lbl0" xml:lang="en-US">Standby Equity Purchase Agreement percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StandbyEquityPurchaseAgreementPercentage" xlink:to="iinn_StandbyEquityPurchaseAgreementPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees_lbl0" xml:lang="en-US">The amount of issuance of ordinary shares- commitment fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" xlink:to="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl0" xml:lang="en-US">Number of shares exercise of share based payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl0" xml:lang="en-US">Exercise of share based payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_Subcontractors_lbl0" xml:lang="en-US">Subcontractors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl0" xml:lang="en-US">Temporary differences and tax losses for which no Deferred Tax Asset is recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_WarrantsToPurchaseOrdinaryShares_lbl0" xml:lang="en-US">Warrants to purchase ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToPurchaseOrdinaryShares" xlink:to="iinn_WarrantsToPurchaseOrdinaryShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_MonthlyDeductionFromTerminationFee_lbl1" xml:lang="en-US">Monthly Deduction From Termination Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MonthlyDeductionFromTerminationFee" xlink:to="iinn_MonthlyDeductionFromTerminationFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl1" xml:lang="en-US">Class Of Private Warrant Or Right Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:to="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl0" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_YorkvilleMember_lbl0" xml:lang="en-US">Yorkville Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_YorkvilleMember" xlink:to="iinn_YorkvilleMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl1" xml:lang="en-US">Sales And Marketing Expenses Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl1" xml:lang="en-US">Effective Income Tax Rate Revaluation Of Financial Liabilities At Fair Value Through Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExpirationOfFinancialLiability_lbl1" xml:lang="en-US">Expiration Of Financial Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpirationOfFinancialLiability" xlink:to="iinn_ExpirationOfFinancialLiability_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet_lbl1" xml:lang="en-US">Exercise Of December2024 Warrants And Prefunded Warrants Into Ordinary Shares Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" xlink:to="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CostOfRevenuesTextBlock_lbl1" xml:lang="en-US">Cost Of Revenues Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostOfRevenuesTextBlock" xlink:to="iinn_CostOfRevenuesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0" xml:lang="en-US">Interest Income, Deposits with Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Lessee Operating Leases Disclosure Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:to="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OrdinarySharesPurchasePricePercentage_lbl1" xml:lang="en-US">Ordinary Shares Purchase Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesPurchasePricePercentage" xlink:to="iinn_OrdinarySharesPurchasePricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ContingentUponFutureSales_lbl1" xml:lang="en-US">Contingent Upon Future Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContingentUponFutureSales" xlink:to="iinn_ContingentUponFutureSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PurchaserMember_lbl0" xml:lang="en-US">Purchaser Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchaserMember" xlink:to="iinn_PurchaserMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfApprovedBudget_lbl1" xml:lang="en-US">Percentage Of Approved Budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfApprovedBudget" xlink:to="iinn_PercentageOfApprovedBudget_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl1" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeductingOfferingCosts_lbl1" xml:lang="en-US">Deducting Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeductingOfferingCosts" xlink:to="iinn_DeductingOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationNonproduction_lbl0" xml:lang="en-US">Depreciation, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TwoThousandTwentyFourJuneOfferingMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four June Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandTwentyFourJuneOfferingMember" xlink:to="iinn_TwoThousandTwentyFourJuneOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation Nondeductible Expense Revaluation Of Financial Liabilities At Fair Value Through Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl1" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitment_lbl1" xml:lang="en-US">Other Commitment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Financial Liabilities Fair Value Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract_lbl0" xml:lang="en-US">Changes During The Period Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ChangesDuringThePeriodAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl1" xml:lang="en-US">General And Administrative Expenses Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl0" xml:lang="en-US">Derivative Liability, Measurement Input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Financial Income And Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OrdinarySharesSEPAAmount_lbl1" xml:lang="en-US">Ordinary Shares SEPAAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesSEPAAmount" xlink:to="iinn_OrdinarySharesSEPAAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePriceOnePointOneMember_lbl0" xml:lang="en-US">Exercise Price One Point One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePriceOnePointOneMember" xlink:to="iinn_ExercisePriceOnePointOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_BankLeumiMember_lbl0" xml:lang="en-US">Bank Leumi Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BankLeumiMember" xlink:to="iinn_BankLeumiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_December2025OfferingMember_lbl0" xml:lang="en-US">December2025 Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_December2025OfferingMember" xlink:to="iinn_December2025OfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NetBookValueAbstract_lbl0" xml:lang="en-US">Net Book Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract" xlink:to="iinn_NetBookValueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Annual Depreciation Rates Of Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateBudget_lbl1" xml:lang="en-US">Aggregate Budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateBudget" xlink:to="iinn_AggregateBudget_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl1" xml:lang="en-US">Revaluation Of Financial Liabilities At Fair Value Through Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl0" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CostAbstract0_lbl0" xml:lang="en-US">Cost Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostAbstract0" xlink:to="iinn_CostAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OfficersAndDirectorsMember_lbl0" xml:lang="en-US">Officers And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OfficersAndDirectorsMember" xlink:to="iinn_OfficersAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Short-Term Debt, Percentage Bearing Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NonCashTransactions_lbl1" xml:lang="en-US">Non Cash Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_NonCashTransactions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OrdinarySharesNoParValueMember_lbl0" xml:lang="en-US">Ordinary Shares No Par Value Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesNoParValueMember" xlink:to="iinn_OrdinarySharesNoParValueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees_lbl1" xml:lang="en-US">Stock Issued During Period Issuance Of Ordinary Shares Commitment Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" xlink:to="iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfCostOfRevenuesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Cost Of Revenues Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfCostOfRevenuesTableTextBlock" xlink:to="iinn_ScheduleOfCostOfRevenuesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted-average Exercise Price Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfCapitalGainTax_lbl1" xml:lang="en-US">Percentage Of Capital Gain Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfCapitalGainTax" xlink:to="iinn_PercentageOfCapitalGainTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalent, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract3" xlink:to="iinn_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract2" xlink:to="iinn_UnlabeledAbstract2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract5" xlink:to="iinn_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract4" xlink:to="iinn_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesAndDirectorsMember_lbl0" xml:lang="en-US">Employees And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesAndDirectorsMember" xlink:to="iinn_EmployeesAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract_lbl" xml:lang="en-US">Schedule Of Shareholders And Other Related Parties Benefits Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:to="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract1" xlink:to="iinn_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract0" xlink:to="iinn_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IncrementalBorrowingRate_lbl1" xml:lang="en-US">Incremental Borrowing Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IncrementalBorrowingRate" xlink:to="iinn_IncrementalBorrowingRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RDEquipmentMember_lbl0" xml:lang="en-US">RDEquipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RDEquipmentMember" xlink:to="iinn_RDEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DescriptionOfFeePayments_lbl1" xml:lang="en-US">Description Of Fee Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DescriptionOfFeePayments" xlink:to="iinn_DescriptionOfFeePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SeverancePolicyTextBlock_lbl1" xml:lang="en-US">Severance Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SeverancePolicyTextBlock" xlink:to="iinn_SeverancePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses_lbl1" xml:lang="en-US">Deferred Tax Assets Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAccruedExpenses" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateGrossProceeds_lbl1" xml:lang="en-US">Aggregate Gross Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateGrossProceeds" xlink:to="iinn_AggregateGrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NetBookValueAbstract0_lbl0" xml:lang="en-US">Net Book Value Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract0" xlink:to="iinn_NetBookValueAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl0" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantyMember_lbl0" xml:lang="en-US">Warranty Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantyMember" xlink:to="iinn_WarrantyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Rsus To Services Providers And Advisers Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RothCapitalPartnersLLCMember_lbl1" xml:lang="en-US">Roth Capital Partners LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RothCapitalPartnersLLCMember" xlink:to="iinn_RothCapitalPartnersLLCMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_JunePlacementAgentWarrantsMember_lbl0" xml:lang="en-US">June Placement Agent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_JunePlacementAgentWarrantsMember" xlink:to="iinn_JunePlacementAgentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RoyaltiesToIIAMember_lbl0" xml:lang="en-US">Royalties To IIAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesToIIAMember" xlink:to="iinn_RoyaltiesToIIAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfPayFees_lbl1" xml:lang="en-US">Percentage Of Pay Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPayFees" xlink:to="iinn_PercentageOfPayFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IssueOfPrivateWarrantsShares_lbl1" xml:lang="en-US">Issue Of Private Warrants Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssueOfPrivateWarrantsShares" xlink:to="iinn_IssueOfPrivateWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl0" xml:lang="en-US">Warrants To Purchase Ordinary Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:to="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_December2024PrivatePlacementMember_lbl1" xml:lang="en-US">December2024 Private Placement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_December2024PrivatePlacementMember" xlink:to="iinn_December2024PrivatePlacementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfCostOfRevenuesAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfCostOfRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfCostOfRevenuesAbstract_lbl" xml:lang="en-US">Schedule Of Cost Of Revenues Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfCostOfRevenuesAbstract" xlink:to="iinn_ScheduleOfCostOfRevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl1" xml:lang="en-US">Exercise Of June2024 Prefunded Warrants Into Ordinary Sharesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PrivateWarrantsMember_lbl2" xml:lang="en-US">Private Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsMember" xlink:to="iinn_PrivateWarrantsMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Sales And Marketing Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DecemberPrivateWarrantsMember_lbl0" xml:lang="en-US">December Private Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivateWarrantsMember" xlink:to="iinn_DecemberPrivateWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NumberOfSharesPerUnits_lbl1" xml:lang="en-US">Number Of Shares Per Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfSharesPerUnits" xlink:to="iinn_NumberOfSharesPerUnits_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Operating Lease, Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl0" xml:lang="en-US">Employees Directors And Subcontractors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:to="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FundraisingExpenses_lbl1" xml:lang="en-US">Fundraising Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FundraisingExpenses" xlink:to="iinn_FundraisingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Exercise6875Member_lbl0" xml:lang="en-US">Exercise6875 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Exercise6875Member" xlink:to="iinn_Exercise6875Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_MaterialsAndSubcontractorsMember_lbl0" xml:lang="en-US">Materials And Subcontractors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MaterialsAndSubcontractorsMember" xlink:to="iinn_MaterialsAndSubcontractorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_UnlabeledAbstract" xlink:to="iinn_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DecemberPrivatePlacementMember_lbl0" xml:lang="en-US">December Private Placement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivatePlacementMember" xlink:to="iinn_DecemberPrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl1" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccruedIssuanceExpenses_lbl1" xml:lang="en-US">Accrued Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccruedIssuanceExpenses" xlink:to="iinn_AccruedIssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl1" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AgreementAxis_lbl0" xml:lang="en-US">Agreement Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AgreementAxis" xlink:to="iinn_AgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccumulatedDepreciationAbstract0_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciationAbstract0" xlink:to="iinn_AccumulatedDepreciationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PreFundedWarrants_lbl1" xml:lang="en-US">Pre Funded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrants" xlink:to="iinn_PreFundedWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl2" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestBearingDepositsInBanks_lbl0" xml:lang="en-US">Interest-Bearing Deposits in Banks and Other Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDepositsInBanks" xlink:to="us-gaap_InterestBearingDepositsInBanks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateOfferingPrice_lbl1" xml:lang="en-US">Aggregate Offering Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateOfferingPrice" xlink:to="iinn_AggregateOfferingPrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract_lbl" xml:lang="en-US">Selling and Marketing Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_SellingAndMarketingExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAbstract" xlink:to="iinn_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl1" xml:lang="en-US">Issuance Of Ordinary Shares Advisor Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsToPurchaseOrdinaryShares_lbl1" xml:lang="en-US">Warrants To Purchase Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToPurchaseOrdinaryShares" xlink:to="iinn_WarrantsToPurchaseOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SaleOfRightsValue_lbl1" xml:lang="en-US">Sale Of Rights Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SaleOfRightsValue" xlink:to="iinn_SaleOfRightsValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Number Of RSUs Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ProjectBudgetAggregateAmount_lbl1" xml:lang="en-US">Project Budget Aggregate Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProjectBudgetAggregateAmount" xlink:to="iinn_ProjectBudgetAggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExecutivesAndDirectorsMember_lbl0" xml:lang="en-US">Executives And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExecutivesAndDirectorsMember" xlink:to="iinn_ExecutivesAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl1" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercise Of Share Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PreFundedWarrantsPerShare_lbl1" xml:lang="en-US">Pre Funded Warrants Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrantsPerShare" xlink:to="iinn_PreFundedWarrantsPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ServiceProvidersMember_lbl0" xml:lang="en-US">Service Providers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ServiceProvidersMember" xlink:to="iinn_ServiceProvidersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RegisteredDirectOfferingMember_lbl0" xml:lang="en-US">Registered Direct Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RegisteredDirectOfferingMember" xlink:to="iinn_RegisteredDirectOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherLosses_lbl0" xml:lang="en-US">Provision for Other Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherLosses" xlink:to="us-gaap_ProvisionForOtherLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PrivateWarrants_lbl1" xml:lang="en-US">Private Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrants" xlink:to="iinn_PrivateWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl0" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StandbyEquityPurchaseAgreementSEPAMember_lbl0" xml:lang="en-US">Standby Equity Purchase Agreement SEPAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StandbyEquityPurchaseAgreementSEPAMember" xlink:to="iinn_StandbyEquityPurchaseAgreementSEPAMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl0" xml:lang="en-US">Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NumberofAdditionalOrdinaryShares_lbl1" xml:lang="en-US">Numberof Additional Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberofAdditionalOrdinaryShares" xlink:to="iinn_NumberofAdditionalOrdinaryShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Information About The Company SOutstanding Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:to="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DecemberStandbyEquityPurchaseAgreementMember_lbl0" xml:lang="en-US">December Standby Equity Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberStandbyEquityPurchaseAgreementMember" xlink:to="iinn_DecemberStandbyEquityPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice55Member_lbl0" xml:lang="en-US">Exercise Price55 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55Member" xlink:to="iinn_ExercisePrice55Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePriceOnePointSixMember_lbl0" xml:lang="en-US">Exercise Price One Point Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePriceOnePointSixMember" xlink:to="iinn_ExercisePriceOnePointSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl1" xml:lang="en-US">Deferred Tax Assets Fund Raising Cost2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFee_lbl1" xml:lang="en-US">Issuance Of Ordinary Shares Commitment Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesCommitmentFee" xlink:to="iinn_IssuanceOfOrdinarySharesCommitmentFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract1_lbl0" xml:lang="en-US">Changes During The Period Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_ChangesDuringThePeriodAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract0_lbl0" xml:lang="en-US">Changes During The Period Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="iinn_ChangesDuringThePeriodAbstract0_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and Administrative Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_lbl0" xml:lang="en-US">General Insurance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl0" xml:lang="en-US">Common Stock, Voting Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl0" xml:lang="en-US">Derivative Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0" xml:lang="en-US">Property, Plant and Equipment, Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl1" xml:lang="en-US">Exercise Of June2024 Prefunded Warrants Into Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl0" xml:lang="en-US">Deposit Liabilities Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl1" xml:lang="en-US">Stock Issued During Period Value Stock Options Exercise Of Share Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SecondTrancheMember_lbl0" xml:lang="en-US">Second Tranche Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SecondTrancheMember" xlink:to="iinn_SecondTrancheMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl0" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialLiabilityAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfFinancialLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialLiabilityAbstract_lbl" xml:lang="en-US">Schedule Of Financial Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialLiabilityAbstract" xlink:to="iinn_ScheduleOfFinancialLiabilityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Subcontractors_lbl1" xml:lang="en-US">Subcontractors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl1" xml:lang="en-US">Percentage For Cars Lease Agreement Cancellation Penalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:to="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Schedule Of Effective Tax Rate Reconciliation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DecemberPrivateOfferingMember_lbl0" xml:lang="en-US">December Private Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivateOfferingMember" xlink:to="iinn_DecemberPrivateOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl0" xml:lang="en-US">Payments for (Proceeds from) Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ServicesProvidersAndAdvisersMember_lbl0" xml:lang="en-US">Services Providers And Advisers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ServicesProvidersAndAdvisersMember" xlink:to="iinn_ServicesProvidersAndAdvisersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DecemberPreFundedWarrantsMember_lbl0" xml:lang="en-US">December Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPreFundedWarrantsMember" xlink:to="iinn_DecemberPreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl1" xml:lang="en-US">Percentage Of Future Lease Payments Discounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:to="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostAbstract" xlink:to="iinn_CostAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract_lbl" xml:lang="en-US">Schedule Of Measure The Fair Value Of The Option At Grant Date Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" xlink:to="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Leasing Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Employee-related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_CostOfRevenuesAbstract" xlink:href="iinn-20251231.xsd#iinn_CostOfRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CostOfRevenuesAbstract_lbl" xml:lang="en-US">Cost Of Revenues Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CostOfRevenuesAbstract" xlink:to="iinn_CostOfRevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IIAParticipation_lbl1" xml:lang="en-US">IIAParticipation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IIAParticipation" xlink:to="iinn_IIAParticipation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PaidRoyalties_lbl1" xml:lang="en-US">Paid Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PaidRoyalties" xlink:to="iinn_PaidRoyalties_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract_lbl" xml:lang="en-US">Schedule Of Theoretical Tax Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="iinn_ScheduleOfTheoreticalTaxAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CapitalGainTaxRate_lbl1" xml:lang="en-US">Capital Gain Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTaxRate" xlink:to="iinn_CapitalGainTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl1" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0" xml:lang="en-US">Government Assistance [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl2" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PurchasePricePerUnit_lbl1" xml:lang="en-US">Purchase Price Per Unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchasePricePerUnit" xlink:to="iinn_PurchasePricePerUnit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl1" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl0" xml:lang="en-US">Other Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_JunePreFundedWarrantsMember_lbl0" xml:lang="en-US">June Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_JunePreFundedWarrantsMember" xlink:to="iinn_JunePreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PrivateWarrantsExerciseShares_lbl1" xml:lang="en-US">Private Warrants Exercise Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsExerciseShares" xlink:to="iinn_PrivateWarrantsExerciseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice156Member_lbl0" xml:lang="en-US">Exercise Price156 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice156Member" xlink:to="iinn_ExercisePrice156Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl0" xml:lang="en-US">Cost, Maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfMovementInWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Movement In Warrants Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:to="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StandbyEquityPurchaseAgreementPercentage_lbl1" xml:lang="en-US">Standby Equity Purchase Agreement Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StandbyEquityPurchaseAgreementPercentage" xlink:to="iinn_StandbyEquityPurchaseAgreementPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US">Research and Development Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl0" xml:lang="en-US">Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RoyaltiesPercentage_lbl1" xml:lang="en-US">Royalties Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesPercentage" xlink:to="iinn_RoyaltiesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares_lbl1" xml:lang="en-US">Issuance Of Ordinary Shares Commitment Feesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares" xlink:to="iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl0" xml:lang="en-US">Employee Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl1" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccumulatedDepreciationAbstract" xlink:to="iinn_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PlacementAgentWarrantsMember_lbl0" xml:lang="en-US">Placement Agent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PlacementAgentWarrantsMember" xlink:to="iinn_PlacementAgentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl1" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl0" xml:lang="en-US">Labor and Related Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl0" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Options To Services Providers And Advisers Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares_lbl1" xml:lang="en-US">Exercise Of December2024 Warrants And Prefunded Warrants Into Ordinary Shares Netin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" xlink:to="iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity, Number of Shares, Par Value and Other Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl1" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OthersAsset_lbl1" xml:lang="en-US">Others Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OthersAsset" xlink:to="iinn_OthersAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialLiabilityPlacementAgentFee_lbl1" xml:lang="en-US">Financial Liability Placement Agent Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityPlacementAgentFee" xlink:to="iinn_FinancialLiabilityPlacementAgentFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl0" xml:lang="en-US">Product Warranty, Liquidation Proceeds, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PreFundedWarrantsMember_lbl0" xml:lang="en-US">Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrantsMember" xlink:to="iinn_PreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of General And Administrative Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl0" xml:lang="en-US">Other Labor-related Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Options Exercisedi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Theoretical Tax Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NonTaxableOrNonDeductibleItemsAbstract_lbl0" xml:lang="en-US">Non Taxable Or Non Deductible Items Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonTaxableOrNonDeductibleItemsAbstract" xlink:to="iinn_NonTaxableOrNonDeductibleItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalesAmount_lbl1" xml:lang="en-US">Sales Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAmount" xlink:to="iinn_SalesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TwoThousandTwentyFourAprilOfferingMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four April Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandTwentyFourAprilOfferingMember" xlink:to="iinn_TwoThousandTwentyFourAprilOfferingMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAbstract_lbl" xml:lang="en-US">Deposits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccountsPayableToRelatedParties_lbl1" xml:lang="en-US">Accounts Payable To Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccountsPayableToRelatedParties" xlink:to="iinn_AccountsPayableToRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PayrollAndRelatedMember_lbl0" xml:lang="en-US">Payroll And Related Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PayrollAndRelatedMember" xlink:to="iinn_PayrollAndRelatedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RevenueAchievementMember_lbl0" xml:lang="en-US">Revenue Achievement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevenueAchievementMember" xlink:to="iinn_RevenueAchievementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesMember_lbl0" xml:lang="en-US">Employees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesMember" xlink:to="iinn_EmployeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl0" xml:lang="en-US">Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl0" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl1" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl1" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl1" xml:lang="en-US">Share Based Compensationplacement Agent Warrants Against Additional Paid In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdvisorMember_lbl0" xml:lang="en-US">Advisor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdvisorMember" xlink:to="iinn_AdvisorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">Schedule Of General And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeaseMonthlyPayment_lbl1" xml:lang="en-US">Lease Monthly Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeaseMonthlyPayment" xlink:to="iinn_LeaseMonthlyPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl0" xml:lang="en-US">ISRAEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl1" xml:lang="en-US">Other Receivable In Connection To Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:to="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl1" xml:lang="en-US">Temporary Differences And Tax Losses For Which No Deferred Tax Asset Is Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl0" xml:lang="en-US">Travel and Entertainment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="iinn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl1" xml:lang="en-US">Finance Income And Expenses Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchasePricePerShare" xlink:to="iinn_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl0" xml:lang="en-US">Compensation Expense, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialExpensesDueToCommitmentFee_lbl2" xml:lang="en-US">Financial Expenses Due To Commitment Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialExpensesDueToCommitmentFee" xlink:to="iinn_FinancialExpensesDueToCommitmentFee_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<!-- [WMV6][ImVGv0QwZFTii6eH9m6IYxAukoQOCVN3XhUoR75uKObEccafDHq5Nhdsj0YdiADX5/Px7/s+WCgP1iOZmBbXJIh/lcDap5HffaSOFLkBpyPHUvvXtTt7BG9rwSqD0nu7aopuvoAbE5MMoc7iIkiPQV3aqo66VvAYhg5GJz9Ghlpy+Mn/oivSksIALWSCGOco/GPmVEJA57Ma87MfRiY4LhTu1VyRrMFO3YeBr/bShHBAh7RVNdrMOZtsyDHLyiH+hvzT8J6GXwgW603ojYi/vNJAphyV9KXovtCNpqsgYIoB8pEZrR7kbeZIEdDb03MYCneRpogSgdLtv/3hKEZRpCTBZ70w1p89AnuVOrcsUi3JQb1Ipg==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>iinn-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 26 19:16:31 UTC 2026 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ShareholdersEquityType2or3" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_GENERAL" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERAL"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_CASHANDCASHEQUIVALENT" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENT"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_DEPOSITS" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITS"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_OTHERCURRENTASSETS" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETS"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_INVENTORY" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORY"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_PROPERTYANDEQUIPMENTNET" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNET"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_OTHERACCOUNTSPAYABLE" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLE"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_COMMITMENTSANDCONTINGENCIES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_LEASELIABILITIES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINACIALLIABILITIESATFAIRVALUE" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUE"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREHOLDERSEQUITY" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITY"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_REVENUES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/REVENUES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_COSTOFREVENUES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_RESEARCHANDDEVELOPMENTEXPENSES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_GENERALANDADMINISTRATIVEEXPENSES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SALESANDMARKETINGEXPENSES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINANCIALINCOMEANDEXPENSES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_TAXESONINCOME" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOME"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREBASEDPAYMENT" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENT"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_RELATEDPARTIES" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIES"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SUBSEQUENTEVENTS" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_AccountingPoliciesByPolicy" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_OTHERCURRENTASSETSTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETSTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_INVENTORYTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORYTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_PROPERTYANDEQUIPMENTNETTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNETTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_OTHERACCOUNTSPAYABLETables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLETables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_LEASELIABILITIESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINACIALLIABILITIESATFAIRVALUETables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUETables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREHOLDERSEQUITYTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_COSTOFREVENUESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_RESEARCHANDDEVELOPMENTEXPENSESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_GENERALANDADMINISTRATIVEEXPENSESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SALESANDMARKETINGEXPENSESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINANCIALINCOMEANDEXPENSESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_TAXESONINCOMETables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREBASEDPAYMENTTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_RELATEDPARTIESTables" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIESTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofInventoryTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOtherAccountsPayableTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofFinancialLiabilityTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofShareCapitalTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofMovementinWarrantsOutstandingTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofCostofRevenuesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofFinancialIncomeandExpensesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofTheoreticalTaxTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofEffectiveTaxRateReconciliationTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_GENERALDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_CASHANDCASHEQUIVALENTDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_DEPOSITSDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_LEASELIABILITIESDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_FINACIALLIABILITIESATFAIRVALUEDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREHOLDERSEQUITYDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_TAXESONINCOMEDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SHAREBASEDPAYMENTDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20251231.xsd#iinn_r_SUBSEQUENTEVENTSDetails" roleURI="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OperatingIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20251231.xsd#iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20251231.xsd#iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" xlink:href="iinn-20251231.xsd#iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" xlink:href="iinn-20251231.xsd#iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesCommitmentFeesinShares" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesCommitmentFeesinShares" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProvisionForOtherLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForOtherLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ExpirationOfFinancialLiability" xlink:href="iinn-20251231.xsd#iinn_ExpirationOfFinancialLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ExpirationOfFinancialLiability" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesAdvisorFees" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfOrdinarySharesAdvisorFees" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialExpensesDueToCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialExpensesDueToCommitmentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="FinancialExpensesDueToCommitmentFee" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_IssuanceOfOrdinarySharesCommitmentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfOrdinarySharesCommitmentFee" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfOrdinarySharesCommitmentFee" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCash" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherReceivableInConnectionToPrivatePlacement" xlink:href="iinn-20251231.xsd#iinn_OtherReceivableInConnectionToPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="OtherReceivableInConnectionToPrivatePlacement" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedIssuanceExpenses" xlink:href="iinn-20251231.xsd#iinn_AccruedIssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="AccruedIssuanceExpenses" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialLiabilityPlacementAgentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialLiabilityPlacementAgentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="FinancialLiabilityPlacementAgentFee" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCashTransactions" xlink:href="iinn-20251231.xsd#iinn_NonCashTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="NonCashTransactions" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERAL" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositLiabilitiesDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORY" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNET" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLE" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUE" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITY" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/REVENUES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CostOfRevenuesAbstract" xlink:href="iinn-20251231.xsd#iinn_CostOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="CostOfRevenuesTextBlock" xlink:href="iinn-20251231.xsd#iinn_CostOfRevenuesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostOfRevenuesAbstract" xlink:to="CostOfRevenuesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpensesTextBlock" xlink:href="iinn-20251231.xsd#iinn_GeneralAndAdministrativeExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20251231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="SalesAndMarketingExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOME" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENT" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIES" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeAndExpensesPolicyTextBlock" xlink:href="iinn-20251231.xsd#iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="FinanceIncomeAndExpensesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePolicyTextBlock" xlink:href="iinn-20251231.xsd#iinn_SeverancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETSTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORYTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLETables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUETables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CostOfRevenuesAbstract" xlink:href="iinn-20251231.xsd#iinn_CostOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfCostOfRevenuesTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfCostOfRevenuesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostOfRevenuesAbstract" xlink:to="ScheduleOfCostOfRevenuesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="ScheduleOfSalesAndMarketingExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfTheoreticalTaxTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIESTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:to="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:href="iinn-20251231.xsd#iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems" xlink:to="AnnualDepreciationRatesOfPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestBearingDepositsInBanks" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OthersAsset" xlink:href="iinn-20251231.xsd#iinn_OthersAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="OthersAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RDEquipmentMember" xlink:href="iinn-20251231.xsd#iinn_RDEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="RDEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableToRelatedParties" xlink:href="iinn-20251231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="AccountsPayableToRelatedParties" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialLiabilityAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfFinancialLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialLiabilityAbstract" xlink:to="FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="PrivateWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable" xlink:to="FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable" xlink:to="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfMovementInWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice55Member" xlink:href="iinn-20251231.xsd#iinn_ExercisePrice55Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice55Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Exercise6875Member" xlink:href="iinn-20251231.xsd#iinn_Exercise6875Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="Exercise6875Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOnePointSixMember" xlink:href="iinn-20251231.xsd#iinn_ExercisePriceOnePointSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceOnePointSixMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice156Member" xlink:href="iinn-20251231.xsd#iinn_ExercisePrice156Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice156Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOnePointOneMember" xlink:href="iinn-20251231.xsd#iinn_ExercisePriceOnePointOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceOnePointOneMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCostOfRevenuesAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfCostOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" xlink:href="iinn-20251231.xsd#iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCostOfRevenuesAbstract" xlink:to="COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MaterialsAndSubcontractorsMember" xlink:href="iinn-20251231.xsd#iinn_MaterialsAndSubcontractorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="MaterialsAndSubcontractorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PayrollAndRelatedMember" xlink:href="iinn-20251231.xsd#iinn_PayrollAndRelatedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="PayrollAndRelatedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantyMember" xlink:href="iinn-20251231.xsd#iinn_WarrantyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="WarrantyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesToIIAMember" xlink:href="iinn-20251231.xsd#iinn_RoyaltiesToIIAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="RoyaltiesToIIAMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COSTOFREVENUESScheduleofCostofRevenuesDetailsTable" xlink:to="COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems" xlink:to="us-gaap_CostOfRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationNonproduction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_DepreciationNonproduction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Subcontractors" xlink:href="iinn-20251231.xsd#iinn_Subcontractors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="Subcontractors" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IIAParticipation" xlink:href="iinn-20251231.xsd#iinn_IIAParticipation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="IIAParticipation" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:href="iinn-20251231.xsd#iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralInsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_LegalFees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostMaintenance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_CostMaintenance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_Depreciation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FundraisingExpenses" xlink:href="iinn-20251231.xsd#iinn_FundraisingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="FundraisingExpenses" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_OfficersCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_ProfessionalFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAccruedExpenses" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxAssetsAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAccruedExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsFundRaisingCost2023" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:href="iinn-20251231.xsd#iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20251231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20251231.xsd#iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" xlink:to="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:to="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ServicesProvidersAndAdvisersMember" xlink:href="iinn-20251231.xsd#iinn_ServicesProvidersAndAdvisersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="ServicesProvidersAndAdvisersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="EmployeesAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeesAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:href="iinn-20251231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:href="iinn-20251231.xsd#iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OfficersAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_OfficersAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="OfficersAndDirectorsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_OfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OfficersCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="GENERALDetailsTable" xlink:href="iinn-20251231.xsd#iinn_GENERALDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GENERALDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_GENERALDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="GENERALDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DecemberPrivatePlacementMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="DecemberPrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALDetailsTable" xlink:to="GENERALDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateOfferingPrice" xlink:href="iinn-20251231.xsd#iinn_AggregateOfferingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALDetailsLineItems" xlink:to="AggregateOfferingPrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateGrossProceeds" xlink:href="iinn-20251231.xsd#iinn_AggregateGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALDetailsLineItems" xlink:to="AggregateGrossProceeds" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeductingOfferingCosts" xlink:href="iinn-20251231.xsd#iinn_DeductingOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALDetailsLineItems" xlink:to="DeductingOfferingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GENERALDetailsLineItems" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="IncrementalBorrowingRate" xlink:href="iinn-20251231.xsd#iinn_IncrementalBorrowingRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="IncrementalBorrowingRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesAmount" xlink:href="iinn-20251231.xsd#iinn_SalesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SalesAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaidRoyalties" xlink:href="iinn-20251231.xsd#iinn_PaidRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PaidRoyalties" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesSEPAAmount" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesSEPAAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrdinarySharesSEPAAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShortTermInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="DEPOSITSDetailsTable" xlink:href="iinn-20251231.xsd#iinn_DEPOSITSDetailsTable"/>
    <loc xlink:type="locator" xlink:label="DEPOSITSDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_DEPOSITSDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="DEPOSITSDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEPOSITSDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEPOSITSDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BankLeumiMember" xlink:href="iinn-20251231.xsd#iinn_BankLeumiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="BankLeumiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEPOSITSDetailsTable" xlink:to="DEPOSITSDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEPOSITSDetailsLineItems" xlink:to="us-gaap_Deposits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DEPOSITSDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="AggregateBudget" xlink:href="iinn-20251231.xsd#iinn_AggregateBudget"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="AggregateBudget" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfApprovedBudget" xlink:href="iinn-20251231.xsd#iinn_PercentageOfApprovedBudget"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="PercentageOfApprovedBudget" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectBudgetAggregateAmount" xlink:href="iinn-20251231.xsd#iinn_ProjectBudgetAggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ProjectBudgetAggregateAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesPercentage" xlink:href="iinn-20251231.xsd#iinn_RoyaltiesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="RoyaltiesPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_Revenues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentUponFutureSales" xlink:href="iinn-20251231.xsd#iinn_ContingentUponFutureSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ContingentUponFutureSales" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="LEASELIABILITIESDetailsTable" xlink:href="iinn-20251231.xsd#iinn_LEASELIABILITIESDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LEASELIABILITIESDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_LEASELIABILITIESDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="LEASELIABILITIESDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASELIABILITIESDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASELIABILITIESDetailsTable" xlink:to="LEASELIABILITIESDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASELIABILITIESDetailsLineItems" xlink:to="us-gaap_PaymentsForRent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MonthlyDeductionFromTerminationFee" xlink:href="iinn-20251231.xsd#iinn_MonthlyDeductionFromTerminationFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASELIABILITIESDetailsLineItems" xlink:to="MonthlyDeductionFromTerminationFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseMonthlyPayment" xlink:href="iinn-20251231.xsd#iinn_LeaseMonthlyPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASELIABILITIESDetailsLineItems" xlink:to="LeaseMonthlyPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageForCarsLeaseAgreementCancellationPenalty" xlink:href="iinn-20251231.xsd#iinn_PercentageForCarsLeaseAgreementCancellationPenalty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASELIABILITIESDetailsLineItems" xlink:to="PercentageForCarsLeaseAgreementCancellationPenalty" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASELIABILITIESDetailsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfFutureLeasePaymentsDiscounted" xlink:href="iinn-20251231.xsd#iinn_PercentageOfFutureLeasePaymentsDiscounted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LEASELIABILITIESDetailsLineItems" xlink:to="PercentageOfFutureLeasePaymentsDiscounted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="FINACIALLIABILITIESATFAIRVALUEDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DecemberStandbyEquityPurchaseAgreementMember" xlink:href="iinn-20251231.xsd#iinn_DecemberStandbyEquityPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="DecemberStandbyEquityPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="iinn-20251231.xsd#iinn_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="AgreementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomainDomain" xlink:href="iinn-20251231.xsd#iinn_AgreementDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StandbyEquityPurchaseAgreementSEPAMember" xlink:href="iinn-20251231.xsd#iinn_StandbyEquityPurchaseAgreementSEPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="StandbyEquityPurchaseAgreementSEPAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="YorkvilleMember" xlink:href="iinn-20251231.xsd#iinn_YorkvilleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="YorkvilleMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="December2024PrivatePlacementMember" xlink:href="iinn-20251231.xsd#iinn_December2024PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="December2024PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecondTrancheMember" xlink:href="iinn-20251231.xsd#iinn_SecondTrancheMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SecondTrancheMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrivateWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsTable" xlink:to="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPayFees" xlink:href="iinn-20251231.xsd#iinn_PercentageOfPayFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="PercentageOfPayFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_PaymentsForFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_OtherCommitment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfRightsValue" xlink:href="iinn-20251231.xsd#iinn_SaleOfRightsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="SaleOfRightsValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesPurchasePricePercentage" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesPurchasePricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="OrdinarySharesPurchasePricePercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfFeePayments" xlink:href="iinn-20251231.xsd#iinn_DescriptionOfFeePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="DescriptionOfFeePayments" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FINACIALLIABILITIESATFAIRVALUEDetailsLineItems" xlink:to="us-gaap_LegalFees" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SHAREHOLDERSEQUITYDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREHOLDERSEQUITYDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="SHAREHOLDERSEQUITYDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourAprilOfferingMember" xlink:href="iinn-20251231.xsd#iinn_TwoThousandTwentyFourAprilOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="TwoThousandTwentyFourAprilOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourJuneOfferingMember" xlink:href="iinn-20251231.xsd#iinn_TwoThousandTwentyFourJuneOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="TwoThousandTwentyFourJuneOfferingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecemberPrivateOfferingMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPrivateOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="DecemberPrivateOfferingMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="December2024PrivatePlacementMember" xlink:href="iinn-20251231.xsd#iinn_December2024PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="December2024PrivatePlacementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="December2025OfferingMember" xlink:href="iinn-20251231.xsd#iinn_December2025OfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="December2025OfferingMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="iinn-20251231.xsd#iinn_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="AgreementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomainDomain" xlink:href="iinn-20251231.xsd#iinn_AgreementDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StandbyEquityPurchaseAgreementSEPAMember" xlink:href="iinn-20251231.xsd#iinn_StandbyEquityPurchaseAgreementSEPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="StandbyEquityPurchaseAgreementSEPAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RothCapitalPartnersLLCMember" xlink:href="iinn-20251231.xsd#iinn_RothCapitalPartnersLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RothCapitalPartnersLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvisorMember" xlink:href="iinn-20251231.xsd#iinn_AdvisorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AdvisorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="PrivateWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RegisteredDirectOfferingMember" xlink:href="iinn-20251231.xsd#iinn_RegisteredDirectOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="RegisteredDirectOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember_0" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrivateWarrantsMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PlacementAgentWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JunePlacementAgentWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_JunePlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="JunePlacementAgentWarrantsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JunePreFundedWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_JunePreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="JunePreFundedWarrantsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourJuneOfferingMember_0" xlink:href="iinn-20251231.xsd#iinn_TwoThousandTwentyFourJuneOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="TwoThousandTwentyFourJuneOfferingMember_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecemberPrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="DecemberPrivateWarrantsMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecemberPreFundedWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_DecemberPreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="DecemberPreFundedWarrantsMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsTable" xlink:to="SHAREHOLDERSEQUITYDetailsLineItems" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="iinn-20251231.xsd#iinn_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="PurchasePricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfPrivateWarrantOrRightOutstanding" xlink:href="iinn-20251231.xsd#iinn_ClassOfPrivateWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="ClassOfPrivateWarrantOrRightOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberofAdditionalOrdinaryShares" xlink:href="iinn-20251231.xsd#iinn_NumberofAdditionalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="NumberofAdditionalOrdinaryShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyLiquidationProceedsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsPerShare" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrantsPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="PreFundedWarrantsPerShare" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesPerUnits" xlink:href="iinn-20251231.xsd#iinn_NumberOfSharesPerUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="NumberOfSharesPerUnits" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrants" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="PrivateWarrants" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerUnit" xlink:href="iinn-20251231.xsd#iinn_PurchasePricePerUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="PurchasePricePerUnit" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrants" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="PreFundedWarrants" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfPrivateWarrantsShares" xlink:href="iinn-20251231.xsd#iinn_IssueOfPrivateWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="IssueOfPrivateWarrantsShares" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPayFees" xlink:href="iinn-20251231.xsd#iinn_PercentageOfPayFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="PercentageOfPayFees" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsExerciseShares" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsExerciseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="PrivateWarrantsExerciseShares" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREHOLDERSEQUITYDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="TAXESONINCOMEDetailsTable" xlink:href="iinn-20251231.xsd#iinn_TAXESONINCOMEDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TAXESONINCOMEDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_TAXESONINCOMEDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="TAXESONINCOMEDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TAXESONINCOMEDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TAXESONINCOMEDetailsTable" xlink:to="TAXESONINCOMEDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TAXESONINCOMEDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TAXESONINCOMEDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TAXESONINCOMEDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="SHAREBASEDPAYMENTDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SHAREBASEDPAYMENTDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SHAREBASEDPAYMENTDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="SHAREBASEDPAYMENTDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_EmployeeStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_OfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExecutivesAndDirectorsMember" xlink:href="iinn-20251231.xsd#iinn_ExecutivesAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ExecutivesAndDirectorsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServiceProvidersMember" xlink:href="iinn-20251231.xsd#iinn_ServiceProvidersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ServiceProvidersMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesDirectorsAndSubcontractorsMember" xlink:href="iinn-20251231.xsd#iinn_EmployeesDirectorsAndSubcontractorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesDirectorsAndSubcontractorsMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenueAchievementMember" xlink:href="iinn-20251231.xsd#iinn_RevenueAchievementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="RevenueAchievementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsTable" xlink:to="SHAREBASEDPAYMENTDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalGainTaxRate" xlink:href="iinn-20251231.xsd#iinn_CapitalGainTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="CapitalGainTaxRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCapitalGainTax" xlink:href="iinn-20251231.xsd#iinn_PercentageOfCapitalGainTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="PercentageOfCapitalGainTax" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SHAREBASEDPAYMENTDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsTable" xlink:href="iinn-20251231.xsd#iinn_SUBSEQUENTEVENTSDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SUBSEQUENTEVENTSDetailsLineItems" xlink:href="iinn-20251231.xsd#iinn_SUBSEQUENTEVENTSDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SUBSEQUENTEVENTSDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember" xlink:href="iinn-20251231.xsd#iinn_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PrivateWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PurchaserMember" xlink:href="iinn-20251231.xsd#iinn_PurchaserMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="PurchaserMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsTable" xlink:to="SUBSEQUENTEVENTSDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrants" xlink:href="iinn-20251231.xsd#iinn_PreFundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="PreFundedWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseOrdinaryShares" xlink:href="iinn-20251231.xsd#iinn_WarrantsToPurchaseOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="WarrantsToPurchaseOrdinaryShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StandbyEquityPurchaseAgreementPercentage" xlink:href="iinn-20251231.xsd#iinn_StandbyEquityPurchaseAgreementPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="StandbyEquityPurchaseAgreementPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialExpensesDueToCommitmentFee" xlink:href="iinn-20251231.xsd#iinn_FinancialExpensesDueToCommitmentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="FinancialExpensesDueToCommitmentFee" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SUBSEQUENTEVENTSDetailsLineItems" xlink:to="us-gaap_OtherCommitment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityListingsTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="13.0"/>
    <loc xlink:type="locator" xlink:label="dei_NameChangeEventTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NameChangeEventTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="14.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesNoParValueMember" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="OrdinarySharesNoParValueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20251231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="WarrantsToPurchaseOrdinarySharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable_0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable_0" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesNoParValueMember" xlink:href="iinn-20251231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="OrdinarySharesNoParValueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20251231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
<!-- [WMV6][tQ2SY6h3zXNvmVLgOg0ajVa0e1jWyumjmYYhhtgXVJl26P/An3s4cn9uueP/13e7UC3M5+K+VlnhrJTKt1obrUZw5OMntIEPcaFD4f/Q4jxjolS/qbONtVDD7Ac0yhb62bxdW1oYXXacJzl6mk8Nc6i4aPtRuqNZlBIF2qCqnMXSvxPkGGNoK2HDTC+WYCYRilCz9qocGw3N/xNndqCSH7pj9TC6winczWEyCbkbqqmwXJWq7Xi7TWkOlaYoQC96qeYDalazd0av6gEFbQCvEKrPGsz1RmsB30ey2sJjlUBmiupCSnjJD58CsreucDUJM7OP1Wie26EV0FcTPrFdPluiqJvSWk5CJazvnKD95WyzrIabrwU=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="WarrantsToPurchaseOrdinarySharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001837493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Ha-Tidhar St<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ra&#8217;anana<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4366504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">35,949,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iinn_OrdinarySharesNoParValueMember', window );">Ordinary Shares, no par value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IINN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iinn_WarrantsToPurchaseOrdinarySharesMember', window );">Warrants to purchase Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase Ordinary Shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IINNW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Dagi Ben-Noon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Ha-Tidhar St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ra&#8217;anana<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4366504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">4.6230333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iinn_OrdinarySharesNoParValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iinn_OrdinarySharesNoParValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iinn_WarrantsToPurchaseOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iinn_WarrantsToPurchaseOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ziv Haft<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,159<span></span>
</td>
<td class="nump">$ 5,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,411<span></span>
</td>
<td class="nump">6,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">930<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">5,341<span></span>
</td>
<td class="nump">8,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payables</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payables</a></td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">1,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Financial liabilities at fair value</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">3,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non- current liabilities</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, no par value: Authorized 100,000,000 ordinary shares as of December 31, 2025 and December 31, 2024; Issued and outstanding 35,949,247 ordinary shares as of December 31, 2025 and 24,252,096 shares as of December 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Share capital and additional paid in capital</a></td>
<td class="nump">82,117<span></span>
</td>
<td class="nump">70,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated losses</a></td>
<td class="num">(79,794)<span></span>
</td>
<td class="num">(66,574)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="nump">2,323<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and Shareholders&#8217; Equity</a></td>
<td class="nump">$ 5,341<span></span>
</td>
<td class="nump">$ 8,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, Authorized (in Shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, Issued (in Shares)</a></td>
<td class="nump">35,949,247<span></span>
</td>
<td class="nump">24,252,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, Outstanding (in Shares)</a></td>
<td class="nump">35,949,247<span></span>
</td>
<td class="nump">24,252,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">7,496<span></span>
</td>
<td class="nump">6,323<span></span>
</td>
<td class="nump">7,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">5,532<span></span>
</td>
<td class="nump">4,185<span></span>
</td>
<td class="nump">4,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">754<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expenses</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">13,623<span></span>
</td>
<td class="nump">11,267<span></span>
</td>
<td class="nump">12,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest income from deposits</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Finance expenses (income), net</a></td>
<td class="num">(339)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(529)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before tax</a></td>
<td class="nump">13,220<span></span>
</td>
<td class="nump">11,053<span></span>
</td>
<td class="nump">11,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total comprehensive and net loss</a></td>
<td class="nump">$ 13,220<span></span>
</td>
<td class="nump">$ 11,053<span></span>
</td>
<td class="nump">$ 11,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share, basic (in Dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share, diluted (in Dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares outstanding basic (in Shares)</a></td>
<td class="nump">29,623,194<span></span>
</td>
<td class="nump">18,515,545<span></span>
</td>
<td class="nump">12,095,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares outstanding diluted (in Shares)</a></td>
<td class="nump">29,623,194<span></span>
</td>
<td class="nump">18,515,545<span></span>
</td>
<td class="nump">12,095,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary Share</div></th>
<th class="th"><div>Share capital and Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance as of (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">11,338,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,866<span></span>
</td>
<td class="num">$ (44,235)<span></span>
</td>
<td class="nump">$ 13,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net (in Shares)</a></td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of placement agent warrants (Note 11.3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of ordinary shares (pursuant to an at-the-market facility)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of ordinary shares (pursuant to an at-the-market facility) (in Shares)</a></td>
<td class="nump">17,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments', window );">Exercise of share-based payments (in Shares)</a></td>
<td class="nump">37,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments', window );">Exercise of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;) vesting (in Shares)</a></td>
<td class="nump">1,226,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;) vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Comprehensive and net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,286)<span></span>
</td>
<td class="num">(11,286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance as of (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">15,652,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,259<span></span>
</td>
<td class="num">(55,521)<span></span>
</td>
<td class="nump">5,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net (in Shares)</a></td>
<td class="nump">6,231,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="nump">19,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares', window );">Exercise of June 2024 pre-funded warrants into ordinary shares (in Shares)</a></td>
<td class="nump">1,709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares', window );">Exercise of June 2024 pre-funded warrants into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;) vesting (in Shares)</a></td>
<td class="nump">594,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;) vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of ordinary shares- advisor fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of ordinary shares- advisor fees (in Shares)</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Comprehensive and net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,053)<span></span>
</td>
<td class="num">(11,053)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance as of (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">24,252,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,896<span></span>
</td>
<td class="num">(66,574)<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, net (in Shares)</a></td>
<td class="nump">1,565,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of ordinary shares (pursuant to an at-the-market facility)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of ordinary shares (pursuant to an at-the-market facility) (in Shares)</a></td>
<td class="nump">5,485,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="nump">101,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet', window );">Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares', window );">Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net (in Shares)</a></td>
<td class="nump">1,514,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;) vesting (in Shares)</a></td>
<td class="nump">2,711,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;) vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of ordinary shares- advisor fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of ordinary shares- advisor fees (in Shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees', window );">Issuance of ordinary shares- commitment fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares', window );">Issuance of ordinary shares- commitment fees (in Shares)</a></td>
<td class="nump">218,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Comprehensive and net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,220)<span></span>
</td>
<td class="num">(13,220)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance as of (in Shares) at Dec. 31, 2025</a></td>
<td class="nump">35,949,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance as of at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,117<span></span>
</td>
<td class="num">$ (79,794)<span></span>
</td>
<td class="nump">$ 2,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net (in Shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exercise of june 2024 pre-funded warrants into ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of exercise of June 2024 pre-funded warrants into ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares- commitment fees (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of ordinary shares- commitment fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares exercise of share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOW - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOW FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,220)<span></span>
</td>
<td class="num">$ (11,053)<span></span>
</td>
<td class="num">$ (11,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherLosses', window );">Capital loss</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expenses</a></td>
<td class="nump">3,575<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share based compensation &#8211; placement agent warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Evaluation of financial liability at fair value</a></td>
<td class="num">(720)<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExpirationOfFinancialLiability', window );">Expiration of financial liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Issuance cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IssuanceOfOrdinarySharesAdvisorFees', window );">Issuance of ordinary shares - advisor fees</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Prepayments of lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLeasingReceivables', window );">Decrease (increase) in right of use assets, net</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Decrease (increase) in other current assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">(Decrease) increase in trade accounts payables</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">(Decrease) increase in other accounts payable</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="num">(190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) decrease in inventory</a></td>
<td class="num">(291)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gain) loss</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialExpensesDueToCommitmentFee', window );">Financial expenses due to commitment fee &#8211; Standby Equity Purchase Agreement (SEPA)</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IssuanceOfOrdinarySharesCommitmentFee', window );">Issuance of ordinary shares - commitment fee (SEPA)</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,861)<span></span>
</td>
<td class="num">(9,374)<span></span>
</td>
<td class="num">(9,691)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOW FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Change in deposits, net</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">1,488<span></span>
</td>
<td class="nump">4,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of ordinary shares, pre-funded warrants and ordinary warrants, net</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="nump">7,898<span></span>
</td>
<td class="nump">3,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants and pre-funded warrants, net</a></td>
<td class="nump">912<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of ordinary shares (issuances pursuant to an at-the-market facility), net</a></td>
<td class="nump">4,646<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,327<span></span>
</td>
<td class="nump">7,902<span></span>
</td>
<td class="nump">3,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="num">(1,969)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(1,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">5,130<span></span>
</td>
<td class="nump">6,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">3,257<span></span>
</td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">5,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">5,111<span></span>
</td>
<td class="nump">5,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">3,257<span></span>
</td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">5,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OtherReceivableInConnectionToPrivatePlacement', window );">Other receivable in connection to December private placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccruedIssuanceExpenses', window );">Accrued issuance expenses</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(220)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialLiabilityPlacementAgentFee', window );">Financial liability- placement agent fee (Note 10-A)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital', window );">Share based compensation- placement agent warrants against additional paid in capital (Note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NonCashTransactions', window );">Total non cash transactions</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AccruedIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AccruedIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExpirationOfFinancialLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expiration of financial liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExpirationOfFinancialLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialExpensesDueToCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial expenses due to commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialExpensesDueToCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialLiabilityPlacementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financial liability placement agent fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialLiabilityPlacementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IssuanceOfOrdinarySharesAdvisorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance of ordinary shares advisor fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IssuanceOfOrdinarySharesAdvisorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IssuanceOfOrdinarySharesCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IssuanceOfOrdinarySharesCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of non cash transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OtherReceivableInConnectionToPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other receivable in connection to private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OtherReceivableInConnectionToPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share based compensation-placement agent warrants against additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLeasingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLeasingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to other loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">Inspira Technologies Oxy B.H.N. Ltd (the &#8220;Company&#8221;) was
                                            incorporated in Israel and commenced its operations on February 27, 2018. The Company operates
                                            in the medical technology industry in the field of respiratory support technology engaged
                                            in the research, development, manufacturing related activities, and go-to-market activities
                                            of proprietary products and technologies. The Company is developing the following products:</td></tr></table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The INSPIRA ART (Augmented
                                            Respiratory Technology), which is a respiratory support technology targeted toward utilizing
                                            blood monitoring and direct blood oxygenation to boost patient saturation levels within minutes
                                            while the patient is awake. The aim is to provide an alternative to invasive mechanical ventilation,
                                            associated with high risks, complications, high costs and high mortality rates.</td></tr></table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The HYLA blood sensor,
                                            which is a non-invasive optical blood sensor designed to perform real-time and continuous
                                            blood parameter measurements, potentially reducing the need for intermittent blood samples
                                            from patients.</td></tr></table>

<p style="text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.75in"></td><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The INSPIRA ART100
                                            System, an advanced form of life support system, better known by the medical industry as
                                            a cardiopulmonary bypass system, has been designed for use in procedures requiring cardiopulmonary
                                            bypass for six hours or less.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The Company&#8217;s INSPIRA ART100 system received U.S.
Food and Drug Administration (&#8220;FDA&#8221;) 510(k) regulatory clearance for cardiopulmonary bypass procedures and Israeli Medical
Equipment Division certification for extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures. The Company&#8217;s
other products, including the INSPIRA ART and HYLA&#8482; blood sensor, have not yet been tested or used in humans and have not been
approved by any regulatory entity.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">2.</td><td style="text-align: justify">On March 14, 2025, the Company entered into a sales agreement pursuant to which the Company could offer and sell, from time to time, through the sales agent, ordinary shares, no par value, of the Company (&#8220;Ordinary Shares&#8221;) pursuant to an at-the-market facility (the &#8220;March 2025 ATM&#8221;), having an aggregate offering price of up to $1,019. On April 10, 2025, the maximum aggregate offering price was increased to $1,917, On July 1, 2025, the maximum aggregate offering price was increased to $7,118. On September 16, 2025, the maximum aggregate offering price was increased to $14,687. As of December 31, 2025, the Company has sold 5,485,898 Ordinary Shares under the ATM for aggregate gross proceeds received of approximately $4,888, before deducting offering costs of approximately $272. Subsequent to December 31, 2025 and following the expiration of the Sales Agreement due to expiration of the related Registration Statement on Form F-3 (File No. 333-266748), the Company entered into a new sales agreement pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (&#8220;ATM&#8221;), having an aggregate offering price of up to $2,016 To date, no Ordinary Shares have been sold pursuant to the March 2025 ATM.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"></td><td style="text-align: justify; width: 0.25in">3.</td><td style="text-align: justify">The accompanying financial statements (the &#8220;Financial Statements&#8221;) have been prepared assuming that the Company will continue as a going concern. To date, the Company is at the deployment stage with respect to the INSPIRA ART100, and is in development stage with its other technologies. Therefore, the Company has suffered recurring losses from operations and negative cash flows from operations since inception. As of December 31, 2025, the Company had incurred accumulated losses of $80 million and expects to continue to fund its operations through fundings such as issuance of convertible securities, Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that such financing will be obtained. Considering the above, our dependence on external funding for our operations raises a substantial doubt about our ability to continue as a going concern. The Financial Statements do not include any adjustments that might result from the outcome of these uncertainties.</td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">4.</td><td style="text-align: justify">Our offices are located in Ra&#8217;anana,
                                            Israel. On October 7, 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from
                                            the Gaza Strip and conducted a series of attacks on civilian and military targets. Following
                                            the October 7, 2023 attacks by Hamas terrorists in Israel&#8217;s southern border, Israel
                                            declared war against Hamas and since then, Israel has been involved in military conflicts
                                            with Hamas, Hezbollah, a terrorist organization based in Lebanon, and Iran, both directly
                                            and through proxies like the Houthi movement in Yemen and armed groups in Iraq and other
                                            terrorist organizations. Additionally, following the fall of the Assad regime in Syria, Israel
                                            has conducted limited military operations targeting the Syrian army, Iranian military assets
                                            and infrastructure linked to Hezbollah and other Iran-supported groups.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 13, 2025, Israel launched a
strike against Iran, aimed to disrupt Iran&#8217;s capacity to coordinate or launch hostilities against Israel. Iran has retaliated in
response, firing missiles and drones at Israeli military and civilian infrastructure. More recently, in February 2026, hostilities between
Israel and Iran escalated again.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In late February 2026, Israel, together
with the United States, conducted a major joint military campaign of air and missile strikes against targets in Iran, which triggered
a broad Iranian response and contributed to significant regional instability. The situation remains highly fluid, and we are unable to
predict when, or on what terms, this escalation will be resolved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Although certain ceasefire agreements
have been reached with Hamas, and the level of hostilities has since decreased, the situation remains volatile, with the potential for
escalation into a broader regional conflict involving additional terrorist organizations and possibly other countries, including as a
result of instability arising from developments in Syria. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Other regional hostilities, since October
7, 2023, concurrently became more pronounced. This includes and has included a northern front war igniting between Israel and Hezbollah,
which as of February 24, 2025 we are under a ceasefire, hostilities between Israel and Iran, which have included Iranian strikes against
Israel in April 2024 and October 2024, and subsequent retaliation by Israel to both instances, and a continued conflict between Israel
and the Houthi Movement in Yemen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">Currently,
one of our employees is serving in military reserve duty. In addition, due to the ongoing security situation, we may experience occasional
delays in the shipment of inventory. However, as of the date of these Financial Statements, these events have no material impact on the
Company&#8217;s operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">5.</td><td>These Financial Statements were authorized by the Board of Directors
                                            on March 25, 2026</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying Financial Statements have been
prepared in conformity with the accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The
significant accounting policies followed in the preparation of the Financial Statements are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Use of estimates:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of Financial Statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting
period.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Items subject to such estimates and assumptions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">stock-based compensation expense;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">fair value financial liabilities;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">recognition, measurement, and
disclosure of contingent liabilities;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Interest rate used for lease
liability measurement.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#8217;s Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Foreign Currency</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#8220;USD&#8221;). The Company&#8217;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#8211; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#8211; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>C. Property,
Plant, and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual rates of depreciation are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">6-15</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Inventory</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost or
net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items, technological obsolescence, excess
inventories, discontinued products, and for market prices lower than cost, if any.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company periodically evaluates the quantities on hand relative
to historical and projected sales volume (which is determined based on an assumption of future demand and market conditions) and the
age of the inventory. At the point of the loss recognition, a new lower cost basis for that inventory has been established.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost is determined for all types of inventory
using the moving average cost method plus indirect costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company implemented Accounting Standards
Update (&#8220;ASU&#8221;) 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;) using the modified retrospective approach for all
lease arrangements as of such date. The Company leases office space and vehicles under operating leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Arrangements meeting the definition of a lease
are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability,
calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental
borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized
over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing rate. The Incremental Borrowing Rate
applied was 11.27%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. Revenue recognition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s revenues are measured according
to Accounting Standards Codification (&#8220;ASC&#8221;) 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).
Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange
for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from product sales is recognized when
control of the goods transferred to the customer, which is generally upon shipment, unless contractual terms indicate otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the five-step model under
ASC 606:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify the contract with
a customer;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify the performance obligations
in the contract;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">determine the transaction price;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(iv)</span></td><td style="text-align: justify"><span style="font-size: 10pt">allocate the transaction price
to the performance obligations; and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(v)</span></td><td style="text-align: justify"><span style="font-size: 10pt">recognize revenue when (or
as) performance obligations are satisfied.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Standard product warranties that provide assurance
that the product complies with agreed specifications do not represent a separate performance obligation and are accounted for under ASC
460.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Determining whether the Company acts as a principal
or as an agent in the purchase and sale of machines requires significant judgment. While none of the evaluated factors are independently
determinative, after analyzing the guidance under ASC 606 for principal versus agent considerations, the Company concluded that it is
acting as an agent in these transactions. As such, revenues are presented on a net basis. This conclusion is based on the contractual
relationships involved and the manner in which business is conducted, indicating that the Company does not control the machines before
they are transferred to the end customer. In addition, the Company does not bear significant inventory or credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the Company accounts for variable
consideration related to discounts and rights of return in accordance with ASC 606. Given the Company's role as an agent, it does not
bear the primary obligation for machine performance or the ultimate risk of product returns. Accordingly, the Company recognizes net
revenue only to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Estimates for returns
and discounts will be recognized as a reduction of the net commission at the time of sale, once the Company has established sales and
sufficient historical data to provide a basis for such estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>G. Cost of revenues</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues consists of products purchased
from sub-contractors, raw materials, shipping and handling costs to customers, salary, employee-related expenses, depreciation, royalties
to the Israeli Innovation Authority (&#8220;IIA&#8221;), provision for assurance and overhead expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues are expensed commensurate with
the recognition of the respective revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H. Research and Development Costs.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>I. Government Grants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives royalty-bearing grants from
the IIA for approved research and development projects Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grants are linked to the exchange rate of
the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) per year (SOFR is
a benchmark interest rate which replaced LIBOR).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts of grants received and recorded into
income should be disclosed for each period presented. The research and development grants are presented in the statement of operations
as an offset to related research and development expenses. Companies are required to pay royalties in connection with such grants at
specified rates, up to the total dollar-linked amount of such grants. research and development (&#8220;R&amp;D&#8221;).&#160;As of December
31, 2025, the Company generated sales in the amount of $288 and paid royalties in the amount of $9. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No liability was recorded in these Financial
Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>J. Finance Income and Expenses.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance income is composed of interest on deposits
and revaluation of financial liabilities at fair value, while finance expenses are composed of the revaluation of certain financial liabilities
at fair value, bank charges and net currency exchange rates differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>K. Current Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>L. Share-Based Compensation.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Share-based compensation
expenses related to employees, directors and subcontractors&#8217; options or restricted share units (&#8220;RSU&#8221;) which recognized
based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using
the graded vesting method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>M. Warrants and Pre-Funded Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues warrants and pre-funded warrants
as part of its financing activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder
to purchase a specified number of the Company&#8217;s Ordinary Shares at a predetermined exercise price. Warrants and pre-funded warrants
issued by the Company may have various terms, including expiration dates, exercise prices, and conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#8220;ASC&#8221;)
815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as equity if they meet the criteria for equity classification
outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>N. Severance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli labor law generally requires payment
of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#8217;s
pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation
Act, 1963 (&#8220;Section 14&#8221;), the Company&#8217;s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly
salary, made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance
payments in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance
pay.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>O. Basic and Diluted Loss Per Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares and pre-funded warrants
outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants issued during the year, if applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>P. Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;), ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC
820&#8221;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; unadjusted quoted prices are
available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Line Financing Arrangements- </b>The Company may enter into
standby equity purchase agreements or similar equity line financing arrangements with third-party investors. For example, on December
12, 2025, the Company entered into the Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) with Yorkville pursuant to which the Company
has the right to sell to Yorkville up to $25,000 of Ordinary Shares, subject to certain limitations and conditions set forth in the SEPA,
from time to time during the term of the SEPA. Under such arrangements, the Company has the right, but not the obligation, to require
the investor to purchase shares of the Company&#8217;s Ordinary Shares from time to time, subject to certain conditions and limitations,
up to a specified maximum commitment amount during the term of the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates these arrangements under
ASC 480, &#8220;Distinguishing Liabilities from Equity&#8221;, and ASC 815, &#8220;Derivatives and Hedging,&#8221; (&#8220;ASC 815&#8221;)
to determine whether any component of the arrangement should be classified as a liability or as a derivative instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that the Company maintains the
discretion to initiate drawdowns and settlement occurs through the issuance of the Company&#8217;s Ordinary Shares in exchange for cash,
the issuance of shares under the agreement is accounted for as an equity transaction. Proceeds received upon the issuance of shares are
recorded within stockholders&#8217; equity, typically as Ordinary Shares and additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares issued to the investor as commitment shares
at the inception of the agreement are generally accounted for as equity issuance costs associated with establishing the equity facility.
The fair value of the commitment shares on the grant date is recognized as a reduction to additional paid-in capital, consistent with
the accounting for costs incurred in connection with raising equity capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When shares are issued in connection with drawdowns
under the facility, the Company records the gross proceeds received as an increase to stockholders&#8217; equity. Any issuance costs
directly attributable to the specific drawdown are recorded as a reduction to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also evaluates whether any features
embedded within the arrangement meet the definition of a freestanding or embedded derivative under ASC 815. If such features do not qualify
for equity classification, they are recognized as derivative instruments and measured at fair value, with subsequent changes in fair
value recognized in the statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the December 31, 2025, the Company has
not sold any Ordinary Shares pursuant to the SEPA, and therefore all issuance expenses were recorded as financial expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Q. Concentration of Credit Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Part of the Company&#8217;s operating expenses
are denominated in New Israeli Shekel (&#8220;NIS&#8221;), and therefore, subject to foreign currency risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R. Cash and Cash Equivalent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from the date of purchase that are
not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash consists of funds that are contractually
restricted to bank guarantee due to rental agreements. The Company has presented restricted cash separately from cash and cash equivalents
in the balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank deposits with maturities of more than three
months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at cost which
approximates market value. As of December 31, 2025, the Company had no short-term deposits, and as of December 31, 2024 the Company had
short-term deposits in the amounts of $0.7 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>S. Segment Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a single operating and reportable
segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Chief Executive Officer, evaluates the performance
of its business based on financial data consistent with the presentation in the accompanying Financial Statements for the purposes of
making operating decisions, assessing financial performance, and allocating resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>T. New accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounting Standards Issued and Not Yet Adopted
in 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03, Income Statement &#8211; Reporting Comprehensive
Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;),
which requires the disaggregation of certain expense captions into specified categories in disclosures within the notes to the consolidated
financial statements to provide enhanced transparency into the expense captions presented on the face of the statement of income and
comprehensive income. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted,
and may be applied either prospectively or retrospectively to financial statements issued for reporting periods after the effective date
of ASU 2024-03 or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating
the impact that the adoption of ASU 2024-03 will have on its related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-04,
Induced Conversions of Convertible Debt Instruments (&#8220;ASU 2024-04&#8221;). This new guidance is intended to improve the relevance
and consistency in application of the induced conversion guidance in Subtopic 470-20 for (a) convertible debt instruments with cash conversion
features and (b) debt instruments that are not currently convertible. ASU 2024-04 is effective for fiscal years beginning after December
15, 2026. Early adoption is permitted. The Company does not plan to early adopt this standard. The Company is currently evaluating the
effect of adoption of this standard on its consolidated financial statements and disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2025, the FASB issued ASU 2025-10,
Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which provides comprehensive guidance
on the recognition, measurement, and presentation of government grants. The amendments are effective for annual reporting periods beginning
after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company is currently
evaluating the impact of this guidance on its accounting for government assistance arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Newly issued and recently adopted accounting pronouncements:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups (&#8220;JOBS&#8221;) Act. Under the JOBS Act, emerging growth companies can delay adopting
new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as to those standards apply to
private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards
that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging
growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories
for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective
for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">CASH AND CASH EQUIVALENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 3 - CASH AND CASH EQUIVALENT:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company's cash and
cash equivalents are primarily held in U.S. Dollars and New Israeli Shekels (NIS), in current accounts and short-term deposits with leading
banking institutions in Israel and the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company had cash
and cash equivalents in amount of $3,159.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As of December 31, 2024,
the Company had Cash and cash equivalents in amount of $5,111.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEPOSITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAbstract', window );"><strong>Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesDisclosuresTextBlock', window );">DEPOSITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 4 -
DEPOSITS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company&#8217;s
deposits consist of short-term bank deposits with maturities of more than three months but less than one year. The deposits bear annual
interest. Interest earned is recorded as finance income, net in the statement of operations during the years for which the Company held
short-term deposits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company had no deposits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company had a deposit
in NIS at Bank Leumi in the amount of $668, including interest that bore a fixed annual interest of 4.108%.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478353/942-405-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph e<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 5 - OTHER CURRENT ASSETS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">216</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">240</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">517</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6 - INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Finished goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">461</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">293</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Raw materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Work in progress</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">66</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">55</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">735</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7 - PROPERTY AND EQUIPMENT, NET:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">For the year ended December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Computers</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">R&amp;D<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-weight: bold">At January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">182</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">535</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">869</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">103</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At December 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At January 1, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">32</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">107</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in"><b>At December 31, 2025</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">520</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">As of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">319</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">87</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">452</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">For the year ended December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Computers</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">R&amp;D<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">172</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">381</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">705</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">154</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">164</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">535</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">869</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">44</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">116</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">171</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">As of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">36</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">346</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">93</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 - OTHER ACCOUNTS PAYABLE:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">506</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">508</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employees&#8217; salaries and related liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">414</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">421</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,349</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,364</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A.&#160;Royalties to the IIA:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-indent: -0.7pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2019, the IIA approved a grant to
the Company for the development of intravenous blood oxygenation system for an aggregate budget of NIS&#160;4,880,603 (approximately
$1,500). The IIA committed to fund&#160;60% of the approved budget. Eventually the project budget concluded in the aggregate amount of
NIS 4,623,142 (approximately $1,333). The program is for the period beginning October 2019 through November 2020. From 2019 to 2021,
the Company received total funds in the amount of NIS 2,773,885 (approximately $809) from the IIA, which were recorded as IIA participation
and were deducted from R&amp;D expenses. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2023, the IIA approved a grant to support another development
project of the Company at an aggregate budget of NIS&#160;3,850,869 (approximately $1,062). The IIA committed to fund&#160;40% of the
approved budget. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The program is for the period beginning January
2024 through March 2025, and as of December 31, 2025, the Company received total funds in the amount of NIS 1,410,925 (approximately
$385) from the IIA, which were recorded as IIA participation and were deducted from the R&amp;D expenses. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the agreements with the IIA, the
Company will pay royalties of&#160;3% of future sales up to an amount equal to the accumulated grant received linked to the USD and bearing
interest at an annual rate of SOFR. Repayment of the grants are contingent upon the successful completion of the Company&#8217;s R&amp;D
programs and generating sales. The Company has no obligation to repay these grants if the R&amp;D programs fail, are unsuccessful or
aborted or if no sales are generated. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2025 the Company generated revenues in
the amount of approximately $289; accordingly, royalties to the IIA in the amount of $9 were incurred and recorded as cost of sales,
and were paid during the year. As of December 31, 2025, the maximum obligation with respect to the grants received from the IIA, contingent
upon entitled future sales, is $1,363 includes SOFR interest and after deduction of the royalties payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has obligations regarding know-how,
technology, or products, not to transfer the information, rights thereon and production rights which derive from the research and development
without the IIA Research Committee approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B.&#160; Legal Claims</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, various legal
claims and other contingent matters may arise. Management believes that any liability that may arise from such matters would not have
a material adverse effect on the Company&#8217;s results of operations or financial condition as of and for the years ended December
31, 2025, and 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 12, 2021, the Company terminated
its employment agreement with Dr. Udi Nussinovitch, one of its founders who served as the Company&#8217;s Chief Scientific Officer since
March 2018. On February 24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and
former officer of the Company. On November 9, 2022, Mr. Nussinovitch filed a Statement of Claim against the Company, as well as a Statement
of Claim with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch alleged certain deficiencies in the
Company&#8217;s&#160;Extraordinary General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a
minority shareholder. In addition, with respect to the labor dispute, Mr.&#160;Nussinovitch is seeking renumeration and the issuance
of Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2023, a partial hearing about the
labor dispute was held, in which the parties were required by the court to file their positions on a stay of the proceeding pending the
decision on the case initiated by Mr. Nussinovitch in the District Court. On January 21, 2024, a partial hearing about the civil case
was held. During the hearing, the court suggested the parties consider the possibility of resolving the case through an out-of-court
arrangement or mediation. The parties agreed to a mediation process which did not succeed.&#160;&#160;On January 7, 2025,&#160;Mr. Nussinovitch&#160;filed
a motion to amend his Statement of Claim, requesting to modify the requested relief. Instead of the original remedies sought,&#160;Mr.
Nussinovitch&#160;now requests that the Company or Mr. Ben Noon and Mr. Hayon purchase all of his rights and shares in the Company at
their average value from the date of the Company&#8217;s initial public offering until the date of the general meeting held on December
17, 2021. On January 13, 2025, a pretrial hearing was held. The court denied Mr. Nussinovitch&#8217;s motion to amend and instructed
him to notify whether he wishes to withdraw his original claim or maintain it.,</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 14, 2025, Mr. Nussinovitch informed
the court that he would proceed with the original claim, despite the court&#8217;s instruction to address the Company&#8217;s motion
to dismiss and explain how the case could continue after he had stated it was moot. On May 7, 2025, the court partially granted the motion
to dismiss, ruling that continuation of the case is subject to payment of court fees. Claims deemed no longer relevant by Mr. Nussinovitch
were dismissed, including requests to nullify past resolutions, reverse his removal from the board, challenge director independence,
invalidate certain decisions, and appoint an auditor. The court allowed certain declaratory claims to proceed, including allegations
of breach of duties, minority oppression, and wrongful removal from the board. The remaining operative claim&#8212;entitlement to benefits
granted to controlling shareholders&#8212;also requires payment of court fees. A preliminary hearing was held on September 8, 2025, setting
deadlines for witness statements. On September 18, 2025, Mr. Nussinovitch agreed to dismiss claims against the directors of the Company.
On December 8, 2025, he submitted his witness statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that it is&#160;not probable&#160;that
a payment will be required to settle this matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, in accordance with ASC 450,&#160;no
provision has been recorded&#160;in the financial statements</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASE LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 - LEASE LIABILITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Lease Commitments &#8211; Operating Leases:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, the Company entered into a
lease agreement for its facilities in Ra&#8217;anana, Israel. The lease agreement is for a period of 69 months commencing September 1,
2021, and the Company began to pay lease and related expenses after completing 3 months of lease. The Company has the option to shorten
the period and terminates the lease agreement after completing 45 months of rent by paying an amount of NIS 500,000, (approximately $157).
This amount of reimbursement will be deducted monthly in NIS 30,000, (approximately $9) if the Company terminates the agreement after
45 months of rent. The Company is reasonably certain that it will not exercise the termination option. During 2025, the monthly lease
payment, including management fees, was approximately NIS 69,000 ($20). As security for the obligations under this lease agreement, the
Company provided a bank guarantee in an amount equal to three monthly lease payments plus the Israeli value added tax and an unlimited
guarantee according to the terms specified in the contract.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 27, 2025, the Company signed a new lease
agreement replacing the prior lease agreement for a new period of 60 months starting at the date of the facility acceptance by the Company.
According to the new lease agreement, the Company has the option to shorten the period and terminate the lease agreement after completing
48 months of rent by paying an amount of NIS 650,000 (approximately $204). This amount of reimbursement will be deducted monthly in NIS
50,000, (approximately $16) if the Company terminates the agreement after the 48 months of rent. The new rent agreement started on January
2026, therefore, as of December 31, 2025, the Company did not incur any operating liability or lease assets regarding the new lease agreement.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has various operating leases for
vehicles that expire through 2028. The Company leases vehicles for approximately three-year periods from multiple different leasing companies
and from time to time increases or decreases the number of leased vehicles according to its current needs. The leased vehicles are used
by the Company&#8217;s headquarters staff and other employees whose employment agreements include an obligation to the Company to provide
a vehicle. The agreements with the leasing companies include termination options, allowing for early cancellation by paying a penalty
of up to 400% of the monthly costs. The Company is reasonably certain that it will not exercise this option or that the employee will
bear the cost for early termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total expenses related to the leases were
$469&#160;for the year ended December 31, 2025, and $390&#160;for the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use asset and lease liability are
initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate
cannot be readily determined, the Company&#8217;s incremental borrowing rate based on the information available at the date of determining
the present value of the lease payments. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s incremental borrowing rate
is estimated to approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has various operating leases for
vehicles that expire through 2028. Below is a summary of the Company&#8217;s operating right-of-use assets and operating lease liabilities
as of December 31, 2025, and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Operating lease liabilities, current</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">277</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1pt">Operating lease liabilities long-term</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">194</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">378</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">655</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Weighted average of remaining lease term</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.74</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2.52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average discount rate - operating leases</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11.27</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">9.92</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lease payments for the Company&#8217;s right-of-use
assets over the remaining lease periods as of December 31, 2025, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Year ended December&#160;31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">U.S.&#160;dollars<br/> in&#160;thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">324</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">201</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">Total undiscounted lease payment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">525</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Interest (*)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(45</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Future lease payments were discounted by&#160;7.98%-25.59% interest
rate.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINACIAL LIABILITIES AT FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FINACIAL LIABILITIES AT FAIR VALUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 - FINACIAL LIABILITIES AT FAIR
VALUE:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Financial liability (A)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">Private warrants (B)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">786</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,506</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><b>Total</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,575</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A Financial Liability</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The Company agreed to pay fees of 4% from the funds that will be received in an event of exercise of part of the Company&#8217;s ordinary warrants that were issued in a certain December 2024 private placement which created a financial liability presented on the total potential amount which was $46 as of December 31, 2025 &#160;and $69 as of December 31, 2024 (Note 11).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The Company agreed to pay a commitment fee in the amount of <b>$</b>500, representing 2% of the $25 million SEPA. As of December 31,2025, the first half of the commitment fees was settled while the second tranche of the commitment fee amount, which represents 1% of the SEPA, settled on the 30-day anniversary of the SEPA through the issuance of a variable number of ordinary shares determined based on the VWAP formula defined therein, created a financial liability in amount of $250, measured at fair value through profit or loss until settlement. As of the date of these Financial Statements, the settlement amount of the committee fee shares were issued and transfer to the investor (see note 12(13)).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The financial liability as of December
31, 2025, and 2024 is $296 and $69 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B Private warrants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 26, 2023, the Company entered into
a certain securities purchase agreement (Note 11.3), pursuant to which it issued unregistered warrants, to purchase up to an aggregate
of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (the &#8220;Private Warrants&#8221;). The Private Warrants were exercisable
immediately upon issuance and will expire three and a half years following their issuance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Private Warrants include cashless exercise
mechanism, according to the terms specified in the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Private Warrants may create obligation to
transfer cash to the investors at fundamental transactions within the Black Scholes option pricing framework.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therefore, the Company accounts for the Private
Warrants as financial liability instruments that are measured at fair value and recognized financial expenses or income through profit
and loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company measured fair value by using Black-Scholes
option pricing model;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the Private
Warrants fair value as of December 31, 2024, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">risk-free interest rate 4.26%</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected volatility 88.61%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected dividend yield of
0%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">expected term of warrants &#8211; 2.5 years.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The key inputs that were used in the Private
Warrants fair value as of December 31, 2025, were:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">risk-free interest rate 3.48%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected volatility 80.59%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected dividend yield of
0%</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">expected term of warrants &#8211;
1.5 years.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Private Warrants as of
December 31, 2025 and 2024 was $786 and $1,506 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">C<b>. Standby Equity Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 12, 2025, the Company entered into
the SEPA with Yorkville pursuant to which the Company has the right to sell to Yorkville up to <span style="-sec-ix-hidden: hidden-fact-0">$25,000</span> of Ordinary Shares, subject to
certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA. The Company also entered into
a Registration Rights Agreement with Yorkville pursuant to which it will register the resale of Ordinary Shares issued to Yorkville pursuant
to the SEPA. Sales of Ordinary Shares to Yorkville under the SEPA, and the timing of any such sales, are at the Company&#8217;s option,
and the Company is under no obligation to sell Ordinary Shares to Yorkville under the SEPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each advance (each, an &#8220;Advance&#8221;)
the Company requests in writing to Yorkville under the SEPA (notice of such request, an &#8220;Advance Notice&#8221;) may be for a number
of Ordinary Shares. The Ordinary Shares purchased pursuant to an Advance delivered by the Company will be purchased at a price equal
to 97% of the lowest daily VWAP of the Ordinary Shares during the three consecutive trading days commencing on the date of the delivery
of the Advance Notice, other than the daily VWAP on a day in which the daily VWAP is less than a minimum acceptable price as stated by
the Company in the Advance Notice or there is no VWAP on the subject trading day. The Company may establish a minimum acceptable price
in each Advance Notice below which the Company will not be obligated to make any sales to Yorkville. &#8220;VWAP&#8221; is defined as
the daily volume weighted average price of the Ordinary Shares for such trading day on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;)
during regular trading hours as reported by Bloomberg L.P.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEPA will automatically terminate on December
12, 2028. The Company has the right to terminate the SEPA at no cost or penalty upon five trading days&#8217; prior written notice to
Yorkville, provided that there are no outstanding Advance Notices for which Ordinary Shares need to be issued and the Company has paid
all amounts owed to Yorkville. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any purchase under an Advance would be subject
to certain limitations, including that Yorkville shall not purchase or acquire any shares that would result in it and its affiliates
beneficially owning more than 4.99% of the then outstanding voting power or number of Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">In connection with
the execution of the SEPA, the Company agreed to pay a legal and structuring fee in the amount of $25, of which (a) $15 has been paid
prior to the execution date, and (b) $10 has been paid within 3 days of the execution of the agreement. The company also agreed to pay
a commitment fee of $500 in ordinary shares to Yorkville, payable as follows: (i) $250 has been paid three days following the date the
SEPA was entered into, in the form of the issuance of 218,627 Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date, and (ii) $250 has been paid on the 30-day
anniversary of the date of the SEPA in the form of the issuance of Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date. The Commitment Shares issuable hereunder were
included in the initial Registration Statement. Throughout the month ended December 31, 2025, the Company did not issue any</span>&#160;<span style="font-size: 10pt">Ordinary
Shares pursuant to the SEPA.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Share capital:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares as of<br/> December 31,&#160;2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares as of<br/> December 31,&#160;2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Authorized</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issued and outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Authorized</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issued and outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 2.5pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right">35,949,247</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right">24,252,096</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On April 4, 2023, the Company entered into a sales agreement (the &#8220;Roth Sales Agreement&#8221;) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (&#8220;Roth ATM&#8221;). In 2023, the Company sold 17,566 Ordinary Shares under the Roth ATM. On October 23, 2023, the Company terminated the Roth Sales Agreement and the associated Roth ATM, effective immediately.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On December 26, 2023, the Company entered into a securities purchase agreement with an institutional investor in a registered direct offering , pursuant to which the Company issued (i) 1,375,000 Ordinary Shares at a purchase price of $1.28 per share, (ii) pre-funded warrants, to purchase up to 1,656,250 Ordinary Shares, at a purchase price of $1.28, less $0.001 per pre-funded warrant and (iii) Private Warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (Note 10-B).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company concluded that the pre-funded
warrants are not within the scope of ASC480. Further, applying ASC 815-40, the Company concluded that the pre-funded warrants are indexed
to the Company&#8217;s own stock and meet the conditions for equity classification, and thus should be presented within equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As for the Private Warrants, the Company
concluded that they should be classified as a liability under ASC 815-40, as they are not indexed to the Company&#8217;s own stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The pre-funded warrants were exercised
on the same day and the day after the transaction in full in an exercise price of $0.001 per share and the Company issued 1,656,250 additional
Ordinary Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The aggregate proceeds received by
the Company from the December 2023 offering were approximately $3,424, after deducting underwriting discounts and commissions and additional
cash offering costs totaled in approximately $454.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company issued the placement agent
in the December 2023 offering a number of warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction,
total to 212,188 warrants to purchase up to 212,188 Ordinary Shares, were issued (the &#8220;Placement Agent Warrants&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Placement Agent Warrants were substantially
on the same terms as the Private Warrants issued to the investor in the offering, except an exercise price of $1.60 per share. The Placement
Agent Warrants were exercisable immediately upon issuance and will expire five years following their issuance. The Company accounts for
the Placement Agent Warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC
718. The fair value of the Placement Agent Warrants at the issuance date was $131.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Those cash and non-cash issuance costs
were accounted proportionally to issuance expenses and decrease of additional paid in capital, according to the ratio of the liability
versus equity in the December 2023 offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">During the year ended December 31, 2023, the Company issued an aggregate amount of 1,226,448 Ordinary Shares in connection with vested RSUs and an additional 37,972 Ordinary Shares in connection with option exercises.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On April 1, 2024, the Company completed offering, whereby the Company sold 1,339,285 Ordinary Shares at a purchase price of $1.232 per share. The gross proceeds received by the Company from this offering were approximately $1,651.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On May 20, 2024, the Company issued warrant to purchase 220,000 Ordinary Shares to a service provider, at an exercise price of $2.25 per share. These warrants are immediately exercisable and are due to expire six months from the initial issuance date. The Company accounting treatment for those warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $125. The warrants were not exercised within the designated timeframe and expired on November 21, 2024.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">6.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On June 14, 2024, the Company completed an offering, whereby the Company sold: (i) 941,541 Ordinary Shares at a purchase price of $1.30 per share, and (ii) pre-funded warrants to purchase up to 1,709,760 Ordinary Shares, at a purchase price of $1.30, less $0.001 per pre-funded warrant. Each pre-funded warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. As of December 31, 2024, all of the pre-funded warrants were exercised, and the company issued 1,709,760 Ordinary Shares.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Net proceeds received by the Company
from the 2024 June Offering were approximately $3,102, after deducting cash offering costs which were approximately $343.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company also received $2 from an
exercise of the June Pre-Funded Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company concluded that the pre-funded
warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded that the June Pre-Funded Warrants are
indexed to the Company&#8217;s own stock and meet the conditions for equity classification, and thus should be presented within equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company issued the placement agent
in this offering warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction. A total of185,591
warrants to purchase up to 185,591 Ordinary Shares were issued. The placement agent warrants had an exercise price of $1.56 per share.
The placement agent warrants were exercisable immediately upon issuance and will expire four years following their issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company accounting treatment for
the placement agent warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC
718. The fair value of the placement agent warrants at the issuance date was $254.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The cash and non-cash issuance costs
were recorded against additional paid in capital, due to the classification of the Ordinary Shares and the pre-funded warrants as equity
instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">7.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On June 30, 2024, the Company issued 45,000 Ordinary Shares to an advisor in connection with a consulting service agreement.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On December 27, 2024, the Company completed private placement, whereby the Company sold (i) 3,950,343 Ordinary Shares and private warrants to purchase up to 3,950,343 Ordinary Shares at a purchase price of $0.70 per unit, and (ii) pre-funded warrants to purchase up to 658,372 Ordinary Shares and private warrants to purchase up to 658,372 Ordinary Shares, at a purchase price of $0.70, less $0.001 per unit with pre-funded warrant. Each pre-funded warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. Each private warrant is exercisable for one Ordinary Share at an exercise price of $1.10 per share. The private warrants are immediately exercisable and may be exercised at any time until the end of June 2026. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. As of December 31, 2025, all pre-funded warrants and amount of 855,714 of private warrants were exercised.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company concluded that the private
warrants and pre-funded warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded that the private
warrants and pre-funded warrants are indexed to the Company&#8217;s own stock and meet the conditions for equity classification, and
thus should be presented within equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The gross proceeds received by the
Company from the private offering were approximately $3,228, before deducting underwriting discounts and commissions and additional cash
offering costs totaled approximately $233. In addition, the Company agreed to pay fees of 4% from the funds that may be received in an
event of exercise of part of the Company&#8217;s private warrants issued in December 2024 which created a financial liability in amount
of $69 which is the total potential amount (Note 10-A) following the exercise of 855,714 of the private warrants , the financial liability
as of December 31, 2025 is $46.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The cash and non-cash issuance costs
were recorded against additional paid in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">9.</span></td><td style="text-align: justify"><span style="font-size: 10pt">During the year ended December
31, 2024, the Company issued an aggregate amount of 594,943 Ordinary Shares in connection with vested RSUs and an additional 19,048 Ordinary
Shares in connection with option exercises.</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">10.</td><td style="text-align: justify">On March 14, 2025, the Company entered into a sales agreement
with A.G.P./Alliance Global Partners, as sales agent, pursuant to which the Company could offer and sell, from time to time, through
the sales agent, Ordinary Shares pursuant to the March 2025 ATM, having an aggregate offering price of up to $1,019. On April 10, 2025,
the maximum aggregate offering price was increased to $1,917, On July 01, 2025, the maximum aggregate offering price was increased to
$7,118. On September 16, 2025, the maximum aggregate offering price was increased to total $14,687. As of December 31, 2025, the Company
sold 5,485,898 Ordinary Shares under the March 2025 ATM for aggregate gross proceeds of approximately $4,888, before deducting offering
costs of approximately $272.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">11.</td><td style="text-align: justify">On August 8, 2025, the Company issued 100,000 Ordinary Shares
to an advisor in connection with a consulting service agreement.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">12.</td><td style="text-align: justify">On December 12, 2025, the Company completed its 2025 December
Offering, whereby the Company sold 1,565,217 Ordinary Shares at a purchase price of $1.15 per ordinary share The gross proceeds received
by the Company from the offering were $1,800.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">13.</td><td style="text-align: justify">On December 17, the Company issued 218,627 Ordinary Shares,
in connection with the commitment fees issuable pursuant to the terms of the SEPA.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">14.</td><td style="text-align: justify">During the year ended December 31, 2025, the Company issued
an aggregate amount of 2,711,947 Ordinary Shares in connection with vested RSUs and an additional 101,376 Ordinary Shares in connection
with option exercises.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Warrants reserves -</b>Composition and
movements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 29px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The following table reconciles the movement in warrants outstanding at the beginning and end of the period:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.8pt; text-align: justify"><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining contractual term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in years)</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold; padding-bottom: 1pt">Balance as of December 31, 2024</td><td style="width: 1%; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,728,611</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4.14</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1.63</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt">Issued</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,514,086</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.09</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.49</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(277,835</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5.5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.54</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Balance as of December 31, 2025</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,936,690</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4.20</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.80</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 29px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">The following table summarizes information about the Company&#8217;s outstanding warrants as of December 31, 2025</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants<br/> outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, <br/>
2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 31%; text-align: center">5.5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 31%; text-align: right">1,640,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 32%; text-align: center; padding-left: 1.4pt">15/07/2026</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&#160;</td><td style="text-align: center">6.875</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">145,455</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt">15/01/2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: center">1.6</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">212,188</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt">28/06/2027</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&#160;</td><td style="text-align: center">1.56</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">185,591</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt">14/06/2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">1.1</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,753,001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 1.4pt">30/06/2026</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Balance as of December 31, 2025</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,936,690</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Loss per share:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share has been calculated using the
weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant financial periods, the weighted average
number of equity shares in issue and profit for the period as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,220</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,286</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 9pt">Total number of Ordinary Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">35,949,247</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,252,096</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,652,176</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average number of Ordinary Shares and pre-funded warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">29,623,194</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,515,545</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,095,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Basic and diluted loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.45</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.60</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.93</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 - REVENUES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2025, the Company has only
one stream of revenue from sales of the INSPIRA ART100 systems and carts to a distributor in the U.S, therefore the company has one segment
at this stage.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COST OF REVENUES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CostOfRevenuesAbstract', window );"><strong>Cost Of Revenues Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CostOfRevenuesTextBlock', window );">COST OF REVENUES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 - COST OF REVENUES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Materials and subcontractors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">235</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Payroll and related</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Warranty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1pt">Royalties to IIA</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">287</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CostOfRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CostOfRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CostOfRevenuesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of cost of revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CostOfRevenuesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 - RESEARCH AND DEVELOPMENT EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,461</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,429</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">663</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">812</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">291</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(286</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">280</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">206</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">268</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,496</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,320</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GeneralAndAdministrativeExpensesTextBlock', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 16 - GENERAL AND ADMINISTRATIVE EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,966</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,758</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,432</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,079</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">766</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fundraising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">68</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">45</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,185</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,063</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GeneralAndAdministrativeExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GeneralAndAdministrativeExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SALES AND MARKETING EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpenseAbstract', window );"><strong>Selling and Marketing Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalesAndMarketingExpensesTextBlock', window );">SALES AND MARKETING EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 17 - SALES AND MARKETING EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Share-based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">194</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">89</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">348</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">93</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">51</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">61</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;&#160;&#160;<b>Total</b></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">588</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">754</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">746</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalesAndMarketingExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalesAndMarketingExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL (INCOME) AND EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">FINANCIAL (INCOME) AND EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 18 - FINANCIAL (INCOME) AND EXPENSES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(247</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(306</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign currency transaction income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(77</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(233</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(339</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(42</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(529</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 19 - TAXES ON INCOME: </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Taxes on income:</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Israeli corporate
tax rate was 23% in 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Net operating losses carry forwards</b>:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Carryforward tax losses of the Company
as of December 31, 2023, amounted to approximately $24,000; however, a full valuation allowance of $7,000 was recorded against the potential
future tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Carryforward tax losses of the Company
as of December 31, 2024, amounted to approximately $29,000; however, a full valuation allowance of $8,000 was recorded against the potential
future tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Carryforward tax losses of the Company
as of December 31, 2025, amounted to approximately $41,000; however, a full valuation allowance of $11,000 was recorded against the potential
future tax benefits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The deferred tax assets and liabilities
are composed of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,404</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,739</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">R&amp;D temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,218</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Fund raising costs 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,810</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,097</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Net deferred taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b>Theoretical tax:</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss before taxation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(13,220</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,053</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,286</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Theoretical tax credit at applicable statutory rate: 23%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,041</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,542</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,596</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-allowable expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(704</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(391</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(244</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,337</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,151</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,352</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Effective tax rate reconciliation:</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Tax</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">IL statutory tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3,041</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Non-taxable or non-deductible items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.7</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(166</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.9</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20.5</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(376</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2.8</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary reconciling item between the Company&#8217;s statutory
tax rate and the effective tax rate is the recognition of a valuation allowance against of deferred tax assets related to accumulated
net operating losses carried forward, due to uncertainty regarding their realization.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED PAYMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-Based Payment Arrangement, Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED PAYMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 20 - SHARE-BASED PAYMENT:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">On January 22, 2024, the Company&#8217;s Board of Directors
approved a grant of 320,000 RSUs to employees and a grant of options to purchase 80,000 shares to consultants. The RSUs represents the
right to receive Ordinary Shares at a future time, 245,000 of which vest over a period of three years, with a one-year cliff period and
70,000 vesting immediately on the grant date. 10,000 of the options were vested immediately on the grant date, 25,000 option vest over
a period of three years and 45,000 option vests over a period of one year and nine months. The RSUs designated to employees were granted
under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">On February 5, 2024, the Company&#8217;s Board of Directors
approved a grant of 2,277,000 RSUs to officers, a grant of options to purchase 30,000 Ordinary Shares and 90,000 RSUs to directors. The
RSUs and options represents the right to receive Ordinary Shares at a future time and vest over a period of three years, with a one-year
cliff. The RSUs designated to employees and directors were granted under Section 102 of the Israeli Tax Ordinance, which enables the
employee to pay a 25% capital gain tax upon exercise.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">On February 20, 2025, the Company&#8217;s Board of Directors
approved a grant of 644,000 RSUs to employees, a grant of 2,360,000 RSUs to certain of its executives and directors and options to purchase
an aggregate of 55,000 Ordinary Shares to service providers under the 2019 Equity Incentive Plan. The RSUs and options represents the
right to receive Ordinary Shares at a future time and vest over a period of three years, with a one-year cliff. The RSUs designated to
employees and directors were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital
gain tax upon exercise.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">On August 6, 2025, the Company&#8217;s Board of Directors
approved a grant of 1,200,000 RSUs to certain of its executives. The RSUs represents the right to receive Ordinary Shares at a future
time and vest over a period of three years, 25% of the amount will vest on January 1, 2026, 25% of the amount will vest on July 1, 2026
and the rest will be vested equal quarterly amounts along two more years. The RSUs designated to employees and directors were granted
under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise. The board also
approved a grant of 300,000 RSUs to certain of its executives based on revenue milestones to be measured at the end of the fiscal year
of 2027.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">On November 18, 2025, the Company&#8217;s Board of Directors
approved a grant of 490,000 RSUs to employees, a grant of 30,000 RSUs to certain director, options to purchase an aggregate of 20,000
Ordinary Shares to employee and options to purchase an aggregate of 20,000 Ordinary Shares to service providers under the 2019 Equity
Incentive Plan. The RSUs and options represents the right to receive Ordinary Shares at a future time and vest over a period of three
years, with a one-year cliff. The RSUs designated to employees and directors were granted under Section 102 of the Israeli Tax Ordinance,
which enables the employee to pay a 25% capital gain tax upon exercise.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all granted options was estimated
by using the Black Scholes option pricing model, which was aimed to model the value of the Company&#8217;s assets over time. The simulation
approach was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company
and the volatility of its assets, on the date of grant based on certain assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following inputs were used to measure the
fair value of the option at grant date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">November 18,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">February 22,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%">(i)</td><td style="width: 1%">&#160;</td> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center">123.41%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center">128.78%</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>(ii)</td><td>&#160;</td> <td style="text-align: justify">Dividend rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">0%</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">0%</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">(iii)</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Expected term (vesting period)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Three years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">One year - Three years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: top">(iv)</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Contractual life</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>(v)</td><td>&#160;</td> <td style="text-align: justify">Free risk rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">4.12%</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">4.5%</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">January 22,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">February 5,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%">(i)</td><td style="width: 1%">&#160;</td> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center">144.83%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center">143.98%</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>(ii)</td><td>&#160;</td> <td style="text-align: justify">Dividend rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">0%</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">0%</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>(iii)</td><td>&#160;</td> <td style="text-align: justify">Expected term (vesting period)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Three years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Three years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>(iv)</td><td>&#160;</td> <td style="text-align: justify">Contractual life</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>(v)</td><td>&#160;</td> <td style="text-align: justify">Free risk rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">4.03%-4.07%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">4.16%</td><td style="text-align: left">&#160;</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of all granted RSUs was the Company&#8217;s
quote price at the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2025, the Company recorded
share-based payment expenses to employees, directors and subcontractors in the amount of $3,575.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2024, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $1,767.</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2023, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $1,427.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to services providers and advisers outstanding
as December 31, 2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">185,111</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3.359</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">105,111</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">4.085</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">114,512</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3.058</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.405</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.367</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">240,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.370</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.359</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">105,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">200,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.362</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">162,154</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.251</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">94,242</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.267</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">66</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to services providers and advisers outstanding as of December
31, 2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,433</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,266</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,833</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSUs outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSU&#8217;s Vested</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,067</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to employees and directors outstanding as of December
31, 2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">368,641</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">357,689</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">386,260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3.56</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,571</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">277,265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.91</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">368,641</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">357,689</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">244,765</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">338,641</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">350,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">47</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to employees and directors outstanding as of December 31,
2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,518,796</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">445,140</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,727,842</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,024,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,687,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,087</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,711,947</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">587,508</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,215,615</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSUs outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,745,512</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,518,796</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">445,140</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSU&#8217;s Vested</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,396,644</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,684,697</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,097,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,536</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,352</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 21 - RELATED PARTIES:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The following transactions arose with related parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Transactions and balances with related parties</span><b>:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Shareholders and other related parties&#8217; benefits</span></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Salary and related expenses &#8211; officers and directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,819</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,710</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,761</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share based payment &#8211; officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,009</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">Balances with related parties</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nature of transaction</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%">Officers</td><td style="width: 1%">&#160;</td>
    <td style="width: 69%; text-align: left">Salaries and related</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(343</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(381</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Directors</td><td>&#160;</td>
    <td style="text-align: left">Compensation for directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 22 - SUBSEQUENT EVENTS:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">On February 5, 2026, the Company&#160;entered into a Securities Purchase Agreement with a single institutional investor (the &#8220;Purchaser&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering: (i) 4,000,000 Ordinary Shares, at an offering price of $0.70 per share; and (ii) pre-funded warrants to acquire up to 2,785,715 Ordinary Shares at an offering price of $0.6999 per re-funded warrant and (iii) private warrants, to purchase up to an aggregate of 6,785,715
Ordinary Shares at an exercise of $0.70 per share. The gross proceeds were approximately $4.7 million. To date, prefunded warrants to purchase 2,197,714 Ordinary Shares were exercised. The Company also amend the terms of 3,031,250 Private Warrants held by the same purchaser, which were issued in December 2023 from $1.28 per share to $0.70 per share, amended the expiration date from June 27, 2027 to February 5, 2031, and revised the fundamental transaction provision in the warrants and the cashless exercise provision with respect to computing the valuation of the Ordinary Shares. Following such amendments the Company concluded that the revised Warrants are indexed to the Company&#8217;s own stock and meet the conditions for equity classification, and thus should be reclassified within equity.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0"></td><td style="text-align: justify; width: 0.25in">2.</td><td style="text-align: justify">Subsequent to December 31, 2025 and following the expiration of the March
                                            2025 Sales Agreement due to expiration of the Company&#8217;s Registration Statement on Form
                                            F-3 (File No. 333-266748), the Company entered into a new sales agreement with A.G.P./Alliance
                                            Global Partners, as sales agent, pursuant to which the Company could offer and sell, from
                                            time to time, through the sales agent, Ordinary Shares pursuant to the ATM, having an aggregate
                                            offering price of up to $2,016.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0"></td><td style="text-align: justify; width: 0.25in">3.</td><td style="text-align: justify">Subsequent to December 31, 2025, the second half of commitment fee amount of the SEPA, which represents 1% of the SEPA, or $250, was settled as agreed on the 30-day anniversary of the SEPA through the issuance of a variable number of Ordinary Shares determined based on the VWAP formula defined therein. Following the filing of the re-sale registration statement in connection with the SEPA, the Company&#8217;s share price declined. As a result, the Company issued the registered 245,098 Ordinary Shares as commitment shares in lieu of cash, which were valued at $231 based on the VWAP calculation as of the due date. The remaining balance of $19 was agreed to be settled in cash.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (13,220)<span></span>
</td>
<td class="num">$ (11,053)<span></span>
</td>
<td class="num">$ (11,286)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">The cybersecurity process
has been integrated into the Company&#8217;s overall risk management system and process and is solely internally managed<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Management is
responsible for identifying risks that threaten achievement of the control activities stated in the management&#8217;s description of
the services organizations systems. The risk assessment occurs annually, or as business needs change, and covers identification of risks
that could act against the company&#8217;s objectives as well as specific risks related to a compromise to the security of data.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Governance</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has developed
and maintained a cybersecurity risk management strategy, consisting of cybersecurity policies, procedures, compliance and awareness programs
to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. The cybersecurity process
has been integrated into the Company&#8217;s overall risk management system and process and is solely internally managed. Management is
responsible for identifying risks that threaten achievement of the control activities stated in the management&#8217;s description of
the services organizations systems. The risk assessment occurs annually, or as business needs change, and covers identification of risks
that could act against the company&#8217;s objectives as well as specific risks related to a compromise to the security of data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The level of each identified
risk is determined by considering the impact of the risk itself and the likelihood of the risk materializing and high scoring risks are
actioned upon. Risks are analyzed to determine whether the risk meets company risk acceptance criteria to be accepted or whether a mitigation
plan will be applied. Mitigation plans include both the individual or department responsible for the plan and may include budget considerations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the critical elements
of our overall risk management approach, our cybersecurity program is focused on the following key areas:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborative Approach: The Company has implemented a comprehensive, cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technical Safeguards: The Company deploys technical safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incident Response and Recovery Planning: The Company has established and maintains comprehensive incident response and recovery plans that fully address the Company&#8217;s response to a cybersecurity incident, and such plans are tested and evaluated on a regular basis.</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>A. Use of estimates:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of Financial Statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting
period.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Items subject to such estimates and assumptions include:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">stock-based compensation expense;</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">fair value financial liabilities;</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">recognition, measurement, and
disclosure of contingent liabilities;</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Interest rate used for lease
liability measurement.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#8217;s Financial Statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B. Foreign Currency</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#8220;USD&#8221;). The Company&#8217;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#8211; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#8211; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>C. Property,
Plant, and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual rates of depreciation are as follows:</p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">6-15</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D. Inventory</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost or
net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items, technological obsolescence, excess
inventories, discontinued products, and for market prices lower than cost, if any.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company periodically evaluates the quantities on hand relative
to historical and projected sales volume (which is determined based on an assumption of future demand and market conditions) and the
age of the inventory. At the point of the loss recognition, a new lower cost basis for that inventory has been established.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost is determined for all types of inventory
using the moving average cost method plus indirect costs.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company implemented Accounting Standards
Update (&#8220;ASU&#8221;) 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;) using the modified retrospective approach for all
lease arrangements as of such date. The Company leases office space and vehicles under operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Arrangements meeting the definition of a lease
are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability,
calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#8217;s incremental
borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized
over the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing rate. The Incremental Borrowing Rate
applied was 11.27%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>F. Revenue recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s revenues are measured according
to Accounting Standards Codification (&#8220;ASC&#8221;) 606, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;ASC 606&#8221;).
Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange
for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from product sales is recognized when
control of the goods transferred to the customer, which is generally upon shipment, unless contractual terms indicate otherwise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company applies the five-step model under
ASC 606:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify the contract with
a customer;</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">identify the performance obligations
in the contract;</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">determine the transaction price;</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(iv)</span></td><td style="text-align: justify"><span style="font-size: 10pt">allocate the transaction price
to the performance obligations; and</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(v)</span></td><td style="text-align: justify"><span style="font-size: 10pt">recognize revenue when (or
as) performance obligations are satisfied.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Standard product warranties that provide assurance
that the product complies with agreed specifications do not represent a separate performance obligation and are accounted for under ASC
460.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Determining whether the Company acts as a principal
or as an agent in the purchase and sale of machines requires significant judgment. While none of the evaluated factors are independently
determinative, after analyzing the guidance under ASC 606 for principal versus agent considerations, the Company concluded that it is
acting as an agent in these transactions. As such, revenues are presented on a net basis. This conclusion is based on the contractual
relationships involved and the manner in which business is conducted, indicating that the Company does not control the machines before
they are transferred to the end customer. In addition, the Company does not bear significant inventory or credit risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the Company accounts for variable
consideration related to discounts and rights of return in accordance with ASC 606. Given the Company's role as an agent, it does not
bear the primary obligation for machine performance or the ultimate risk of product returns. Accordingly, the Company recognizes net
revenue only to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Estimates for returns
and discounts will be recognized as a reduction of the net commission at the time of sale, once the Company has established sales and
sufficient historical data to provide a basis for such estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>G. Cost of revenues</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues consists of products purchased
from sub-contractors, raw materials, shipping and handling costs to customers, salary, employee-related expenses, depreciation, royalties
to the Israeli Innovation Authority (&#8220;IIA&#8221;), provision for assurance and overhead expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues are expensed commensurate with
the recognition of the respective revenues.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>H. Research and Development Costs.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>I. Government Grants </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives royalty-bearing grants from
the IIA for approved research and development projects Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The grants are linked to the exchange rate of
the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) per year (SOFR is
a benchmark interest rate which replaced LIBOR).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amounts of grants received and recorded into
income should be disclosed for each period presented. The research and development grants are presented in the statement of operations
as an offset to related research and development expenses. Companies are required to pay royalties in connection with such grants at
specified rates, up to the total dollar-linked amount of such grants. research and development (&#8220;R&amp;D&#8221;).&#160;As of December
31, 2025, the Company generated sales in the amount of $288 and paid royalties in the amount of $9. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No liability was recorded in these Financial
Statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinanceIncomeAndExpensesPolicyTextBlock', window );">Finance Income and Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>J. Finance Income and Expenses.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance income is composed of interest on deposits
and revaluation of financial liabilities at fair value, while finance expenses are composed of the revaluation of certain financial liabilities
at fair value, bank charges and net currency exchange rates differences.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Current Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>K. Current Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>L. Share-Based Compensation.</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Share-based compensation
expenses related to employees, directors and subcontractors&#8217; options or restricted share units (&#8220;RSU&#8221;) which recognized
based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using
the graded vesting method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants and Pre-Funded Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>M. Warrants and Pre-Funded Warrants</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company issues warrants and pre-funded warrants
as part of its financing activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder
to purchase a specified number of the Company&#8217;s Ordinary Shares at a predetermined exercise price. Warrants and pre-funded warrants
issued by the Company may have various terms, including expiration dates, exercise prices, and conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#8220;ASC&#8221;)
815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as equity if they meet the criteria for equity classification
outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SeverancePolicyTextBlock', window );">Severance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>N. Severance</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Israeli labor law generally requires payment
of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#8217;s
pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation
Act, 1963 (&#8220;Section 14&#8221;), the Company&#8217;s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly
salary, made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance
payments in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance
pay.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>O. Basic and Diluted Loss Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares and pre-funded warrants
outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants issued during the year, if applicable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>P. Fair Value Measurements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;), ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC
820&#8221;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 &#8211; unadjusted quoted prices are
available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 &#8211; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 &#8211; pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Equity Line Financing Arrangements- </b>The Company may enter into
standby equity purchase agreements or similar equity line financing arrangements with third-party investors. For example, on December
12, 2025, the Company entered into the Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) with Yorkville pursuant to which the Company
has the right to sell to Yorkville up to $25,000 of Ordinary Shares, subject to certain limitations and conditions set forth in the SEPA,
from time to time during the term of the SEPA. Under such arrangements, the Company has the right, but not the obligation, to require
the investor to purchase shares of the Company&#8217;s Ordinary Shares from time to time, subject to certain conditions and limitations,
up to a specified maximum commitment amount during the term of the agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates these arrangements under
ASC 480, &#8220;Distinguishing Liabilities from Equity&#8221;, and ASC 815, &#8220;Derivatives and Hedging,&#8221; (&#8220;ASC 815&#8221;)
to determine whether any component of the arrangement should be classified as a liability or as a derivative instrument.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that the Company maintains the
discretion to initiate drawdowns and settlement occurs through the issuance of the Company&#8217;s Ordinary Shares in exchange for cash,
the issuance of shares under the agreement is accounted for as an equity transaction. Proceeds received upon the issuance of shares are
recorded within stockholders&#8217; equity, typically as Ordinary Shares and additional paid-in capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shares issued to the investor as commitment shares
at the inception of the agreement are generally accounted for as equity issuance costs associated with establishing the equity facility.
The fair value of the commitment shares on the grant date is recognized as a reduction to additional paid-in capital, consistent with
the accounting for costs incurred in connection with raising equity capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When shares are issued in connection with drawdowns
under the facility, the Company records the gross proceeds received as an increase to stockholders&#8217; equity. Any issuance costs
directly attributable to the specific drawdown are recorded as a reduction to additional paid-in capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also evaluates whether any features
embedded within the arrangement meet the definition of a freestanding or embedded derivative under ASC 815. If such features do not qualify
for equity classification, they are recognized as derivative instruments and measured at fair value, with subsequent changes in fair
value recognized in the statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the December 31, 2025, the Company has
not sold any Ordinary Shares pursuant to the SEPA, and therefore all issuance expenses were recorded as financial expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Q. Concentration of Credit Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Part of the Company&#8217;s operating expenses
are denominated in New Israeli Shekel (&#8220;NIS&#8221;), and therefore, subject to foreign currency risk.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalent</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>R. Cash and Cash Equivalent</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from the date of purchase that are
not restricted as to withdrawal or use and are readily convertible to known amounts of cash.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash consists of funds that are contractually
restricted to bank guarantee due to rental agreements. The Company has presented restricted cash separately from cash and cash equivalents
in the balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bank deposits with maturities of more than three
months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at cost which
approximates market value. As of December 31, 2025, the Company had no short-term deposits, and as of December 31, 2024 the Company had
short-term deposits in the amounts of $0.7 million.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>S. Segment Information</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a single operating and reportable
segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is the Chief Executive Officer, evaluates the performance
of its business based on financial data consistent with the presentation in the accompanying Financial Statements for the purposes of
making operating decisions, assessing financial performance, and allocating resources.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>T. New accounting Pronouncements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accounting Standards Issued and Not Yet Adopted
in 2025</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the Financial Accounting Standards
Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2024-03, Income Statement &#8211; Reporting Comprehensive
Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;),
which requires the disaggregation of certain expense captions into specified categories in disclosures within the notes to the consolidated
financial statements to provide enhanced transparency into the expense captions presented on the face of the statement of income and
comprehensive income. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted,
and may be applied either prospectively or retrospectively to financial statements issued for reporting periods after the effective date
of ASU 2024-03 or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating
the impact that the adoption of ASU 2024-03 will have on its related disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-04,
Induced Conversions of Convertible Debt Instruments (&#8220;ASU 2024-04&#8221;). This new guidance is intended to improve the relevance
and consistency in application of the induced conversion guidance in Subtopic 470-20 for (a) convertible debt instruments with cash conversion
features and (b) debt instruments that are not currently convertible. ASU 2024-04 is effective for fiscal years beginning after December
15, 2026. Early adoption is permitted. The Company does not plan to early adopt this standard. The Company is currently evaluating the
effect of adoption of this standard on its consolidated financial statements and disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2025, the FASB issued ASU 2025-10,
Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which provides comprehensive guidance
on the recognition, measurement, and presentation of government grants. The amendments are effective for annual reporting periods beginning
after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company is currently
evaluating the impact of this guidance on its accounting for government assistance arrangements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Newly issued and recently adopted accounting pronouncements:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups (&#8220;JOBS&#8221;) Act. Under the JOBS Act, emerging growth companies can delay adopting
new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as to those standards apply to
private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards
that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging
growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories
for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective
for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinanceIncomeAndExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finance income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinanceIncomeAndExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SeverancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SeverancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock', window );">Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual rates of depreciation are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Computers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">6-15</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Leasehold Improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of depreciation on straight-line method, over the estimated useful life of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">216</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">240</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Institutions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">74</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">517</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Finished goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">461</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">293</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Raw materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Work in progress</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">66</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">55</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">735</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">444</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">For the year ended December 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Computers</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">R&amp;D<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-weight: bold">At January 1, 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">182</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">535</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">869</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">80</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">103</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At December 31, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">615</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At January 1, 2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">32</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">107</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">150</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0in"><b>At December 31, 2025</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">520</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">As of December 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">21</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">319</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">87</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">452</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Computers</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">R&amp;D<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">172</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">381</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">705</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Additions</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">154</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">164</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">535</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">869</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">44</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">116</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">171</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">189</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">As of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">36</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">346</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">93</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accounts Payable</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">506</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">508</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employees&#8217; salaries and related liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">414</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">421</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,349</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,364</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock', window );">Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities</a></td>
<td class="text">Below is a summary of the Company&#8217;s operating right-of-use assets and operating lease liabilities
as of December 31, 2025, and 2024:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Operating lease liabilities, current</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">286</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">277</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1pt">Operating lease liabilities long-term</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">194</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">378</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">655</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Weighted average of remaining lease term</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.74</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2.52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average discount rate - operating leases</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">11.27</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">9.92</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Right-of-Use Assets Over the Remaining Lease Periods</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lease payments for the Company&#8217;s right-of-use
assets over the remaining lease periods as of December 31, 2025, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Year ended December&#160;31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">U.S.&#160;dollars<br/> in&#160;thousands</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left">2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">324</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">2027</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">201</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">Total undiscounted lease payment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">525</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Interest (*)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(45</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">480</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Future lease payments were discounted by&#160;7.98%-25.59% interest
rate.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial Liabilities Fair Value Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Financial Liability</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December&#160;31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Financial liability (A)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">296</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt">Private warrants (B)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">786</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,506</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt"><b>Total</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,082</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,575</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Share Capital</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares as of<br/> December 31,&#160;2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of shares as of<br/> December 31,&#160;2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Authorized</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issued and outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Authorized</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issued and outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 2.5pt">Ordinary shares</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right">35,949,247</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right">100,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right">24,252,096</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Movement in Warrants Outstanding</a></td>
<td class="text"><span style="font-size: 10pt">The following table reconciles the movement in warrants outstanding at the beginning and end of the period:</span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> Warrants</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted average remaining contractual term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(in years)</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold; padding-bottom: 1pt">Balance as of December 31, 2024</td><td style="width: 1%; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,728,611</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4.14</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1.63</td><td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt">Issued</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 9pt">Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,514,086</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.09</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.49</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 9pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(277,835</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5.5</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.54</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Balance as of December 31, 2025</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,936,690</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4.20</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">0.80</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Information about the Company&#8217;s Outstanding Warrants</a></td>
<td class="text"><span style="font-size: 10pt">The following table summarizes information about the Company&#8217;s outstanding warrants as of December 31, 2025</span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrants<br/> outstanding</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>December 31, <br/>
2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 31%; text-align: center">5.5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 31%; text-align: right">1,640,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 32%; text-align: center; padding-left: 1.4pt">15/07/2026</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&#160;</td><td style="text-align: center">6.875</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">145,455</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt">15/01/2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&#160;</td><td style="text-align: center">1.6</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">212,188</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt">28/06/2027</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">&#160;</td><td style="text-align: center">1.56</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">185,591</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt">14/06/2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: center">1.1</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,753,001</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: center; padding-bottom: 1pt; padding-left: 1.4pt">30/06/2026</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>Balance as of December 31, 2025</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,936,690</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center; padding-left: 1.4pt">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Loss per share has been calculated using the
weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant financial periods, the weighted average
number of equity shares in issue and profit for the period as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,220</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,053</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,286</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt; padding-left: 9pt">Total number of Ordinary Shares</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">35,949,247</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">24,252,096</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,652,176</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average number of Ordinary Shares and pre-funded warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">29,623,194</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,515,545</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,095,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Basic and diluted loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.45</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.60</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.93</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COST OF REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CostOfRevenuesAbstract', window );"><strong>Cost Of Revenues Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfCostOfRevenuesTableTextBlock', window );">Schedule of Cost of Revenues</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Materials and subcontractors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">235</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Payroll and related</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Warranty</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1pt">Royalties to IIA</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">287</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CostOfRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CostOfRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfCostOfRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost of revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfCostOfRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Salary and related expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,461</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,079</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,429</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,634</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">663</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">737</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">812</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">291</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(286</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">280</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">206</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">268</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,496</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,320</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,966</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,758</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,432</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,079</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">766</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fundraising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">68</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">112</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">45</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,532</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,185</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,063</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SALES AND MARKETING EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpenseAbstract', window );"><strong>Selling and Marketing Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock', window );">Schedule of Sales and Marketing Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Share-based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">194</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">89</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">348</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">93</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">51</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">61</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;&#160;&#160;<b>Total</b></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">588</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">754</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">746</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL (INCOME) AND EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Financial (Income) and Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Revaluation of financial liabilities at fair value through profit or loss, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(247</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">36</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(306</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign currency transaction income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(101</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(77</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(233</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Others</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(339</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(42</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(529</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The deferred tax assets and liabilities
are composed of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,404</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,739</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">R&amp;D temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,218</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Fund raising costs 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Operating lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,810</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,097</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Net deferred taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfTheoreticalTaxTableTextBlock', window );">Schedule of Theoretical Tax</a></td>
<td class="text"><span style="font-size: 10pt"><b>Theoretical tax:</b></span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Loss before taxation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(13,220</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,053</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(11,286</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Theoretical tax credit at applicable statutory rate: 23%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,041</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,542</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,596</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-allowable expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(704</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(391</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(244</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,337</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,151</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,352</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income tax benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Tax Rate Reconciliation</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Tax</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Rate</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">IL statutory tax rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(3,041</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Non-taxable or non-deductible items:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">747</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.7</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Revaluation of financial liabilities at fair value through profit or loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(166</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.9</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in valuation allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20.5</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(376</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2.8</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfTheoreticalTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of theoretical tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfTheoreticalTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED PAYMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-Based Payment Arrangement, Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Measure the Fair Value of the Option at Grant Date</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following inputs were used to measure the
fair value of the option at grant date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">November 18,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">February 22,<br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%">(i)</td><td style="width: 1%">&#160;</td> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center">123.41%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center">128.78%</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>(ii)</td><td>&#160;</td> <td style="text-align: justify">Dividend rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">0%</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">0%</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; vertical-align: top">(iii)</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Expected term (vesting period)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Three years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">One year - Three years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; vertical-align: top">(iv)</td><td>&#160;</td> <td style="vertical-align: top; text-align: left">Contractual life</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>(v)</td><td>&#160;</td> <td style="text-align: justify">Free risk rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">4.12%</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">4.5%</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">January 22,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">February 5,<br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%">(i)</td><td style="width: 1%">&#160;</td> <td style="width: 64%; text-align: justify">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center">144.83%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: center">143.98%</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>(ii)</td><td>&#160;</td> <td style="text-align: justify">Dividend rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">0%</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">0%</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>(iii)</td><td>&#160;</td> <td style="text-align: justify">Expected term (vesting period)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Three years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Three years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>(iv)</td><td>&#160;</td> <td style="text-align: justify">Contractual life</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">Ten years</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>(v)</td><td>&#160;</td> <td style="text-align: justify">Free risk rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">4.03%-4.07%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: center">4.16%</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options to Services Providers and Advisers Outstanding</a></td>
<td class="text"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options to services providers and advisers outstanding
as December 31, 2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">185,111</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3.359</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">105,111</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">4.085</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">114,512</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3.058</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.405</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.367</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">240,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.370</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.359</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">105,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">200,111</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.362</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">162,154</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.251</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">94,242</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.267</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">44</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">66</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <br/> average <br/> Exercise <br/> price NIS</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">368,641</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.70</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">357,689</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">386,260</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.37</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.37</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">30,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3.56</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,571</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.37</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">277,265</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.91</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">368,641</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">357,689</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Options exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">244,765</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.57</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">338,641</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">350,131</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">47</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSUs to Services Providers and Advisers Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The RSUs to services providers and advisers outstanding as of December
31, 2025, 2024 and 2023 were as&#160;follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,433</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,266</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,833</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSUs outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,433</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSU&#8217;s Vested</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,500</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,067</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended<br/> December&#160;31, <br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<br/> RSUs</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,518,796</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">445,140</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,727,842</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,024,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,687,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,087</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,711,947</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">587,508</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,215,615</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSUs outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,745,512</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,518,796</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">445,140</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">RSU&#8217;s Vested</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,396,644</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,684,697</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,097,189</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt">Share-based payment expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,536</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,683</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,352</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Shareholders and Other Related Parties&#8217; Benefits</a></td>
<td class="text"><span style="font-size: 10pt"><span style="text-decoration:underline">Shareholders and other related parties&#8217; benefits</span></span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Salary and related expenses &#8211; officers and directors</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,819</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,710</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,761</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share based payment &#8211; officers and directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,009</td><td style="text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nature of transaction</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&#160;31, <br/> 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 10%">Officers</td><td style="width: 1%">&#160;</td>
    <td style="width: 69%; text-align: left">Salaries and related</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(343</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(381</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Directors</td><td>&#160;</td>
    <td style="text-align: left">Compensation for directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(40</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Sep. 16, 2025</div></th>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Apr. 10, 2025</div></th>
<th class="th"><div>Mar. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GENERALDetailsLineItems', window );"><strong>GENERAL (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,687<span></span>
</td>
<td class="nump">$ 7,118<span></span>
</td>
<td class="nump">$ 1,917<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Ordinary shares sold (in Shares)</a></td>
<td class="nump">5,485,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateGrossProceeds', window );">Aggregate gross proceeds</a></td>
<td class="nump">$ 4,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeductingOfferingCosts', window );">Deducting offering costs</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Incurred accumulated losses</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivatePlacementMember', window );">December Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GENERALDetailsLineItems', window );"><strong>GENERAL (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="nump">$ 2,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeductingOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deducting offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeductingOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GENERALDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GENERALDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="nump">11.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalesAmount', window );">Sales</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PaidRoyalties', window );">Paid royalties</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employees monthly deposits rate</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OrdinarySharesSEPAAmount', window );">Ordinary shares SEPA amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of Incremental borrowing rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OrdinarySharesSEPAAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of ordinary shares SEPA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OrdinarySharesSEPAAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of paid royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of generated sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual depreciation rates of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,159<span></span>
</td>
<td class="nump">$ 5,111<span></span>
</td>
<td class="nump">$ 5,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEPOSITS (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=iinn_BankLeumiMember', window );">Bank Leumi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DEPOSITSDetailsLineItems', window );"><strong>DEPOSITS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposit</a></td>
<td class="nump">$ 668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DEPOSITSDetailsLineItems', window );"><strong>DEPOSITS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed annual interest percentage</a></td>
<td class="nump">4.108%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DEPOSITSDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DEPOSITSDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=iinn_BankLeumiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=iinn_BankLeumiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS - Schedule of Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestBearingDepositsInBanks', window );">Institutions</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OthersAsset', window );">Others</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 517<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OthersAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OthersAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestBearingDepositsInBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For banks and other depository institutions (including Federal Reserve Banks, if applicable): Interest-bearing deposits in other financial institutions for relatively short periods of time including, for example, certificates of deposits, which are presented separately from cash on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477263/942-210-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestBearingDepositsInBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 461<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 735<span></span>
</td>
<td class="nump">$ 444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">972<span></span>
</td>
<td class="nump">869<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_RDEquipmentMember', window );">R&amp;D equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_RDEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_RDEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE - Schedule of Other Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 506<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employees&#8217; salaries and related liabilities</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccountsPayableToRelatedParties', window );">Related parties</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Total</a></td>
<td class="nump">$ 1,349<span></span>
</td>
<td class="nump">$ 1,364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AccountsPayableToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AccountsPayableToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateBudget', window );">Aggregate budget</a></td>
<td class="nump">$ 1,062<span></span>
</td>
<td class="nump">&#8362; 3,850,869<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">&#8362; 4,880,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfApprovedBudget', window );">Percentage of approved budget</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ProjectBudgetAggregateAmount', window );">Project budget aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">&#8362; 4,623,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Total funds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 1,410,925<span></span>
</td>
<td class="nump">&#8362; 2,773,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RoyaltiesPercentage', window );">Percentage of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Liability amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ContingentUponFutureSales', window );">Contingent upon future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateBudget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate budget.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateBudget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ContingentUponFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent upon future sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ContingentUponFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfApprovedBudget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of approved budget.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfApprovedBudget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ProjectBudgetAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of project budget aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ProjectBudgetAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE LIABILITIES (Details)<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 27, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 27, 2025 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LEASELIABILITIESDetailsLineItems', window );"><strong>LEASE LIABILITIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent termination penalty</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">&#8362; 650,000<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">&#8362; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_MonthlyDeductionFromTerminationFee', window );">Monthly deduction from termination fee</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">&#8362; 50,000<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">&#8362; 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LeaseMonthlyPayment', window );">Lease monthly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">&#8362; 69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageForCarsLeaseAgreementCancellationPenalty', window );">Percentage for car lease agreement cancellation penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">up to 400%<span></span>
</td>
<td class="text">up to 400%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LEASELIABILITIESDetailsLineItems', window );"><strong>LEASE LIABILITIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfFutureLeasePaymentsDiscounted', window );">Percentage of future lease payments discounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.98%<span></span>
</td>
<td class="nump">7.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_LEASELIABILITIESDetailsLineItems', window );"><strong>LEASE LIABILITIES (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfFutureLeasePaymentsDiscounted', window );">Percentage of future lease payments discounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.59%<span></span>
</td>
<td class="nump">25.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_LEASELIABILITIESDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_LEASELIABILITIESDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_LeaseMonthlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of lease monthly payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_LeaseMonthlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_MonthlyDeductionFromTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the value of monthly deduction from termination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_MonthlyDeductionFromTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageForCarsLeaseAgreementCancellationPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the description of percentage for car lease agreement cancellation penalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageForCarsLeaseAgreementCancellationPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfFutureLeasePaymentsDiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future lease payments discounted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfFutureLeasePaymentsDiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASE LIABILITIES - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities long-term</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average of remaining lease term</a></td>
<td class="text">1 year 8 months 26 days<span></span>
</td>
<td class="text">2 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">11.27%<span></span>
</td>
<td class="nump">9.92%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>LEASE LIABILITIES - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 655<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Future lease payments were discounted by&#160;7.98%-25.59% interest
rate.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 12, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 26, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">$ 1,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.48<span></span>
</td>
<td class="nump">4.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.59<span></span>
</td>
<td class="nump">88.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Aggregate purchase (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=iinn_December2024PrivatePlacementMember', window );">December2024 Private Placement Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfPayFees', window );">Percentage of pay fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AgreementAxis=iinn_StandbyEquityPurchaseAgreementSEPAMember', window );">Standby Equity Purchase Agreement SEPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfPayFees', window );">Percentage of pay fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Commitment fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Total commitment amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OrdinarySharesPurchasePricePercentage', window );">Ordinary shares purchase price</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting power limitation description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Yorkville shall not purchase or acquire any shares that would result in it and its affiliates
beneficially owning more than 4.99% of the then outstanding voting power or number of Ordinary Shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DescriptionOfFeePayments', window );">Description of fee payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company agreed to pay a legal and structuring fee in the amount of $25, of which (a) $15 has been paid
prior to the execution date, and (b) $10 has been paid within 3 days of the execution of the agreement. The company also agreed to pay
a commitment fee of $500 in ordinary shares to Yorkville, payable as follows: (i) $250 has been paid three days following the date the
SEPA was entered into, in the form of the issuance of 218,627 Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date, and (ii) $250 has been paid on the 30-day
anniversary of the date of the SEPA in the form of the issuance of Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date. The Commitment Shares issuable hereunder were
included in the initial Registration Statement. Throughout the month ended December 31, 2025, the Company did not issue any&#160;Ordinary
Shares pursuant to the SEPA.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AgreementAxis=iinn_StandbyEquityPurchaseAgreementSEPAMember', window );">Standby Equity Purchase Agreement SEPA [Member] | Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfPayFees', window );">Percentage of pay fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberStandbyEquityPurchaseAgreementMember', window );">December Standby Equity Purchase Agreement [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SaleOfRightsValue', window );">Sale of rights value (in Dollars)</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DescriptionOfFeePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of fee payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DescriptionOfFeePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OrdinarySharesPurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of ordinary shares purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OrdinarySharesPurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfPayFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of pay fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfPayFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SaleOfRightsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of rights value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SaleOfRightsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=iinn_December2024PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=iinn_December2024PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AgreementAxis=iinn_StandbyEquityPurchaseAgreementSEPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AgreementAxis=iinn_StandbyEquityPurchaseAgreementSEPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberStandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberStandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=iinn_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=iinn_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Financial liabilities at fair value</a></td>
<td class="nump">$ 1,082<span></span>
</td>
<td class="nump">$ 1,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Financial liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Financial liabilities at fair value</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=iinn_PrivateWarrantsMember', window );">Private warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems', window );"><strong>FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Financial liabilities at fair value</a></td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">$ 1,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=iinn_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=iinn_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 17, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 12, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 16, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 10, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 14, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 27, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 14, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 20, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 04, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,485,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,646<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering cost (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyLiquidationProceedsPercentage', window );">Percentage of agreement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares issued for consulting service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IssueOfPrivateWarrantsShares', window );">Issue of private warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">855,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PrivateWarrantsExerciseShares', window );">Private warrants exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">855,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre funded warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberofAdditionalOrdinaryShares', window );">Number of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ClassOfPrivateWarrantOrRightOutstanding', window );">Private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Exercise amount of warrants (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">1,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrant (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyLiquidationProceedsPercentage', window );">Percentage of agreement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrant (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePreFundedWarrantsMember', window );">June Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberOfSharesPerUnits', window );">Number of shares per units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Exercise amount of warrants (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_TwoThousandTwentyFourJuneOfferingMember', window );">2024 June Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering cost (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPrivateWarrantsMember', window );">December Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,950,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PrivateWarrants', window );">Private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,950,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerUnit', window );">Purchase price per unit (in Dollars per Share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPreFundedWarrantsMember', window );">December Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberOfSharesPerUnits', window );">Number of shares per units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PreFundedWarrants', window );">Pre funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,565,217<span></span>
</td>
<td class="nump">6,231,169<span></span>
</td>
<td class="nump">3,031,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issued an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,485,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares issued for consulting service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Vested RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=iinn_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_RothCapitalPartnersLLCMember', window );">Roth Capital Partners LLCMember | Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,485,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering cost (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_AdvisorMember', window );">Advisor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issued an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AgreementAxis=iinn_StandbyEquityPurchaseAgreementSEPAMember', window );">Standby Equity Purchase Agreement SEPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issued an aggregate shares</a></td>
<td class="nump">218,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfPayFees', window );">Percentage of pay fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">ATM aggregate offering price (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,118<span></span>
</td>
<td class="nump">$ 1,917<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | June Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | December Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerUnit', window );">Purchase price per unit (in Dollars per Share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | June Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PreFundedWarrantsPerShare', window );">Pre funded warrants per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | December Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrant (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | December Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberOfSharesPerUnits', window );">Number of shares per units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PrivateWarrants', window );">Private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Vested RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issued an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711,947<span></span>
</td>
<td class="nump">594,943<span></span>
</td>
<td class="nump">1,226,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,376<span></span>
</td>
<td class="nump">19,048<span></span>
</td>
<td class="nump">37,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Roth Capital Partners LLCMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourAprilOfferingMember', window );">2024 April Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,339,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourJuneOfferingMember', window );">2024 June Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivateOfferingMember', window );">December Private Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering cost (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfPayFees', window );">Percentage of pay fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_December2024PrivatePlacementMember', window );">December 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_December2025OfferingMember', window );">2025 December Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,565,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ClassOfPrivateWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the number of private warrant or right outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ClassOfPrivateWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IssueOfPrivateWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue of private warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IssueOfPrivateWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NumberOfSharesPerUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares per units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NumberOfSharesPerUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NumberofAdditionalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NumberofAdditionalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfPayFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of pay fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfPayFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PreFundedWarrantsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre funded warrants per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PreFundedWarrantsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PrivateWarrantsExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private warrants exercise shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PrivateWarrantsExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PurchasePricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PurchasePricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SHAREHOLDERSEQUITYDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SHAREHOLDERSEQUITYDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyLiquidationProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of proceeds from liquidation of asset held as collateral or by third party expected to cover maximum potential future payment for product warranty. Includes, but is not limited to, separately price extended warranty, product maintenance contract, and warranty obligation incurred in connection with agreed upon specification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyLiquidationProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_TwoThousandTwentyFourJuneOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_TwoThousandTwentyFourJuneOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=iinn_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=iinn_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_RothCapitalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_RothCapitalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_AdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_AdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AgreementAxis=iinn_StandbyEquityPurchaseAgreementSEPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AgreementAxis=iinn_StandbyEquityPurchaseAgreementSEPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourAprilOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourAprilOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourJuneOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourJuneOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivateOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivateOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_December2024PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_December2024PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_December2025OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_December2025OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY - Schedule of Share Capital (Details) - Ordinary Shares [Member] - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems', window );"><strong>SHAREHOLDERS&#8217; EQUITY - Schedule of Share Capital (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized, Ordinary shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Issued and outstanding, Ordinary shares</a></td>
<td class="nump">35,949,247<span></span>
</td>
<td class="nump">24,252,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY - Schedule of Movement in Warrants Outstanding (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year | shares</a></td>
<td class="nump">7,728,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price | $ / shares</a></td>
<td class="nump">$ 4.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne', window );">Weighted average remaining contractual term (in years)</a></td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued', window );">Number of Warrants, Issued | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued', window );">Weighted-average exercise price, Issued | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Issued</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Number of Warrants, Exercised | shares</a></td>
<td class="num">(1,514,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Exercised | $ / shares</a></td>
<td class="nump">$ 1.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Exercised</a></td>
<td class="text">5 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Number of Warrants, Expired | shares</a></td>
<td class="num">(277,835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Expired | $ / shares</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Expired</a></td>
<td class="text">6 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year | shares</a></td>
<td class="nump">5,936,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price | $ / shares</a></td>
<td class="nump">$ 4.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years)</a></td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of other than option under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY - Schedule of Information about the Company&#8217;s Outstanding Warrants (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding</a></td>
<td class="nump">5,936,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice55Member', window );">5.5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding</a></td>
<td class="nump">1,640,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jul. 15,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_Exercise6875Member', window );">6.875 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding</a></td>
<td class="nump">145,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jan. 15,  2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointSixMember', window );">1.6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding</a></td>
<td class="nump">212,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jun. 28,  2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice156Member', window );">1.56 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding</a></td>
<td class="nump">185,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jun. 14,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointOneMember', window );">1.1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding</a></td>
<td class="nump">3,753,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice55Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice55Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_Exercise6875Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_Exercise6875Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice156Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice156Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period (in Dollars)</a></td>
<td class="nump">$ 13,220<span></span>
</td>
<td class="nump">$ 11,053<span></span>
</td>
<td class="nump">$ 11,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total number of Ordinary Shares</a></td>
<td class="nump">35,949,247<span></span>
</td>
<td class="nump">24,252,096<span></span>
</td>
<td class="nump">15,652,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary Shares and pre-funded warrants</a></td>
<td class="nump">29,623,194<span></span>
</td>
<td class="nump">18,515,545<span></span>
</td>
<td class="nump">12,095,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COST OF REVENUES - Schedule of Cost of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems', window );"><strong>COST OF REVENUES - Schedule of Cost of Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iinn_MaterialsAndSubcontractorsMember', window );">Materials And Subcontractors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems', window );"><strong>COST OF REVENUES - Schedule of Cost of Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iinn_PayrollAndRelatedMember', window );">Payroll And Related [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems', window );"><strong>COST OF REVENUES - Schedule of Cost of Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iinn_WarrantyMember', window );">Warranty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems', window );"><strong>COST OF REVENUES - Schedule of Cost of Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iinn_RoyaltiesToIIAMember', window );">Royalties To IIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems', window );"><strong>COST OF REVENUES - Schedule of Cost of Revenues (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iinn_MaterialsAndSubcontractorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iinn_MaterialsAndSubcontractorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iinn_PayrollAndRelatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iinn_PayrollAndRelatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iinn_WarrantyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iinn_WarrantyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iinn_RoyaltiesToIIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iinn_RoyaltiesToIIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES - Schedule of Research and Development Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salary and related expenses</a></td>
<td class="nump">$ 4,461<span></span>
</td>
<td class="nump">$ 4,079<span></span>
</td>
<td class="nump">$ 4,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share based payment</a></td>
<td class="nump">1,634<span></span>
</td>
<td class="nump">801<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLaborRelatedExpenses', window );">Materials and related expenses</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">812<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Subcontractors', window );">Subcontractors</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IIAParticipation', window );">IIA participation</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 7,496<span></span>
</td>
<td class="nump">$ 6,323<span></span>
</td>
<td class="nump">$ 7,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IIAParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expenses of IIA participation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IIAParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Subcontractors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subcontractors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Subcontractors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLaborRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of labor-related expenses classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLaborRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details) - General and Administrative Expense [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems', window );"><strong>GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">$ 1,966<span></span>
</td>
<td class="nump">$ 1,758<span></span>
</td>
<td class="nump">$ 1,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">1,747<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salary and related expenses</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">808<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance expenses</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Director fees</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Office maintenance</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel abroad</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FundraisingExpenses', window );">Fundraising expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Others</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 5,532<span></span>
</td>
<td class="nump">$ 4,185<span></span>
</td>
<td class="nump">$ 4,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FundraisingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fundraising expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FundraisingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SALES AND MARKETING EXPENSES - Schedule of Sales and Marketing Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpenseAbstract', window );"><strong>Selling and Marketing Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold', window );">Share-based compensation</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and related expenses</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingAndMarketingExpense', window );">Other</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Total</a></td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">$ 754<span></span>
</td>
<td class="nump">$ 746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling and marketing expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL (INCOME) AND EXPENSES - Schedule of Financial (Income) and Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfFinancialIncomeAndExpensesAbstract', window );"><strong>Schedule Of Financial Income And Expenses Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Revaluation of financial liabilities at fair value through profit or loss, net</a></td>
<td class="num">$ (247)<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="num">$ (306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction income</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Others</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total</a></td>
<td class="num">$ (339)<span></span>
</td>
<td class="num">$ (42)<span></span>
</td>
<td class="num">$ (529)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revaluation of financial liabilities at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfFinancialIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfFinancialIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TAXESONINCOMEDetailsLineItems', window );"><strong>TAXES ON INCOME (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Carryforward tax losses</a></td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Valuation allowance</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TAXESONINCOMEDetailsLineItems', window );"><strong>TAXES ON INCOME (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TAXESONINCOMEDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TAXESONINCOMEDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TAXES ON INCOME - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of Deferred Tax Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 9,404<span></span>
</td>
<td class="nump">$ 6,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxAssetsAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D temporary differences</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxAssetsFundRaisingCost2023', window );">Fund raising costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxLiabilitiesOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">10,810<span></span>
</td>
<td class="nump">8,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(10,810)<span></span>
</td>
<td class="num">(8,097)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxAssetsAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of deferred tax accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxAssetsAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxAssetsFundRaisingCost2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fund raising costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxAssetsFundRaisingCost2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxLiabilitiesOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxLiabilitiesOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME - Schedule of Theoretical Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfTheoreticalTaxAbstract', window );"><strong>Schedule Of Theoretical Tax Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxation</a></td>
<td class="num">$ (13,220)<span></span>
</td>
<td class="num">$ (11,053)<span></span>
</td>
<td class="num">$ (11,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax credit at applicable statutory rate: 23%</a></td>
<td class="num">(3,041)<span></span>
</td>
<td class="num">(2,542)<span></span>
</td>
<td class="num">(2,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-allowable expenses</a></td>
<td class="num">(704)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized', window );">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</a></td>
<td class="num">(2,337)<span></span>
</td>
<td class="num">(2,151)<span></span>
</td>
<td class="num">(2,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfTheoreticalTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfTheoreticalTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary differences and tax losses for which no Deferred Tax Asset is recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME - Schedule of Effective Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract', window );"><strong>Schedule Of Effective Tax Rate Reconciliation Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">IL statutory tax rate</a></td>
<td class="num">$ (3,041)<span></span>
</td>
<td class="num">$ (2,542)<span></span>
</td>
<td class="num">$ (2,596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">IL statutory tax rate, percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">$ 747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation, percentage</a></td>
<td class="num">(5.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Revaluation of financial liabilities at fair value through profit or loss</a></td>
<td class="num">$ (166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Revaluation of financial liabilities at fair value through profit or loss, percentage</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Others</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Others, percentage</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="nump">$ 2,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances, percentage</a></td>
<td class="num">(20.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">$ (376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments, percentage</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revaluation of financial liabilities at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation of financial liabilities at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED PAYMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2026</div></th>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Nov. 18, 2025</div></th>
<th class="th"><div>Aug. 06, 2025</div></th>
<th class="th"><div>Feb. 20, 2025</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CapitalGainTaxRate', window );">Capital gain tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfCapitalGainTax', window );">Percentage of capital gain tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Share Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member] | Share Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_ExecutivesAndDirectorsMember', window );">Executives and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_ServiceProvidersMember', window );">Service Providers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member] | Revenue Achievement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_EmployeesDirectorsAndSubcontractorsMember', window );">Employees, Directors and Subcontractors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,575<span></span>
</td>
<td class="nump">$ 1,767<span></span>
</td>
<td class="nump">$ 1,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CapitalGainTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital gain tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CapitalGainTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfCapitalGainTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of capital gain tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfCapitalGainTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SHAREBASEDPAYMENTDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SHAREBASEDPAYMENTDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_ExecutivesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_ExecutivesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_ServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_ServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=iinn_RevenueAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=iinn_RevenueAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_EmployeesDirectorsAndSubcontractorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_EmployeesDirectorsAndSubcontractorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details)<br></strong></div></th>
<th class="th"><div>Nov. 18, 2025</div></th>
<th class="th"><div>Feb. 22, 2025</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">123.41%<span></span>
</td>
<td class="nump">128.78%<span></span>
</td>
<td class="nump">143.98%<span></span>
</td>
<td class="nump">144.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (vesting period)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife', window );">Contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Free risk rate</a></td>
<td class="nump">4.12%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (vesting period)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Free risk rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.03%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (vesting period)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Free risk rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.07%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual life of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=iinn_ServicesProvidersAndAdvisersMember', window );">Services Providers and Advisers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding at beginning of year (in Shares) | shares</a></td>
<td class="nump">185,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Outstanding at beginning of year | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 4.085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted (in Shares) | shares</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Granted | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi', window );">Number of options, Exercised (in Shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Exercised | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Options outstanding (in Shares) | shares</a></td>
<td class="nump">240,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Options outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 4.085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Options exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Options exercisable | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of options, Share-based payment expenses (in Dollars) | $</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=iinn_EmployeesAndDirectorsMember', window );">Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding at beginning of year (in Shares) | shares</a></td>
<td class="nump">368,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Outstanding at beginning of year | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted (in Shares) | shares</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Granted | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi', window );">Number of options, Exercised (in Shares) | shares</a></td>
<td class="nump">101,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Exercised | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Options outstanding (in Shares) | shares</a></td>
<td class="nump">277,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Options outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Options exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Options exercisable | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of options, Share-based payment expenses (in Dollars) | $</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited (in Shares) | shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price NIS, Forfeited | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=iinn_ServicesProvidersAndAdvisersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=iinn_ServicesProvidersAndAdvisersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=iinn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=iinn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_EmployeesAndDirectorsMember', window );">Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">2,518,796<span></span>
</td>
<td class="nump">445,140<span></span>
</td>
<td class="nump">1,727,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">5,024,000<span></span>
</td>
<td class="nump">2,687,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="nump">85,337<span></span>
</td>
<td class="nump">25,836<span></span>
</td>
<td class="nump">67,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="nump">2,711,947<span></span>
</td>
<td class="nump">587,508<span></span>
</td>
<td class="nump">1,215,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne', window );">RSUs outstanding</a></td>
<td class="nump">4,745,512<span></span>
</td>
<td class="nump">2,518,796<span></span>
</td>
<td class="nump">445,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested', window );">RSU&#8217;s Vested</a></td>
<td class="nump">6,396,644<span></span>
</td>
<td class="nump">3,684,697<span></span>
</td>
<td class="nump">3,097,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars)</a></td>
<td class="nump">$ 3,536<span></span>
</td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="nump">$ 1,352<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems', window );"><strong>SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">18,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">10,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne', window );">RSUs outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested', window );">RSU&#8217;s Vested</a></td>
<td class="nump">32,500<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="nump">25,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of RSUs vested under share based payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES - Schedule of Shareholders and Other Related Parties&#8217; Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_OfficersAndDirectorsMember', window );">Officers and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and related expenses &#8211; officers and directors</a></td>
<td class="nump">$ 1,819<span></span>
</td>
<td class="nump">$ 1,710<span></span>
</td>
<td class="nump">$ 1,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based payment &#8211; officers and directors</a></td>
<td class="nump">3,107<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transactions</a></td>
<td class="num">(343)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transactions</a></td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Feb. 05, 2026 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StandbyEquityPurchaseAgreementPercentage', window );">Standby equity purchase agreement percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialExpensesDueToCommitmentFee', window );">Commitment fee amount of SEPA (in Dollars) | $</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );"></a></td>
<td class="nump">245,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Ordinary shares value (in Dollars) | $</a></td>
<td class="nump">$ 231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining balance of commitment (in Dollars) | $</a></td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Purchaser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Ordinary shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Ordinary shares price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PreFundedWarrants', window );">Pre funded warrants</a></td>
<td class="nump">2,785,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.6999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_WarrantsToPurchaseOrdinaryShares', window );">Warrants to purchase ordinary shares</a></td>
<td class="nump">2,197,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Purchaser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Purchaser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price (in Dollars per share) | $ / shares</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_PrivateWarrantsMember', window );">Private Warrants Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to ordinary shares</a></td>
<td class="nump">6,785,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Purchaser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SUBSEQUENTEVENTSDetailsLineItems', window );"><strong>SUBSEQUENT EVENTS (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to ordinary shares</a></td>
<td class="nump">3,031,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialExpensesDueToCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial expenses due to commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialExpensesDueToCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SUBSEQUENTEVENTSDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SUBSEQUENTEVENTSDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StandbyEquityPurchaseAgreementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standby Equity Purchase Agreement percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StandbyEquityPurchaseAgreementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_WarrantsToPurchaseOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_WarrantsToPurchaseOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_PurchaserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_PurchaserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>247</ContextCount>
  <ElementCount>392</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement</Role>
      <ShortName>STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3</Role>
      <ShortName>STATEMENTS OF CHANGES IN SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - STATEMENTS OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow</Role>
      <ShortName>STATEMENTS OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERAL</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - CASH AND CASH EQUIVALENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENT</Role>
      <ShortName>CASH AND CASH EQUIVALENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - DEPOSITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITS</Role>
      <ShortName>DEPOSITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETS</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNET</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - OTHER ACCOUNTS PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLE</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - LEASE LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIES</Role>
      <ShortName>LEASE LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUE</Role>
      <ShortName>FINACIAL LIABILITIES AT FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITY</Role>
      <ShortName>SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/REVENUES</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - COST OF REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUES</Role>
      <ShortName>COST OF REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSES</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSES</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - SALES AND MARKETING EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSES</Role>
      <ShortName>SALES AND MARKETING EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - FINANCIAL (INCOME) AND EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSES</Role>
      <ShortName>FINANCIAL (INCOME) AND EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995324 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOME</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995325 - Disclosure - SHARE-BASED PAYMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENT</Role>
      <ShortName>SHARE-BASED PAYMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995326 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIES</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995327 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996002 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETSTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996003 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORYTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORY</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996004 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNETTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNET</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996005 - Disclosure - OTHER ACCOUNTS PAYABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLETables</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLE</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996006 - Disclosure - LEASE LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables</Role>
      <ShortName>LEASE LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIES</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996007 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUETables</Role>
      <ShortName>FINACIAL LIABILITIES AT FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUE</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996008 - Disclosure - SHAREHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables</Role>
      <ShortName>SHAREHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITY</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996009 - Disclosure - COST OF REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUESTables</Role>
      <ShortName>COST OF REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996010 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSESTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSES</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996011 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSESTables</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSES</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996012 - Disclosure - SALES AND MARKETING EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSESTables</Role>
      <ShortName>SALES AND MARKETING EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSES</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996013 - Disclosure - FINANCIAL (INCOME) AND EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSESTables</Role>
      <ShortName>FINANCIAL (INCOME) AND EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSES</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996014 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOME</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996015 - Disclosure - SHARE-BASED PAYMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables</Role>
      <ShortName>SHARE-BASED PAYMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENT</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996016 - Disclosure - RELATED PARTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIESTables</Role>
      <ShortName>RELATED PARTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIES</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996017 - Disclosure - GENERAL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails</Role>
      <ShortName>GENERAL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSESTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996020 - Disclosure - CASH AND CASH EQUIVALENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENTDetails</Role>
      <ShortName>CASH AND CASH EQUIVALENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENT</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996021 - Disclosure - DEPOSITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails</Role>
      <ShortName>DEPOSITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITS</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996022 - Disclosure - OTHER CURRENT ASSETS - Schedule of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable</Role>
      <ShortName>OTHER CURRENT ASSETS - Schedule of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996023 - Disclosure - INVENTORY - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable</Role>
      <ShortName>INVENTORY - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996024 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996025 - Disclosure - OTHER ACCOUNTS PAYABLE - Schedule of Other Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE - Schedule of Other Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996027 - Disclosure - LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails</Role>
      <ShortName>LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996028 - Disclosure - LEASE LIABILITIES - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable</Role>
      <ShortName>LEASE LIABILITIES - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996029 - Disclosure - LEASE LIABILITIES - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable</Role>
      <ShortName>LEASE LIABILITIES - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996030 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails</Role>
      <ShortName>FINACIAL LIABILITIES AT FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUETables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996031 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable</Role>
      <ShortName>FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996032 - Disclosure - SHAREHOLDERS??? EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails</Role>
      <ShortName>SHAREHOLDERS??? EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996033 - Disclosure - SHAREHOLDERS??? EQUITY - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable</Role>
      <ShortName>SHAREHOLDERS??? EQUITY - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996034 - Disclosure - SHAREHOLDERS??? EQUITY - Schedule of Movement in Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable</Role>
      <ShortName>SHAREHOLDERS??? EQUITY - Schedule of Movement in Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996035 - Disclosure - SHAREHOLDERS??? EQUITY - Schedule of Information about the Company???s Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable</Role>
      <ShortName>SHAREHOLDERS??? EQUITY - Schedule of Information about the Company???s Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996036 - Disclosure - SHAREHOLDERS??? EQUITY - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable</Role>
      <ShortName>SHAREHOLDERS??? EQUITY - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996037 - Disclosure - COST OF REVENUES - Schedule of Cost of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable</Role>
      <ShortName>COST OF REVENUES - Schedule of Cost of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996038 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES - Schedule of Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES - Schedule of Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996039 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996040 - Disclosure - SALES AND MARKETING EXPENSES - Schedule of Sales and Marketing Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable</Role>
      <ShortName>SALES AND MARKETING EXPENSES - Schedule of Sales and Marketing Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996041 - Disclosure - FINANCIAL (INCOME) AND EXPENSES - Schedule of Financial (Income) and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable</Role>
      <ShortName>FINANCIAL (INCOME) AND EXPENSES - Schedule of Financial (Income) and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSESTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996042 - Disclosure - TAXES ON INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails</Role>
      <ShortName>TAXES ON INCOME (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996043 - Disclosure - TAXES ON INCOME - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable</Role>
      <ShortName>TAXES ON INCOME - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996044 - Disclosure - TAXES ON INCOME - Schedule of Theoretical Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable</Role>
      <ShortName>TAXES ON INCOME - Schedule of Theoretical Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996045 - Disclosure - TAXES ON INCOME - Schedule of Effective Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable</Role>
      <ShortName>TAXES ON INCOME - Schedule of Effective Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996046 - Disclosure - SHARE-BASED PAYMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails</Role>
      <ShortName>SHARE-BASED PAYMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996047 - Disclosure - SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable</Role>
      <ShortName>SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996048 - Disclosure - SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable</Role>
      <ShortName>SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996049 - Disclosure - SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable</Role>
      <ShortName>SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996050 - Disclosure - RELATED PARTIES - Schedule of Shareholders and Other Related Parties??? Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable</Role>
      <ShortName>RELATED PARTIES - Schedule of Shareholders and Other Related Parties??? Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="iinn20f123125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996051 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>iinn-20251231.xsd</File>
    <File>iinn-20251231_cal.xml</File>
    <File>iinn-20251231_def.xml</File>
    <File>iinn-20251231_lab.xml</File>
    <File>iinn-20251231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="iinn20f123125.htm">iinn20f123125.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="867">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>117
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "iinn20f123125.htm": {
   "nsprefix": "iinn",
   "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
   "dts": {
    "schema": {
     "local": [
      "iinn-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_def.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_lab.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025_pre.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "iinn-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "iinn-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "iinn-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "iinn-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "iinn20f123125.htm"
     ]
    }
   },
   "keyStandard": 303,
   "keyCustom": 89,
   "axisStandard": 20,
   "axisCustom": 1,
   "memberStandard": 29,
   "memberCustom": 42,
   "hidden": {
    "total": 11,
    "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231": 4,
    "http://xbrl.sec.gov/dei/2025": 4,
    "http://fasb.org/us-gaap/2025": 3
   },
   "contextCount": 247,
   "entityCount": 1,
   "segmentCount": 78,
   "elementCount": 826,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 867,
    "http://xbrl.sec.gov/dei/2025": 46,
    "http://xbrl.sec.gov/cyd/2025": 12,
    "http://xbrl.sec.gov/ecd/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - BALANCE SHEETS",
     "shortName": "BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DepositsAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - BALANCE SHEETS (Parentheticals)",
     "shortName": "BALANCE SHEETS (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY",
     "shortName": "STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c24",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c24",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - STATEMENTS OF CASH FLOW",
     "shortName": "STATEMENTS OF CASH FLOW",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProvisionForOtherLosses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERAL",
     "longName": "995306 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "995307 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENT",
     "longName": "995308 - Disclosure - CASH AND CASH EQUIVALENT",
     "shortName": "CASH AND CASH EQUIVALENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITS",
     "longName": "995309 - Disclosure - DEPOSITS",
     "shortName": "DEPOSITS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETS",
     "longName": "995310 - Disclosure - OTHER CURRENT ASSETS",
     "shortName": "OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORY",
     "longName": "995311 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNET",
     "longName": "995312 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLE",
     "longName": "995313 - Disclosure - OTHER ACCOUNTS PAYABLE",
     "shortName": "OTHER ACCOUNTS PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "995314 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIES",
     "longName": "995315 - Disclosure - LEASE LIABILITIES",
     "shortName": "LEASE LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUE",
     "longName": "995316 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE",
     "shortName": "FINACIAL LIABILITIES AT FAIR VALUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITY",
     "longName": "995317 - Disclosure - SHAREHOLDERS\u2019 EQUITY",
     "shortName": "SHAREHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/REVENUES",
     "longName": "995318 - Disclosure - REVENUES",
     "shortName": "REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUES",
     "longName": "995319 - Disclosure - COST OF REVENUES",
     "shortName": "COST OF REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:CostOfRevenuesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:CostOfRevenuesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSES",
     "longName": "995320 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSES",
     "longName": "995321 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES",
     "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:GeneralAndAdministrativeExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:GeneralAndAdministrativeExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSES",
     "longName": "995322 - Disclosure - SALES AND MARKETING EXPENSES",
     "shortName": "SALES AND MARKETING EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:SalesAndMarketingExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:SalesAndMarketingExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSES",
     "longName": "995323 - Disclosure - FINANCIAL (INCOME) AND EXPENSES",
     "shortName": "FINANCIAL (INCOME) AND EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOME",
     "longName": "995324 - Disclosure - TAXES ON INCOME",
     "shortName": "TAXES ON INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENT",
     "longName": "995325 - Disclosure - SHARE-BASED PAYMENT",
     "shortName": "SHARE-BASED PAYMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIES",
     "longName": "995326 - Disclosure - RELATED PARTIES",
     "shortName": "RELATED PARTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTS",
     "longName": "995327 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskManagementProcessesIntegratedFlag",
       "p",
       "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskManagementProcessesIntegratedFlag",
       "p",
       "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "996001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETSTables",
     "longName": "996002 - Disclosure - OTHER CURRENT ASSETS (Tables)",
     "shortName": "OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORYTables",
     "longName": "996003 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNETTables",
     "longName": "996004 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLETables",
     "longName": "996005 - Disclosure - OTHER ACCOUNTS PAYABLE (Tables)",
     "shortName": "OTHER ACCOUNTS PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables",
     "longName": "996006 - Disclosure - LEASE LIABILITIES (Tables)",
     "shortName": "LEASE LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUETables",
     "longName": "996007 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE (Tables)",
     "shortName": "FINACIAL LIABILITIES AT FAIR VALUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables",
     "longName": "996008 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUESTables",
     "longName": "996009 - Disclosure - COST OF REVENUES (Tables)",
     "shortName": "COST OF REVENUES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:CostOfRevenuesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfCostOfRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:CostOfRevenuesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSESTables",
     "longName": "996010 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSESTables",
     "longName": "996011 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)",
     "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSESTables",
     "longName": "996012 - Disclosure - SALES AND MARKETING EXPENSES (Tables)",
     "shortName": "SALES AND MARKETING EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSESTables",
     "longName": "996013 - Disclosure - FINANCIAL (INCOME) AND EXPENSES (Tables)",
     "shortName": "FINANCIAL (INCOME) AND EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables",
     "longName": "996014 - Disclosure - TAXES ON INCOME (Tables)",
     "shortName": "TAXES ON INCOME (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables",
     "longName": "996015 - Disclosure - SHARE-BASED PAYMENT (Tables)",
     "shortName": "SHARE-BASED PAYMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIESTables",
     "longName": "996016 - Disclosure - RELATED PARTIES (Tables)",
     "shortName": "RELATED PARTIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails",
     "longName": "996017 - Disclosure - GENERAL (Details)",
     "shortName": "GENERAL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "iinn:AggregateOfferingPrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "iinn:AggregateOfferingPrice",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails",
     "longName": "996018 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "iinn:IncrementalBorrowingRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "iinn:IncrementalBorrowingRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
     "longName": "996019 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c36",
      "name": "iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c36",
      "name": "iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENTDetails",
     "longName": "996020 - Disclosure - CASH AND CASH EQUIVALENT (Details)",
     "shortName": "CASH AND CASH EQUIVALENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails",
     "longName": "996021 - Disclosure - DEPOSITS (Details)",
     "shortName": "DEPOSITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c41",
      "name": "us-gaap:Deposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c41",
      "name": "us-gaap:Deposits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable",
     "longName": "996022 - Disclosure - OTHER CURRENT ASSETS - Schedule of Other Current Assets (Details)",
     "shortName": "OTHER CURRENT ASSETS - Schedule of Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable",
     "longName": "996023 - Disclosure - INVENTORY - Schedule of Inventory (Details)",
     "shortName": "INVENTORY - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996024 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable",
     "longName": "996025 - Disclosure - OTHER ACCOUNTS PAYABLE - Schedule of Other Accounts Payable (Details)",
     "shortName": "OTHER ACCOUNTS PAYABLE - Schedule of Other Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "996026 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c63",
      "name": "iinn:AggregateBudget",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c63",
      "name": "iinn:AggregateBudget",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails",
     "longName": "996027 - Disclosure - LEASE LIABILITIES (Details)",
     "shortName": "LEASE LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable",
     "longName": "996028 - Disclosure - LEASE LIABILITIES - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)",
     "shortName": "LEASE LIABILITIES - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable",
     "longName": "996029 - Disclosure - LEASE LIABILITIES - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)",
     "shortName": "LEASE LIABILITIES - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
     "longName": "996030 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE (Details)",
     "shortName": "FINACIAL LIABILITIES AT FAIR VALUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c80",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable",
     "longName": "996031 - Disclosure - FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details)",
     "shortName": "FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c88",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
     "longName": "996032 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Details)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c94",
      "name": "iinn:PurchasePricePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable",
     "longName": "996033 - Disclosure - SHAREHOLDERS\u2019 EQUITY - Schedule of Share Capital (Details)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c150",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c150",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable",
     "longName": "996034 - Disclosure - SHAREHOLDERS\u2019 EQUITY - Schedule of Movement in Warrants Outstanding (Details)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY - Schedule of Movement in Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c152",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c152",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
     "longName": "996035 - Disclosure - SHAREHOLDERS\u2019 EQUITY - Schedule of Information about the Company\u2019s Outstanding Warrants (Details)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY - Schedule of Information about the Company\u2019s Outstanding Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c154",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c154",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable",
     "longName": "996036 - Disclosure - SHAREHOLDERS\u2019 EQUITY - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable",
     "longName": "996037 - Disclosure - COST OF REVENUES - Schedule of Cost of Revenues (Details)",
     "shortName": "COST OF REVENUES - Schedule of Cost of Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c165",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfCostOfRevenuesTableTextBlock",
       "iinn:CostOfRevenuesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable",
     "longName": "996038 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES - Schedule of Research and Development Expenses (Details)",
     "shortName": "RESEARCH AND DEVELOPMENT EXPENSES - Schedule of Research and Development Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable",
     "longName": "996039 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details)",
     "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c169",
      "name": "us-gaap:ProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c169",
      "name": "us-gaap:ProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable",
     "longName": "996040 - Disclosure - SALES AND MARKETING EXPENSES - Schedule of Sales and Marketing Expenses (Details)",
     "shortName": "SALES AND MARKETING EXPENSES - Schedule of Sales and Marketing Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable",
     "longName": "996041 - Disclosure - FINANCIAL (INCOME) AND EXPENSES - Schedule of Financial (Income) and Expenses (Details)",
     "shortName": "FINANCIAL (INCOME) AND EXPENSES - Schedule of Financial (Income) and Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails",
     "longName": "996042 - Disclosure - TAXES ON INCOME (Details)",
     "shortName": "TAXES ON INCOME (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable",
     "longName": "996043 - Disclosure - TAXES ON INCOME - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "TAXES ON INCOME - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable",
     "longName": "996044 - Disclosure - TAXES ON INCOME - Schedule of Theoretical Tax (Details)",
     "shortName": "TAXES ON INCOME - Schedule of Theoretical Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationNondeductibleExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable",
     "longName": "996045 - Disclosure - TAXES ON INCOME - Schedule of Effective Tax Rate Reconciliation (Details)",
     "shortName": "TAXES ON INCOME - Schedule of Effective Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
     "longName": "996046 - Disclosure - SHARE-BASED PAYMENT (Details)",
     "shortName": "SHARE-BASED PAYMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable",
     "longName": "996047 - Disclosure - SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details)",
     "shortName": "SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
     "longName": "996048 - Disclosure - SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details)",
     "shortName": "SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c206",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c208",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
     "longName": "996049 - Disclosure - SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)",
     "shortName": "SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c226",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c226",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable",
     "longName": "996050 - Disclosure - RELATED PARTIES - Schedule of Shareholders and Other Related Parties\u2019 Benefits (Details)",
     "shortName": "RELATED PARTIES - Schedule of Shareholders and Other Related Parties\u2019 Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c232",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c232",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
     "longName": "996051 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c245",
      "name": "iinn:StandbyEquityPurchaseAgreementPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c245",
      "name": "iinn:StandbyEquityPurchaseAgreementPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iinn20f123125.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS PAYABLE",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30",
      "r33",
      "r1131"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other accounts payables",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "iinn_AccountsPayableToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "AccountsPayableToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableOtherCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "documentation": "Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Accounts Payable To Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payables",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r28"
     ]
    },
    "iinn_AccruedIssuanceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "AccruedIssuanceExpenses",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "iinn_NonCashTransactions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued issuance expenses",
        "documentation": "Amount of accrued issuance expenses.",
        "label": "Accrued Issuance Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableOtherCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Accumulated depreciation, Beginning Balance",
        "periodEndLabel": "Accumulated depreciation, Ending Balance",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r115",
      "r604"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated losses",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r47",
      "r122",
      "r600",
      "r626",
      "r627",
      "r1150"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and additional paid in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and Additional Paid in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1151",
      "r1225"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1101"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of placement agent warrants (Note 11.3)",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r22",
      "r65"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AdvisorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "AdvisorMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advisor [Member]",
        "label": "Advisor Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AggregateBudget": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "AggregateBudget",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate budget",
        "documentation": "The amount of aggregate budget.",
        "label": "Aggregate Budget"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AggregateGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "AggregateGrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate gross proceeds",
        "documentation": "Aggregate gross proceeds.",
        "label": "Aggregate Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "AggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price",
        "documentation": "Aggregate offering price.",
        "label": "Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r889",
      "r905",
      "r940"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r908",
      "r943"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "iinn_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "AgreementAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement [Axis]",
        "label": "Agreement Axis"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AgreementDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "AgreementDomainDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AgreementDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r909",
      "r935",
      "r944",
      "r948",
      "r956"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Number of options, Share-based payment expenses (in Dollars)",
        "netLabel": "Share-based payment expenses (in Dollars)",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r364",
      "r373"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance cost",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r278",
      "r1059",
      "r1167"
     ]
    },
    "iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "AnnualDepreciationRatesOfPropertyPlantAndEquipment",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual depreciation rates",
        "documentation": "Percentage of annual depreciation rates of property, plant and equipment.",
        "label": "Annual Depreciation Rates Of Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r89",
      "r117",
      "r149",
      "r150",
      "r151",
      "r185",
      "r194",
      "r206",
      "r207",
      "r244",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r414",
      "r416",
      "r475",
      "r587",
      "r588",
      "r595",
      "r684",
      "r789",
      "r790",
      "r794",
      "r821",
      "r836",
      "r837",
      "r849",
      "r1096",
      "r1097",
      "r1174"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r126",
      "r149",
      "r150",
      "r151",
      "r244",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r414",
      "r416",
      "r475",
      "r821",
      "r1096",
      "r1097",
      "r1174"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r865",
      "r885"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r865",
      "r885"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r865",
      "r885"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "iinn_BankLeumiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "BankLeumiMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank Leumi [Member]",
        "label": "Bank Leumi Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "verboseLabel": "Board of Directors Chairman [Member]",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact [Member]",
        "verboseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r885"
     ]
    },
    "iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "COSTOFREVENUESScheduleofCostofRevenuesDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COST OF REVENUES - Schedule of Cost of Revenues (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_COSTOFREVENUESScheduleofCostofRevenuesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "COSTOFREVENUESScheduleofCostofRevenuesDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COST OF REVENUES - Schedule of Cost of Revenues (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_CapitalGainTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "CapitalGainTaxRate",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital gain tax rate",
        "documentation": "Capital gain tax rate.",
        "label": "Capital Gain Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r113",
      "r768"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/CASHANDCASHEQUIVALENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH AND CASH EQUIVALENT",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r598"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalent",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r57",
      "r146"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r57"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ClassOfPrivateWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ClassOfPrivateWarrantOrRightOutstanding",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private warrants",
        "documentation": "Represent the number of private warrant or right outstanding.",
        "label": "Class Of Private Warrant Or Right Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r118",
      "r119",
      "r120",
      "r149",
      "r151",
      "r177",
      "r178",
      "r180",
      "r182",
      "r187",
      "r188",
      "r244",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r282",
      "r283",
      "r285",
      "r286",
      "r288",
      "r290",
      "r293",
      "r294",
      "r297",
      "r300",
      "r307",
      "r475",
      "r634",
      "r635",
      "r636",
      "r637",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r672",
      "r693",
      "r716",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r987",
      "r1063",
      "r1064",
      "r1072"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "verboseLabel": "Exercise price per share (in Dollars per share)",
        "netLabel": "Warrants price (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r153",
      "r308"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of warrant",
        "verboseLabel": "Warrants to ordinary shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre funded warrant",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r77",
      "r597",
      "r671"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r262",
      "r263",
      "r751",
      "r1087",
      "r1092"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Share",
        "verboseLabel": "Ordinary Shares [Member]",
        "netLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r841",
      "r843",
      "r844",
      "r845",
      "r846",
      "r1068",
      "r1069",
      "r1071",
      "r1151",
      "r1218",
      "r1225"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Authorized (in Shares)",
        "verboseLabel": "Authorized, Ordinary shares",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r672"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Issued (in Shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Outstanding (in Shares)",
        "verboseLabel": "Issued and outstanding, Ordinary shares",
        "netLabel": "Total number of Ordinary Shares",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39",
      "r672",
      "r690",
      "r1225",
      "r1226"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, no par value: Authorized 100,000,000 ordinary shares as of December 31, 2025 and December 31, 2024; Issued and outstanding 35,949,247 ordinary shares as of December 31, 2025 and 24,252,096 shares as of December 31, 2024",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r283",
      "r289",
      "r599",
      "r821"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting power limitation description",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": "us-gaap_SellingAndMarketingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Compensation Expense, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r1015"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ContingentUponFutureSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ContingentUponFutureSales",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent upon future sales",
        "documentation": "The amount of contingent upon future sales.",
        "label": "Contingent Upon Future Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office maintenance",
        "label": "Cost, Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost of revenues",
        "terseLabel": "Cost of revenues",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r149",
      "r150",
      "r151",
      "r244",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r475",
      "r789",
      "r1096"
     ]
    },
    "iinn_CostOfRevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "CostOfRevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Revenues Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_CostOfRevenuesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "CostOfRevenuesTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COST OF REVENUES",
        "documentation": "Disclosure of cost of revenues.",
        "label": "Cost Of Revenues Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenues",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r156",
      "r157",
      "r277",
      "r295",
      "r510",
      "r531",
      "r594",
      "r771",
      "r773",
      "r774",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1146",
      "r1147",
      "r1148",
      "r1149"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r968"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r968"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r962"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]",
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r963"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Text Block]",
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r963"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r961"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r961"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r961"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r965"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r965"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r966"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Role of Management [Text Block]",
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r967"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]",
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r964"
     ]
    },
    "iinn_DEPOSITSDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DEPOSITSDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEPOSITS (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DEPOSITSDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DEPOSITSDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEPOSITS (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_December2024PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "December2024PrivatePlacementMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2024 Private Placement [Member]",
        "verboseLabel": "December2024 Private Placement Member",
        "label": "December2024 Private Placement Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_December2025OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "December2025OfferingMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 December Offering [Member]",
        "label": "December2025 Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DecemberPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DecemberPreFundedWarrantsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Pre-Funded Warrants [Member]",
        "label": "December Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DecemberPrivateOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DecemberPrivateOfferingMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Private Offering [Member]",
        "label": "December Private Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DecemberPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DecemberPrivatePlacementMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Private Placement [Member]",
        "label": "December Private Placement Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DecemberPrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DecemberPrivateWarrantsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Private Warrants [Member]",
        "label": "December Private Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DecemberStandbyEquityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DecemberStandbyEquityPurchaseAgreementMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Standby Equity Purchase Agreement [Member]",
        "label": "December Standby Equity Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DeductingOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DeductingOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deducting offering costs",
        "documentation": "Deducting offering costs.",
        "label": "Deducting Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r75",
      "r392"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering cost (in Dollars)",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "iinn_DeferredTaxAssetsAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DeferredTaxAssetsAccruedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "documentation": "Represents amount of deferred tax accrued expenses.",
        "label": "Deferred Tax Assets Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DeferredTaxAssetsFundRaisingCost2023": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DeferredTaxAssetsFundRaisingCost2023",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund raising costs",
        "documentation": "Fund raising costs.",
        "label": "Deferred Tax Assets Fund Raising Cost2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D temporary differences",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred taxes",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "iinn_DeferredTaxLiabilitiesOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease liability",
        "documentation": "Operating lease liability.",
        "label": "Deferred Tax Liabilities Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred accumulated losses",
        "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax",
        "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r321",
      "r323"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees monthly deposits rate",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r912"
     ]
    },
    "us-gaap_DepositLiabilitiesDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositLiabilitiesDisclosuresTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEPOSITS",
        "label": "Deposit Liabilities Disclosures [Text Block]",
        "documentation": "The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r74",
      "r101",
      "r102"
     ]
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit",
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_DepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r20",
      "r140",
      "r775",
      "r776",
      "r778",
      "r780"
     ]
    },
    "us-gaap_DepreciationNonproduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationNonproduction",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, Nonproduction",
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r20"
     ]
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liability [Member]",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability amount",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r425",
      "r447",
      "r448",
      "r461",
      "r469",
      "r470",
      "r471",
      "r655",
      "r656",
      "r657",
      "r658",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r685",
      "r687",
      "r688",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r770",
      "r772",
      "r773",
      "r774",
      "r1155",
      "r1156",
      "r1157",
      "r1219"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at fair value",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of private warrants",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and Pre-Funded Warrants",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r158",
      "r174",
      "r418",
      "r422",
      "r424",
      "r426",
      "r427",
      "r428",
      "r430",
      "r431"
     ]
    },
    "iinn_DescriptionOfFeePayments": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "DescriptionOfFeePayments",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of fee payments",
        "documentation": "Description of fee payments.",
        "label": "Description Of Fee Payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "verboseLabel": "Directors [Member]",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1220"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED PAYMENT",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r329",
      "r360",
      "r361",
      "r362",
      "r800"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r912"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r865",
      "r885"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r865",
      "r885",
      "r936"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r865",
      "r885",
      "r936"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per ordinary share, basic (in Dollars per share)",
        "verboseLabel": "Basic loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r136",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r175",
      "r177",
      "r180",
      "r181",
      "r182",
      "r184",
      "r281",
      "r363",
      "r410",
      "r413",
      "r445",
      "r446",
      "r586",
      "r610",
      "r783"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per ordinary share, diluted (in Dollars per share)",
        "verboseLabel": "Diluted loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r136",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r177",
      "r180",
      "r181",
      "r182",
      "r184",
      "r281",
      "r363",
      "r410",
      "r413",
      "r445",
      "r446",
      "r586",
      "r610",
      "r783"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r183"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate, percentage",
        "terseLabel": "Corporate tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r801"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IL statutory tax rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r152",
      "r382",
      "r401",
      "r801"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowances, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r801",
      "r1061",
      "r1066",
      "r1135"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r1061",
      "r1066",
      "r1135",
      "r1137"
     ]
    },
    "iinn_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of financial liabilities at fair value through profit or loss, percentage",
        "documentation": "Percentage of revaluation of financial liabilities at fair value through profit or loss.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Revaluation Of Financial Liabilities At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r1061",
      "r1066",
      "r1135",
      "r1137"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r1061",
      "r1066",
      "r1135",
      "r1136"
     ]
    },
    "iinn_EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revaluation of financial liabilities at fair value through profit or loss",
        "documentation": "Revaluation of financial liabilities at fair value through profit or loss.",
        "label": "Effective Income Tax Rate Revaluation Of Financial Liabilities At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableOtherCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees\u2019 salaries and related liabilities",
        "label": "Employee-related Liabilities",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r1185"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock [Member]",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127"
     ]
    },
    "iinn_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Directors [Member]",
        "label": "Employees And Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_EmployeesDirectorsAndSubcontractorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "EmployeesDirectorsAndSubcontractorsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees, Directors and Subcontractors [Member]",
        "label": "Employees Directors And Subcontractors Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees [Member]",
        "label": "Employees Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r103",
      "r104",
      "r105",
      "r132",
      "r133",
      "r134",
      "r159",
      "r160",
      "r161",
      "r163",
      "r170",
      "r172",
      "r174",
      "r186",
      "r245",
      "r246",
      "r258",
      "r280",
      "r309",
      "r363",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r494",
      "r496",
      "r504",
      "r608",
      "r623",
      "r624",
      "r625",
      "r642",
      "r716"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r889",
      "r905",
      "r940"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r886",
      "r902",
      "r937"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Officer [Member]",
        "label": "Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "iinn_ExecutivesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExecutivesAndDirectorsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executives and Directors [Member]",
        "label": "Executives And Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_Exercise6875Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "Exercise6875Member",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.875 [Member]",
        "label": "Exercise6875 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net",
        "documentation": "The amount of exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net.",
        "label": "Exercise Of December2024 Warrants And Prefunded Warrants Into Ordinary Shares Net"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net (in Shares)",
        "documentation": "Exercise of December 2024 warrants and pre-funded warrants into ordinary shares, net (in Shares)",
        "label": "Exercise Of December2024 Warrants And Prefunded Warrants Into Ordinary Shares Netin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of June 2024 pre-funded warrants into ordinary shares",
        "documentation": "The amount of exercise of june 2024 pre-funded warrants into ordinary shares.",
        "label": "Exercise Of June2024 Prefunded Warrants Into Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of June 2024 pre-funded warrants into ordinary shares (in Shares)",
        "documentation": "Number of exercise of June 2024 pre-funded warrants into ordinary shares.",
        "label": "Exercise Of June2024 Prefunded Warrants Into Ordinary Sharesin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePrice156Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExercisePrice156Member",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.56\t[Member]",
        "label": "Exercise Price156 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePrice55Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExercisePrice55Member",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.5 [Member]",
        "label": "Exercise Price55 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePriceOnePointOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExercisePriceOnePointOneMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.1 [Member]",
        "label": "Exercise Price One Point One Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePriceOnePointSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExercisePriceOnePointSixMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.6 [Member]",
        "label": "Exercise Price One Point Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "iinn_ExpirationOfFinancialLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ExpirationOfFinancialLiability",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expiration of financial liability",
        "documentation": "Amount of expiration of financial liability.",
        "label": "Expiration Of Financial Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FINACIALLIABILITIESATFAIRVALUEDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "FINACIALLIABILITIESATFAIRVALUEDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINACIAL LIABILITIES AT FAIR VALUE (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FINACIALLIABILITIESATFAIRVALUEDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "FINACIALLIABILITIESATFAIRVALUEDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINACIAL LIABILITIES AT FAIR VALUE (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "FINACIALLIABILITIESATFAIRVALUEScheduleofFinancialLiabilityDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINACIAL LIABILITIES AT FAIR VALUE - Schedule of Financial Liability (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the warrant (in Dollars)",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r462"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINACIAL LIABILITIES AT FAIR VALUE",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r456",
      "r458",
      "r459",
      "r460",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r584",
      "r809",
      "r813"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r462"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Evaluation of financial liability at fair value",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r765",
      "r819"
     ]
    },
    "iinn_FinanceIncomeAndExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "FinanceIncomeAndExpensesPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Income and Expenses",
        "documentation": "Disclosure of accounting policy for finance income and expenses.",
        "label": "Finance Income And Expenses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinancialExpensesDueToCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "FinancialExpensesDueToCommitmentFee",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial expenses due to commitment fee \u2013 Standby Equity Purchase Agreement (SEPA)",
        "verboseLabel": "Commitment fee amount of SEPA (in Dollars)",
        "documentation": "Financial expenses due to commitment fee.",
        "label": "Financial Expenses Due To Commitment Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r279",
      "r305",
      "r429",
      "r442",
      "r468",
      "r474",
      "r477",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r593",
      "r609",
      "r793",
      "r809",
      "r810",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r822",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1152",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liability fair value (in Dollars)",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1153",
      "r1154",
      "r1158",
      "r1160",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinancialLiabilityPlacementAgentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "FinancialLiabilityPlacementAgentFee",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "iinn_NonCashTransactions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liability- placement agent fee (Note 10-A)",
        "documentation": "Amount of financial liability placement agent fee.",
        "label": "Financial Liability Placement Agent Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transaction income",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r480",
      "r481",
      "r482",
      "r483",
      "r713"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign exchange (gain) loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r691",
      "r847",
      "r1165",
      "r1166",
      "r1224"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r909",
      "r944"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r909",
      "r944"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r909",
      "r944"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r909",
      "r944"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r909",
      "r944"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r896"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "iinn_FundraisingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "FundraisingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fundraising expenses",
        "documentation": "The amount of fundraising expenses.",
        "label": "Fundraising Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures [Member]",
        "verboseLabel": "Furniture and office equipment [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "GENERALANDADMINISTRATIVEEXPENSESScheduleofGeneralandAdministrativeExpensesDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL AND ADMINISTRATIVE EXPENSES - Schedule of General and Administrative Expenses (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_GENERALDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "GENERALDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_GENERALDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "GENERALDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GENERAL (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r695"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "iinn_GeneralAndAdministrativeExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "GeneralAndAdministrativeExpensesTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The entire disclosure for general and administrative expenses.",
        "label": "General And Administrative Expenses Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance expenses",
        "label": "General Insurance Expense",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grants",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r493"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r50",
      "r88",
      "r149",
      "r150",
      "r151",
      "r244",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r475",
      "r786",
      "r789",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1096"
     ]
    },
    "iinn_IIAParticipation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "IIAParticipation",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "IIA participation",
        "documentation": "The expenses of IIA participation.",
        "label": "IIAParticipation"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "IL",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israel [Member]",
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r865",
      "r885"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before tax",
        "terseLabel": "Loss before taxation",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r83",
      "r88",
      "r587",
      "r589",
      "r606",
      "r777",
      "r779",
      "r781",
      "r786",
      "r789",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r419",
      "r420",
      "r421",
      "r423",
      "r453",
      "r457",
      "r462",
      "r476",
      "r477",
      "r478",
      "r620",
      "r622",
      "r700",
      "r764",
      "r765",
      "r802",
      "r803",
      "r807",
      "r808",
      "r811",
      "r819",
      "r1140",
      "r1141",
      "r1189"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r152",
      "r378",
      "r382",
      "r387",
      "r388",
      "r389",
      "r390",
      "r396",
      "r402",
      "r404",
      "r405",
      "r406",
      "r592",
      "r629",
      "r638",
      "r801"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "negatedLabel": "Taxes on income",
        "terseLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r97",
      "r149",
      "r173",
      "r174",
      "r185",
      "r197",
      "r207",
      "r381",
      "r382",
      "r403",
      "r611",
      "r777",
      "r779",
      "r781",
      "r801"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r379",
      "r380",
      "r390",
      "r391",
      "r395",
      "r398",
      "r633"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r801",
      "r1135"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Theoretical tax credit at applicable statutory rate: 23%",
        "verboseLabel": "IL statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r801"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-allowable expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r1135"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r1135",
      "r1137"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r1135",
      "r1137"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofEffectiveTaxRateReconciliationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r1135",
      "r1136"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) increase in trade accounts payables",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase) decrease in inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInLeasingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInLeasingReceivables",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in right of use assets, net",
        "label": "Increase (Decrease) in Leasing Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments of lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r989",
      "r1058"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) increase in other accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "iinn_IncrementalBorrowingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "IncrementalBorrowingRate",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental borrowing rate",
        "documentation": "The percent of Incremental borrowing rate.",
        "label": "Incremental Borrowing Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r909",
      "r935",
      "r944",
      "r948",
      "r956"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r960"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r960"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r960"
     ]
    },
    "us-gaap_InterestBearingDepositsInBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestBearingDepositsInBanks",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Institutions",
        "label": "Interest-Bearing Deposits in Banks and Other Financial Institutions",
        "documentation": "For banks and other depository institutions (including Federal Reserve Banks, if applicable): Interest-bearing deposits in other financial institutions for relatively short periods of time including, for example, certificates of deposits, which are presented separately from cash on the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r78"
     ]
    },
    "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeDepositsWithFinancialInstitutions",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income from deposits",
        "label": "Interest Income, Deposits with Financial Institutions",
        "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r99",
      "r100"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r144",
      "r145"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r769",
      "r821"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r112",
      "r123",
      "r255",
      "r256",
      "r257",
      "r548",
      "r782"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "iinn_IssuanceOfOrdinarySharesAdvisorFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "IssuanceOfOrdinarySharesAdvisorFees",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares - advisor fees",
        "documentation": "Amount of issuance of ordinary shares advisor fees.",
        "label": "Issuance Of Ordinary Shares Advisor Fees"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_IssuanceOfOrdinarySharesCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "IssuanceOfOrdinarySharesCommitmentFee",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares - commitment fee (SEPA)",
        "documentation": "Issuance of ordinary shares commitment fee.",
        "label": "Issuance Of Ordinary Shares Commitment Fee"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_IssuanceOfOrdinarySharesCommitmentFeesinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "IssuanceOfOrdinarySharesCommitmentFeesinShares",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares- commitment fees (in Shares)",
        "documentation": "Issuance of ordinary shares- commitment fees (in Shares).",
        "label": "Issuance Of Ordinary Shares Commitment Feesin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation \u2013 placement agent warrants",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "iinn_IssueOfPrivateWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "IssueOfPrivateWarrantsShares",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of private warrants shares",
        "documentation": "Issue of private warrants shares.",
        "label": "Issue Of Private Warrants Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_JunePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "JunePlacementAgentWarrantsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June Placement Agent Warrants [Member]",
        "label": "June Placement Agent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_JunePreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "JunePreFundedWarrantsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June Pre-Funded Warrants [Member]",
        "label": "June Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_LEASELIABILITIESDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "LEASELIABILITIESDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE LIABILITIES (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_LEASELIABILITIESDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "LEASELIABILITIESDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE LIABILITIES (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary and related expenses",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r779",
      "r1015"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_LeaseMonthlyPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "LeaseMonthlyPayment",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease monthly payment",
        "documentation": "The amount of lease monthly payment.",
        "label": "Lease Monthly Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r503"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director fees",
        "verboseLabel": "Legal fee (in Dollars)",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1222",
      "r1223"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Right-of-Use Assets Over the Remaining Lease Periods",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1169"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payment",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r1062",
      "r1067",
      "r1184"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r1062",
      "r1067",
      "r1184"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r1062",
      "r1067",
      "r1184"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASE LIABILITIES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and Shareholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r79",
      "r601",
      "r821",
      "r836",
      "r837",
      "r1061",
      "r1065",
      "r1084",
      "r1164"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r111",
      "r149",
      "r150",
      "r151",
      "r244",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r415",
      "r416",
      "r417",
      "r475",
      "r821",
      "r1096",
      "r1174",
      "r1175"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non- current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r32",
      "r33",
      "r34",
      "r37",
      "r149",
      "r150",
      "r151",
      "r244",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r415",
      "r416",
      "r417",
      "r475",
      "r1096",
      "r1174",
      "r1175"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_MaterialsAndSubcontractorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "MaterialsAndSubcontractorsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Materials And Subcontractors [Member]",
        "label": "Materials And Subcontractors Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r264",
      "r265",
      "r266",
      "r267",
      "r325",
      "r355",
      "r356",
      "r357",
      "r374",
      "r451",
      "r547",
      "r619",
      "r621",
      "r628",
      "r663",
      "r664",
      "r724",
      "r726",
      "r728",
      "r729",
      "r738",
      "r746",
      "r747",
      "r749",
      "r750",
      "r761",
      "r762",
      "r792",
      "r795",
      "r799",
      "r802",
      "r804",
      "r805",
      "r812",
      "r813",
      "r817",
      "r818",
      "r832",
      "r1098",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Expected Dividend Rate [Member]",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Expected Term [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Price Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r812",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r449",
      "r450",
      "r451",
      "r802",
      "r804",
      "r805",
      "r812"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r802",
      "r804",
      "r805",
      "r812"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r264",
      "r265",
      "r266",
      "r267",
      "r325",
      "r355",
      "r356",
      "r357",
      "r374",
      "r451",
      "r547",
      "r619",
      "r621",
      "r628",
      "r663",
      "r664",
      "r724",
      "r726",
      "r728",
      "r729",
      "r738",
      "r746",
      "r747",
      "r749",
      "r750",
      "r761",
      "r762",
      "r792",
      "r795",
      "r799",
      "r802",
      "r804",
      "r805",
      "r812",
      "r813",
      "r817",
      "r832",
      "r1098",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "iinn_MonthlyDeductionFromTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "MonthlyDeductionFromTerminationFee",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly deduction from termination fee",
        "documentation": "Represent the value of monthly deduction from termination fee.",
        "label": "Monthly Deduction From Termination Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOW FROM INVESTING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r59"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOW FROM OPERATING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive and net loss",
        "verboseLabel": "Comprehensive and net loss",
        "netLabel": "Net loss",
        "negatedLabel": "Loss for the period (in Dollars)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r59",
      "r84",
      "r105",
      "r109",
      "r129",
      "r130",
      "r134",
      "r149",
      "r150",
      "r151",
      "r155",
      "r162",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r173",
      "r174",
      "r179",
      "r244",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r281",
      "r284",
      "r287",
      "r291",
      "r363",
      "r410",
      "r413",
      "r446",
      "r475",
      "r607",
      "r692",
      "r714",
      "r715",
      "r777",
      "r779",
      "r781",
      "r847",
      "r1096"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900",
      "r901"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_NonCashTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "NonCashTransactions",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non cash transactions",
        "documentation": "The total amount of non cash transactions.",
        "label": "Non Cash Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r909",
      "r935",
      "r944"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "iinn_NumberOfSharesPerUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "NumberOfSharesPerUnits",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares per units",
        "documentation": "Number of shares per units.",
        "label": "Number Of Shares Per Units"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_NumberofAdditionalOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "NumberofAdditionalOrdinaryShares",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares",
        "documentation": "Number of additional ordinary shares.",
        "label": "Numberof Additional Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OfficerMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer [Member]",
        "label": "Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r1220"
     ]
    },
    "iinn_OfficersAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "OfficersAndDirectorsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officers and Directors [Member]",
        "label": "Officers And Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": "us-gaap_SellingAndMarketingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary and related expenses",
        "verboseLabel": "Salary and related expenses \u2013 officers and directors",
        "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r777",
      "r781",
      "r786",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expenses",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Operating lease liabilities long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate - operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r820"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average of remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r820"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforward tax losses",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "iinn_OrdinarySharesNoParValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "OrdinarySharesNoParValueMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares, no par value",
        "label": "Ordinary Shares No Par Value Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_OrdinarySharesPurchasePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "OrdinarySharesPurchasePricePercentage",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares purchase price",
        "documentation": "The percent of ordinary shares purchase price.",
        "label": "Ordinary Shares Purchase Price Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_OrdinarySharesSEPAAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "OrdinarySharesSEPAAmount",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares SEPA amount",
        "documentation": "The amount of ordinary shares SEPA.",
        "label": "Ordinary Shares SEPAAmount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERAL"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r106",
      "r107",
      "r108",
      "r630",
      "r631"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableOtherCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r821"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total commitment amount (in Dollars)",
        "verboseLabel": "Remaining balance of commitment (in Dollars)",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1067",
      "r1184"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r1223"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLaborRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLaborRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Materials and related expenses",
        "label": "Other Labor-related Expenses",
        "documentation": "Amount of labor-related expenses classified as other."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL (INCOME) AND EXPENSES",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expenses (income), net",
        "negatedTerseLabel": "Total",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r806"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1085"
     ]
    },
    "iinn_OtherReceivableInConnectionToPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "OtherReceivableInConnectionToPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "iinn_NonCashTransactions",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivable in connection to December private placement",
        "documentation": "Amount of other receivable in connection to private placement.",
        "label": "Other Receivable In Connection To Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total funds received",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r679",
      "r790",
      "r836",
      "r837",
      "r1187"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_OtherSellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": "us-gaap_SellingAndMarketingExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Selling and Marketing Expense",
        "documentation": "Amount of selling and marketing expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "iinn_OthersAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "OthersAsset",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "documentation": "Amount of assets classified as other.",
        "label": "Others Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r891",
      "r907",
      "r942"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r894",
      "r910",
      "r945"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r894",
      "r910",
      "r945"
     ]
    },
    "iinn_PaidRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PaidRoyalties",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid royalties",
        "documentation": "The amount of paid royalties.",
        "label": "Paid Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment fee (in Dollars)",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in deposits, net",
        "label": "Payments for (Proceeds from) Investments",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent termination penalty",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, plant, and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "iinn_PayrollAndRelatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PayrollAndRelatedMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll And Related [Member]",
        "label": "Payroll And Related Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "iinn_PercentageForCarsLeaseAgreementCancellationPenalty": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PercentageForCarsLeaseAgreementCancellationPenalty",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage for car lease agreement cancellation penalty",
        "documentation": "Represent the description of percentage for car lease agreement cancellation penalty.",
        "label": "Percentage For Cars Lease Agreement Cancellation Penalty"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfApprovedBudget": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PercentageOfApprovedBudget",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of approved budget",
        "documentation": "Percentage of approved budget.",
        "label": "Percentage Of Approved Budget"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfCapitalGainTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PercentageOfCapitalGainTax",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of capital gain tax",
        "documentation": "Percentage of capital gain tax.",
        "label": "Percentage Of Capital Gain Tax"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfFutureLeasePaymentsDiscounted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PercentageOfFutureLeasePaymentsDiscounted",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future lease payments discounted",
        "documentation": "Percentage of future lease payments discounted.",
        "label": "Percentage Of Future Lease Payments Discounted"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfPayFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PercentageOfPayFees",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of pay fees",
        "documentation": "Percentage of pay fees.",
        "label": "Percentage Of Pay Fees"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement Agent Warrants [Member]",
        "label": "Placement Agent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "iinn_PreFundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PreFundedWarrants",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre funded warrants",
        "documentation": "Pre funded warrants.",
        "label": "Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "label": "Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PreFundedWarrantsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PreFundedWarrantsPerShare",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre funded warrants per share (in Dollars per share)",
        "documentation": "Pre funded warrants per share.",
        "label": "Pre Funded Warrants Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PrivateWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PrivateWarrants",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private warrants",
        "documentation": "Private warrants.",
        "label": "Private Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PrivateWarrantsExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PrivateWarrantsExerciseShares",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private warrants exercise shares",
        "documentation": "Private warrants exercise shares.",
        "label": "Private Warrants Exercise Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private warrants [Member]",
        "verboseLabel": "Private Warrants [Member]",
        "netLabel": "Private Warrants Member",
        "label": "Private Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds (in Dollars)",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (issuances pursuant to an at-the-market facility), net",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares, pre-funded warrants and ordinary warrants, net",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r11"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants and pre-funded warrants, net",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r549",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r766",
      "r776",
      "r779",
      "r781",
      "r796",
      "r797",
      "r831",
      "r832",
      "r833",
      "r835",
      "r838",
      "r988",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1093",
      "r1094",
      "r1188",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_ProductWarrantyLiquidationProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductWarrantyLiquidationProceedsPercentage",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of agreement warrants",
        "label": "Product Warranty, Liquidation Proceeds, Percentage",
        "documentation": "Percentage of proceeds from liquidation of asset held as collateral or by third party expected to cover maximum potential future payment for product warranty. Includes, but is not limited to, separately price extended warranty, product maintenance contract, and warranty obligation incurred in connection with agreed upon specification."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r549",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r766",
      "r776",
      "r779",
      "r781",
      "r796",
      "r797",
      "r831",
      "r832",
      "r833",
      "r835",
      "r838",
      "r988",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1093",
      "r1094",
      "r1188",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": "us-gaap_SellingAndMarketingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r789",
      "r847",
      "r1222",
      "r1223"
     ]
    },
    "iinn_ProjectBudgetAggregateAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ProjectBudgetAggregateAmount",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project budget aggregate amount",
        "documentation": "The amount of project budget aggregate amount.",
        "label": "Project Budget Aggregate Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r503"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r94",
      "r95",
      "r96"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cost, Beginning Balance",
        "periodEndLabel": "Cost, Ending Balance",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r114",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Net book value",
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r503",
      "r591",
      "r605",
      "r821"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r94",
      "r95",
      "r603"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/PROPERTYANDEQUIPMENTNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r503"
     ]
    },
    "us-gaap_ProvisionForOtherLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProvisionForOtherLosses",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital loss",
        "label": "Provision for Other Losses",
        "documentation": "Amount of expense related to other loss."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r53",
      "r82"
     ]
    },
    "iinn_PurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PurchasePricePerShare",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "documentation": "Purchase price per share.",
        "label": "Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PurchasePricePerUnit": {
     "xbrltype": "perUnitItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PurchasePricePerUnit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per unit (in Dollars per Share)",
        "documentation": "Purchase price per unit.",
        "label": "Purchase Price Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PurchaserMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "PurchaserMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchaser [Member]",
        "label": "Purchaser Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "iinn_RDEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "RDEquipmentMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D equipment [Member]",
        "label": "RDEquipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r264",
      "r265",
      "r266",
      "r267",
      "r320",
      "r325",
      "r355",
      "r356",
      "r357",
      "r362",
      "r374",
      "r451",
      "r521",
      "r530",
      "r547",
      "r619",
      "r621",
      "r628",
      "r663",
      "r664",
      "r724",
      "r726",
      "r728",
      "r729",
      "r738",
      "r746",
      "r747",
      "r749",
      "r750",
      "r761",
      "r762",
      "r792",
      "r795",
      "r799",
      "r802",
      "r804",
      "r805",
      "r812",
      "r813",
      "r817",
      "r818",
      "r832",
      "r841",
      "r1091",
      "r1098",
      "r1156",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r264",
      "r265",
      "r266",
      "r267",
      "r320",
      "r325",
      "r355",
      "r356",
      "r357",
      "r362",
      "r374",
      "r451",
      "r521",
      "r530",
      "r547",
      "r619",
      "r621",
      "r628",
      "r663",
      "r664",
      "r724",
      "r726",
      "r728",
      "r729",
      "r738",
      "r746",
      "r747",
      "r749",
      "r750",
      "r761",
      "r762",
      "r792",
      "r795",
      "r799",
      "r802",
      "r804",
      "r805",
      "r812",
      "r813",
      "r817",
      "r818",
      "r832",
      "r841",
      "r1091",
      "r1098",
      "r1156",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r886",
      "r902",
      "r937"
     ]
    },
    "iinn_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registered Direct Offering [Member]",
        "label": "Registered Direct Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r154",
      "r155",
      "r213",
      "r322",
      "r324",
      "r508",
      "r509",
      "r596",
      "r602",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r689",
      "r723",
      "r1221"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transactions",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r154",
      "r155",
      "r213",
      "r508",
      "r509",
      "r510",
      "r696",
      "r697",
      "r700"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r154",
      "r155",
      "r213",
      "r322",
      "r324",
      "r508",
      "r509",
      "r596",
      "r602",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r689",
      "r723",
      "r1173",
      "r1221"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTIES",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506",
      "r507",
      "r509",
      "r511",
      "r639",
      "r640",
      "r641",
      "r698",
      "r699",
      "r700",
      "r720",
      "r722"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r156",
      "r157",
      "r277",
      "r295",
      "r510",
      "r531",
      "r594",
      "r771",
      "r773",
      "r774",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1146",
      "r1147",
      "r1148",
      "r1149"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Expenses",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]",
        "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate."
       }
      }
     },
     "auth_ref": [
      "r1133",
      "r1134"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r764",
      "r777",
      "r778",
      "r789",
      "r1182"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/RESEARCHANDDEVELOPMENTEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r763"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r887",
      "r903",
      "r938"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r904",
      "r939"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r884",
      "r895",
      "r911",
      "r946"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1060",
      "r1183",
      "r1186"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows",
        "label": "Restricted Cash and Cash Equivalent, Current",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r113",
      "r146"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1060"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs [Member]",
        "verboseLabel": "Vested RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r159",
      "r160",
      "r161",
      "r163",
      "r170",
      "r172",
      "r174",
      "r245",
      "r246",
      "r258",
      "r280",
      "r363",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r432",
      "r434",
      "r435",
      "r437",
      "r444",
      "r494",
      "r496",
      "r623",
      "r625",
      "r642",
      "r1225"
     ]
    },
    "iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of financial liabilities at fair value through profit or loss, net",
        "documentation": "The amount of revaluation of financial liabilities at fair value through profit or loss.",
        "label": "Revaluation Of Financial Liabilities At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_RevenueAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "RevenueAchievementMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Achievement [Member]",
        "label": "Revenue Achievement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/REVENUES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUES",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r135",
      "r149",
      "r150",
      "r151",
      "r185",
      "r195",
      "r196",
      "r205",
      "r207",
      "r209",
      "r210",
      "r212",
      "r244",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r475",
      "r587",
      "r589",
      "r789",
      "r806",
      "r836",
      "r837",
      "r1096"
     ]
    },
    "iinn_RothCapitalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "RothCapitalPartnersLLCMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Roth Capital Partners, LLC [Member]",
        "verboseLabel": "Roth Capital Partners LLCMember",
        "label": "Roth Capital Partners LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_RoyaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "RoyaltiesPercentage",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalties",
        "documentation": "Percentage of royalties.",
        "label": "Royalties Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_RoyaltiesToIIAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "RoyaltiesToIIAMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties To IIA [Member]",
        "label": "Royalties To IIAMember"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "iinn_SHAREBASEDPAYMENTDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREBASEDPAYMENTDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED PAYMENT (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREBASEDPAYMENTDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREBASEDPAYMENTDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED PAYMENT (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREBASEDPAYMENTScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED PAYMENT - Schedule of Measure the Fair Value of the Option at Grant Date (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREBASEDPAYMENTScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED PAYMENT - Schedule of Options to Services Providers and Advisers Outstanding (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREBASEDPAYMENTScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED PAYMENT - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREHOLDERSEQUITYDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREHOLDERSEQUITYDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 EQUITY (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREHOLDERSEQUITYDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREHOLDERSEQUITYDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 EQUITY (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 EQUITY - Schedule of Share Capital (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SHAREHOLDERSEQUITYScheduleofShareCapitalDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS\u2019 EQUITY - Schedule of Share Capital (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SIGNIFICANTACCOUNTINGPOLICIESScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SUBSEQUENTEVENTSDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SUBSEQUENTEVENTSDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SUBSEQUENTEVENTSDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SUBSEQUENTEVENTSDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SaleOfRightsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SaleOfRightsValue",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of rights value (in Dollars)",
        "documentation": "Sale of rights value.",
        "label": "Sale Of Rights Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM aggregate offering price (in Dollars)",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds (in Dollars)",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares sold (in Shares)",
        "verboseLabel": "Sale of stock",
        "netLabel": "Ordinary shares",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "verboseLabel": "Ordinary shares price (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SalesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SalesAmount",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales",
        "documentation": "The amount of generated sales.",
        "label": "Sales Amount"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SalesAndMarketingExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SalesAndMarketingExpensesTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SALES AND MARKETING EXPENSES",
        "documentation": "Disclosure of sales and marketing expenses.",
        "label": "Sales And Marketing Expenses Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERACCOUNTSPAYABLETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Payable",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfCostOfRevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfCostOfRevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cost Of Revenues Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfCostOfRevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfCostOfRevenuesTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/COSTOFREVENUESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cost of Revenues",
        "documentation": "Tabular disclosure of cost of revenues.",
        "label": "Schedule Of Cost Of Revenues Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1138"
     ]
    },
    "iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets",
        "documentation": "Tabular disclosure of depreciation on straight-line method, over the estimated useful life of the assets.",
        "label": "Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Liability",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1145"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r801",
      "r1135"
     ]
    },
    "iinn_ScheduleOfEffectiveTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfEffectiveTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Effective Tax Rate Reconciliation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfFinancialIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfFinancialIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Income And Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfFinancialLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfFinancialLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of General And Administrative Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALANDADMINISTRATIVEEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of General and Administrative Expenses",
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "Schedule Of General And Administrative Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information About The Company SOutstanding Warrants Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/INVENTORYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r44",
      "r45",
      "r46"
     ]
    },
    "iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/LEASELIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities",
        "documentation": "Tabular disclosure of lessee operating leases.",
        "label": "Schedule Of Lessee Operating Leases Disclosure Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Measure The Fair Value Of The Option At Grant Date Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfMovementInWarrantsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfMovementInWarrantsOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Movement In Warrants Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Options To Services Providers And Advisers Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/OTHERCURRENTASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINANCIALINCOMEANDEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial (Income) and Expenses",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r503"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r154",
      "r155",
      "r508",
      "r509",
      "r510",
      "r696",
      "r697",
      "r700"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/RELATEDPARTIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shareholders and Other Related Parties\u2019 Benefits",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r1170",
      "r1171"
     ]
    },
    "iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsus To Services Providers And Advisers Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfSalesAndMarketingExpensesTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SALESANDMARKETINGEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Sales and Marketing Expenses",
        "documentation": "Tabular disclosure of sales and marketing expenses.",
        "label": "Schedule Of Sales And Marketing Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSUs to Services Providers and Advisers Outstanding",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information about the Company\u2019s Outstanding Warrants",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Options to Services Providers and Advisers Outstanding",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Measure the Fair Value of the Option at Grant Date",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Shareholders And Other Related Parties Benefits Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement in Warrants Outstanding",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "iinn_ScheduleOfTheoreticalTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfTheoreticalTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Theoretical Tax Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfTheoreticalTaxTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ScheduleOfTheoreticalTaxTableTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Theoretical Tax",
        "documentation": "Disclosure of theoretical tax.",
        "label": "Schedule Of Theoretical Tax Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SecondTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SecondTrancheMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Tranche [Member]",
        "label": "Second Tranche Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r210",
      "r211",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r587",
      "r588",
      "r589",
      "r590",
      "r657",
      "r659",
      "r661",
      "r725",
      "r727",
      "r730",
      "r739",
      "r746",
      "r748",
      "r749",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r767",
      "r784",
      "r796",
      "r798",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r834",
      "r841",
      "r1188",
      "r1190",
      "r1191",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r208",
      "r210",
      "r787",
      "r788",
      "r791"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      },
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Sales and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ServiceProvidersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ServiceProvidersMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Providers [Member]",
        "label": "Service Providers Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ServicesProvidersAndAdvisersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ServicesProvidersAndAdvisersMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services Providers and Advisers [Member]",
        "label": "Services Providers And Advisers Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SeverancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "SeverancePolicyTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance",
        "documentation": "Disclosure of accounting policy for severance.",
        "label": "Severance Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expenses",
        "verboseLabel": "Share based payment \u2013 officers and directors",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Exercised",
        "documentation": "Number of warrants, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Exercised",
        "documentation": "Weighted-average exercise price, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Exercised",
        "documentation": "Weighted average remaining contractual term, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Expired",
        "documentation": "Number of warrants, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Expired",
        "documentation": "Weighted-average exercise price, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Expired",
        "documentation": "Weighted average remaining contractual term, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Issued",
        "documentation": "Weighted average remaining contractual term, issued.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year",
        "periodEndLabel": "Outstanding at beginning of year",
        "terseLabel": "Outstanding at beginning of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs outstanding",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average exercise price",
        "periodEndLabel": "Weighted-average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Issued",
        "documentation": "Number of warrants, issued.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Issued",
        "documentation": "Per share or unit weighted-average fair value of other than option under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted-average Exercise Price Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1103"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual life",
        "documentation": "Contractual life of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Contractual Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Free risk rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Options exercisable (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price NIS, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Forfeited (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Granted (in Shares)",
        "verboseLabel": "Number of shares granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Exercised (in Shares)",
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Options Exercisedi"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, Outstanding at beginning of year (in Shares)",
        "periodEndLabel": "Number of options, Options outstanding (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average Exercise price NIS, Outstanding at beginning of year",
        "periodEndLabel": "Weighted average Exercise price NIS, Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to purchase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price NIS, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price NIS, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price NIS, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU\u2019s Vested",
        "documentation": "Number of RSUs vested under share based payment.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Number Of RSUs Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r333",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow": {
       "parentTag": "iinn_NonCashTransactions",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation- placement agent warrants against additional paid in capital (Note 11)",
        "documentation": "The amount of share based compensation-placement agent warrants against additional paid in capital.",
        "label": "Share Based Compensationplacement Agent Warrants Against Additional Paid In Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of vesting",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (vesting period)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercise shares",
        "verboseLabel": "Vested options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price (in Dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance as of (in Shares)",
        "periodEndLabel": "Balance as of (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed annual interest percentage",
        "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate",
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r1088",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r1088",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposits",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r1004"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "iinn_StandbyEquityPurchaseAgreementPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "StandbyEquityPurchaseAgreementPercentage",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby equity purchase agreement percentage",
        "documentation": "Standby Equity Purchase Agreement percentage.",
        "label": "Standby Equity Purchase Agreement Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_StandbyEquityPurchaseAgreementSEPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "StandbyEquityPurchaseAgreementSEPAMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby Equity Purchase Agreement SEPA [Member]",
        "label": "Standby Equity Purchase Agreement SEPAMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareCapitalTable",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r118",
      "r119",
      "r120",
      "r149",
      "r151",
      "r177",
      "r178",
      "r180",
      "r182",
      "r187",
      "r188",
      "r244",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r282",
      "r283",
      "r285",
      "r286",
      "r288",
      "r290",
      "r293",
      "r294",
      "r297",
      "r300",
      "r307",
      "r475",
      "r634",
      "r635",
      "r636",
      "r637",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r672",
      "r693",
      "r716",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r987",
      "r1063",
      "r1064",
      "r1072"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39",
      "r41",
      "r42",
      "r103",
      "r104",
      "r105",
      "r132",
      "r133",
      "r134",
      "r159",
      "r160",
      "r161",
      "r163",
      "r170",
      "r172",
      "r174",
      "r186",
      "r245",
      "r246",
      "r258",
      "r280",
      "r309",
      "r363",
      "r399",
      "r400",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r494",
      "r496",
      "r504",
      "r608",
      "r623",
      "r624",
      "r625",
      "r642",
      "r716"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r210",
      "r211",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r587",
      "r588",
      "r589",
      "r590",
      "r657",
      "r659",
      "r661",
      "r725",
      "r727",
      "r730",
      "r739",
      "r746",
      "r748",
      "r749",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r767",
      "r784",
      "r796",
      "r798",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r834",
      "r841",
      "r1188",
      "r1190",
      "r1191",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r186",
      "r282",
      "r283",
      "r285",
      "r288",
      "r496",
      "r549",
      "r632",
      "r643",
      "r654",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r694",
      "r695",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r716",
      "r779",
      "r781",
      "r842",
      "r1221"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r186",
      "r213",
      "r282",
      "r283",
      "r285",
      "r288",
      "r496",
      "r549",
      "r632",
      "r643",
      "r654",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r694",
      "r695",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r716",
      "r779",
      "r781",
      "r842",
      "r1221"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r890",
      "r906",
      "r941"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127"
     ]
    },
    "iinn_StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares- commitment fees",
        "documentation": "The amount of issuance of ordinary shares- commitment fees.",
        "label": "Stock Issued During Period Issuance Of Ordinary Shares Commitment Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares- advisor fees (in Shares)",
        "verboseLabel": "Ordinary shares issued for consulting service agreement",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares, net (in Shares)",
        "verboseLabel": "Issued shares",
        "netLabel": "",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r39",
      "r65",
      "r634",
      "r716",
      "r741"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (pursuant to an at-the-market facility) (in Shares)",
        "verboseLabel": "Issued an aggregate shares",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share unit (\u201cRSU\u201d) vesting (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r65"
     ]
    },
    "iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share-based payments (in Shares)",
        "documentation": "Number of shares exercise of share based payments.",
        "label": "Stock Issued During Period Shares Stock Options Exercise Of Share Based Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r39",
      "r65",
      "r339"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares- advisor fees",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares, net",
        "verboseLabel": "Ordinary shares value (in Dollars)",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r39",
      "r65",
      "r642",
      "r716",
      "r741",
      "r848"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (pursuant to an at-the-market facility)",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share unit (\u201cRSU\u201d) vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r39",
      "r65"
     ]
    },
    "iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share-based payments",
        "documentation": "Exercise of share based payments.",
        "label": "Stock Issued During Period Value Stock Options Exercise Of Share Based Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39",
      "r41",
      "r42",
      "r65"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r1144"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase (in Shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r39",
      "r65",
      "r637",
      "r716",
      "r743"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Shareholders\u2019 Equity",
        "periodStartLabel": "Balance as of",
        "periodEndLabel": "Balance as of",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r41",
      "r42",
      "r60",
      "r673",
      "r690",
      "r717",
      "r718",
      "r821",
      "r849",
      "r1061",
      "r1064",
      "r1065",
      "r1084",
      "r1164",
      "r1225"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 Equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r292",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r309",
      "r429",
      "r443",
      "r719",
      "r721",
      "r745"
     ]
    },
    "us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_Subcontractors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "Subcontractors",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subcontractors",
        "documentation": "Subcontractors.",
        "label": "Subcontractors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r513"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r513"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r513"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r514"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/GENERALDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_TAXESONINCOMEDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "TAXESONINCOMEDetailsLineItems",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_TAXESONINCOMEDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "TAXESONINCOMEDetailsTable",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/TAXESONINCOMEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized",
     "crdr": "debit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary differences and tax losses for which no Deferred Tax Asset is recognized",
        "documentation": "Temporary differences and tax losses for which no Deferred Tax Asset is recognized.",
        "label": "Temporary Differences And Tax Losses For Which No Deferred Tax Asset Is Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1172"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREBASEDPAYMENTDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r279",
      "r305",
      "r429",
      "r442",
      "r468",
      "r474",
      "r477",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r593",
      "r609",
      "r809",
      "r810",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r822",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1152",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Travel abroad",
        "label": "Travel and Entertainment Expense",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "iinn_TwoThousandTwentyFourAprilOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "TwoThousandTwentyFourAprilOfferingMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 April Offering [Member]",
        "label": "Two Thousand Twenty Four April Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_TwoThousandTwentyFourJuneOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "TwoThousandTwentyFourJuneOfferingMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 June Offering [Member]",
        "label": "Two Thousand Twenty Four June Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/DEPOSITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USD [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r189",
      "r191",
      "r192",
      "r193",
      "r587",
      "r589",
      "r785"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r843",
      "r844",
      "r845",
      "r846"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding (in Dollars)",
        "verboseLabel": "Exercise amount of warrants (in Dollars)",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expire, term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "iinn_WarrantsToPurchaseOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "WarrantsToPurchaseOrdinaryShares",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase ordinary shares",
        "documentation": "Warrants to purchase ordinary shares.",
        "label": "Warrants To Purchase Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_WarrantsToPurchaseOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "WarrantsToPurchaseOrdinarySharesMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase Ordinary Shares",
        "label": "Warrants To Purchase Ordinary Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_WarrantyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "WarrantyMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofCostofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warranty [Member]",
        "label": "Warranty Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r182"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ConsolidatedIncomeStatement",
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding basic (in Shares)",
        "verboseLabel": "Weighted average number of Ordinary Shares and pre-funded warrants",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r182"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "iinn_YorkvilleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://InspiraTechnologiesOXYB.H.N.Ltd/20251231",
     "localname": "YorkvilleMember",
     "presentation": [
      "http://InspiraTechnologiesOXYB.H.N.Ltd/role/FINACIALLIABILITIESATFAIRVALUEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yorkville [Member]",
        "label": "Yorkville Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477263/942-210-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "e",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>118
<FILENAME>0001185185-26-001072-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001185185-26-001072-xbrl.zip
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M$^]KS282F\8:-+,O2HHP^\AE2<7CD%:M=[<;6!438WA"9$3I)X%]5,7=@)I
M[FX68VJV$&?&1%/'*-;3Z\&QZP_Q[D:[&FF#266^,(N*+$>=BD,B;10;?+EF
ME;3=>HIM&KB (ZGVSO6!/C'&JJ%?:D1N<@L+F/"=BC\C:15SL]@NBZ$U-TFF
MA=K7T,;J7!U_UO ^B,1&>BFA^5CQ=N#V,/NR%NNIN)V5/T!FMCZ NUH->:%(
MW&,4X^[*.A7'1]::\B)N[^?89\5@7\T\ O,,]4J;# ?Q&!;X5?R%9S=V*AX.
M7%\9#I2XA5H5;K#+.E8G6F^D7I^7XXC57T66KHI/ S?3P.TH24/U3G@30[*O
M&H@%XXK'J?03W[[O5+P621-*TD8]<00GSL4Q\CL@,QW%F4JF0_E'_I)3]4UD
M;2AQ([4C4)0WJF5YD1O:[GSD.;8%RQRO\5_K I<8Q3C\>M-J5;9;#ZTI:7._
MH&- <8O*B_0C*=&V9N/&N4J&>>. 0#QC*2G/-]TA;RM[+T[FDO(B;KW.H=XZ
M'X/ 3FHAWBH'.5C9?)&R,UALXXSA/Y=U65H%@6/EWX0F6V6OE;7"X4_-'O$$
M#@*SV"4%YEAE"\9(YV"RLF:D8%H'34F2B_%MF,I&C9S?43-OURP! N,H1;C[
M:\BVRA:NDC-0<VR_N0,$_@E5X$_!RK:/GT10+XO[2"8@[1]HA006PTH<FYY:
M4.\6=HIO$QA'+"!D?'*CW36S]AKU)C!/J )7D5;S\;GA;[8>K9F[11B<P%[!
M*NR #^3O-O'P>H._S^ X:<7DE.5/VXVBY/6,W6.TG&+3,@L+[$ZJAP8XL?-Z
MA=TEAD[@(NEWO@5;/3-0BJC7RG0?X77:MH-0AKLDBL39Z\WBKO%VHLE**""R
MWZB>&2A%W^M)MKU5V@.A:3M$ZS/]24 -5APRJ9WY(FFD-C[V$\ EL4NH M^H
MK#IC>/%;%F]KUI)8:RW -'* -^L!. J6C=%X[B3T37N^""$N< ["A3<=W@(_
M7  M".TENH+G(@"SR.G;,U@7?E># (0!UGI%47B,#@3F?\4CQ),=6"*!JG@S
M)0]6@?]+X3807B4&_(N"("L0FY*!5F+4"H*-VD$_QL@YBJ<63^$K4D@:AUF0
M9X%5SUS0[DOA,;'F(NOF%!+CRK^)F%_50Q5I*_4DVVD-&$)UY7<C'UTHR5?H
MM-+<Z2:6U5-4R+@S)>E-1*76K&:R6G=OX1!X_IK%X5(A_K);/7'QD 54Y&?6
M=#UE=^+C*+[K>&VZ4W2[Y0I=<3@ (8NKS"K<R;M1NE"1YVG'"NQ9R;J&)4%8
M+ZQ[T-Q)ZG(P,M>(EUS=32POM "+9AR1='C:JY)T6[-^NV Z]6H9HGW,+RZ@
MW2MN+^9]-#5C]Y%S1N(FK0Q7>5>\8H24L]H_MH,:7J%W8VQW/D;. F]V$21^
M"[CB9;_U@1F OFW>V(Z-'BE@ZNGM&^0*0\6]5A6&DOY..U0PFH8W:T \J3&.
M%O6'$AB3D@-5VWD[25:9_XFW; R6)B0PD8$1\&UORA2HS=L16!<JSC:>))'D
M)W.F95@2(4K0U,O)_A-B28N+6 V!%(+#BEM-)"FV9O(N:N+$=DW7LDTGU;S,
M_3VM-&_I.*PXX 0X6]0 6=?9&E%[ O:3$4T,R%%+B6SW#JO978RLZ#H&M_7L
MQ6^5=,V5'9H.:]Y6RXFHXXIOCL'%XF3%_2E)A[6*WHW)Y]XM?HC$=K^:OF^Z
MT :+0O2X'WJ.DL5U@8I\6^VPXK\3EH*T?\5VE12!DH-0Z^\=/?+H<5$,QKSQ
MHA":PNCI4=-=Y_F<#CS;;;]Y2]QLC$-RFIJ(X.3P*!@0-O,32$G-HB1EXE7K
MFIUDJN\% =P^)>M%# QE5L QABSX"M V#$Q5N/,RYV 0+6^ [\V&/N2!Z:]Q
M+>1H&/G@)'*G8"HB?(_:I<@R5W%2"LLI@HYVF]EZEZ)7,'PLM2D!2D*!$I.
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M<*@PS%6AC6QW.#?1F19U.L7G>TQG9-I3*%SQA=XRC](>J63X+#U8*%@8L)7
MQ)--ZHE"@LN(ZA=R'PUP'QX[T+A*"9R&_OLP_?C$%C0-&G5GQ4MLE(HZ<;",
M/0"Z#E E74<H$Z4"*+F&&ZCD:XX\Q[;64A$J"I655PO0O=&P$0G)HV)[NA-
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M7+35U0INAL"T2.'S!148V&A*'*[)?P KC$MEXR"_LF#BIA&;J<Z'@7I^II%
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M@HG0/'^BG!!*9&9\:$(* VA#+4U,\O\#4$L#!!0    ( ):">EQO<_J_V!(
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MXN @? JPJ6P(\(:9WKPU>X-&5H8]P9:(2CJKJ 2:\4A::YTN0F4B!>=9HM&
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M3?ABO/PX+50E=B""T#.-30T$=&%<VLOAW<K;>\T:M1B[+.A&.HL@+<VRQ=S
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MW0MI_7[6(^;'ORK-?J]:_=&]46EZ)Z0%C.S ]$.-DWYD[BM?J?\'4$L#!!0
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MN)=))&D89SC+@ N57!Q@70+2*@:UCR(?2N2/U9'O\:S#B%*JA$MN@.0&8%>
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MYOM.A.\-"O9O5.BH&D8U)E9UJ9V*I Q=VS %!G(Y$2<=<>O%)(%GR^D^4<G
ML]T-.Y"=JI+>D$ROG/#S=8!0_AJZ[T=V+;_/5DD[%#E/L:8.XP I3&'D9[T_
MPF7@$PLC")-&/H].B/^XB*,PPG]WO'M&. #2$2[*&G1(H#5]0?M+$3\@\8%6
MM)5M&\)1 BB5X@D6M!-7^YB!S)&7[&4;_(N\H0.!XZD\MD*O=>MP L1"*[5
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M)\_(*:IJ7$]%>P'*1F5L%(OZ1)IZB@IJ!=-EHS-AIJ5D5&7(7)G>YQF*]XY
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MF*>QN3:FJP_&[';"\FP)JQ 7.3$WE^"0,I%5+A+\#C"!X92EV=0[P^3$<UP
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M5,JNR[F_-(/D-BB0I,,80FOR)'W='WU4+ 2 <RFY7,@"Z',.I<?A)" &7DA
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M[" 62A,LN1A@<Y;3_;&8IP)P6I2&&XZ)6D8AQQLP(SG; Z^=8#]MI^CED88
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M_]'[+?A]^]\O1NO5JU<#V)>X5#9?+*R<;DIYKG^^)B3OS! 1W?S_4$L#!!0
M   ( ):">EQHR6D(,L@  .T9"@ 5    :6EN;BTR,#(U,3(S,5]L86(N>&UL
M[+W_<^LVDCCX\WW^"ERF;BJILO/LEV1FDNS.E6S++]JS+:TD)YN:VDK1(B1S
M0I$:DO*SYJ\_ /Q. B  @@#MF:K=B9]-H!O=C49WH[OQ'__OZ]X'+S"*O3#X
MSR\NO[[X L!@$[I>L/O/+QY7YY/5]6SVQ?_[5P#^SW_\W^?GX!,,8.0DT 5/
M)W =[@^KC0?6D1/$VS#:@R^3_5?@'#PGR>&'#Q\^?_[\]09]$V^\",;A,=K
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MAG$YLL38Q_^^0YAE^.$!G,U!YLNV8F6-\#6!@0M+Z<<SAYO:-S[>>F&4#R2
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MYO5I-6^@QN3&JZCJ\+O?[L B:?GBG\Z/J@A1%J7:=V"RV41'6'1CSB]=A*Y
M6&.-UT@S$&%5NZ5?@]S2LI[E+\*(X@*#MU:E*['BPJU(65KD:<V3G<JU.6<>
M:]?F;)PZK\WS?+73>2O?F]R$I3U/+LXG5KM@2W"Q?=7:01W)?,JTV)Y:\'"H
MS5^\#;=SO"!.&#U6A(1/(SC#G4VT(2Y9Q-"6YC( DL(!3@$('! DG)*TR0KJ
M\DX_]K) ] M8V2A"+T_Z)'\BX4%G/9ZS]2:NAFRZ^NPVJG3J*+#B)=E71 IM
MI[]1.5+/<VNO2?7"@&3(%8G%:6%Y=N+KEX<.8!K%X_M4/ *X0[Z/RQ,0/DX,
M>2&#VE:=!7$1XU]5>@06K%POF EF.ND-/(2QE\2_>,ES80C,D"KSDB.YD1A(
MVXA"UQ?W$Y<V21R[U)5'I@%8)(";338.]24I C3U)D,CQ8(<LA<>PB"D;H<A
MM!\;F#WMQ\2)Z[F47BV.0N-1S9L"6^JPDZ$M=<BG@#9[O<Z7=9?MTHT:[89@
M'2*ST*X2&((+%^KAQUO'BT@/MO0F/&L / N*WW]"%C9N@'&I><=+ +9Q&(FC
MQXK$OZ"OTH+U< NV[8 &</ ]HA<!_"&T:2?)RT!5/"4II1+.0*+N1?7ZY4K8
M1"A$T3&%T0-& "%FQD0^B"%4-A\C$.%1Y=6!SN5K*R3&):%(;2[A!GHOI+A0
MNW4M %)7<8N,0=V-%K.;5U8(]V5>$H>+XT#D[9[)[>(1_<F)8SB2/$,9GO.K
MXA@4TEE"3,[SZV,4X6@6H>'@XD@!.09Q;*,E)XYIB>8FG2"31YL'J0RO!8HS
MVY31*8:X<B%  SP#ZK *:R"/04[R*@BQJH)GA:2YN?0AD?.R@2?;H00!=O)%
MK$F"'A57MV$$O5V0RNOFM(Z<(,8=2<,@M_T> P35]_ZI/<E:"K0%T9/!CR&)
MY0?XO74\6YG<\R6^ /EJ%!T6582@YD?(4JJ'P.8-Q=?A9/./HQ?!182]:W(%
MBQ1NX.+TG@/^1+.X2@"VX?6*H\?J.9/7J^.'2K*Q9_BN,TC.2-(9S">P>4[+
ML[^6F"E')-7FLAD4M"UJF:"DWI#R[((VT>0 M* _N['B/LB%C^P\^-_R5"Q*
M7C=7:1+70035+#1B;)8>SRRX#H, $M6[#A<1^FT"B]P4H6B+W(SF@R]2^''O
M.:-B$I*@44R#RP:0K07W3^BC0SICF?-A,U=)B=M%W$:><I+ZSX7>;U='Y(/#
M.$9S)\@$N"=4Y*B[&&Z^WH4O']#85-.A'TH%QY[18,X%$PF&=.7?@NQC\+?T
M\_^U$N'K9 J6#_X2S?5VX>)!NQ5JTMJ&:=*?PHH]6>J-.!["A9-&[6F;CJ7M
M^5.83COEH\/2YGDEV"HKM Y"<' L7LY(,*=4SMTK5[E^R;/MD(+/S/LZ( E1
M$9S*> Z[&%X,V<D'XS/_D#M #8&R)D)RS"M$28(@JAE1E5*VSA->Q:%ISV_^
M(806#D+JQZ9OS.1*U2&A+\O\$P=4/&A'?&,W4JPI*^Z@.K$O!G#&$VE27](<
M;_(A(%_:M5K[4_FRQT-MU)3T010='Y:%I],XZ'#K)/+Z!APH+&<!BZS\(9O(
M]@-G HRMOU3618X>@>PE3!SD#KA3)PJ\8$<UQ314D5*!F#]-Z8BP"PV/^Z./
MXT# A5MOXUF-.?,Y5:\O9:Y2-94WVCE!]@($\AOCT/=<\H])X"X0IR!R)1NI
M."OT&Q+#B6^\>..'\3&":_B:7/GZ^XMH1\]"+8WN-3"$^M/T8;J<W-G-(QY(
MFFHYKT.04_4L7WF[P$,*!-_NI/VR\?/%"*6-!^.A-H4@4!OM+,108YWTLT\/
ML]O9]>1A#2;7U_/'!](K=#&_FUW/IBO+!KD<JVMOC(D31:W!^FKS#-VC#^?;
MZON5<V2R1@Y.R[M#9\8]3)Y#=XX\I_4SG,:)M\?'WV,,MT?_SMNBL>CW:3[1
MFCQ%0!=>5IGOH!B8?]M]R.6PI#^#B>_'JU !\9A2N.<8,$@AGP$,&R3/$!30
M00H>8/AX'OS'23WWS<*UDA'Q+(N$!^>=4C!]$@1'QZ^BA/O+Q/.M8'X)J]6'
M_+2F@^[R*++,=C(1OK0O-P=N862GVV1/KI9]0]3(HVCO9QV+&GV*AC?DQ>&:
M?DM+&#->>^C)PPT@/TS_^W'V\^1N^K"VG70GS>E:R$N**.JYQUF9ZEWY]%@)
M8S#[61"H#?M9##56*OQT,5_-UBN;L0PYAC:>7A==NG))8SMW?K# !0>2^>@8
M!QO6K=/ZI^D27#\NEU/LC:U6TXI<62N.Y;.N51G+6;'B\5D:EQ0 '+>IO\\O
M#MC"F^["R GX/FGR7#:'7>]%G>LU]U^..GUZ,I!W/3TWJ__.( VAV>B 3)MN
M;%1X[YYZ+J6QH"V-QN582Z&QU]J_E]45="(OV.6-0V;!E1/\/E2S&08PBYVN
MZ!@Q.\F4C53LOBDOQ#Q:FQC.>E6#X?7NI\-H'SH,TXJ'BD5W#]OK:@];ZPUL
M.<J&O3YY/5/FAL?DS!,*:U6_-\7<)F!><K_5>"J%F/4D_ K^/=X1SJI9AX\-
M<4'9>3.8C1#K1'CX&3E*\^6OEH^#;J;5#X..A2J+3VGT%C R-6+(3>H :\'2
M$,5-P$>:M4K-K7I%8BRF^T0"M%#OJYA-?>L%7HP ?@I#5[]%2P5BW@FG(\+N
M14>^ 3O\D=W&&#PF4955>X'*_8"R&9?.YWL'4=AS_,'DHP;#M,%*Q8)EL#J?
MP3[_QG+DA<LAJG"T%MC',\[F_"6,?I\%I+XV'DP^ZD LZH\:(JRZ%O0-SKL]
M1.$.86.]>RJ/450Q:2]2M1B?=4L[O-TL!=IXKK<,=JQPW7*^F"[7OY+K57RS
MNKA'1O89>)BNK?:(4&!YX_DN.<KT:6?"@F5<*,<HBC(V=SX)*4$H9D#"6.L<
M,29Q5!/"WJ)'XA#789S0GQ]G1'QJ \R=?BW8K"P/](D=-C/)6<1\6N@/H2_R
M6I4!7JOM C@>?5'@Q,I0R_\^4HW08J*01JBO6E4C/ ;D7]#-1?4;(;U &68\
M';B- X/_5A\J8Q.XT!2,A:@EM)9%5-7D12FEWS6'T=!_!S)"M63E,(LYJ6*,
MJ3Y<U[ENM;J$EKA]J[;EOQW!EO_V36SY;[NW_+?J6QZ9NE=A^#MI'"*USZD#
M3>>ATY!@,!5]"I[0MVF/EQ_L[64>Q0L6,Q>FTM&E:DQ>2%ON%^9W:@V\F/5N
MU7R_:/&OO8(A#F0Q9G9.8M@UZ\)'^50>V['<%@NAI:M:XS2=(28A])%&+34J
M"K*J?!2ZO,UU]MJ4[^*SHM-XX9SPY2IR[;*WBJFY]D,%!E6QL'!3KX@J-Y4^
M*VA>@<7DU\G5W=1JGDA/B:CU,.E!*^6J^R)[H W+4'I))V";6?A=R EGX>?,
M!1EWQY%N(LIT>L*)$'$4+P/;<^?9_H'[@)8X2$JL(% ;B71BJ+%M.#R8DJQO
M2V=*\+:A(D6IH'S&3_<'/SQ!N(3$8#0K@9+ 32>_R*''>E\MFR3^XQ_^\O'R
MSS^"V/$=_$(*N0^,TJF+U]8\:/W1#36)J,JM MT4T\,;1L0ZS$ NG"AI/4+$
M]ERY<YB.)?.0898*I%)T2+^RZZR*,*3JJW:NMU_5KI6C50:RC?-5 C]>-<,(
MGKU5/UUE:: LAK@-J)>^J8%;(X2DC1,,-D:\9TG@QIMH2*''BM+.[^]G:YSB
MM4H;:LQ) [#I0[/[EZU.L?+<;[:1E:21>N[J'8QC".?YN]#X[<KA&FIT +,0
MP>%CQ)"_N^ED-05WL\G5[&ZVKLF<!8$3XV!5P 06K72Q4/K.5 @5X>W3.$YN
M;M.7AXIXBD1:\IG DK1X"[?GCS',&A\0YZ+\@@ #=_:=#!UR0>G8)D];U6X)
M-1"_0$QYZ$Y>T&]WR-_9.UZ0_W$-H[WN%^ZEP5LQ+B619)4*9 .!DX[$,A_E
MHX%/)!KALK=LA"H*1,T252&8NE?$@X;W#';(<"NY!422H=\UD@4_.A&F(-DA
MPN>Y"+O94-)^$)R#L-#01)XM]Q51% QA46813EF4:6H_/^1.]TYRC-!_![W8
M4<' M(^E@*. ^4$S.HK&LH72RBP/Q&VO6B]JR1?K(2]=]K((0?5Z907$_"G/
MFR-\0/#6GZ'_ N^1F_BL.^=>&8U1B3P'48;<(T+\:=2R*R "P@+<19[AI?A7
MZ$3KSZ$EX<VAF[^(E\20+:Q_MGG?KLAE%?FL$D+1H;MUO/1!0P/]8_FPC%<K
M<=%A]7^8/4RN9Y.[:K0+3-;@=C);@I\G=X]3N^Z8$#NKHM9-A!Y%<=66\N0=
M8^\%5H(PDZ2 ;BC[2!(-T\>V*J("YFKQIDL1!3M9=;;ZB@8]1TF!;.K'.7G8
M[CGT7<167/.7G!["! Y_I24.U[C\BF+&$MB?)LOI3_.[F^ERE:>+X/8%:[O=
MP:0971-.*9KTD,9B$[0A&M*NG8!MYG9V(2>@0],7%5M/)EK5GJ+,INM+(:+T
M;OE-WP+Y<\CSB(12AGOU2QF/<8DK%U<!Z;T/7\A;;KC]4/&\]OR8Q(D3N,C+
M&$>.LJ*LB(IW-Q%5:O^(8KA"3II['>YQTFU:<(3![ C-KT[E)YG_-OGL1&Z*
M%.Z*'!V)4T>2<M;/3C _D,X!%?ZP[D5P0@0N=CDZ/KX=B><!K.\@U@WRV) V
MY@".<OFBMX#E%>"FG(1<!((OT<X^02>*O[)[O3TRRK;OS4>&8)\,X%:9^G="
MFY\RS'ZK@._>1*N [UKRQ%B(6L[08+*9'WNS.#Y"U_(1T4#FO:C^^K)8E;5'
M_/@T-LGRS\] .L!>OP338F= %U-XH:AC!\2QD2 Q?871QHOA(O(V<!P;50!#
MXSF%-E<KFNH"LZ'@@,>V=O@[VN#B,FQBUPMR<%QN7HJ8J,EH625((FNT?FPL
MJ];JS;7-@W?EU:D)OP%=HL!RQ7?H!UM"KO[<69#FH%G6'6U\#/=%,K@T"?._
M&&NQ=-6"$!K8PW2NJ'9_,H!G0]U\PA)RXR2PN,,>RP[N1O3];>W.-:MZ!VT%
M\ ZWO[!HF]0+8BQ].PICK%Z#/+[O)2@HO7+-SL._HFX9@_N@QO?1Q2BGKP<O
M&I$#4<?F_<0>&RN3\A[(2)N->HV+GY']VV;(N,*&&8;C=QD$T7QWFWE ?Z&Q
MY=_=AA^7LR#!S;>@(L;K),AA^XXB#%(+U^XA_(MIDW&X!_(L[U.+-::D-]TI
MWJ-:F_&JFS&M_EVDL8Z2LM14]S$AJ*^ B;HJ\MMX<DR>P\C[)W0? Q=&),,_
M11D_OQ=?G6H)'TM,!P.%)4,A;*/WS_#+$BA6F07;,-H3>,!Y"H\)::N"T7""
M4U8:6*M>*<(A=NNOS0DQH^)E2)8I]RDB\)^4L&KCE/T&UZDU<KXFE)0OW1WH
MK"[%>(L$FZME]9//(R'D*V(LW(2^C\P%<( 1B#%N7UFM91N!L+=L!)L\U.ZT
M*.*>AL[GV\JID:W!B#NB'VLKUH&9M;'<B+QN-:34K8[(11A,0KN-_V%8T>_H
M5_)0<'B$?(Q#K*,)&-2Q>CNN?@UOYM&:?P1<])7U0U2?V.CQF=LTU.'M3IT(
M>]/Q FW3#*ZWF03NC><?T;EJJ'>''!86.M,KHBK@:]Z%<8P[=!;]/?Q-]@+J
M8XP]2^QY%O&KS,P!Y3W\/$+*THE.Z?"T\_@B@N>W1Z1Y79I?:M<Q59(WNK<I
MSPG5EPN7\ 4&1WB+UI2'G7[QDN?K8YR$>Q@-M3^$P5K8$**XL=Y,FOX\?7BL
MO0]B02QE^5J50RD"*!5CXP>FY]L,#JM!#>=U;]I8*^]\4Q!AOB6S6H/Y+6B)
MAXVGOSFTKST"SEI>SU<[&E/W>:2#.Y5QD1##2^#HQ,-),^QL IOE*U)LH[RA
MT4D*];,KAF@5SS=H:C\\$'LR(,8G.B2C5;A-D'5IH&^@.A[F&V$IX\H\[5;3
MR?+Z)_(^U@W2;7?S!7XP"TS_9S%]6-E_)JNWD-1/QC[44^SWE@/%]E\%;NE7
MY8?T.D3V(K[>N0TC<NTX6.LW+2C9B++I0%SD#8,,#/%9*H!P0E#SZ6"+>T*'
M1-&V1V_JJC_<X3R%$0*?O?:9D5NS]#. 6.CK3D6$)9_X>>!3[7'@D3QDS6=:
MK7\[>\&J#Z3[Y._0I4>O,@@/$%DP:^=5LR!) C<=%)5#CR5V)/9#KLG (0WZ
MV38)U'A>>T!=GC+J$4VB((GDU\5>]^T:&XZ%( P3&8:8W:-O(L_QXTX%9^U%
M81X+6^\',Y>NZBS=P$,$-QZ1SX<P.$2A>]S@?VB6(C8<"U+$1(8A1=7OK?:A
M[N1656#XJU2+U1R?\O31,!(L7J@/,5QD7 /..HIJ']EM^D.E;QD\:2^GY_E!
M-\V'L8\% !I/N.K&2? ]>FO'AQ '6^=(]Y)5.S!\@@&,'!]-/''W7N#A#JWX
M@9#\M)*+Z(K/9K3MF3!:#.GY-'V8+B=W)#HVN;F?/<Q6Z^5D/?MY2@N0F=9"
MTBPL%)0<712;=Q41Y$YH?6X0)"<WVW5/$4N!$%4V(3&7ZU/2@E0VKQW4N$^Y
MB%"@H7(@:A&%6QC'R AS_%NHW5=K36\Z-M!$@"%QU<_ %MH.?+*X4CTVJ2M3
MM[[$0@56 DM6(O!BJ/&"2>=I,&E3&6755Y/CL'P8J:6(M##J!49/H2Y675!X
M529RA6F^ZQFHLB^+!18AFFK!@=4R Q/LO- 9#/D^96@ $SW,O.S8>&*<>[=;
M\;+'89!9(+,@/D8.6LTPVI\%Q8:Z9^#"T._%9^W(K05IZN!657QXRU2_S(2[
M08S'<E[C89@"-"L ZT40Q[P:MJ*5UZ9W;!NQOHP!]I7 Z5S#@78 DP\P(5D*
M>MQDO5"]TL7Y9O>.%R00O\RK6[DV9[=PJ]% @16XW&YQ'>>^_-#NV<Q@2Y7_
MM(6IWG>M(^<%8E]_BJ:+$C3K< %O/BSC2I:+#D-:TC' >8I"QTZ_(BG&5:6F
M>[FJ(6Y<:1(Y'BY6H=^Y,X*+M'%F[\,H&# 87_G2JM'51? BGL=:6L\+LH[@
MX!!79%T@3<?T1)#BW9+9-=ADN-BZ)A-9M6H#8<>',9KXWHE^ATE%:B4O++JG
M,7SEWHD0*X@WN9NNR(W8_63Y_TW7LX=/U&QQXS<.PHPJ[Q;$:* J.67W&2:<
M/C=?HK,:EBM9_$0>F,<SD:NN8J[V+9>]&RY)]E*NMF1(I7Y04B)BT]>-?W1)
MTS)<Y?,I#%V$Q@I&+\CY6(6^J_G@5$+!?&:V"IJJ=QY6?#EU0:@[?(ID4@P-
MI#YQ%%?AZK;L:"!L)-!2\.A3&6##HN-PJV;!L9:J^^ 2B,JQ<*$%Z#AT!Z05
MW^6/Z/!*YR-?N5ETU&I4O"]7+M0#XL147T$?_6U'.>R&\-$XT*RX9VQ\A/(7
M;?EEW4QKN60=*^WI[C^$07B V,D+=K, G:L0!Y#2^8>JFI0 ;-YB$4>.%4B:
M/4P>KF>3._#E[.%Z?C_]BOAX=M,<U7G>DD=QVB@:)Z4USX"7 S/3N$@*"?,-
M-)7P%' 5;SU\]^ Y/A)C,M%7Y.AMYT1:[36D(B'T5D/2Y%,-IB_AB^,?B1DP
MWQ94OO.<)\_W$@^YKTGQWL?Z.0J/NV><BN<E\P@WDA**;?2%8;QA2$^$64T9
MREFQ2&\+D?;+B8&3@"V:&N!/(4C2R<&!S [""/AH_C,0P,1B@KHFF2D")CK(
MK7HA>1M&T-L%U\<H@L'FM(X<9!23,JU/CA?@Z:_@%GVCO\Q8!K*-'"$)_%BV
M1SH#V&13@*2< WA$H=FU/Q287U77LA3JYV&ATV#CQ,^U@V @4[@-QU:M,0T9
ML<LNB^8LDTTTZY6^/%5UELZ$!&[X_DI<4#84%@\A5G[%Y'^F*S!_ *EO9%<;
MB?"N*D&=ZU7O8ES8H3=P"Y%V<Q&421S#!-]F5 YF0TZ/'!96N[5*H2K@^.3S
M 30A2&<DGD]ESI$X/TJB0O=^Y(FH5$[?!O,4D^IN(:^&/=KTNYY,3)C]%#*9
M2I!,.63$#_8>P^OD0N$G\->I&-]I33K/76YLP%T[471"-AQNB*T[X5L&LHWS
M5 (_UNO-$/FL^2#BNH)-99CEI&<%SM?[>\B11ZW<NBWSFTUT9'4;$E95C4D,
M/RS:A0]#G+*OK/</DF(,1WM1%MWC\9C6_+-@$84;&,?T;A-#:[,N\*-0:1U(
MLB)Y?W3VAQ]O0 +WAS#"M\6NMT4S0R0R=LTQ52'@*C81(FG2;CB->)FF$>-,
M$R1EWZAI.-I$1IM$B&#$2?X&>?;W!GUK+QM.AD%L3<=:NK*#6H%0#1-3S7>=
MFHT&S$H#-1Y&(E9_Y<KA!UO'J!PS&1J*M?Z>O?#7SS",8.)M'!\!Z97/RYW*
M8B]\'EX"@8G*<!R;L/B8NA33*%FZG83H'8Q=0KP()*;DCJOX=6;Y7<$ ;KUD
MDMQ"%Y<[K!(G.:)93^5X_4^"Z<7-?&*,5OQ9T>&*B&.EN4$JQTOP%:US./CH
MUTA20)S/B$[L!/X /G[S_XPDC*Q3ZJAQ9VVDUVR8"22$:E\#+9-T=E>1#BQ
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M8CABM4$ZXN<0J0I\RW :()O/!,;F&] .ORC&9LT_!B_%UW:OT0U*9&U3&N)
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MD3@U[BQ)+/Y/4:L>P=[AQ<'0RE6#_G6P:D>/^R<8X7T6ID//TNL$Y*9]Z06
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M<"R%C@63]]_]Z?^R>ODH0'0ZR^M+4PV84:4(_;>O#BBG&(4.*-!ARL'E>'5
MBQU\'5!?JXH.N$>>0N0Y?CP)W-7Q:9,]9QQ&,J&+SDD,ZX4N?)A!]&P80.-
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MZ<XX1CAFL9L3^G$2N.1C].,:[5F'\N#Z8#>P"BC9WL!:5M'S!A?OQ +B&:C
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MZ%_2L6\R,5E$TK1D)G=263ERTW&C@\#8NQEL #?N#$JAQXR;A''<F9PXPLM
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MW73=+2$"^9799(?^1T4.>!.8%P8.-BR)*.Y R9AQB84 =TK9Z%J[DH#\US&
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MP&>EY>=?C<,F91"Z3+ZG+$KQ]D&DJV!O:X/7*M:HP2'5:U"D-ZP-HZ.[99W
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M&3U6^+(RU1__\)>/EW_^$:13-K1@6F*=-[QGFPK&PXT]9* ,$ZH25/E95SF
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M8-$(#3Z#^?FGHVKHSR-\<7XP%ZE2,]&83,Y\8 XV9BNR,)!@.M5\L,QXMO'
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M_AP<LN^_MNCQT%? )C=EH9HO\L2)/M]N882T.'EEM9OH8?8YHCOZ?A1$KZV
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M:?)'NFR+\$4UI%@$LBIB=EHWE/WF]=5\3LN'AH;TMRT2^BML1&@KX:8V+KH
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M(7W 9[987^-G7&QQK</%&6]B!;65.@?)OZ('U(\BF0!@JXM&_5H=P)HO(_!
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MI%@HWV@1'82>J5BL;W;4L\D4N0Q<T0X05@ O(KHR))JXA!*'6IK;NR7W3@Y
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MO;:3+58_A!>F!=Z'JQ%/GHH^7,+D6&GI0*AEVH*7STZY;!8J3.OB)#AVA(H
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M/.[ 2Z$Q[B"0+]&,-\Q@5]-:JZ#>TA2$Y[PF/_H<):PEDDW1G"9IL,:&,Y3
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M80"\ @7J@!I'P%I:X0?R?$A+_25N(!NH!F <7,^A2H>CWH<*-,$,2)TNN_A
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MAV[@CQRRK+]ODH6M'Y6W#@GO:"NI;LN!,)ZD#ZC;3$1+=N=UC>-7&;O$B.Q
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MBQ)"G3U5:\I1@Q7RD>X9>TRQ,09GNY%K,GE\0(X/M1L6&!)\AS@CV<90-?.
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M2F&6(SD2J$WH37MC:E6],<%M6QTLI<%G+FM72S$H+TY(M>)>H!JE%RBTNC5
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MLL, _$F9!J4?&B?$O3.ATO"^DJ3FRN%8BVWI052&,O+!'HZ?S4G3E/\ [SN
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MFG8L5XOE9+7YA.\WY&ZSO,6Z,I_4W&Z$JU.JR^/G2-YQPP!2T'NCKBU?E;A
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M*_WK+;X*>I9N2^->#H;*@TF4=7DB*?7JSCA]=+W/4P??WPWD2^-<'L@P]:Y
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M\1 UJIR[SA'Y 3+C(%5?3C=NO%5/=P#S*T DEI_ML.UI>RKCA6*I&V(UQGJ
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MDP%)=//$0??")TH.<!9:%[>FHFGPRCWI-IDIO7&G4XV#R)4?*@ILL!"[>J/
M?6P'XVB(NMFJALSGO&#PV&UV;57&N=W%)Q^CS=&J1=Z!&^AV_FVVRYO["J^(
MZ;;7'7.,-V.[#^0A</)(7@R;;O(B,I;"TZK@27K98H,I_#*.F>=ZE[,\61=X
M#Q0@:O.]N9B9U1X:R>#2=T08J=G1OR.S^NT\P7*.L.)O]$=@!G,"5QD)%68[
M+X'!KB,BTA#U@X@$-2^ET"_5=#B*7["$V5Q#.14395*TQ@A#-*R(A'/7>8A]
M6?P78(;2X0R5H3644S*#)1>[8(O_YS]1FG?+S8;B?I7,!<'WN:7N!99A/>AE
MI:&0O?31H(ZM\I8%JI(HV3;")U+M+F0<3?4 AZ5)/)0$G.D ?U/J\H8T4!ZS
ML5=D=D'AQM[YG?T&.<C3;7QEU\R#Y5B$!H%U1&RW=M'7]P2J1H,J^![/O"S_
ML\+-9#Y9:3-M/M;&M]/Y=+U9:9OIA\GDC^5DOL[&?YHHROV,+PDTY\$!CD4I
M)-8M$6:Y? &E&0.\VD LDRQY5-<D*TZ(6F/:1R4%,_++A OPA=)UD-0$P>1:
ME^Q)5DME=<QO4 $I1=-L,-5&11F4(LM=1C)"AT:?E*;(/.A F@\(*=C2<[?(
M]S&#=/L:@0<>2\NKN)S+=U&RNE:F*'#O AD/#DH>&I0]T78K$*P<4)08]7R?
M&+L5@X;W2(!\K!8.UM3Q0T]W#"2'[30HS\, 4&FLJ"7<62+13LJA?UE7252O
M8[6^$!'LS420GR1?Z%:WG  Y1,PD9%=E5U<4'NF6NR620O6,:_NX+/$]^5F<
MQGE:PKW#B/!UX^E'1"[G$RQG'L;=D?<*4P_K&=CK!F(#CIOFD@72 <33+=(Z
MI#H'B!+_KOKN"7.QDDQ0<Y'%'\P;XFLRGLR;0#[]0 L;Y94,)&:,NW8;N%::
M&,.C)AR1:[BL^([?U]>Z'35_NM6]SRC(F#/X=/@ULO&/=UH9F*1<> : XN4C
MI<#9Y-&P0S.:E$;*)6Y<U[S4=*[=BT#"=0CB1T%QSW1F"2BT"!*@-6!W3+'S
M>+O%N'A^%GOH\[<*A.I>VD(LKB:6VB:0S^%%JAW7J"],$#6]PCXP?2\RW-\:
M:,-C:"/]% >*.V/MD^(J T-%0L7%S-".'==KBT1"+?*<05)0L O+F!(JEA%:
M *==P GF@C(LR.N<KM!1M\.(R)GU9Y9^;]D6J537@O,\[,W><\/=GIAP*UAX
MY:ZDM"K]EC!4O;2)<#*J\F]+4]5^Z+7K(6OGC$(,US%.&T_'_E54T'2C6P[!
M\0IM\>_ 5WGR0!Z:6 A15ZT_&QWN<]<Q='\?[U&B6U0)1WDBLQB/:PBGJH=-
M$37W 9%PE+/K@K$48(HOGHWB7<52&MU:=YK>J&P'/TX0QD9'\WT4D/A>YL0"
M](^R(1K7P=OP%V7H6@ZZI%B?" ;"S]^%Y1>I%!%[/](][X1-/ADO !TSX(&L
MNCMP"Y'(OX]S$%M-2XWR[@S#"VD]%"A^=>,B:B.W+;G93"+%2:<E!*<.=N,-
MY/O5I96R%;L)_%/5[D:RJ\E2+>%)WO]7\?L_>8+ #/U>3,VK%E(98H)6]$I"
MP841!9F8V<7E/$$Z7CKYAQ,O-QE65.P@PW&6A7H"@47862VE+=YX\)-W*$ &
M?58W$;!%YFD^9 S"U0]I=(Y4MWR5D&[, G'8FLU%6X$,59I>M^%_?%_/VR))
MC*\$]<3\KVIRPK4- 5'U#&YS)-T#+T ;L$_&3- 6^:LJ4]@V>^1Z*+ ,W<9;
MDS60)0]%\-&/LHBPCER&]%QCB1FY#G;%PFB.*HK'6B;/#V?]1O[D$<-TD]F/
M44XK"9J2EFMN]$P\)>GHR(?6+YF8JM!-5L$H][:0Q"W%TZ#/.*\01L_ 9B7:
MT?G'2:3G"CEH:P5:<(U,DD]+.D>$>-73Y7OXP;FPN*EQ[L7E#8PG@"$Z2!'#
M"H%M.^G1B0V_G)<O'LCJ7[);"T@U156TL]T@[/EXV/2-K2T&B/ 5A#@\Q%'%
M5A3YUZ[W<6\9^[E;=&ZF/MG3SB'SR)D.:2!0RM^XF[D/153 9,!V]B!OQV3I
M?@'*(/6\2"FH2O&./?X)EEN#5-\D9U/>?,%5KEQH70]1\#; N"C\D?GBE8$K
M(Y^ R/?2!.X!Y8FY(B)W)D0.KP(Y.A4T"(R&*UX@_(!R_26[_=6-K<B[H[H+
M00U.B@?!@ILL7I:H[3C%HAA*A4P"@D_;C G*7Z?S/&C[D%^Y(0>R\OLNOTA)
M8@%DQ@.$1#5IADJ9DXW;X$Y694R$ZB/605 W2MI7Y\C%X-6'?3IQVQ):@_4C
MZ])!DR$G[7!1^T#9O=.5EY[.>Y@UR/MHKSL[O*7N<\D $!JJ*$'P JR_FL0;
MHSKA@L9N<#Z4-#:!M6Z#M&*1C=7,OT(_()41<F;0-$,=K)0PDS6-?:K*K&$1
M9\G"((3"TXXUT>5$S03GY_X8#F (*(_C;T7BTP#YS]526)4UV(FV5P)^:CI>
M3=U4$$0"Q:62ER[S)&Z1[H<>PJ;J' 1RM_AOBP<"1 ]N/-T)QGC?4EHF)= W
M&>A1TDH,7;M %TR?X%^?U[BN?]56DRMM/1DOM4^WD_E&@+3<XS3!@?*['H H
MS+BF:$H!K-A%%5:#:!PZN 1"S%#DD27?"_Y<D<L6ZZ!,_$'FE,)_NYQ0^;64
MA$(D603"ZP*E !@EQ"?V698LG,I.J52@AI72ER-VQ<Q);I>-+'9K.=8A/(!1
M+[^>HF?66O(5=JRFNUF$B/X(2_K<>KTD?7['T(DT3\2@RG%C(&:D"C6_K<QD
MT3R/" F)05R=+K^RU$_D1QIIC'3>H>;[X2':H$_NND: S ^NC9<A+1LD)%YV
M@;$:YTZB?YSKW-L%RQ47#DK9X]@Z6B8BG6>&(=0Y? =OB+N7Z3R_P3P187F^
M;][?/<_^-L@[O)4AR'(05944V*4(2V*QJHZRH&I)PJ@DDA&25+0M8]A+)@)/
MTZ3*Y9GJ60^0FUM9_N=K#Z&T74+?_8)*?)^F$'?(;["YR!T_X\3T] ,W&7#E
M+SV7^#N>'\TM/%H^_N,B#/P _]UR=HTM<,3><Q(T-F4TM$HT!)]UA,%P!CQK
M!)N7X)!O/*U@<X?/X!$!>_!I#5]MJF1;;6D(8+43T8[?%E(;']GK#?Y%UK<@
MCO,WO[:RA!2Y1B5[8!:(V3%+ZZ2Z*A!/T__F991$^&HE-E)-AOVK:4<_.3S8
M[@E%/5W&EH<OERX72^J^5]O8ELJ,VBW#UJX_+5LB]?@'>"CI].*8[#BSIWG(
M^J+8Q461BM_3$$XYMT,Z4\6M\P/R+-=<![H7*(MRE/?U$5F[?8!,[8@\?8<F
MC\@S,*F7G@5>:M(5UD_'B^M*N.N%0/PHK!)Y%?(>A93(E) ('QDM_65@^"+'
MXLQ5/6*O<5,^UZ[Z9*4!,>]=;%J)?$.*@J+GE[8Z''M7Y_!7NBG3DOL(V B]
M;WE"D/(ID6=@3R9J;&^ZE4&:7S[D^Y=ST4L3S"D18.UQ>A')^/.[GCG+E;$,
MA1%&-09':J"#\+QMJ&/BF$IO?8P7W#Z+=Z/M?I'Y+L2C;00DJPEJC'JR)1+)
M[V5XNHR?RM%9PQ?N"G[W/B3"OJ4^^>- 6*L>#?BD1+ZC&(E0,HL=_3LRJ[<K
M9Q(1(] 7&63ECGB HSPN08DQO7:]+;*"T+O0JF>&LPK#EQ<1<>:"-655%96K
MV%6?_ !H]%_>1J0(!6!WV8[S^5?K.ZAD?K%,_I4?2D_C%X,A4KE&%W0N0D,F
M\8L#!FQ1)8)$2<>[I, LU[))B=&$49&&U,H68@G1O4GPV'_6R?NM+8G<S/VN
M';G+#AQS:>O.7#^@L7O0+:<WSEH-BOVL*)#+E3;MK5+,5@B;.8L4JZ\#U_A\
MYUB!CQ6#O>\2!^/K8?6;@PUT4CE,;X5L$A19ZEYPVF")\O&I1;SOJU/V7R18
M> [ O;LO@1I_'@ZH:C65Q42*6:\ H#IDR:\9-*Y6F]R7$BYQ*G=2W_4D74YY
MUT/QMY?6-Q'AJ.KD2V@%IZF#C^<P\J2B+OZ;O>ZDF9"N<\2'-S+[];3.C7?_
MD@%!@A$@H75^(1AJA[S&G>;ST0<C[06T^Y;:/2!1+PJ FAZ^\O>9/"X@<W"R
M7L;\25R/%,E[A1Q )5/U2^ _1 ?8X*2]@/:+90<3 +ARLDZJR7B=M(4CN<ND
M"$*J0QI=FY=6M6A"'%?38:=UKD-:<$?L24Q*&.$5@/LBHT#\4^LZOR2C]DO$
M!--0>;S0]['T.*C8A*;+5*9H6WO73MR@B$"92"[^.AFGZ#<U)17+9,K"UVKA
M"Z8Q"0!H$>FYI)\PQ<DK<I7:._=".+2(YE+ 4#*19#U$%G*/%&8>B8MT[F8A
M)DHP^46\ YPV5D PG>)[$[Y1A;H--"NN>EWEYU$;+4\G0%%(UCW_%MLMO@Q[
MHD^5-9^KJ!MLE$9"_[HM*WHK('@G:(&-0<NOIW ,6B-#*G8/_RK,SHA4*, X
M45BPMXI1M7G8^.H0S36[HP.1[R/FA*4F+7LY 7:\*D$HLBJ\OF>6C=6D$K?[
MY3I"N*>$3@+__4PI$HB[MSDU*JI!(6]#VL$-20!BF_E9-Q>C2LBJ76@1GG-1
M%K#%0MN(3 3#1\:W._?XQC@E(9C1Z9X ,D*/#'*T_,^WNJ/'X2SLEJ[QO3!
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M_]$'$U@1EL-8:^2_/MYH<L\YD2YJCAG],FEZB*5/#_SN8J0"*#U)403B5B*
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M\A4$ O0,15AVBW3R+DTV,74>0ED]WZA@!FC\Z"03K_EK9_>J,))B_&H J;2
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M7,_2]&N5K)EV2F<DO#3.5R@&S,WR!0)2;4UO@G#^CM*D^A1CS+K6 #PF9K)
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MV=_T/[7;9RW_UH$^=*O(F0+6Q8@?>!R%Y)04+)U!#,I HJ<<EQ$GF*;Q#%^
M'HY+3V!7X)M,7$:21(%>-ZZT2"C;1WF0(!M*LJ/VWL.KII?1L.*/E0&7Y\%<
MJ,5#X^JN34\W<<;WLD&<L15<!V%Q@_ACMO)<#+N\!L,NKS<%*_;>394VM6SB
MS9L$6_#.+S[4?+ZY ]OAWB<6HWRYTHSHU3$55J9+SL?" R]VHGV3NW":=E@R
M,1(9504AKQ931/[@#)=)_1Z:^[3+^_0UQ_H?4_@/%C2 5*J_8C\=1B.4/,B\
MP0AC'>UI%L7^2\P_;N]LVMOGD?1?G?!?<P?:"DGKE YN(CBD09X+%/VXJ6KW
M847!!:D"4P= 50 2/]("4XQ&@N(>B2JWCTAQP*DD<,0H,;,T]C'[7U*05Q9F
M%"!K,B.*][;VK*KS?I - KCMQNGW6,PH^/U\^R6IH/U-__7.*RQ1_TG3E5,7
M,XA!7%MT.HJ KFVMAP4UGB),7'%0#*-<;<FJG.JU"'39F:*3]"Y@0J/HNQB"
MM(D1;+?4==UPE+5Q-].L7=+481Q<N-INSS+>_@+:[O[L-%FF]H$PZ^J[+&O%
MJ_9E++3#; E0:]VE\QG9)(R+(1<@\,]4.F<44Y8':WO2+%,K2=G$S#(N39NB
MHD@+&<^TP*][ZO)LJA+$*>GGD[R#Z]@WJYNGMY</;5VMFVI #4TT@-5:=(Q>
M>;J:%BUZ(?%IT@:H/ZBH:P8W"N*9C*3JCL?0P:780!#N(5GP(I&!*A$(!7Q%
MIH!YNDV!6L]XU>Y<L"FL'$@&WL0E$JQ9@O(9;(91*96]K<WMK8.-;>":S14'
MV-?GP+$N$LZ#CZA4BUZ-HU9(S@DI/;E8?+C"(I)*6JQG1'H=,T<&.-&<A[9Q
M7<'UZMD'XW4W)4GU2^BRP8E2!JBT=#%,QMPK_0<@<M<C<7^\V"MY>OFY^B6<
MDOIX<IM!QIKRC6D+M--KRF%(YK)$!,TY!2TJT)-5:7NRCOP_"M"I0&G7V&T1
MI>'G1"[X*6)R76P-JW92L)2NGKP,U@Y-%W=L^[5O_^UMOWDZVU,6<#J5FZI6
M<YX$O6N"!]Q3(1%&T&3)G\Y.KLA[YDBQC=7H&@.O_UI>\SH,,;&:L6N;M<V0
MD_5!KK_>P/P+M27=,)D ]_(]_!"4(OB-</]R8VF$#_]@ :V\JDD6O+)(H-*2
MO_FR/.?RO>;;RFZ5D7!VS*QRT:H'F0B^;0P$\#^\Y)1>^A9O8J_3VM5;/-LF
MVONAU\4D0_\3D- ZQZ#[Z4A-5))(#,&'>V$8&V"G_?&H@_"R^Z<GYYV3\SZV
MCZZV+W&MZZ(\'(V5*7(IDTNU.3-['(A5;%+]K2.E-K8VMSE3IEYR [-D*+W4
MQ]<]Z<T-3[H);:,>D\5^D85T@WS"G<:Z9J"Z4["SF%CZY=G.LVMV[1E2_SA#
MG?^WX/]M85WV\G)TW9/SWNG!%T);-FFNX$/M7BW:B[KWCZ)HV>^]L\SWWF]_
MP5=N][[Z)Z?G';_7^=3N'71//OF'I[W?X9\;1Z>GO^+?9L9)?YG[<[GT[5DJ
MX$#_R_$Q[DVOV__5/VSOGY_VEOSZRZ"/:_CZ+HNQ;F,MYP:4C?G%[CY;; ,L
M\VS.VKUSOSM7_7=[,;Q4^0&\ ::0DR%?MC"O4OK+I;[  ;!V]_PK*OB#;J]#
MI Z7=TZZISW_N'W2_L03CG"$7OO@MVZ_LUQ6V%Z+(]Q9[1$NM63O]/"PTR,Y
MW>V?=_?UM,,S.,O.@7_>/>Z0"??X#FUWM8?V>IDO\&OGJ]\]P3%][67;'@]^
M..W[/9=%!>;.82T5H.F_>T**[%(,_^^C.J>/J^6?I9:P*T0C!1-/%5==6.L@
M%T,LG-I\5 >UO]*#VMY:YMI[A IAVI;]T]&(:B6&_A<&M3G+TE"(H7Q4)W:P
MVA-;JD_<B^0W! '.T^QQ'0H9#7NK/9FE>NV6P>##_^$X*#5$:IGGM/?@!W7/
M!D3UC)8:.O@<26"<&4FX W$IXG1JE_>J)-3C.J_5&A+;2X6S_5C(B$JM3^')
MEY&X6NK1[#STT:S8=%AJ;.+4&@04Q'X_SXHP+S*QS!-ZM?70)[1B4V&IH0>P
MW:;PR%G+/XL)OA:E7N>/(B*9][C.B:V'%:NFI<8<OIST.OW3H]\Z!Q@M.L2,
MWO'2(_MK<E O5WM.2PTWG)YU<,#\R2>*Y!UV3]HG^UV:ZOU;M_,[?7C6.^UC
M@&^Y1_?@AL2*N6NI$8G3*7;38YEK3\@BSI?J.SW\T:S6QMM9:@SB* *5-(QR
MMLHU&#8<4UIDH5CN0>T]]$&MUN+;66[H04@19.&8SFE8>D\M6""5O- 7<02[
M+?$^(@^7&NE[]?JA3V^UUN#.4L,3YYE(L%B;RS(CG&7WF(ZFL]JC66I48A\;
M(D.W&Z,C\PC.:<GR[\U#'Q.9?Z]6>U9+C4C<F(;O')\=G7[M=/K+E7T/?G*K
MM?YVEAJK.(BPT3/-6$/U11*EF7]L&OX?V4FMV!A<:LQBW^J@7>JQO'YBP;Z=
MI08GN"/PC$ _EVR3O]Y]Z(-9L56WU&A$9S*-TYE8[I&\>6K6W%)##32@Q#^]
M2D0FQ]%TJ0?SX+KE<)7GLKO4.,-!)'%63Y%184-0 \3@J\DU>:JQ%@@I(A$,
M]!%<@1"LH#P\KM,EZ_SU2GEO=ZDABN/V/\ B[W]N]SJ?3X\..CVNM^QUCMI8
M;HG5R5_]\U[[I-^FKH*E1FC?O'WH\UNMC;Z[U/C$<? O,,I)>([3>"B66][R
M\&>S6JM\=ZD!BIZ("8KV+,CRF4^XCBPJEWI&;Q\\.;5:$WUWJ8$)PO40DJ&N
M.M\Q\\ON[GY:)%+$2SVI!T]XD*9ZL]KC6FI(HDP<WE.A^<.?T8JUT5+C$/T2
M^@EYB$%@2J2=[OV$T1_^S%:LI98:I.C#4P@K-<G]?<(U7JYZ>O! !0F]MZL]
MH:5&*[ FEANBT"H_PHZHDT^/ZXQ6+/266R1AJO^/P#/&+-2!R(,H?F1LM%H9
MM[?4( 96\M$<6@Q=1(-BZ1KHP4]GM3;XWG+##S3!_9&QRVK#XWM+#2KT14R@
MOO<55GCXTUEMI'QOJ6&%@RA^A +L<+4GLM0@ L8-L'A+-\30M.C'=3P,"K&U
MVD-::NB@?7#0)7R8^XL=//@IK=:,WEMN[( 2@*J0]7$=RXI-YZ6&!X[%),W
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MZ3OF"UU,PTG057OG%U-0WF$@!=C'AX>=GM<_;Y]W^^?=_;Z/--3YYQD06>?
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M%KA(2;6Z#"5&0UE+["FG9!Y3=(EI-'8F7' EH=W'BK6-5 W-0V&!&?)(EYZ
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MIOZXH,[3%'9M_MD<;[B.SZLM;Z8S2[5K>=RNE4<7:J&J-;;@@^+V*LF&Z+]
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M-\K+R@BG05HU15OS>3D<K3XE(P:QQ82]IFA^0Y6MXE4]KVI'LZ$R,N:0,=B
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MI%,X/QX^;S7CC.%"3'WA,M!&Q[BH"+)\#+843:K()5AWDPB5-';FX-=3L %
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ML/[7W3HM22E;$M'("<?VD9QK0!N*8D$NA \^_0KG+49<^D1EH)R;UT.SAF)
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M<77]=JO+ I$X=1R56KP3/2W;6E,;FCX2,C=ROBZ;Y79U7)7'5?D;/D$O@3M
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M/02A[DFB4GD()J4S=AN(EKYI&[7]]ZK3TAO<T;^)D#&"ZZ'1U!UVG[2[)XW
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M<6:N_-*!JAV1 "1,'5O@!.=;',I^:4P)@*RM!P#H[-& FK=(QY-[YN]*4$?
MQR>VT@8B_BM>8CY"G0&SU"Q)1L+-*:4ME40FMV ^$K"N\&;7K:*%M9'-?&V>
M*JY9BJW[M';NGK>V&2$$'SYX\H*V\>/3[%7TS?V#QR3S&_\T\C:O=5;PU;,G
M[!Q:!>$ B[@?=W0X4D;26FXTK16=C]K/X]Y8_>R1QNIXNO\X.PO_MMF7;F_Z
MA;[E?_B:BN)X,=A#^%TFG6!R"8L"R6.;29C!N]M<DTIX&W,MM$V6RQ[I<3A:
M!4&B5H>+BV$$@0NN:R5Q4M_G$-DG< 5T*>U3X )TPH$[VA3@4A-\Y^N:D=W.
M\MZB\F+'/^BV6T*&/?-&@7?-5JS $A4:WM/LQ^(29[%0(HWHO&&)$]ZZ-^&Y
MX^8^01OO^:+9M&&E&-F?$()R([-YOTC%(VQA[-I9$X1L7N[,G9%>V7"Z#^P1
MVSDAM%JK<Y\"_X.G:,<Y&QWG_5TMO;J'> ?B0PUQCK9/-&8]A^]G:$0P1WWG
M^(!7Z_XB*7\Y90)UWTTE!XV?5O3.B\#2&GFKUBU]8F-9DB%VO!,6MV!:B0VV
MK W+$LY#OS+FU8933S%#]64Z-[?%+7Q]Q"T,< M?'W$+=YL#Y.>#1C0I"(CE
MV:)R0'8/2#.U0@B#(_E>R$>7Z5&74O9)8C[Z]FA+GRZJ\E)K C$_P6WJ+)HM
M!XEF*OC([A*/C<Q?/>,CZL^?W (>550_9Q75N/ 7Y7[_I>>V?3RIZN.R^F,N
M*S1VVP:<>E3^F>."X\HZKJP;/T%"*H7@+2ZLP*^Y::O)5LA>$H6C@T?T<?$=
M%]\-S!JYB$*[E O,)E>9\2!AFBNGJ9*[!#(!2"0%QF?IFO'^&Z=J-5.JA)[<
MT\%PI,&7CPOVN&!OMF"5-R#7UADVE9S+VR\1F!$WP]R'],W'6VK'\.(+7'_%
M)JIK"X==]YZTEV=19_EHS8ZKZ9I@%73:O2)>S[TCB@TBE.E+&0Z3ZH$487"N
MI@J&5.&5VH>"/?>A#I_0IX_+^+B,#X<P%@>P4XU*]-E+D5XD#P8@5E/S!^N&
MJ3[GF8]XD%94N $1>A #02S5Y2I]H\I?.5C\@L1"U,$QH?MT05(X=:"45( R
M=3X0DAN8FI/M&J!PA3P;B4ZS6V5O5I=1PQ-$GN ?;IC8K1S)$YQ^KL['QVP#
MHCE?T?+0L$",42P<2IH:J6$6M:;U ?1&KO+6K?"\F@L8 =KN-.M)2H:B[IA$
M*AQ+FBQ3VW5),5];LF.-]_!U) LY1 :( I \\C",^M\^A/K/W*\3_S\\AGQ2
M(29F4"(Y6(<, (J,\@!=E!&ZU>V#@EQX)SE<G 'R<'J_A(XF:XSK:PO('LH5
MZ[::8C^W9;6:^"TAU)B,D:G:V0E-*'5#[)IVF$$;?U07']7TZ(/5H5\15D09
MUY*I5C%?TO&*+IQ$!Q>/]-];_S2\?_5'>G5T$OG?T?^%J@%:'H5T=YULFA/I
M\V(6QJJ+0L)BG?!/(WL?RR:$QF]FVF-5Q6_J6Y<MP#V@9WD%B[:M8SUEYK@&
M'QI.Z/8?C;7J$S6D_GQ3.);#O.H:YW8G93:HB<^*9B"6V^\D^O5\&4UDPC%B
MD23")UT$5901!$S$OOWP[#SBG\Y?GK_)%4AZ:RB=;GK,W2GZL(T9"CUU^AT4
M"\4VZ;SRI]E@=KT^0VY[!-<1BP\!MG@!SWJY](X)[]A 0)*[/HI1-<I&)&V%
MC60B_4KE3:H(=4F7+MK=,+\+])I%$UYGR5%Z%;HGXAQ'F9=YE.813Q3&,,CU
MRF#N'^WT0!K;9/:,6I3%9<5P9_0[\.AE $E1Z$)U7XL]'#I_Q\KO,0HY7/F5
M/7C3JJ\T31SR@D *N_'W%>X@ V]@POUCCN>X+ \_P4B8,&KU&1E:[T:6X7&1
M'1?9X2<(*@N(4>L%FMH+XSIX^W59,9BT\[?W'Y5_^*'EG]J2%Q[:=-!<*$S3
MF/@4-JP*+H-8[7J+J@H.2B(HHK]:$D08U+]9($2C!NF_OGQ]W!#'#7%S5(45
M(0%?-2PP@ZH#/6/>6W2IH!66:$KWR-3O1:U\TLA,0<!)DEITW__>%A)?S,K_
MWG(+G>P4D]GO)^=9 QIYE$A-><M]EBMH$J!./F/*V7'?'/?-X2?8"P3IPS^H
MQ^[HJ1P7V&V?8%EL:PG->HF-4=<7IB\ S6_J2^=962%)&B3Z)KM(0L_].YRB
M /MH;B]Q&' 78%#LM83T4,.TM.&;_M_'O7#<"X>?@#I96^Y75;N[]\2_+LUW
M7&W'U79ME9Z(LA$A^L4#;Q1*>)52,G"I7!L;*7-..E%4Z>Y4'>=S@Q?_^BO?
MKO/P\;'S<-!Y^/C8>?@Q.@^/=O>/:7<3+H $&3$6HN<?4*4()5<UW>19;VO5
M^!F"+#X'RWU<M)_SHBUKB#&/HDD[56K!@H6K.@+M221(5"\B']>J%U8'NF6+
MHELBBL6J[\RU%SE[D_N'^.T(ZS\N]P^)Q&:SEMFO&,O!N8 @D1+4HD-:-F1L
MM:*Q6A="3G,+PQU4891QBQ!WVX[<A\ENW!$_FN[C6C[\!'5YT6PJ('2*RZ8U
MJ@6H#^Y24),V^(D:$8> 1=L6]86P6%>UC_T2K@=$%-Q'P+A$;DXP,F_,7 0<
M47*WX_(]+M\;EK)#9U^_L2^T\(&S?K3+KZTN%IL$3D8H66A0\0]:^5/QQ+:8
ME43YWI9BMPDI=[)HKH[K];A>KW$=+IMJ)E"S.2$=51?/AEV@0YY[+Q9\BY"P
MA&8QRQE 9>^XTHXK[9J5QCVG/H:2>JQVG@)F,*^2WM-CX]YQ15U?C&VFC/F>
MD5AD!].D]?YNR^T0I#U-X&]1>[3MJ--E52L'8J2H3($TYMMIS9>/=(IJCMUP
M?_K/?5UJ(;'AKJ,>3=K3>ET"!W,W:>V;RN),9AG9Y)D!MR<R[D#6)OF=<0I0
M6^!G]2H?#^@C"='TH%OAE66%4R$%H86;E+N&G4'O\;'S)H2K16MD628[;4#)
M1SM 8S9JUJQ(;W1*'Z/R@W\]=*E,%Q3_8 A'D8_2"=IUTNBZ:9R&0J815#M%
M6<H8*K72BQ8Y7N,P2ZMB?)^42R_*TXUT'':QY=#U.T2N+1WGTJ/&S3-ET=9*
M@)Q,F%E#*J_#O1WDPTA;9FA%=-J*&,%L0=;'NT)MY1^_ZL,[+O;U4]*G[+-T
MW.K'N70Z]EJB[!Y^JB\)%? C2;:R_S5PK0*-PL2NBQ(+B+;E52U2V,&*<:@A
MM+/^B_IRN]AX21>/7:0C&4P%_456W=Y&2M=@BGE)'SV\C(PY]#U8D(9VM=.>
MPZA#=A/Z\M[8!RLC+V Z,./JA5Z(L$B.W<T=)$L/8V/H)H/^$D [K)"V);9>
M:,U/@R:PH<W.GFV#D/AU=+_>H!%//!-]ZZ)/3K8*R.591=VN)+3=(_G=5"O)
MHL2^YJB]'*F6A?!WT(,E@D'.=-;"/ MV->ED^_)[.S$D)$ 6M=RL9E[LPG<B
M^J6$I+:M5M6[QH6_@HJG7\#^@T*X(49"I<1&OLE@"=,:-"FZJL/>4C*!;6>6
M9\Z4" (0BWI<YH!.R+5%\2L<70D/_!WL3=VG+TCMZ-"I@V=)/]#H^P.#4SW=
MP@_C"<T8'51-5XF31$0/O5]?E>H5106!1Z=!T2#'@HK9).KH]X<#V6?<MIF[
M__C^N_S!@P?<[:EB!=E5T[YGQ3Q6!QZ143C])M%1^""!@[_ PM#9ZPR_&BE?
MP%,B]0=:7Z;_7+G?A28AH6"/W+Q&[V]LC'F/0GMDDK  >'>(9?V,AHR17:S]
M)/NCX)=LY=?.HC."@:EPD6ZF\7T?!I7V[%J[5V>#EEDW\)*ORF!8C 8B,3L-
MU2*A;T\[GW?TF%JA4L[3VLTV5Z4_0\*;O0H]_&JF]*TXN6Y;9!OIA:63ODEE
MP([=L,?0_G9/ -WAMKEH >)7 HHHUZ **#7+0%I2*(U@QKID0LB_(>E57.;F
M]<YCBO.X:J]?M;0^<W6F1;V$%#&PV$QTV+(TTG$%'E?@[[ "L=HT]E)E/HK_
MHV]Q0LVS)3I2QY.>.WN$\T715RABKR&A8UL4>PD>;9.=QLZ3LKXH+E@;-!:8
MXOT)0:4BM)_#<O_8".UOC@CM 4+[FR-"^XC0/MK\0S8?JNWY=2[S:%IP4W9,
MUI\< G2M<JQ"=B._6LE ]K*L:Z!,2:= R2X)HRM*EDD:2W+N[!$=T;''_?$K
M?*(>*2'1<ERBM&O]G*3-MB]H,6ROG19K3FEK-6A/'[!@%Z-R:W91^JU:K!<[
MP8='T>!][#I[REF?@9-T7/^?^_J/B7\M\\S[8-K+TH)I8T-E@J:U=CMLE<_!
M3S\NP<]]"1HOI%P7[&/,O>G4]%W;=.5TNXEPUQ[*U8:8S!-%A52-;0\A:0V\
MD3X^^M$3#6T%SG@$H!V7]8V6=2A-"2! ^B)W>>"@537N +I@[@ZQP->1ANQW
M"H[ LS_]YSF1KZ95+RJV$^),Z] (,2I:T J(*BX2#F_J8)H5.Z+ GA$#M?$+
M8TF^F/DK="#2G,]5R-M@<S2(&3###.MWU_#=OHC(JUP_-Z_JHH:M&X4'@!HL
ME"\9OL$%^%I/_H !<*!"L*+,V<NF+:G=,<^BJR"K,[WQ8!#H\XMF289)V\'4
MYOH+T%\HGR=^-YGW-F I'7V6= Y ]D>W,\($X9,1OT1EQPV#$,J)#ULG.[R&
MW'3==%TELZ&('[UXCF=G[6Q#3@9\E!L^&R:3 MH2Z".!#Y;RE+3^)OZ<J*G?
MCO%]'&IGB%85+C.O?B'T3[%CYM;86Q0J[ (&4M0?8#,^=F=-/(;UA$(][?^I
MGR'B3.^$OKWHN)PJ5=R4$CJ*CYM1Y7$[^"47=-,Z4E/W@ROZ:=>?KPG6PX ,
MI'Q.=',8K;B&3-.A>>QI4X,LFWX]V?J=[ <:)7;Y.O'#FW$+M6\I>$N=/G%:
M>V1'-)K*A9TF'8"<(PCALJ+^KXTW%*3U6YN/7.$I ![LJI:S'^,S"N!/Z=>1
M_V>WT*&BQR5]=%EWL4>3,9GC79;A]BXL$=ZEV]HTR?&^%DV2:+F V"LR EZT
M#$' !!!.!W:,UX .=9Y.8<@A:8NG2%((;G7BWX^ 7AH6X%[&%/&D*!N0LF0V
M0[$,5&\C2JZ/9E"L1#77W4O+I&((+<'UXC  E1:?Q3\S(?8R2XKN(YR9@23=
M'2C2BP!OW-:Z9CC1YBQ>+,&%Y7N6=JH]<0U4C-GI5TT;%GY@N8ZD?+19'3*8
MQ2J<)@D!=CN4>HKNUAZ)DKTIR ;""7$@3(]>1,>XQ#[(,@0V.-TV_BO45T"L
M%3BUO'6&@2!&#-Z*;+YT%Z9^1-Q\<MX"DRX+'(?EJ 3'%[IV%47YAAVY,3O
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MV9^?_W2?P#O??O7MUX_OGQ(R2 2]P@-T/6*7JF-$%G[951M%A2G/8N%7U"_
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MYDK[^;6F_LFK%K\KO?$/X\HV1JR!"=B#[M!0Z";T7&Z%7F- A6\U*"PE:.C
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MZ_>"LTEK@OQ+X>J=EU S]YM-,SG>=[U@9LD%CK=NP>< M:KS$*Q;:FT[=>]
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MQ?X$Z8SNECY='(J*"[/#<2<?ST_^MI[Y0,DX7R<K@FZ*L=)+APO[8V.KM&V
MK# KI<0WFGW;.^@Y;)C?^G6DH,P3ESSOX=!D743 ,P\'5HA=0P8''=92,(#]
MQ1;B@1OA_4ZSUS*8@PM['[\17"&/AJQ*-BYWL!@]4%SU,;+P+CO)5?H#C?&7
MM*MF+7*,NES#YMMC'N+AI@38^^,Q;!79MPA;.+O@5\VTFBG1MOJZ*E!Y?7]=
MZ!*0C<OE%4U=J%:3 1.6=AS*F7SOU+TMR_>BQ;K8>S.ZYF@CH!#V&#,<+CU&
MI'J:O?1/V:#^S*$H9[R=2085,YZ- !/M$\":O$[(U<Q1ZAST;]),#+/XULN
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M@Y-9>7NC [5'XYPS#)<,A9S19L(69MI>D:K'CWXS!GV4R+J,+W*B/3#]LME
M88J,;X*_%4;QT!26]K7J&ARG8HLD<[.*#+:M$>IS2V]=))262P*3+9<]S7Y>
M5$O%)B>LQ1UU947*8FUS%G64B3>[(!X-:S:0D_MEJXB[I,FQ7@8FZ00/FFOU
M,<+^&$TJSPO;N*\WJ%".LW*6]0A63K.GP+2$^N!(_TQ"46^.)+ZU]$C>8'OG
MF.2DK1QFW<_J"8ZP%1=;(R"4T;%HDK369)_Y\.- J8NP& $:D-:\];*HC>T8
M- ''4RW:&;0UCZCDN$.+\:9C4<WCMR>[OHA:KD^S]%LELH29Q4HSY6B9[FE[
MY;C+;%Q4GK=H3[V1,:8'2)EA91MAX["FG*$\E^8^PYN36'%,IW0E<'Z2GF<<
M:;_OB6)O @)P$ 5+0R/. 0(4L!1G[-GJY5?,PJ*0O*JW?**4)>=I@C0!;5+N
M'8_D[W:VPYEG.LI4-11]N=JZ*>MW-D24)9>!+Y)>!J!?KL!O*04MRSH>BG6C
MRV,2Q8QT)$S*+/0A5'5HP8>)ODL'XIN1]667ES.D>[-&P!EEW3':/.Z8?(^=
M34EJ+;_14")1=^?H55WOJK;!^S!;Z&_[W"X\]Y";GSK6PW"=9C\J%V2AO6A)
MT^KX0<%PA<.30AQ+]/YJT0TE4*!.B%1 YH"F*PKG>QC_3U3P^J10V[]K?OBR
M[(UW2\9TI4TJ3%LKE9/G/TGSUWM"\O#*(]M/=F@CC34@L&%:T?3PN\Z(#[ID
MN+W%A-NY&VT[2[Y4S$DA8,^:Z>1QO-&]BZ[_#W!L*\;NT/]S6R9P?GAF+8W?
M3.HX&PPJEZV5.=E2M:1.0!1$E"*I;#7-"T?9CM1?'M/A<:.RC$9VD0KHOZOH
M(E:?7^?NYJ*+T;-.%N"-11?;0/;2TRJ$Y^28!JIM2QYM8=**NV6HV?CJ4NJZ
MRX(8U:2"M/-?- VFE#^C0A@8]G7OHQS=98_/'MQ[?]^\C%C.')$9?$;^*NU?
MT7\4W1C#H=7W-4--9U9L"IX[=5=H1DA6'?4B0<;15<<M#HASTW0<45ALJB7S
M9)1[7T";6RNK6/ #<G(%U4-00O^'7[!4:"3(QG<Y-\J%\DO$=/A+;1;3AF(4
M)^HJVO-.7V%1>"XC2CNPGU#:"?*,?AV)64OZ_-;%9D&D*KQ0W@HP3EXH- $^
M]8?L^1">YF+[L#XFXS@WB'=J=E5E]9DYI%^V="2DH\I#JEM7GD$?<-, "FZH
M/>J2I&S]>\U811IQ45>:^\@JF>%ITLPH>&SJKHRENV8I6R7"F4 HP\"VSMQ(
M!FM\YOEQ>>GV;HBR)$33EL3EYU\AN9LPK91UY*]CGP+[C#^^(L+(EB5[#>*X
M5!Y!YOT.C^J2&X \KN'@O?9' .]1>G%$*2_]*/LU^'W<M +ZIP'DBNK<1U!
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MS:*Y-=Q&"%WAGY";M+D[C"M/UZAE@FI[)X3G[.;:*RLUD3W0<%,276SFQ5L
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M+@9QXX5<K@:N/[J]?NB3[]_]Y_=/]&]HG&N2*KV1#;?YNERPO7UN" !4_8^
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M,6D'61&56Y+K]^0+%!)9C0EJ93G1 P%%G NI'\V*_@IE%$A209GJ\5_I(;I
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MA2'\K6C*S$/*AZ8$-:@]%B3*&=P"8_*>BQ)?>T1&=_ MQHWF+U+]%%@*6%W
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MW".:1M@1L.:?/MPF6E'98O_%Y+@XST+1L-/C/V@V*68V+ L*;F. B,)-0Q2
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MJ^2J"2^\#J.8SLSZ?- FIZ)1KN9L+BSH(RJ2N&7R YE]-BJR%,X)-=*/(TG
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M5,PUQ(=IW+6ZKS0=15)^P;9GZ5@1!I>ZH^FU%9(+;B%,;1#;^O5J6'N9.(A
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M;=)>.><(=V'E?;MSZ$B\1S<BF,A=HW@[JZ"Y']H6NR'=_X-+KGUS?E\38_-
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MPD/Q[DR82(5#%$9(Z$"OIC25.?!HQ/SB=A-85.JO,"#[,8-(%F:!WJM).%R
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MP$U!H8!BW.Z$9!P=^M$VE"/[UT5NP">HX0C5&<CNEL^@OJL<WI(2J.C&KB[
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M@,WB_XVIW.)Z?9W&VM<N9L]$_]U'CV.[W:._L<S]EG+6=M(D(>L:S5!S&4O
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MW[IB<*=.$]MVR-",L*80Z7M[<#>';@V-]2."I-PJ!(N>$CF>%.Q0'6K:N)V
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M,I-&2+@2. %2#:YQ,G[UYHP@]TBFJ7WYPL_#C ;P'3!_#-'/V"9Y/7WLMM*
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M?@O:CZL+S.MFS46&$ ]"FC,LJ"B8'H?M<PL$G-N8'$,5&8V%!?Z3^.^V'?T
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M=J=H?3W,0<+,E[ .60I[L3;2?/VB+&!5-EIZA4F7*A29B4++&BY6S!>PY4H
M7)2%^W'!:"^]^*@TO:_F6*5I_@FCH:I'V:;VVRRKB>U('<M)\T<AP#3Q'W@I
M#8W Z\*DQ]@N\3Z= MU^%<((C<-=;9]ZV_<HTG-3V:.:\(F37GG^L<')M\ZO
M5(X1)8(<C-:5PT%W1BM][88N8^1M/]DCZ[IU#.KL,]A9!9PH[P S@3N[/(FZ
M.#BU.9C&Q#Z]6E>HW!KM-,;GE#SA4#HG_;(8_@;3AR=+OIED_!+1>@REW+!-
M!CN8DP..;H@,0XSQ.3,*"\.S+!G\-,LH[M,W_$B'/XG_ME6F.86B=P"E$RV
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MI$0&>&'$R:,I<T-B[Y8HEK8]?+9Y-#[Q#W'+D[Q H4?3\;B]H70-(52-M$6
M_Y9YZ()P$[ YQ06(79Z0 5-JU/'TY-0E>MC=-3WL/9TJ4!RO5H >]B)*Z&B]
MI_X@5TA9'/88^+1FB:WM4W[0>-4HT.A+ST:OW(:STK79=UN$/OT1_J:>7)MZ
M()**Q5E?2FNCEK96>6P/<T&GGE7S.O\4;C1"G=&-!T)TFV$WQ+$7.6MJUI%9
MTEP>S2KY(;@-B=KN>>3^&.\<['35@T'!/+"UEFVW:TF/Q^F8)'O*35<\^-F
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MYH6U.52NCH7GWQK^(<*O2?@OW7-^C.<\\% @8#$DK#9*^UCJPP>?_A#UQ1_
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MUMO ".]<2[^TEBU7LO"[3B%FD^WS$8$=V3,M3!;4&QK4I-6<[5AF)\2O+*0
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M ?_JL??IKJ3:G24X(0/0;5=@(B?#Y"-LS*_B[E4>PVGMTI#)V!Q&?<;\ABS
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MCDTK+]RN%8N7-)LMWDE+-C&US_6+S]57_Y#*8.F:=<ML\%Y U*7$Y4K4C*^
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MNT1*[R$D-F4PUB:%8[S"6I=GNBP]9O72KH_.V4VMZ'*/"VFJ>4#+;("D(N2
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M'_#Y)QW+(^C!PMC6O91J12E5F@#L$9 +:"P0'7"#QNC#[PLX+N N8V[Y'-^
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MM1K]\99O4>[:B*WE$"^IIJF-3FF/Z'YTW&:J;CHK#80_*BT$V(=6>!F8JN7
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M I>[4UK0Z)U:1QLIN9Z X,]VFR4TB'9I#V450BP*[F4M,]^31?1)T@&UC=!
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MX&5=)%->SX1: <=Z)&84#=]XX$2<AK'YD\DOS/0W46<G"S_X[]$1D\$A:L[
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M/H*O/JTU5#F"U5/J7B^H=R/3U>:P9X0>?6$5\07Y,3$&%5&A]*<GQ&LB3H9
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MBH!J/=C2"3D94 &AA[E'/WC3Q"O&0)_('8KAH-"U6@/8!@V +1G -F@ ; V
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M[R9YR%A<X99:Q==6,*//>]P#_,H)9+8H$JG;X+U>.?]"-XG<83NFC8H+/NJ
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MU6U[OEG@)>341&_9"@Y2PG9%MN5H0@:9@.?IL 9D.FV>W6HN;Y_@6"Q-P7P
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MOU"_4S[<L'^CVW2GF!?QD *=_D,J=Z<X#VG.8$S#>TMWE!0BV3,L>C_W! ;
M8NX)1\6GZ!(Y1.1^-E@#]@/W1Y5ZZ^WO(+(L8A(TJC.>X0;#U=U=?)_02+0M
M#>)WQI\;EKT6GK3%W)N1'A(WF^X(-MEXAK?&@O4?M;%!*0@IW&O3)SW^NXZ,
M=IS+QN.[G<)U9>]<ER4PD)*YCF3L>$1P+E9%/)OA^5PN#9S:'FC!B1_WFI!2
M_U>X[&D<"GQ HX:FI#S]-O2>I4 E3':@QV^X9^\?_YQ\)W)L%AI\:$Z?H"$(
M!FC6W9:!$1QJDDF.#W<GRHC%[<4ID6!;YCD\W<%2N51?6>;<6-,D!]/&H7]K
M8^$PD 8V.&=B:X0-F'2^IW+G3:7N.!+O?CM 1U_H<50?RKS#P:"1ISD'Q9YC
M(8_IM 1^T>TUK.^C#5\B*(HD?Y243P>ZSLM[\(ZVOG%B&39O6M$.L]CE=K>X
M%HG6E"JM2GSRA*,S?)'01:E;4..-4!#IE3[%\,CBK>(>TU4, T]^U1<ADM+8
M<V2BNCEAOC_9IT.E)$\(;_E>J#,]%3LHPCTY?0K/T7*]CJ[RJ8-_QXMMC4J-
MW?'8SYXIO<W2TA\-F[W"I6V'K%KWJ6Q>!P[;>GS$&3MKO946.1B$SKJ8Z9S<
MK<WIG[>Z^_H9F^_[G8HH[TAK>T=$#!P1V_E3\)3TVF.E(Z(A%7,Y"3?N;<Z>
MBE<4A@\"48.4Z[>7W0!R-WF^T&S[9OY/1O ;ZQ;CIA?.JT'4I[KW1]OYJRW%
M[AM4 ] F;O<X JHK1Z&#@2+LCRAH& B1Q9_= ^:^EGXM_?R)S5_9_BN[.1UB
MX:W7,IZ?]9G!Y@1M5EC2ZYI3J%<I6.,W?M?9;S5FTF+'(+?^U1G# *:"^_UF
M4FYL6PZE:<N1W)9#:=IR-)-RFUX=1]"KHR:J-QN:^9A&Y_)ASMW)N;P(]<HV
M&6MLN#/OIIK]M-!MV[/26L\Z6(E+PW[NA(<"4DZ%QO:@1V3,#9;%"0VY/)$I
M/!%J/6MO3I I/(:PY44WD([;(0XR@#&]ICG3D^C3S&9D PD=^C'+X&[Z9.)$
M'V>VW@J,,IH[:,'77TWKS],@KCNV-.B0H9QM@MUA' :T/ 9@,Y?8T)Z]MC:L
M+(E2C*A;$R)DJ( M?6H^+HW_P!_]QWFC^^#E<"S,Y^UH&LW9Q'#::7# F7P9
MF/ 6H-+#FS.XC63RS)')UI9,/ILS?5'Q2O=%C3]UE*/5)I2EQK&FKG:+"&-0
MJ.)SE!UZ2FWZ#KV'K.1__]>H/QC]7&)JTC+L/\_FEKX]QFYW"*.?/X01A6*]
M_<:.*&JX*Y31V(!%-*LS:(_5KAP-R'ZH,L3^3LISJ0PW8X5N9M$M)KEXH]&P
M^!<3!P?35;E;:@=UD-IA>SP<=OLQ^<@@:<(EK(W8GJ#8@@]FS'0PNMXPV (W
M;&NW] [SQ\;+D]Y1>QP-B1^AY#8F0(Q$HN.+EIZ7*R.LH_1SBEH-80BEPPBF
M(E*O_VC2@G($E2;=C]J([QVM$=_</7LR]H=B#<PF!=LZ=M68AB;'=_<TDKL'
M8W^8 UQ:OM3*8.R+L5UL&K%]5V*;T=@?RC4P]A7E1(S]1G(K< I2!%BI@U.
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MD.?EJCWJT?14%:&@D3@8._N@.393*OL@[\5MJ#,#Y<:J.EDWJ>=G. )>=ZF
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MTZR\5EL?(>L=6>YWU)CY--$^PI$F*0(:% @6O/O=\767P>-7(0UP1725(#=
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M6UB;@@:&(SS+>-BL30OA.?C%W[MW]&J+^K?1KZ:A1<#[]4?$@+9H#*YAPWK
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MD25\CA )>9BN@IHV:65$3TK@%P)HQ::MW7[B-B7P"]Q;N9\^X:]22'U4(W-
M18*0ZUUJ6NPBV+Y!RZ=*5 G"!%[_H*/FZ&KYSIN8%5'<); -G/U^1^$H@VO8
M5IK^+H%M SQM"D=%W E6J^3L!_"+OM0M;0%$G\R>C26VF0!'YD5WDQZQ.%U%
M&9:+A.X+9\(O%]<7MY-O!(2>?/WMZOKJ[OYV<G_UQT5%6.A0SY#"[112"9G8
M8$%1&]3S2751. U2O&NLLW"$,.=BH./JOGTX8')[_-TRY[IM@PV@+82Y?AQ
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M;1C-1YTL"X?'>=JPR9:D=GHQ%>#O@U6G<-KZ>+>)O6A]6J'R-#Y;-^!"_<*
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MG=#3SB8_'\S^^(Q^-G"&^MG_ U!+ P04    " "7@GI<V4->O"LQ  "I @$
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M%@&:K]L2ZDR$0:_C&ZEP<T]W]V;);"X?CPQ8LR(NYUQ8!R5O4=(^D9!L2J3
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MZLA,TMQ>75S8%,#DY^K80U,F[F!&"AWA"7$Q((; Q"4>IFMC!.%E'D*;)Z!
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M$$%L);J-05 0HG<AS(@,8C#14M,PVS7<3-!]'AV"MF98*0$C"61?PE'8<J0
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M6BQ8R^5)\Q&I"A;$09_*(3\ZE<-3GEJ*D?;,)$^?>F!L];3&#(30!5?=++1
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M%VXK-$6NUTB!0;FH2JS*I?!/T./)0(RX7(.[9L!NP=6;ZVB>MUK\]U6B\^&
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M<5@M&)7?,"1CZT0X+=8.KW 5RHNP#C?EX5IGUT^6.C9T771I9(!7;-:H0N(
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MH TQQWR8#.-#IJ;U2GCY"815D=SFCCR!X-Q)PGY-.&3_)[&I\%&K?;IFB2+
M</RH)5>^%E&J%=^Z@*=7@5&.T"8Y7UY+\MZB2LH8CG0=G'\PXLX:0@]:WIW6
M+J\0(XYP3H)E6)XL@M O)F"%5V"^""E>+B6#D MANV.&I<*(-8?TV':941:^
M@%:TN_=&%_@FR3#,Y"BAS5@GF'24UD9=,['(29>":T23:7>/";PV^6[-R_.U
MD?=94ZFP.L5P$&AY8("\_;W"W)<U#[;M%E$;=-M##D3V)47@*9#135TKF]<L
MI7V"'@<]F0"OMQ67<8C[SV#$P/5/2[#A03_:W<LG:IIDF%1F[37XVV\(>=G?
MNQ,_ZEU:+^S*5^_C A6UATOP 677V4)8E%!]T,5$_^[!_HOU8I0EUC=W<O+A
MPZ_B?OOKZ.<O7Y"_KL%+HZCANG/X]='+PZY(\><J,8]MQ+$O(MS;38!4\[_V
M [=>Z)A:ZX@;VU7!B*C\UX^(!H/\&RC3KI!;H">O/K[Y#=$R3WX\^^G]R_\'
M4$L#!!0    ( )>">EQM:L\5MBX  ,$O   -    :6UA9V5?,# Q+FIP9Z6X
M9U2331@M&@0$"R 6D!J4IB(@*+W$\M%$0%1 "1 5$!!#+Z$E"I\@74! :5%I
M(B7T#I$:BA ED "1#H86DE!"" DY?.><=>Z?^^.N>^9=ZUWK73/KF6?//#-[
M[Y<SSID%G+IK;&8,X.+B CP]?  <(N#.?U__5^V_(/^W,;@X/P#"_(#[@"5N
MKHN (\)<W,)<G&X $ #@XOU? P#_NW$=X>;A/<K'?^SXB<,!=:< 1[BXN8_P
M<//R\O <]D8<]@-XA'E/7U"[=?2,]3.^B[YGU=^D?.&7O5W5<>[!;ZK<]>=^
MD<>.BXB>%Q.75U"\=/G*#0U-+6T=W3O_&!F;F)K=??C(QM;N\1-[9Q?7%V[N
M'B_] P*#@F$AH5'_OHV.>1<;EYKV(3TC\^.GK*_Y!85%Q=]*OE?7U-;5-S0V
M-7=V=??T8OKZ!T9PHV-XPOC$Y-S\PN+27]+RRBIM<VM[A[[+V&/^AXL+P/U_
MH/^_XA(^Q'6$AX>;A^\_7%Q'@O\;(,S#>T'MZ.E;UGS/?,]<5'_#?_9VRI>J
MCF.RUQ]0SSWW^WU<1.[&G#SM/VC_$]G_-V"1_[^0_1]@_P^N2<!);J[#S>,6
M!H  !VJU9,L3C6C"_$*QOG]>#*B/ WA75@[IFC[7R@$D]QZ&E558Q:\_)279
MY2"_;5> '^/NX1M$[I_)+E4+<XV*(I;P2,^0)$."WY*S*-V:F@0QF48L9$X_
M#T;&. #](94O=+!:*D*B'Z8TTSRF7I(#FX/:QI)C!S:7=NP2'W@43-8?F$V4
MTT/MI["W1MNE]R#HRC%H10RDVG$QSZ02L\",6WI!K6CR4'&K:NSH![JL@YST
MG//:UJ:?1_&\(<HF>V]>9W Y\FA&\#,/\P7U'?"---'$5 0*Z,T6*H2[,X$C
M>])TB3.X0:M!9C6E"#/(N,8!8'[() D:\\L24/<D=[ZV?Q@+4(HPL4"_)A(U
M>H:RN0),[KG)?N'FCEKU,^ -[[.UD0<UWD6(4E/1(^W.:IT<@"L(')Y&1/N/
M=WEZZ\$U.0#U4)13^1R6?SFK*-$YPI<7,ZD8:7283VN G(N@H.Z"?MP$!_#6
M^ZLY!Z!<Q[7=[&30'I6TH._O,"@0D-M00VQ&;^[E]4JH]+1YYY._$VP88*9;
M?,*L6X4.<V1(R H>LX=P\%TW"K-B*4F=.$ $ K$@%*+<*6:.%/-%-KLT[0T'
MH/I1,1G%E_Q<R+K7$WDF>@+5LA&$6VQ?&.]R:6S8FF&RA/AB2NC];#5+F;['
MMP4ZI(R/,:-FDN#M+,(O*D.QL]<Z]RHMTLPP:E12S<#**Y1)><(()5CJE2F7
M^Z<E_DE9%@R1$]1-F9$J19XAX+;==ZE_%..AADQ*'0<P^WAOGMAY<*DI'ELW
MLM&.?6W:!+S<)_E-^X(5-6F62;.]2(7GI]%7!(I"%A+.+%^#\2Q(3S%0WV0R
M:RSHGF]GG8N,N3IFG>L-= .^[0CH#LS+:F F"F1.3OEV4# 5QB"5,+N\"+CH
MZ\I$A2GB7;:&A^;!/AOS>ISA-<"/Q=+31I/\K'1^8/1)#6)\1PNRN^JW$-^L
M7YGXKAI^WD\(Z)-2&G&CKFZ^XF^)C7V11^#"Z;\'')X&_?FJOY7MU6+"$GDP
MOF^ A;P]*88A.S&$$KS*:J[!<0"VE;'@_2LK'D-%]2.[CF3$IR6M=FDT;G/E
ME+O@DSRB'E%_X]6&7I)?1/]"H77T<T$U_XY>P[RVV(4<9\.HN)VTH&<^F%W8
M/CZJ1?(,5I:U_Z*:<C5@D#P4[%6_=?IN-@2]==JOJT11GT:0L=.:#]GLEQ7!
M"_O53GKLUX_M?Z<3O:8T=2)4P?N2L]DC (-C2Z%'BG7XN DX,93C+[B,1@U_
M8:/HE:[SVK/.W#J]/MJ2"6Y)O"%2I&BG"\V]?X]=3U4^/U<@=G#5^:]L&B[O
MV,4J_;;;/SZ^N/7J&$9,1MJ'KW*9[]NBK6!DCR:J9A,,L4"@< V*V"TOZ5Z%
M='Q6Z78$-"R"-,G4BB_S/LX=WF<*R2#IV<EN?#N876[B_EQ!)ZXS$\*")_\D
M'!&M[%M W5KI-5UT\8?DX4/_T%]9(7U,-[27U=(7))-(]3H4I[0YK!26AX9L
MT$W\#AJ)5?H5L''3X*C:F[5^:M43KXK^#?J.&R5<<<$6**QR;\$4,U4##=>,
M&V-"FC::.^N3Y]LTCP$>[YSW*O_!O<2_OOPY#&!'E%(W\LN[,%*1N*YF?Z=U
M\E)C3%X]?GS?ZB^7U'7L^=E$,U65<,>O':6QORM8!F'2FX:4]QME;V$@%8#2
MFU\12M\]3EM S+,>W[ESU4CNN2[[VY&?_*3</;D%*1VLM)M2IPXT']?6 BYJ
MV,?6,\M@Z0,%X@'?S88_9)2FPEDV8V,C'X*"\?CE$/+P]_=$P]RSKNN!)1?0
M(R[:1Z8#NAR_<!<1KA9 UY5J1RJ>D!=:!9J#7,S ";4RSCZ]L"O!0H-U/H8W
M]@U*!Z6^=>NJU,;=U.G\4PK@FQ>2CC+\1 F_?!S"@%^6Y0 <O11,L9+K/*IB
M'?I"#PD7&_V%Z+!](Y3N ]R0OW=%20/;@<Y0+RW/7M@,!UOJ&)VS%8#*\U:/
M;=EC/2?)!I^*2U8,PP5\H=T<0$A,@4!?!P<0#(3<W<HUZ:)3_JI+RE6)Q:"0
MI^0QC<J-XCO)0MBK=-%KJ?"1MR->Z-7WZ3JL-IV_C4(B9?6_.V-WY3PCV]H?
M@+T7U7ZP2OL_4^*C#EYD[Q5@Z^=_*@BVF^GC"8_R7<KHUFL1\*%RAN3/F]-@
M8@W)[Y]W\"]G)3=U%JA?J\K+7)JJZP.T90;."U&\( ?M>J'63J53S!K:^'R5
MI9KOP-[7$=\TS^EXLY)PG-5?G_O8_5)_W'H#\OGNVD'H#L7!HJU !"&\%"FH
M?$!(&3:D'^L@$:I6/5$U<8C*U:UA72=!_L4<#F"'F57% ?#7[C:SV]$G\?A?
MKE83U<$G 4(-!F&;UR%CXV6&JB*;R.]*$\5*R]NA#0B57*M-[ZO=9:JZ7BL]
MA:WIZV59A @;LDO0*2IX%5$8L(-E)\$02V@=\AK2LC6 9= (J9D* ;[<4M5O
M)6_!?TR;O7)SS_;. +-SB35YZDJ_N_<;VE=W=^S0\Y_67)N;#,GHM@9F]NFI
MCN,6E[%,Y7SIFVN])L#[:AMZA$&MAQN-S8W<.BH1)M,OUF82?'L"=?$-J,;&
MI!#OA_?TTEVAAO_$4D.$!P9DO=3>)TSYKEE/PJ[W-MB?P\25ZY]9 %-.% 4S
M(D''/:MA(4>B,B*<M)/>?5<;U!K03<.W _5^VBJ=334W5VT"XPHY (4(8S'R
M)EOH ?4"-N85MC3MD*O$UYYQ !#0X;WG9K_8#GSN+?ADCYO[IZQBTIU3=MS<
M>HTR/D+G>Y50\91KE#3DSZ!R:A)#DX6V6BNAB[V@.+UERE 8',#=U^;'LON>
M.%;XIKB*ZR<$^QU[=/*'IH_Z46.UG/E:Y[K6)_B)]3K>9M^/ZTF?KJ7>#"N
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MUM1H!#[N'_=Q_^@'O"'C"9K9&X2B*L>&'9:5W8ENZ8XRG$"A_>E%7W!/A]^
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M W0:A;Q)$TR=%J7%Q 3."#BL_C;,+G.?F3Q35X0LGKF-=7%I"+K]RTS.5?)
MHI,O;?T6%@TW@8=@[FT1LC[YOC;A2<@)7D"C%K)FP]!:>YH1[:(R'7ZN9W%+
M(1+I1FZN*H$>6MYQJT..#4'$ORT@=_1L$[(.\R.9"*17,1QI$'H@K8E&B@K7
MV==@"'6(9I6,U &%V,D]H>>&!Y<%DAIXZTO\%^42LLL7'OD5E)H6Z(5O'9HE
MW']%PKI]^/8*#QR%RWJ(&Z&ZD6^1PK4EK0(T]"Q[G7(N)IFE**LO_++2\'OX
MQSJT$,;?GYT8=F4O-+&58.]2]0$ '*X$<+_!2@H*5>X ^P*_;_Y=91IHO)#V
MO#+EX)9C=/X/G\YR?K$B6I)@J&B16XY087L7@W?'F7]$!9>$YY@Y^C-:]1_^
MYF3YM9G=_?[2:UCY;B$N6:DYWK8.N_*P%UV-8$EP /M@3SN$Z($ HN-.ZYU]
M@97)*1(=&8MV\WZ7=U04TQF:.)H87 )FN&J47&Q-4FS-<JD%GV [C=ZNB@^[
M\5HN< -2'4S>.T2<=8CU,2N$X3LK-#ZYWPT4*Z)A$FZ4 ^G?V:T'2@Q[=@ '
M<#)<N;)12SPF&GX&=KOK;I1C+(IB*ZPQAHRA:-7<>+/S= "*3BL'=S$]\O26
M%S.FBFP@E[ZC/_HFSJ;D:%DO"_AG3>=#YXBFY?G<V)3J)JD[_L/:PWZ"? ^G
M6SF ,OG KX2-[3$BLSXF'ASI"N&G/J'[]PC)FJ<7:_?[84PKW"AWU1*<SV_I
M/5'8RT.1(8S+)KT(0+@WN_D_2Q./.%ZW4,8R9#30W![31"/#;P>L;!>U4,EC
M%4C>#XE2(_(_)4C10;"-YTGS%TWSM)<$2X&1K6;4WK4?,S5&%24E+/6V6D;P
M-T:JMX3]&@= O,X@F(LR?_H_[G(M^'/NE\IV6.6O-N*?D]K/%U][;NW>K<RT
MQYNU-&[]>1.BR[R)U+X).W_LM0_?/1_/VYO\7YL\X\%!]6=:C%.,HERO>.DY
M/3>5J>S2/A A]_@;@",DO"G0@^:@\9V5A]'/,I:J\R_?31+_^L5L@#6<#OR#
M^\#T]WM0?/E&9NO2(AP%"YX'=:F^,[S*0,QU6[W=-51.HG0$XUJ=CHT$[&NK
MDF]@11"=4-]OS1X*(KCM'2O!JW"'1 F3\R[!/-?]0D$]0E'TYC\-DZTS)RAU
MX!,@(62B\!_WX_H&-&Z+*NKNNTRG*H:7Z)WTAP_B(5:"\OA!*8U[<P.KIR^I
M X?6[-"?/MNE0VU'Q-YYRKS*X5V(C3X1"0!P .?%EBW,#$OT*T\H_W(0._M4
MYP\'<(TO8S;#>;#!Y%FJNJ7^;LL.(G!B5;]J>!Q-!FN[S[D%Y!>KVHU,E97!
MLZ;";=E)2R.O['%WJ7//"E="IXN_@I>!*PVZ,=WUN&V(..S5-9S\$+8+K*P1
M*'6M;#/JFZ=6]UW&M#<L<S[XA\23@POFK@7A(/2O"I56T?PGGM*2U2,[Y9 G
M5%Y,LLC6H^IKV'Q&T&"GM)RTF/<Z9E^^HO"[DP=>^>^4P]U>-U89#DH19R(4
MS1Y;(EV5.])]HZ\49 (IDDA?C/WZ]GXPY"A8[*C"H<Y>_ CEWGU^$U,E,_M>
MZ OF7$=L-]%B$OVG=H4-NCXU][,=UJ1_^T-J5/I,:[Z\R$*PIWP$ ?4H&5<.
MFK?J>&RH75\S!W6>XWM;9R7D<7 R[3;-O389W( /%_*8'R0.!9LI^<YF2UCH
MS1^'V4)5I@=.F.:/EI/M^C(=&AN-&Q$_O257@@CP&V-U85((H]'U<)-23_%6
M*\^_Y</IWL'S2OL?9=(50EZ8%279"%8/7GU=3TB)R]#.LEETZ\Z3;[5H=_S:
M#SW/_?K"LR,YH?/7KA.D(O8L+O0<U 3+53E8N2M\B@3[3'N\3\G[J)\VK"-;
M[V&'5QIR!->U)K&N=#ZS%1A:NPJ%JKHJV904H68FIE8I4)&8%^*=TQ,C2@_6
MT6T>0JQ*KR)01,P2)MS&'/P%/J)-<@D_=<VT]Q;&*?1 GW2T!)9J2B[_7!-I
MN@Y=O*S1?7KJ8-,X7.1T2;_=JIC_:S_^%9O:R^^-0!FWDL->76@XTJ1G^E1G
MS^>601/%"3&&*@6O-42$YB^3\HSKU;4O34 LE ,J1HBNGD&C5<)O[!VG[B58
M1@1+'HKQ.2/7J6'E%T]]]'L]0)0B128'D'@V CQ(Y0!>^UJI=1G[Q\=[J:>&
MMHUF(>*TO[G&L!'$\HI0E)537LYB3D#'D48!\\Z:R:IVX(HF3\;^_<4=4O)6
M$MO"N\MMR=P;N>V9L\ RUDO>C&B..DE##")JN'N%+",:I3F A5^(1\\KT0X<
M0'C-'N+'!B*]T9MNM;8Q.36UJY^GK#7, 5@[^_OO!6()>S1&UGA,5^CBS.H-
M5(T@<@6Q"-??V?W;=N1$TUSF.SXQ,F%&,I 9O%.1=Z)/H5OQXNP"^XR!F1AI
MC5 (XP#&/YI/8YE[R%O1W3,DY@J!Q&#F/>.+#.SB )2WB5X?*6DKE,.K_*UG
M%W5[IWW,9 2/*ZX0 @VNK#E%"=F2^Q=PA>Z(0=4M]B2HQB>(@3X!O!7=!7%B
MLID[.Q%AJSZ_6 :_YC*O9V>G)"1O5Q[K8](V=.D&_!51EE143,!>>%]M2U >
M@21ZKZ<*)T;Z)F6U]*8G@/LS23]P9[>PS+ D:CVWOJT!HD+"S566#FXXMAZ$
M&3*SQ*3"G#>EFNE'&LG.#EL5<U7UC2<\7$.D=L@< &O[,2WWO',:"6 B7?=I
M'G)Z\'I%^M=KC>]G1>O60AE=QJ8;0@,P_2@[ELY<4?UCK\#D&9VG^,D@G9KW
MFX\7&-4AZV:DMI#Q["<HR"C=9QQ5CJ@*(6YO;O^6RHVZ1_^YI3(!5#T=,)Z<
M8;3RPT;F::C+3KFJW-!%#@ K"6!Q *> 6JNAB.@KB5.CFCY[6T/TYP4)>3DN
M7,A70IO^C]'4='>?;L2(BE=(_S9?4JZ?.HQ4I-37';AW4$R<\SVO?]&\'^)6
M:S/6XL%V#SKU^@07498Z>[S*X62[1M6_KE<K+!H>A/JS0TCM:HZVL16//47^
M;G8+2U7N7S_:>ROSVZ+@+3+64BUK*_G;X'5]A<M$U)X'.VBMI$EF\P=RO\5_
M&V.)3M(-7/5,3B9'/7&TZ_^I^<N<MW(1OOF@>W8_#>/=VUSZ93_Z3$ O7^./
M837L%';.1B%S(')ZX];FP#\O37;M7OMBO0P\HX1;#HN"/$,5^N+( :!6>W;<
M\I2\#U5TP53&PQM_7IS/YO/&JVV2M!<2Z%L0"0OY^GSQGF3-, ]9J_F]D./&
MOI'&NI+^%(ROP;KF^S^.]WSJ2_ZZE4R&\"7I *3_/>F?YG0_<##1VS'>NC$&
M6F#QAH^UDPA? 5)4%3^+_<"<&VK8;F?'#:M]?/6/;*1?&M0(%+)CIN<)I43H
M0D>)U,)$_"=ZVYW[>=,C'N5CSJ^1639JB643W*G7,'P).4P[$_]O5L5$<[^1
MJ_6[PE>RP9Z./V<N&?A&FI*T,0Y)F.=TW#_-(\"'Z :BG&^R,J+Y(Z^)V/+K
M(X@NI&;+F$K%(^7<AG'E]] G:KOO?<I7,LXKIHV2> C<4TST3W*.G="L+7!O
M3DP9E*7FF8\?>MG^(B^WA(A]"9VM(GPQ28__2![+O$KR<1!J%KSIU BP64MO
MF.0Y\Y/_O.MH&<]3'W50+>8:5]]L>)M_KZ<X]I:A@];E"@EPAK<2ECL^S<?L
MVBP'$-#TP)24%$9X5LBPL]MWG#1!W3 F]$4O>4'OR(_ZO94V[=/+](2*K5X+
MJ0@WCETK;P/Q-K"X&^3RLQ>NXI\,YWVW-<^BIP:U9UH8H@TL0'PF4BV>HN*?
M'U>Y/(O[I_UTJ<D-A)+LD3M*2BY:$KT2%VLKO/ #769N>E\K,^8?/;US-*ES
M?$K637OOW]G%I\C>$I6DC)%^Z/')CG.E#43[/Z<.[*M.=I_9S'&!+NL J"_K
MMJT58L.KJAJ%H/I!^:G_:&E9+*7JDCSL:7D4TE[-=O.IGEGUDKD<63$+QU(Y
M7&C=5RMC<A%>!ZHYPM^J]'TUU5?E2["O'&SUB.G/?)1/J-!(*]9B3$/),R-N
M<G-^Y/)4[KR4PK3Y:?Z.+GC4'SOH@H*N[:=G7^6R76!/4XWT7P4EFE_&<O/)
M+.Y@[VZ.X#"9_8;62GF?KOC M@TX@/2@N?11[PEXS*+^PV28PPN;3"V*:[KM
M%=L@?$%;Z=B-W;0@>-FJ1F9,GTU.FGZJ"$].*I@GU0K>M$NJ"V2>WM,,<GF#
MO,STX>O/0Z)V4(:_%G0K2E^F21Y->E)%%O1-FN(BH20#4=:V1O7'K?)&OM9>
M4GMK)V;3A[EY$[.2<WRIQWUIE7SHV5(V? HX@-JJIKQ72&J)>]UR*W&YM4ZM
M[J$:6/UZU)F4Y-MV0!+AABWZW04P5*OK]WJ71OEB13%0UMRG[%'@LI\N_6N3
MB$*_TGKJ3'TN]EO ,]60S6+5D"FE_<'L/8@_9^)_ %!+ P04    " "7@GI<
M1NZ%5U#+ 0!TS $ #0   &EM86=E7S P,BYJ<&>DF6=4DT';H(,@11 $I%>E
M2>^0T+%01$! Z44%I,302^@=I(4FH)0@4B)"0(&$WCL(2)?0";TFU-#7=W?/
MMW_VQY[]9G[-F?O,G.O,//?<UWEN_MXL NX]U]#6 ! 1$0'>_.N FQG D_^,
M_EOM/XO\=]<@NFD%T)(311$])B9Z"+A%2T1,2W33"> " (AN_Z\ P/]N1+>(
M26Z3DI%3W*'\%X"Z![A%1$Q\BX3X]FT2DG^S0?_F 22TM^D>2*J3TAN\)7OH
M?E\J+"6?G.?QKS8&PQ$<K_0[CW"*.XQ,S"RL?/P"CP2%9&3EY($@A2=/GVEH
M:FD_-WKUVMC$U,S<UL[^O8.CD[.GE[>/+]3//R(R*CKF8VQ<:MJG](S,SU^R
MOA44%A4COI?\J*RJ1J%K:NOJVSLZN[I[>OOZ1\?&)R:G_DYCEI:Q*ZMKZQN;
M6_B#PZ/CDU/"V?E_N(@ Q/^%_G_EHOW'=8N$A)B$[#]<1+=\_Q- 2W+[@20I
MG;H!V5MW^H=28>3W'Z?D_VJCX)$VQ#&\\QBYP\@KL\2'_P_:_R3[?P,+__\B
M^R^P_\.% 5 1$_T[/&):@"I@[5HX4'SRDFDYB:"MI/1MP;@2KJ,X$UBO7NJT
M;+ V8_EUR/0>7[@E/54D]D%6C8PJTPSS-S Z==[PAQ6'C605E11]34I*U(?%
M17CZN<V%UJ6PZ3';P.==:,K\BR@@;TY>O824!G =N'4WV'T[F($1T]_Z\;7Y
MG(6C0*I],CN<IER#_+INV7FB[;4SA8*'[TKZ3N'<7GWIS*MJ5PN;D.&).\ ?
M8,RS[C*>@6$V06!ILYE 8=G>\D(C6J_GJU.P^&BLFK@M#W=H9X)_T"4M/*:D
M.P >I*J-5XX,TZI/2CC@-9C:WO]SS-%T^>0%+L55--*2ZIX$-;6.&[E23JAD
M@OL^[$(/%Y$*^,@>JG6';"([X;1;GRS5[T>T@Z+PJ'Y!5=#EF$V(SI9G8S,%
M1CH$6-'G.^6][170G5T^;6_F\,(>T!'.QI.LX,6R1QIP5/%D3+841$97FAP@
M!V@C>7.JW,K^QFMQ?3U;G'16"I%A;S1^R]+.%C1,#*"RC4B)V_G0^. []VV^
MVA>TI]8OZ%L74T%[B@YA8PPU)\7]+W,;"_/Z)RVN+DHI%JW[P=]&3W>O5FOT
MTU..8'FE7>D/7T+)[OAQ1H9MD7.?J!3$[<OLW]LA,GXL#?,-?IIPD:0&ZB%M
M-D?C3NJH27Q]G[Q7>;?GIDQ&XA^JS7S<-N@U:<PI$*4Q4%?U-YGB!,3#$<N=
MYT%C4.CY''P=K'%M<IDU REK>[/.01_?/*C,F;63ONLR#!FNOZ9'9L9=NGZ%
MAI@TU=6,>;/%+M=G8-[>7WI879LEJVW&_TI<2B,J0<R'/I2&9^>N_I)XI-=.
MO*[A!;>;"RJ&)P%G]@'+O4YR-=(MI3"U,A5QJ8ZUH=BN-VY!#-RO\7_6/]=U
MMY-?:^U.>1++2[4'6)^7M>T9).%2PL=,9H2\166!I9,DY';6ZL1:7>G&9%9U
M^Z-=.8RV+Z#V0L3XGK:K< ^D5IUWC]>,4][^[1]_9B5[I1=9"2NKG!8(TM1X
MGS5?)UEOEPJ(K,+F2(*@_HQ1A"_DN5$5"MF?X]\@EPX_]?GUV]F:JWKL2_.@
M5]IM$7FY7_)L_MZ)^B_=]^&HGKFMS$G[RZ@J2!D48KAZX4TV^((3Q!V0UC;<
M,\]/V%\69R1@-7X17)?)Q8Y\,[25M!$#B+_9GS\@IS%K 13S?JSSWN%R(0]7
ML^33/O:2(%TLH;MV(KQ->+!=SJ=?8Z2@(6F4)G$M1R\S5ME;DF!.YU;"]SM]
M,E;0J][7MVID [7QYOM0T:J>V!186U1T?M.UWG\N<#A? %_QD5LQ1>98",A_
MOEGO'U)DF\]-'S;U]7LF5A7FM4 X&5]%"[>?L:)__(CTL:J/2UAQ>[6XSOGE
MK-F&<9/N7N4<]#=.39CQ,Z)<[:+C:P\VJ;U@.YCYTSMP$EN)TM+H;VIRD+%A
M*UV0@H<B/N\D@]37)+(QJ_CZF/=H"K)W!\8OAC>*1^/38-?N59>J3[;N7R&N
M19RPC-=\358(19N7X^^I.KZK!*WD";8MYC8>*$P65>P6X;,F8B[U159?T@SX
M%4_/PA37[-[I-R\''3P+3!6[9!(DVKM\(T7ZI(_.%G#+K4 @X3"'?@I8'+%(
M*A!T&N>AOJ;3WN#9ZJ+@V]HV).4'H$)\;!V?AW%:94>Q;6^D+]@'W;4UXJ")
M;H*BOC4Y-RE,H]%G%IZ[C%<-U^)/P]R7G+0 9XGY_(<Y@9U\F*\@@6_'9#"P
MROK),:&;7K)OR4MID8NZLT.E<Q8>,T[?NQDNC#U&X=CS?%].F280K3GK*5/T
ML;G#&]<Y?K7].-BXIG;_["I[RS],K!1(XMDGU)F3X,720TS&7PDFW2F(^5K1
ME,\T/X-NMAHXGW]S U@3JZRY4DZ?/[T0/E267[X![+[&QRQGQA3AT'7+^K\<
M,PW/:N3\;T?!$T_&JLO<%BS-$1@']&.=CZQOV50X)OJ+554NG^&PNE.!'<%5
M.DTUKDQ&S^0\])[^4M JHV"V?].:[+=[[(>;BK)K$SD0Y&[>-3YU4P82A0IP
M#,T#3__EDF'2OE#;]-@A[?$*K770^C )=G-3;_R5GRWY=^LM03ZVS:"'R) >
MG2U;09.<LRUC;_Z).H2 H)EU_ZX5W\B'\A.@39@_:0L2[&/-T#(E=JQ*3;!H
MO^:>%$5ZQQH9UL(&-"JEBB(5$I>;OWZM_O@SJ1JD5LI)Y4>\*:PKH!>6-I X
MP@/I8P7=*2,;:+Q: [P)E2O68*:U=(UI5%W*HUXH1A3$?Q1_AIS+3F_,Q:9B
MSGFH-A\JE95Q^*#)NU<M#WMW#?<X?>H70R5KJ7R/N883W(><2HJ\^RM&&M"3
M<#0*O;L*MC60*W 8.>3%).[M(A##!P$LQF3?>4"6]$G%"NQ4ZPDXS]':/-BD
MOYT-32#KJ!6F:&)UJ,&/5UJ72B_.C#MIU8%E5E2'*BS9,\'#OW<E(?3)[H84
MPD>?E^J<*.>"'3_O&B>A+M^^3RIB\&2=0[/3U5O&O;MR5ENV3>M%Y6T:'A%W
M<NS\(.J^$. K\<AS%]VN'2S?A%-SYICF=C$F_W'V:>.WK(D0I1 V\)7I.?;D
M_=67HV%Z@G0[)S>^N<C6?2FVFD,JB*LC@VF$,M&,'V5F'O0<RD<W_8RALU(C
M T_K^R!>Y(W^<9[AW'4?%YF+!T1F@7:3_9YJE9)."0D)C@W2@U'O80:U<C28
MK.7N[O]=_0F;&/S6]FU#\!JV3[-O.U*6:FC,;ZFH53:D-B#-]"%5.Q"N.G&D
MJ!._J:1?YH1&CS2.Z9#^^FX1^EU*<M6R^.2=7/='2L5[7^F@:S_P>F4YDFF%
M:9]L]7+HPE<A8#Q(^SC-M[F/-V5KI/.-D]&)MT>OL?OD:P?CPS2?Q@H^IMOE
MR7HCYE9--K-PT:O4:V9"@,9$XY.20&U\9E0UY.&DSI6.T7A%=4.\,*76JZK&
MZ.4NJSZ@%M;P4)^G4**'-_6A_(IO;#5+\$-"LTZ0V*'5Q"4+I-1/A?KGA,@R
M:D*V[&?TF/&$S, ]6_! I8ZI:8KPS#->Y^WUJJD?VLLA<7ELD>;6!4@";+_-
MF$KVD5>BC7%3D (OFFJ@8GO7720#7T9Y./-$\BT+ST#B'L<3;\Y[DPZ$D'+,
M-IRI-L$YR^&SB+=B-F5 /IN2!HO+F^JF\.5' P6]HD702P)M1"DO@G)"VZ1(
M=YC!8F8(?/IJE7G,G'\L.^%^V5PYQDFT@/]M;$EDB9!AQQ(G8Q88HZL]GE,^
MZDS[Z4R4>=OA_2JXMC#MY 9 ==VF(E^#.\DNZ2F'6NCB&79KX1>:$XOCYKJB
M]FO"LHT_=3X^Z^_V]&%D-%U]'\4KS.*[W,P;W);'=FFPE'T#H#$;6(Q.7;9P
MVD4]DLV.-9ZW\.4]J_?>43"!5W8/A5(27NB]O@% ?XS4Y,]<3W$Q[=XYRXJ.
M\"]-*)H/@V22L?>>I&+D0<S"-0)<ZG\L@C$VM ] #7\".0*!K1:ZQK]ATG4O
M_'.^GK])TE.<XNE<4QI$17ZO\&9B$19N$)X7+2PKGVQR&8JL%#2[ =2,.4_Y
M&#;H++L[.^\6']7K;I2E'#Q;V*'%PSGDGZ"FE.YZER\XUBNC4S$Q,<<MY!86
MLYJ.APH#C+EB14H9!_UCC54AA8.\A]+]PTV81JS5U1<5^4!Y=#/^?C IOM_1
MW%)JSOF/LS'Z5,[M;[NTS+5+KI^O"]VC-H>\@8@!]18WHH]7?+^N:KWOO72V
M)AI=(WYH\FMR7_0OK*5!)UXXRE"9]<D0#=*%:R:F/97WSU8>#2K"5<:5H5.[
M=//TER[)]SY>PV?N]J[L*=IL"@IUF(WG<(K[D_*L+;&1!<"K(E:DN7CP:_YC
M-.:H:H1LPB-V(5.BLWB_O_2EGF##_H"VHM6V0X#5QD[P6P)/NPWN\ZRY,]/P
MLBY;Z^A/BWT&1\X[DY>V(E+?- Z=\!9.;F>2"U_=>.G[4V9V::0!MC#]D>'(
M9O&K^&::F9FY31/S!,X'3V?<_[T/K 3I+GIHV%J@R###>!8+:C3]YZL>Q!/G
M >9ID=1%5. 2K@8[&8837QYJ\EV\X#!6C;!6J7/(ZV#-G6AJG&>;>J\1(/BF
M%J83KP7YUNCY]J1F^$N15KQ7-%C&,P8_<((BY&&K2@F.YD[7E'_B9S=/,6+9
MMZR</;NU85JRHCY;_+6Y'#3[I-D<4:C.#V7?3+^8E=(.&SR2-;XO]$S6.-VQ
M[?E%>R&(3P#8Q,=@*.DOZ_7[YV''8L'N6P6&7T*&<0BC.UO5RZ,)FY/>MN1&
M.1_&<\6=<R<3K:X3MVW0FCOX@DUZY\EFY1H\9??SCD)"B/ZXRS&XQ"W$YZ<E
M9KK#A8C-?/E@>9Y\@6B67?#RE-!T$1#X#/]\WBF8))HKQO_^#SQR(J']L,NS
M*\<ET\1.)TAVE@K[/.I]DCM%\*4DP6=>&6SJ9/1B;']_@LLNS[:R%B[S*;15
MF]?@<X$'.3 E/3QT_EO5,1<Y%&4D;H_X6X7^O37/CQM*38%[O+=Z8H9.E9">
M*! 0X/ 0OF.J\&I!QDFOK$8O^-PJYUVJ;C'2]]]Q&_/(_98T>*G_MVU3_"U%
M5]^Q7H&+\5X!\+C!@6EYF&G>6M?;[_O"K.7L[(#(*9/OE+3EK.6P,%.JTWJM
M'S_<B3G#C]?'US;#=K19D8#T+((.Z&4^'3]BXZ(U+<Y';/UZ5CK#-YC#6AP?
M1%U0N,6(TT+(^_ODN]Z>J/XJ%$L/+DM1[%YX[QQ"<NGNF2\?OPZYA>TH7H)8
MF%9.Y3>/%61IPVG$+QZ3L^F)U9!/[B3/]0GD?DPW*_WM$LQ%,.QC#:$CU.A7
M61=/_A:IH59(O\OSC'&I6^.Z09\G2\CHMU#-G5?L#\"@UY^<NA#7@A"$%E(T
MOX?Y3Y'39+:G3^KSW4M,PUZS6/DY&LH4%6B$Y^J:S-J+7>;0ZVJ4=_BQP8JJ
MB)'1IX3JM'.R6[W?LM(8N%"OMB';8&7X=%XS[?#E;5,M3 ,VMJM]CWHU>G]W
M^P>THLU<-2:8'*JJ7XTSZ4BBW3A7J<."$Q\N%8Q?>B\7%)G-9HNZ^-0&'(]X
M[:IL]9O*M \@AI4.*C7R^1(;GBP/1\S3CI<9Z<$.#NB_B]1''<_-S"4_J*Y_
ME2JJ,/*F.M5MM%JBL=)*FP9C)_$#=&@RPO;O]D-*P2J2S6,[,7'[+A#7AZ,R
M<SI/JQI;?!B[VR72G(U/#?XBZSO8;VF[O-7*CY;I??52/O=.J1B<L5C0"/EH
M %Z94Y@N;P1_Z>$B]<E*L5U;6[RRNCZC&J%GF@3N/6-,L2R_WK&H-[:YGX6J
M\87,KR\1!RK6S/Z-4[([55^8=3C\UF(6TVWU!D#6P:(& )!=/OP+H 9<W0#T
MGPNOAU3B6HXX-&\ ).,W@-48FTG[&X#:P47^M</.#:#'AJRXZ*VG5"?"F5'U
MT7JYGH>$FSK/7]J4K,M,?$5$5$LLC[X 5RT(.*3U!>?OF7.\GM?>XM?H68 \
M25<*("*59ZOMEFQC]QHV&#]6>M<BJ<)/4.?&<Y26V9XFS_*[@02ETB(2W-B(
M$:J(_"RC]>?&DWCS<^3U_B'HZYF Z,28Z[GQ%4W.D2H%J=#3IS#JL1T "$CV
M?>680R'-^E<A0=2TP _:/;%(K=:G7*G>1OSUWSY3?DL+5&$HC&0R $"M>G>N
MEF0%JXJH<FQFMBSU4_-:.=U08^FQQI:H^M=N_(E'9VZB6W(7C@\,TYHR;72:
M;/*P06BEN)[6T.3 @H1';60@X K1,(A'Z<UBV#CU:,_2.8BKX0UPBXV$N)6$
M>&B'ZKH.(SPOT@ABH?R(T[),)N.0A"MB$VQA&NYQN]4MU Z.DK8L J$:>J:A
M9$HX=1X2;]"M^N82:O"!N&*3*F(&+Z2$\=D?"R&X9AJM_U7A*)#@E^,.5WG-
MW,OU"-2V/Z0AI>QN@;X!4-M:9B3@81+0Q97%-_<T7W@FX$>;"W_AQFW$]X)?
M8_<N8%\XO]K1P_P&7367/L<N2PZ!>'AM63@DPR7<)'NX\7$>[8_-BQB\ZE6W
MKVF>.G\J1Z%V1U2[,">3F#.>5: *IV;WFP^I0(-NR6Z_MD6[%6I?!R'01>EB
M4M2.S T@TCP\6]C(WSM7#^12B([=P\Q:S'SF=IIF?1_'/>HGR720K#7#\.3-
MP4NH^4-U"5CMD/1!!$PB^,,ZP!N+!E3XXYY]^TN0?E7UDD&O< <(N#[! * K
M[,E:+"  %@:V5&;0*$A%QRV<R?A:>%UFH6.>TC7H+LRF:B/SQ*Y>CS8OE)SE
MOL4M/*W%B\-D/\O,F'I#]R%>?\L7PX&(Z^%Z<*RX:$+*CXRX]["'6WK,7UF(
M'U1PQ4C^$D*O"+*G(DJ4I<B>#$EY$"EW@^<::0J0/7%*3HZO& ,V"OLL\72_
MU;C"!,H5[;PK+&S(U5H.ADLX&!ZOI$0IP0O7.?P3W"W>,T/'.^MX\_8V$?4-
MJPT^QDW[UQ\ZJ&\ W@XM,E/6NR[P^3R>92<5-LT<-N]6'CX> <0[BS!XA!+5
M^A@#'P%"*<ZXDES'EK;*OG*@7(\+6%QN7G0E>]JY+.$YM<+<RWX@.:5,MMXE
M>\E&3;;7RA-Z"P_+<=F@($O@_+L+(PN/WX286-T N%+/'+W$3!'@N;-_UX'I
M2FQOAZ!@$UU 1GN/O/UZ!Z:A0&47D3+DGJK=#>RJ)7B0+N(D+&F[R8>I] U]
MSM=A&HI3"VD$J=F,3ML4&!E)4D,.,4QR#$ARV$VC[+<X?KOF:<&J,M&B VBS
M[5@5RHF]506G[C_9A838=#A,']V%>.U7O&IY?049)SQVC4D,-Z:[%PH0DB!5
M@+D/NR_\"1NR:Z&!C66[]0 .OO F)-S3!'%=??#,JQ7 )=@M/BW@^.*A3,2%
M$_$<\H>!^4/N/%4YX@$JW>[P5J;@ 0VI];4-:9:K&J>:--;/]YNT/"NX 80=
MWGT]8[ =;-<<I)!'W[=(YS^3DJQ'>CPW9)*NW$.<'"0%_:&[^(6'6=V=Z:6<
MME!*7[<>%@X]V?$ [U!4ZXJ^/TB<^)K&]]0Z\);:$Z^9-3J%JUDJ.3TR8-KU
M/50F23NUFOV[T#TJM?Z5G',7%A('L@BC8_^3M:;7,_-9KB/HM,VJD(>OOLY8
M_G)U]>Z:*9]3+0YT;F:8X.'IKZUG 5!IK0"FF5?N/<=Y^)T67??BV4E(FFO?
M- ;VUBF[U=TA#=ZWUE0ZM'G/=2N<^N$6LUMI?\YZ#BDWIYN"FS[I9R529J(5
M^,HM4O4-LA>G2C#W'O]T?891[\RK%CZ7>>3) 1>?H/,2V39#T;7Y#<!815DK
MT(BBMR[E)^#?" ':H):8W@!ND>J#&#;/X^>'<8<=/N<3W9\+%Y30CUQ8%<>:
M#XY=!U>,&*(,;':6_V R19F39R&0T("?A,#/ GV&[BD?>T"M+$=])\0SO&GK
MP2 ;2J?4C6:N\7>C&@6N;(I//,&.IR)I@[PC7YUL#WG%RE@>SEJ Q?ZH=?F;
MV78^KIYS&G<_\:A1;&X< 0?YM$#$2Q(=-=,]'C-Y:&_V8ZJV,M.OK:97K+GQ
MJA_?3>X_C+LMH3;RN.IW%X_IFYI$1C-[52'^+F.R9A.VV)?SJ"6NF$E,ORFA
M=+G\Z[E)]%*HC>,\0]*I?\_'.]\EG>7ED@9S(SOW4!D;I!)A$DE44575IC(#
MWZMO /<6F/>\&QR+TG2K4@>-7J#C5B(3A^!?32UGS9ZPNYOK!H"]90Q)X3SL
MJ636E>OM_B<U]S,5RJ;>!W3^;E_3#,@,C8A,^9RANZ7F>)@<R0.0Y_,M*>,%
MFW2^AF:EY>3>,=#V*%[EK=9_M5*'$*4S%\:<_7!/2[#5M]\'>0+1R%+=?=2W
M6==2?RMVS4Y5&"9P@"LRD"E?+&E)F$5>#TU>A(K?:/M]FOF4PI7N%LM;.GKR
MP$9G+3.VWT;+MSC:\NOTOO0?YF"5B&<28'EJVL=.UPS?DAFIB%H?J@#V%#F5
M-?3UU(!EI4G1'T/7.+^L/*485HJ 7WI B4&\N&#_\K>?^SW2O')7%L1Y,T5G
M?'311^9@GU.'IQN&/H:>>I/&SH)^? S]F3J\J<U3OH',^*L"TMYD+F-K8&L?
M&8R,Y\\Z4OR2/T./V*\704;T1;VME8/PX1BCSNL?9L%D0VWJ]I.),YZ-/O5Q
MJ 3"?<5-(R1F])=L2$R/!CJ@R8I>HPHFE[+O7<(]LC,JN[H2,&BLHVCWU)(I
M^3>#AMGG=U5F&6^#34<B+_,IM%M2=7=',?=PU2%9(?X3^RUBS;&S 5#TW&%L
M\AMJX@3\AO\;#S<WT*Y9C8I 6(V+&X"7J$ZKC0>]-)L&\Y"VYJBXU+_*4U+T
MY<]%7OH3! J=R?.S1M>76T*#1R.(/IU);!^@M03"<F!=4;9FE\\(@LN4$9"E
MEH1_MBO[I9?JIQ-<!3<X\-/E?K[NB^A9J&7@;[W[[$89]DGAEH3G)2KC/V9T
MO9ODM\L74L_3>2L&Y4.RIHQ;%O<:JVMH+W2"IYLIKG)V /BDCKRX8.'J\=UO
M:?KCC8)%&VD$VY>]GYU9GYZCUDI)SE5:$.GHU E92F#UE;9+B.?W)[RB[,VQ
MN.&3'%Q,3\5M@D6G-14KY7Q(NS*B)P!2/F>^-2\^)O^8DX.GR]PENU3_V\RV
M.:]'HM!C1GR6(M2@W(&V]"Y;WMV>VQ.Y0S5%%ML8DM6HM>P2"_623?_B/&_B
M&3U=Y)^,(<(S]K7E.7:ILY&N6!X^TT!Q?-()"8$+XNFY_,_.)/"(MA;F[(RZ
M:OQIQYSM2UTQ1RI:653SKR6V$KH Q:)<E@K#!:/*.V8%<0]_4?">5B8,T\1%
M=$R^++"FTY^>R&ZR*-KOEM9^ALPQ@C1!()7(Z/1'"C^3I(SU# S28$G+$6FY
M12'+?/U9.G/U+?/^A>9#E7TG,Y/0;_I"E%H/:ZK&WJKM/IA&;.(MIL^B-7R<
MS!ESZY4*'T9U1G1DTM;= !['5E)O/E!GPY9+_)T'S1W FVLK^K6N16X ;<]"
MWA/*1<U=8_)0)AW;D"2^HY&NKX0ST8+VT$$VBUGET8@ZUB=(F3F+@'MDA9>J
M-X#PRD">H.<S'2W,1Q#?Q<Q8.^]H"ZZ/"O8[K/HY/;:4-K28Z<YB*3?;U//V
MB5O)5!?JMD>2!N::F?55)DXS0U<MQ -IWZ=D]SGQNF;; 4C6(_"!ZA/9;8M$
M3TT5ROHF%8Y1[_M6RB@V,_OP&X >W&_TU7B9ZW$I\HGV*$(GM$($MSG2::S]
MI3UZMED:&S(=O+#4$QUH]H,0885WC44]\@J8:1+"FDZ6=57+\\_&"U#F4T)=
MI:5['J(Z^MA;N#%&+$=!XEBR#M6/YTHF\\QX\9C+)PB;[Y)S&UGH/.3F$+L=
M#<KI4"\EK8&(G[:7>O'5N^_;YI^R,J..;>ZP%#7^:JE*[=!O $\K#7+'ONSF
MD:=T)YF4J#^$N%/RON'B_7:)R*-_;K2Z6FI\5]OJL;-DJJ&AL_6V/V904 !<
M\6"DXCZJ>FSZ  %V0NY<S&]NSQB=75R5J #!-P"R9IY+U9&CNF;NN<=9Q:'-
MXF.-@DMSOB:Z.EK5.+V&91I:9.A(=?9)W);.P!R)S9:/XW[1$Y<QQ1G@^A'-
M8LMNT(5,H#?*?4GUHX)/=KF%69MWV4:PD-RY2HD=>[44ZK!QGPK,,<OTLD]T
M!^TRIL[SZ4Z_)<ZF2W\Z1I>P4 @5Z%&E;0057+IG]KR$>FKC-'Z..LT_F!JS
MF%C"O4\]5RX:1/YX@9F["C>;?K+>.17 "3U(LSAK>1NH=06[!EQ:U8!58Q?(
ME,B6-[GO4IGGKD7=1GR$C#[TB5>EWU2=OGY8_5)C52?(4/;8*!71V5,TJ*OK
M^:RNJ$_X.5VX=IW ((45JF UU7S.T;^ZL.Y#OF%VPKMQC'%6FLN65 *KCOTC
MW3EAQP2V(&G-AG#*!BL=[094?;1B/+@48MP> /[,_RR5+=YO.7<YBZ+ /E7P
MW7N8UK05<PE)>JO3 DZW8EI:>VQ'!JFZ9(>>9+5/+\^S_:#DB;\=U93[B0("
M 3C@%17)\Q-YJ'9,=P?H/!S+]6TUSW[< !;K;2ZKBXN"!!"(&X"7*B+7XZ^.
M_4.BVOMO^]9KE!6"_+E>'.*&NX)(.(RT,ON-8EUM/V!3+A#$" %8SM2"D4;E
M#!"XR.F^0);CR[R]T R5/;@!=(D*VEPHZ'YE:$G1!GBN/;Z>CY/<GFKR!]8>
MJI="?NP7H<9P5_Y/L0Y>*)N*S1(L)]<(65]4+Z_M*C%Q@JTR<+.7C$,Y*$EK
M))3VO93:=G)PS P+X&0X\%T)(4#'8/4R L^\ =R03(!C6Y@YE&UUQR1,$G"D
MJA6;8=M3Y> [DMJ0U9"\S:WW!4$VEZK'".NN@+O<]U3^:2HVX1P[PQ%PM-T-
M1HU5OY%#$WUP"_(;D@S5+];F=D_**#=UZC)5&?M#/7M/98/C\$^.UQ[X5U45
MS_=>CJ1_/MK;#3UWF)W<%3X+L9E:]NH2#FQ@**O^*7=9F"K121L:Y!Z604RF
M+$'!7P^4Z2)C[NU6Z[&DKN6V5?:E<>UY//0G <#F;@!7.R;C^DSLX]G+$RY<
M@$;U\L)H]&+&J37T@GPBIL(TA_>N&UAG](WH[DJJ+<EAK\HU+;W62TXXPF2G
M-G^Q!;&]U.M>$^BIV&M?<>\%LFPF2^CSTBF^JWT@H;82=K2"([,=QW)4WC;]
M+*,0-!HV$.E#$@J<5=E<5Z)*@/DGO(M$.JPA#X,K^FX YK.O43X$ZUSC/)S)
MET/QCGCW&P E?>?+7>;,73$]]W:1B#\P"I7/P/64I (F?6-FC$13P"F)![27
M15EK'2;<%LS1K=DE^O2VZ[SY0G+MXN[Y#8!1S__TI.)[8 3L50EELH*7 $F2
MI9=*#]+5?"APYB+Y!C :\EABO$C(1=M*<&BOC\_/L>9PH;F>)T?!V79O':8&
MQ*I"CWKTWT YMAJSG-/:U]$Z=J=#$GH2TK"Z8X:):B#7H\4$KW4RXHK =5SO
ML/^;&MZD]&CI;A#)8LB+-^Y]971--X"*[3VY5^\GSJR:% )WRUM6/1.#9&P5
M_6\1 <\:<N 1YRO&5D/I]"6D<B0.[KP2?<3,K=:2,'W@)=&17,U*>$'ZHJU*
MX0F0VWO(,R+!IXCO.Z@5).0/4._6H.&@UI!LXXH2]T;G-A^OCS2WK @PYN9.
MW@!"CF<J4E9J_('/?#" EVX^QWU**[9*;M#M,1AXS29.M'3AF:L]PF9ZXP13
M7.1>:#X[-^M'OO NUL)X?(73[OT:I?9JA.Y8=1NO4\F6AZ5LAW)1Y)_!D_)2
MQ^ >N?LK_$3 X9=2(6(4.YXY4[T*784*Z=V9_!6(32/"^P%]3Z2S>3&",YLF
M9D_F2L>F7B%\0";Y&8M"0K'P%W/'WSI"#0RZG<>+CNW><Z.?;)GX&,MS*NR+
MCDWF_%V_@20A!X^$+W:?56-&4 &H']9@\ (X3W N\-X?,:Z.OF4+BZ1=*WTK
MB+1A[62@%3+$T:KCX'/1G\&HR5PPQ%/H;) A,1%5D7X@X_)4T?Y<<8FL/2G.
MFFM<EBV(<\^&.5"E.G4II/)2&]DFG]BH>I\-(XQD]&N?)50\2;UO7 ?;;$%5
M?^%+$)TL8-Q(34IR?3OE0 BA"5,RPFTMKT#W7]1.R+*U,&V,83;.7RGX%%VG
M,V;;^SM,[/'6,YZ@3[0]'6A3.M-FSR2EY,L1[3H^N'GDLCQ^UKB^44'O>R4!
M:XQG&,_*K?>[RYOFJ* 972CI9#PY)3>Y[WH[*I+<6,XD8TTSPTSY^5ZN8X#@
M\ZRU:MM!ZF SZRD#Q#ZBVBAQUGIS"^8,U1[)=HFR,%IU,1]IV@QXFEW"P%:+
M,LDP-HHPU,\P2-OG'EF"RZ3<HWTH+*;A)OD']O6$&TNE+"%T /4VM>NNZS$Z
M"*>6@+* SL_=-TL7>]<:_GA-B_%99$>\?3=%7P9AM?Q]DJRCM,D>9O<,;NSW
MPB,JQ3?*V]B0S)OCXTL*:Q7;B'":K^Q>).N<N=+6)%\_%;'-=1LF3J"JG+>N
M9%I^'[W;*X"(I5WLKE^#CP^7E@;<6J3">CYP:O&*24BXY\ Z@X17AY/R*CFS
M\7!')?4B:.I^6[/<SVH+'5%=2-'X$65UM-7)<.D&WMKIU-7=N0@;?=+Q$OV9
MF.YY:J$6V1S8CDVTNMS#/0P6@ 50^]/.L+ H#9[(J':DDH.XJ2[>V/+4A 2R
MOS$PF#D"5P2IWCUW-#+WVCPXNP&8_"5,+9GL[/KBSB=GKNE:6*T"U2=$.=]7
MU6<_KOXC*C)ISYQ@_B2@9,!'M.B0<Q2<G2=)G"1I!TWO^3D+]>#Z3-[*R[5T
MIO4!3DVJ-0R\U/.K> ^63)5S#PN5HEBO"#R @H81S+(K+2S7_%">1=>.X7N7
M>H2( .7,Z$MECC(/=8398"D8LU;U8_Y9$2&@'<XP HFPVH8+X_5JO!V^04,T
MJXV43XI\[X?POM.V_3*V5@611Z9IGX7HK >1I#[?U6PXQNR=3KGV^0"5_0>>
M_/%JTC2;W#^:8],:1;YOF? .,C^?TAVM;A!V'!CV"PGQ$Y'+,$9OE(WJNHNX
M?XNHG5H]30IQN8VW0G_/J]1O#[@!P%C?9[O+YI[VT'""W2_9KCX?7<2[#3S<
M7* -U"2:;.8=9@^-^DGP7KHRM628X?S6,#*4V;,KT&5#^_Z/=PMF[#EJW-5E
M#W*IN<CU=TQK@C<DNH7J:-N=8S(=&?Q'H3F;EPS+U%DCSC!QG>(N?BF<1-Z/
MT!D]RG7> GF;!8TM]>SDXTU.$C-?X!U@Y2)*?$OQ 3ILD+LH42FV1V5'WBQ5
M,6W-%'$ZS,CJ6DB&!JI^!M'FSBJ2L;SKQ_+*5.'>:^&+@[PV#070,U>?IFWS
M2>>1(%;S)C>"/Z'N5>(=GU=9KX6&MG+8Z[7G]PQF4N5]1YI&+]NFO$,P#<NS
M4'S>+LVR*\7F%,BL4?A"%/JN8TDO_!=H;5(_GE.^!D_3.>?$]/EZ&F'N2'[9
M=TN#C:'3,>^79L>NOE&:P>3EO1;:XVF[0[Y)%2%"]K)^C_B]Y\]_5)\:$<8Z
M3_T=LOK[*^.#."D]/QG0A8:%%(>0!/=SW;IF=\+/+3@:08M/2)F$2PCS>"2Y
M3\IU%Y6Y(OFE7&@AW>S VI?" T+Z?5G_[CKL?@PGU62C+ 2BDH)P4JBW4D$$
M+&6SR8U!RD6^AC'.O-*GZ7AH/L!;XT;+,%@6]X2"*F/;53B)O]G]CI >-8PN
MQ^\UXI&P8 US<Z;EI)ZN3BF$2S=T:=TD76?;M Y3< -PB%QB$GJY]LFVCTF
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M4P&T"85J8JHHJA[# ^_>^?W(4OP-C1Y92[.&IHOD?).\'NJBD=V-YLF80-X
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MF(R9! 9^2O,I7+*-38<J)66FG 8;KJGF1O)Z+GKUI_O4 0DV7)4]%+B6*1V
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M1X_2/*AG1O5()1^OYU;O</^=X-4R\RS[6F95Y)PY=Q/Z9'_^)N"OYP^^E>1
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MV?J%]#LA#<IBK; =>9!L+J4&_85VK;U%%X_ QBRSI9*E#VW7 %-2)XZO@Y&
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M(/@/@C_X?G/!/*Z? 8*15J-N699H:+VMJ>66C%JF'#9A"=^X</E5W9$V^AK
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M.4>T>:T8L/0%>H1?:&"'6/JO!#H2]3WH7!\=ZM;F]<K+GW6>V$[)GWH%-W*
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M9S !3NV?6P_YSNW*VCSZ+4MISO7_-IXI<3\F%U/7L65NDI%AD#41D> 5(@I
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M:'%M28RW_YR$,;7GO)AJX/3T1-Z.QH>$[Y1+X]]$*"_]"7,!\]=?TJ!!G']
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M;,EO)/0-(OU]^_#%6.KS\.>X;\IZN&_CQS?W<412E\#T3/"M\Z,&JEML=P7
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MT"".S"V0W?3)G^O">Q0\6W]@#\IAHY:8W[6!J0#VZ6%FD,0G+V;51U4A.B4
M,^@TN$]-_.D>$.*@%"+=9A;<',Q4M<KM,6JKHF&>W:8OJ4]-I.R$['T?KOG'
M#K9K2(?6I-.$B!Y=\,W-FV6?VUT445D-O&X#B>7OA)LF_K)[H-QI[9VQJ'1!
MGB;]FUQG+/@7$SP&TR(DS>]=<?DB,<9-MEG( ,TYB/'$M+FI#ZMQ*9R]03;W
M;J?P%4Z%_<R=AAH#D5X87$MS#F/J1;_)K@1E-62V;TA/T;K;]G;Q 3'.:,5:
MK]\'LV6<I/%PZBB9UD&R.84M+UO%.B%A73Y,,(VEG>W*E3> JTS]LOZ+  QT
MU*:I8@T@OGD,G3BII]"+[.!<.4O33RV1)2[8.<S()@3<V?693X94LU-;[C&A
M74Y%9R<5^8L(OJD_MR#C3Y@]^^WED__=_+$0(5/L5OJD>AB]S!)V#=SD[6[#
MN%/^]8_EV]KHI>WC2/)VV6;&GKS!U=3J9%IJHE>@0,U@M-B-A0I296<8G/0\
M.'MKMW:A^[53\Z=I:)G+N\B/R&:"T_?=EW==KJ1O5&73=Z A&2PC9=K>>V(Z
M+BGX!TX3>L5-#+9</!_NZ_T^K*8:O##)\QBRJQXQPB[V#\GJ+^4LK,;'EU-4
M-0[ !Y5M%*7IDOSDUID+M;\-,DRJAM1VK$GB0U[+\2J#%: U48PSHR47&=)'
M:ORW-N4VE9"EMG+HH#) Z0Q=^7/V4<\WF:]R?W!;,UX_!Y*+!@K^T73A3PH\
MZ\NUY.B4PWXE\GT*]X?BN:/3\:(;T08$Q=%I&#["FG!X4ML,K+>F#H9(=F7>
MD4K?TB0^J[FCY4Q,7AV+$FS^!Y6<Q%TJI_? 8$2CWW#H'W7]>Q+-/\1NG!<I
M;(83@?S1[* [7:^Z"&WO-4#1TD>RWDZ1HQ>_YR"P5.WF3SYM-_'\US<;Z>^K
M)/$Z_'&)Y>(I>N^GO.)759$DEB:^XK$^"Q6KK>1237.]J'R*$B\M.1]]KH4>
M]<FFWGW<GS7<&^2!3'>N5;8>S9#*N,*-+]_O5^"8K,#X'Y](_\69HK:,5NL:
M]&.@55-].Y]WTJ@*H7, 435Q=[1B@LZJ)"]S#6J)RU_YRAZD@7F=8_G0F0WY
M=6F3*@Z%=.<+M>@Y1=S8J\H2R!FIB[-O8L?*5>EA3BWWV;+I3:=<(*\L#BS9
MGQKG4O[K:ICT?$F\^ WAS4?<-F8CY!1FC^X4.^MG7+GW!KSB<FY7^KAYI*U(
M["TB!#W]ABJ9@];@F6R8)D-(!>A8WK$(>*"+ (@1ML7S)N/JMTG*M*+3:?&'
M^2T;_W8[G7.\6O+@!38JK:S29LL?IR0YL1ZQ_":C?/%!9L=( W9_N.16W3K4
MX5&:>0 0E3,Q;1HZM1IZU_YD(TRR;]5059J13%4+)X3'@6Y)[#X@;GR CGOY
M+R<4W'"VY),@AU8MV:I/G^4CO(HZ1G8SP=YCZF/NI#F=5^)T(3%HT(=C?FZ-
M*V H;L0&8T>ZWBW-W9E:N#7M:7B15(!(;H*YV'%U33@EJJOX00H]9,:BTN9E
M7@6X_PZU3>0W(16KEJ9 $605T@F:>-%Q./+ ZC>1H]?K6^M/A<5'^BV)J%/7
M]+=0@^<R?64]/ 1V)?&F*^N,LPQXS:AE%+:O(,:F,^9ZC'Q-(OL=<H7]K7L,
M.26P6-1Y*$NOSY_2_VS4E(_BE0-L]5S,(1!ZAZ6KUQ[J/#!+DS47,4H_Y;5)
MDG99-31>:%A5QI9NZY R)4ZA0\6YP$)=1OU.%B[N=&2PO^-? <VM/!?5+R$\
M-$>/."+V=+.5VMZ@EO\\0!;"S'JI5QNQ_5E0+TA559\SC;P-,'[EXG ZT^P:
MK79OOVY3&BV@JB2%BP=FJJ%TD1:P^*@/Q-3EP7@5'.5_2<,! PXXT)!>M90L
MM+]:NJ1!YPL1\W.@B"W59S'.\1<\)L21W8)PR/V/=G,+-B,,ZV#6T.25X6;U
MQU40AW])%BWA-STROX[^'GL?,;=9[(KJ^O 4/O,J&B1Q^F/U=D(*39+?[S#^
MBURI3@8*A#Q(NMX3[W6\',N-C=J5TEXOO$T?@(/RH(];0XM5M2=)>*]Z#].M
MO3*K6DFAU.*/<D+?-@XHV,@BS3O[&K+?]:/N6O*(CNPG#)58E:L//^Q_@3"3
M,H%"XH9)WK @0(-P)+*XQ7&8OV-(N=3K[4$^ZT /TD[!#BL^(B/_98XZ.O(M
MO<)L %",/9=2HW^(9W5F[VP"G&>6_]RFZ!(K=3#DC%',3AW9>>!,*4Z*ZYU8
MEZ?F+/?O%]\V;K,SSP]3:F_+/O71W$G_8@/IXI;WZ;0-DH0#JG59)?W$YK@.
M>?CO%'4+(X99Z^UM(4W_9/^1341"Y]@.XN0NZ"IFYCR^P?*GUUC.-:UJ0V+#
M2);_ZJT5#-W[!G#\K#Y>1M^!9WK7$@UO.P9?Y':YCWT \4KEX+3S1B-Q]OSV
MR7W!R[V)P2/(3O[-&C]7A+9PCH?OC*%?S5:FK^T6DRW9"_U7C5*.,LPJ#)Q9
MC;T+ 'V:LS.=[*/?5/H5HVVC>EV/O%/[\"Z%^E& \40;8S>Q]/NQ1==OF>-,
M2W1W>^B'AM?J;& 5=EH93KX4A==0?>5F8/IM5:,J''=*D0G27/!Z3-6>RM"=
MQ.JEV )D>'V[H@VB1S/RD6&156>AR+OVQ[BVMH;$!SD_8HPBMI;P:]H9QTW-
M'9CVQJ8W(;!%Q^:#;.V9+JM9.'U+OJ&!56J/C<,BY+\FC.<&OTM]7B'+@M%^
M/XG0'/+A3O$;')N48-#[3ZJ?1]S(?CT.[&1-'%0$K<BBY7NFD04NR8,,LY?^
MF2M:(Q LP9<T]4B+DG1) BX#P'S-1&)?T6J>-$"X@MMCA 4<-I&P[]L5\(M/
M%^__>DVQ]9-0#1AO"B+4Q*O++ S2^'B)?!R[^NGQT.>LM!_<79&+RF@&(CD[
MC<04I<0U:)I<7WX+/G[B*)];J.J-$*K0-C^IF@ 7G27=8ND+>2[OIJUOD"YJ
MD,U2(-F2:^N3DH8(Y.E[[%E425F_:*?>"\->TEQK__>DZYK&#5@FGO']X5I+
M)^GZAW9V0@VL#?!7VH,\=]NU<3-X0^,7$T6-G^5X;XW^Z9$L"9G*_?&*/SW^
M_"[%[:*$<I^X@>\BO",!5SFZ:QC@>B1'38;.VQ3YQFFX\;EAV,0+IU&H>+?F
M=2KG9LIFTQ(GH/[-V5YB^[.31E7ZO%Y@\%1!].'Y@\D]S:_A;_/%2$J]R6S6
M?QIM"M"/C<V:\RS9B)F]HLAJ:4009Y^[_W!4LI(!9^+B;E6"L/U[/[RH75@+
MA9?\#X[Q7_)R;P%[@W%,)TLMN1+/RZA';-A(RC=#PIIA7MIO==UP%TKF^9#X
M<$9R:&=(HM;S7_<G7DXW*-@;6,6_:+?:Y<C/AT:GK3V5%W%@BD\ "MES^Z4%
M%1',C,;UQ=/+]<<6?>J?'[%;*#\QBG+_E9JR4?YJJUE[SF%H+'UPL$&\[,]D
MJN%??GC<51M#N2.."^]!^IF2ATG;:)O=3#=\_ B+Y<0EC>L8!_SYE(;TYMRU
M/-SITCF:CA0Y$/C>EO*,Y(KL7?:<I(CBCF*^JX:5?K)9M(?UJ%GF=<&0ZG1?
M^@6@2OJ3.R_K$YG['P:$#.L5)2G#RP1J,4XPI 02=ZL6?4O.]OM;758G!:N!
MB>R^DO3#9,DAM'C40X1?^;/%7/HJ!KE GZF6[1'XNW/3L%__>WSHLA?#L<S2
M*4-&F!"/DQFS&**^N(L&5)'1_=P5GU?C=8@QT573$((E83U[2:VMU H5RL<5
M==P0[OBJYG$0.9NI;U2=:.':H/RP4Q^\/:R?:^=,^V9^3?]\,-4F\DLQ?N$T
MS7/+T&^PID'%_#U^WL$>Z>SL, GL/J/?12+)-=;$TG<E-O8@R-QN3=EFRI]6
MADS'JRG&9=O9^?42EHIGKU^*/_XY(=@R]WXWB.V2)LV++*I$80?ID6YYA-_4
M=,FQOV[SUQ1YVGCVDFV2(]J5*LDY?8TV*097,_.OU$_)QZ<38]X7-X&UDV-W
M">LDH_:*3%7%/,3,M>R3E4L:LN@>A?TZ'D2XUJ38-+<X\#:,%<R! >#XWW>R
M3M/C078SSY>,D*NA+D)WR&.]1%IFPQ"9^)Y.KN;0;(M/GX-.0(D8\@ :Q--Y
M'=(ZG8B_I&&'<?3.)?="527#^X!SCZ<JAHFG[3P>G?<FU"7+[9:>4X6QGG#G
M!R6.UVIX.],5TJL+P$*?=&D'+?Z41$0SBWDZ8)C<*\R%5>/2'#(V3'+32GC\
MU(326SR/(.H:W,PIZ>[[XX;#66)PDO$25($3P7YXTHHZY?MP1F=+C(EO6*9[
M0DI]T3&A8-QHYS!C:QSH1S^U'N]:"AX,*7/8;+W]5"T48M&,6KY(QLT;:IT;
M SN30(I<SDU9 T/+=S2D!VO(('OJSX9SOBS<(C/:A'@M1JA)U+=3)+)7]39Q
MNS7>/5#5&W0'$BB@$J!0KQ/2IC<:+Q$],F=3U2E(1*#/K2GB_YL_P30GF9A?
M$%)DN\V]__DE29[;/QM:W50.%ACB?(F9FT(V5(:J3CZ1[(HMF9;Z[68PE33V
MLUT!)VD\H,,?HW$WWCB^ET]F$M7%Z#Z7=USHXPCVDMPAS?=!@OPZ""]KLW%?
MTO<<9G<E?W^XEVMK*!2PC2/ZUECF@I^6P"WO8PJ-LJ$M4S6#^JQE&-,$:5.D
MO@^"/W@_-W07[,?IY',HDU:BV@!V_ 8# ID<JK 2CEJ,!+%)I$-QD>A<^JT
M$5/#A_VL6TJTK%_"+BYINEFH2LDQW \*5F:.W*750TE^?S692QVXLLV3)S#?
MGYU8$RL-?-(^O2-?>2HA+=SP+6[0,Z 78[KV6K+PP5:WJ^T3T*0TA66^]R]X
M@!+#Y,)^+/-(H/;B.YF)!0EA]^;@PI/P<!Q2#%*Y3 /SW)T8-L' +>C[WBO:
M=):X!<K;V"R!B?,:A<<AY271>@3>KU2Q3OJ_IY(*AXY=W^R\2S['5>YQDL5-
MB%UQ#04L<"42\#V<]RO\.3&Q(+9@C%C,O=N&EQ2WGO3TMY>VK,,0:$<+R_]8
M8N_8+FAMS#_NBQ2D7M*$#<A09_@8?N7T@5#7NE9X;8_'2<]L]J(Z&6$\N*42
MU^KR_W&M<U/!:F!OHCC:^?G$X3D,N:O0-G9K=@%0N@"+, 1X*824[PD*:$X=
MP)]GTN+EC(0&W=<:_KC\^N[:\"VER-3DY_YKH")?J6>Y4UA]QKIIE)TG'6],
MKTZN:Z1?0*%ROVQXP6],S[ FHI>+/0#XZ#OVI^MGYT)[BS5DYH:R\E(&0.67
MU6LLS9;I]U7?P15JK:ASB[-.L6TN[B+2CF)&]B-2#] .S)F6&/_M1 >(-#U9
MJ:?5Z6E3<%3/L_'-,Y$8>0-HLO3L#I(WJJ&D=7YVQM; 3VU^MENHG/"*Q,R6
MX6)U\[^?U>.[":MIGS[6L3L$GKK^DKG/]?9:E]0ES<N:60_IV0T<-;V2C.U+
MI=B1,8%0/ZG*51![2>16/F>\I;EJ9G2[>/F\S:#Z&]^K>D<\;2V[U37Z\<J[
MJYC".(Z=3C7J(O\5#6;R N4^EBKL_J: P\O?/2 $]*^QM\!4U>'VYDAGIOB8
MA"\86K'-+&[\U7W$YZ(FT(TU.WMS?T;"4/-@E-ZI7/40)YP8E[;(B?/>-R\?
M1Q2E6918FHPK;G!JB\NGV6,)4UN.:SK1TES\.U'*F.-MWCB$ZD2-K94)O(+5
M @SQ\$X'# $3<A'LH?.AJR"&62\6#\L](6B! !<['C:O*?;YJ]26%;$P(D.0
MQB>.6!"OR45E_7-V.^.2AMFL>Q.W",@>D5 /Y,OT@U2JQ_V<SLA6+.3M;3IA
MUKD[ (9"'R]$/E#F83O=)JFM*O5N&]#E:3YI_D6A#?'/X-B'==DZ5R]N6BHE
MO.J0_/(D!!IPT0*]ZENL.+>VGGFGLR4"(+D6,Z*]$L8#R>?'-,3" 8IY^"X.
M<O;OG\+DY%6"SKP5J25Z%YA..-S,&#;&4!1*7GZU=J=RUF$DJ3\^Z08<MWP<
M6FRVX?SI;Z][GNV3*99F&@C>2D,*S4%L%=P0"N-KZRI)]IE3B5RC135B/N7<
MI@ +DY035P58A1A@27W++,TF)2*^;9!<?JX8U@?B4'<LIH"(_#V@!+YKY$CB
M)8WQ--(?Q 2[WD-]/*$N4CY+CK["@'"%KB3SV=B2W>P@,S_EA"]IHB7]1[0-
MD>V"IOLOGH"R-!L">VKX_P3+$\ XKP\:,L0,A.?XLD<P CW&"@LSU)B^*IQJ
M/V&45SG@?"?V+:0^2#*E[I,@>OZ$@\H2PC-A>M.1^0?9M67?N=E-:,UF%VR%
MROEFQ^Y[<^W.1W&Y2YH7[0E>>IZ"X>V9 B3+Q=CG.*%$NY1K3Y2Y1B&'\!BE
M4=^!*(2$"ZE972#-_:5L[?LRLX32+7WY"K-$=<.'+4-F*(]1]9%.X)OD=Z.R
M*J_$\F4=OWGW3/<-&C#%HZ<JQ:9<OI27FYO&HT?M:A-X_(MVBU%U7N1@$L?W
M"SFB1_**\8>P^T2XDMG"\..8&'6?BL'BV,E'H[5@(&-XL9;,2_A48Q)3U[TO
MFF*4DFKJX$EV?6R[]?\@Y]-/G,W0UB7-C_=9_.[6[%."UW_^$#S13O+^9XQ_
M5HD@><Y.H;OXPF<(M"(*=T53_$_^Q5'\B"<V.=_#!";M0?!X_,W7*$E==*=(
MW&J!HM<=]^RD+U$)&4W'^[0^9!)I@'JSA;3<K13(C>VA?T(5(GM.MF/(0(LI
M_\\4*.3N,TZ@T>152U5@[(1,H?Z(5[%'Q37+)2)EZMP!V&>MZ/:45?:SW@JD
M$FR)JL!M&1CC)A/U/94@N%Y3&\TDPX+8]=DWCI$U8C/J%G;:BK^7Z]$/+4IK
M D(P9<733>E<"-<JY\)36J(6CC%*@Q-N2CS,YVML?9._W#^G,'*$2P'\;HD_
MEYA=@/KK[&NAY1ZQF:Z_^$Z*/&/[\LQU&EF]>T5;.2!KU:=!\%8)BW/BE\PK
M&W:D_<A)Y]^7- S5;2M[<QQH*@]I+"H@^>96:SM5?*(8TS ?,BS>UYR)#E1=
M\!N !D%?-QN,\+GGXZ_XIMQLC!T2^^<H.K6\+Z"49X:W")AAT>1VR^5I7?^W
MZ(#O J;%Y3NVG=IA1:GZJ<.GW@N=@U-YZ0K\KVJXH;[[!^+*#9*\2S4MQ)E8
M\WS9J=XA"S'EFF#?U')A(PN!T]S%R>K3@%EY9#UHO 9=PSJ[ -<@2J(=GK2&
M7X<YO5H48%^4BG7:$!G=SE Y^=KU2)V'] 8_UDUEK0<3I_-Y?B$_NQ5&&C1\
M2/*%B28!-$KCJ,']L! ;V$^[U9N^8QSQN0'): G+!R:7-(,NR?/?*,[#,>A^
MTHGWH>!QV,@M62IHMZ"P1ADJ6M\_,_ ?X_,[L,?DJ[G4_[(ILN3%2D/(N2F9
MBH;)CJR )RMO[[Z0W"5Z^_2/#]@=Y*Y@"17#;?I.G+XQ6[ ];.3,ZG9^.EGI
MW,#N(N:X=1K[AO8DPF[EI><K3!:,T"8Z:NS@$PF*7S=M9$YH'6#2(IDUE>2=
M4\["$C,&LCL"W$:.;#HS[0HF"! [LM8QD.05#><E-1UG_VHW(YH])<\S%)YK
MD;>-QE&2D(%.*7(H7WP%Q*8Q,8B>PET0Q1\PMTQ'1GJ^G/P*@0G\BQ=U#)=I
MVIH,4R#JOOU*VJTM">L%U:'.DGL:)5<A/%V)RRC^>&G_P.3>-P[LS=<YSC22
MPZ !BT_GEG#0(VF9&,@'4ZM/G\-4X&H?_US2H( $A6 N05D*^-N4X^T>F7T0
M61JM.K9[(J-6DK)\C\&7[FX<-8*J&=ZMI\%,'5^^U@XA^OTU<WJJ\.Q6YZ,F
MS#W5L=@ XQCB'QO_#(W[$PI8.2N8GR%W:=&Q-D8(X]_B*5WT"=<"2=2N]GSB
M6.PAS!T[F291P\;C,>=U*CR%J&QLG-M99@.HGIQH/#Q0T3%L&+Y*\/AFXH.U
MS#NW*U@))WRE/IQ&V1K2'8,ODMOY)?L([2SV!E\HMB3>J2J&][%?0[7PYCK
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MB'8K>YDB9]V30<6F:F]U9W P&";K%,YU"^A55Q&%>B%577H2WD-B-LR&J)E
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M?L?550G)&O8,*ITLT6)W@*@A6:WL__9K7M9&W@(<O1>\UVV3_*^./P;8/;)
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M75.MM&FU#A,U_83WVS5)?+6,$S6%2AYB?NH)[E(>D[O#A8N6K*#6LU'9#*]
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M^B];] (N7TRXS^,IX!"X3G9.5PF]WO2 87+>G&%B11]0W91"3]4(&.M0#UN
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M&DZ?TTZ19-T!/V 36=/02&4-3=($W2QN*(7)7QO]_P^=J_X"]84?7AMS<W=
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M1WZ$EU5>L+0& [<<J5RY!>3C..ZZM.6&_*VQ_8-1[A':^*AK,(!.8O%?3+)
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MB9<29[*><Q0[^VLMQO1&A=;(($L@>Q UA'GVP-LH%]FO^54]])QK*2WN+*\
MQ]C?3A)(BT]69;?\C8]&KVQOAZJ2[]D^G_:/1/V<5Q@P@QM.!93U,I_V(/RW
M98%TX29'7[Q()(:(O!L]E.[=BN93T4^Q%^7K8\,@H?-MG')F34WB;XO,92$/
M;WL5BU.E!B\F]:=1'WT%&L[J]CAHSO:G#MB>7_8IJ$:O:(M$G0_E!]5 HD-#
M$]([6$*J6A@LO;ZT2Q$] GE>S[VY.&%"K\BI/3T+8^QG46#09 SIVIQXTB!\
MTS_&DD/ULQGPJ@RMV02(^/:JSNF^ $-/(3H#,OI08K-'T*_!T-3V3-Z97QL6
MXLY266E.^(">_E &>CF73O<7-'BJ%M)"T3TC\&2BXSLR0"@WM];Y[S&F)\J6
M!WNR]!<]]5'Z_K*0Z+V4F-+9LC@R_:4)'[:#/R>?%K(G6Y+H8XU8:;7QEX,<
M#Y5DO&IJ F!D[LTM[/; ['QR/,QBVJOF2;1;+@<P3.)^H(.L5/)>0=RD3_Z*
MLF/O(WU/ >YV@2]YH@(3:D+N PS/Q6AE?%_T<]GK)-[-7 IWGPMG5/<N[Y1%
ME8*U$QKI7+7O/WSTX;%ST+U^0:=4P(_-^2BXDU3%3((G8J**6X?I8]Y8AG$Z
M-^K22#^@07FI0W[ 7F!D.M&17YVO/6!O/:VY%JU@O,.PW/S>_:I2F;J_RY(.
MJ?>MW2Y&R96MJ[$SBP8_=!-@)>B/)GES\6C);L_@A<Y17$T ZUMRYV>_2.R8
M<1^S5'C%06G:;,@*%XBGL /R[%K087'SOU?N!2;.'G>94T%'9*:9ZH"=\]"+
M2;R"<#>K;(*2I,/#@O6VSOTRD^>X,TG6F^['8JP[\7P7MK&RP1Y/,]XS_Z>:
MU4Z?\S#NF>?VV]3&>L5B$8GQWW?3.I@V']*_H% C.L,W)Y/YMTRR<P5FBVQT
M!XT^?I_-*1K12\W0ZO-)]2\+R> D.2;)51^[XC'*U2EEWAY5ROACG,$TLQ/@
MRH(K8U9(JUC7,2I=NRE6#=(Q<74V0.B>UD8?<D^GTKP+G_P\P$A&8O%.\F2H
M%2"B' L Z#-=,:X?#^;J]UTE2B0L1O&?U$N,DQF-;9E$:_R/B^K12Y7(S@7_
MWR04BVI17$ZIU*3EO'LOAKG6W^LZ:9>-QD#M3X#LY(9[#P]DY=\D*QRK'@2P
M('\H/9#K2_34X[<4;]?FROQLVCPZP97"4RJ/J9<8F$M+,N,5!8DB>);_+M]L
M+LXI!Y[;E:-D\BEO 6Z+BC:VF N..U"3NFCZ.MQ@#DV"L$LH6[X] E>=SN?2
MDR0S_$3AIMS3:_(9TY>]P+J2PAMN+",F?U!0/WY%!A^%&_YA:?;A_P!00*^_
M=3^%G@#3/!OB'_A#[V]OK/XE^$-6\2-X@\/>/_"$MT\NEWGV'4]-U>WGM8K]
M8;B+5[B+[1IM]IS:=-^)_A7Q?JWA^YA-G=-;>3C<J[E"J2&92N K;MO0@,3R
M6+!FK]3OV>/B#J7Q)\+_ !BBO)FN/["^&'@ZSB$X7%O!_P )1XDO;AH@Q;#%
MYED49 .">1G/YIQIPSE5# YMQ+A:2P>8^S@\72H*%/#9A6G7HT88C%4%!1^M
M4?;.3Q5/V<ZRE*.)56RJ'Z!PQQ)C,9B<%D.*E[;#PE4^JSJ.4JV&I*E.I4I8
M>MS7>&JJBD\/4YXTFHRH2IW<7[Q\?/\ @I#\"_$?PP\1?&GX4:!\0_&MIX6O
M4\.MINN>$[SP;:S>);E();2WOKV\>]FBL8Y9U%Q=6]K+'*1)#;R^9AUL?#+X
MF?LC?M(_#7]G;XC_ !6^.UO9?$OX&_!S2?\ A9'AG5/AYJ&M^%]*U73]6O?$
M&OV^I:[JNB7,$=AH^H^);&!=.L+N=]3M9(+2&*7[4QKXQ_:F?6/B;JWP:TGX
M0:3XMT_X":1\)K32_'NB:+=G4]&\6_&&WEU&;5?%/B/0-*A\[1KW5#+IMSI_
MVE#I326D[V<ZO +<>2:1X3^.6@?LJ?&[P7=>'9M#L_$OQ=^ 5GI:VNC+)/?:
M1<W^OZUJX_M"U6>ZG2Y7P'H$-Y;7J6YMI)]DV/.39^(2J9KPYG->G7;R_,(X
M>=*K3J1IOGPV-@Z<I495J<Z56C5HN,X5::J>[)RA4IU(-4_T2I1RSB+*L.IP
M5?"+%4<1!JM4BZ=?!555H^U]E.G.-2G5@I3IRY(M^[.-2FVI_57A[X*?LV>)
M=.TFR^*_Q*^!GP#OAX=M9]!U_P ?^%= AB\;ZQ]I1-3L+:=6TTB[T^!X]0N2
M9)7,4R[551N/3V_[)WP2,;+X'_:__8^NY"[-"VFZIHVC7#R Y0,UOJ,L@+'U
M<D-C(.,5\+_MT?#3Q'\1_ ?P M?#%C]OO[/_ (2;4;R&-7<BVDT_3K<2D1AM
MJ^>%1F;Y=SHH)/!_,VY_9F^*D&6D\%7Q4':76U5T)/3)SR2""" >G;D#W*7'
M&=Y'5KX+ 3P$*-#%XQP5;*\OKUXNIBJM247B*F'^LM*3?(O;6A&T8*,8I+Q,
MQX$R#/Y0QN82S"5;$T,/&K&CFV94,/)4J,*<>7#4\?#")N$5SOZM>I)N51SD
MW)_U%^&?@5J/AO\ 9/\ VQOAC<_$?X;_ ! B\9_#?7/%.@7?P_\ $2ZR;'5_
M#OAS4;B*345!D:WMYKRPTEH&C5_/\FZBWAVCQ^H_P0\<Q^,/!GPG\=6T$5[9
M>*_!O@C7D29L.T>J^'=+O2KO$SJTJ23,LA7*&4,N<=?Y4O\ @E+>ZI\!?VE+
MWP_\0/#NM6/A/XU^!-2^%]U?6^CS7]OI^M7=_::AHUQJMO"2RZ>YM]0L+J[6
M.<6IN8VDA,#32)_0#_P3_P#'_A"?X'_#OX67WCGPJOQ+^#B77PV\<^!9=?TN
M#Q7X<U/P;KNH:/:6]_H4US%J9BFT:VTV\MK^&VEL;JWN8Y(+AU+$<.)S/'9Y
M4K9QC5%U<36]E6KTJ"HT)UZ=*#4(J*=-5/8JG4E!2YG']YRJ+N=^$R[!9%A<
M-D>7MNA@HQK4*,ZZKUZ>'K5:D>:;;E5=+V_-"-22Y5)^S<KI(_HHT?6H[[P;
MIT_D"W$,3PB-2&4%<-U*A1G>01CKZ8K^63_@I+XZB^*7[:]AH-A=:=>1?!*>
MSTS5]3D>VBL?#49\*ZI:3:++J,K!8=8U[Q)XEN9?[-BF\]K#1+C4+F*"*.W$
MW]!'C[]H#X3? #X3R^+OBS\1/"'@SP[I<$M_)+KOB/2;&YU)8K?SAINC6$ES
M]NU;5;]E2ULM.TZUO+RXN9HHHX&W5_'!X$\7:Y\1O ^O?%[Q7<[[KXS?%'XL
M?&"PDW/<F'3_ !YXMO\ 4;&QU*3&Q=7L$5K1K9KB=K>!;:&.5HU6*+Z_@-*>
M<UG9/V.7UJ[GRJ;@J5?"U%97=G5J4Z=/FLVH\Z5G--<?&M?DR>A%IJ=;%T*2
MCS."J2J8?%0>M[35*G.I4<+Q7-RMN2ARO]//V;? O@#XD^%/#GPV\<Z?%K'P
M_P#%?CKQI=^*M*Q)<VNJ6VA_\))?M&#9NLS[[^&WN89X&4J\4<HD)49^U_C7
M\%O"UIX:_92^&O@#24M]#\-?'/0VTJXN[9+Z^T+X;^'O!-UK?BA)+S5([F\B
MAO4LM/TV]G5_M,L<\$!F,@0'\9/B+KWBGX:?LF6WBOPQ>ZA9:WH>HV.OV?V+
M7IO#=R\%YXI@O]4\O4K2YL[DLU@]S;SV"7)34K1[BRFM[F)WB?\ <[Q3X[TS
MP)\'_"GQ:OK2[UC6/"?[/>DVFDZ8TI:V3Q/\1-%\-F">?S69IM3E@BDC,C?O
MX+>)2) UZ#)\9FKG+&9A6;7++&XOGA*;Y4OK%2I.3@URIR@^5.]^C5M3TL$Z
M=/#X2F_B^J8>GS67,^6C"*NE>5HM.6UKI-'X5_\ !;*^\8_$7P9X*L_!WB[1
M([*]^(^NZ?KGA2UU>.PGUBWT/PVTFG1O>).EC+;V=V=4 TR66%;J>ZM1EY(-
M@_$C]A?0]1;XY:EX=N;:X@DU'P7%JTD%W;R*\D'A;Q_X&\5+*A>/+0R#0[B%
M'96C,FY8Y&)R?U"_X*#^+- \077[-%CI4;Z;9Q_%?4]1\2S>(['['IAL7_X1
M^">YU078\N:P1)[F745D_=BV,AD($G/TUX5_9&^&G@OQ$WQP\"VFG:7?:_IV
MG^'; Z)J]OJWA'6=+\0:]I-]J<OAZ.4W%YH]REG82VL%E8ZGJ6B317,AMQ92
M1+"<,HP-+$97]>K5ZM+%O&UW",J+EAZL85(-4E6A+FIUO>O!R4J3ITVG:5I+
MKJ9E5P^*>$ITJ53#3H:N-10Q%*<N=>TG3DG&I14*:@U%JJIRBU=71^0'_!6F
MX:+XY^!M.#Q/%9?"^V*1.6&R6Z\1ZTKM$./GDCM8%<9(^3/';XO_ &AO&'AS
MQ3>?!VS\+ZM;:UIO@KX _#/P;<W$$$JBUUNQM=0U37M.E\R&%WGL-5U:YMY7
MPX)7Y'D7!K]?OVU_V7K/XV^--0^(=QX[OM N='TZV\*0Z3_PCEMJEA)9Z7J]
MY)Y\=\U[:W$%Y-<ZB^]!&R 0A2S%SM^$8?V+_"-CA-3\;>([IU8EEL]/TNQ0
M@=]TOVUU[@XR<]C@UY->O351J4O?5I6U;V<-D[='OL]>Q[N!G%T()77+%Q:V
M5Y2<O2Z?;=>J/ACP=XW\8_#SQ%8^+/ GB76?"7B73FS9ZUX?O+G3KZ)&*L\+
M/ R+/;2; L]K<I-;7"#9+"RG%?HG\,O^"H/QBT&WCT;XJ6?_  L/0W&V74+.
M9=)\06V[(DN8X;@7>C32N?F9;.WT5Y&/S7 Y-4K?]EOX1Z:ZRWJ^*-4C$#XB
MGUU;4R3EHU23?9V5N1$I8ED'+GHV0JG7A^"WP;TYT6'P-#=-M4O_ &EJ>K:B
MO#8R5DN]F]B-Q4@KT&T'&*P^8UJ$H_5ZM6G>6R;Y&W;>%Y1:[WCZO8Y<RR;*
M\VA;,,OPV*?+RQJR@E7A'6RIXBFH5HV;NE[644V_<W3^XOAA^T;\-?CL-:U/
MP3X@\0:9X@T>W@U+6M.U+3KK2YK*TNI1$K7E[;F73YT%P?*0-/=(S(?WSC)7
MZ \(W^GWOB'3M?\ [;TWQ+I^GQW-TC:9>V31MJNGP-(J7$UI(5@*2.CL)UCV
MM& JAL9^!/ ]OH_@G1/&+>$?#&A:-9ZAH?\ Q-;/3;>WTAM7CTPRW=C%/J,4
M37$21S/,BS.)1&MQ.)8I4=J^4=1^)6FZ-J3^,?@W?>(/AOXI@N<Z_P"'FDB5
M+FUSMNXK[3(6FT+Q;H4ERN'F,7VNW6=6,-IA)J^XR[%RJT8U)2A[>+O.-W3C
M-I\T?9W;@Y\NLHRY&Y+330_'L]X:6%Q]3"X=5HX&K3IK#59.&*GAN9.$XXM1
MC1Q,,/[6*ITZ]&-?V:G%U5=R3_H@T'XD7LMK+_9^@V\41WE+RVFM]3BR,_,9
M8P6R%'(5Y,$_,<C%9/B;Q.=8CCBO)XYH]ID=846"-'7E$=!M*\G)!Y. /4C\
MRO@M^UO9:GH\M]XN\(:M\/H=#NM-AOOB-X0NKC4/#4MQJ\ES%;MJN@3H+VVB
M:XMIXKM[;^V;2%61)XH]Y(^HKOXHZ'XITVT>TU?PS<#4)D2V\2:7?PMHVLP.
MV5:2:"6:TT[4E)59;>YELT)?"K&ZF*OH</B(5-')WZQDK.]E*[347:TD^:TH
MN+3C)IZ_ YAE=?!5+2I)*ZM4A)5(ZMVM4C*<;NVL'.G5C)-2I+7E]);^RRS'
M[-I[98G=Y?WLGKW//7J:*X@1.H -I>,0 "T<4\D;$#!9'165T/575F5E(*D@
M@T5VVCW_  /+YJW\S_\  X?_ "1^O4VOZKX]\8:YXPUN<37^I:E/J%R-H6W2
MX*[+:PLHP2(=/TJT$5K;0)E$5$7 *M766< 9F95&5D4X*N3T4;CQ@ $G=SA0
M!CFO/O#226UM;Q1H(H8HUC$K3 R2RR%I)I3A&=GD?)+%N QX!QCU/3H[E8E
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M 'BKQ+JQM[KQM;>$_@_XI\816P83ZI%X5^)-MK&E^-9WW&*75;O0=.^S:S)
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M)=!U>%WYFL-9TSR-1T^\0RPW%K<QE6#"0+O?L2#X<ZU\;]&^&_Q>\9ZAX&\
M?$6QU7PS;^+H7$UCX,\=ZC;$>!_$FI6,KQVESHX\016>D^($FDMT_L?4[NX-
MS;SVUM<P_P MT_$"MA.(,XH9K4J8G+*F;8Y4L32N\1A*2QN(A37+2<7BL-"G
M!*-.RJTX)NC*2O3?]$XS@G#8K),!B,L4<+F-++,&ZE.<%*ABJGU6@ZC7M%+Z
MOB93E)NHKTYR5JL$TIGID>E6L9+G?/T8S&,R<] 4?=M+* #P 1TS@8K]R_\
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M.@=%*(SH4+A4Q'(4*,'C.&%>S> IH"BJ%)D7<KP#.\.VTJ?E.!D@$,=A)49
M5CC^F<&G&I23UM:-MKI73TD_2]U^I^&UY>TJ-7M%-O76ST2O9+IV_#<_6[XM
M>%[3XC_#WX<^"M UFX\-GXJ^&/"/ASQ7J]L<"SM=2L;.UO;VY9ID58;"&29[
MJ"0B"ZB$MK*=C5^UW[''[)?PC_9S\":!\/\ X9^"QIW@/PLR7$]MI\,$>J^,
M/$\\$)U+Q-XIU1T O=4U.2..:ZNISMAM?L^FZ;';:?:VL$7\_=]XY\.:3\,?
M"UW>W,D6L)X6LM$VWL0BL[J?49XM-B@69IC%=32M,EK!!&H<R&)8XSS7H?[.
M'[?OQ4^#LMGH7A_Q1_PE_ARSE"3^#?%%U</J5O;0,/,CT:_D,U]!!$F&2&>+
M4=*12A%M%G</X8E]7PV=\049+EKK/,VHQDU\-*&8XQ*,7II>6LEJM$[)*_\
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MXBM[6UN8;S1=9E@5[47H*Q:QIUFEG+'-%:120_U':UI>HVNI0:<M\?(=!/.
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M>Y*>'HU8E#M%^-?QRCC-N=J3MS^N772UX%$TNT%(-&?!V_C&SYPU74]UD7[
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ME5645<'["-DD6WFUM__>GO%YDF=N_E8^V$L6K/?_ :0?<S]7>/!+[.F#$Z_
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M7EW#/\%O&,L\-S/%-)%:W$L4DL<KI(\<D$,L$D;N"R/#++$ZD-'(Z%6)3O\
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M7#2 KD,,G-J'_@EC^P?!*DT?P*)EC5DC:7XG_&6?RU9S(0BS_$.15^?D;0"
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M!7WM%:^HW1I/>E3=M%[D=%VV\Q8?^"37_!/R"Z:]C_9^B%VQ!-PWQ.^,TDH
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M\$H/V U1HU^ K*CNTCJOQ4^-2AW9@Y+X^(XW995.&R 57 &!@HI^SI_R0_\
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MM9I&RN<;3LQL 45F_P""'W_!+QAM;]F-V4R"4@_&W]HDAG6-(@S9^+?S82-
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M=J'&!:RN1FVQ- U=;IP&=#8M#^]FJW*1(Y=6J-NU2B&1_/&-$18,$CVOZE3
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MKO*C6 #;1G'TQ,_C?O5ZDH]Q:3DKX,U[LJX=!!?H\R6 V^:*I&WHDNA:?")
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MS*P2P8XQV1T:*\*;;-@.2*#@P"<T%$.KXN82JNM:H8S&E('1E&&6E4PWM@B
M<2_&A[0NVEXA5!0PN%=AQG(.T:@TFGQE:V0N>?N^SWN_/WLY>@*=D17)VS!N
MDY&Y21,L./^58(%%JGX#%#L&D]MO]]P)<PN9LMG$U%)?C/?#*>P&RS#GEC'K
M_<L?A-6-M%R5U)Q\]BV^X."8.?+[X^]6:/?JGCWXB0VLYJ"-]'HQ_6YHP#2>
MO#P(@E:GKGLSX^^[%&EDTS4T8/:@Y18]?X2ZV!!.*DWSS;1_42]#>8#JG=_*
MZW<_K/,RYXP;3QMFFAH\^;*PL!A_=@D0MYD[%GHZ ^K\UC@AV@S[=F%L@43#
M,7^==-2LL;&KT8^=W)9O-VI2T=HQ/$SPF64)O7!?)1Q>\<=K3:]9SE>G5]=3
M5[ Y6C_C>FXT/[XG\Z<Y4M6U@IM4C)()<ID[?6L[$CBX]IX\"U%RV#L"M0XO
M%XQ_)\(CG'*@RL+T=&M%ON5NV;YQYMZ4Q%'$:<G?*C.[M(->"TM[5Y&*I1)[
M>L.H>3\2+95WT7Q0UT+*>T-=**'_&A7%-[0%K5^QK_)F(6W+5=WS_N]NFI<N
M :QYW=4YCSV9"8B^VEQUZI%>_?$JKJ<QN5"KQN0[Z_MOP\N*)OOO,=4P42$K
MC4O9Q-R;'MNR+/CZ]$Z$[HV;&8=P'6_[Z3]-S@/55N3;"+'G>65:=.ZW,+3<
M7W)_IW2T8*)AN[-\QEE][AZYC/_]",[03N,+$#SE5YX!#(U=.\5_[XT*4]X%
M4,)TS_TB%U:__B0HK.YDWPJ)4?-6"E+:9!ZMJ"M.W'#E"Z;JV( W"MX+UAOD
M8M&-UM\?%, 25:>&U(P?,#&_0+"(*O/AVF[A,G;&Y(Q-2X5&Q.0;Z[,:<JM)
MRTN8UY8$Q[??:K)"*UU:I0/W+A;NI..W+GY\4<U;U4EDWS"5LP[>GG-X()>F
M4\!_0+.JIV??2Q_4X7T>04+>T,. ?M&X<O&P@_C_K3/'Y/;F6B_^^L$%($M)
M$QT<?+B%^%(3]-P?$'2TYX?,_U$B^_>Y&K_M=1,^7\80I?5C_G8+K]0K;C*2
M[[E\T@!;WUNX!,CI^^F:>-PG8BKR%3:WY\_G*H%$5D=\<<,#X8O"< -61]]9
M J*'7I-1WQ[71U3FO6;BK/;R* K[-'W^&D,%>&X%S>O^:>^ J(O:2?UT[;5:
M4XIKFHDI@K)E4W10QHE1_\68S. _O;65K6?1B7^?E\)$W/8>]ANLK522RU\4
M<2F<?X4V^2)QVW>5JZO,O?8#L\ZGT_Z"5K]%<4I.&R%_,26+_OS*KSV3J"'+
M).+U*35-_9ZR0B45D2T9+6BM""37D.UG(WO!5YSG^V!-L"%T.$$ QI>F2GO8
MQ=>B)%,C5_Q ,MTX.DWY0H5;I[F9H=?=/$W#%('@4U)[BF<]0Z3;\WA#C_)Z
M&Q?L)<N3C:O;.RJVJGT'C$?5%8[574 $<>]W74 ( 81K6GSNY?A)ZQXY7Y0/
M-#>R['TI(2QP)IE$NQG /MX8+D.8C5Z5*[F^HO=A343&_2GOR6EH>G^[_O,&
MVH\)&J4\I68 P?, 4LY+)4]=8FUZ5=<S ._FG\ C04><@E01SXZ^O2)^$UG:
M=GOL>^02)JR2<_N\Y!$$C+4&78><!-8&EVCBD(F[%3F.82LL!"9P0^W;=?+-
ME9RB%T]:' 5^/ A92K'<N@3\ LZWH=(QY"^NC\<K1*B$>''<[Y_!\[1Y?&&5
M25.D%XI=E])O^JF=D4VI^0N)FA[+*P?;CGC[O/ (H1^>&*'_,W!'5NEY5\9$
M##T-E<![/346IM_SOCLE=4']4=3AA@1/R?YT[$KOV=^*#!QY=ZY1LUXMO+U(
MIP!MR&/5OZ#/OWM1C$-1OY//;;YN\+VKPE]TR$$Q3K\QL(4OJZYNYA( 3;UM
M5A908!9_#-%P:U[>?Q8Y<$R2F0K:-[0#]XRSV08CNR+Y<0K07DO1JJT?AH)_
M[@47HUAU7P_VW*HV^-X#N45)KLPV;\F,;"%<L6<JFIJH_S[<:!B3*R2J>)7Y
M$^)0[9M\.F2K5]J[+XH=6 ]*1/3"R>$OBU3T.2/BT)> %-B8Z<<;\[]=WM1E
M,C>]F\I5/IA+8\TG38-65]>9KCC.IXM*,J5>,-/L:YIAPB6@YXVC^F%*E$,.
M,934,Q.[CP+OYM!G]2=3]8+X]1N1//"UT>S8D?2BNE[Z=9^4@*/7^BJ2BAXF
MS.(=.2V2I_">VA'+@GD-6_LND8#R++B):J2B^D[7B_2$\$<'M;[%$CA*RLA_
M:0N&*=&Z0G1[ N]#?0[BP!W6S$1> N=;IKQ+ .V:[BO^L@^2:3I^/>Q#0..?
ML"LM2+X;Q4#H% H>UEXK8?UV?:'%G$Y^?H"+[OVL():#[?QWOPA!$2M3)PMG
M.'K-&'Q+ZU498URTKD9T_E;OL,,DHUV;QV!^6M(.[$M09U5A]@:BU7 Y4%];
M5,1U-*)C^5F$]P34 ,S4X %D"=?",B4<WYO<:CU):5<L=Q<KV\OL/[%H3-J^
M]2M6;=:P6Z]';-#@_>R+L[RU]/F1?B!3E!L3<_BM20T@@<F$8(*M \;LKS%Q
M[C@(3<L;:2YH$CK6P-3AH 03IJU[;I*H'0\0I0FZ =F8O/34MK'>GD>GI8%Y
M8=17^M4E0+J3S;[+%0=&18SLNV':(U!A[]A8&U)Y53K:FOK6_&XP3@^.A>+
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MF GO"U37.?S=+/IA]GES=--(A7<2\LXL%CIYFS]5NN_OJ,*+/'-/E]S/(@?
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M!](?T6:I8CTH'@:(NHC'; JX'9LP%E%5G8N<?C"J0E$"SCW'N/L$@/5$\9P
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MJ!N^ID\5E^_6+5;GLFX+G$QRFD$F.+%<:SQ;:!C1_R2AH0PQ*UQRY<.Y9[P
M*3N7);&5*I1U?78J%RY1'2S[^XRWF(-]WO-OZ0JOYAYS?F 7T6+S_*/UJ'<\
M+3-/3G8B^[&K82-ZS%QM9QW:W_NIL+J 97!M<PL6O'X?=-ZNL>KOXB^&_PD
M!GR_B 5N5AY;(-N<FF!?PL9.  )ZT/)Y9)N"'R81Q[[WRD&?NWVQ6B4MB#S5
MX\P=B;A&2DK5GW@[&28!!YGCR-WU9#&;NJPN'4I-G6C%%Z@?,11D44N^C5=E
M5]W:RCL!M-VX1#TF9SS\_TJ!8PB@#I0DL>X 5Y/<)32Q1BTI8[3A>%M49FE7
M(RFQ,%%,TI:>.H'NTF$@0B_P:@(*)3ZOFM"S>W.0+OC179,K'[<7@:OBWI07
MZL'PAXWMD#CPZ*F>$X 86&?U[3)WG!U#I'Z\R8S@>"J-DJ>!9=TIRHJ5.P',
M>.YS<3PAX4,OGP",ZJM#;Q!&_MAA%Y62YE9 WY-I?)FS2TY%QS=O'\O16('5
MC,IEX;!+&ZASB_C7B:J1L"9?Z!]C-\)T3:\?91[S]&D;:]J+XA@A#1U^TR_V
M>CI7.<YT$D<=!L(TC@=RSO<'VPC1.TY-4#H(1N-%$4"=N'@0Z4'R[^33^Q2D
M/2JGKO6(+D9L03%Z_@0^I8:#I!HNCBY)6=+:6QJD?'[H>,O:FHQ\6Y-\ 1YW
M_/1#-210]%-FO=NQN\N2Y&523UR3[@F I1=><0+P0+ZOXDY$D2R R59P4.M1
MT7L].>Y(@S-S<#="3"M:[&X3U9>TM?EM9!_&8^I; D_N"4:]IWD74;/L)_.5
MBX;>Z,E_4\EB(X[-P^T>C.AIXA?9P1K!&F_QCT?+]Q*YC4>W:AS%C$;\((^K
MQFIR@ ]JHV?Z>BR^5\6)Z7*(:5VJJ:Z+4)!.4GCT.,@ 2^*C@,C [B=(]V8D
M)8AJ6H$(K:MTO+&XK((A%;4?)7<>AVJKF6&XE-\Y:3:.%I"9->+QQ-EF3H?"
M+Y<8O?6YK5=JTY8]P9,QZD8+R>FF:.LJ;(:C<@!ZRM<X!KVY1$\S6R@8?5?1
M_'=F8\IN<B&!$:!WA9RYMN1&XS%CG-==.@&PA8TOR).+ND"L8>.X.K=P/UA<
M\$Z7LF+G8@TPMHD%CYIAW1@BH#J;;QR;C%\:WT$X?$/P&URG9ES^AA<3"T%R
MKU,622E@P<E@FYP:XM'_O^7LKJ5"3BN+(]L,#2XP!B0O2<K0$\,$PX9!9PET
ME,7'9:@EP?)MDVXY=98"IMHLJR:$"9"$DM2AD,Y T>A$V+*^%3?O1N;CX#][
MHJ XA$U%=ILWTIN7OD\Z 5#<Z;$&?,)9>+=--$D>?]P56.I\C\%!E3D=ZT@6
MV*[']P^Q03*\6S+R9FX\@SCQCL-HJF46^:8E\##*CG$SN%SE<AWL 0GV+HP?
MH4%RS.C 1(*X]&1(U6T:=KN+LW#+UESN83T.O(-85G]=<TM#U7"3)OA%H:%_
M\7RC99">;:Q<YZ]_@]LKF:5IZS_,'>>["KY-8"&JUX?S'&:MO-+NI9EHS-F;
M7E&L"_%\2+W'1J%/2QA,+Y?G9G,+]$\5A>%NKS\-+DA.KK$4(-H=<68FOU=#
M@_\T'%\NP+C7:BR(X9+(A%!=L^H)M1RC/YNJGODA)6M)?PR&?/D?&C-_[+/E
M@KV[%%T7\C&2,B1Q5HS17>^=VR3)+5$O;CO5OI,<QDJM)X#XJ2X=F;#83770
M^=M@_] 3P#E@S,H(OJFVH;Z^^B9X2[=I+%_3MCQAUY Y\+H9RT3D_&QUKV -
M+LJ2QD/[*-SLK14_2YW0!6%WM4P+J45T#-*SP;]I1OIV>7_!!B^1P<,[$ (6
MD92,6+9$GNV5:Q*MYI-869=I29,,1/>(595O,A3MP0USP^#@UZ@R\U('2Y;<
MK%+JU=&QI]7UWY,@QR4[:!H'/\EI9B/.LVZQ9M3YJ4#]&4=$*N5BW*6?2=="
M Q3V)%'W'3^F)I:@O@R)TR$.C?;;\Q5;!TZ+;X?ZQ1;3-7?Z, <S)X#8?^K;
M*+*\_3A"I6$A[:N'#AA;#0U;MFHF;1=YYSD^NX,IO9TWV[M$);1<<S04?^BL
M]H9>R.)(YOKU8E\UI@K^FWB0SI"MJX&J<$C,N-("%R'--V,SY6O2M:!*Z"^5
M@E]%MM*>\\D.>7,F2RMYZN<# $R @)[[]G8!][?[74>"E3-Z65*@^14' 79A
MF("P.V&S*:K38<![8A<6KI%G 8]3.N_R)IP9,I(*-WAYJ]M$_7"$C.S0.0'$
M($ PUXJ_#44Q%9A](.>BP^S&D>/@9_WYG(5J=YG&.H?WP[U\GJ$5364JXHKB
MP%,4G?U(/@&<7__X?9V  OY,B;ZT_$KPS'U*7_65%=[S>]KJI,4M%G)D-XY?
M;>L\L7LFI[;$UZ44;FU4>6U]L@'A/<OE,VKWVLQ?$OKK7W%*4"Q+7U2BM&5Z
MBQE0?/_UH><_6AUW?%OW&W_BXP*C_))=V^(RK!5LQBK[2G'#U4_.-=#=OJL*
MAYNA.D-"VD;9^9D%KKT6#S\IRST:M$*0/_%:9,8A!OIHM7;T0WJ.':R=F_VX
M#6[\_3CT9\\Z=1_CA1&BYU*2WSE=E &H8_%,1: 9S><)P2L\R1Z4N*/562CV
M]?S,Y@(:@7%9^+IS/^M^;[M.P(%MS/(03>A3P^E)J(ITKQ96ZG:.GM<)#Y.E
M/G&3. ( 5E)/]?'B">#[KH4:#""[DAY/N!?+=Y:?<=3.-O-;F_EY!?S@@+%X
M EAJW*S\?Q&0^Z'PQQJ:)K2#:DQ3&CK'N5:KK2V>=-VY(W#SD;^2#C R7\QQ
MC(#092-]#]60/ -8BS &Y/3OR^,X:"Q%M)8R3!^*=CW13&= $U.=F.%0N\5P
M^WLAO(?!ATFZ>M@'[[8[[*'?0]SZXC9VZ8?^T?X:1;&CU?18"\&N .B)WK;T
MZG<;]NMQ\N%VTA&EN9%JNM=Z<&)FXAGD>PFM3!T:Z(K4&LG6:T0:D1+2W@';
M'".)[\]^<;XD>^&IY,1MB0O<LLM36/_'H^<'9XQW'@6> %HK6E9\K X\QJN"
M2RK2S?4/_FY3YGI)ET"D2KVS^:=P*M#SSGL\UY]X!E5H*I-T05_QP)@@E][,
M6K:TP^=NKTA-0IZC9C(HQW?K<)5CZF);NH^'L3M<\_T%<QNI]NNPD"*D9U<)
MA^)Q/SOF"_9'7=*_<PL2)X HQKDU@GQXCK'B,NI<FO .O;%H3^*P"WEGZB(=
M8Q7159#"G[WP8(?GT>5+KY_S5_T0^R%R]<W-[B",(H\3W--(M%FM.5^_(#O5
M8]2"S^+J0(F1C[U'3N:$A-<[CY%/EV<3;41TW9<5^F[&$P-%[J@,&4/47P_)
M9/3HD%U0D2W:'R,O2F MHY]A@-=D>A):>29,AI@2]DH1_H27%D.1!LK,%UBZ
M<:1_4MZMVC&==3^8.?]=T-UUFD%< 2=G'CR42?'V/L]X$CGV;_,*CA3[VRT^
M_E\33U;UQ]G$RN(V(-W3+D]\M3&N!<@M\M0C)Z1H[;@?5"^^HQP?"(^;#-4&
M([:^VA])7@'&TR R9<:DR$?Q+5YZ8#P\@)QDV&3G1JS3&GHPGDQ(?E_1>@)H
MS[?26!&BQG]3,3*Z,/(%9)#/>[W'*_0[W,X<J/D9X4 O6Z_L>:""'YL2D<'J
M,GB@B@GTFG!MH%?]RM&*UOJZN9M6KH..ENT)X'-W8\@BS#-CR:J_1+G49LRR
M<G90B<Q*5NWT[D-<J3329T;QJK4&"3-=P6=H#XTQ91_=4.5#/$VY54E3(35)
MO/%BR#;%8$0$6RX\]V'3VU^?:1YC\"1*D8;G?LA\<W:\/D2G;>L0TII4OQKW
MVU=%SN_  "Z;YJV]/7K!;H4L;DK+O.CM%RZA0MNENBWQ]HN8C.)_&\ A.T<#
M!4SCW.+JT6&N/#V9S-8U$Q/CT'D$C-+3_0H/Z4PWN.); (^WFE(W(\Y?GCE2
M-A@4WE93EAR<F1UJN>G\S%2]$\TOO;"PZ-<-UY&WY'.?ROP4K)X<@]4'68V[
M3O!O9*(I68%@_<YKAMY>,C6C^^P5+\#*-.H?L/**I5J[BVN"]EXEGLZ"_#-Y
M\R/-SDZ)??^P0A^7H^4N*NA+$?,=$TFW9?CL;J5 AKH?HY,^R3D]GJJ.3Y"Q
MR(J(\UD-&836;I5![J4XU/U=$NO/GN<PFU%\;!/*@*@MA[JXB8'[(?L/=BVW
MN"6^MPXC9&,"E1HFJW66Q9\C71Q2IEM?M#(EK,09C^L%1N">D_Q<;_?U>J/O
M7]^W/B,KV7DFEPYIF:@9T.FQ#"G3?8)/UX923#F^ZSJ]2IQX^WJ7)VWP-D4J
MXJJY8'OWOS85+ZC4CTRPVX5=Z9^+#3]2^ T' TI+ ?PNV:GILE,<[?(42N $
MLFUX3Q(<%ZJ@[.!<GX!>'[@<-$6)23IWM6SID]5_GFWH>F;RH#J<>B1.^2F=
ME_J03/!\G-'J)LO9G-3X@<V3^^*KM<K!&]H"F]Y_[?V21HSS9WNEUQ!@=XDI
M9J;Z.S<QLDS9SS_H+#U4R[EN<0'EKI'"?JRGS:8EPP)O6R+W2">7*JH/[B#5
M_S4$LGTF-(0(MVPDB-$<TYM3C.-[BZF;G,H';Y=[NZTM)IX<T:>FD!=\/P2O
MHE@+EJO6<4ZD[*OYO,]'O,3)6QJUM]=R?K1M_L:XB8:&GP RQ R0ZY-,"0G>
MQTT)1V/IW3_]:K#"VB> 9+AQW0$;9FH!-2$SZN.,/"3N#J.V]-QV1T_W53"(
M%CM(4Z_6L-]\HU;F]P\<C/XS,-D:L;'-8,QL;R_=R<\W4_]5U= ![!7]GGBC
M++411L#PU382="'H"T,/QM2.)VJ']P4:JX.P96_DP5ZB MSJ#7?T\J^\^5Z'
M4BJ-ORK_^;'>Q>+<F\V)@,=Q4W:Q%UUX2IVF/X2[18D<&K_XH"60AE[XJ].=
M5^QP>SE^@/6@HZ&<$D@&.TF-^65$'ZUJ7XZ;M<).;'I!,61^F.S#,](*-V!S
M8DE)#D:*J#2CJ0SE':]T1\J_.7SV'_DKC8,^B('YR[/!+8N3,6ZGK*928<9%
M3OS">V]R+347\,_'@M672.P"DCYZ?.%U?;0YVLG>NRW("6PE$]?_I"QX#.L:
MOB #.P(##B""=+MG\8:-$VJ3<TLY*OT=WNNB!IBU!"6STG+6T5<W?A[E^X2F
MBT8<31FZ-HXQ+LUM-*1*F6V!NH10D%%UDTD\IR44^G7=MI+J!3%RXWGF7FL)
M4_)I<)YV%D9GBE4WH=0\,QJP![D'S<T38S9%CH+UN_V6\_T.SD_6J428ZJ_]
M$\#6EMW OY8)20VAA=>>2;>6E(O9,$S:^_OH 5[&T2K5T-M[M=O*\I/&DLC9
M*E2FFM1NTLUNXZFU+>/. YU?DS//%F1'_="B&W"@S633S7*(K<Y 08U*54L:
MF)(EF*[9TI#$OC()]4*_CNOR6CKFM'IV;Y^(X]YQVOKE"Z&TR(9HYL[H6W&(
MU!QG_6?%CJA75W <J*G[<_[P0-1/H_8FSZHQA*-1NL(VQ>LKM'9.(#?9U0];
MUWOPP\C+O.*IT;S]R!'P,ZY.$8J,,>F,@H809-[2M/G<^TSUEJ)<D@]B]5G"
M7!%W_: W[P!8E9>=SVWUO%$O>VFWGO1C67+_R/$X\$%\"&E4];^;&T#>/^*(
M1I<6TER0'GWI54_%7&X.\@8M@*,-_V30Z 0 I-YR*[0[MKTLY9T=KJWU\V?%
MG'S]'91*+BTU)+3$D1B:%#QIG39)-@UN3J%9KB.7SB93'TMRR"AF*79+2:X]
M;F%&5=S<ESW O&*2Q,5>;HI9$@U"LB,NUK.)0GM__O4M=<X%Z>P?_4EMRC\!
M-)T -/S:Y(3SRS]9F6%30$#<4I.' ^,<^-C\3)(R0X(G^Q0MA73;EF7F^&A$
MJC,]7M2]QI*]Q/4ECG<K[AH;,STA@9/R3$&_2I^5[<#XU*(7#T%+Z<Y8IJ6+
MZ:@+_P%8C0P4J$J2"W3+!YD,(>3+ Z,1FM07 1"I.N].N4G/=@#C%N?1OL'^
M_#L&T[\R4"_RP0I:\:54&J8?!YU!RD^9 4/AEZJ7<8F<%H'PJ+FD&^P3^^&^
M^_,]85_(76&C\*=UC%^+9P=-V S'N0&4]#-M>WVI.Y%MK#A>&HO*C@3MA?4'
ML:>?P[4WU-%F>I(Z*5J]/?;T"A(*5"W4FG#1DF)4#F#FO56?+"\9'NQ2J3_@
M_]C<^AU&PG;J;QIEIS+1P.:*QOSHIYH)C>W]?_3S3N>>XR[JL<YK4!?;7WW0
M1]PM\M])\.L)9L3<Y:::E$]EO_?G29H^3/ZW?AALMUN_5-G8D\O>'VZ9V"3?
MK0V 1UK0JO]J@^P9[]^?;MFGSU40:!- D!X3E3(DV9*V0IC:<=?7_SMQJ&B(
MZ=S,*W?XNQ#O:."H#M(X 4"<9Q4IN509,HQ@&<[@H[%%$@+?J0$!C,$6^1&:
MJQL>QD>,:=?!Q#&DX3DM:K/P/W[S1J.CC+%'5$-\_WL#[K:"+$@MM83B*.,8
M$B]A-6#7.<8X'T->[K$7Q(3@N:?A5"6/!28#)=+\IP6%<9HKF:DC."Q*M4L7
M)4RTLW?-"%<'L4)F?G$L03G:@@,[B,0!,8=1@TL0NR.W][\"-"A"@:@?@L1B
M+1G+B*>U6G9P6@%[)U--4Y20-[/DS;J2+OM7Y$>R<LV]S)&[\[<,O&NB?V8S
M17R)[&;_N7:V6A.D=P)X[3RKVNT,;+G*?8:(8I,F:<2$DEXBXT61[]6.%X&0
M&W^/!G#)VWK $H0R&7^::CNLZ[G\Y+5H:->7B9J1P))9HGVG_1'5X@1@,TH#
MA?K@0ID^Z)NPY4F$8;]0&#(I-RF-3SD5.%-8&Z(?GBV9LV$N-V.>8[WQYLU5
M+#J13KL3POX5?D[*9%?6XY?.5JN/]W"VB]Y#5@VL\HJH"L8@M_R M)XQ.GU5
MY5!T0Q<L>484R1]]*X_?9R#\C+S KMM;]1/ ^UUN44>X_4Q_EY-:9,?( 'Y+
MK$>TX$],C)?_.?5F'=W*D"#LPEC?V,+1JVOR_[V*NM1JYW'4^3=,"A0@)K=^
ML!V[\_/PN7YIP2H*^?(#O4'1\YG))>.W=6=N C\*?[J["VQXXQMA\A-C=NZ_
MNQP1OZY5M3WLM!0MN0J/2_3%IVFR*73YW+=0U_9_F*,9L'B]([:MG\<^RN9]
MV7VU(,QYJ(J;0N^5PNWZY0&_/^?0RJ_AG)(R].\5FS!Y%#ZYU5&:(6%GJN-8
MWJ(^KO*R8=1I<E^]9N*=AN99[;P&P>3"_J)%HP&1)+/W^5S>8"%M6#EC'C5-
MY,_EHW^VHCALF6=N(/D@JP[Z!N#<4&7;A<F>S0PAC3=#%%:6$>'?M_V5ZI2#
MM"(W1O"A#E+18]9)FB)SD75O_]UCD[CY4^K-#<,'+<(35&7_HBO+NB[9Y/$$
M?B=(VDM>&#V+X_4.S$TC(Z798;8"C;L&OW)_JF=55-'1MDAPOWE1171NJ,%>
MF7<C:'^4>)TJ;QC?F3K]C)JI#.RX#L_=L;AG)H;AZ8&^S-SJ^A*G]56P>J/,
MCW3XJ(<G\=/7JW@CR2;$$QQ'TY,%IF@QE!BR'41X1<K!#HP^N>N-$6AB#,5O
MC?8H:5@/Z+)OJ:PE;J%W1!<@!1K]5RKJNAX.0%\$0K03"^(VNAS'MK^#\?XO
M/IR/X+[[LVTEP2:9HTUN("H1W?C55+UK?6[I^ZT,.][[L\9*=U3[/HO(^K&I
M1P9"_U;,5MG>WVJ4&U&<5HF5&]Z*^Q.7./O'U+&Q[E7:;$@=I&ZB]@B5[2P,
M<K-,1HHR^!$<I,48K+D;OJ#HG3HFH6&A&0_CH1YW6L&K%CN.%CN @NO <P@9
M H@/;MG5\&!F\;T?4-0C4V.(9\YCAE[X%NH&+5]T/QKXTS0B?P8/C,*1[!3U
M[[:FV^-ZG-\%&/!B)_?T=7M(\X51&"(8;ZYJ3=K.*5^D7C@::J7XG  Z%]OM
MDV.QJMSK+5=S3P".HPCKI7E1Y1"'B?(FAT#EC,W/I,Y?85#KN:WJ6TA5K800
MOZ/1Y/-USEO:0=I:=<ELJ$ M&JC]PV#HM+VIR$5IM:1'9^1?"LK9R:8$)'"F
MF/;HC4'R#039*@J\VWYV7L/L>84.AK:5TRT-'358ZH5\!O7^?GV5]A(0FUWQ
M^"OF:J>DL8P^M]J93JJ4)NWR4>R@<4;YOM[:EJT>RJD(8W&E195ZQ95 ?^!A
M#5F0&5Z]: E3( U6TA.Y#K+@=9!0)+^&3U:.A7+A@MBZ^)! ?LIL&=37BJJD
M0*[(?_ODM82;3+$BI4PR1CX;9;^[Q?V 7NX'XW,G;;3H4S715#UBP%3NU0R;
M4?].\IV_8_/GU)45.Y#3R47@VKKT#V5W"_M+V_R]^K52 KF$/KD6R(Y9&J_7
MP:1^$Z6I9[X95VPL2.GLQ+LV3$*Q_0YE&N37I0T/'L(C@-)D);6?]P(HRAY1
M6:8ITU;F&K:[RC^?__ $5O=$XT=4]0PRAQ*BLX)*GVYL6R8U6<V\T[35X"IL
MDR@LA!GN8U,==-6[,G^]_%'OXGL-?,OC(!59],_\3\FR_,&(9"0Q-R+3WUS-
M3;.V0YQG%2.\7 A6: ,C;086^Y970___(QSCE%F$\ @:0],O*6#4'+0(UXZA
M_3Z[D2_4O2D13(,IH[\YW56>2BL>'!Z2GK=$U/$Z7K?+N"%]8XNJBP^(6D+;
M[SX9'9AN;,$>"W3,.3LN"(4[F@>4AHTI7MW,)=A:O6>W?=+&8Q37C)]4:[VE
M^7WEB#?X8$F<V[=GS<IA0]#.2GAKU53\[&] Q"TMV5><2Q_'B.9&5]9QQ1J+
MUN0.RBXTLZY#X.4U-^K7CN3/2 ($?\L"__<"8$T\V&X5DR@N1+HO*/^+&H^7
MV[880Z9&C@/8+'(@>]\HNR\;AMII'RP,%'(!Z_1*O)[XP4\K0,]+'^^>U8P$
MH^/%F)^LB,7W#(&A9^$J\[O;_&=-*VC2]Q/%&C6O* <$C^/,9UHPZ-PB"><Z
MV2P/XHBR"N[NT1LJSPE -J:5>BHDL0]^:!,9J*#(S/W*8;<*5DAO&(N4\[LP
MIF=G+[S'Y%[?G7_6PB;!NKTXV>SU8V%G@N&YD=PA!G7U:A9R*EJ1IPG!@53_
MP"WSMREJBS&=OHL,P8R(-T'$J0+D>6051V0A]9YQVPD@JH#]]>!=@;>_DSLC
M/_9(>1/I4R> MH#Z$T#$D[#Q8^^/A0A];6*XP16J/.K+6I$Z32ZLUTI6PXEO
M^E\)M;0R7)</IBF58D 6.=!FDBD*XYF)W$6#V@P9RK@?*^6C&.;-PZ]3!:FA
MC9"&$: _0N\_4'*8<D+J"8!/NU??9W$V,V)I+3MG^N?/'NNVGBU,)(IQ/63)
MM#M@O:%O>YMM9L+8Z<TU$,\H[F*+J,$I=SUK _V[F$T>/HT-QG%114@PG1M4
M9W .>@*H6FOC3'B_B>WJ?G/KV/?Y;E*84[:OH[^VN#2ZW'[*^31[\H:,J5C1
M8!_B'T$T\AZJK-ZZK>MTN?.V?DP6I3Y<V5]V&DN"KZ=H'^TZCX@"%F3&WMS\
MSU_Z]\^5B#>Z+JFI0P]R+R@>3I!B'RTG,__S/K4FS#OJSY^#C441H5%(0P5O
M E2322OY<2^%O77Y^]^@97205G>.IXZ#PD3UX;WM_+$&!\6PRS'O_;G?BR*C
M)F'11S:Y&$Q=[*3VYL[H_)8%BIXC^^-'RMJ3D:B"\ID(,"4C,X%W<7Z]-E!3
MJ+;!H$1)>H)4,R2*"(BY,ZY<P1 P+*?63CT:2V']06:-Q:,%0V]:1P<V-)J]
MW_'_Z77A;0A4KGIFUE%](:_PV;K=J')ZGC>RZ"D)B&7;XBYE] &K3@!=.S-"
MQE0; C!1",BII*)G[+T$Y((TL$6KPOP:P6KD<H^ZX(/WJV82FL8DRJ>#S-4R
M96P%NLS,[85<;?+7C<P$"B4%D4<>8IR7(>/P&3VG364,GA[=N4TL!&=AB*:D
M:"WU>ID'4GCG^<BV_:E%GP NTH)T:#ZB0N'J[ZCFQ?#9-MQY@TL>B^?T0&XA
M!-Q%2 !#(O4A^34*[Z@!+](6 Q8M"$[0W,JF/7S@'6VU81=39 TKZVK)ZG6Q
MHF1[$:[^/DI#Z"?;,OZW5CP-KW.$&\M9 B39GM9148%+6UP&0ALZEU'%M67^
MDM67ZT5;U-*25I<'QCAF%@SI^5/IM0TOE7\YNYJ96VP?TGK+H?A4@NIO&./\
MS3+&]()&^AQ":8PF0.H@<+<OBM!LJ$!T#R$^T:5;TQ[8/A3WD"9 _5B >#B\
M:%PY2M-%FR^;-9H[M/5^\<B<*%B+^O-IP]=^HW9T-A$W>TQ9JZ&_/0&X4EMD
MGH S)>O)?%T&EPT$J+[?J)78$!"+\N8Y7PSUFS,Y%Y/?Z>4WS]9AP#VZWVPA
M+)W)L<A#?><NR3LFFW3L%$>88R)VHBAQR7>&H>5JN)@4HN!181X4XT0MLQL_
MF'?_J)KS;7Y&-49MI3;5*L=12=T.KO1\=^G'N-*F=!P<*KVY(GDUE,/<0"7^
MKODK> 37"#7,85UM#+RJ.9U$ORU3?WS;BIE8US=G\" AE4:FHA@<AL?WC.7&
M6R1(4YO+!> 6!6H@N8CR^316"!^7;S6XG>9'>.8)H/L$P.T!/-/D+>MTK=*4
M84!SREH:#V2PD8T^U8IJQ,,(7 $C#'%J+HR]_*AGS[5T@>NN"8E^?%N]LKEQ
M5)6K9ADZ4#>3MTN+76Z=59/K]*DX<Z%<ZPOWI7$$&[D!* 1ID1W5"W7QS:_%
M7B[ +Y[WT(G^47N^$3W-]^CZO<J"[%KO.7<^]^OQ.3?X,QB\_:;6G9<NF7H:
MB-!.6<)0L!G8!=YO]&OX#M_3A_H+CFTI[:X2-1ZA"^8T9I(IB8-YI4IVF>A/
M!_9AJ$+XZ]D'(2)+XQ4P QERW=9' H8U[#0.Q1G<1%2-<RN."Z$;0PDE'[Q'
M" 15P'U-(+"W($$]'MC24\^]$T!<X#I9E%L0TM!=_8W:84V-!<6H)W/"@1T+
M<B3_]"A7TFQG\" Z'_[/ ?;U!+"4LRB"<#SU8(H52;X+)DPS(_5T$9/Y/1C:
M61TX'CWM%WA'46+G C.6G%L/7M(WZPX3)QF4H>%F[:B+*@CY"ZF@!,25KXM5
M<)A=.A3XL+9JTG-?40N@3^SYS&2KCQSU:[F9P#4Y=[2GM5RD!K_"D:.CWX68
MG+QX8__.J?B)Q?R8_;@GHG\5)!G182-%4O&K,@I.OC%%TB(FW\[,:$L:Z7)1
M>ZC>.7("\&QZ8_0WV?MJ?/M'V90;W=%69Q5-^N*>W*PJ?@G@8L.KM8B,@BK]
M+,7@R1:U?.N\Z#G6<UAM/HM193]B34/]>-@B2\=&H,97!M@PW\DT$_[-*.6N
MOU/&U_7==5%H<]0"IAB2VK&:/HZ]#:&L=Z8TQ5T^YD(7U%ZRO=AMQ0Q3YONE
M<IR#,T NY3I=I7_7>[B(53H!U,IWG #$$/ID4_H7BQ+2\1VR"GK)W*V]@;MC
M/@0?TS%[S,V,4!UO8BO9J+4?BD0(%<<?BR7S>@A9EL!CNC1SI5J:!3,6/4?5
M<"--XMD'VQ?8)6ZMQP'\?1<NBXQ=7_=W_WUZC6\TAH1B7D5@EPCC%W#_P/TZ
M\7/&T>MPO?ZV5RAQ#ZWE:Q#QH]<;G4FZ^_2K3Y234('%YS#^^O><B<$MI3O%
M'AJCO3#*86#%9W?F1Z&H^V.T2D&45]\.IV%DKPSOGUPN\Y8;XT\X5Y4]DW[T
MS'B^N?ES0V<J';Y&@$YF$"RIQMM8=CT6Z?Z00)>0THYOCG/42'-SQ[U'004J
MU7*)!>\4_?7?"FE>)+X?=7K_ZKM)WO&#DL+-U$=0]*LL4_]F[&_S:?^PF+(*
M>^.9JN<L4F*5X0:>=;W",NZ 6N,WIEWW1A62"$\OQVD16$T+4Q_FR$0QH]12
M#88_?G%N&?BG("]G9(XX!,:V ,TK()EN[]5#W3H9"B-"]KD;VVO=1-<2J@N#
M1VOE!YEG^#FI(O[;M#O97J<IHZP@/J,I1;WVYH(Q_T4YAR%AZN._4\&8.'_,
M13BQ?>9"9='Z-;#.0$M>\:P#9";GPZ124IX+'L.$7HR?]NM]F;*P8X-M&:O)
MF!OU'+_3]'0P9W6E2-U]NH [T7GS>,NY+V"L(OWR+GA&(U3,8^'9Z=1@C[U"
M_F#>ZRG[HY_^?0C_UC$5C-T4\G58MPT^<MK@+2@U5ON5'E"E%N42^2LG/NJ7
MJ=)[$9F/&4VD_ID<6X*PRJ5,,Z-<CO\(__7*E1=J9=_V%;N>LO P7ROI5GE;
MW9F(<X>%.YTMXA-"'6$2PX@;:E?\Z_<DW.Z,Z^G"",[<!FF^Q;)3.J]+#XA+
M)NB]Z=$)K_+M_W7VY=%0>/_?(T*B2=E&&$6I1$79F526(2:[*%.ICP]"EC$8
M9BQ1E@@A2S-)D<24->O8AY2QRSH&I;'-#(/!+#]]O^=WSO.<Y[_GC_L^=SUW
M.?>\7Z_7O>?<.[ CA0JA>534)VN];MZ Q>STQJMQR'&7_$07C>3N2 U-ZTUZ
MUE4UYO$ GK4Y!S1+O$8RTQ=W2FYW&/Y8:3N8[7$TL7OU5YI/1Z=>$>W/KW<O
M?6DCC'2H2[]-=6;C0-@'E%7H-G)7N^I3I=/PK:GM;7 NKB9?I1TN,OOG.ECB
M-E:XS;M)^LH%?UR=WE$60'4]I@-*<&(%10(PE/NLQ]%"6V)M[H-Y_"L)' E.
MX]X>;W6BMVJ^L.V9O9&7D@6<E=_/UPT.V?:8X$-7;?>7K<^"XQ("*$W'_Q3Q
MRT7M7XX,(AT3TL7;B:07F-)@Z#N8S!++IN=JUF$#K.4<Z.4(PZ420ST7*MJ,
M2:-;7<<<8 L"9>@;Q0N< J54:AYV"IVQ>"5FH*%GIN\>O:+Y#H '>.('T]D\
M#2O*EZ0.+[R^R3K.%>8!J*?9B7OT<Y&"F<D$5WFJ%#ZGL_]21A-8,]NC!NW-
MTN1D%DH%HQ54!,P8: #?@N_2K8 0Y@9(@#E+:,"PU-<E]YK;<T=N"!\+@@ 0
M,YAN>[HVM5>7AK/@\C<!IJNS\ZFCHZ*++]@N@\'15TM4XT^<A&U!5=+CF/AK
M@@3$I14/W4L[A6^K5W;R,N;"OF2M$:UWIO2W(XA_4EH+@QFTCI@DZ:^9CZ+]
MB<]\U_Q_RN5%AQ '"/[LPYJ[:N'2CXTYG=4%GR'4\J.+(<USD^L=:"FV2CWI
M>=/)"V#TX:47H6:COK>KS=S,B;YFEW=S9^*!; U<RU.9KCN! LE1^-]=I!I6
MPN+K/,7IYU5OD<$C1INO_=Y&)(?KNXU IW>J&G/N**1858:A!:5CE0/G</M%
MOY"2V*IY[E&<QGLD2DHGH2 <S#)G#F@()SITR>T3]6LQU"0G;>CV\N%_\P!M
MA[KGX()-5_8 JZV5</&/\&C07J8,$>S"?>&1H^KC]FV5POYP?#?,\HQMB\$O
MQ//<?\\=16MK72A([PAUKLSPDN*ZU/  W=8[EM,?F,/3/0^JJW/#0 1)+I"M
MRLE'B[/F9C"=SI?ES2CDE'P]C\1*>94.[AFZVDC]VV\C@;#WEK-@06\C!8:H
MB\^2R\$(BY$VQQK+74VU#%JVI_\YC7 &D@<0F.7$5!TCQ->,T]JFX.U[_<E4
MP0XM\0!'\ 9F#/P<[IEZ.'06+D)U@3UE0B1#ZU+:4>D%(66C;6%J*;'O&>>?
M8LH1)7LDO;J $G%U<^G*".*YT2YUBV'V]-5ZA.A7XAF)U<#E\%3<FT)\?+@1
M5%7Y2=+:N=5DF-M%<=*-D3-3\'4M75H<F8_PCU]TD_H>3+<#GV#$#*1G_&3#
M+2H&? S@'T-<H=CN#6^??6.4@4_GEF]69^3_C M$A#Y\,T8-#BLK)(^/-SC5
MX7:<F6I-1X?#53ZP]#OK?+#U!5Z;6^/!7]XNCL,VF])+J%DM3S:S-@-<)\?O
MN,*.5@9.]"8EUXH^D5T@)@3=U8@/^<ZGXWI@"R 8,EE"JO;'%I5>;+ IK)6I
M&KX]EW3+1P@;ZFD*D3U6XV<ZT'?("Q.%*X^8FJY%!=+Y*?(;M'BTDB=$QL X
M$$%/;-V2EB5U^ A#.?$,)9M,FO%YQ-QSY1^!IW"S\;>J$J%^?@O1C%.$QE .
MQF7D[A"EPO+TJE Z4GZPH?_5UR=I2B)$?T^-4,6S[GGS(A1XA]:BL)6F0T (
MG!ER<U\$DI2D8&:S-/ JW$K[V"4?:#G?PG+QZ*!F'O=E[4C6P$KIHU+?G3]"
M<']P9-EE,3N'6KI;-J+$^X*SRY+>2Z[\P,FFX=+*_,=U=ZK?1YPP[,SW*U3[
M-?O3!*'\9:QTN*O:O'TM;F 047K4O#+%NK_!Z%*]L.6K1Y5+EF)Z TI*E6DR
MI:4YI]TU]#5K[6U[.W)/QAO]E6B7MY5\8Y$QG-W$(*7DF7/9+4O1>K-_7Q%[
M:J?(ET]PSVQ,>H!I]NFB#AWB /-[J]:"J?B<47M!7,)O[6KI+1_P2W7U1R"E
M<V5=J58"7G))^ZRGR.KV1P2M=;-:!QL+<>X($66\6,>F37+SXI:V>%=^7+#6
MZ$E7@7U" K(+'D,(0^N35=C.@^8*SM-.ZUA/D/O=Q:@;_K&3B_6Y>>J/#QF+
MUM2-! VCO"U1JHE^1K<*-$%IUX]T/;@8HR#Y\N))2U%*]4+2P$**MMI&U8XK
M[:O"YW!8$*RGL..%7F[GG&&\U*(_=HK%+-QSY- /V$Q'+\/5A_<A?(<O_R(Z
M,\2[I,9=_%M.4&N5DE(NPX2H _EZ-?'=Q@2+J\9=KKH3J=@GDWDI 4Y4!\14
MQ!*[F;G)D/H<6#W>$JK3,UD=,J?SD/A'/\S!M=32=LC=W+?IAX3%TO'#JD^1
M2:M77*!R^^W6'P"L >?"P'J[F/AG8IN-ALXXRN!P)%,G]!4C!=Z9JLXV?[!_
M0P<@D*>>[2OD%ED=LM(;43SEA_#=XB^@!Z3.65T_8K:Z$:EAK*,M)<14I'OW
ME1F<?#]E[:MB?.YKALWOZ'%DLFZ>P0NB<E_])_49S>O'W"^(-G\6;$ #5PZ>
MB9UZONY*CM):(JCKREY[;)SU/=GDWRGGCR_>/WYOC[<@<"IFV]*XRGF86H^B
M#^Q +_]EB(L5L23E!WZ=?]B=7I:E8'Y+^TA[W3/Q9+9?S[GC*=E1OQ^\WI/%
M>:+.<.#/,]]R,Q3O2KQ^$44^MF^#MC3=@*B"B4/@1Q=!D,G=LZ(H@2?N=*+<
M!I5_>NF)'"O=247G['E00.#/TS+\AE]GGRIG_/V\_BXJI/\1D7$[;VVL+F]5
M)8VX\"M^P:BV1&HGXGW)]I>"T%=GY:>AM^PW1&Y7#ZOL_Y*<E^<4!:H"261?
M;KRSWB)D6R>TM/;M'; 0T@E6=X0T-A'RCGZ#?IBNJS;O0FBN^"?-B\=,%XR;
MY5PDM.>ZE*J1;T*T(7ZM)7/GXP#RBT%P<$]J$EB[O0YJG=UUE@]$$C)P6D 7
M?N2>8[DD"QXC[OCS&\Y](:!C/A/A@0D<84Z33(ILN-J-C\\:P+.G'.3"*[RK
MO4IQ,&; !_V9%]9BZ/ I5<LY6*SYIU!&1ZVBNV+A:Q1I, V&1^O@70]*?>BO
MN/U1@VS*&<^JHX7ZC5XCE1J>)59B&_7K(:H1FY B?,RB- 49&1V3PC)A%H(4
MZ2-=S1[)Q*\*+ .G=TZOV:?V&X%"#A@:J!4\>($::_=?&2W&7\?KKG+@OWO_
ML"_R *(89?0U3 NR"\XZJ;WBY1K%B9J12]-,8CO2+P@IM(]N4UF:-M@>2L'M
MDHN[P/8?NME]HA(:75U(N3+3VV%E?,V]WIR#A)GZ$@+W@.6NZQNYFJ<-^_B:
M=51F"5&ZBILR'&_VRJ.RXX/<_=ZV!1HZK*R[L=G!F2'O:__I#6F9V:>S?/'.
M*],A2>R&"@_P3@E;Z1HP,CWO5#I/IM3,HM^%RV&E&-H)I%<W:G+$JL;%UZ7L
M/ES_+K-P/"I5@A$-56:25FE1[NN8![CH4>%KILJC=X-M9;;?;C*^U>3#SD4#
M%6/Z$K@>1J)LDTQR1]A)SE#?M7>+I\,AB& S\=)YK5*)0:R6F>";ZF^]QFM]
M6?<BO7>4.,ELG\*0"8I30A,?_,Y$45*X[B?8+(%_?.K&"ZV2A\$#W<BBUK6Z
MY]1 ?Y3(1W;]PF=RM8JG=/5'FP*1%Y[3GO8VOHXN$XP*I(M:L Y]S:MA=KCV
MS0"J6'F6[#-;N>ZH$O=[R7HH:,5B2/6.ITML7/&CM @B#E8?MR89S@,<A.XK
MH9//&"AD[&:\08\0  TV;SUW.O;04A[8YE3CR# JR ]Y7E0^5#FQ>=.WU U2
M88 \3(2\>N'F6M\2>!@J47P_D9523)7>S+*[AO!#>!L<J;1SG6REPT2[@KLE
MZ%UOS=^9"D@\E@GPEK(T%1+-+8?:\DVE=/'E@7_ES)5:2-J[I">]G;#6\ION
M+WP]_#IY6-UQ\MQN45 N#>7IVSW.(4W50CS)8ZV')YK.A5S>\3\XW9,6R@-D
M!I\[(*]#2W50X>R1! ]5M.NL[[/VP&=!'"^[F*%9M8L5G?ZCAA7PN(.>O_9@
MI%.G>RIY6S[9S(A)N.^A.QZZH(Q^U<+/W%JY=4[YR$C5K<N8>:>U\IB:Z1M+
M#HE>_4B+R3I:Z>H*FKC*C_X)KWAR_0LKD5_T:/5Y("N#H[,=E"36EJ_3!7%Y
MAWE$&^M /V2\GY^(;VVC^(E#Y&\9^QCR;9"N F\G.<UZ_ 2%GJT%S3_P:+I(
MA/4EGW'L[X7>% SIA TFA<VCW1M5H@O4'NIEU>]"]>&6XWH3.Y^'/:O3H:KZ
M5?U,IWIVRO@!B._YL=^*'0CRD=OJ5Q2<GB!N(P7$N&X'E/V3 @ZLV#_@U',!
MIN;)"YU(.0]QUE6*.8 IIL9TEZ$VD^R(L$Z*QW%=Y\D\OJV0396E2+[YS=\9
ME;MY>5?YB$K>O@MO*.C(,*QN2:9@##(]%XV0Y0$&;/?;^H3[P]C2U?4T'@#
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MRE%;#IW'D)Q?^F]T,XLWG9W>%0\,;N>0?RG3.!=-'8YY?@M&>5;GN$XU-O$
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MID<BV/7:X(E?Z<9U>'.1%U7I;#+"F8\[_@*D^UOES"/W><.ZUW5O0X:[E1T
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MX2+R]Q!U(_RXB'1 !C9TH!6\[B8\A*%G1QL]USVZQ$#;+*1?FF3@6TR6J?Q
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M==Q%' R)JV1@Z%U@5Z;3JHJ>(:WR*=@-<C=$3M&O[ ]//IV)BY/:O>.J1IC
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M2!Y)68>5AZH]5_7$HJ?5O?^[")G0R/^,G) X[SO[%3/!G+ ;E +>:XWB[*8
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M<]^?^_O]W_?]^_V^W__O]__/8X_-=;WW?K\.S_?S]7INUR7\)AR!;+6VL+*
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M%9G^$"1Q=8-&EA% (R\RL*F/25*<N^F3(*:F^>'8C3O!']:I+"P%_65IBYC
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ME%7V5E!32!ZU2''_FMLI%5+46#J"F]$%JK@I^([#\#7XMF _$M0P3<>6DYY
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MVJ85!=P>7VE/8,TX&4)!B_65ABW/_+=X!LUD"^BZ.^?-[DD<F'7Z\"*/-$T
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M8^&M-P-^"$12!VG8K2_G.F(V?W3Y18/P*^?D3PVU],4RTS2(,PQH=5\25Y"
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MR'&[VB?'U"$S^-C2)NR&/$:PUDDA:Y"6#3)**DD9S&49=L8I\ M(S:0U9+G
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M-?:K%T_?Q"V@VNV"8O,&*M8_BPH"5 TH:ZCH3/CP$JV(8XE8)EA/5(73<'*
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M$6LI[[)L"+ $&"DR1BH+Z>00)%+K)8IPICQP*VM79BUSCF2[/[\6U!U<,.5
M33%WH*@MCW\^]H6J*Q\7FO\4+*(J%9BX,B;D3C<^FW@4.ERZ"Q G%V.Q-$^
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M7@$2'/ILSN;FJ@/.=9CV%N'F++P^I>S^IH;(VRC7Z5S<,JJ=?S/6K$CUP'<
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M"&R2Q 2*;[V2X->@= F.YF/^TLNBU4#D]2E_FL!#O'-_1:)\HY29'.11"WB
M<;R<%2=U)\0DY,T;K]/<:5<'[P@/!H7>*Z+]5ET:'Z,G7QS3%2G3AU:5P D1
M]YR":47O!KAU6$T(*\XVF!$$(*6DFW49CT)R'%LT$EZ K?N [>7BG1@#-PG
MW2HE #? \@K+2U]T;J?C#C/ZL;RWU5IDD_XG>:+"&)*HDS^"2]Q"INUKM[97
M_5Z&52EG(8G5B]IZCET5YWBPU$:H1LWV;_,)OY9T66Q3C=C*E@S4C?>T2F+@
M5I''$Z[@G.MOZ%7V W5D%^ >B*H-18G8*>%CYC75Z/F[?U26^8:5BE$KWZ$$
M-J4G:2%@9.T=UWZ0LXX@8:A;'F\E5[1X9%V=FD)V#T@<>$3F\@#B'5!/K%PK
MU**^PY;$\\6Z>2QR#Y^FCA59@&.R75A>-O*DE!W;(V@25:GRC369>)+VPM/O
M>B9U&.O-.2KE)R376Y7;+D:"52,;[O5.>7L/5_[H:(HY)"^-9WM$$>3XV+G+
M$ER7R?05Z;PP:0JK0]EY+21GB[0X2ZKD(]6-$^/TR5C!,TFV*I\)Q \&V+12
M7$6,E62B(&>-= E5WT($#@ ?/^8U&.ZYU;)U6\,':-=\O )Q#INRO=JX DP!
M&#CI!6,#((WB6$H_(55.,7#>_886''J!C*VWS%GG0XEYA%SYG,Q\+[V;8]4K
M69QCN42H=8FKVTO]S"T_5I!B-L^\X->/84NOP$'A<4O;!VKQHTP#&[XA0XTL
MG+XJK:^_7,A_:)[4+H&K6 *#CJ.; 4G2V%4-F-COR[2V'0%W3P^"LY%!LIWD
M C&&T8]?!&V5NMWDQ "%XO':4"0_BG43O=.\#J\D;\E9"RY]2#:S.RP^@7;I
M=U82<Z+TIA6(6 K.B5SC5>?XD7U]P^RU[,X_/K17#91W<JWT+ C=,][[&XC<
M*YW-J!,U558=/=;38P.LOIC.8FH=OM0M2;ZYAT+HH&H$=[,$69Z7:S ;*CK'
M;>RYEN2"-TNPURG!E=J9<R ![2FZY&,%[9>OP6RZ>4KUOH[FV<;R>3KW7,RV
M!O'!M" @Q=7?4%SZFMS*?_><_(IC;TH0+Y+0+/B5JN3['.=^%4/!&.K&,8X1
M272($O!1_(?&0]T0F?;E)I8S)N>OFP #_GG7&AE3FBR/A)>%D1>0VO_HF7!;
MN*'Q<J&\E@;S%HJFB*8$QKVIS'G]D.PMR&2F0#MI+,IN\'XA*/'LC*@RP".)
M::X2X4IR.BDIB7+X(;K;_$:X.^>@U8^Q_7Z]OF4W2@JXE.T@L9\1)U\.+%Q(
MR-%K1:_NQR\G2(>JUP 5J9J,_9\FW\Y4$J(.'/AV1SMF]+G/2\Z$AUK4)I6T
MWRXSIV%!>P?KB,#AYE5[.H>QCL;FFF8$3'#?V,[MK!C_+"'LO)++?(!JJ%W+
MNZM=P0PF1BEF/!4U_2MJ)38]P;^X%."*ZF^@?0(EO22>HS5+/.;$"]@(T@I&
M#.Z]\&XQOTZYN#W9/*EL2^2^U%PPF>/\V/[#@1*3WV^\O:GV[J3WO[S"^5E'
MJ$.H4:53N/^+S2J^'_W]BIAA,QBG3[0SW*X>OERU$UKT$/005)K'133G6G5D
M%5#\0?ZY#;<R$<I[6R#-(A>IKE" 0MK9:!1+].@<0X<$RV/7[[%Y[PR)%,OY
M=(PA9  FQTBX2_UZ@Z>; .X;!6(9&M4_MC.PE;.IG[0(M/#II+@8IST<3)>=
MB0D4]*V7&I>RP%+!-E;WCRX3Z_KWF<.XPE>PL%8@6%/PK[M#;8R&?_XMW9&1
M=V\\/XN;_I'+;STT5[$ZY&&&?PMT!UT@X"Z7&X*LVAP#*3>)LEK4&U3;I][,
M\7E$ONSS^H_4_%:[)N/J:VA"?MV)V6C*/COG=>=^IN^2_W(!]:!!5*TRGT0[
M)UQ$OES?MPJ@\3R,M%S #)$?<@GXO@.K!78>E9%BRP(=IG&Q9:E>OE++[B8Z
M9VGH?.'3W]%;19LH6-&OI2<?EB;[YUQ=N"<PQQ)$ GG\.>ZULG$D.Y6Z%CH)
MN@!>_&[6#6@<W(TV?PKSF$9Z_^]0H%B!*(UU&C1>8_ LDYSWZ\3;YK7>WIOP
MZR&?^6?8$/P2<IH JV:'U:(VJDN8<<R2@20NH2G9>)MT:4:*!! *8FSW2!FW
MPJT,:^3*S=Z"YG>BNZK]SA<@%ZEE*9DO7SG=07$PV#.Q+QGKN>+$*YO4LG%2
MU/'F'R^ZK]S+B!XA6KRPZ.!9IWA.XK]U")\,"(=D: J*(0ZX+2T6BN0I>H)0
MI#MC?W/$"+G<#SGZ<4OPS^#]ST13]RD.YDEZO[1/X=5L4@SYF\1?@?#ZFJ'(
MZ1U068L4.ZI  )%U..DJO#;%N=D^3WJ.L@JS/J;(?B4EH'I1&D;%X*U[JX7H
MY8<5L1>O_8R]9C&A)\ "AQ2(;JXOQEP*HTP)TOQ$19%W>\W3PZ<!;\%J*$"^
MI8H[_Q(R 69\VUL%!@7TKR<F53#Z(SD[5NVN:-DCO7#XHUI)7>V2^8XL63"U
M/8J90M&487OP\J8HM]HB_'06^$V&(2H0J^R-D'7F;]X]H6P%=U M@^?D<?U/
M.7LVT%9^L4L6]3#4&B0.QS9VJ@VK;ND9WL%-R>X-Z4FKW/^QNJ1E>/I(>R'>
M"\D2686Y]H1B+6*F,1#0-)H@0Y,]Q.%<?8H3T'"P5;ZNNE"2[6OE4TY;C?<A
M=+,8J,A;UAP'T5B@P!8,Y*>*@3^ET2"1?R5.4*]U4L5GQWO&]/KY>Y/"A.HU
MH$4N94T+9-./4B9WXA?F,D]REQ,Q%D!8@0AO &8<Z[2/B188ZTF9B9"[B*5'
MIOE+U3N3(CIR0E4%%:-G.\Y9JV>N8]6'FD^72&FU-BM9=:250\<KNKDW:$&D
MSS/N[= FT;@1F>\)N$MM:36_5%M1-G1P ON++O-SUN&TD!KD>W9;6;_\>=YC
M7VAK?7&M>DR5B-1C*.XH!6@2FS%;.&/74)1!(I#)]P69_>.)<MUV"E:"U"1W
M\JHW &YU+/"8@6G 3AP2O,O0)--K,4<)"L1R;L)A7ZPN2.=KNFYRR]G^'*2<
M85=9^6=_,W\>ZB>.(H5>X+!./4KBA8Q6]K@.?)N_0$T802VE&HP(54^!6XO!
M\\(38%CF\?MY"@3/[&E(9=6$YY/!S'B#BALE(T@G<BST+/SIV2-AF;L"5YJ4
MU/5 W /SJ0K$^50+L>=,[6M:@N_)/G1U!V;=R)&0J%LL<1'^0.L4*<4@N+EZ
MXW"WP_6ICU<YFT2S5+-ZK1[P/4X-#$."'C7NY4H1MI8CLQDBF^Z!:1;(ED9/
MGP&JN"D40^ S@5:!&U.& >/_LHVC:IW)U2QC+H80:>+B:]T%]$Y!GQ5>%?S-
MC&\"7K'1JX,AD?Y\&<UZR3&TGNP\A=B&-L/&4=7Y /N- QY)U5JX;%9&2K&G
MI1ITWD(3GI#S#@#(L:62IB6#&)7FB-Y 08KXM-([43\E1DQXQP9^ER(3K2!=
MTX0[*^[%UEK(I@D;6DCG1W.R>A^75;_NN3A/6R[GM?>00"-D.RE!@2@9>(.-
M_XV@2582]3$?;XCMIZVDV+;HRKPZT0<J:=>FJBY2=A>!CDIB]<L"E-3SHWBI
MSZUK+>Y++A7N?7IX/_-!M0FMQHX;9!39+ZREP:1(C;.U@+*!*;Z2(FK2^$*^
MEATHWMJ"MA>-&P3W.3135N<%8QRE:Z3D:%'3](^;^7)]\,A/7@[R=F_\E=LZ
M:REY10I$C8L"$3Q_T$83.@ZPK\MUR9$B/;ZGZK25%'^38B)^B@[@KHKXB)U^
M3E)7)^UML:?94[;F?A1I%>?Y[@L-PNE<M71X<X!HTT5#8(.QR7VV\P^K'2CZ
M(%\CM9^I3PX9J:6:@C& N)-?R1O.I//4+>I2%LZ 00>;T>'V/5PU4,;OVPQ
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M%;; "W17("1'_\WUE-.O&W[09Q/N?QCV365 =JS8^IX+V*\)T*$=,M\!%/
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M+T!E=AAT7Y(I$+)3"Q7PFP+Q]L$D:BE&R?5<@8\+(!&5%S.?D(D\S,J6L?7
M]WA+2XY%O_,I<MR;J/6NWZZZYX*7\2YBI"HO<?FZW^^/W?:___5;&.T<HRMJ
MW!=,$*N[]=?S#(OPXF^<::YV>19KQ># $>F$BJ0S8E_$]#GA)6RY79%%P/T?
MZ ]-B[^PQP7>)BUP>O\=,/+E5VG]^/F_"LDE.$]PF++Y^[1S,BQ</E:6@$Y
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MHRF?D"S2Y5GO[]A;W+/CJ8[X:]0-! <%@HVK51U?#N:)(@4]ZN'0P1* DEP
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M2=#1 0T3 ]>[W_;O"!O\.S*TTO[\J2WAB$-Y/Y4]3?A^*49,_X=8IV=*FY@
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MC:(=V;M%) 7NY<_=IGMC>G1GI1"1:AK\"GI,1[3P%RX_!/;"\FJ=[3#2,W9
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MK:'6E\ U'Q^S0YA17A%1MN:@ZH G8PY\1 "CH(PZC6W0*58BO?+#6^D+Y,^
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M6Q7;M1_:-&^]\M ![NTJS8Z2BF;TC-6Z%E6&A59R%ZQ8E&5XG(I)@KA- R<
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M FZBA3PDR"/FSU*J$.@OME"&[;K"-T%3O+1[)"W!D 3E::Y8XU<$'_./<,6
M@U$ZP"HBI7ZG>(.& ;G):5V_]&]7$DG7K9X"=>:D-<6]X6P38[)5!."3J=*,
MNXQ>2SS"SX\#O'($%_WI7N<MM(>JN$F&85IB^7QOU0;3;N\:5S%:EFB0EZ1-
MGGLPX9VZ[/">Y!>Y'ZA7!$%AF6^IGAT<6H'MQM*-HV]5Z,EL$.=W-;!5[U2G
M48:J"QY/JVKS?\APJ*BH4E)RVOAR7VI5?>^/B*!,@Z_M@>8[^+OKK*.%!F\]
M['J#@EZ?Z\$'!^_H[75V5LW(2+C]XM6&$[MOUB>W(7Y2A&=(3I"=@!M#5Z5?
M*W)[Y[I"]/SBTMG69<Q1IM"4C[XG5G$AML8DXMR]8%E0BP&HL7FN%;3-/^'N
M/8#BCPK5:_J5P,<Q3%EH[T$OLY\H-5<P@>*F!4+#,I R^[@B#,<OS@#3)2B^
M8P)GEM!&,[ J:!1N;.$ET-?!)B7'<AK&L''RC&22M<5>BU4Q#5.U'XB6A7=3
MX^Q:4[6P^ UOS#[T__BB/Y8[7WYKKJ@%+*@H;*]==Z2T*BQT?LY%@G+9Y]E.
MVR<JQ;G38V@;0=U$^)*P^IT*+C)<][P$Y0.M<!9_48G4V-EQ99Y>$:"9W7AC
MTNNR[GE<I7#V['GIYFV7JVNE>P5 O6V?*A\;.T;;0CSM)\4SNM\=ON5'JM.K
M6G*D81X82"?3RV:&<ZR^H.'-*DW)?(_] ;N/%]6>MR TTK^D,ALEJ)+4-Z 6
M']-$1:H3 28N ">'5"DXVDIX'?AMXHZ%X@A.EF0'9C"S5@HI23-T#7A?=X#^
MANUF5CF8.%EHZEVN<DXJ9I,+R3Q*6Y._HQK8M$NL"6V9$TL;@!-X49:%D4\0
MI5)IJ4E8?SA+%G+DU762C%_XT#:+'M?@0-US(#FQ/'/5%7#B-E)(8>6@$+P<
ML=7L_,Y3R-Z0U7J])_A4K@^XWR_9KM@A_7II]85NNWXP<;[6?$,@N9' "^T=
M"^C-+1\*_S%<59Y4F??9U\F]J^+9\Q^IZ6&S::%7@ZR"\G]D[XL[:;W"-X>Y
MY4&90/K'IMTR3B,A1OTY+[T=JC*?+-#B19DB:MXA$_.QVUWW,[5]CA=/-ES3
M.J]N'-W_ZM.SVR<EJ'1<1<S=&O^GXF;<:GC[LQ_]%A5"XPC\[=PNDB["+20[
MX:XHH98#:'7WFR/D*<CTY<EHZ(+<*-B1KW!\K.;$7;'52K [>#]F_0]7.2&7
M0;U'+T]K=!2E25!>IF1UTBWHT.)VXD,L>CC+#&*]/#?D=,.+B?A,<4L7[+W4
M_.J>T80LO/WR%?_UT'ER GSES>CQY_+!;686KF^,YSJZ)JF!^Y)+;SU*;<[K
M&1JOM)Z^O!==X-QW36SWHYMC/<[Z'1^+2&8:AJ0"K.HECIS+:K&'XOF+N.5$
MU8/LZ3[G!HO-0D*LYT/'19T'N5[[YDY7YY%51VZNBB+%7QP?&7Q^\CU]C7@?
MC(-X>;Y57$;8C<$&%4PT[%A(W!/F8:YUCAU0/88_^& ZTVU1]4*W9AQ6=JC=
MI_U7YCV2(;O7\'53GO=!;P_8'-J[: Y?@)X),%_6GH3>\@A)QOW*T/G%\^(>
M.ICH8Y++:D2O_)$E!R&U^B[A,NAD:7/A4J^G< VPUW?,C[?4C++>D7_KX6J
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MYK>[LV7FVV]V=I,Y?V3NS;GW.>=]GW*3X[GC51#_+6,S8Q 3$Q/H'N,-.EX
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M^['^<V.3\FO_]Q_J7^#?P7^XF$ L_P?T_R$N 08N9E96%E;V_W Q,8?_=X(
MZXG3E]@$K]NPWP\2DE-_RB%\([.DH9=37L.6+.+^:()+5$&3<(;R'[3_%=G_
M.V#1_Y^0_1_ _D]<>! /"Q-C\U@$0! 0G7ZN-!GT/QVOR[UM#;RYYK@$SX:M
M9&=]87E;(@[6#(CF7'X$<M?OKHY;K ENF9\-_'I-5:7,>O%[I3K;R5\G0>P_
M9FDB9=0A(.Z0"SV(XX?XJL7AV3*):I*^^.'8;IWRWGK#JS-)Y:/$]X$J5UN.
M[N*_W9QT\?LZK!QT/O]4UN;F:=UV(SO:"_K8"CF,?><2X4AL./<8!*;+TG2
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M/MU-"[' 1ZT^*D89$OF2#C(&I1AQ;N6DEL/T)$QF.4 G#RNHM:(XFK5BDC%
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M.B/ZKOO7.,'2 . <E?=_@SQ1ZDH/PO3ZX^!*) 9QL0-?4 '$JR9FG62^Y.^
M"CFAG]J:'?#7)30COG;2?,?1=-*6+>!Z_:9D7<5;MRWURT7F>A\?N!<J/X"K
MK-)&CD'Q/93X;/],+!^8W_7J>'8KKZR2Y_FU,LN(RJ@$E]:BD<5;&YHC7#"M
M/@N%PJ_&KYFH&;W@E&-0$]_V2])[<R)F8 FRBAO8T2/TO*]:I&D"&B0PES]+
M+X9/%5[5T0UWF"*T)7A_W0FM%TOA?B$Y-5!T/L.E:/Q(=AT:&3!8\ .VK':2
M4>KVQR"/^@46@D,2"9L(;IB-[K8A0*7\+:KKD1CGR6**[S$H%GU9!9YG\30$
MH)F5WOU@_V,IJ#:JZ':^?*'G^;.8I)4,#4"'F@.,L&?0_.J0V;TQKHT3FN/\
M/W41\15-G;..AG$UQ(X);T^XI(J_I=IVP8/]I9O+(0[\=Q8UV]0M];%M, ZT
M 7T,PXUFHZD UM7AC"Q#0,3L8@_9OLSV&]I3TNO?WDW$M-1U(XA2YP7I1KY9
MG+RQCKCYH%-\(HUFFFM]%Q[@!G!V?Y7Z9)D9FF9-,[G$?0Q*6&E6BRZ;\1+C
MABL[XLM;N8/E;V8$O$4J0BFR;T(R'F55S7E.!7-5O?K[Q/(7:NO0B*9U%&O
M 7293M)E8#1W(*G^SH@FWK'/8;HY<B? #<7DI=QY<V+>'RWYM3@'0H03H;);
M1>)3A"2O1&4=T1($1$7_/J,PH #4CRCC2@C?'A=]4XSTZ9OY2=<'"*H),G'T
M@KP=!;$P Y:)7<'-*RW7>:RO#E5'"<]\'0P6:.%?,M2O_[=%P=&YI%1SO&J1
M>E3OJ5 9*>MO,QC TD =6;JZ::!#T6\Z'YFO$FK>A)R]?^^78I-[^,;?IF5N
M>?CUMZE1+U%O#P*\OC]FW]E@W(D"\*T.B1V @1A&=<- H)5L3YY H" 5*7N
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MGP3-^>@9S:YF:U96X!V8LT?'95.W)6VL%1OQUIR0QC#EE3DEO<%AO,U92VY
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M=D)_^+Z3YDP8W6"RAF"^E<1]%[_LVPCU">>8/KMOH ED,_ICB3$C"CEV=W\
MUE05_7O,SB;7#^M,+@\&O,DJ UGB7BVZ^C.9?3UFJ;1H_4]N2Q:I7Y;'*.-T
M;CO&EY],PDD93D?5*".BWFL\ 7Z:G)M!X1[D9X],A''1%29J0X;;<V(;-B:C
MNOCS?7Z=3?/*A$V'P%)P3&AE^AA:Y*B*QD=A7K@!N%+8;5HF:0((4I!?";+*
M9B9T7*PM#J55"2WU.UBN1<B6U&Q>6KR6F=NT@!#!Y55=LZ]JYRQ*L?I)BZ%@
M:/QE5'4*>H:L.%"?@N63/)%)F")29%\2J^V+W-;61(LNQ3@SZQBG2U]7MCWW
M1)QZ27F%G3X!(QMB$U?8>T2!T6$PGX&N$\IJHOM2%6QS=/5]0&_X8X?67)L;
MXS_P6[D'L;J>?TWN.[0<:@QIQ__Z9/H64GY.*\K SRO1==,A263PT^YTS5DG
M%U.?K/,\F9]Y(I)-\7@=>UG/BR:GE7=WYXHTBU;LR(CDYI\KT&^Y6X;?5G7]
MKY\A=#R?NW4_7HK=Z^+G\69.]UP%1?][\ >Q)HX^;V>CH/M0(/CUYCZ@2'+(
M8;TT2#S7#7O4F=-M8.O?*MJW FT5;1MT3ZQXU>3ZN1*_R!WJH9#<\Z#I$B+U
M#&!?3A.:^.-VX1AD"Q$1LIU.2 K!_HZ;^CW*VI LO3'Q+W[IE-]:/%3KM+-%
MGY'ZO4Q8 ZQYA29H2"U!).MB!\#S) )[6NC"N)"ZF[^LP.1+JSCE%I4;7Y2Z
M] HC3N>YM4O>G%S4F^\/]YR,JJBS=0@(;4O33Z%+CS)(3(,"3@A4?DE5T)6M
M?XOO=BGJ($$2\8[Q-24Z63?;=+BT(M_++2H6/FAZG7Y.)2=8TCC6JD9R";^D
M%P(1I8-^UH1$.0ZHI_T*$$OQXID4-0BG/KZN=R7+6+4.H:K:EOC1P3;SG>=-
M>ZJ:\,8^K+50IK:XJ^B*>(_L1OJ5J$K-9+=5/3TVE5?:'YCEDH^N,Q@_6@Z]
MTJE2E$]8,ND#<]!TQ.('VL+%1'$2^A)$SL ?!<ZJ=76B_7V=7VI^L>WKUY\N
M$WJ3D"BJG8B;7&'8W-5T!E'] =PQ#!MYHJV?8[ [M4 GVD"VM3J$/ ")5*/V
M5)>[X/">09KLOCDBIY*-VMVW&YZ@V3/8 [H<K?/,+AGW(_"8)H7$$E9:*7'S
M',FM./KZ'>;@[.QH&-_=ZVM:G\="SL(S:_(ZK>:NCK0&^-BS'@WSF+@-7&0Y
MT&YAW+T-??# \XS!*1KFJ+KG+%1RT>1J2]PRMGC#+.+DYP^V)GZBISY/YG&N
M/2BT5OW^ (&G]V/(5N-<0/RHQ:0!-[)I@$\B6:>3 AW02S/:Y9LG8M373A<M
MW7_TV;DX'?(\*SSG83(3;6G)E[SA0!E_XY\;%C8>N\3;?1#S9M-+W<7-(N79
MC7_>[$KOVDY/<VPO]#LV5E1BPXDJCS;6!(HG]*]4+^6+/XU5.<J5-V$X%I9[
MZH4#.N!9L3@#=O0GM$!'JRY?'X1IP\&FF?=\UQ1IIL[#X7G9L'";:)OA%X&A
M+A?;.85+^OL'$J&$8]#<L"T CRP'Q*X#2:O0)$Z1>JHJKLH7P]L"/TG<O6G4
M&:^B='@"07 -Y7[8](6F_#9UW5N8!2@D8[>_4>R&C&?X6%$G 1Q1!4V_XC[I
MWDJFER!4BV?YQ>U5@OS@%\9\UJ7*%X(D]W(56<;B=6";.#JGT*$%0]=M<:M8
M+&L(WWS&W:.8A2$,[SJ0H),84B^.W!\.P_)IP4YNH!53S&)<VSI:N[J_!4JH
M^$P%_K%1\O/ST5HZ^N!,^]9IP]>+Y=W03=CA+4>)'[TQN(2>7F8GJPVJ">.1
MB@3P$".TP00->)!*?0;2,^M3NW^X73&)D@JZ)X83-4<1_"-^P15^!]3LUQLD
M\_8X1P>C)_A/47M$,(V_>G5VD-=Q0/8$X,9HK2#*>@K*DL0=$](# O))8SK$
M:3G/ H>L$=@M2JSZ?&WR4Z[Q^](ZCGS2&4JWZ@7/L6_7#T !E97M2/*EYI\]
M5S<EV_KG0^'VO\W/AT09]F'X?U/>N"[T!J&RQ@@8?AE[E9V"U1NUJG'"&=^[
M8]$4#RBC?[SV%K:HID=-%=-E1R\9>A%,M"HI]=,^6'Y?.H_WQP=VE?F).<9
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MTB?B#:6"]D%%NJ\>?5X'O>)I$OH@DV!D+7W[8N]'\';3>=IT#."=FPR*U@M
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M12\H=P]&#O;\AW@[#:)B<6'><KNU([N 3J=Z_'628];[X]'XF_+FT2D =);
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M.N717QNC@+]D+'$EP< >!3P#>7?,-\#]!^0/>C[;(2\!@R9_#*5'6*S]J\A
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MW*GA[[B*ALO1_^.$<?E[7XJ@-WOJ0R$IY=N]1%!/UI7$S9_..CL@T4CYS8(
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M1K-J[*E_^YVKS5<5^)U50Y V6?>)KB[E:6;5IM#A=QG*<PAZ_0L(_\"/W33
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M'14VFR-#!?O[<XSUE8=7L]>6@LZ7G@$HG+^"5G@@(#>%.%O\:D6HPXLQ^O+
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ML^'4!OUX0P[;5N!=PIBJUIL2+*F^:GTO162ORO>TENOT810+K N$]O!;^*S
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M8I('1[2KU[Y)D,O."2T2O8Y&LZ,@&WM"1*/3%E1P9+T]-/V/%XB%*DKZ^8'
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M0+PM;F%848BG+:'[Q ?,=TE"8O2BC(6 CX* @,B#@_FQ8P)Z1!/&[!')/B"
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M--OK'_.IR2;S/#(TSE<KBPO"NIKF3OB\U-73IW.+]*:,5-A??"VA^V5\VOI
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M/SM^-WQ7A^+*WT>H0+HUHB&-]_B#7=5U3;<8$0N0)K"T=R(&.Y+2-5.<HPP
M$N23LW^9^.MQX6U6SW-??8+&-!EC=:C:+("/O PPR3NI3C<)?+SD;=V&V\GJ
MDFA)!):WVJZ5<Q3 @VX?[5#)L'/FPX4%E#CRCNXRQQ7W]+\&?A43,;RVU?6+
MJWMX[N>)BH@<7&XQ(CI"CDN(WW&1K@C"A=N6W[5G\+?A/8R,+/X=VTI2QBO!
M)<HKEI#O/D8=.2/XI!V(^0 8('/'O^#/R%N_"7@GSYVTR;4+1[@Y$5E;?:8
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MU8D]!@8S7ID'A>[F"[;89F65 5>W.TC:,C,Z.V<]$1NG..,VM/\ AMK'V2>
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M9 "V0#N+X &W!))06\:RR3#(>0(&VA4!*;L,S1JCR$[O^6KR!,?NPFY]T]%
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MM:5<!48OGFU5%IX5,*-"C>Y9?4]R10T';#>.;SW94SKOTI:06]?!E7PH3KP
M."UFC-Z#8$J6_;C/M9Y&+%X ;@Q1$FE^.HIV9869U@OB'U- JVCFD!C^=TU/
M7Z2:+"H _H6F]:B.NA6J/GK/W\$4YR4JFBQHF'0?K&N(\IPB[V>^GH>9#>P]
M:+5ISCK2GTLB!I&>9CK<E:6OH@K?$2&F'6K?Y%I)78<;MA4UJ_1;TU(^P'W/
M]RT0P*VGSN(%Z\*#MJ+M;UAW,WB@P$2$RSS-\P,R1'V:)=A9<_D5XT+DQHCW
MQN"F!)K64'-$W*OBV):8H;P\?IQ.W)WXAYIJN "@H?6C.SUX4&;,>(=,"E)4
MK_T-\>H%X'T<?@1;F&\NNM.*=XBG,<*UBHJFL&Y%[ET V#FY3K8EL3.E+WM7
M;[ZEX,.J:8U^V98T%S.,S.H1C5(5=J9:"==?W[%P4[<1WZC%UA)%X(.(PI+.
M:E!-YQLX0TWYRFYX..=.*1Z4:F^"FS%+AFZ#(PN# 1< KW0ZP+EBOG<BZ5\K
M@6;9:%1@$\[R&DGRX&BLWFPKK-=JDXGRF_'T=]^ [=YJCN]9SPM::_&/?%VP
MPA+#+/E-*GR P?R42SI?(%HTF7*>.0(H,4D>F9<SJW_'3$_10\6V:4J3#JE5
MNJ.?E]9BI[UO4R5M6S Q,3[Z)T[0U668J \)+$0FA;AZ6LSYG?$T:=^:].ND
M#Q>\AY<F9^_/*77PY/Y39UPK?[F;IXUT/&[/2Z*3^0"I-IJCVXD.)^35!E5N
MHVM(]^!XNV::5+(T29_PR<.K>LFZO#)1*47#\$=SHF1%(D=] \XS#8ULEN0:
MC,*LD5D.KLE1"C1RY!P@8EXP? 8(Q E5>H8DKUTB4N29VG=\3GQ^[&GCW/3R
M-7ZDS%M]C\_'FZ !?:5\)^IJ2;U]5[B/2MN8]NL\6XNZ',NZ#&6SZGS'@.T&
M4%GK$ZO.AJXV^R=;M8'W)AKB2UO(J,)G_JY)*->S]U4:S]['T]UJAHL?SPT6
MQ/N@WO\PYN5/^_5D10"(V6%2\U@XIN;EI9+$:H"[)HZ&!D^6D65A#HKW*PF/
M>Z6:B%U++3U"]X;WYW;FS3(+.K!M*V?(44XKFW>OA1Y/4FLP_(YBTAG1_1"]
MI$6<GGR9>4NC:;6BS6X$)'/.!@E6TE82@P6^+LJ"+6XNK82EX'U_3B,MD>[2
M)4,IZWD!OLG7N00EU8:P&ZDA5DM W,,%\4,O:O+8-&(DD2Y"A."&X0U^4'^?
M%_B^E'6(BO5J*E!5.,+]0=(:UV3KR\_(#Z:!-:J41#T27_KC>4,L9=J'[24R
MS,&B>-)_BW_'O=:M2=M1<O -K+*!33VJN)QC3_#C/;1%D:]$/I.D8>&Y^$2
MN4^2R8DALHW@M5JJF+A:PY-MFJZ0N-KQ-+.VJ\AYN\8_U 5R;RZG;A51IT]
M'B1<@IPA!VH=4<3N^L&4ZL=L$/"G\HF9OI3YJ)=PF__P7]!-*X6:>!%0XG?F
M!8/4"/.RHS0"M#]5!\(:]-ZOASP+5UM/CFT1TA0?M5/](K.<#@ZW/%[C!;?/
M;M<EG^18!IQP(J]Y%,HA.=/[D(K:HPMQZ2\'(RT,'G-4TIG<K:[^[OF\BE@-
M'-[=G0,KVP:W-90SV8%KECYI6=:4+)PC>I=^Y+SS<[>6=B+>8-5,%'9V24O%
M@.ZD*H!&*54W\E_";;MH_TT_)IR@3U-1L_>"BO32#!*5;ANL72LW4:AC,M$W
M"<; U;NN@L5<[%]6?_T!J&9:.AH!K'^V& %L-%^!&T=<TV.&AM$J'^)%/H;K
M2P6O3_"].-H O]Q1L33K;'V58YP%<^13<,OM_%K.6^ZNO +S1X:?S0I^%1+-
M7_&-C-S:,OGRMZ T-5EW:T(K6.W<S7"?^;%8F3"..EA54X"F+MQ%L()&B[A^
M]OC*V$.Y7>'4:"2\.>(0L TU.QW3H_E,^O+Y*FREE,Q@3PML9/JB+V)*09"O
MWS3_M:,[PA1A,2"/5#IW1^X'7WKIRX]<>Y2C>;;8"H10K,E!DZWR[?;BH6 F
M7V3TJ$GK25T'6]-MF>%_AR8+J9J^30(V]HO0G(@*TVVEZZ8,KBO7G -U9VZ9
M[13&=L'/Z_43MB-H44'PGT^X&H&TF]?G%R*]^']K9RG/P/AOIZNQ_W'"?*C[
MJ9/R4>XT\A1X?/-'JSV]C5KLPPN =0K6<UX,ZWJS:@A[TW>T/"*+<*(#82'=
M1=[5:'>/YB@NLP,W#;X28NU&@V\9B-[Q_N"-3+_J8;MT/=>R<C@@M[/-[>CO
M2$P65>[)O+_5]HZ[Z]8_:'P$*WD0V'S2#Z4( F-,XKQQ78C>",5Q#Z4+ '-%
M)ZRNZ.MPJ9N\U#%G3K8E#T?Y5=C<S5<MJ0N[-OXQ$Z.IW(%Z6@[ %[($,3&&
M9AN"(EMDRC#&?3:S4$WR D#[<3F$,LJ[4/+XQ[']A-6#\P)M.M=; 1> UR1%
M7$R\G4_)DEXCE$H@:&Z4>SBT6_CH"#L?H#2(?^)1]F56Q6G(+[O=_6 A[SZS
MP+-F]82&PG3#X?+0T$Y!?<@GTB9TAH%,K_!L&Q_8W6A7; +[LJZ]&B8V[QN-
M>.1M^?(\$KA<"IH8L*?($%X/J*K1COB(BQ_P">8U/2+'Z_#K(-")=)2P4]*_
MLS]+AL;^#?8;6L KA3PR2YVUE2<3I&6(5GU$#QQG]GXE"+%,W]HM=19;1Z*<
MH.S!%H7EO\"/JCPY9KJ$L<17BD%;QQ$+.\&P*\#]$8<!N2 @U(8<&3<A, \Q
M%'N6F& S63N7UDF&(!\'!;4OEEOY>[QJ:'YZRO:(Q#,!?'$!F)L+]G#$T'2?
MZ-#D\*>68AA>TF[:PM'T;Q%_ 1HKB=-YQRSG+<]49LFWPCCOA02C<N)7&* G
M85P4VI64E28 V#Q&!Q&6?\V*$;MT>9\PDCE<W[K;LY*"ER\  %>5)WE@X_L#
M K?'PS3<@_W8_KB#U?S![1;MK<\.A,!SW*]9HE:5H]RF)6HSGXJ=VF3#0P+/
M'WS[9GFR:1V8?@%885X9Q5X ^NU13X[?$N;JPNCP*BF:PF01W'$!NM/QR=1=
M?FK9ZZ[?9PCI/Z5-QGFIIVL;*HR@WP=9 ]J^?;J=J9:H9N5NY?B9/ VY+GTG
MD?NP5NCY8KP-UN+*[,?K:LIGQK699DT^!I9"-)1<0S@@0>(" #U,VIOC'%CB
M);,3XM"5 W#*H+AN,FT#CU>DMFS0;2"_ZQDBQN_9X?"]G_:TA-03_73LSNU9
MYXDZO[FM&9F25GH!C0]_F4?C+P#NS"G*KU%DQ+$Z/KG)F$JA>_$F ;K<R8-9
M$X6&*.I>0^[1,4 5U#A]\NM :VTE4R;Z8EY70Q^6E7L%VPS5!MC,^COSA5?#
M5(<6T[UFFW\ON*U\7<SUA-R+H"=L8)C9C#R;%WEQ.PT^'K]0!98*7.?;BG;?
M!N3> F[N@X;#-9:E-7IMPO:J; C^'KM'#-EM[?Y3_BK,&@5_+$1S+2RD^I;%
MZ(,HK\ _[=%?%IB&$1*$"(.L"X#CL36&JD,?R_%^&<3UL^1C ^@I1\]OZL%-
MQ>FN.IPSB;T4*R3=XC73!(I/NR$-[S\7T)?/9S4R*BM17 'HH$)26^I"#C,\
M!@K 8L0A\?VFQO%?J)G-F&=ER(;$4)]6&?<ER[KC^G,.=QN.!*P[F#?<D'?.
M_YO,,6;D4&1"0>P#/,]+-M<TNX7X[L792I@'\1'I 8&3*(=8'NH2"=-KP(7#
M4^UMXNYE]+V0L#7^C' 4^9QF[$I!]2 WIO[#KX3F/_=;(SW@(@13,KTO?N])
MI*ST!>"%*=]F0)[>VEB$1)"Y*Z<:-YU,?N +YU4-!9VZ7@PLOH.=Z.IBSR0;
M(4U2FHZX[F;'D-.WP_Q>TZEF U5^:AQ^=[ L?7V;P]V=X@*0\,J#-QBV=F^9
M%"UQ^WU>/EN,RQ,K:$>ND;Y[91U1 _C1TC+ZK;>ONWYHE0S*;KH+5O^[<J>'
MR/]<H9K\MXB)89!2]M/7^/N4:=!%O;+"?"S-E@V>/%7T@W_3JX& 7 :EO7/*
MUGIVXT6OF 6I\[T<#14K$[.YY)I7DCW.Y!)LNT1PY0.-RTE YJ7S3TZ/C\\\
MH55S=^ME3J5GAQLBGXG;*]SNR>2+H:*TKX;C'A1%:E/_A;_:XW$1$"=X+(?^
M/A?"+J7N.(;K_U1G7ZER\0/2&E_S-@IVN%OCR>/Z*I4=(B*:[<@J^G'YQ-B\
M$C1U4GU'K+_?**U2<G:A?\&U,:<*06/G[P#Z\F0MN7S8^>Z\>9M-1<%BPJ&V
M2=-YQ07 6?26%5;VW61&LG8S?3Z1^M'Z_*':GFU3'KYR>33^ZZZ'GVQ"!.N4
M3-WV+K8Q=O1IK&6++U7T*V<*VX\K@++\?'\,/,)^.;#'FDXA[";A^7JZ$0F(
MRQ/T,7(5Q<,&1N<@9#I;?!P&CJ BM!*E"$G+]N_\>"\ #/]0 >TX8A]*IAZ=
MY(373CX9DXUO:(?3N81T?7SRN#Y<7>.WZV&2=<I4ALF)BJ"+H\#=K;',S%?E
M)AH':N+N%= %2[A)(JJ K=SNNH_=R _[UQ)O/;1D8")YMG6PI?MK>Y''>G?>
M>;SA_!@5+.J7KM $;-.CU7P5'GS.2U#-B[A%  1HWYGHX=N_,JC+=Y:\CEMO
M[BED.H^^ "S7=+&8WG2#UT^7C#E([P'1(OCSKNNO**5;"'[$?,K6J+8:OBA
M#ZP1\AHR&WI\ <!5]ET Z AYV*4^R&PLMEM=Y/-9=NEGDCIN+W5/T]%?6/F
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MMVAF@J99CI QDNC":]$\AEI8W-,5\:U^J#X@M7O,-;#71^<(9"%S?:=,*"-
M;_MQV6^GB+\3(OC(Q_")=;/O%N'B?]$.P-0 Z\#7[P4ZF8?3M;RA;J=[ [N<
M&,Z?!-N>=)1IPG6-J\L=(2(?_R\.SCP>RN_MXZ-$LJ6R+U,1E?#-O@_)'A.R
M+Q,JRX2493!F0DBV$+)7]BQ3&&,?C"458Q<RS-BRSU@',^/Q>_Z^7^><Z]SG
M7-?G\S[G?MV"L2]*/1]SMP:.?+@]7,&\>,.0V[E#<3A64W2J><BXPEX&/N"A
M.U+V%1,R5J5OO.87.*D18C =\@_&O2%,;IX/[L%.EN* G(BS,/P#JA])"](S
MI=U(XA;U5H]I=M6.)VZ=66N:2'P>T*\,XG19R>Y?HZ)ZCOC?:"I5Z?E]_3.-
M(_H8NF33E32N::<@=[11Y$+&A4ZECW K(CXIP^$9:MY,K->*,I 83$+&N$B2
MDR/@QGYE-,><!V0D;N.R'?5I20<PJB[,)YA(T[XZ(:'"N$[1+\ECVO%H&PHV
M/<HB]XSM<;-3$6,>V^S3WMMU.<$7OT-MB0T_SL6K;R\S/UE6^D>F(H13+6>[
MI#7>DM)3KZ _5%IM;4MH._U>$VESRK>B3P9I#[\8(PVG/\I^UV(5U.*W]BR[
M<</M$/'=T5BR9,1\X$A_QK.R<CQI>?X@"G$>V:%WAZ$$$P,)47_A5$X  -H-
MTI80#&N7#Q)>L17[CU+P%JY;#->I':'9EJTT2;VI$[P3R+9,@0EM17]I3NN\
M]F48%>"L8L+HC>F<V-A@[P#R".M0DM*(6!XGFBQ%N93E39-A@J]B@]*'>B%$
M9:9#@AXXY$'PO:,?QM[WJWC8[V89!3"'V\$EUKEI9J52!.9V33%M1)A_ H^]
M;=.C<=LF1'[F/9O1^"^_)%P?N!A;B?M8Q78]N<+J.;.=+SV!6_I3*7GY\IO2
MV,\WW4I-+/,<O(L*;[]\\^5+0?.O6_=N6V2GIOHH_.QZ7.YV>Z1LV4&6YP.D
M-B=Z_H;$OK=%:NOHE]$TVP<[^!AUPRZ9L\2#6$70NWSE$88X;,TLW@(SUN)>
MLE(P^9_W>'^9DW;JC;IMF6 7QY4J9I7,ZP1QS=4!PO.<ZAOKUQLOFB1>E6#C
MB8Q(/?.?5-E"0H#6*[S)2FP,<R(Z, O"9,H<PYWNN'F)SSR!:<I(^/6\ZO4/
M5!!HYTHFEH".P^8P$.AN2[0#^H;EHP]/U4Q>)JIVYFE[*4^]X6\VO]5L<.'G
M[3Z)5-.OB:H6Q4)W/RP*]-RU+%M40XOF+DO_?+EU2WEAS_>H0 LN0>:=C0A(
MYM<++'5>.1#:>K>U%R?1/)'IHEYV?.6%,LKO:F.C>F#Z<6SVK&GF^D'0; NT
MPNY)VM(ZXN+*?A,VUJ\N9S&K$@UD]0P-)$W/.-L-[&,R;.LGV,]MO!F?J']9
M)TN2SM%X*UOU)\YGZ=T38_ZVL=U&Q0]OA.L;DP(;$D+>\J0/S_QU]Q+W$IR;
M?Z\^P48VL766?_:@62J:IFRA=IBK&USWV%TBER-X0&/<^U5Y7+EZAE6Z:GUJ
M#7K4]N\7++'*]^-PM.:EA]@[T&[) V1SV6Q&$GC13V''MA-26TJ[,DLTCR)B
MF>"RU*'2%01KDE:H]"S5:&]#BM0;'Q!6T=BB]3([DR8%$0C 7H$56*8N;Q#^
M\U%38J/I/2UV\<H7^>9\:4(7^IJ /Y:'"3,NJ'R&AX%Y&8,,63(!39[N.I)9
M=]$<W*V"=&Q[3@5ABV O!_"=&,+9D5T\F_U:AM"#S%.=-*5?7]HFK&XSMFPG
ME,)#MX?QN";.\-CYV3@@+TVA2L]G[I2.3_/H4IU*A-"RQ8BF.S&9?7;:V=CO
M3MO]4&3<YTCVCZ2&1)EE?WCR)?.TVS^MA]MNGPI9(>(4E]&VZ\UD]G8Q5?I'
M;0'NMV)W*"K=?EQ4JUZ'HGP !=(U[1>3SSFJF&=R=.S<0$9&5M]!)WK65T&?
M?NXNO[=6ZJ@UE.IYT,^BQ0#^H.2:YBUFL4"LSAH*Y[@1HW#6O[__@6.8S(N(
M#J7:TJ+O/GBZEM\<S%NV6%,QSQ6_G>[5Z2+KGTVL>8 2SB$1X\JCVQ]F7*_[
M#Q;ZL>414?">9MU_HU;E#H6!XIZ&CK>,T0)]J+&O,7,*NJHZIA^?G.>-_.Z6
M6"=]E\DNUS4.('))AY<6!T,R+IQ.ZIQ;\[@VD%.<>"ZS*RPQN)MQ>200!# \
MYF<,YC./RREN6#G5CZ!SQ$EY[C9IND-M_7X2M8G/C*7J(O\:AHL+#-M)'[VE
M1LPGOV4(-H\@B=Q4?Y7D*H_S1Z-\;9)#+5K(HM[]:9BO^#=GW[/0BAG=IS>Z
MU_W9*SPWI\YAC%V]+*975)=Q+3NXP\6' ]];M.)#6N\X.ZGLBX6\Z5\T?EQA
M46BC.F4'ZZSFLDKWU-2HXO:(BZRXK>2Q_O4F%2[=DV4K8/A?R#-A51S2X]%G
M$^Q^M3U$=CE#,G?5"A9BG6YD:Y$ K%M(7S'N,+]]%!*\?CB'BG.PC4/(47=(
M-I])#7O<0E+1SW>Q[-X')P#H8)V,!LX%&,:29M:_L9IG^[ MK'PO)UY/+,]?
M7,__F;+YD"ZY="-35M.*W&T$X&:&/N#2O58 05M>X8!_NKVPK;L%J73AH'"_
MA1L31T=IIL3X4QY:Q?"%QK62VXK#B[TG''0CESQE-&<<[Z6:W2:O*I=E=LC,
MY(\]X=M._?<;*8%\?G"V&\L>"J1^0D>^^,\ KN_+RARI<]Q^E$V-=2A^\."V
M^<#*O<$$MT(!JT1U[R%3SRK'EN**#\62D[ODST*/6O-4)!N+-0;,+5]^^+LP
MG>9G,Y,1YYEJ;$<5[DVH 9./)#ELP'$,%DO>=PK_C>F5,?/0C.3OCF@&HE;2
MB!?6J= Y2F+1"L]WP;[#DBQL^4IO,5*A3<$ZS8KZG$T;0I/A9FF<ESFNZ'LB
ME:1SSE#3O\"!D<7@39WE:KEJ"U*.]31\OM"(1XGG[H+2O9RU[31*<DNAH8;;
M=-.$1QX2&;G?PV:#)?%Z7]Y)?QR4/JPY 405O >M2YTR6 ,D64COHOK[-@Y*
MS%9?\.7=O6ZD,9HV=0+HP#^XO,]#OO+F3#EE]H',Z LX[[QNA\BRE*I(JK0#
M_U&WL'0S'GP<"QIF%#VBWEBA(Y1! *1;^7R\.=5!_![?_*D3BKM^6/OS1].G
M!T_R"N\\XCB;AG_N2Y-^>(K;#WVFW"C*7UO2HB579Z5F=%QW+JH#3>9!;K=2
MPS6(CQJ"\!%PG;?&'5,8H7?BO&L1:0FA9\!*TW#%ZZ!8C+#!79*,?2RK5, ^
M*I++7$<+*9N^(ETL6Q]9NU7=AE&%.MRUS/]+\9$)'ZT>SYZ$Z(_2EZF59PK8
M^%Z\FD-Q?^M1H_\N5!6<R]W=ZWWLO;7>-0WRE(MIG^?\ZBVNI<*];F:8L@Y;
ML2_@S8&[L,,?%YRAPMZSZB[\UET>?;77?4H@QB> F$BJ1\?4%/K(H_P$\%ZR
M<&+MQXI3&N/*+J99NAA-7Y@H#&Y67YGL&[A5IFJ8/O4+$7^TB6B[MP2*'Z_J
MX"1CNHU_],UW$;@[5I+D0T3?;NH'$32IUZ22X7HEL.KIKB 'BUB<39/60$H9
M]1GW)2^'\:XV1WMTA>.,^:1DO*&9S?8)X'X46,B] Q4O8_NP873$O*8V]@T!
M1/2Q+P=X$)'Q\B]?*E.3.SX"%A(NCX8%HJIVYW/8Y2#?I])6?I^'599@)U]<
MFJ;G/*UU&6X"DQG5[M&I^PU_JL9E?5W DZX!N[7@I:$E!B?9,#Y C:856$W=
M/ '8.E_&'27'; 9$1YNG5[1GE^?@FA:G3>N)FH:E_R@=I:NV0Q%BY1*9\K\$
MZ'U@TY830+)&&W)Q"@D^7&",/:L@('N+)^AAX%.RR/ZF3L /36]ZX!&25*4O
M-!<R/CJF]NMJDU.^6'(7N.A7\8^4CVA1BXWYR/WY%S.:-CY/F,?/&'T>]5EN
MJ&EZY:-8+IF13*[MS=9.YHHJH5EDZGS_-HX*E%8>U)3^;'AE//L[=$//F/%[
M]%-;_=!NCI;#*O6?$*) $V<VTM;K?:!RBS5#2Z5]HQFG_@HY,6%>0-E3@?@/
M-TT-UZ =*M#&J":S"[*4^*TKC-WDN]1P(K<PS&3-&7P%;CB*N.H5C#-+TV=,
M#@=,<UH9-29II%2*SWCY3SO.V!%,?)Y\C]YH.;Z19)1/FOLOE+PE^HHB31SJ
M[:=_IFC.7Q5!/O7ZRMK&$K(U.[LV+G[V\]JN)I"R0FB[1QGG[IJ-?<#"O1_;
MM2B>?,3\)W]6]S#,YH_J3GA(4,=8ZDK09^LB6O.1> ZOWU_I.L9W\_$UCRJ&
MH3^YJ4?+L3,[*/,%SZ=11>#E/[^K1>?O$KPSZ[=9[8HC#<Q2_WN:!'MR]7U-
MSY_ 'K+<^DHP^0C*IN@G^O?GK-MH@,\S>H",@LDX:M?'RCSF[/.FJH_9BSGW
MVD84[6GBRVJ9.IAXR[<SLWWE^%LK",[% "0W@$N[HWI9"S;AB^U5[<6PM/Y[
MKWYP %S>1BE<F"Y%;H'ZQ*I5Z*M8ZF;+2((0#21^&>=@O13[R4M=^W,E@?KN
MP+PF9GC9>=0]1DO/.I5WRN^T8%IRHQ\ O*8D[J>:#?"H^ A.#2")U\GM>.&M
MOKZSJN\TF=9&"W"-U7470WA_K!F*G3Z:SNT+QY>()Q?\HM"A#@473@ BH-VB
M5X;!_TX XIUUD,FV$T"GT%(S"<1"LZ(\*RB'B@F/* H0Q]*5\K2GYL%ABNHY
MTZW]C8U!M3&K[(ZVTGQY-P;#U,1C)#$Y?UOXB7FVG>/\^PZH^$"D@!:A*J1L
M>A;JWXZI#SK0O[!2?J/MST(=^C;B-[-_B'?WF3F.($%1>865;(=!0]YYA;=U
MA!?PXTKDW!4L ]734CB'G[;2;4XS-PU1 E+U:-K[%C,*57697WZN3]_X97C<
MA4E]'"=MN%/Y]!V\W?8K[$\*2ZXA;;]EN0'DFB/ 0#Z4_LTXKV8F\T/P%M&/
M\[U"Y#W=P+]B"FLI=H9T4BD]-):1+EXU,U<XZ2;:LL6"WOWG7P\2;5,ODEB#
MU"0GN@<T7114Q K 3-;-+E])V[!P""\N,G+'9*FP^3*G.ND&7S"H?B^QXPWD
M8VC'KT&^P;E;Z[\WH\E[G<6K>0:DGSYNP[/'MF:CLKMTE_/N!3B'Y(_9T8NM
M>=U5A+S <P.YLK)U&P8_CJ1B95K<H6)%;=<G<FPS? RVU\RRI\9D^DL^4*;C
MP]@RQMG/I1I)'NN%)&!DW3VC9HPFV;_X!EX4R?+CZFF_G63JJGLNHH$U'X97
MPJ;\")WA73A#HK]!:@W*=IB+9R:42P&< IG]\8-BG \2$4\"=OP0UI8J^LU;
M? +72G[,G5%/RP^UK-E>9RUW?@5]J>6S= (8\H'$8>O]3P#OIHG93.E [KT@
MYH74WJ[Q-?QSIMQCGK\7Z)&#^7Y2%L;%Z9U3^(B;%Q"6JUR#^ &F937QLP F
M2 JR_EQB3^$\/J9^__TOK=%\IE'QR"F"5#8TKH2B>.UQC$!'JK%]NK4%;]:?
MKU_S.5TA/(87TN'ZGH.%9FJ/RM5N=MY>(Z2%W1@ZG Y"\4J6=_2O5\W:3!E[
M!5>$<[^&.PFL8=D'_\/!S<@=<RP]XTVK:@-LK,FZU!. &>C"!Q0N^5SD2R11
M;"3)/R'JO&OOX,2._WPRQYHZZ!U"V!XJY/*Y:-81_K^SU*D[:%/I'.%?'FR*
M7S3BH<5)GEF%TM=9=5O_^V'W>&(WDXQ=I ;/?7O!31//A@ =G]"EG91!K!^)
MU]ZVD[S<RL(<OEG?,LW6),/1XC5>/2;#9I+Y*YZOB%^_IN98+@W=<CDP,S'I
M5\P>WF]RB0W1EPR/HV%[WM56.C">GP#FEM&<QVPPP.6($P#[_(,^4 #37('0
M);O]E8Y]U(H\-@=$56?:1W2TG94"JO0F7@/QD4&)KX%Z ^%8\7IA^E(RM1AI
M;EQ*%1QCB+1!CBQ!>9 _V0L22);4F0%),C;.9T&X05A.B:=.SF?RAT1"4BZ3
M2Q[YQV';6>RY/C:2L[M4B?*-G)O+HJ^V$_;6NF&SZR9=!5'RCI+W'5C?)A2R
MBOE-;<4SC4C_&%!EGM>2GFP3?-UV9BP63"T/? ;P2-X-DW3MVQ/92?H[46IN
MDN/W;-CA (%9<<=W&=^[:Q6\F)^,SOQWL#5*'Z5F(X<T.>:Q$9K:&FGI2:ZY
M^;CI=R/TCQB5#7;R]T?TC6>'27/_ 8:4KG<WXGVYG<95N@SDBJEL2<9(IG_R
MEXQF(E.9<A]?3E@6>0E;0I\ GND@B9^U^>1/R:AK?_U)V/\.]OVWUGH=YBMH
MZDWTK+4)+Q5LA49Y?_V'*N!+N8P^%S"X-PQ875,R&Q_J#TB<Y=!T*50[;=VI
M/Y<;N#?3^TU5 *5%K\/Z^EU"=#&X8WMFR;VS=<&GT:WI4#U(X#@@#T(<+M1$
ME?$B@F+$1,DVN4<9-8R[F:38[H+8J;(L1:ACO]O=3ROJHV8>T.N"Y^;UO1GI
M+RBG(Q"&Y^^P@W!R D;<#]R[Q-@ (GL]\JW^([SS6/)#N=<G +X3@/<L&Z,?
M6PN.5C2:G0-V@9)<F"DJ&\FDQL 9#;-CN74Z.8Z?Y%3 L5&7Y9%L.R%)G9VG
MG^U <J/M=G-"YFK(/K/Q$-OMJE,/-%;3_M1!":[X!?4T4"A]:F^(OJS,>P*H
M<Y^@WW<^:@K@7T@6',+.U4)8]T#Q0"X::QB9>__MH#:06MH-J3T-E_LM$*@4
MSMI!/F5BX+$I8T2,B3S;!8H!U:*Z7K?]A^3C%DR4ZW'A'J2YHJC!N.S92)KH
M/) ?!L4YC#=S$@JEIQ =A!- ;]XL/11_ZE;RL;G(> @9C)\^VP6ID^KQ>XT0
MH?K,;9CNZ].+0'-%L[4HVA5(%[!N9K:KB@_G3/4KHDG540U)W&\+F$NI#\E
M?BA"GL*?Q&"EAN+:M<6'V:F6$YWY\MB&";]U.;AV/3]RJ'M)NR\PGW6R%#_R
M,W3!$65]6-BX3@<NX*-/WRUD:JEW7Y:>IRE'T6H3I&;.\[^%VU/ Q/\9]3-P
M!7+F6TU1HA:T&Z%*_4RJ_?0OPY3D]U9](K8%^-G>OKQY3,G,"C+^_,Z=W37V
MK*6&Q"L-AZ!Y6QJ?( *@3VR&O$5^Q_3Z48WATF1# WH)\CF0D^K877!>TUYE
M/9#,VE5P$8V,S69-:G&M6!%3S-2G%I:M\@NQ8$D8<D%GSM9%[XQ\-O+RV\##
M!>#DD ,A7/#8@W;W?Y ^B>G,%R//GG8BO+^2;$[-(<[RK!4PG0 \Y02]Q-C(
M_9O))4C?SQ103*#?)9AX;SYO3D^^6&M+3=J#;Q3)=*]B?,G?-6;ONY ;Q:UX
M(KV4=NDRXP(;.6>NOIGL2$RFW<0*3C(F(=]YZ/$@3S/#KA/ %;BM1S&CU^$N
M=8:2V4L0;:6"^0J)9GI.U%_D+6)!QZDGS9>BFA%!%]#X-WM>>[-G8!J/W)\2
MFX^GG4$F6P=COGO[:!";_"WDA?2#_1<G@&$WI-VX4'3&]U([[RGGORI3STJ?
M^I1['=0/2&!:OK=&R/K(5BV(:*KP;1=]5R6FC,6RM)E0>F:I]J>8$[I\[$B*
MK58;6D\"#;"*<.WMSD;!99[.^;%0#3O4G6I-2Z@@G#IW=,"AQU6\3'+L;H69
MY+#Q#PE!%\*P\H>%Q/40U$=-;S!-!AB;T^Q].CEY;GK$G9])"G^1FGO+*!E;
MQM#:<TY(.M%ZAC9!&'""PO\8E4))_V8.G'ZN+8>%YF>2 TZK"U9O@5:/N.HD
M%J6^.-2GNE6/E3LM&Y%XSZG>T[T%G8'JT3,8<BL,*2K3L3Z-E9[9QDY3I\9J
M(CEHT&-#N F]<"O AYOX[-,4**X.MJ5]B2K5I3Z YJI@09-RP@TM(+$IITGW
M5#O9SU_3!0@L@[!^%)73!Z3""W@\)AAZ&)@(64?PK!8K+Q4[CZ=*>FST48))
MI1L8BG07 70Z-'!U5D!;F_$3B0:O]W^E&JR19N-]X8*4V/T[K61$"AEC2&TL
MA#9)1GB44?E)4A$TF4 O"@<5;!GNB#MJ:WY)$$ZV0'^K"Z*\\ F3&GK5++E7
M8\I@VUCB.YIQE,QL&#LB7 P^_#M.D:/QX4FR!84P7"?A,CUN3XZ?,0RJ38HX
M-H;KT-%M;-Q)^2)#N_A()#OR::)MI[*8(L40AWIKBV!/G9@7JZ!(FU':HDC@
MR#9A=>[(34W3HA. EUR<+.U6H-NU!OHG<G)RBQK%%G<"8$'<A&FO.FZQG8HS
M(FY^ZP(!SX;)WL+ERY,9>2292TO0((U/&>%R%NATHML#\V[A%$B4.HIV27Q_
MT!05#Q2@7:-L[;\</.T>/&V%0Z)M._'3NFB_\W"3\;8KL%=$CPV5<M@E+:&#
M_> 83O #BM+I(G._)O"1S\7$$T/:KE;%1,RO57D\;*6(ML7QYE75S383F*C^
MGVG7R,CVK3<,H=15,"=-FBP5PQ"A(APGC.6>#FGR$Q.E<0YZ!&.A+UJ_,X2>
M<+[X]S7QUONOKW6$;%)-5*#S40B;U)G=&9&Z"<4J^B2VZ3+R,]GC#6BNN$V6
M N[&4F\"<?'(/]/S*Z#OMF\0@M2H=A<@9L0'0CK8 (&Z1/5(!E'GMDXKYU]Z
MBJ;&'-VP"\E=BB8'Q\'U4#<G6M1D>A,#V;4NZ[]C4I;-.@&<4Z!DO@7-Y4)J
M#C8B/L&YAS:UU1E_Q*Y30604$=B>LR6&A\X=RR44"&MZJ435B4IW8R^YDA?'
M9DJC-,5YJRM(2'[H47!T]5;Q4)WH/4Z@6?;V$E[CB'7]^[$/U7%_D(X&>6U<
M)MFNU^0+TS\C+L" 1&0GBL-;FXE:%8:B&MI2%>02EZ@6530=+(;2&I-7O7)0
M S>FZ%"C78G4@,;J8;P.A,O)ZYF6S@RMD7S 8+,]=O^'_-Z[OGQ\&Y:YCZ)>
M*W5B] G%1C)NP-DHO9%M9ZGUICE^25A6A.P*\"*"%U;0,YY_E5I\>ZV-I8V<
M0%"A!E*D.OG.FK2,^[280JO_91/2@DOZ? )1BC;;IGUUND=LQ[*(D=#E#3.R
MR0F@6UN%K)2)@\0#V=OD:6[T FTE&+_!Q +%(Z8.& \\UP*N@*ETRYQF^A5P
MB2?&Y2HYJ.5.)1Q,]#$X-AI1XAL*;-;P,?DI?!P6C0JD7B^@W'II] MFA9O+
MG7/_T22H'47><!$\ED/\=BA=1Y'='Y%+XUN"H10Y4FDW,.$$('!:Q),3&&K#
M-$W&1?+!6^W;-"^*=OD\D$_E38N4;'DUGH@_[YD8YDK$<JQDAHZ7([(-DJ'^
M9;-@Y*N74 +B_%6?J[=49X@%7)+AV<+?0O;4:,=/;"R\2+?M9P]>8*LFI^4.
M^4=VNA\A R62U.5X.D@5%?'0>@HD<JIS;[>BBN7F[DV_O2%QB?K,^J-X0@D&
M6@KEB7W7Z:QQK+VZX=:0I%:8\M3Z-^//\!<5_"?8+YN1NN;SM+5I&4?C0;B#
MXF?%"BC'J7$.+7T74^7EH;A@\'Z5/SA%ZQ=S7?8-?Z:#Z>08%\'&T33[AI&Z
MM40W4.WSL=+A]<51PS])S[$C(H(_:C6G.?]$Q"MZLXN,Q1.!D41H:;+NX!?H
MOZOHMKN>H6XYOQRAR?6.CL[/_L:_O=K</6IAVBK>0%\M0T"+C8M]9"9[9$#*
MN8$(G[\[,ZKUBUN21^7&2@N5PZ9-IE;M)P#BC>'J]779%D-2N'U 6N!U8^[8
MW7!@9VC@MI<Y&=*KC3H!L/DP6FO8NLS*=#VJO(XE01X?PS-TSZX">?5<*PC4
M,%V*(B7DO>! #DE+]I<3Q2"A?DCQ*+<)7D--4A,C$,:&EU31_Y28ZSSDXZ3J
MP#5R:&-R6H?E9)ZZ&>O]-#"T.6?>[4@R>[_ I_5IV#3.=_!C]M+&D-B26XQQ
MUI4?=J_U=ZD^Q#?8-&MG[2[O-/%>[2^*,YHNOU/O?S-*=8I'J@W-Z4>GY\:\
M"3&\:72;88'Q$$#/0H,GD-NLS$<#],/%WW3GXR#3G[TJY%FK$251%8<87)>*
MR_4<L/&74<G1IT.SUC7Y2PJO.*L_\T5#GY9VM,UT=W_I]:W<KRFL;7L)D@5Y
M5[E;D ^ZMJ+5">D!XTT9B7/$KUX[7^]$$K;Q79VD*;#,V+"^W,5+!JMZLH_(
M9@CL"N+*4(N*WU?E= \_SXE!8!T]>XHP:N(:H_^V:;I7($C?[2T^M?R-T\TS
M6"#2VV#X,NE4U3[2C&^0J(^I]P:ALY,+>29:UR&\3=[R#EQ8+U,+Z7O\<BT7
ML]P^44-. -]"?&5(96!> U7OVO)[>?.WXU3M]3NDA%4$7^F[W-9<41'6%L$_
M$#D8?K3OH^357;)0/1Q?EXOVDEQ?AZ=0K$C\[]HD:*9DUK@65R0OXWL%[!CW
MOJ&N-JESF$#X.;PJ<+4>D\"KGZB;DF^;8>MSO'"U#/(/1?S"3 V?&UTMQ&6;
M*^3F3AF$T'KG\\=H5-K39&(F3>8$$%M._K)ED].Q,=\JO,Y>Q5ZKUIALUJA2
MQ9S]FI\T^>S"XV/+./8^Y:'%\WV,:&U1#AAWQWR)IEK1J7% W83&O[F1J9D-
MFJ3>_B,0#KVR.H*R++8?J[I=-5;]==0BW6X\;UDHZ58?='3Y9U'IG?N;BY:6
M!XL#JP8O$XKRC 8LXC\\VXM?M'68MJK]\DYZE?N);KM8)S8'3%4_8\&]+CPG
M>-X2243\:[ 1E-(^1_GU@ENM'2\RL9LU2P:-T!A*M&ED!YXBSNC(9PJY\KX
M6/?@\7S4'%B,JS7FT>7!7)L_8>%NB?M+F8R<K'0/;RN$Z0G )(XV@\!E>D*(
M(M]OW<7&:NI?COPO&+W>+_YX(9);8+X,]83ZK!-\%NI]_J&F:05WCI2OSQUN
M+?]4V$92GG0GR'6M["%<//M>2D\ EE?\S'^5-BO;YQ>6(W7W!J2GM?F5X9=)
MU@F7DR][GPL5$P9_<S-TR7FUEH976ADQ1ND+0ZJ_'FP4GP#.XKMZC9Q+*T(W
M@M*0R;-!B'7:_7.*?K'Z.F<9O)NO/P+O=A9]XC*^%A8U??5)T"C]XP*(/%C
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M-A$C3BY]O9M!_MLF.XH0A;T\[N*;>I+BU1U3R)+GY>X3ZIZ\6A!Q J@%X4X
M$6(2U)13C&2GIO6ZB%,,NRM L?L$92SEZ2F8Z9<4!Y)G=0MPV;*-7%%$;G:8
M'JZ^36)4L3$#R /]5:Q<7-'A7F2G2?$*U<YRAY8!#6S,FRNGJ&%&;>-^%@N8
M[XFBI/@SQ@[&E@*%]V9O9Z3JG\MYS:8J=:9.R+/PAHN^3<^+KEV:\3RETCET
MQ&@B(&<&:%' ESGTU6C(Z)+=E!J?YY-$\KV65P9)*M+2/E.KUF^K;A[+^1A.
M[ZB+C6=B%JCT9,UPE-1!HUHC?'_T7?[()'[RY;&Y<9BV7VP^/C/GY[[?(#$
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M7'%^19"U)@G,^#8F01M/M!#-*ZE0#_\R>RP/;0Y; G/T"BMLZARE_F26=;J
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MC2"CJCF/415;KH+&@M<N3EB;EU0%'E@SYM6;>G[^W-J>T)O_* SBU>::>US
MX[T=,58KEG@7?^_NB.HZ]"B:[,].Y+ZPITHFQ,BSTO5DD!<83E59R=VS45^Y
M+JP>'4?DDA5M<.X-4F6KH;9[HL1SXIT(?E9!"->_B _+D8J_'NH*?Q\-102V
MW;"WVK$Z/!['KJR]NBT\6CND6+7L RG\EY3Z[F:U59'T8=L)(.J3N#UHKB"?
MA>L%]\:UN>ZY.1J#DQJ3&YH/.T"ML&!S(52UQ> 30 >HA4OC!( SAHD^.E*
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M0=6"/C-VA>O?N7ZU*"AI)SD(#$2Y)A1J,W#O*B5$/O-U;,'[<7DJ&5:IA$D
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M'0 8 ,BH_C,!^%\'&3D%)=4ET&5J&MJ+A)HK #D9!04Y)045%27EQ6S0Q3Q
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MDOI+N<%DW8] #9.A^&_I.%84L6.B?8,J(II]$WD8#,ZW*^;C[L:P8WBDT"0
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M1/5[]^\]8]7E%(];OJ2ZJ"M)YFG^X,O1#"(#PV\5OZKD/;D>0I"SWKAY^*'
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M7"-KLIB6].AK$ P7 W!F[.X;96@9WK.3\R%G1E1-/^0>]O#PO#_AHR<WO>U
M:3$\5):,SC\!F2QPK@9JV;]V4GQFY%L8*('E[S#=.DVO+%R+*2/(?,5%K$8*
M3(([-A<DK-%PII%&;U!$AMKS)6KO-[LT%DZLBKY#)C(++@6*0K/F)K&?BKVV
MO3);G"<RJVOJW!\0*B:GMK+&A4Z%-QJ^*PG;N4J?OQ6WP<[E5_C:J>$5%B 1
MO$Q-H_HUGDX+L"G,TF0;+;TQ+-)93J]VGZ"'$YII"S,S,Z.VC9W4Y64.>Y+
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MQ6:\3?=9C%;?_6UT_PX$:>H_ %!+ P04    " "7@GI<80_ XC<6  ! &
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MX.E2GJB,/M/, +37/YTA#IW?&L16A,:@4D_F&?<\.J!+?15Z(4-+ZS3<T9V
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M,C,Q+GAS9%!+ 0(4 Q0    ( ):">EQO<_J_V!(  !7P   5
M  "  48=  !I:6YN+3(P,C4Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "6@GI<
MKV H! M8  "*C 4 %0              @ %1,   :6EN;BTR,#(U,3(S,5]D
M968N>&UL4$L! A0#%     @ EH)Z7&C):0@RR   [1D* !4
M ( !CX@  &EI;FXM,C R-3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( ):">EP<
M'C%(%E@  #6\!0 5              "  ?10 0!I:6YN+3(P,C4Q,C,Q7W!R
M92YX;6Q02P$"% ,4    " "6@GI<$7LU1C3$ P "=1X $0
M@ $]J0$ :6EN;C(P9C$R,S$R-2YH=&U02P$"% ,4    " "7@GI<V4->O"LQ
M  "I @$ #@              @ &@;04 :6EN;F5X,3$M,2YH=&U02P$"% ,4
M    " "7@GI<K6H@:NP&  "Q(P  #@              @ 'WG@4 :6EN;F5X
M,3(M,2YH=&U02P$"% ,4    " "7@GI<TI\8K.,&   6)   #@
M    @ $/I@4 :6EN;F5X,3(M,BYH=&U02P$"% ,4    " "7@GI<'^]UE0 #
M  !,"@  #@              @ $>K04 :6EN;F5X,3,M,2YH=&U02P$"% ,4
M    " "7@GI<BIT&9P0#   W"@  #@              @ %*L 4 :6EN;F5X
M,3,M,BYH=&U02P$"% ,4    " "7@GI<G6E,DWP#  # #   #@
M    @ %ZLP4 :6EN;F5X,34M,2YH=&U02P$"% ,4    " "7@GI<2KITN@DI
M   CV@  #0              @ $BMP4 :6EN;F5X,BTQ+FAT;5!+ 0(4 Q0
M   ( )>">EQM:L\5MBX  ,$O   -              "  5;@!0!I;6%G95\P
M,#$N:G!G4$L! A0#%     @ EX)Z7$;NA5=0RP$ =,P!  T
M ( !-P\& &EM86=E7S P,BYJ<&=02P$"% ,4    " "7@GI<XJ:K."*<  #4
MG0  #0              @ &RV@< :6UA9V5?,# S+FIP9U!+ 0(4 Q0    (
M )>">EP41S9'ER4  .TF   -              "  ?]V" !I;6%G95\P,#0N
M:G!G4$L! A0#%     @ EX)Z7&6ZENU8]P  !!,!  T              ( !
MP9P( &EM86=E7S P-2YJ<&=02P$"% ,4    " "7@GI<4N0'?ZQY  #P>P
M#0              @ %$E D :6UA9V5?,# V+FIP9U!+ 0(4 Q0    ( )>"
M>ES\[O67_U$  $E3   -              "  1L."@!I;6%G95\P,#<N:G!G
M4$L! A0#%     @ EX)Z7#@B)TX.F0  J9H   T              ( !16 *
M &EM86=E7S P."YJ<&=02P$"% ,4    " "7@GI<^6H3LYDF   S*   #0
M            @ %^^0H :6UA9V5?,# Y+FIP9U!+ 0(4 Q0    ( )>">EQA
M#\#B-Q8  $ 8   -              "  4(@"P!I;6%G95\P,3 N:G!G4$L%
3!@     7 !< >P4  *0V"P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>iinn20f123125_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iinn="http://InspiraTechnologiesOXYB.H.N.Ltd/20251231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="iinn-20251231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:OrdinarySharesNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2025-04-10</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2025-07-01</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2025-09-16</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">iinn:BankLeumiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2021-09-30</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2025-04-27</startDate>
            <endDate>2025-04-27</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-26</startDate>
            <endDate>2023-12-26</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">iinn:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberStandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-12</startDate>
            <endDate>2025-12-12</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-12</startDate>
            <endDate>2025-12-12</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-04</startDate>
            <endDate>2023-04-04</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-26</startDate>
            <endDate>2023-12-26</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-26</startDate>
            <endDate>2023-12-26</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourAprilOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourAprilOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-20</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-20</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivateOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivateOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-14</startDate>
            <endDate>2025-03-14</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-10</startDate>
            <endDate>2025-04-10</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-01</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-16</startDate>
            <endDate>2025-09-16</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:AdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-08</startDate>
            <endDate>2025-08-08</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:December2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-12</startDate>
            <endDate>2025-12-12</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:December2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-12</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iinn:AgreementAxis">iinn:StandbyEquityPurchaseAgreementSEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-17</startDate>
            <endDate>2025-12-17</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice156Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice156Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iinn:MaterialsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iinn:PayrollAndRelatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iinn:WarrantyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iinn:RoyaltiesToIIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:ExecutivesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:ServiceProvidersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-06</startDate>
            <endDate>2025-08-06</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2025-08-06</startDate>
            <endDate>2025-08-06</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-01</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-07-01</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:RevenueAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-06</startDate>
            <endDate>2025-08-06</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-18</startDate>
            <endDate>2025-11-18</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-18</startDate>
            <endDate>2025-11-18</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:ServiceProvidersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-18</startDate>
            <endDate>2025-11-18</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2025-11-18</startDate>
            <endDate>2025-11-18</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2025-02-22</startDate>
            <endDate>2025-02-22</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-22</startDate>
            <endDate>2025-02-22</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-22</startDate>
            <endDate>2025-02-22</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-05</startDate>
            <endDate>2026-02-05</endDate>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-05</instant>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-05</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-05</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-05</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:PurchaserMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-05</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-05</startDate>
            <endDate>2026-02-05</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-05</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-20377">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-20378">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-20379">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-20380">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-20381">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-20382">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-20383">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-20384">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-20385">001-40303</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-89">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</dei:EntityRegistrantName>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-20386">IL</dei:EntityAddressCountry>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-20387">2 Ha-Tidhar St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-20388">Ra&#x2019;anana</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-20389">4366504</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-127">Dagi Ben-Noon</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-20390">2 Ha-Tidhar St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-20391">Ra&#x2019;anana</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-20392">4366504</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-20393">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-20394">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-20395">4.6230333</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c2" id="ixv-164">Ordinary Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c2" id="ixv-169">IINN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c2" id="ixv-20396">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c3" id="ixv-178">Warrants to purchase Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c3" id="ixv-183">IINNW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c3" id="ixv-20397">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-20398"
      unitRef="shares">35949247</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-20399">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-20400">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-20401">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-20402">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-259">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-266">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-20403">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-20404">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-20405">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-20406">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-20407">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-20408">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-12091">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has developed
and maintained a cybersecurity risk management strategy, consisting of cybersecurity policies, procedures, compliance and awareness programs
to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. The cybersecurity process
has been integrated into the Company&#x2019;s overall risk management system and process and is solely internally managed. Management is
responsible for identifying risks that threaten achievement of the control activities stated in the management&#x2019;s description of
the services organizations systems. The risk assessment occurs annually, or as business needs change, and covers identification of risks
that could act against the company&#x2019;s objectives as well as specific risks related to a compromise to the security of data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The level of each identified
risk is determined by considering the impact of the risk itself and the likelihood of the risk materializing and high scoring risks are
actioned upon. Risks are analyzed to determine whether the risk meets company risk acceptance criteria to be accepted or whether a mitigation
plan will be applied. Mitigation plans include both the individual or department responsible for the plan and may include budget considerations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c0" id="ixv-20409">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c0" id="ixv-20410">The cybersecurity process
has been integrated into the Company&#x2019;s overall risk management system and process and is solely internally managed</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c0" id="ixv-20411">Management is
responsible for identifying risks that threaten achievement of the control activities stated in the management&#x2019;s description of
the services organizations systems. The risk assessment occurs annually, or as business needs change, and covers identification of risks
that could act against the company&#x2019;s objectives as well as specific risks related to a compromise to the security of data.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c0" id="ixv-20412">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c0" id="ixv-20413">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-20414">As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-20415">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-12106">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Governance&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-12114">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-20416">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c0" id="ixv-12125">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As part of the critical elements
of our overall risk management approach, our cybersecurity program is focused on the following key areas:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborative Approach: The Company has implemented a comprehensive, cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Technical Safeguards: The Company deploys technical safeguards that are designed to protect the Company&#x2019;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Incident Response and Recovery Planning: The Company has established and maintains comprehensive incident response and recovery plans that fully address the Company&#x2019;s response to a cybersecurity incident, and such plans are tested and evaluated on a regular basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <dei:AuditorFirmId contextRef="c0" id="ixv-20417">1185</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0" id="ixv-12714">Tel-Aviv, Israel</dei:AuditorLocation>
    <dei:AuditorName contextRef="c0" id="ixv-12717">Ziv Haft</dei:AuditorName>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-20418" unitRef="usd">3159000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-20419" unitRef="usd">5111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent contextRef="c4" decimals="-3" id="ixv-20420" unitRef="usd">0</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c5" decimals="-3" id="ixv-20421" unitRef="usd">668000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-20422" unitRef="usd">517000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-20423" unitRef="usd">587000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet contextRef="c4" decimals="-3" id="ixv-20424" unitRef="usd">735000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c5" decimals="-3" id="ixv-20425" unitRef="usd">444000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-20426" unitRef="usd">4411000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="-3" id="ixv-20427" unitRef="usd">6810000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-20428" unitRef="usd">478000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-20429" unitRef="usd">761000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-20430" unitRef="usd">452000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-20431" unitRef="usd">499000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-20432" unitRef="usd">930000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c5" decimals="-3" id="ixv-20433" unitRef="usd">1260000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-20434" unitRef="usd">5341000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c5" decimals="-3" id="ixv-20435" unitRef="usd">8070000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c4" decimals="-3" id="ixv-20436" unitRef="usd">107000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c5" decimals="-3" id="ixv-20437" unitRef="usd">154000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="-3" id="ixv-20438" unitRef="usd">1349000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c5" decimals="-3" id="ixv-20439" unitRef="usd">1364000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-20440" unitRef="usd">286000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-20441" unitRef="usd">277000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-20442" unitRef="usd">1082000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-20443" unitRef="usd">1575000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-20444" unitRef="usd">2824000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-20445" unitRef="usd">3370000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-20446" unitRef="usd">194000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="-3" id="ixv-20447" unitRef="usd">378000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c4" decimals="-3" id="ixv-20448" unitRef="usd">194000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c5" decimals="-3" id="ixv-20449" unitRef="usd">378000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="0"
      id="ixv-20450"
      unitRef="usdPershares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c5"
      decimals="0"
      id="ixv-20451"
      unitRef="usdPershares">0</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-20452"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-20453"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-20454"
      unitRef="shares">35949247</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-20455"
      unitRef="shares">35949247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-20456"
      unitRef="shares">24252096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-20457"
      unitRef="shares">24252096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c4" decimals="-3" id="ixv-20458" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c5" decimals="-3" id="ixv-20459" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c4" decimals="-3" id="ixv-20460" unitRef="usd">82117000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c5" decimals="-3" id="ixv-20461" unitRef="usd">70896000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="-3" id="ixv-20462" unitRef="usd">-79794000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c5" decimals="-3" id="ixv-20463" unitRef="usd">-66574000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-20464" unitRef="usd">2323000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-20465" unitRef="usd">4322000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-20466" unitRef="usd">5341000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="-3" id="ixv-20467" unitRef="usd">8070000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="-3" id="ixv-20468" unitRef="usd">289000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="-3" id="ixv-20469" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c7" decimals="-3" id="ixv-20470" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="-3" id="ixv-20471" unitRef="usd">287000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c6" decimals="-3" id="ixv-20472" unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c7" decimals="-3" id="ixv-20473" unitRef="usd">0</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="-3" id="ixv-20474" unitRef="usd">2000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c6" decimals="-3" id="ixv-20475" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c7" decimals="-3" id="ixv-20476" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-20477" unitRef="usd">7496000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-20478" unitRef="usd">6323000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-20479" unitRef="usd">7320000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-20480" unitRef="usd">5532000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-20481" unitRef="usd">4185000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-20482" unitRef="usd">4063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-20483" unitRef="usd">588000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-20484" unitRef="usd">754000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-20485" unitRef="usd">746000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c0" decimals="-3" id="ixv-20486" unitRef="usd">-9000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c6" decimals="-3" id="ixv-20487" unitRef="usd">-5000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c7" decimals="-3" id="ixv-20488" unitRef="usd">-4000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-20489" unitRef="usd">-13623000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-20490" unitRef="usd">-11267000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-20491" unitRef="usd">-12133000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c0" decimals="-3" id="ixv-20492" unitRef="usd">64000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c6" decimals="-3" id="ixv-20493" unitRef="usd">172000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c7" decimals="-3" id="ixv-20494" unitRef="usd">318000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-20495" unitRef="usd">339000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="-3" id="ixv-20496" unitRef="usd">42000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-20497" unitRef="usd">529000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-20498" unitRef="usd">-13220000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="-3" id="ixv-20499" unitRef="usd">-11053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="-3" id="ixv-20500" unitRef="usd">-11286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-20501" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c6" decimals="-3" id="ixv-20502" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="-3" id="ixv-20503" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-20504" unitRef="usd">-13220000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-20505" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-20506" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-20507"
      unitRef="usdPershares">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-20508"
      unitRef="usdPershares">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-20509"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-20510"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-20511"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-20512"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-20513"
      unitRef="shares">29623194</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-20514"
      unitRef="shares">29623194</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-20515"
      unitRef="shares">18515545</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-20516"
      unitRef="shares">18515545</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-20517"
      unitRef="shares">12095477</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ixv-20518"
      unitRef="shares">12095477</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-20519"
      unitRef="shares">24252096</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-20520" unitRef="usd">70896000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-20521" unitRef="usd">-66574000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-20522" unitRef="usd">4322000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c11"
      decimals="INF"
      id="ixv-20523"
      unitRef="shares">1565217</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c12" decimals="-3" id="ixv-20524" unitRef="usd">1739000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="-3" id="ixv-20525" unitRef="usd">1739000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c11"
      decimals="INF"
      id="ixv-20526"
      unitRef="shares">5485898</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c12" decimals="-3" id="ixv-20527" unitRef="usd">4616000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="-3" id="ixv-20528" unitRef="usd">4616000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c11"
      decimals="INF"
      id="ixv-20529"
      unitRef="shares">101376</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c12" decimals="-3" id="ixv-20530" unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-20531" unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <iinn:ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares
      contextRef="c11"
      decimals="INF"
      id="ixv-20532"
      unitRef="shares">1514086</iinn:ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNetinShares>
    <iinn:ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet contextRef="c12" decimals="-3" id="ixv-20533" unitRef="usd">942000</iinn:ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet>
    <iinn:ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet contextRef="c0" decimals="-3" id="ixv-20534" unitRef="usd">942000</iinn:ExerciseOfDecember2024WarrantsAndPrefundedWarrantsIntoOrdinarySharesNet>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c11"
      decimals="INF"
      id="ixv-20535"
      unitRef="shares">2711947</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c12" decimals="-3" id="ixv-20536" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c0" decimals="-3" id="ixv-20537" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c11"
      decimals="INF"
      id="ixv-20538"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c12" decimals="-3" id="ixv-20539" unitRef="usd">116000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c0" decimals="-3" id="ixv-20540" unitRef="usd">116000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <iinn:IssuanceOfOrdinarySharesCommitmentFeesinShares
      contextRef="c11"
      decimals="INF"
      id="ixv-20541"
      unitRef="shares">218627</iinn:IssuanceOfOrdinarySharesCommitmentFeesinShares>
    <iinn:StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees contextRef="c12" decimals="-3" id="ixv-20542" unitRef="usd">223000</iinn:StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees>
    <iinn:StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees contextRef="c0" decimals="-3" id="ixv-20543" unitRef="usd">223000</iinn:StockIssuedDuringPeriodIssuanceOfOrdinarySharesCommitmentFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c12" decimals="-3" id="ixv-20544" unitRef="usd">3575000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c13" decimals="-3" id="ixv-20545" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c0" decimals="-3" id="ixv-20546" unitRef="usd">3575000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c12" decimals="-3" id="ixv-20547" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-20548" unitRef="usd">-13220000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-20549" unitRef="usd">-13220000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c14"
      decimals="INF"
      id="ixv-20550"
      unitRef="shares">35949247</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-20551" unitRef="usd">82117000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-20552" unitRef="usd">-79794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-20553" unitRef="usd">2323000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c17"
      decimals="INF"
      id="ixv-20554"
      unitRef="shares">15652176</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-20555" unitRef="usd">61259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-20556" unitRef="usd">-55521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-20557" unitRef="usd">5738000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c21"
      decimals="INF"
      id="ixv-20558"
      unitRef="shares">6231169</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c22" decimals="-3" id="ixv-20559" unitRef="usd">7679000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c23" decimals="-3" id="ixv-20560" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c6" decimals="-3" id="ixv-20561" unitRef="usd">7679000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c21"
      decimals="INF"
      id="ixv-20562"
      unitRef="shares">19048</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c22" decimals="-3" id="ixv-20563" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c23" decimals="-3" id="ixv-20564" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c6" decimals="-3" id="ixv-20565" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares
      contextRef="c21"
      decimals="INF"
      id="ixv-20566"
      unitRef="shares">1709760</iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares>
    <iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares contextRef="c22" decimals="-3" id="ixv-20567" unitRef="usd">2000</iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares>
    <iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares contextRef="c23" decimals="-3" id="ixv-20568" unitRef="usd">0</iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares>
    <iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares contextRef="c6" decimals="-3" id="ixv-20569" unitRef="usd">2000</iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c21"
      decimals="INF"
      id="ixv-20570"
      unitRef="shares">594943</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c22" decimals="-3" id="ixv-20571" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c6" decimals="-3" id="ixv-20572" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c21"
      decimals="INF"
      id="ixv-20573"
      unitRef="shares">45000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c22" decimals="-3" id="ixv-20574" unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c23" decimals="-3" id="ixv-20575" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c6" decimals="-3" id="ixv-20576" unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c22" decimals="-3" id="ixv-20577" unitRef="usd">1892000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c23" decimals="-3" id="ixv-20578" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c6" decimals="-3" id="ixv-20579" unitRef="usd">1892000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c22" decimals="-3" id="ixv-20580" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c23" decimals="-3" id="ixv-20581" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-20582" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-20583"
      unitRef="shares">24252096</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-20584" unitRef="usd">70896000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-20585" unitRef="usd">-66574000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-20586" unitRef="usd">4322000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c24"
      decimals="INF"
      id="ixv-20587"
      unitRef="shares">11338940</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" id="ixv-20588" unitRef="usd">57866000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-20589" unitRef="usd">-44235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-20590" unitRef="usd">13631000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c28"
      decimals="INF"
      id="ixv-20591"
      unitRef="shares">3031250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c29" decimals="-3" id="ixv-20592" unitRef="usd">1806000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c30" decimals="-3" id="ixv-20593" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c7" decimals="-3" id="ixv-20594" unitRef="usd">1806000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c29" decimals="-3" id="ixv-20595" unitRef="usd">131000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c30" decimals="-3" id="ixv-20596" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c7" decimals="-3" id="ixv-20597" unitRef="usd">131000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c28"
      decimals="INF"
      id="ixv-20598"
      unitRef="shares">17566</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c29" decimals="-3" id="ixv-20599" unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c30" decimals="-3" id="ixv-20600" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c7" decimals="-3" id="ixv-20601" unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueOther>
    <iinn:StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments
      contextRef="c28"
      decimals="INF"
      id="ixv-20602"
      unitRef="shares">37972</iinn:StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments>
    <iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments contextRef="c29" decimals="-3" id="ixv-20603" unitRef="usd">3000</iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments>
    <iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments contextRef="c30" decimals="-3" id="ixv-20604" unitRef="usd">0</iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments>
    <iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments contextRef="c7" decimals="-3" id="ixv-20605" unitRef="usd">3000</iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c28"
      decimals="INF"
      id="ixv-20606"
      unitRef="shares">1226448</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c29" decimals="-3" id="ixv-20607" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c30" decimals="-3" id="ixv-20608" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c29" decimals="-3" id="ixv-20609" unitRef="usd">1427000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c30" decimals="-3" id="ixv-20610" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c7" decimals="-3" id="ixv-20611" unitRef="usd">1427000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c29" decimals="-3" id="ixv-20612" unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c30" decimals="-3" id="ixv-20613" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-20614" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c17"
      decimals="INF"
      id="ixv-20615"
      unitRef="shares">15652176</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-20616" unitRef="usd">61259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-20617" unitRef="usd">-55521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-20618" unitRef="usd">5738000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-20619" unitRef="usd">-13220000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-20620" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-20621" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-20622" unitRef="usd">150000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="-3" id="ixv-20623" unitRef="usd">171000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c7" decimals="-3" id="ixv-20624" unitRef="usd">111000</us-gaap:Depreciation>
    <us-gaap:ProvisionForOtherLosses contextRef="c0" decimals="-3" id="ixv-20625" unitRef="usd">9000</us-gaap:ProvisionForOtherLosses>
    <us-gaap:ProvisionForOtherLosses contextRef="c6" decimals="-3" id="ixv-20626" unitRef="usd">5000</us-gaap:ProvisionForOtherLosses>
    <us-gaap:ProvisionForOtherLosses contextRef="c7" decimals="-3" id="ixv-20627" unitRef="usd">0</us-gaap:ProvisionForOtherLosses>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-20628" unitRef="usd">3575000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-20629" unitRef="usd">1892000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-20630" unitRef="usd">1427000</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c0" decimals="-3" id="ixv-20631" unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c6" decimals="-3" id="ixv-20632" unitRef="usd">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c7" decimals="-3" id="ixv-20633" unitRef="usd">59000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c0" decimals="-3" id="ixv-20634" unitRef="usd">720000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c6" decimals="-3" id="ixv-20635" unitRef="usd">-47000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c7" decimals="-3" id="ixv-20636" unitRef="usd">306000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <iinn:ExpirationOfFinancialLiability contextRef="c0" decimals="-3" id="ixv-20637" unitRef="usd">0</iinn:ExpirationOfFinancialLiability>
    <iinn:ExpirationOfFinancialLiability contextRef="c6" decimals="-3" id="ixv-20638" unitRef="usd">11000</iinn:ExpirationOfFinancialLiability>
    <iinn:ExpirationOfFinancialLiability contextRef="c7" decimals="-3" id="ixv-20639" unitRef="usd">0</iinn:ExpirationOfFinancialLiability>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="-3" id="ixv-20640" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c6" decimals="-3" id="ixv-20641" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c7" decimals="-3" id="ixv-20642" unitRef="usd">205000</us-gaap:AmortizationOfFinancingCosts>
    <iinn:IssuanceOfOrdinarySharesAdvisorFees contextRef="c0" decimals="-3" id="ixv-20643" unitRef="usd">116000</iinn:IssuanceOfOrdinarySharesAdvisorFees>
    <iinn:IssuanceOfOrdinarySharesAdvisorFees contextRef="c6" decimals="-3" id="ixv-20644" unitRef="usd">62000</iinn:IssuanceOfOrdinarySharesAdvisorFees>
    <iinn:IssuanceOfOrdinarySharesAdvisorFees contextRef="c7" decimals="-3" id="ixv-20645" unitRef="usd">0</iinn:IssuanceOfOrdinarySharesAdvisorFees>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-20646" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c6" decimals="-3" id="ixv-20647" unitRef="usd">-9000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c7" decimals="-3" id="ixv-20648" unitRef="usd">-7000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInLeasingReceivables contextRef="c0" decimals="-3" id="ixv-20649" unitRef="usd">-99000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInLeasingReceivables contextRef="c6" decimals="-3" id="ixv-20650" unitRef="usd">-31000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInLeasingReceivables contextRef="c7" decimals="-3" id="ixv-20651" unitRef="usd">5000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" id="ixv-20652" unitRef="usd">-78000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="-3" id="ixv-20653" unitRef="usd">84000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c7" decimals="-3" id="ixv-20654" unitRef="usd">-190000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" id="ixv-20655" unitRef="usd">-47000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c6" decimals="-3" id="ixv-20656" unitRef="usd">-44000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c7" decimals="-3" id="ixv-20657" unitRef="usd">46000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c0" decimals="-3" id="ixv-20658" unitRef="usd">-58000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c6" decimals="-3" id="ixv-20659" unitRef="usd">118000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c7" decimals="-3" id="ixv-20660" unitRef="usd">-190000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="-3" id="ixv-20661" unitRef="usd">291000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c6" decimals="-3" id="ixv-20662" unitRef="usd">444000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c7" decimals="-3" id="ixv-20663" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c0" decimals="-3" id="ixv-20664" unitRef="usd">25000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c6" decimals="-3" id="ixv-20665" unitRef="usd">55000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c7" decimals="-3" id="ixv-20666" unitRef="usd">-65000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <iinn:FinancialExpensesDueToCommitmentFee contextRef="c0" decimals="-3" id="ixv-20667" unitRef="usd">250000</iinn:FinancialExpensesDueToCommitmentFee>
    <iinn:FinancialExpensesDueToCommitmentFee contextRef="c6" decimals="-3" id="ixv-20668" unitRef="usd">0</iinn:FinancialExpensesDueToCommitmentFee>
    <iinn:FinancialExpensesDueToCommitmentFee contextRef="c7" decimals="-3" id="ixv-20669" unitRef="usd">0</iinn:FinancialExpensesDueToCommitmentFee>
    <iinn:IssuanceOfOrdinarySharesCommitmentFee contextRef="c0" decimals="-3" id="ixv-20670" unitRef="usd">223000</iinn:IssuanceOfOrdinarySharesCommitmentFee>
    <iinn:IssuanceOfOrdinarySharesCommitmentFee contextRef="c6" decimals="-3" id="ixv-20671" unitRef="usd">0</iinn:IssuanceOfOrdinarySharesCommitmentFee>
    <iinn:IssuanceOfOrdinarySharesCommitmentFee contextRef="c7" decimals="-3" id="ixv-20672" unitRef="usd">0</iinn:IssuanceOfOrdinarySharesCommitmentFee>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-20673" unitRef="usd">-9861000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-20674" unitRef="usd">-9374000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-20675" unitRef="usd">-9691000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-20676" unitRef="usd">103000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="-3" id="ixv-20677" unitRef="usd">164000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-20678" unitRef="usd">206000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c0" decimals="-3" id="ixv-20679" unitRef="usd">-668000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c6" decimals="-3" id="ixv-20680" unitRef="usd">-1652000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c7" decimals="-3" id="ixv-20681" unitRef="usd">-4800000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-20682" unitRef="usd">565000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="-3" id="ixv-20683" unitRef="usd">1488000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-20684" unitRef="usd">4594000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c0" decimals="-3" id="ixv-20685" unitRef="usd">1759000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c6" decimals="-3" id="ixv-20686" unitRef="usd">7898000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c7" decimals="-3" id="ixv-20687" unitRef="usd">3424000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-20688" unitRef="usd">10000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c6" decimals="-3" id="ixv-20689" unitRef="usd">2000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c7" decimals="-3" id="ixv-20690" unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="-3" id="ixv-20691" unitRef="usd">912000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c6" decimals="-3" id="ixv-20692" unitRef="usd">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c7" decimals="-3" id="ixv-20693" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-20694" unitRef="usd">4646000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c6" decimals="-3" id="ixv-20695" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c7" decimals="-3" id="ixv-20696" unitRef="usd">26000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-20697" unitRef="usd">7327000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="-3" id="ixv-20698" unitRef="usd">7902000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="-3" id="ixv-20699" unitRef="usd">3453000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="-3" id="ixv-20700" unitRef="usd">25000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c6" decimals="-3" id="ixv-20701" unitRef="usd">55000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="-3" id="ixv-20702" unitRef="usd">-65000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-20703" unitRef="usd">-1969000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c6" decimals="-3" id="ixv-20704" unitRef="usd">16000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c7" decimals="-3" id="ixv-20705" unitRef="usd">-1644000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-20706" unitRef="usd">5201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20" decimals="-3" id="ixv-20707" unitRef="usd">5130000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c27" decimals="-3" id="ixv-20708" unitRef="usd">6839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-20709" unitRef="usd">3257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-20710" unitRef="usd">5201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20" decimals="-3" id="ixv-20711" unitRef="usd">5130000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-20712" unitRef="usd">3159000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-20713" unitRef="usd">5111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20" decimals="-3" id="ixv-20714" unitRef="usd">5041000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c4" decimals="-3" id="ixv-20715" unitRef="usd">98000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c5" decimals="-3" id="ixv-20716" unitRef="usd">90000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c20" decimals="-3" id="ixv-20717" unitRef="usd">89000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-20718" unitRef="usd">3257000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-20719" unitRef="usd">5201000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c20" decimals="-3" id="ixv-20720" unitRef="usd">5130000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <iinn:OtherReceivableInConnectionToPrivatePlacement contextRef="c0" decimals="-3" id="ixv-20721" unitRef="usd">0</iinn:OtherReceivableInConnectionToPrivatePlacement>
    <iinn:OtherReceivableInConnectionToPrivatePlacement contextRef="c6" decimals="-3" id="ixv-20722" unitRef="usd">-70000</iinn:OtherReceivableInConnectionToPrivatePlacement>
    <iinn:OtherReceivableInConnectionToPrivatePlacement contextRef="c7" decimals="-3" id="ixv-20723" unitRef="usd">0</iinn:OtherReceivableInConnectionToPrivatePlacement>
    <iinn:AccruedIssuanceExpenses contextRef="c0" decimals="-3" id="ixv-20724" unitRef="usd">-43000</iinn:AccruedIssuanceExpenses>
    <iinn:AccruedIssuanceExpenses contextRef="c6" decimals="-3" id="ixv-20725" unitRef="usd">-220000</iinn:AccruedIssuanceExpenses>
    <iinn:AccruedIssuanceExpenses contextRef="c7" decimals="-3" id="ixv-20726" unitRef="usd">0</iinn:AccruedIssuanceExpenses>
    <iinn:FinancialLiabilityPlacementAgentFee contextRef="c0" decimals="-3" id="ixv-20727" unitRef="usd">0</iinn:FinancialLiabilityPlacementAgentFee>
    <iinn:FinancialLiabilityPlacementAgentFee contextRef="c6" decimals="-3" id="ixv-20728" unitRef="usd">-69000</iinn:FinancialLiabilityPlacementAgentFee>
    <iinn:FinancialLiabilityPlacementAgentFee contextRef="c7" decimals="-3" id="ixv-20729" unitRef="usd">0</iinn:FinancialLiabilityPlacementAgentFee>
    <iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital contextRef="c0" decimals="-3" id="ixv-20730" unitRef="usd">0</iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital>
    <iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital contextRef="c6" decimals="-3" id="ixv-20731" unitRef="usd">-254000</iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital>
    <iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital contextRef="c7" decimals="-3" id="ixv-20732" unitRef="usd">-73000</iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital>
    <iinn:NonCashTransactions contextRef="c0" decimals="-3" id="ixv-20733" unitRef="usd">-43000</iinn:NonCashTransactions>
    <iinn:NonCashTransactions contextRef="c6" decimals="-3" id="ixv-20734" unitRef="usd">-473000</iinn:NonCashTransactions>
    <iinn:NonCashTransactions contextRef="c7" decimals="-3" id="ixv-20735" unitRef="usd">-73000</iinn:NonCashTransactions>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" id="ixv-20736" unitRef="usd">65000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="-3" id="ixv-20737" unitRef="usd">72000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="-3" id="ixv-20738" unitRef="usd">93000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-15217">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 - GENERAL:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Inspira Technologies Oxy B.H.N. Ltd (the &#x201c;Company&#x201d;) was
                                            incorporated in Israel and commenced its operations on February 27, 2018. The Company operates
                                            in the medical technology industry in the field of respiratory support technology engaged
                                            in the research, development, manufacturing related activities, and go-to-market activities
                                            of proprietary products and technologies. The Company is developing the following products:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The INSPIRA ART (Augmented
                                            Respiratory Technology), which is a respiratory support technology targeted toward utilizing
                                            blood monitoring and direct blood oxygenation to boost patient saturation levels within minutes
                                            while the patient is awake. The aim is to provide an alternative to invasive mechanical ventilation,
                                            associated with high risks, complications, high costs and high mortality rates.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The HYLA blood sensor,
                                            which is a non-invasive optical blood sensor designed to perform real-time and continuous
                                            blood parameter measurements, potentially reducing the need for intermittent blood samples
                                            from patients.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.75in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The INSPIRA ART100
                                            System, an advanced form of life support system, better known by the medical industry as
                                            a cardiopulmonary bypass system, has been designed for use in procedures requiring cardiopulmonary
                                            bypass for six hours or less.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;The Company&#x2019;s INSPIRA ART100 system received U.S.
Food and Drug Administration (&#x201c;FDA&#x201d;) 510(k) regulatory clearance for cardiopulmonary bypass procedures and Israeli Medical
Equipment Division certification for extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures. The Company&#x2019;s
other products, including the INSPIRA ART and HYLA&#x2122; blood sensor, have not yet been tested or used in humans and have not been
approved by any regulatory entity.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 14, 2025, the Company entered into a sales agreement pursuant to which the Company could offer and sell, from time to time, through the sales agent, ordinary shares, no par value, of the Company (&#x201c;Ordinary Shares&#x201d;) pursuant to an at-the-market facility (the &#x201c;March 2025 ATM&#x201d;), having an aggregate offering price of up to $1,019. On April 10, 2025, the maximum aggregate offering price was increased to $1,917, On July 1, 2025, the maximum aggregate offering price was increased to $7,118. On September 16, 2025, the maximum aggregate offering price was increased to $14,687. As of December 31, 2025, the Company has sold 5,485,898 Ordinary Shares under the ATM for aggregate gross proceeds received of approximately $4,888, before deducting offering costs of approximately $272. Subsequent to December 31, 2025 and following the expiration of the Sales Agreement due to expiration of the related Registration Statement on Form F-3 (File No. 333-266748), the Company entered into a new sales agreement pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (&#x201c;ATM&#x201d;), having an aggregate offering price of up to $2,016 To date, no Ordinary Shares have been sold pursuant to the March 2025 ATM.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The accompanying financial statements (the &#x201c;Financial Statements&#x201d;) have been prepared assuming that the Company will continue as a going concern. To date, the Company is at the deployment stage with respect to the INSPIRA ART100, and is in development stage with its other technologies. Therefore, the Company has suffered recurring losses from operations and negative cash flows from operations since inception. As of December 31, 2025, the Company had incurred accumulated losses of $80 million and expects to continue to fund its operations through fundings such as issuance of convertible securities, Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that such financing will be obtained. Considering the above, our dependence on external funding for our operations raises a substantial doubt about our ability to continue as a going concern. The Financial Statements do not include any adjustments that might result from the outcome of these uncertainties.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;4.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Our offices are located in Ra&#x2019;anana,
                                            Israel. On October 7, 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from
                                            the Gaza Strip and conducted a series of attacks on civilian and military targets. Following
                                            the October 7, 2023 attacks by Hamas terrorists in Israel&#x2019;s southern border, Israel
                                            declared war against Hamas and since then, Israel has been involved in military conflicts
                                            with Hamas, Hezbollah, a terrorist organization based in Lebanon, and Iran, both directly
                                            and through proxies like the Houthi movement in Yemen and armed groups in Iraq and other
                                            terrorist organizations. Additionally, following the fall of the Assad regime in Syria, Israel
                                            has conducted limited military operations targeting the Syrian army, Iranian military assets
                                            and infrastructure linked to Hezbollah and other Iran-supported groups.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On June 13, 2025, Israel launched a
strike against Iran, aimed to disrupt Iran&#x2019;s capacity to coordinate or launch hostilities against Israel. Iran has retaliated in
response, firing missiles and drones at Israeli military and civilian infrastructure. More recently, in February 2026, hostilities between
Israel and Iran escalated again.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In late February 2026, Israel, together
with the United States, conducted a major joint military campaign of air and missile strikes against targets in Iran, which triggered
a broad Iranian response and contributed to significant regional instability. The situation remains highly fluid, and we are unable to
predict when, or on what terms, this escalation will be resolved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Although certain ceasefire agreements
have been reached with Hamas, and the level of hostilities has since decreased, the situation remains volatile, with the potential for
escalation into a broader regional conflict involving additional terrorist organizations and possibly other countries, including as a
result of instability arising from developments in Syria. &#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Other regional hostilities, since October
7, 2023, concurrently became more pronounced. This includes and has included a northern front war igniting between Israel and Hezbollah,
which as of February 24, 2025 we are under a ceasefire, hostilities between Israel and Iran, which have included Iranian strikes against
Israel in April 2024 and October 2024, and subsequent retaliation by Israel to both instances, and a continued conflict between Israel
and the Houthi Movement in Yemen.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;Currently,
one of our employees is serving in military reserve duty. In addition, due to the ongoing security situation, we may experience occasional
delays in the shipment of inventory. However, as of the date of these Financial Statements, these events have no material impact on the
Company&#x2019;s operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;5.&lt;/td&gt;&lt;td&gt;These Financial Statements were authorized by the Board of Directors
                                            on March 25, 2026&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <iinn:AggregateOfferingPrice contextRef="c31" decimals="-3" id="ixv-20739" unitRef="usd">1019000</iinn:AggregateOfferingPrice>
    <iinn:AggregateOfferingPrice contextRef="c32" decimals="-3" id="ixv-20740" unitRef="usd">1917000</iinn:AggregateOfferingPrice>
    <iinn:AggregateOfferingPrice contextRef="c33" decimals="-3" id="ixv-20741" unitRef="usd">7118000</iinn:AggregateOfferingPrice>
    <iinn:AggregateOfferingPrice contextRef="c34" decimals="-3" id="ixv-20742" unitRef="usd">14687000</iinn:AggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c0"
      decimals="0"
      id="ixv-20743"
      unitRef="shares">5485898</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <iinn:AggregateGrossProceeds contextRef="c0" decimals="-3" id="ixv-20744" unitRef="usd">4888000</iinn:AggregateGrossProceeds>
    <iinn:DeductingOfferingCosts contextRef="c0" decimals="-3" id="ixv-20745" unitRef="usd">272000</iinn:DeductingOfferingCosts>
    <iinn:AggregateOfferingPrice contextRef="c35" decimals="-3" id="ixv-20746" unitRef="usd">2016000</iinn:AggregateOfferingPrice>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax contextRef="c4" decimals="-6" id="ixv-20747" unitRef="usd">80000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-15313">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 2 &lt;/b&gt;- &lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying Financial Statements have been
prepared in conformity with the accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The
significant accounting policies followed in the preparation of the Financial Statements are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;A. Use of estimates:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of Financial Statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting
period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;Items subject to such estimates and assumptions include:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;stock-based compensation expense;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;fair value financial liabilities;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;recognition, measurement, and
disclosure of contingent liabilities;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Interest rate used for lease
liability measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#x2019;s Financial Statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;B. Foreign Currency&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#x201c;USD&#x201d;). The Company&#x2019;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#x2013; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#x2013; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;C. Property,
Plant, and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Annual rates of depreciation are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;D. Inventory&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at the lower of cost or
net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items, technological obsolescence, excess
inventories, discontinued products, and for market prices lower than cost, if any.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The Company periodically evaluates the quantities on hand relative
to historical and projected sales volume (which is determined based on an assumption of future demand and market conditions) and the
age of the inventory. At the point of the loss recognition, a new lower cost basis for that inventory has been established.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost is determined for all types of inventory
using the moving average cost method plus indirect costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;E. Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company implemented Accounting Standards
Update (&#x201c;ASU&#x201d;) 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;) using the modified retrospective approach for all
lease arrangements as of such date. The Company leases office space and vehicles under operating leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Arrangements meeting the definition of a lease
are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability,
calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#x2019;s incremental
borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized
over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#x2019;s incremental borrowing rate. The Incremental Borrowing Rate
applied was 11.27%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;F. Revenue recognition&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s revenues are measured according
to Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;).
Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange
for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenue from product sales is recognized when
control of the goods transferred to the customer, which is generally upon shipment, unless contractual terms indicate otherwise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies the five-step model under
ASC 606:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;identify the contract with
a customer;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;identify the performance obligations
in the contract;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;determine the transaction price;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(iv)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;allocate the transaction price
to the performance obligations; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(v)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;recognize revenue when (or
as) performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Standard product warranties that provide assurance
that the product complies with agreed specifications do not represent a separate performance obligation and are accounted for under ASC
460.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Determining whether the Company acts as a principal
or as an agent in the purchase and sale of machines requires significant judgment. While none of the evaluated factors are independently
determinative, after analyzing the guidance under ASC 606 for principal versus agent considerations, the Company concluded that it is
acting as an agent in these transactions. As such, revenues are presented on a net basis. This conclusion is based on the contractual
relationships involved and the manner in which business is conducted, indicating that the Company does not control the machines before
they are transferred to the end customer. In addition, the Company does not bear significant inventory or credit risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Furthermore, the Company accounts for variable
consideration related to discounts and rights of return in accordance with ASC 606. Given the Company's role as an agent, it does not
bear the primary obligation for machine performance or the ultimate risk of product returns. Accordingly, the Company recognizes net
revenue only to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Estimates for returns
and discounts will be recognized as a reduction of the net commission at the time of sale, once the Company has established sales and
sufficient historical data to provide a basis for such estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;G. Cost of revenues&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of revenues consists of products purchased
from sub-contractors, raw materials, shipping and handling costs to customers, salary, employee-related expenses, depreciation, royalties
to the Israeli Innovation Authority (&#x201c;IIA&#x201d;), provision for assurance and overhead expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of revenues are expensed commensurate with
the recognition of the respective revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;H. Research and Development Costs.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;I. Government Grants &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company receives royalty-bearing grants from
the IIA for approved research and development projects Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The grants are linked to the exchange rate of
the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) per year (SOFR is
a benchmark interest rate which replaced LIBOR).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The amounts of grants received and recorded into
income should be disclosed for each period presented. The research and development grants are presented in the statement of operations
as an offset to related research and development expenses. Companies are required to pay royalties in connection with such grants at
specified rates, up to the total dollar-linked amount of such grants. research and development (&#x201c;R&amp;amp;D&#x201d;).&#160;As of December
31, 2025, the Company generated sales in the amount of $288 and paid royalties in the amount of $9. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;No liability was recorded in these Financial
Statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;J. Finance Income and Expenses.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Finance income is composed of interest on deposits
and revaluation of financial liabilities at fair value, while finance expenses are composed of the revaluation of certain financial liabilities
at fair value, bank charges and net currency exchange rates differences.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;K. Current Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;L. Share-Based Compensation.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Share-based compensation
expenses related to employees, directors and subcontractors&#x2019; options or restricted share units (&#x201c;RSU&#x201d;) which recognized
based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using
the graded vesting method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;M. Warrants and Pre-Funded Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues warrants and pre-funded warrants
as part of its financing activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder
to purchase a specified number of the Company&#x2019;s Ordinary Shares at a predetermined exercise price. Warrants and pre-funded warrants
issued by the Company may have various terms, including expiration dates, exercise prices, and conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;)
815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as equity if they meet the criteria for equity classification
outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;N. Severance&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Israeli labor law generally requires payment
of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#x2019;s
pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation
Act, 1963 (&#x201c;Section 14&#x201d;), the Company&#x2019;s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly
salary, made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance
payments in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance
pay.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;O. Basic and Diluted Loss Per Share&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares and pre-funded warrants
outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants issued during the year, if applicable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;P. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), ASC 820, Fair Value Measurements and Disclosures (&#x201c;ASC
820&#x201d;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 1 &#x2013; unadjusted quoted prices are
available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 2 &#x2013; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 &#x2013; pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Equity Line Financing Arrangements- &lt;/b&gt;The Company may enter into
standby equity purchase agreements or similar equity line financing arrangements with third-party investors. For example, on December
12, 2025, the Company entered into the Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;) with Yorkville pursuant to which the Company
has the right to sell to Yorkville up to $25,000 of Ordinary Shares, subject to certain limitations and conditions set forth in the SEPA,
from time to time during the term of the SEPA. Under such arrangements, the Company has the right, but not the obligation, to require
the investor to purchase shares of the Company&#x2019;s Ordinary Shares from time to time, subject to certain conditions and limitations,
up to a specified maximum commitment amount during the term of the agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates these arrangements under
ASC 480, &#x201c;Distinguishing Liabilities from Equity&#x201d;, and ASC 815, &#x201c;Derivatives and Hedging,&#x201d; (&#x201c;ASC 815&#x201d;)
to determine whether any component of the arrangement should be classified as a liability or as a derivative instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To the extent that the Company maintains the
discretion to initiate drawdowns and settlement occurs through the issuance of the Company&#x2019;s Ordinary Shares in exchange for cash,
the issuance of shares under the agreement is accounted for as an equity transaction. Proceeds received upon the issuance of shares are
recorded within stockholders&#x2019; equity, typically as Ordinary Shares and additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shares issued to the investor as commitment shares
at the inception of the agreement are generally accounted for as equity issuance costs associated with establishing the equity facility.
The fair value of the commitment shares on the grant date is recognized as a reduction to additional paid-in capital, consistent with
the accounting for costs incurred in connection with raising equity capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When shares are issued in connection with drawdowns
under the facility, the Company records the gross proceeds received as an increase to stockholders&#x2019; equity. Any issuance costs
directly attributable to the specific drawdown are recorded as a reduction to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company also evaluates whether any features
embedded within the arrangement meet the definition of a freestanding or embedded derivative under ASC 815. If such features do not qualify
for equity classification, they are recognized as derivative instruments and measured at fair value, with subsequent changes in fair
value recognized in the statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the December 31, 2025, the Company has
not sold any Ordinary Shares pursuant to the SEPA, and therefore all issuance expenses were recorded as financial expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Q. Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Part of the Company&#x2019;s operating expenses
are denominated in New Israeli Shekel (&#x201c;NIS&#x201d;), and therefore, subject to foreign currency risk.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;R. Cash and Cash Equivalent&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from the date of purchase that are
not restricted as to withdrawal or use and are readily convertible to known amounts of cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Restricted cash consists of funds that are contractually
restricted to bank guarantee due to rental agreements. The Company has presented restricted cash separately from cash and cash equivalents
in the balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Bank deposits with maturities of more than three
months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at cost which
approximates market value. As of December 31, 2025, the Company had no short-term deposits, and as of December 31, 2024 the Company had
short-term deposits in the amounts of $0.7 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;S. Segment Information&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has a single operating and reportable
segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), who is the Chief Executive Officer, evaluates the performance
of its business based on financial data consistent with the presentation in the accompanying Financial Statements for the purposes of
making operating decisions, assessing financial performance, and allocating resources.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;T. New accounting Pronouncements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Accounting Standards Issued and Not Yet Adopted
in 2025&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2024-03, Income Statement &#x2013; Reporting Comprehensive
Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;),
which requires the disaggregation of certain expense captions into specified categories in disclosures within the notes to the consolidated
financial statements to provide enhanced transparency into the expense captions presented on the face of the statement of income and
comprehensive income. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted,
and may be applied either prospectively or retrospectively to financial statements issued for reporting periods after the effective date
of ASU 2024-03 or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating
the impact that the adoption of ASU 2024-03 will have on its related disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-04,
Induced Conversions of Convertible Debt Instruments (&#x201c;ASU 2024-04&#x201d;). This new guidance is intended to improve the relevance
and consistency in application of the induced conversion guidance in Subtopic 470-20 for (a) convertible debt instruments with cash conversion
features and (b) debt instruments that are not currently convertible. ASU 2024-04 is effective for fiscal years beginning after December
15, 2026. Early adoption is permitted. The Company does not plan to early adopt this standard. The Company is currently evaluating the
effect of adoption of this standard on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2025, the FASB issued ASU 2025-10,
Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which provides comprehensive guidance
on the recognition, measurement, and presentation of government grants. The amendments are effective for annual reporting periods beginning
after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company is currently
evaluating the impact of this guidance on its accounting for government assistance arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Newly issued and recently adopted accounting pronouncements:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Emerging growth company:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups (&#x201c;JOBS&#x201d;) Act. Under the JOBS Act, emerging growth companies can delay adopting
new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as to those standards apply to
private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards
that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging
growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09,
Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories
for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective
for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-15320">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;A. Use of estimates:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of Financial Statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure
of contingent assets and liabilities at the date of the Financial Statements, and the reported amounts of expenses during the reporting
period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;Items subject to such estimates and assumptions include:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;stock-based compensation expense;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;fair value financial liabilities;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;recognition, measurement, and
disclosure of contingent liabilities;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Interest rate used for lease
liability measurement.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the date of issuance of the Financial Statements,
the Company is not aware of any material specific events or circumstances that would require it to update its estimates, judgments, or
to revise the carrying values of its assets or liabilities. These estimates may change, as new events occur and additional information
is obtained, and are recognized in the Financial Statements as soon as they become known. Actual results could differ from those estimates
and any such differences may be material to the Company&#x2019;s Financial Statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-15401">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;B. Foreign Currency&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The currency of the primary economic environment
in which the operations of the Company are conducted is the U.S. dollar (&#x201c;USD&#x201d;). The Company&#x2019;s funding and expected
revenues are mostly in USD. Thus, the functional currency of the Company is in USD.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Transactions and balances originally denominated
in USD are presented at their original amounts. Balances in non-USD currencies are translated into USD using historical and current exchange
rates for non-monetary and monetary balances, respectively. For non-USD transactions and other items in the statements of income (indicated
below), the following exchange rates are used: (i) for transactions &#x2013; exchange rates at transaction dates or average exchange rates;
and (ii) for other items (derived from non-monetary balance sheet items such as depreciation and amortization) &#x2013; historical exchange
rates. Currency transaction gains and losses are presented in financial expenses (income), net as appropriate. The functional currency
of the Company is USD.&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-15413">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;C. Property,
Plant, and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are stated at cost. Depreciation
is computed based on the straight-line method, over the estimated useful life of the assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Annual rates of depreciation are as follows:&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock contextRef="c0" id="ixv-15421">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Annual rates of depreciation are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Computers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c36" decimals="2" id="ixv-20748" unitRef="pure">0.33</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c37" decimals="2" id="ixv-20749" unitRef="pure">0.20</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c38" decimals="2" id="ixv-20750" unitRef="pure">0.06</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c39" decimals="2" id="ixv-20751" unitRef="pure">0.15</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c40" decimals="2" id="ixv-20752" unitRef="pure">0.10</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-15459">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;D. Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventories are stated at the lower of cost or
net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items, technological obsolescence, excess
inventories, discontinued products, and for market prices lower than cost, if any.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;The Company periodically evaluates the quantities on hand relative
to historical and projected sales volume (which is determined based on an assumption of future demand and market conditions) and the
age of the inventory. At the point of the loss recognition, a new lower cost basis for that inventory has been established.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost is determined for all types of inventory
using the moving average cost method plus indirect costs.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-15504">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;E. Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company implemented Accounting Standards
Update (&#x201c;ASU&#x201d;) 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;) using the modified retrospective approach for all
lease arrangements as of such date. The Company leases office space and vehicles under operating leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Arrangements meeting the definition of a lease
are classified as operating or financing leases and are recorded on the balance sheet as both a right of use asset and lease liability,
calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company&#x2019;s incremental
borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized
over the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The lease liability was measured at the present
value of the remaining lease payments, discounted using the Company&#x2019;s incremental borrowing rate. The Incremental Borrowing Rate
applied was 11.27%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For operating leases, interest on the lease liability
and the amortization of the right of use asset result in straight-line&#160;rent expense over the lease term. Variable lease expenses
are recorded when incurred.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <iinn:IncrementalBorrowingRate contextRef="c4" decimals="4" id="ixv-20753" unitRef="pure">0.1127</iinn:IncrementalBorrowingRate>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0" id="ixv-15520">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;F. Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s revenues are measured according
to Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &#x201c;Revenue from Contracts with Customers&#x201d; (&#x201c;ASC 606&#x201d;).
Under ASC 606, revenues are measured according to the amount of consideration that the Company expects to be entitled to receive in exchange
for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenue from product sales is recognized when
control of the goods transferred to the customer, which is generally upon shipment, unless contractual terms indicate otherwise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company applies the five-step model under
ASC 606:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;identify the contract with
a customer;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;identify the performance obligations
in the contract;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;determine the transaction price;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(iv)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;allocate the transaction price
to the performance obligations; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(v)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;recognize revenue when (or
as) performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Standard product warranties that provide assurance
that the product complies with agreed specifications do not represent a separate performance obligation and are accounted for under ASC
460.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Determining whether the Company acts as a principal
or as an agent in the purchase and sale of machines requires significant judgment. While none of the evaluated factors are independently
determinative, after analyzing the guidance under ASC 606 for principal versus agent considerations, the Company concluded that it is
acting as an agent in these transactions. As such, revenues are presented on a net basis. This conclusion is based on the contractual
relationships involved and the manner in which business is conducted, indicating that the Company does not control the machines before
they are transferred to the end customer. In addition, the Company does not bear significant inventory or credit risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Furthermore, the Company accounts for variable
consideration related to discounts and rights of return in accordance with ASC 606. Given the Company's role as an agent, it does not
bear the primary obligation for machine performance or the ultimate risk of product returns. Accordingly, the Company recognizes net
revenue only to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Estimates for returns
and discounts will be recognized as a reduction of the net commission at the time of sale, once the Company has established sales and
sufficient historical data to provide a basis for such estimates.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c0" id="ixv-15622">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;G. Cost of revenues&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of revenues consists of products purchased
from sub-contractors, raw materials, shipping and handling costs to customers, salary, employee-related expenses, depreciation, royalties
to the Israeli Innovation Authority (&#x201c;IIA&#x201d;), provision for assurance and overhead expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost of revenues are expensed commensurate with
the recognition of the respective revenues.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-15632">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;H. Research and Development Costs.&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Research and development
expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c0" id="ixv-15640">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;I. Government Grants &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company receives royalty-bearing grants from
the IIA for approved research and development projects Under Israeli law, royalties on the revenues derived from products and services
developed using such grants, are payable to the Israeli Government.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The grants are linked to the exchange rate of
the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) per year (SOFR is
a benchmark interest rate which replaced LIBOR).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The amounts of grants received and recorded into
income should be disclosed for each period presented. The research and development grants are presented in the statement of operations
as an offset to related research and development expenses. Companies are required to pay royalties in connection with such grants at
specified rates, up to the total dollar-linked amount of such grants. research and development (&#x201c;R&amp;amp;D&#x201d;).&#160;As of December
31, 2025, the Company generated sales in the amount of $288 and paid royalties in the amount of $9. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;No liability was recorded in these Financial
Statements.&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <iinn:SalesAmount contextRef="c0" decimals="0" id="ixv-20754" unitRef="usd">288</iinn:SalesAmount>
    <iinn:PaidRoyalties contextRef="c4" decimals="0" id="ixv-20755" unitRef="usd">9</iinn:PaidRoyalties>
    <iinn:FinanceIncomeAndExpensesPolicyTextBlock contextRef="c0" id="ixv-15657">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;J. Finance Income and Expenses.&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Finance income is composed of interest on deposits
and revaluation of financial liabilities at fair value, while finance expenses are composed of the revaluation of certain financial liabilities
at fair value, bank charges and net currency exchange rates differences.&lt;/p&gt;</iinn:FinanceIncomeAndExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-15664">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;K. Current Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The current tax liability
is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments
required in connection with the tax liability in respect of previous years. The Company has no tax liability due to its carry forward
losses.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-15705">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;L. Share-Based Compensation.&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;Share-based compensation
expenses related to employees, directors and subcontractors&#x2019; options or restricted share units (&#x201c;RSU&#x201d;) which recognized
based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise price using
the graded vesting method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes compensation expense for
grants of share-based awards to its employees based on the estimated fair value on the grant date. Compensation cost for awards is recognized
over the requisite service period, which approximates the vesting period. Share-based compensation is included in research and development,
selling and marketing and general and administrative expenses. Forfeitures of equity grants are recognized as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All issuances of stock options or other equity
instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value
of the equity instruments issued.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c0" id="ixv-15718">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;M. Warrants and Pre-Funded Warrants&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company issues warrants and pre-funded warrants
as part of its financing activities or compensation arrangements. Warrants are derivative financial instruments that entitle the holder
to purchase a specified number of the Company&#x2019;s Ordinary Shares at a predetermined exercise price. Warrants and pre-funded warrants
issued by the Company may have various terms, including expiration dates, exercise prices, and conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies warrants as either equity
or liabilities upon issuance, based on specific terms and conditions and in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;)
815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as equity if they meet the criteria for equity classification
outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <iinn:SeverancePolicyTextBlock contextRef="c0" id="ixv-15728">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;N. Severance&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Israeli labor law generally requires payment
of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. The Company&#x2019;s
pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section 14 of the Israeli Severance Compensation
Act, 1963 (&#x201c;Section 14&#x201d;), the Company&#x2019;s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly
salary, made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance
payments in respect of those employees and, as such, the Company may only utilize the insurance policies for the purpose of paying severance
pay.&lt;/p&gt;</iinn:SeverancePolicyTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="c0" decimals="4" id="ixv-20756" unitRef="pure">0.0833</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-15735">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;O. Basic and Diluted Loss Per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic and diluted loss per share is calculated
by dividing the loss attributable to equity holders of the Company by the weighted average number of Ordinary Shares and pre-funded warrants
outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants issued during the year, if applicable.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-15742">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;P. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures and discloses fair value
in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), ASC 820, Fair Value Measurements and Disclosures (&#x201c;ASC
820&#x201d;). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value,
and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such,
fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing
an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes
the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 1 &#x2013; unadjusted quoted prices are
available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 2 &#x2013; pricing inputs are other than
quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Level 3 &#x2013; pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This hierarchy requires the Company to use observable
market data, when available, and to minimize the use of unobservable inputs when determining fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of cash is based on its demand
value, which is equal to its carrying value. Additionally, the carrying value of all other short-term monetary assets and liabilities
are estimated to be equal to their fair value due to the short-term nature of these instruments.&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Equity Line Financing Arrangements- &lt;/b&gt;The Company may enter into
standby equity purchase agreements or similar equity line financing arrangements with third-party investors. For example, on December
12, 2025, the Company entered into the Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;) with Yorkville pursuant to which the Company
has the right to sell to Yorkville up to $25,000 of Ordinary Shares, subject to certain limitations and conditions set forth in the SEPA,
from time to time during the term of the SEPA. Under such arrangements, the Company has the right, but not the obligation, to require
the investor to purchase shares of the Company&#x2019;s Ordinary Shares from time to time, subject to certain conditions and limitations,
up to a specified maximum commitment amount during the term of the agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates these arrangements under
ASC 480, &#x201c;Distinguishing Liabilities from Equity&#x201d;, and ASC 815, &#x201c;Derivatives and Hedging,&#x201d; (&#x201c;ASC 815&#x201d;)
to determine whether any component of the arrangement should be classified as a liability or as a derivative instrument.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To the extent that the Company maintains the
discretion to initiate drawdowns and settlement occurs through the issuance of the Company&#x2019;s Ordinary Shares in exchange for cash,
the issuance of shares under the agreement is accounted for as an equity transaction. Proceeds received upon the issuance of shares are
recorded within stockholders&#x2019; equity, typically as Ordinary Shares and additional paid-in capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Shares issued to the investor as commitment shares
at the inception of the agreement are generally accounted for as equity issuance costs associated with establishing the equity facility.
The fair value of the commitment shares on the grant date is recognized as a reduction to additional paid-in capital, consistent with
the accounting for costs incurred in connection with raising equity capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When shares are issued in connection with drawdowns
under the facility, the Company records the gross proceeds received as an increase to stockholders&#x2019; equity. Any issuance costs
directly attributable to the specific drawdown are recorded as a reduction to additional paid-in capital.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company also evaluates whether any features
embedded within the arrangement meet the definition of a freestanding or embedded derivative under ASC 815. If such features do not qualify
for equity classification, they are recognized as derivative instruments and measured at fair value, with subsequent changes in fair
value recognized in the statement of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the December 31, 2025, the Company has
not sold any Ordinary Shares pursuant to the SEPA, and therefore all issuance expenses were recorded as financial expenses.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <iinn:OrdinarySharesSEPAAmount contextRef="c0" decimals="0" id="ixv-20757" unitRef="usd">25000</iinn:OrdinarySharesSEPAAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-15855">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Q. Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company maintains certain cash balances in
a well-known Israeli banks and U.S based banks.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Part of the Company&#x2019;s operating expenses
are denominated in New Israeli Shekel (&#x201c;NIS&#x201d;), and therefore, subject to foreign currency risk.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-15865">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;R. Cash and Cash Equivalent&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash equivalents are highly liquid investments
that are readily convertible into cash, typically with an original maturity of three months or less from the date of purchase that are
not restricted as to withdrawal or use and are readily convertible to known amounts of cash.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Restricted cash consists of funds that are contractually
restricted to bank guarantee due to rental agreements. The Company has presented restricted cash separately from cash and cash equivalents
in the balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Bank deposits with maturities of more than three
months, but less than one year, and which are not restricted are included in short-term deposits. Such deposits are stated at cost which
approximates market value. As of December 31, 2025, the Company had no short-term deposits, and as of December 31, 2024 the Company had
short-term deposits in the amounts of $0.7 million.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ShortTermInvestments contextRef="c5" decimals="-5" id="ixv-20758" unitRef="usd">700000</us-gaap:ShortTermInvestments>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-15879">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;S. Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has a single operating and reportable
segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), who is the Chief Executive Officer, evaluates the performance
of its business based on financial data consistent with the presentation in the accompanying Financial Statements for the purposes of
making operating decisions, assessing financial performance, and allocating resources.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-15887">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;T. New accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Accounting Standards Issued and Not Yet Adopted
in 2025&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2024-03, Income Statement &#x2013; Reporting Comprehensive
Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;),
which requires the disaggregation of certain expense captions into specified categories in disclosures within the notes to the consolidated
financial statements to provide enhanced transparency into the expense captions presented on the face of the statement of income and
comprehensive income. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, with early adoption permitted,
and may be applied either prospectively or retrospectively to financial statements issued for reporting periods after the effective date
of ASU 2024-03 or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating
the impact that the adoption of ASU 2024-03 will have on its related disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-04,
Induced Conversions of Convertible Debt Instruments (&#x201c;ASU 2024-04&#x201d;). This new guidance is intended to improve the relevance
and consistency in application of the induced conversion guidance in Subtopic 470-20 for (a) convertible debt instruments with cash conversion
features and (b) debt instruments that are not currently convertible. ASU 2024-04 is effective for fiscal years beginning after December
15, 2026. Early adoption is permitted. The Company does not plan to early adopt this standard. The Company is currently evaluating the
effect of adoption of this standard on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2025, the FASB issued ASU 2025-10,
Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities, which provides comprehensive guidance
on the recognition, measurement, and presentation of government grants. The amendments are effective for annual reporting periods beginning
after December 15, 2026, including interim periods within those fiscal years, with early adoption permitted. The Company is currently
evaluating the impact of this guidance on its accounting for government assistance arrangements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Newly issued and recently adopted accounting pronouncements:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Emerging growth company:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is an emerging growth company, as
defined in the Jumpstart Our Business Startups (&#x201c;JOBS&#x201d;) Act. Under the JOBS Act, emerging growth companies can delay adopting
new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as to those standards apply to
private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards
that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging
growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09,
Improvements to Income Tax Disclosures, which requires disclosure of disaggregated income taxes paid, prescribes standard categories
for the components of the effective tax rate reconciliation, and modifies other income tax-related disclosures. The ASU will be effective
for fiscal years beginning after December 15, 2025, and allows adoption on a prospective basis, with a retrospective option.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="c0" id="ixv-15952">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;NOTE 3 - CASH AND CASH EQUIVALENT:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The Company's cash and
cash equivalents are primarily held in U.S. Dollars and New Israeli Shekels (NIS), in current accounts and short-term deposits with leading
banking institutions in Israel and the United States.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025, the Company had cash
and cash equivalents in amount of $3,159.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;As of December 31, 2024,
the Company had Cash and cash equivalents in amount of $5,111.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-20759" unitRef="usd">3159000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-20760" unitRef="usd">5111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositLiabilitiesDisclosuresTextBlock contextRef="c0" id="ixv-15964">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;b&gt;NOTE 4 -
DEPOSITS:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The Company&#x2019;s
deposits consist of short-term bank deposits with maturities of more than three months but less than one year. The deposits bear annual
interest. Interest earned is recorded as finance income, net in the statement of operations during the years for which the Company held
short-term deposits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025, the Company had no deposits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2024, the Company had a deposit
in NIS at Bank Leumi in the amount of $668, including interest that bore a fixed annual interest of 4.108%.&lt;/p&gt;</us-gaap:DepositLiabilitiesDisclosuresTextBlock>
    <us-gaap:Deposits contextRef="c41" decimals="-3" id="ixv-20761" unitRef="usd">668000</us-gaap:Deposits>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="c42" decimals="5" id="ixv-20762" unitRef="pure">0.04108</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-16000">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;NOTE 5 - OTHER CURRENT ASSETS:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;216&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;240&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Institutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;74&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;517&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-16005">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;216&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;240&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Institutions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted Cash&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;74&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;517&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-20763" unitRef="usd">216000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c5" decimals="-3" id="ixv-20764" unitRef="usd">240000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:InterestBearingDepositsInBanks contextRef="c4" decimals="-3" id="ixv-20765" unitRef="usd">200000</us-gaap:InterestBearingDepositsInBanks>
    <us-gaap:InterestBearingDepositsInBanks contextRef="c5" decimals="-3" id="ixv-20766" unitRef="usd">183000</us-gaap:InterestBearingDepositsInBanks>
    <us-gaap:RestrictedCashCurrent contextRef="c4" decimals="-3" id="ixv-20767" unitRef="usd">98000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c5" decimals="-3" id="ixv-20768" unitRef="usd">90000</us-gaap:RestrictedCashCurrent>
    <iinn:OthersAsset contextRef="c4" decimals="-3" id="ixv-20769" unitRef="usd">3000</iinn:OthersAsset>
    <iinn:OthersAsset contextRef="c5" decimals="-3" id="ixv-20770" unitRef="usd">74000</iinn:OthersAsset>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-20771" unitRef="usd">517000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-20772" unitRef="usd">587000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-16070">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 6 - INVENTORY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;461&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;293&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Work in progress&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;735&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;444&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-16075">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;461&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;293&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Work in progress&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;735&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;444&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="c4" decimals="-3" id="ixv-20773" unitRef="usd">461000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c5" decimals="-3" id="ixv-20774" unitRef="usd">293000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials contextRef="c4" decimals="-3" id="ixv-20775" unitRef="usd">208000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c5" decimals="-3" id="ixv-20776" unitRef="usd">96000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c4" decimals="-3" id="ixv-20777" unitRef="usd">66000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c5" decimals="-3" id="ixv-20778" unitRef="usd">55000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryNet contextRef="c4" decimals="-3" id="ixv-20779" unitRef="usd">735000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c5" decimals="-3" id="ixv-20780" unitRef="usd">444000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-16131">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 7 - PROPERTY AND EQUIPMENT, NET:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;For the year ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;R&amp;amp;D&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; font-weight: bold"&gt;At January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;535&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;At December 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;107&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in"&gt;&lt;b&gt;At December 31, 2025&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;319&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;87&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;For the year ended December 31, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;R&amp;amp;D&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;At January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;705&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;164&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;At December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;535&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;44&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;116&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;171&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;At December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;As of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;346&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;93&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-16135">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;For the year ended December 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;R&amp;amp;D&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%; font-weight: bold"&gt;At January 1, 2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;535&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;869&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;80&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;103&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;At December 31, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;615&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;107&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;150&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0in"&gt;&lt;b&gt;At December 31, 2025&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;520&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;As of December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;319&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;87&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;452&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;R&amp;amp;D&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;At January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;172&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;705&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;154&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;164&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;At December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;535&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;869&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;44&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;116&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;171&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;At December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;189&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;As of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;346&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;93&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;499&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c43" decimals="-3" id="ixv-20781" unitRef="usd">182000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c44" decimals="-3" id="ixv-20782" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c45" decimals="-3" id="ixv-20783" unitRef="usd">535000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c46" decimals="-3" id="ixv-20784" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-20785" unitRef="usd">869000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c36" decimals="-3" id="ixv-20786" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c40" decimals="-3" id="ixv-20787" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c47" decimals="-3" id="ixv-20788" unitRef="usd">80000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c48" decimals="-3" id="ixv-20789" unitRef="usd">2000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c0" decimals="-3" id="ixv-20790" unitRef="usd">103000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c49" decimals="-3" id="ixv-20791" unitRef="usd">203000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c50" decimals="-3" id="ixv-20792" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c51" decimals="-3" id="ixv-20793" unitRef="usd">615000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c52" decimals="-3" id="ixv-20794" unitRef="usd">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="-3" id="ixv-20795" unitRef="usd">972000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c43" decimals="-3" id="ixv-20796" unitRef="usd">146000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c44" decimals="-3" id="ixv-20797" unitRef="usd">12000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c45" decimals="-3" id="ixv-20798" unitRef="usd">189000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c46" decimals="-3" id="ixv-20799" unitRef="usd">23000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-20800" unitRef="usd">370000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c36" decimals="-3" id="ixv-20801" unitRef="usd">32000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c40" decimals="-3" id="ixv-20802" unitRef="usd">3000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c47" decimals="-3" id="ixv-20803" unitRef="usd">107000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c48" decimals="-3" id="ixv-20804" unitRef="usd">8000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-20805" unitRef="usd">150000</us-gaap:Depreciation>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c49" decimals="-3" id="ixv-20806" unitRef="usd">178000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c50" decimals="-3" id="ixv-20807" unitRef="usd">15000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c51" decimals="-3" id="ixv-20808" unitRef="usd">296000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c52" decimals="-3" id="ixv-20809" unitRef="usd">31000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-20810" unitRef="usd">520000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c49" decimals="-3" id="ixv-20811" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c50" decimals="-3" id="ixv-20812" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c51" decimals="-3" id="ixv-20813" unitRef="usd">319000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c52" decimals="-3" id="ixv-20814" unitRef="usd">87000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-20815" unitRef="usd">452000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c53" decimals="-3" id="ixv-20816" unitRef="usd">172000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c54" decimals="-3" id="ixv-20817" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c55" decimals="-3" id="ixv-20818" unitRef="usd">381000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c56" decimals="-3" id="ixv-20819" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20" decimals="-3" id="ixv-20820" unitRef="usd">705000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c57" decimals="-3" id="ixv-20821" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c58" decimals="-3" id="ixv-20822" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c59" decimals="-3" id="ixv-20823" unitRef="usd">154000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c60" decimals="-3" id="ixv-20824" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c6" decimals="-3" id="ixv-20825" unitRef="usd">164000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c43" decimals="-3" id="ixv-20826" unitRef="usd">182000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c44" decimals="-3" id="ixv-20827" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c45" decimals="-3" id="ixv-20828" unitRef="usd">535000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c46" decimals="-3" id="ixv-20829" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-20830" unitRef="usd">869000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c53" decimals="-3" id="ixv-20831" unitRef="usd">102000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c54" decimals="-3" id="ixv-20832" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c55" decimals="-3" id="ixv-20833" unitRef="usd">73000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c56" decimals="-3" id="ixv-20834" unitRef="usd">16000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20" decimals="-3" id="ixv-20835" unitRef="usd">199000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c57" decimals="-3" id="ixv-20836" unitRef="usd">44000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c58" decimals="-3" id="ixv-20837" unitRef="usd">4000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c59" decimals="-3" id="ixv-20838" unitRef="usd">116000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c60" decimals="-3" id="ixv-20839" unitRef="usd">7000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="-3" id="ixv-20840" unitRef="usd">171000</us-gaap:Depreciation>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c43" decimals="-3" id="ixv-20841" unitRef="usd">146000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c44" decimals="-3" id="ixv-20842" unitRef="usd">12000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c45" decimals="-3" id="ixv-20843" unitRef="usd">189000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c46" decimals="-3" id="ixv-20844" unitRef="usd">23000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-20845" unitRef="usd">370000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c43" decimals="-3" id="ixv-20846" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c44" decimals="-3" id="ixv-20847" unitRef="usd">24000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c45" decimals="-3" id="ixv-20848" unitRef="usd">346000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c46" decimals="-3" id="ixv-20849" unitRef="usd">93000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-20850" unitRef="usd">499000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-16822">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 8 - OTHER ACCOUNTS PAYABLE:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;508&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employees&#x2019; salaries and related liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,349&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,364&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-16827">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;508&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employees&#x2019; salaries and related liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,349&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,364&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-20851" unitRef="usd">506000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-20852" unitRef="usd">508000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-20853" unitRef="usd">429000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-20854" unitRef="usd">414000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <iinn:AccountsPayableToRelatedParties contextRef="c4" decimals="-3" id="ixv-20855" unitRef="usd">384000</iinn:AccountsPayableToRelatedParties>
    <iinn:AccountsPayableToRelatedParties contextRef="c5" decimals="-3" id="ixv-20856" unitRef="usd">421000</iinn:AccountsPayableToRelatedParties>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-20857" unitRef="usd">30000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-20858" unitRef="usd">21000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="-3" id="ixv-20859" unitRef="usd">1349000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c5" decimals="-3" id="ixv-20860" unitRef="usd">1364000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-16900">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9 - COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;A.&#160;Royalties to the IIA:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-indent: -0.7pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2019, the IIA approved a grant to
the Company for the development of intravenous blood oxygenation system for an aggregate budget of NIS&#160;4,880,603 (approximately
$1,500). The IIA committed to fund&#160;60% of the approved budget. Eventually the project budget concluded in the aggregate amount of
NIS 4,623,142 (approximately $1,333). The program is for the period beginning October 2019 through November 2020. From 2019 to 2021,
the Company received total funds in the amount of NIS 2,773,885 (approximately $809) from the IIA, which were recorded as IIA participation
and were deducted from R&amp;amp;D expenses. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In October 2023, the IIA approved a grant to support another development
project of the Company at an aggregate budget of NIS&#160;3,850,869 (approximately $1,062). The IIA committed to fund&#160;40% of the
approved budget. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The program is for the period beginning January
2024 through March 2025, and as of December 31, 2025, the Company received total funds in the amount of NIS 1,410,925 (approximately
$385) from the IIA, which were recorded as IIA participation and were deducted from the R&amp;amp;D expenses. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;According to the agreements with the IIA, the
Company will pay royalties of&#160;3% of future sales up to an amount equal to the accumulated grant received linked to the USD and bearing
interest at an annual rate of SOFR. Repayment of the grants are contingent upon the successful completion of the Company&#x2019;s R&amp;amp;D
programs and generating sales. The Company has no obligation to repay these grants if the R&amp;amp;D programs fail, are unsuccessful or
aborted or if no sales are generated. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During 2025 the Company generated revenues in
the amount of approximately $289; accordingly, royalties to the IIA in the amount of $9 were incurred and recorded as cost of sales,
and were paid during the year. As of December 31, 2025, the maximum obligation with respect to the grants received from the IIA, contingent
upon entitled future sales, is $1,363 includes SOFR interest and after deduction of the royalties payment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has obligations regarding know-how,
technology, or products, not to transfer the information, rights thereon and production rights which derive from the research and development
without the IIA Research Committee approval.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;B.&#160; Legal Claims&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the normal course of business, various legal
claims and other contingent matters may arise. Management believes that any liability that may arise from such matters would not have
a material adverse effect on the Company&#x2019;s results of operations or financial condition as of and for the years ended December
31, 2025, and 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 12, 2021, the Company terminated
its employment agreement with Dr. Udi Nussinovitch, one of its founders who served as the Company&#x2019;s Chief Scientific Officer since
March 2018. On February 24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and
former officer of the Company. On November 9, 2022, Mr. Nussinovitch filed a Statement of Claim against the Company, as well as a Statement
of Claim with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch alleged certain deficiencies in the
Company&#x2019;s&#160;Extraordinary General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a
minority shareholder. In addition, with respect to the labor dispute, Mr.&#160;Nussinovitch is seeking renumeration and the issuance
of Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 19, 2023, a partial hearing about the
labor dispute was held, in which the parties were required by the court to file their positions on a stay of the proceeding pending the
decision on the case initiated by Mr. Nussinovitch in the District Court. On January 21, 2024, a partial hearing about the civil case
was held. During the hearing, the court suggested the parties consider the possibility of resolving the case through an out-of-court
arrangement or mediation. The parties agreed to a mediation process which did not succeed.&#160;&#160;On January 7, 2025,&#160;Mr. Nussinovitch&#160;filed
a motion to amend his Statement of Claim, requesting to modify the requested relief. Instead of the original remedies sought,&#160;Mr.
Nussinovitch&#160;now requests that the Company or Mr. Ben Noon and Mr. Hayon purchase all of his rights and shares in the Company at
their average value from the date of the Company&#x2019;s initial public offering until the date of the general meeting held on December
17, 2021. On January 13, 2025, a pretrial hearing was held. The court denied Mr. Nussinovitch&#x2019;s motion to amend and instructed
him to notify whether he wishes to withdraw his original claim or maintain it.,&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 14, 2025, Mr. Nussinovitch informed
the court that he would proceed with the original claim, despite the court&#x2019;s instruction to address the Company&#x2019;s motion
to dismiss and explain how the case could continue after he had stated it was moot. On May 7, 2025, the court partially granted the motion
to dismiss, ruling that continuation of the case is subject to payment of court fees. Claims deemed no longer relevant by Mr. Nussinovitch
were dismissed, including requests to nullify past resolutions, reverse his removal from the board, challenge director independence,
invalidate certain decisions, and appoint an auditor. The court allowed certain declaratory claims to proceed, including allegations
of breach of duties, minority oppression, and wrongful removal from the board. The remaining operative claim&#x2014;entitlement to benefits
granted to controlling shareholders&#x2014;also requires payment of court fees. A preliminary hearing was held on September 8, 2025, setting
deadlines for witness statements. On September 18, 2025, Mr. Nussinovitch agreed to dismiss claims against the directors of the Company.
On December 8, 2025, he submitted his witness statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company believes that it is&#160;not probable&#160;that
a payment will be required to settle this matter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accordingly, in accordance with ASC 450,&#160;no
provision has been recorded&#160;in the financial statements&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <iinn:AggregateBudget contextRef="c61" decimals="-3" id="ixv-20861" unitRef="ils">4880603000</iinn:AggregateBudget>
    <iinn:AggregateBudget contextRef="c61" decimals="-3" id="ixv-20862" unitRef="usd">1500000</iinn:AggregateBudget>
    <iinn:PercentageOfApprovedBudget contextRef="c61" decimals="2" id="ixv-20863" unitRef="pure">0.60</iinn:PercentageOfApprovedBudget>
    <iinn:ProjectBudgetAggregateAmount contextRef="c61" decimals="-3" id="ixv-20864" unitRef="ils">4623142000</iinn:ProjectBudgetAggregateAmount>
    <iinn:ProjectBudgetAggregateAmount contextRef="c61" decimals="-3" id="ixv-20865" unitRef="usd">1333000</iinn:ProjectBudgetAggregateAmount>
    <us-gaap:OtherReceivables contextRef="c62" decimals="-3" id="ixv-20866" unitRef="ils">2773885000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c62" decimals="-3" id="ixv-20867" unitRef="usd">809000</us-gaap:OtherReceivables>
    <iinn:AggregateBudget contextRef="c63" decimals="-3" id="ixv-20868" unitRef="ils">3850869000</iinn:AggregateBudget>
    <iinn:AggregateBudget contextRef="c63" decimals="-3" id="ixv-20869" unitRef="usd">1062000</iinn:AggregateBudget>
    <iinn:PercentageOfApprovedBudget contextRef="c63" decimals="2" id="ixv-20870" unitRef="pure">0.40</iinn:PercentageOfApprovedBudget>
    <us-gaap:OtherReceivables contextRef="c4" decimals="-3" id="ixv-20871" unitRef="ils">1410925000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c4" decimals="-3" id="ixv-20872" unitRef="usd">385000</us-gaap:OtherReceivables>
    <iinn:RoyaltiesPercentage contextRef="c0" decimals="2" id="ixv-20873" unitRef="pure">0.03</iinn:RoyaltiesPercentage>
    <us-gaap:Revenues contextRef="c0" decimals="-3" id="ixv-20874" unitRef="usd">289000</us-gaap:Revenues>
    <us-gaap:DerivativeLiabilities contextRef="c4" decimals="-3" id="ixv-20875" unitRef="usd">9000</us-gaap:DerivativeLiabilities>
    <iinn:ContingentUponFutureSales contextRef="c4" decimals="-3" id="ixv-20876" unitRef="usd">1363000</iinn:ContingentUponFutureSales>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-16969">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 - LEASE LIABILITIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Lease Commitments &#x2013; Operating Leases:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2021, the Company entered into a
lease agreement for its facilities in Ra&#x2019;anana, Israel. The lease agreement is for a period of 69 months commencing September 1,
2021, and the Company began to pay lease and related expenses after completing 3 months of lease. The Company has the option to shorten
the period and terminates the lease agreement after completing 45 months of rent by paying an amount of NIS 500,000, (approximately $157).
This amount of reimbursement will be deducted monthly in NIS 30,000, (approximately $9) if the Company terminates the agreement after
45 months of rent. The Company is reasonably certain that it will not exercise the termination option. During 2025, the monthly lease
payment, including management fees, was approximately NIS 69,000 ($20). As security for the obligations under this lease agreement, the
Company provided a bank guarantee in an amount equal to three monthly lease payments plus the Israeli value added tax and an unlimited
guarantee according to the terms specified in the contract.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 27, 2025, the Company signed a new lease
agreement replacing the prior lease agreement for a new period of 60 months starting at the date of the facility acceptance by the Company.
According to the new lease agreement, the Company has the option to shorten the period and terminate the lease agreement after completing
48 months of rent by paying an amount of NIS 650,000 (approximately $204). This amount of reimbursement will be deducted monthly in NIS
50,000, (approximately $16) if the Company terminates the agreement after the 48 months of rent. The new rent agreement started on January
2026, therefore, as of December 31, 2025, the Company did not incur any operating liability or lease assets regarding the new lease agreement.
&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has various operating leases for
vehicles that expire through 2028. The Company leases vehicles for approximately three-year periods from multiple different leasing companies
and from time to time increases or decreases the number of leased vehicles according to its current needs. The leased vehicles are used
by the Company&#x2019;s headquarters staff and other employees whose employment agreements include an obligation to the Company to provide
a vehicle. The agreements with the leasing companies include termination options, allowing for early cancellation by paying a penalty
of up to 400% of the monthly costs. The Company is reasonably certain that it will not exercise this option or that the employee will
bear the cost for early termination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The total expenses related to the leases were
$469&#160;for the year ended December 31, 2025, and $390&#160;for the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The right-of-use asset and lease liability are
initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate
cannot be readily determined, the Company&#x2019;s incremental borrowing rate based on the information available at the date of determining
the present value of the lease payments. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s incremental borrowing rate
is estimated to approximate the interest rate on similar terms and payments and in economic environments where the leased asset is located.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has various operating leases for
vehicles that expire through 2028. Below is a summary of the Company&#x2019;s operating right-of-use assets and operating lease liabilities
as of December 31, 2025, and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 80%; text-align: left"&gt;Operating lease liabilities, current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;277&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating lease liabilities long-term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;194&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;378&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;655&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average of remaining lease term&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.74&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average discount rate - operating leases&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Lease payments for the Company&#x2019;s right-of-use
assets over the remaining lease periods as of December 31, 2025, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;U.S.&#160;dollars&lt;br/&gt; in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 90%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;201&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total undiscounted lease payment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;525&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Interest (*)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(45&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Future lease payments were discounted by&#160;7.98%-25.59% interest
rate.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:PaymentsForRent contextRef="c64" decimals="-3" id="ixv-20877" unitRef="ils">500000000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c64" decimals="-3" id="ixv-20878" unitRef="usd">157000</us-gaap:PaymentsForRent>
    <iinn:MonthlyDeductionFromTerminationFee contextRef="c64" decimals="-3" id="ixv-20879" unitRef="ils">30000000</iinn:MonthlyDeductionFromTerminationFee>
    <iinn:MonthlyDeductionFromTerminationFee contextRef="c64" decimals="-3" id="ixv-20880" unitRef="usd">9000</iinn:MonthlyDeductionFromTerminationFee>
    <iinn:LeaseMonthlyPayment contextRef="c0" decimals="-3" id="ixv-20881" unitRef="ils">69000000</iinn:LeaseMonthlyPayment>
    <iinn:LeaseMonthlyPayment contextRef="c0" decimals="-3" id="ixv-20882" unitRef="usd">-20000</iinn:LeaseMonthlyPayment>
    <us-gaap:PaymentsForRent contextRef="c65" decimals="-3" id="ixv-20883" unitRef="ils">650000000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c65" decimals="-3" id="ixv-20884" unitRef="usd">204000</us-gaap:PaymentsForRent>
    <iinn:MonthlyDeductionFromTerminationFee contextRef="c65" decimals="-3" id="ixv-20885" unitRef="ils">50000000</iinn:MonthlyDeductionFromTerminationFee>
    <iinn:MonthlyDeductionFromTerminationFee contextRef="c65" decimals="-3" id="ixv-20886" unitRef="usd">16000</iinn:MonthlyDeductionFromTerminationFee>
    <iinn:PercentageForCarsLeaseAgreementCancellationPenalty contextRef="c0" id="ixv-20887">up to 400%</iinn:PercentageForCarsLeaseAgreementCancellationPenalty>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" id="ixv-20888" unitRef="usd">469000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c6" decimals="-3" id="ixv-20889" unitRef="usd">390000</us-gaap:OperatingLeaseExpense>
    <iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock contextRef="c0" id="ixv-20890">Below is a summary of the Company&#x2019;s operating right-of-use assets and operating lease liabilities
as of December 31, 2025, and 2024:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 80%; text-align: left"&gt;Operating lease liabilities, current&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;277&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Operating lease liabilities long-term&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;194&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;378&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;655&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average of remaining lease term&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.74&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Weighted-average discount rate - operating leases&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-20891" unitRef="usd">286000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-20892" unitRef="usd">277000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-20893" unitRef="usd">194000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="-3" id="ixv-20894" unitRef="usd">378000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-20895" unitRef="usd">480000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-20896" unitRef="usd">655000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="ixv-20897">P1Y8M26D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-20898">P2Y6M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="4" id="ixv-20899" unitRef="pure">0.1127</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="4" id="ixv-20900" unitRef="pure">0.0992</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-17139">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Lease payments for the Company&#x2019;s right-of-use
assets over the remaining lease periods as of December 31, 2025, are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold"&gt;Year ended December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;U.S.&#160;dollars&lt;br/&gt; in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 90%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;324&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;201&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total undiscounted lease payment&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;525&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Interest (*)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(45&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;480&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Future lease payments were discounted by&#160;7.98%-25.59% interest
rate.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c4" decimals="-3" id="ixv-20901" unitRef="usd">324000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c4" decimals="-3" id="ixv-20902" unitRef="usd">201000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c4" decimals="-3" id="ixv-20903" unitRef="usd">525000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c4" decimals="-3" id="ix_0_fact" unitRef="usd">45000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-20905" unitRef="usd">480000</us-gaap:OperatingLeaseLiability>
    <iinn:PercentageOfFutureLeasePaymentsDiscounted contextRef="c66" decimals="4" id="ixv-20907" unitRef="pure">0.0798</iinn:PercentageOfFutureLeasePaymentsDiscounted>
    <iinn:PercentageOfFutureLeasePaymentsDiscounted contextRef="c67" decimals="4" id="ixv-20908" unitRef="pure">0.2559</iinn:PercentageOfFutureLeasePaymentsDiscounted>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-17201">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 - FINACIAL LIABILITIES AT FAIR
VALUE:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Financial liability (A)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Private warrants (B)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;786&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,506&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,082&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,575&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;A Financial Liability&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company agreed to pay fees of 4% from the funds that will be received in an event of exercise of part of the Company&#x2019;s ordinary warrants that were issued in a certain December 2024 private placement which created a financial liability presented on the total potential amount which was $46 as of December 31, 2025 &#160;and $69 as of December 31, 2024 (Note 11).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The Company agreed to pay a commitment fee in the amount of &lt;b&gt;$&lt;/b&gt;500, representing 2% of the $25 million SEPA. As of December 31,2025, the first half of the commitment fees was settled while the second tranche of the commitment fee amount, which represents 1% of the SEPA, settled on the 30-day anniversary of the SEPA through the issuance of a variable number of ordinary shares determined based on the VWAP formula defined therein, created a financial liability in amount of $250, measured at fair value through profit or loss until settlement. As of the date of these Financial Statements, the settlement amount of the committee fee shares were issued and transfer to the investor (see note 12(13)).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The financial liability as of December
31, 2025, and 2024 is $296 and $69 respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;B Private warrants &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 26, 2023, the Company entered into
a certain securities purchase agreement (Note 11.3), pursuant to which it issued unregistered warrants, to purchase up to an aggregate
of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (the &#x201c;Private Warrants&#x201d;). The Private Warrants were exercisable
immediately upon issuance and will expire three and a half years following their issuance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Private Warrants include cashless exercise
mechanism, according to the terms specified in the agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Private Warrants may create obligation to
transfer cash to the investors at fundamental transactions within the Black Scholes option pricing framework.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Therefore, the Company accounts for the Private
Warrants as financial liability instruments that are measured at fair value and recognized financial expenses or income through profit
and loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The company measured fair value by using Black-Scholes
option pricing model;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The key inputs that were used in the Private
Warrants fair value as of December 31, 2024, were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;risk-free interest rate 4.26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;expected volatility 88.61%&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;expected dividend yield of
0%&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;expected term of warrants &#x2013; 2.5 years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The key inputs that were used in the Private
Warrants fair value as of December 31, 2025, were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;risk-free interest rate 3.48%&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;expected volatility 80.59%&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;expected dividend yield of
0%&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;expected term of warrants &#x2013;
1.5 years.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the Private Warrants as of
December 31, 2025 and 2024 was $786 and $1,506 respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;C&lt;b&gt;. Standby Equity Purchase Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 12, 2025, the Company entered into
the SEPA with Yorkville pursuant to which the Company has the right to sell to Yorkville up to &lt;span style="-sec-ix-hidden: hidden-fact-0"&gt;$25,000&lt;/span&gt; of Ordinary Shares, subject to
certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA. The Company also entered into
a Registration Rights Agreement with Yorkville pursuant to which it will register the resale of Ordinary Shares issued to Yorkville pursuant
to the SEPA. Sales of Ordinary Shares to Yorkville under the SEPA, and the timing of any such sales, are at the Company&#x2019;s option,
and the Company is under no obligation to sell Ordinary Shares to Yorkville under the SEPA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each advance (each, an &#x201c;Advance&#x201d;)
the Company requests in writing to Yorkville under the SEPA (notice of such request, an &#x201c;Advance Notice&#x201d;) may be for a number
of Ordinary Shares. The Ordinary Shares purchased pursuant to an Advance delivered by the Company will be purchased at a price equal
to 97% of the lowest daily VWAP of the Ordinary Shares during the three consecutive trading days commencing on the date of the delivery
of the Advance Notice, other than the daily VWAP on a day in which the daily VWAP is less than a minimum acceptable price as stated by
the Company in the Advance Notice or there is no VWAP on the subject trading day. The Company may establish a minimum acceptable price
in each Advance Notice below which the Company will not be obligated to make any sales to Yorkville. &#x201c;VWAP&#x201d; is defined as
the daily volume weighted average price of the Ordinary Shares for such trading day on the Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;)
during regular trading hours as reported by Bloomberg L.P.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The SEPA will automatically terminate on December
12, 2028. The Company has the right to terminate the SEPA at no cost or penalty upon five trading days&#x2019; prior written notice to
Yorkville, provided that there are no outstanding Advance Notices for which Ordinary Shares need to be issued and the Company has paid
all amounts owed to Yorkville. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Any purchase under an Advance would be subject
to certain limitations, including that Yorkville shall not purchase or acquire any shares that would result in it and its affiliates
beneficially owning more than 4.99% of the then outstanding voting power or number of Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In connection with
the execution of the SEPA, the Company agreed to pay a legal and structuring fee in the amount of $25, of which (a) $15 has been paid
prior to the execution date, and (b) $10 has been paid within 3 days of the execution of the agreement. The company also agreed to pay
a commitment fee of $500 in ordinary shares to Yorkville, payable as follows: (i) $250 has been paid three days following the date the
SEPA was entered into, in the form of the issuance of 218,627 Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date, and (ii) $250 has been paid on the 30-day
anniversary of the date of the SEPA in the form of the issuance of Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date. The Commitment Shares issuable hereunder were
included in the initial Registration Statement. Throughout the month ended December 31, 2025, the Company did not issue any&lt;/span&gt;&#160;&lt;span style="font-size: 10pt"&gt;Ordinary
Shares pursuant to the SEPA.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="c0" id="ixv-17205">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December&#160;31, &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Financial liability (A)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Private warrants (B)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;786&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,506&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,082&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,575&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c88" decimals="-3" id="ixv-20909" unitRef="usd">296000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c89" decimals="-3" id="ixv-20910" unitRef="usd">69000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c90" decimals="-3" id="ixv-20911" unitRef="usd">786000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c91" decimals="-3" id="ixv-20912" unitRef="usd">1506000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-20913" unitRef="usd">1082000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-20914" unitRef="usd">1575000</us-gaap:DerivativeLiabilitiesCurrent>
    <iinn:PercentageOfPayFees contextRef="c68" decimals="2" id="ixv-20915" unitRef="pure">0.04</iinn:PercentageOfPayFees>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c69" decimals="-3" id="ixv-20916" unitRef="usd">46000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c70" decimals="-3" id="ixv-20917" unitRef="usd">69000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:PaymentsForFees contextRef="c71" decimals="-3" id="ixv-20918" unitRef="usd">500000</us-gaap:PaymentsForFees>
    <iinn:PercentageOfPayFees contextRef="c71" decimals="2" id="ixv-20919" unitRef="pure">0.02</iinn:PercentageOfPayFees>
    <us-gaap:OtherCommitment contextRef="c72" decimals="-6" id="ixv-20920" unitRef="usd">25000000</us-gaap:OtherCommitment>
    <iinn:PercentageOfPayFees contextRef="c73" decimals="2" id="ixv-20921" unitRef="pure">0.01</iinn:PercentageOfPayFees>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c72" decimals="-3" id="ixv-20922" unitRef="usd">250000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c4" decimals="-3" id="ixv-20923" unitRef="usd">296000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c5" decimals="-3" id="ixv-20924" unitRef="usd">69000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c74"
      decimals="0"
      id="ixv-20925"
      unitRef="shares">3031250</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c75"
      decimals="2"
      id="ixv-20926"
      unitRef="usdPershares">1.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c76" decimals="2" id="ixv-20927" unitRef="pure">4.26</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c77" decimals="2" id="ixv-20928" unitRef="pure">88.61</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c78" decimals="0" id="ixv-20929" unitRef="pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c79" decimals="1" id="ixv-20930" unitRef="pure">2.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c80" decimals="2" id="ixv-20931" unitRef="pure">3.48</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c81" decimals="2" id="ixv-20932" unitRef="pure">80.59</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c82" decimals="0" id="ixv-20933" unitRef="pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c83" decimals="1" id="ixv-20934" unitRef="pure">1.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c84" decimals="-3" id="ixv-20935" unitRef="usd">786000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c85" decimals="-3" id="ixv-20936" unitRef="usd">1506000</us-gaap:WarrantsAndRightsOutstanding>
    <iinn:OrdinarySharesPurchasePricePercentage contextRef="c87" decimals="2" id="ixv-20937" unitRef="pure">0.97</iinn:OrdinarySharesPurchasePricePercentage>
    <us-gaap:CommonStockVotingRights contextRef="c71" id="ixv-20938">Yorkville shall not purchase or acquire any shares that would result in it and its affiliates
beneficially owning more than 4.99% of the then outstanding voting power or number of Ordinary Shares.</us-gaap:CommonStockVotingRights>
    <iinn:DescriptionOfFeePayments contextRef="c71" id="ixv-20939">the Company agreed to pay a legal and structuring fee in the amount of $25, of which (a) $15 has been paid
prior to the execution date, and (b) $10 has been paid within 3 days of the execution of the agreement. The company also agreed to pay
a commitment fee of $500 in ordinary shares to Yorkville, payable as follows: (i) $250 has been paid three days following the date the
SEPA was entered into, in the form of the issuance of 218,627 Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date, and (ii) $250 has been paid on the 30-day
anniversary of the date of the SEPA in the form of the issuance of Ordinary Shares, representing $250 divided by the average of the daily
VWAPs of the Ordinary Shares during the 3 Trading Days immediately prior to such due date. The Commitment Shares issuable hereunder were
included in the initial Registration Statement. Throughout the month ended December 31, 2025, the Company did not issue any&#160;Ordinary
Shares pursuant to the SEPA.</iinn:DescriptionOfFeePayments>
    <us-gaap:LegalFees contextRef="c71" decimals="-3" id="ixv-20940" unitRef="usd">25000</us-gaap:LegalFees>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-17452">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 12 - SHAREHOLDERS&#x2019; EQUITY:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;A. Share capital:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of shares as of&lt;br/&gt; December 31,&#160;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of shares as of&lt;br/&gt; December 31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 2.5pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"&gt;35,949,247&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"&gt;24,252,096&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On April 4, 2023, the Company entered into a sales agreement (the &#x201c;Roth Sales Agreement&#x201d;) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (&#x201c;Roth ATM&#x201d;). In 2023, the Company sold 17,566 Ordinary Shares under the Roth ATM. On October 23, 2023, the Company terminated the Roth Sales Agreement and the associated Roth ATM, effective immediately.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On December 26, 2023, the Company entered into a securities purchase agreement with an institutional investor in a registered direct offering , pursuant to which the Company issued (i) 1,375,000 Ordinary Shares at a purchase price of $1.28 per share, (ii) pre-funded warrants, to purchase up to 1,656,250 Ordinary Shares, at a purchase price of $1.28, less $0.001 per pre-funded warrant and (iii) Private Warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (Note 10-B).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company concluded that the pre-funded
warrants are not within the scope of ASC480. Further, applying ASC 815-40, the Company concluded that the pre-funded warrants are indexed
to the Company&#x2019;s own stock and meet the conditions for equity classification, and thus should be presented within equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As for the Private Warrants, the Company
concluded that they should be classified as a liability under ASC 815-40, as they are not indexed to the Company&#x2019;s own stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The pre-funded warrants were exercised
on the same day and the day after the transaction in full in an exercise price of $0.001 per share and the Company issued 1,656,250 additional
Ordinary Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The aggregate proceeds received by
the Company from the December 2023 offering were approximately $3,424, after deducting underwriting discounts and commissions and additional
cash offering costs totaled in approximately $454.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company issued the placement agent
in the December 2023 offering a number of warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction,
total to 212,188 warrants to purchase up to 212,188 Ordinary Shares, were issued (the &#x201c;Placement Agent Warrants&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Placement Agent Warrants were substantially
on the same terms as the Private Warrants issued to the investor in the offering, except an exercise price of $1.60 per share. The Placement
Agent Warrants were exercisable immediately upon issuance and will expire five years following their issuance. The Company accounts for
the Placement Agent Warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC
718. The fair value of the Placement Agent Warrants at the issuance date was $131.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Those cash and non-cash issuance costs
were accounted proportionally to issuance expenses and decrease of additional paid in capital, according to the ratio of the liability
versus equity in the December 2023 offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During the year ended December 31, 2023, the Company issued an aggregate amount of 1,226,448 Ordinary Shares in connection with vested RSUs and an additional 37,972 Ordinary Shares in connection with option exercises.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On April 1, 2024, the Company completed offering, whereby the Company sold 1,339,285 Ordinary Shares at a purchase price of $1.232 per share. The gross proceeds received by the Company from this offering were approximately $1,651.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On May 20, 2024, the Company issued warrant to purchase 220,000 Ordinary Shares to a service provider, at an exercise price of $2.25 per share. These warrants are immediately exercisable and are due to expire six months from the initial issuance date. The Company accounting treatment for those warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $125. The warrants were not exercised within the designated timeframe and expired on November 21, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On June 14, 2024, the Company completed an offering, whereby the Company sold: (i) 941,541 Ordinary Shares at a purchase price of $1.30 per share, and (ii) pre-funded warrants to purchase up to 1,709,760 Ordinary Shares, at a purchase price of $1.30, less $0.001 per pre-funded warrant. Each pre-funded warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. As of December 31, 2024, all of the pre-funded warrants were exercised, and the company issued 1,709,760 Ordinary Shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Net proceeds received by the Company
from the 2024 June Offering were approximately $3,102, after deducting cash offering costs which were approximately $343.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company also received $2 from an
exercise of the June Pre-Funded Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company concluded that the pre-funded
warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded that the June Pre-Funded Warrants are
indexed to the Company&#x2019;s own stock and meet the conditions for equity classification, and thus should be presented within equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company issued the placement agent
in this offering warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction. A total of185,591
warrants to purchase up to 185,591 Ordinary Shares were issued. The placement agent warrants had an exercise price of $1.56 per share.
The placement agent warrants were exercisable immediately upon issuance and will expire four years following their issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company accounting treatment for
the placement agent warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC
718. The fair value of the placement agent warrants at the issuance date was $254.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The cash and non-cash issuance costs
were recorded against additional paid in capital, due to the classification of the Ordinary Shares and the pre-funded warrants as equity
instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On June 30, 2024, the Company issued 45,000 Ordinary Shares to an advisor in connection with a consulting service agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On December 27, 2024, the Company completed private placement, whereby the Company sold (i) 3,950,343 Ordinary Shares and private warrants to purchase up to 3,950,343 Ordinary Shares at a purchase price of $0.70 per unit, and (ii) pre-funded warrants to purchase up to 658,372 Ordinary Shares and private warrants to purchase up to 658,372 Ordinary Shares, at a purchase price of $0.70, less $0.001 per unit with pre-funded warrant. Each pre-funded warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. Each private warrant is exercisable for one Ordinary Share at an exercise price of $1.10 per share. The private warrants are immediately exercisable and may be exercised at any time until the end of June 2026. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. As of December 31, 2025, all pre-funded warrants and amount of 855,714 of private warrants were exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company concluded that the private
warrants and pre-funded warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded that the private
warrants and pre-funded warrants are indexed to the Company&#x2019;s own stock and meet the conditions for equity classification, and
thus should be presented within equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The gross proceeds received by the
Company from the private offering were approximately $3,228, before deducting underwriting discounts and commissions and additional cash
offering costs totaled approximately $233. In addition, the Company agreed to pay fees of 4% from the funds that may be received in an
event of exercise of part of the Company&#x2019;s private warrants issued in December 2024 which created a financial liability in amount
of $69 which is the total potential amount (Note 10-A) following the exercise of 855,714 of the private warrants , the financial liability
as of December 31, 2025 is $46.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The cash and non-cash issuance costs
were recorded against additional paid in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;9.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;During the year ended December
31, 2024, the Company issued an aggregate amount of 594,943 Ordinary Shares in connection with vested RSUs and an additional 19,048 Ordinary
Shares in connection with option exercises.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;10.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On March 14, 2025, the Company entered into a sales agreement
with A.G.P./Alliance Global Partners, as sales agent, pursuant to which the Company could offer and sell, from time to time, through
the sales agent, Ordinary Shares pursuant to the March 2025 ATM, having an aggregate offering price of up to $1,019. On April 10, 2025,
the maximum aggregate offering price was increased to $1,917, On July 01, 2025, the maximum aggregate offering price was increased to
$7,118. On September 16, 2025, the maximum aggregate offering price was increased to total $14,687. As of December 31, 2025, the Company
sold 5,485,898 Ordinary Shares under the March 2025 ATM for aggregate gross proceeds of approximately $4,888, before deducting offering
costs of approximately $272.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;11.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On August 8, 2025, the Company issued 100,000 Ordinary Shares
to an advisor in connection with a consulting service agreement.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;12.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On December 12, 2025, the Company completed its 2025 December
Offering, whereby the Company sold 1,565,217 Ordinary Shares at a purchase price of $1.15 per ordinary share The gross proceeds received
by the Company from the offering were $1,800.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;13.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On December 17, the Company issued 218,627 Ordinary Shares,
in connection with the commitment fees issuable pursuant to the terms of the SEPA.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;14.&lt;/td&gt;&lt;td style="text-align: justify"&gt;During the year ended December 31, 2025, the Company issued
an aggregate amount of 2,711,947 Ordinary Shares in connection with vested RSUs and an additional 101,376 Ordinary Shares in connection
with option exercises.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;B. Warrants reserves -&lt;/b&gt;Composition and
movements:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following table reconciles the movement in warrants outstanding at the beginning and end of the period:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.8pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted-average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted average remaining contractual term&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; font-weight: bold; padding-bottom: 1pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;7,728,611&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1.63&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 9pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-1"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,514,086&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(277,835&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5.5&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.54&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold"&gt;Balance as of December 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5,936,690&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4.20&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.80&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 29px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The following table summarizes information about the Company&#x2019;s outstanding warrants as of December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrants&lt;br/&gt; outstanding&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Expiration date&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 31%; text-align: center"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 31%; text-align: right"&gt;1,640,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 32%; text-align: center; padding-left: 1.4pt"&gt;15/07/2026&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;6.875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;15/01/2027&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;212,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;28/06/2027&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;1.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;185,591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;14/06/2028&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;1.1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,753,001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 1.4pt"&gt;30/06/2026&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Balance as of December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,936,690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;C. Loss per share:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Loss per share has been calculated using the
weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant financial periods, the weighted average
number of equity shares in issue and profit for the period as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss for the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt"&gt;Total number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;35,949,247&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,252,096&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,652,176&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average number of Ordinary Shares and pre-funded warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,623,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,515,545&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,095,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Basic and diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.93&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="c0" id="ixv-17460">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of shares as of&lt;br/&gt; December 31,&#160;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of shares as of&lt;br/&gt; December 31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Issued and outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 2.5pt"&gt;Ordinary shares&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"&gt;35,949,247&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 2.5pt double; text-align: right"&gt;24,252,096&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c150"
      decimals="INF"
      id="ixv-20941"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c150"
      decimals="INF"
      id="ixv-20942"
      unitRef="shares">35949247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c151"
      decimals="INF"
      id="ixv-20943"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c151"
      decimals="INF"
      id="ixv-20944"
      unitRef="shares">24252096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c92"
      decimals="0"
      id="ixv-20945"
      unitRef="shares">17566</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c93"
      decimals="0"
      id="ixv-20946"
      unitRef="shares">1375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iinn:PurchasePricePerShare
      contextRef="c94"
      decimals="2"
      id="ixv-20947"
      unitRef="usdPershares">1.28</iinn:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c95"
      decimals="0"
      id="ixv-20948"
      unitRef="shares">1656250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <iinn:PurchasePricePerShare
      contextRef="c96"
      decimals="2"
      id="ixv-20949"
      unitRef="usdPershares">1.28</iinn:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c97"
      decimals="3"
      id="ixv-20950"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:ClassOfPrivateWarrantOrRightOutstanding
      contextRef="c75"
      decimals="0"
      id="ixv-20951"
      unitRef="shares">3031250</iinn:ClassOfPrivateWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c75"
      decimals="2"
      id="ixv-20952"
      unitRef="usdPershares">1.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c95"
      decimals="3"
      id="ixv-20953"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:NumberofAdditionalOrdinaryShares
      contextRef="c98"
      decimals="0"
      id="ixv-20954"
      unitRef="shares">1656250</iinn:NumberofAdditionalOrdinaryShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c99" decimals="-3" id="ixv-20955" unitRef="usd">3424000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts contextRef="c20" decimals="-3" id="ixv-20956" unitRef="usd">454000</us-gaap:DeferredOfferingCosts>
    <us-gaap:ProductWarrantyLiquidationProceedsPercentage contextRef="c20" decimals="3" id="ixv-20957" unitRef="pure">0.07</us-gaap:ProductWarrantyLiquidationProceedsPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c100"
      decimals="0"
      id="ixv-20958"
      unitRef="shares">212188</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c101"
      decimals="0"
      id="ixv-20959"
      unitRef="shares">212188</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c102"
      decimals="2"
      id="ixv-20960"
      unitRef="usdPershares">1.6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c102" id="ixv-20961">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c103"
      decimals="-3"
      id="ixv-20962"
      unitRef="usd">131000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c104"
      decimals="0"
      id="ixv-20963"
      unitRef="shares">1226448</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c104"
      decimals="0"
      id="ixv-20964"
      unitRef="shares">37972</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c105"
      decimals="0"
      id="ixv-20965"
      unitRef="shares">1339285</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <iinn:PurchasePricePerShare
      contextRef="c106"
      decimals="3"
      id="ixv-20966"
      unitRef="usdPershares">1.232</iinn:PurchasePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c105"
      decimals="-3"
      id="ixv-20967"
      unitRef="usd">1651000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c107"
      decimals="0"
      id="ixv-20968"
      unitRef="shares">220000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c107"
      decimals="2"
      id="ixv-20969"
      unitRef="usdPershares">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c107" id="ixv-20970">P6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c108"
      decimals="-3"
      id="ixv-20971"
      unitRef="usd">125000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c109"
      decimals="0"
      id="ixv-20972"
      unitRef="shares">941541</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <iinn:PurchasePricePerShare
      contextRef="c110"
      decimals="2"
      id="ixv-20973"
      unitRef="usdPershares">1.3</iinn:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c111"
      decimals="0"
      id="ixv-20974"
      unitRef="shares">1709760</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <iinn:PurchasePricePerShare
      contextRef="c112"
      decimals="2"
      id="ixv-20975"
      unitRef="usdPershares">1.3</iinn:PurchasePricePerShare>
    <iinn:PreFundedWarrantsPerShare
      contextRef="c113"
      decimals="3"
      id="ixv-20976"
      unitRef="usdPershares">0.001</iinn:PreFundedWarrantsPerShare>
    <iinn:NumberOfSharesPerUnits
      contextRef="c114"
      decimals="0"
      id="ixv-20977"
      unitRef="shares">1</iinn:NumberOfSharesPerUnits>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c111"
      decimals="3"
      id="ixv-20978"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c115"
      decimals="0"
      id="ixv-20979"
      unitRef="shares">1709760</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c116"
      decimals="-3"
      id="ixv-20980"
      unitRef="usd">3102000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="c117"
      decimals="-3"
      id="ixv-20981"
      unitRef="usd">343000</us-gaap:DeferredOfferingCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c118"
      decimals="-3"
      id="ixv-20982"
      unitRef="usd">2000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ProductWarrantyLiquidationProceedsPercentage
      contextRef="c119"
      decimals="3"
      id="ixv-20983"
      unitRef="pure">0.07</us-gaap:ProductWarrantyLiquidationProceedsPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c120"
      decimals="0"
      id="ixv-20984"
      unitRef="shares">591</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c119"
      decimals="0"
      id="ixv-20985"
      unitRef="shares">185591</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c121"
      decimals="2"
      id="ixv-20986"
      unitRef="usdPershares">1.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c119" id="ixv-20987">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c122"
      decimals="-3"
      id="ixv-20988"
      unitRef="usd">254000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c123"
      decimals="0"
      id="ixv-20989"
      unitRef="shares">45000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c124"
      decimals="0"
      id="ixv-20990"
      unitRef="shares">3950343</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <iinn:PrivateWarrants
      contextRef="c125"
      decimals="0"
      id="ixv-20991"
      unitRef="shares">3950343</iinn:PrivateWarrants>
    <iinn:PurchasePricePerUnit
      contextRef="c125"
      decimals="2"
      id="ixv-20992"
      unitRef="usdPershares">0.7</iinn:PurchasePricePerUnit>
    <iinn:PreFundedWarrants
      contextRef="c126"
      decimals="0"
      id="ixv-20993"
      unitRef="shares">658372</iinn:PreFundedWarrants>
    <iinn:PrivateWarrants
      contextRef="c127"
      decimals="0"
      id="ixv-20994"
      unitRef="shares">658372</iinn:PrivateWarrants>
    <iinn:PurchasePricePerUnit
      contextRef="c128"
      decimals="2"
      id="ixv-20995"
      unitRef="usdPershares">0.7</iinn:PurchasePricePerUnit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c129"
      decimals="3"
      id="ixv-20996"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:NumberOfSharesPerUnits
      contextRef="c130"
      decimals="0"
      id="ixv-20997"
      unitRef="shares">1</iinn:NumberOfSharesPerUnits>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c126"
      decimals="3"
      id="ixv-20998"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:NumberOfSharesPerUnits
      contextRef="c131"
      decimals="0"
      id="ixv-20999"
      unitRef="shares">1</iinn:NumberOfSharesPerUnits>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c127"
      decimals="2"
      id="ixv-21000"
      unitRef="usdPershares">1.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:IssueOfPrivateWarrantsShares
      contextRef="c4"
      decimals="0"
      id="ixv-21001"
      unitRef="shares">855714</iinn:IssueOfPrivateWarrantsShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c132"
      decimals="-3"
      id="ixv-21002"
      unitRef="usd">3228000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="c133"
      decimals="-3"
      id="ixv-21003"
      unitRef="usd">233000</us-gaap:DeferredOfferingCosts>
    <iinn:PercentageOfPayFees
      contextRef="c134"
      decimals="2"
      id="ixv-21004"
      unitRef="pure">0.04</iinn:PercentageOfPayFees>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c135"
      decimals="-3"
      id="ixv-21005"
      unitRef="usd">69000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <iinn:PrivateWarrantsExerciseShares
      contextRef="c136"
      decimals="0"
      id="ixv-21006"
      unitRef="shares">855714</iinn:PrivateWarrantsExerciseShares>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c137"
      decimals="-3"
      id="ixv-21007"
      unitRef="usd">46000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c138"
      decimals="0"
      id="ixv-21008"
      unitRef="shares">594943</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c138"
      decimals="0"
      id="ixv-21009"
      unitRef="shares">19048</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="c139"
      decimals="-3"
      id="ixv-21010"
      unitRef="usd">1019000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="c140"
      decimals="-3"
      id="ixv-21011"
      unitRef="usd">1917000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="c141"
      decimals="-3"
      id="ixv-21012"
      unitRef="usd">7118000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="c142"
      decimals="-3"
      id="ixv-21013"
      unitRef="usd">14687000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c143"
      decimals="0"
      id="ixv-21014"
      unitRef="shares">5485898</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c143"
      decimals="-3"
      id="ixv-21015"
      unitRef="usd">4888000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="c144"
      decimals="-3"
      id="ixv-21016"
      unitRef="usd">272000</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c145"
      decimals="0"
      id="ixv-21017"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c146"
      decimals="0"
      id="ixv-21018"
      unitRef="shares">1565217</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c147"
      decimals="2"
      id="ixv-21019"
      unitRef="usdPershares">1.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c146"
      decimals="-3"
      id="ixv-21020"
      unitRef="usd">1800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c148"
      decimals="0"
      id="ixv-21021"
      unitRef="shares">218627</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c149"
      decimals="0"
      id="ixv-21022"
      unitRef="shares">2711947</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c149"
      decimals="0"
      id="ixv-21023"
      unitRef="shares">101376</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-17750">&lt;span style="font-size: 10pt"&gt;The following table reconciles the movement in warrants outstanding at the beginning and end of the period:&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted-average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted average remaining contractual term&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; font-weight: bold; padding-bottom: 1pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;7,728,611&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;1.63&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 9pt"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-1"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 9pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,514,086&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.49&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1pt; padding-left: 9pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(277,835&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5.5&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.54&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold"&gt;Balance as of December 31, 2025&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;5,936,690&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4.20&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;0.80&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c152"
      decimals="INF"
      id="ixv-21024"
      unitRef="shares">7728611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c152"
      decimals="2"
      id="ixv-21025"
      unitRef="usdPershares">4.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne contextRef="c153" id="ixv-21026">P1Y7M17D</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsOne>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued
      contextRef="c153"
      decimals="INF"
      id="ixv-21027"
      unitRef="shares">0</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued
      contextRef="c153"
      decimals="0"
      id="ixv-21028"
      unitRef="usdPershares">0</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="c153"
      decimals="INF"
      id="ixv-21029"
      unitRef="shares">-1514086</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="c153"
      decimals="2"
      id="ixv-21030"
      unitRef="usdPershares">1.09</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms contextRef="c153" id="ixv-21031">P0Y5M26D</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="c153"
      decimals="INF"
      id="ixv-21032"
      unitRef="shares">-277835</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue
      contextRef="c153"
      decimals="1"
      id="ixv-21033"
      unitRef="usdPershares">5.5</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms contextRef="c153" id="ixv-21034">P0Y6M14D</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c154"
      decimals="INF"
      id="ixv-21035"
      unitRef="shares">5936690</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c154"
      decimals="2"
      id="ixv-21036"
      unitRef="usdPershares">4.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c153" id="ixv-21037">P0Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c0" id="ixv-17907">&lt;span style="font-size: 10pt"&gt;The following table summarizes information about the Company&#x2019;s outstanding warrants as of December 31, 2025&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Warrants&lt;br/&gt; outstanding&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;
2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Expiration date&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 31%; text-align: center"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 31%; text-align: right"&gt;1,640,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 32%; text-align: center; padding-left: 1.4pt"&gt;15/07/2026&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;6.875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;15/01/2027&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;212,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;28/06/2027&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;1.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;185,591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;14/06/2028&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;1.1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,753,001&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 1.4pt"&gt;30/06/2026&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Balance as of December 31, 2025&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,936,690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c155"
      decimals="1"
      id="ixv-21038"
      unitRef="usdPershares">5.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c155"
      decimals="0"
      id="ixv-21039"
      unitRef="shares">1640455</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c156" id="ixv-21040">2026-07-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c157"
      decimals="3"
      id="ixv-21041"
      unitRef="usdPershares">6.875</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c157"
      decimals="0"
      id="ixv-21042"
      unitRef="shares">145455</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c158" id="ixv-21043">2027-01-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c159"
      decimals="1"
      id="ixv-21044"
      unitRef="usdPershares">1.6</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c159"
      decimals="0"
      id="ixv-21045"
      unitRef="shares">212188</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c160" id="ixv-21046">2027-06-28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c161"
      decimals="2"
      id="ixv-21047"
      unitRef="usdPershares">1.56</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c161"
      decimals="0"
      id="ixv-21048"
      unitRef="shares">185591</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c162" id="ixv-21049">2028-06-14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c163"
      decimals="1"
      id="ixv-21050"
      unitRef="usdPershares">1.1</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c163"
      decimals="0"
      id="ixv-21051"
      unitRef="shares">3753001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c164" id="ixv-21052">2026-06-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c154"
      decimals="0"
      id="ixv-21053"
      unitRef="shares">5936690</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-17994">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Loss per share has been calculated using the
weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant financial periods, the weighted average
number of equity shares in issue and profit for the period as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss for the period&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 9pt"&gt;Total number of Ordinary Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;35,949,247&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24,252,096&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,652,176&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average number of Ordinary Shares and pre-funded warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;29,623,194&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;18,515,545&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,095,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Basic and diluted loss per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.60&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(0.93&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-21054" unitRef="usd">-13220000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-21055" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-21056" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-21057"
      unitRef="shares">35949247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-21058"
      unitRef="shares">24252096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="INF"
      id="ixv-21059"
      unitRef="shares">15652176</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-21060"
      unitRef="shares">29623194</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-21061"
      unitRef="shares">18515545</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ixv-21062"
      unitRef="shares">12095477</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-21063"
      unitRef="usdPershares">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-21064"
      unitRef="usdPershares">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-21065"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-21066"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-21067"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-21068"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-18099">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 13 - REVENUES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025, the Company has only
one stream of revenue from sales of the INSPIRA ART100 systems and carts to a distributor in the U.S, therefore the company has one segment
at this stage.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <iinn:CostOfRevenuesTextBlock contextRef="c0" id="ixv-18107">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 14 - COST OF REVENUES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Materials and subcontractors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;235&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Payroll and related&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Warranty&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Royalties to IIA&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:CostOfRevenuesTextBlock>
    <iinn:ScheduleOfCostOfRevenuesTableTextBlock contextRef="c0" id="ixv-18112">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Materials and subcontractors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;235&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Payroll and related&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Warranty&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Royalties to IIA&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;287&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfCostOfRevenuesTableTextBlock>
    <us-gaap:CostOfRevenue
      contextRef="c165"
      decimals="-3"
      id="ixv-21069"
      unitRef="usd">235000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c166"
      decimals="-3"
      id="ixv-21070"
      unitRef="usd">23000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c167"
      decimals="-3"
      id="ixv-21071"
      unitRef="usd">20000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c168"
      decimals="-3"
      id="ixv-21072"
      unitRef="usd">9000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="-3" id="ixv-21073" unitRef="usd">287000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c0" id="ixv-18187">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 15 - RESEARCH AND DEVELOPMENT EXPENSES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Salary and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,461&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,079&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Materials and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;371&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Subcontractors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;IIA participation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(100&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(286&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;280&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;206&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;268&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,496&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,320&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock contextRef="c0" id="ixv-18192">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Salary and related expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,461&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,079&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,634&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;801&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Materials and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;737&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;371&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;291&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Subcontractors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;IIA participation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(100&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(286&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;280&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;206&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;268&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,496&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,320&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
    <us-gaap:LaborAndRelatedExpense contextRef="c0" decimals="-3" id="ixv-21074" unitRef="usd">4461000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c6" decimals="-3" id="ixv-21075" unitRef="usd">4079000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c7" decimals="-3" id="ixv-21076" unitRef="usd">4429000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c0" decimals="-3" id="ixv-21077" unitRef="usd">1634000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c6" decimals="-3" id="ixv-21078" unitRef="usd">801000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c7" decimals="-3" id="ixv-21079" unitRef="usd">663000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c0" decimals="-3" id="ixv-21080" unitRef="usd">737000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c6" decimals="-3" id="ixv-21081" unitRef="usd">812000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c7" decimals="-3" id="ixv-21082" unitRef="usd">1365000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:DepreciationNonproduction contextRef="c0" decimals="-3" id="ixv-21083" unitRef="usd">334000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c6" decimals="-3" id="ixv-21084" unitRef="usd">371000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c7" decimals="-3" id="ixv-21085" unitRef="usd">291000</us-gaap:DepreciationNonproduction>
    <iinn:Subcontractors contextRef="c0" decimals="-3" id="ixv-21086" unitRef="usd">150000</iinn:Subcontractors>
    <iinn:Subcontractors contextRef="c6" decimals="-3" id="ixv-21087" unitRef="usd">340000</iinn:Subcontractors>
    <iinn:Subcontractors contextRef="c7" decimals="-3" id="ixv-21088" unitRef="usd">304000</iinn:Subcontractors>
    <iinn:IIAParticipation contextRef="c0" decimals="-3" id="ixv-21089" unitRef="usd">100000</iinn:IIAParticipation>
    <iinn:IIAParticipation contextRef="c6" decimals="-3" id="ixv-21090" unitRef="usd">286000</iinn:IIAParticipation>
    <iinn:IIAParticipation contextRef="c7" decimals="-3" id="ixv-21091" unitRef="usd">0</iinn:IIAParticipation>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-21092" unitRef="usd">280000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-21093" unitRef="usd">206000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-21094" unitRef="usd">268000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-21095" unitRef="usd">7496000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-21096" unitRef="usd">6323000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-21097" unitRef="usd">7320000</us-gaap:ResearchAndDevelopmentExpense>
    <iinn:GeneralAndAdministrativeExpensesTextBlock contextRef="c0" id="ixv-18338">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 16 - GENERAL AND ADMINISTRATIVE EXPENSES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,966&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,758&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Director fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Travel abroad&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fundraising expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;45&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,185&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,063&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:GeneralAndAdministrativeExpensesTextBlock>
    <iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock contextRef="c0" id="ixv-18342">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,966&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,758&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,079&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Director fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;239&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office maintenance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;115&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Travel abroad&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fundraising expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;112&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;45&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,532&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,185&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,063&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="c169"
      decimals="-3"
      id="ixv-21098"
      unitRef="usd">1966000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="c170"
      decimals="-3"
      id="ixv-21099"
      unitRef="usd">1758000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="c171"
      decimals="-3"
      id="ixv-21100"
      unitRef="usd">1432000</us-gaap:ProfessionalFees>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c169"
      decimals="-3"
      id="ixv-21101"
      unitRef="usd">1747000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c170"
      decimals="-3"
      id="ixv-21102"
      unitRef="usd">716000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c171"
      decimals="-3"
      id="ixv-21103"
      unitRef="usd">675000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="c169"
      decimals="-3"
      id="ixv-21104"
      unitRef="usd">1079000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="c170"
      decimals="-3"
      id="ixv-21105"
      unitRef="usd">808000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="c171"
      decimals="-3"
      id="ixv-21106"
      unitRef="usd">766000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="c169"
      decimals="-3"
      id="ixv-21107"
      unitRef="usd">178000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="c170"
      decimals="-3"
      id="ixv-21108"
      unitRef="usd">196000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="c171"
      decimals="-3"
      id="ixv-21109"
      unitRef="usd">300000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:LegalFees
      contextRef="c169"
      decimals="-3"
      id="ixv-21110"
      unitRef="usd">175000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="c170"
      decimals="-3"
      id="ixv-21111"
      unitRef="usd">239000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="c171"
      decimals="-3"
      id="ixv-21112"
      unitRef="usd">241000</us-gaap:LegalFees>
    <us-gaap:CostMaintenance
      contextRef="c169"
      decimals="-3"
      id="ixv-21113"
      unitRef="usd">122000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="c170"
      decimals="-3"
      id="ixv-21114"
      unitRef="usd">135000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="c171"
      decimals="-3"
      id="ixv-21115"
      unitRef="usd">129000</us-gaap:CostMaintenance>
    <us-gaap:Depreciation
      contextRef="c169"
      decimals="-3"
      id="ixv-21116"
      unitRef="usd">115000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c170"
      decimals="-3"
      id="ixv-21117"
      unitRef="usd">117000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c171"
      decimals="-3"
      id="ixv-21118"
      unitRef="usd">115000</us-gaap:Depreciation>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="c169"
      decimals="-3"
      id="ixv-21119"
      unitRef="usd">82000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="c170"
      decimals="-3"
      id="ixv-21120"
      unitRef="usd">104000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="c171"
      decimals="-3"
      id="ixv-21121"
      unitRef="usd">100000</us-gaap:TravelAndEntertainmentExpense>
    <iinn:FundraisingExpenses
      contextRef="c169"
      decimals="-3"
      id="ixv-21122"
      unitRef="usd">0</iinn:FundraisingExpenses>
    <iinn:FundraisingExpenses
      contextRef="c170"
      decimals="-3"
      id="ixv-21123"
      unitRef="usd">0</iinn:FundraisingExpenses>
    <iinn:FundraisingExpenses
      contextRef="c171"
      decimals="-3"
      id="ixv-21124"
      unitRef="usd">260000</iinn:FundraisingExpenses>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="c169"
      decimals="-3"
      id="ixv-21125"
      unitRef="usd">68000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="c170"
      decimals="-3"
      id="ixv-21126"
      unitRef="usd">112000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="c171"
      decimals="-3"
      id="ixv-21127"
      unitRef="usd">45000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c169"
      decimals="-3"
      id="ixv-21128"
      unitRef="usd">5532000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c170"
      decimals="-3"
      id="ixv-21129"
      unitRef="usd">4185000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c171"
      decimals="-3"
      id="ixv-21130"
      unitRef="usd">4063000</us-gaap:GeneralAndAdministrativeExpense>
    <iinn:SalesAndMarketingExpensesTextBlock contextRef="c0" id="ixv-18530">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 17 - SALES AND MARKETING EXPENSES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;194&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;89&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;348&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;93&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;754&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;746&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:SalesAndMarketingExpensesTextBlock>
    <iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock contextRef="c0" id="ixv-18535">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;194&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;89&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Salary and related expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;348&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;93&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;61&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;588&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;754&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;746&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c0" decimals="-3" id="ixv-21131" unitRef="usd">194000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c6" decimals="-3" id="ixv-21132" unitRef="usd">250000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c7" decimals="-3" id="ixv-21133" unitRef="usd">89000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:OfficersCompensation contextRef="c0" decimals="-3" id="ixv-21134" unitRef="usd">176000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="c6" decimals="-3" id="ixv-21135" unitRef="usd">266000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="c7" decimals="-3" id="ixv-21136" unitRef="usd">248000</us-gaap:OfficersCompensation>
    <us-gaap:ProfessionalFees contextRef="c0" decimals="-3" id="ixv-21137" unitRef="usd">125000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c6" decimals="-3" id="ixv-21138" unitRef="usd">187000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c7" decimals="-3" id="ixv-21139" unitRef="usd">348000</us-gaap:ProfessionalFees>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-21140" unitRef="usd">93000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-21141" unitRef="usd">51000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-21142" unitRef="usd">61000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-21143" unitRef="usd">588000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-21144" unitRef="usd">754000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-21145" unitRef="usd">746000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="c0" id="ixv-18668">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 18 - FINANCIAL (INCOME) AND EXPENSES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Foreign currency transaction income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(101&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(77&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(339&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(42&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(529&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c0" id="ixv-18673">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(247&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Foreign currency transaction income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(101&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(77&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(339&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(42&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(529&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c0" decimals="-3" id="ixv-21146" unitRef="usd">-247000</iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c6" decimals="-3" id="ixv-21147" unitRef="usd">36000</iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c7" decimals="-3" id="ixv-21148" unitRef="usd">-306000</iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c0" decimals="-3" id="ixv-21149" unitRef="usd">-101000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c6" decimals="-3" id="ixv-21150" unitRef="usd">-77000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c7" decimals="-3" id="ixv-21151" unitRef="usd">-233000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="-3" id="ixv-21152" unitRef="usd">9000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c6" decimals="-3" id="ixv-21153" unitRef="usd">-1000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c7" decimals="-3" id="ixv-21154" unitRef="usd">10000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-21155" unitRef="usd">339000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="-3" id="ixv-21156" unitRef="usd">42000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-21157" unitRef="usd">529000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-18763">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 19 - TAXES ON INCOME: &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Taxes on income:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"&gt;The Israeli corporate
tax rate was 23% in 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Net operating losses carry forwards&lt;/b&gt;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Carryforward tax losses of the Company
as of December 31, 2023, amounted to approximately $24,000; however, a full valuation allowance of $7,000 was recorded against the potential
future tax benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Carryforward tax losses of the Company
as of December 31, 2024, amounted to approximately $29,000; however, a full valuation allowance of $8,000 was recorded against the potential
future tax benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Carryforward tax losses of the Company
as of December 31, 2025, amounted to approximately $41,000; however, a full valuation allowance of $11,000 was recorded against the potential
future tax benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The deferred tax assets and liabilities
are composed of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,404&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;R&amp;amp;D temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,218&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Fund raising costs 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,810&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,097&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Theoretical tax:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Loss before taxation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(13,220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Theoretical tax credit at applicable statutory rate: 23%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,041&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,542&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,596&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-allowable expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(704&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(391&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(244&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Temporary differences and tax losses for which no Deferred Tax Asset is recognized&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,337&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,151&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Effective tax rate reconciliation:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Tax&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;IL statutory tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Non-taxable or non-deductible items:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(166&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(376&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2.8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The primary reconciling item between the Company&#x2019;s statutory
tax rate and the effective tax rate is the recognition of a valuation allowance against of deferred tax assets related to accumulated
net operating losses carried forward, due to uncertainty regarding their realization.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c172"
      decimals="2"
      id="ixv-21158"
      unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c173"
      decimals="2"
      id="ixv-21159"
      unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="c20" decimals="-3" id="ixv-21160" unitRef="usd">24000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsNet contextRef="c20" decimals="-3" id="ixv-21161" unitRef="usd">7000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c5" decimals="-3" id="ixv-21162" unitRef="usd">29000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsNet contextRef="c5" decimals="-3" id="ixv-21163" unitRef="usd">8000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c4" decimals="-3" id="ixv-21164" unitRef="usd">41000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsNet contextRef="c4" decimals="-3" id="ixv-21165" unitRef="usd">11000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-18796">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The deferred tax assets and liabilities
are composed of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,404&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,739&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;R&amp;amp;D temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,218&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Fund raising costs 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,810&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,097&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Net deferred taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" id="ixv-21166" unitRef="usd">9404000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c5" decimals="-3" id="ixv-21167" unitRef="usd">6739000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <iinn:DeferredTaxAssetsAccruedExpenses contextRef="c4" decimals="-3" id="ixv-21168" unitRef="usd">86000</iinn:DeferredTaxAssetsAccruedExpenses>
    <iinn:DeferredTaxAssetsAccruedExpenses contextRef="c5" decimals="-3" id="ixv-21169" unitRef="usd">97000</iinn:DeferredTaxAssetsAccruedExpenses>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c4" decimals="-3" id="ixv-21170" unitRef="usd">1310000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c5" decimals="-3" id="ixv-21171" unitRef="usd">1218000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <iinn:DeferredTaxAssetsFundRaisingCost2023 contextRef="c4" decimals="-3" id="ixv-21172" unitRef="usd">0</iinn:DeferredTaxAssetsFundRaisingCost2023>
    <iinn:DeferredTaxAssetsFundRaisingCost2023 contextRef="c5" decimals="-3" id="ixv-21173" unitRef="usd">35000</iinn:DeferredTaxAssetsFundRaisingCost2023>
    <iinn:DeferredTaxLiabilitiesOperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-21174" unitRef="usd">-10000</iinn:DeferredTaxLiabilitiesOperatingLeaseLiability>
    <iinn:DeferredTaxLiabilitiesOperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-21175" unitRef="usd">-8000</iinn:DeferredTaxLiabilitiesOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="-3" id="ixv-21176" unitRef="usd">10810000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c5" decimals="-3" id="ixv-21177" unitRef="usd">8097000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" id="ixv-21178" unitRef="usd">10810000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="-3" id="ixv-21179" unitRef="usd">8097000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c4" decimals="-3" id="ixv-21180" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c5" decimals="-3" id="ixv-21181" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c4" decimals="-3" id="ixv-21182" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c5" decimals="-3" id="ixv-21183" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <iinn:ScheduleOfTheoreticalTaxTableTextBlock contextRef="c0" id="ixv-18958">&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Theoretical tax:&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Loss before taxation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(13,220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,053&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,286&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Theoretical tax credit at applicable statutory rate: 23%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,041&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,542&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,596&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-allowable expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(704&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(391&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(244&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt"&gt;Temporary differences and tax losses for which no Deferred Tax Asset is recognized&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,337&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,151&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,352&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Income tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfTheoreticalTaxTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-21184" unitRef="usd">-13220000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="-3" id="ixv-21185" unitRef="usd">-11053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="-3" id="ixv-21186" unitRef="usd">-11286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="-3" id="ixv-21187" unitRef="usd">-3041000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="-3" id="ixv-21188" unitRef="usd">-2542000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="-3" id="ixv-21189" unitRef="usd">-2596000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c0" decimals="-3" id="ixv-21190" unitRef="usd">-704000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c6" decimals="-3" id="ixv-21191" unitRef="usd">-391000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c7" decimals="-3" id="ixv-21192" unitRef="usd">-244000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c0" decimals="-3" id="ixv-21193" unitRef="usd">-2337000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c6" decimals="-3" id="ixv-21194" unitRef="usd">-2151000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c7" decimals="-3" id="ixv-21195" unitRef="usd">-2352000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-21196" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c6" decimals="-3" id="ixv-21197" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c7" decimals="-3" id="ixv-21198" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-19074">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Tax&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;IL statutory tax rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Non-taxable or non-deductible items:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;747&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Revaluation of financial liabilities at fair value through profit or loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(166&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Changes in valuation allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(376&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2.8&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="-3" id="ixv-21199" unitRef="usd">-3041000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-21200" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c0" decimals="-3" id="ixv-21201" unitRef="usd">747000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c0" decimals="3" id="ixv-21202" unitRef="pure">-0.057</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <iinn:EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c0" decimals="-3" id="ixv-21203" unitRef="usd">166000</iinn:EffectiveIncomeTaxRateRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <iinn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c0" decimals="3" id="ixv-21204" unitRef="pure">0.013</iinn:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c0" decimals="-3" id="ixv-21205" unitRef="usd">123000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c0" decimals="3" id="ixv-21206" unitRef="pure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="-3" id="ixv-21207" unitRef="usd">2713000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="3" id="ixv-21208" unitRef="pure">-0.205</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c0" decimals="-3" id="ixv-21209" unitRef="usd">-376000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c0" decimals="3" id="ixv-21210" unitRef="pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" id="ixv-21211" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" id="ixv-21212" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-19196">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 20 - SHARE-BASED PAYMENT:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On January 22, 2024, the Company&#x2019;s Board of Directors
approved a grant of 320,000 RSUs to employees and a grant of options to purchase 80,000 shares to consultants. The RSUs represents the
right to receive Ordinary Shares at a future time, 245,000 of which vest over a period of three years, with a one-year cliff period and
70,000 vesting immediately on the grant date. 10,000 of the options were vested immediately on the grant date, 25,000 option vest over
a period of three years and 45,000 option vests over a period of one year and nine months. The RSUs designated to employees were granted
under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On February 5, 2024, the Company&#x2019;s Board of Directors
approved a grant of 2,277,000 RSUs to officers, a grant of options to purchase 30,000 Ordinary Shares and 90,000 RSUs to directors. The
RSUs and options represents the right to receive Ordinary Shares at a future time and vest over a period of three years, with a one-year
cliff. The RSUs designated to employees and directors were granted under Section 102 of the Israeli Tax Ordinance, which enables the
employee to pay a 25% capital gain tax upon exercise.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On February 20, 2025, the Company&#x2019;s Board of Directors
approved a grant of 644,000 RSUs to employees, a grant of 2,360,000 RSUs to certain of its executives and directors and options to purchase
an aggregate of 55,000 Ordinary Shares to service providers under the 2019 Equity Incentive Plan. The RSUs and options represents the
right to receive Ordinary Shares at a future time and vest over a period of three years, with a one-year cliff. The RSUs designated to
employees and directors were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital
gain tax upon exercise.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;4.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On August 6, 2025, the Company&#x2019;s Board of Directors
approved a grant of 1,200,000 RSUs to certain of its executives. The RSUs represents the right to receive Ordinary Shares at a future
time and vest over a period of three years, 25% of the amount will vest on January 1, 2026, 25% of the amount will vest on July 1, 2026
and the rest will be vested equal quarterly amounts along two more years. The RSUs designated to employees and directors were granted
under Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise. The board also
approved a grant of 300,000 RSUs to certain of its executives based on revenue milestones to be measured at the end of the fiscal year
of 2027.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;5.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On November 18, 2025, the Company&#x2019;s Board of Directors
approved a grant of 490,000 RSUs to employees, a grant of 30,000 RSUs to certain director, options to purchase an aggregate of 20,000
Ordinary Shares to employee and options to purchase an aggregate of 20,000 Ordinary Shares to service providers under the 2019 Equity
Incentive Plan. The RSUs and options represents the right to receive Ordinary Shares at a future time and vest over a period of three
years, with a one-year cliff. The RSUs designated to employees and directors were granted under Section 102 of the Israeli Tax Ordinance,
which enables the employee to pay a 25% capital gain tax upon exercise.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of all granted options was estimated
by using the Black Scholes option pricing model, which was aimed to model the value of the Company&#x2019;s assets over time. The simulation
approach was designed to take into account the terms and conditions of the share options, as well as the capital structure of the Company
and the volatility of its assets, on the date of grant based on certain assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following inputs were used to measure the
fair value of the option at grant date:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;November 18,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;February 22,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 5%"&gt;(i)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 64%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;123.41%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;128.78%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;(ii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: top"&gt;(iii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Expected term (vesting period)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;One year - Three years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: top"&gt;(iv)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;(v)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Free risk rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.12%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.5%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;January 22,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;February 5,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 5%"&gt;(i)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 64%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;144.83%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;143.98%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;(ii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;(iii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Expected term (vesting period)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;(iv)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;(v)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Free risk rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;4.03%-4.07%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.16%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of all granted RSUs was the Company&#x2019;s
quote price at the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2025, the Company recorded
share-based payment expenses to employees, directors and subcontractors in the amount of $3,575.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2024, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $1,767.&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the year ended December 31, 2023, the Company recorded share-based
payment expenses to employees, directors and subcontractors in the amount of $1,427.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The options to services providers and advisers outstanding
as December 31, 2025, 2024 and 2023 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;185,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;105,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;4.085&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;114,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.058&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,401&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;240,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.370&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.359&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;105,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4.085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;200,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.362&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;162,154&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.251&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;94,242&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The RSUs to services providers and advisers outstanding as of December
31, 2025, 2024 and 2023 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,433&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSUs outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSU&#x2019;s Vested&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,067&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The options to employees and directors outstanding as of December
31, 2025, 2024 and 2023 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;368,641&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;357,689&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;386,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3.56&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;28,571&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;277,265&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;368,641&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;357,689&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;244,765&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;338,641&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;350,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The RSUs to employees and directors outstanding as of December 31,
2025, 2024 and 2023 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,518,796&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;445,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,727,842&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,024,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,687,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,711,947&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;587,508&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,215,615&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSUs outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,745,512&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,518,796&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;445,140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSU&#x2019;s Vested&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,396,644&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,684,697&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,097,189&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,536&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c174"
      decimals="0"
      id="ixv-21213"
      unitRef="shares">320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c174"
      decimals="0"
      id="ixv-21214"
      unitRef="shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c175"
      decimals="0"
      id="ixv-21215"
      unitRef="shares">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c174" id="ixv-21216">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c176"
      decimals="0"
      id="ixv-21217"
      unitRef="shares">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c177"
      decimals="0"
      id="ixv-21218"
      unitRef="shares">10000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c178"
      decimals="0"
      id="ixv-21219"
      unitRef="shares">25000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c179" id="ixv-21220">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c180"
      decimals="0"
      id="ixv-21221"
      unitRef="shares">45000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <iinn:CapitalGainTaxRate
      contextRef="c177"
      decimals="2"
      id="ixv-21222"
      unitRef="pure">0.25</iinn:CapitalGainTaxRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c181"
      decimals="0"
      id="ixv-21223"
      unitRef="shares">2277000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c182"
      decimals="0"
      id="ixv-21224"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c183"
      decimals="0"
      id="ixv-21225"
      unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c181" id="ixv-21226">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <iinn:PercentageOfCapitalGainTax
      contextRef="c184"
      decimals="2"
      id="ixv-21227"
      unitRef="pure">0.25</iinn:PercentageOfCapitalGainTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c185"
      decimals="0"
      id="ixv-21228"
      unitRef="shares">644000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c186"
      decimals="0"
      id="ixv-21229"
      unitRef="shares">2360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c187"
      decimals="0"
      id="ixv-21230"
      unitRef="shares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c188" id="ixv-21231">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <iinn:CapitalGainTaxRate
      contextRef="c188"
      decimals="2"
      id="ixv-21232"
      unitRef="pure">0.25</iinn:CapitalGainTaxRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c189"
      decimals="0"
      id="ixv-21233"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c190" id="ixv-21234">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c191"
      decimals="2"
      id="ixv-21235"
      unitRef="pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c192"
      decimals="2"
      id="ixv-21236"
      unitRef="pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <iinn:CapitalGainTaxRate
      contextRef="c190"
      decimals="2"
      id="ixv-21237"
      unitRef="pure">0.25</iinn:CapitalGainTaxRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c193"
      decimals="0"
      id="ixv-21238"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c194"
      decimals="0"
      id="ixv-21239"
      unitRef="shares">490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c195"
      decimals="0"
      id="ixv-21240"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c194"
      decimals="0"
      id="ixv-21241"
      unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c196"
      decimals="0"
      id="ixv-21242"
      unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c197" id="ixv-21243">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <iinn:CapitalGainTaxRate
      contextRef="c197"
      decimals="2"
      id="ixv-21244"
      unitRef="pure">0.25</iinn:CapitalGainTaxRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-19265">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following inputs were used to measure the
fair value of the option at grant date:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;November 18,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;February 22,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 5%"&gt;(i)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 64%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;123.41%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;128.78%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;(ii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; vertical-align: top"&gt;(iii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Expected term (vesting period)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;One year - Three years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; vertical-align: top"&gt;(iv)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: left"&gt;Contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;(v)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Free risk rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.12%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.5%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;January 22,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;February 5,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 5%"&gt;(i)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 64%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;144.83%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center"&gt;143.98%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;(ii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;0%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;(iii)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Expected term (vesting period)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;(iv)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Contractual life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;(v)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Free risk rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;4.03%-4.07%&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4.16%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c197"
      decimals="4"
      id="ixv-21245"
      unitRef="pure">1.2341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c201"
      decimals="4"
      id="ixv-21246"
      unitRef="pure">1.2878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c197"
      decimals="2"
      id="ixv-21247"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c201"
      decimals="2"
      id="ixv-21248"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c197" id="ixv-19312">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife contextRef="c197" id="ixv-19327">P10Y</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c197"
      decimals="4"
      id="ixv-21249"
      unitRef="pure">0.0412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c201"
      decimals="3"
      id="ixv-21250"
      unitRef="pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c177"
      decimals="4"
      id="ixv-21251"
      unitRef="pure">1.4483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c184"
      decimals="4"
      id="ixv-21252"
      unitRef="pure">1.4398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c177"
      decimals="2"
      id="ixv-21253"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c184"
      decimals="2"
      id="ixv-21254"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c184" id="ixv-19397">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife contextRef="c184" id="ixv-19412">P10Y</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c204"
      decimals="4"
      id="ixv-21255"
      unitRef="pure">0.0403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c205"
      decimals="4"
      id="ixv-21256"
      unitRef="pure">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c184"
      decimals="4"
      id="ixv-21257"
      unitRef="pure">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c198"
      decimals="-3"
      id="ixv-21258"
      unitRef="usd">3575000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c199"
      decimals="-3"
      id="ixv-21259"
      unitRef="usd">1767000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c200"
      decimals="-3"
      id="ixv-21260"
      unitRef="usd">1427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-19469">&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The options to services providers and advisers outstanding
as December 31, 2025, 2024 and 2023 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;185,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;105,111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;4.085&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;114,512&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.058&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,401&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;240,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.370&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.359&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;105,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4.085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;200,111&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.362&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;162,154&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.251&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;94,242&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3.267&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;44&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;368,641&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;357,689&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;386,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.42&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3.56&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;28,571&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;277,265&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.91&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;368,641&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;357,689&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Options exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;244,765&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.57&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;338,641&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;350,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;0.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c206"
      decimals="INF"
      id="ixv-21261"
      unitRef="shares">185111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c206"
      decimals="3"
      id="ixv-21262"
      unitRef="ilsPershares">3.359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c207"
      decimals="INF"
      id="ixv-21263"
      unitRef="shares">105111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c207"
      decimals="3"
      id="ixv-21264"
      unitRef="ilsPershares">4.085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c208"
      decimals="INF"
      id="ixv-21265"
      unitRef="shares">114512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c208"
      decimals="3"
      id="ixv-21266"
      unitRef="ilsPershares">3.058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c209"
      decimals="INF"
      id="ixv-21267"
      unitRef="shares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c209"
      decimals="3"
      id="ixv-21268"
      unitRef="ilsPershares">3.405</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c210"
      decimals="INF"
      id="ixv-21269"
      unitRef="shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c210"
      decimals="3"
      id="ixv-21270"
      unitRef="ilsPershares">3.779</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi
      contextRef="c209"
      decimals="INF"
      id="ixv-21271"
      unitRef="shares">0</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c209"
      decimals="0"
      id="ixv-21272"
      unitRef="ilsPershares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi
      contextRef="c211"
      decimals="INF"
      id="ixv-21273"
      unitRef="shares">9401</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c211"
      decimals="3"
      id="ixv-21274"
      unitRef="ilsPershares">0.367</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c212"
      decimals="INF"
      id="ixv-21275"
      unitRef="shares">240111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c212"
      decimals="3"
      id="ixv-21276"
      unitRef="ilsPershares">3.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c206"
      decimals="INF"
      id="ixv-21277"
      unitRef="shares">185111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c206"
      decimals="3"
      id="ixv-21278"
      unitRef="ilsPershares">3.359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c207"
      decimals="INF"
      id="ixv-21279"
      unitRef="shares">105111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c207"
      decimals="3"
      id="ixv-21280"
      unitRef="ilsPershares">4.085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c212"
      decimals="INF"
      id="ixv-21281"
      unitRef="shares">200111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c212"
      decimals="3"
      id="ixv-21282"
      unitRef="ilsPershares">3.362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c206"
      decimals="INF"
      id="ixv-21283"
      unitRef="shares">162154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c206"
      decimals="3"
      id="ixv-21284"
      unitRef="ilsPershares">3.251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c207"
      decimals="INF"
      id="ixv-21285"
      unitRef="shares">94242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c207"
      decimals="3"
      id="ixv-21286"
      unitRef="ilsPershares">3.267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c209"
      decimals="-3"
      id="ixv-21287"
      unitRef="usd">44000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c210"
      decimals="-3"
      id="ixv-21288"
      unitRef="usd">66000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c211"
      decimals="-3"
      id="ixv-21289"
      unitRef="usd">19000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-19696">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The RSUs to services providers and advisers outstanding as of December
31, 2025, 2024 and 2023 were as&#160;follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of &lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,433&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,266&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,833&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSUs outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,433&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSU&#x2019;s Vested&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;32,500&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,067&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Year ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Number of&lt;br/&gt; RSUs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,518,796&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;445,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,727,842&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,024,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,687,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,087&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,711,947&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;587,508&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,215,615&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSUs outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,745,512&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,518,796&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;445,140&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;RSU&#x2019;s Vested&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,396,644&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,684,697&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,097,189&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 1.1pt"&gt;Share-based payment expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,536&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,352&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c220"
      decimals="INF"
      id="ixv-21290"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c221"
      decimals="INF"
      id="ixv-21291"
      unitRef="shares">7433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c222"
      decimals="INF"
      id="ixv-21292"
      unitRef="shares">18266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c223"
      decimals="INF"
      id="ixv-21293"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c224"
      decimals="INF"
      id="ixv-21294"
      unitRef="shares">7433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c225"
      decimals="INF"
      id="ixv-21295"
      unitRef="shares">10833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne
      contextRef="c223"
      decimals="INF"
      id="ixv-21296"
      unitRef="shares">0</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne
      contextRef="c224"
      decimals="INF"
      id="ixv-21297"
      unitRef="shares">0</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne
      contextRef="c225"
      decimals="INF"
      id="ixv-21298"
      unitRef="shares">7433</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c223"
      decimals="INF"
      id="ixv-21299"
      unitRef="shares">32500</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c224"
      decimals="INF"
      id="ixv-21300"
      unitRef="shares">32500</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c225"
      decimals="INF"
      id="ixv-21301"
      unitRef="shares">25067</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c223"
      decimals="-3"
      id="ixv-21302"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c224"
      decimals="-3"
      id="ixv-21303"
      unitRef="usd">1000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c225"
      decimals="-3"
      id="ixv-21304"
      unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c213"
      decimals="INF"
      id="ixv-21305"
      unitRef="shares">368641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c213"
      decimals="2"
      id="ixv-21306"
      unitRef="ilsPershares">0.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c214"
      decimals="INF"
      id="ixv-21307"
      unitRef="shares">357689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c214"
      decimals="2"
      id="ixv-21308"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c215"
      decimals="INF"
      id="ixv-21309"
      unitRef="shares">386260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c215"
      decimals="2"
      id="ixv-21310"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c216"
      decimals="INF"
      id="ixv-21311"
      unitRef="shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c216"
      decimals="2"
      id="ixv-21312"
      unitRef="ilsPershares">3.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c217"
      decimals="INF"
      id="ixv-21313"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c217"
      decimals="2"
      id="ixv-21314"
      unitRef="ilsPershares">3.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c218"
      decimals="INF"
      id="ixv-21315"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c218"
      decimals="0"
      id="ixv-21316"
      unitRef="ilsPershares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi
      contextRef="c216"
      decimals="INF"
      id="ixv-21317"
      unitRef="shares">101376</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c216"
      decimals="2"
      id="ixv-21318"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi
      contextRef="c217"
      decimals="INF"
      id="ixv-21319"
      unitRef="shares">19048</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c217"
      decimals="2"
      id="ixv-21320"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c218"
      decimals="2"
      id="ixv-21321"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c216"
      decimals="INF"
      id="ixv-21322"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c216"
      decimals="2"
      id="ixv-21323"
      unitRef="ilsPershares">3.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c218"
      decimals="INF"
      id="ixv-21324"
      unitRef="shares">28571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c218"
      decimals="2"
      id="ixv-21325"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c219"
      decimals="INF"
      id="ixv-21326"
      unitRef="shares">277265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c219"
      decimals="2"
      id="ixv-21327"
      unitRef="ilsPershares">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c213"
      decimals="INF"
      id="ixv-21328"
      unitRef="shares">368641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c213"
      decimals="2"
      id="ixv-21329"
      unitRef="ilsPershares">0.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c214"
      decimals="INF"
      id="ixv-21330"
      unitRef="shares">357689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c214"
      decimals="2"
      id="ixv-21331"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c219"
      decimals="INF"
      id="ixv-21332"
      unitRef="shares">244765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c219"
      decimals="2"
      id="ixv-21333"
      unitRef="ilsPershares">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c213"
      decimals="INF"
      id="ixv-21334"
      unitRef="shares">338641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c213"
      decimals="2"
      id="ixv-21335"
      unitRef="ilsPershares">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c214"
      decimals="INF"
      id="ixv-21336"
      unitRef="shares">350131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c214"
      decimals="2"
      id="ixv-21337"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c216"
      decimals="-3"
      id="ixv-21338"
      unitRef="usd">-5000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c217"
      decimals="-3"
      id="ixv-21339"
      unitRef="usd">17000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c218"
      decimals="-3"
      id="ixv-21340"
      unitRef="usd">47000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c226"
      decimals="INF"
      id="ixv-21341"
      unitRef="shares">2518796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c227"
      decimals="INF"
      id="ixv-21342"
      unitRef="shares">445140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c228"
      decimals="INF"
      id="ixv-21343"
      unitRef="shares">1727842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c229"
      decimals="INF"
      id="ixv-21344"
      unitRef="shares">5024000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c230"
      decimals="INF"
      id="ixv-21345"
      unitRef="shares">2687000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c231"
      decimals="INF"
      id="ixv-21346"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c229"
      decimals="INF"
      id="ixv-21347"
      unitRef="shares">85337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c230"
      decimals="INF"
      id="ixv-21348"
      unitRef="shares">25836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c231"
      decimals="INF"
      id="ixv-21349"
      unitRef="shares">67087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c229"
      decimals="INF"
      id="ixv-21350"
      unitRef="shares">2711947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c230"
      decimals="INF"
      id="ixv-21351"
      unitRef="shares">587508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c231"
      decimals="INF"
      id="ixv-21352"
      unitRef="shares">1215615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne
      contextRef="c229"
      decimals="INF"
      id="ixv-21353"
      unitRef="shares">4745512</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne
      contextRef="c230"
      decimals="INF"
      id="ixv-21354"
      unitRef="shares">2518796</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne
      contextRef="c231"
      decimals="INF"
      id="ixv-21355"
      unitRef="shares">445140</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumberOne>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c229"
      decimals="INF"
      id="ixv-21356"
      unitRef="shares">6396644</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c230"
      decimals="INF"
      id="ixv-21357"
      unitRef="shares">3684697</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c231"
      decimals="INF"
      id="ixv-21358"
      unitRef="shares">3097189</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c229"
      decimals="-3"
      id="ixv-21359"
      unitRef="usd">3536000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c230"
      decimals="-3"
      id="ixv-21360"
      unitRef="usd">1683000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c231"
      decimals="-3"
      id="ixv-21361"
      unitRef="usd">1352000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-20224">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 21 - RELATED PARTIES:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;The following transactions arose with related parties&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Transactions and balances with related parties&lt;/span&gt;&lt;b&gt;:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Shareholders and other related parties&#x2019; benefits&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;Salary and related expenses &#x2013; officers and directors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,819&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,710&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,761&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share based payment &#x2013; officers and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Balances with related parties&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Nature of transaction&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%"&gt;Officers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 69%; text-align: left"&gt;Salaries and related&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(343&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Compensation for directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-20242">&lt;span style="font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Shareholders and other related parties&#x2019; benefits&lt;/span&gt;&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;Salary and related expenses &#x2013; officers and directors&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,819&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,710&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,761&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share based payment &#x2013; officers and directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;Name&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Nature of transaction&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 10%"&gt;Officers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 69%; text-align: left"&gt;Salaries and related&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(343&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Compensation for directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(40&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="c232"
      decimals="-3"
      id="ixv-21362"
      unitRef="usd">1819000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c233"
      decimals="-3"
      id="ixv-21363"
      unitRef="usd">1710000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c234"
      decimals="-3"
      id="ixv-21364"
      unitRef="usd">1761000</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c232"
      decimals="-3"
      id="ixv-21365"
      unitRef="usd">3107000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c233"
      decimals="-3"
      id="ixv-21366"
      unitRef="usd">1376000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c234"
      decimals="-3"
      id="ixv-21367"
      unitRef="usd">1009000</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c235"
      decimals="-3"
      id="ixv-21368"
      unitRef="usd">-343000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c236"
      decimals="-3"
      id="ixv-21369"
      unitRef="usd">-381000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c237"
      decimals="-3"
      id="ixv-21370"
      unitRef="usd">-41000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c238"
      decimals="-3"
      id="ixv-21371"
      unitRef="usd">-40000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-20341">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 22 - SUBSEQUENT EVENTS:&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On February 5, 2026, the Company&#160;entered into a Securities Purchase Agreement with a single institutional investor (the &#x201c;Purchaser&#x201d;), pursuant to which the Company agreed to issue and sell, in a registered direct offering: (i) 4,000,000 Ordinary Shares, at an offering price of $0.70 per share; and (ii) pre-funded warrants to acquire up to 2,785,715 Ordinary Shares at an offering price of $0.6999 per re-funded warrant and (iii) private warrants, to purchase up to an aggregate of 6,785,715
Ordinary Shares at an exercise of $0.70 per share. The gross proceeds were approximately $4.7 million. To date, prefunded warrants to purchase 2,197,714 Ordinary Shares were exercised. The Company also amend the terms of 3,031,250 Private Warrants held by the same purchaser, which were issued in December 2023 from $1.28 per share to $0.70 per share, amended the expiration date from June 27, 2027 to February 5, 2031, and revised the fundamental transaction provision in the warrants and the cashless exercise provision with respect to computing the valuation of the Ordinary Shares. Following such amendments the Company concluded that the revised Warrants are indexed to the Company&#x2019;s own stock and meet the conditions for equity classification, and thus should be reclassified within equity.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Subsequent to December 31, 2025 and following the expiration of the March
                                            2025 Sales Agreement due to expiration of the Company&#x2019;s Registration Statement on Form
                                            F-3 (File No. 333-266748), the Company entered into a new sales agreement with A.G.P./Alliance
                                            Global Partners, as sales agent, pursuant to which the Company could offer and sell, from
                                            time to time, through the sales agent, Ordinary Shares pursuant to the ATM, having an aggregate
                                            offering price of up to $2,016.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="text-align: justify; width: 0"&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 0.25in"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Subsequent to December 31, 2025, the second half of commitment fee amount of the SEPA, which represents 1% of the SEPA, or $250, was settled as agreed on the 30-day anniversary of the SEPA through the issuance of a variable number of Ordinary Shares determined based on the VWAP formula defined therein. Following the filing of the re-sale registration statement in connection with the SEPA, the Company&#x2019;s share price declined. As a result, the Company issued the registered 245,098 Ordinary Shares as commitment shares in lieu of cash, which were valued at $231 based on the VWAP calculation as of the due date. The remaining balance of $19 was agreed to be settled in cash.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c239"
      decimals="0"
      id="ixv-21372"
      unitRef="shares">4000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c240"
      decimals="2"
      id="ixv-21373"
      unitRef="usdPershares">0.7</us-gaap:SaleOfStockPricePerShare>
    <iinn:PreFundedWarrants
      contextRef="c240"
      decimals="0"
      id="ixv-21374"
      unitRef="shares">2785715</iinn:PreFundedWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c240"
      decimals="4"
      id="ixv-21375"
      unitRef="usdPershares">0.6999</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c241"
      decimals="0"
      id="ixv-21376"
      unitRef="shares">6785715</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c241"
      decimals="2"
      id="ixv-21377"
      unitRef="usdPershares">0.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="c239"
      decimals="-5"
      id="ixv-21378"
      unitRef="usd">4700000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <iinn:WarrantsToPurchaseOrdinaryShares
      contextRef="c239"
      decimals="0"
      id="ixv-21379"
      unitRef="shares">2197714</iinn:WarrantsToPurchaseOrdinaryShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c242"
      decimals="0"
      id="ixv-21380"
      unitRef="shares">3031250</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c243"
      decimals="2"
      id="ixv-21381"
      unitRef="usdPershares">1.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c244"
      decimals="2"
      id="ixv-21382"
      unitRef="usdPershares">0.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:StandbyEquityPurchaseAgreementPercentage
      contextRef="c245"
      decimals="2"
      id="ixv-21383"
      unitRef="pure">0.01</iinn:StandbyEquityPurchaseAgreementPercentage>
    <iinn:FinancialExpensesDueToCommitmentFee
      contextRef="c245"
      decimals="-3"
      id="ixv-21384"
      unitRef="usd">250000</iinn:FinancialExpensesDueToCommitmentFee>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c245"
      decimals="0"
      id="ixv-21385"
      unitRef="shares">245098</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c245"
      decimals="-3"
      id="ixv-21386"
      unitRef="usd">231000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherCommitment
      contextRef="c246"
      decimals="-3"
      id="ixv-21387"
      unitRef="usd">19000</us-gaap:OtherCommitment>
    <iinn:SaleOfRightsValue
      contextRef="c86"
      decimals="-3"
      id="hidden-fact-0"
      unitRef="usd">25000000</iinn:SaleOfRightsValue>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms contextRef="c153" id="hidden-fact-1">P0Y</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-21392">0001837493</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-21393">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-21394">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-21395">L3</dei:EntityIncorporationStateCountryCode>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c202" id="ixv-21396">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c203" id="ixv-21397">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife contextRef="c201" id="ixv-21398">P10Y</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c177" id="ixv-21399">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife contextRef="c177" id="ixv-21400">P10Y</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Future lease payments were discounted by&#160;7.98%-25.59% interest
rate.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
